<SEC-DOCUMENT>0001493152-24-027145.txt : 20240712
<SEC-HEADER>0001493152-24-027145.hdr.sgml : 20240712
<ACCEPTANCE-DATETIME>20240712173056
ACCESSION NUMBER:		0001493152-24-027145
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		41
FILED AS OF DATE:		20240712
DATE AS OF CHANGE:		20240712

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			JUPITER NEUROSCIENCES, INC.
		CENTRAL INDEX KEY:			0001679628
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				474828381
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-260183
		FILM NUMBER:		241115333

	BUSINESS ADDRESS:	
		STREET 1:		1001 NORTH US HWY 1
		STREET 2:		SUITE 504
		CITY:			JUPITER
		STATE:			FL
		ZIP:			33477
		BUSINESS PHONE:		(561) 406-6154

	MAIL ADDRESS:	
		STREET 1:		1001 NORTH US HWY 1
		STREET 2:		SUITE 504
		CITY:			JUPITER
		STATE:			FL
		ZIP:			33477

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Jupiter Orphan Therapeutics, Inc.
		DATE OF NAME CHANGE:	20160713
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>forms-1a.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>As filed with the U.S. Securities and Exchange
Commission on July 12, 2024 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
No. 333-260183</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PRE-EFFECTIVE AMENDMENT NO. 18 TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>Form
S-1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGISTRATION
STATEMENT<BR>
UNDER THE SECURITIES ACT OF 1933</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>JUPITER
NEUROSCIENCES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2834</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>47-4828381</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
                                            or other jurisdiction</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
    incorporation or organization)</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Primary
                                            Standard Industrial</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Classification
    Code Number)</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
                                            Employer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    Number)</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1001
North US HWY 1, Suite 504</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter,
Florida 33477</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Telephone:
(561) 406-6154<BR>
</B>(Address, including zip code, and telephone number, including area code, of registrant&rsquo;s principal executive offices)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Christer
Ros&eacute;n</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Chief
Executive Officer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1001
North US HWY 1, Suite 504</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter,
Florida 33477</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Telephone:
(561) 406-6154</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name,
address, including zip code, and telephone number, including area code, of agent for service)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Copies
to:</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Laura
                                            Anthony, Esq.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Craig
    D. Linder, Esq.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Anthony,
    Linder &amp; Cacomanolis, </B></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PLLC</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1700
    Palm Beach Lakes Blvd.,</B></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B> Suite 820 </B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>West
    Palm Beach, Florida 33401</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Telephone:
    (561) 514-0936</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Facsimile:
    (561) 514-0832</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ralph
                                            De Martino, Esq.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cavas
    Pavri, Esq.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ArentFox
    Schiff LLP</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1717
    </B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>K Street NW</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Washington,
    DC 20006<BR>
    Telephone: (202) 857-6000<BR>
    Facsimile: (202) 857-6395</B></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximate
date of commencement of proposed sale to the public: <B>As soon as practicable after the effective date of this registration statement.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933 check the following box. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo;
&ldquo;smaller reporting company&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer &#9744;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer &#9744;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated
    filer &#9746;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company &#9746;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company &#9746;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check market if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective
in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date
as the Commission, acting pursuant to Section 8(a) may determine.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXPLANATORY
NOTE</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Registration Statement contains two prospectuses, as set forth below.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Public
    Offering Prospectus</I></B>. A prospectus to be used for the public offering of 2,750,000 shares of common stock of the registrant
    (the &ldquo;Public Offering Prospectus&rdquo;) through the underwriter named on the cover page of the Public Offering Prospectus.</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Resale
    Prospectus</I></B>. A prospectus to be used for the resale by the selling stockholders set forth therein of 3,600,000 shares of common
    stock of the registrant (the &ldquo;Resale Prospectus&rdquo;).</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Resale Prospectus is substantially identical to the Public Offering Prospectus, except for the following principal items:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">they
    contain different front cover pages and back cover pages;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    references in the Public Offering Prospectus to &ldquo;this offering&rdquo; or &ldquo;this initial public offering&rdquo; will be
    changed to &ldquo;our initial public offering&rdquo; and/or &ldquo;the IPO,&rdquo; defined as the underwritten initial public offering
    of our shares of common stock, in the Resale Prospectus;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    references in the Public Offering Prospectus to &ldquo;underwriters&rdquo; will be changed to &ldquo;underwriters of the IPO&rdquo;
    in the Resale Prospectus;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ownership percentages described in the Public Offering Prospectus will be adjusted in the Resale Prospectus to reflect shares of
    common stock sold in our initial public offering;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">they
    contain different &ldquo;The Offering&rdquo; sections;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    &ldquo;Underwriting&rdquo; section from the Public Offering Prospectus is deleted from the Resale Prospectus and a &ldquo;Plan of
    Distribution&rdquo; section is inserted in its place;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    &ldquo;Capitalization&rdquo; and &ldquo;Dilution&rdquo; sections are deleted from the Resale Prospectus;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    &ldquo;Legal Matters&rdquo; section in the Resale Prospectus deletes the reference to counsel for the underwriters; and</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">they
    contain different back pages.</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant has included in this registration statement a set of alternate pages after the outside back cover page of the Public Offering
Prospectus, which we refer to as the Alternate Pages, to reflect the foregoing differences in the Resale Prospectus as compared to the
Public Offering Prospectus. The Public Offering Prospectus will exclude the Alternate Pages and will be used for the public offering
by the registrant. The Resale Prospectus will be substantially identical to the Public Offering Prospectus except for the addition or
substitution of the Alternate Pages and will be used for the resale offering by the selling stockholders (it being understood that none
of the shares of common stock being registered for resale by the selling stockholders in the Resale Prospectus may be sold prior to the
closing of our initial public offering under the Public Offering Prospectus, and only then in compliance with applicable laws, rules
and regulations).</FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>The
information in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration
statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities, and
it is not soliciting an offer to buy these securities, in any jurisdiction where the offer or sale is not permitted.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>PRELIMINARY
    PROSPECTUS</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>SUBJECT
    TO COMPLETION </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>DATED
    <FONT STYLE="text-transform: uppercase">JULY 12, 2024</FONT> </B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2,750,000
Common</B></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B> Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><IMG SRC="forms-1a_001.jpg" ALT="" STYLE="height: 143px; width: 480px"></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
is a firm commitment initial public offering of Jupiter Neurosciences, Inc., a Delaware corporation (the &ldquo;Company,&rdquo; &ldquo;JNS,&rdquo;
&ldquo;we,&rdquo; &ldquo;our&rdquo; or &ldquo;us&rdquo;). We are offering 2,750,000 shares of common stock. The initial public
offering price per share is expected to be between $4.00 and $5.00. For purposes of this prospectus, the assumed initial public
offering price per share is $4.00, the low-end of the anticipated price range. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We have applied to list our common stock on the
Nasdaq Capital Market (&ldquo;Nasdaq Capital Market&rdquo;) under the symbol &ldquo;JUNS.&rdquo; There is no assurance that our listing
application will be At the same time as the registration set forth in this prospectus (the &ldquo;Public Offering Prospectus&rdquo;),
we are registering the resale of 3,600,000 shares of common stock by certain shareholders (&ldquo;Selling Stockholders&rdquo;) under
a separate prospectus (the &ldquo;Resale Prospectus&rdquo;). The shares offered by the Resale Prospectus may be sold by the Selling Stockholders
from time to time, in the open market, through privately negotiated transactions or a combination of these methods, at market prices
prevailing at the time of sale or at negotiated prices. We will not receive any proceeds from the sale of the shares of common stock
to be sold by the Selling Stockholders. No sales of shares of common stock covered by the Resale Prospectus shall occur unless and until
the shares of common stock sold in this initial public offering begin trading on the Nasdaq Capital Market. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> In order to meet the Nasdaq Capital Market public
float requirement of $15,000,000, we are partly relying on the registration of shares of common stock held by the Selling Stockholders.
The per share value of the shares of common stock is $4.00, the low-end of the anticipated price range, which requires us to have, at
a minimum, 1,000,000 issued and outstanding public float shares. Since the number of shares of common stock being registered pursuant
to the registration statement of which the Resale Prospectus forms a part that are not subject to transfer restrictions is 3,600,000,
which is greater than 1,000,000, we will be able to meet Nasdaq&rsquo;s public float requirement of $15,000,000. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;<BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Unless otherwise noted, the share and per share information
in this prospectus have been adjusted to give effect to the fifteen-for-four (15-for-4) stock split (&ldquo;2024 Forward Stock Split&rdquo;)
of our outstanding common stock, which was effective on June 14, 2024. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &ldquo;emerging growth company&rdquo; under applicable federal securities laws and are subject to reduced public company reporting
requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
in our common stock involves a high degree of risk. See &ldquo;Risk Factors&rdquo; on page 16 of this prospectus for a discussion
of information that should be considered in connection with an investment in our common stock.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Per
    Share</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 68%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
offering price</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting
    discounts and commissions (1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds,
before expenses, to us</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">See &ldquo;Underwriting&rdquo; on page 161 of this
    prospectus for additional information regarding the compensation payable to the underwriters.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters expect to deliver our securities to purchasers in the offering on or about &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
, 2024. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"> <FONT STYLE="font-size: 10pt"><IMG SRC="image_004.jpg" ALT="" STYLE="height: 41.25pt; width: 225pt"></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <B>REVERE SECURITIES LLC</B> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
date of this prospectus is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2024 </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.6in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#pp_001">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">3</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#pp_002">MARKET, INDUSTRY AND OTHER DATA</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#pp_003">TRADEMARKS AND COPYRIGHTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>5</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#pp_004">PROSPECTUS SUMMARY</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#pp_005">RISK FACTORS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"> <A HREF="#ar_001">USE OF PROCEEDS</A> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> 81 </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_002">DIVIDEND POLICY</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">83</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_003">CAPITALIZATION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>83</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_004">MARKET PRICE FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">84</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_005">DILUTION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">87</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_006">DESCRIPTION OF BUSINESS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">88</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_007">MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">117</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_008">MANAGEMENT</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">132</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_009">EXECUTIVE COMPENSATION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">143</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_010">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">158</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_011">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">159</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_012">UNDERWRITING</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">161</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><A HREF="#SS_001"> SELLING STOCKHOLDERS </A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> 168 </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_013">DESCRIPTION OF SECURITIES</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">168</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_014">LEGAL MATTERS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">170</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_015">EXPERTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>170</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_016">APPOINTMENT OF AUDITOR</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>170</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_017">DISCLOSURE OF COMMISSION&rsquo;S POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">171</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_018">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>171</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_019">INDEX TO FINANCIAL STATEMENTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No
dealer, salesperson or other individual has been authorized to give any information or to make any representation other than those contained
in this prospectus in connection with the offer made by this prospectus and, if given or made, such information or representations must
not be relied upon as having been authorized by us. This prospectus does not constitute an offer to sell or a solicitation of an offer
to buy any securities in any jurisdiction in which such an offer or solicitation is not authorized or in which the person making such
offer or solicitation is not qualified to do so, or to any person to whom it is unlawful to make such offer or solicitation. Neither
the delivery of this prospectus nor any sale made hereunder shall, under any circumstances, create any implication that there has been
no change in our affairs or that information contained herein is correct as of any time subsequent to the date hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
investors outside the United States: We have not done anything that would permit this offering or possession or distribution of this
prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United
States who come into possession of this prospectus must inform themselves, and observe any restrictions relating to, the offering of
the shares of our common stock and the distribution of this prospectus outside the United States.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="pp_001"></A>SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements
of historical facts contained in this prospectus, including statements regarding our future results of operations and financial position,
business strategy, development plans, planned preclinical studies and clinical trials, future results of clinical trials, expected research
and development costs, regulatory strategy, timing and likelihood of success, as well as plans and objectives of management for future
operations, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &ldquo;may,&rdquo;
&ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;would,&rdquo; &ldquo;expect,&rdquo; &ldquo;plan,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;could,&rdquo;
&ldquo;intend,&rdquo; &ldquo;target,&rdquo; &ldquo;project,&rdquo; &ldquo;contemplate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo;
&ldquo;predict,&rdquo; &ldquo;potential&rdquo; or &ldquo;continue&rdquo; or the negative of these terms or other similar expressions.
Forward-looking statements contained in this prospectus include, but are not limited to, statements about:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability of our preclinical studies and planned clinical trials to demonstrate safety and efficacy of our product candidate JOTROL,
    and other positive results;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing, progress and results of preclinical studies and clinical trials for JOTROL and other product candidates we may develop,
    including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period
    during which the results of the studies or trials will become available, and our research and development programs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing, scope and likelihood of regulatory filings and approvals, including timing of INDs and final FDA approval of JOTROL
    and any other future product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing, scope or likelihood of foreign regulatory filings and approvals;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to develop and advance our current product candidate JOTROL and programs into, and successfully complete, clinical
    studies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    manufacturing, commercialization, and marketing capabilities and strategy;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    plans relating to commercializing our product candidates, if approved, including the geographic areas of focus and sales strategy;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    need to hire additional personnel and our ability to attract and retain such personnel;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    size of the market opportunity for our product candidate JOTROL, including our estimates of the number of patients who suffer
    from the diseases we are targeting;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    expectations regarding the approval and use of our product candidate JOTROL in combination with other drugs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    competitive position and the success of competing therapies that are or may become available;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    estimates of the number of patients that we will enroll in our clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    beneficial characteristics, and the potential safety, efficacy and therapeutic effects of our product candidate JOTROL; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain and maintain regulatory approval of our product candidate JOTROL; </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    plans relating to the further development of our product candidate JOTROL, including additional indications we may pursue;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">existing
    regulations and regulatory developments in the United States, Europe and other jurisdictions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    intellectual property position, including the scope of protection we are able to establish and maintain for intellectual property
    rights covering JOTROL and other product candidates we may develop, including the extensions of existing patent terms where
    available, the validity of intellectual property rights held by third parties, and our ability not to infringe, misappropriate or
    otherwise violate any third-party intellectual property rights;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    continued reliance on third parties to conduct additional preclinical studies and planned clinical trials of our product candidate
    JOTROL, and for the manufacture of our product candidate JOTROL for preclinical studies and clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    relationships with patient advocacy groups, key opinion leaders, regulators, the research community and payors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain, and negotiate favorable terms of, any collaboration, licensing or other arrangements that may be necessary or
    desirable to develop, manufacture or commercialize our product candidate JOTROL; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    pricing and reimbursement of JOTROL and other product candidates we may develop, if approved;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    rate and degree of market acceptance and clinical utility of JOTROL and other product candidates we may develop;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    financial performance;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and
    capital expenditure requirements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    impact of laws and regulations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
expectations regarding the period during which we will qualify as an emerging growth company under The Jumpstart Our Business Startups
Act of 2012 and a smaller reporting company under the Securities Exchange Act of 1934, as amended;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    anticipated use of our existing resources and the proceeds from this offering; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the price of our common stock could be subject to rapid
    and substantial volatility. As a relatively small-capitalization company with relatively small public
float, we may experience greater stock price volatility, extreme price run-ups, lower trading volume and less liquidity than large-capitalization
companies. In addition, if the trading volumes of our common stock are low, persons buying or selling in relatively small quantities may
easily influence prices of our common stock. This low volume of trades could also cause the price of our common stock to fluctuate greatly,
with large percentage changes in price occurring in any trading day session. Holders of our common stock may also not be able to readily
liquidate their investment or may be forced to sell at depressed prices due to low volume trading.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which
we operate and financial trends that we believe may affect our business, financial condition, results of operations and prospects, and
these forward-looking statements are not guarantees of future performance or development. These forward-looking statements speak only
as of the date of this prospectus and are subject to a number of risks, uncertainties and assumptions described in the section titled
&ldquo;Risk Factors&rdquo; and elsewhere in this prospectus. Because forward-looking statements are inherently subject to risks and uncertainties,
some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events.
The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ
materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update
or revise any forward-looking statements contained herein until after we distribute this prospectus, whether as a result of any new information,
future events or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, statements that &ldquo;we believe&rdquo; and similar statements reflect our beliefs and opinions on the relevant subject. These
statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms
a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate
that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are
inherently uncertain and you are cautioned not to unduly rely upon these statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="pp_002"></A>MARKET,
INDUSTRY AND OTHER DATA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus contains estimates, projections and other information concerning our industry, our business and the markets for our product
candidate, including data regarding the estimated size of such markets and the incidence of certain medical conditions. We obtained the
industry, market and similar data set forth in this prospectus from our internal estimates and research and from academic and industry
research, publications, surveys and studies conducted by third parties, including governmental agencies. In some cases, we do not expressly
refer to the sources from which this data is derived. Information that is based on estimates, forecasts, projections, market research
or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events
and circumstances that are assumed in this information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="pp_003"></A>TRADEMARKS
AND COPYRIGHTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
own or have rights to trademarks or trade names that we use in connection with the operation of our business, including our corporate
names, logos and website names. In addition, we own or have the rights to copyrights, trade secrets and other proprietary rights that
protect the content of our products and the formulations for such products. This prospectus may also contain trademarks, service marks
and trade names of other companies, which are the property of their respective owners. Our use or display of third parties&rsquo; trademarks,
service marks, trade names or products in this prospectus is not intended to, and should not be read to, imply a relationship with or
endorsement or sponsorship of us. Solely for convenience, some of the copyrights, trade names and trademarks referred to in this prospectus
are listed without their &copy;, &reg; and &trade; symbols, but we will assert, to the fullest extent under applicable law, our rights
to our copyrights, trade names and trademarks. All other trademarks are the property of their respective owners.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="pp_004"></A>PROSPECTUS
SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>This
summary highlights certain information about us, this offering, and selected information contained in this prospectus. This summary is
not complete and does not contain all of the information that you should consider before deciding whether to invest in our common
stock. For a more complete understanding of the Company and this offering, we encourage you to read and consider the more detailed
information in this prospectus, including &ldquo;Risk Factors&rdquo; and the financial statements and related notes. Unless the context
otherwise requires, &ldquo;JNS,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; or &ldquo;the Company&rdquo; refer to Jupiter
Neurosciences, Inc., a Delaware corporation.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Unless
otherwise noted, the share and per share information in this prospectus reflects a reverse stock split of the outstanding common
stock of the Company at a one for two (1-for-2) ratio, which was effected on January 25, 2022 (&ldquo;Reverse Stock Split&rdquo;)
and the fifteen-for-four (15-for-4) stock split (&ldquo;2024 Forward Stock Split&rdquo;) of our outstanding common stock, which was
effected on June 14, 2024. </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Business
Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Jupiter Neurosciences, Inc. (the
&ldquo;Company&rdquo;) is a clinical stage research and development pharmaceutical company located in Jupiter, Florida. The Company incorporated
in Delaware in January 2016. The Company has developed a unique resveratrol platform product primarily targeting treatment of neuro-inflammation.
The product candidate, called JOTROL, has many potential indications of use for rare diseases, of which we are primarily targeting
Mucopolysaccharidoses Type 1, Friedreich&rsquo;s Ataxia, and MELAS. In the larger disease areas, we are primarily targeting Parkinson&rsquo;s
Disease and Mild Cognitive Impairment/early Alzheimer&rsquo;s disease. Recent developments are guiding us to focusing strongly
on Parkinson&rsquo;s Disease as well as development of our product in the South-East Asian market. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has recently completed preclinical activities in a validated mouse model of Parkinson&rsquo;s Disease (PD) at the University
of Miami. The model of PD that was used mimics many aspects of the disease utilizing a unilateral injection of a neurotoxin precursor
that elicits nigral cell loss, striatal dopamine loss and behavior deficits similar to physiological characteristics of human disease.
We believe that results from this trial indicates that PD might be the best target for treatment solution among the multiple indications
where JOTROL might play a role. The trial design and outcomes are further described in the section &ldquo;Description of Business&rdquo;.
On May 23, 2024, the US Senate unanimously passed the National Plan to End Parkinson&rsquo;s Act, the first-ever federal legislation dedicated
to ending Parkinson&rsquo;s disease. A cross-country strategy to end Parkinson&rsquo;s and atypical parkinsonism has the potential to:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dramatically
    increase federal research funding; </FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Develop
    more effective pathways for treatments and cures; </FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Improve
    early diagnosis; </FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Spark
    new and improved models for patient care; </FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Create
    standards and measures to prevent Parkinson&rsquo;s disease; </FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
    health disparities in diagnosis, treatment and clinical trial participation and </FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enhance
    public awareness of the disease.</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to follow the various opportunities closely with a particular focus on seeking available funding to accelerate research
and development JOTROL&rsquo;s Parkinson&rsquo;s Disease indication. However, there is no assurance that such funding will ever become
available or be awarded to the Company.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> We have over the past 2
years received a strong interest in JOTROL from various Asian organizations. We believe that this interest has been triggered, in
part, by (i) resveratrol becoming commonly used in Asian herbal medicines as a therapeutic strategy as described in available
scientific literature published by PubMed Central: PMCID: PMC7498443 (September 2020), (ii) Hong Kong&rsquo;s and China&rsquo;s
recent approval of the patent for JOTROL, (iii) China releasing a list of approximately 120 rare disease indications issued jointly
by five national bodies, including the National Health Commission, Ministry of Science and Technology, Ministry of Industry and
Information Technology, State Drug Administration, and State Administration of Traditional Chinese Medicine (May 2018), that we
believe JOTROL can be applicable as a treatment for MPS-1 and MELAS in this population, (iv) recent publications regarding JOTROL
in the Journal of Alzheimer&rsquo;s Disease and AAPS Open (Journal of Alzheimer&rsquo;s Disease 86 (2022) 173&ndash;190 February
2022; Kemper et al. AAPS Open June 2022), and (v) the projected increase of the Traditional Chinese Medicine (&ldquo;TCM&rdquo;) market due to several factors which of one is
reformulation of existing compounds. Our Chairman &amp; CEO, Christer Ros&eacute;n, presented in person, our company&rsquo;s status
and pipeline at the BIOHK 2023 in Hong Kong in September of 2023. The presentation led to several follow-on meetings, and we have
therefore recently agreed to service agreements in the areas of CMC (Chemistry, Manufacturing, and Controls), regulatory affairs and
clinical trial management. These agreements are with companies that, we believe, have the knowledge and network in the
South-East Asian market to accelerate steps that is needed to have a product that can have treatment value in the territory. In
addition, we are in active negotiations with Dominant Treasure Health (&ldquo;DTH&rdquo;), a BVI company. DTH has demonstrated to us through several company introductions that they have business relationships,
either directly or through affiliates, with many South-East Asian pharmaceutical companies as well as companies involved in
distribution and sales of TCM, Traditional Chinese Medicine. We are therefore planning to engage DTH in active business development
in China, Malaysia and Singapore as soon as we have financing in place for their engagement. DTH has already introduced us to three
Chinese companies, Beimei Pharma, http://en.beimeiyaoye.com, that specializes in pediatric medications, Sichuan Kelun Pharmaceutical
Co., Ltd., a publicly traded company that is part of the Kelun Industrial Group, https://www.kelun.com/, and Tianjin Pharmaceuticals,
https://en.pharm.com.cn/, that advocates the corporate core values of &ldquo;Love, Integrity and Power&rdquo;. TCM products are run in
a separate division within Tianjin. Discussions with all three companies are ongoing. We believe that with DTH&rsquo;s assistance we
can co-ordinate and oversee the work of our service providers in the territory and more expediently negotiate and finalize an
out-license agreement with one or more pharmaceutical companies in South-East Asia.  The agreements are further described in the section &ldquo;Other Material
Agreements&rdquo;. The Asian market is very large and hard to penetrate for a small company and we believe that our strategy with
these agreements have the possibility to accelerate an out-licensing deal in the
South-East Asian territories. However, there are no assurances that this approach will be successful. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We believe that a high dose of
resveratrol is needed for therapeutic effects. Currently available resveratrol products are associated with severe gastrointestinal (GI)
side effects at the dose levels we believe are needed. Our belief is based on available scientific literature, preclinical trial results
conducted in mice and rats, and previously conducted human trials with resveratrol. We believe that JOTROL, based on the results from
our Phase I trial, see section &ldquo;Description of Business&rdquo;, has the potential to deliver a therapeutically effective dose of
resveratrol in the blood stream without causing gastrointestinal (GI) side effects. Based on our pre-clinical and Phase I study results,
we expect that JOTROL will resolve &ldquo;the major obstacle of resveratrol&rsquo;s poor bioavailability&rdquo; as discussed in
AY Berman&rsquo;s summary article in the Journal of Precision Oncology (AY Berman, 2017). Based on our own preclinical studies we believe
that resveratrol has the ability to cross the blood-brain barrier. Studies conducted in Friedreich&rsquo;s ataxia (FA) and Alzheimer&rsquo;s
disease (AD) patients, resulted in positive effects on oxidative stress, inflammation, and mitochondrial function. The FA study was concluded
in Australia by Murdoch Children&rsquo;s Research Institute in 2015 (Yiu et al.). The AD study was conducted in 2015 by the Alzheimer&rsquo;s
Disease Cooperative Study with Professor Raymond Turner, MD, Ph.D., Georgetown, as principal investigator (Turner et al.). Both studies
have been published in scientific journals and further described in the section &ldquo;Description of Business&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">In
2020, we received approval for full funding, $1.76 million, for our Phase I study from the National Institute on Aging
(&ldquo;NIA&rdquo;). Since there were unanticipated higher costs, mostly due to COVID-19 related additional procedures during the
Phase I trial, a supplemental grant of $233,281 was submitted to the NIA in December of 2021. We were awarded the supplemental grant
on April 7, 2022. In the NIA scientific review summary statement of our Phase I study application, it is stated that the NIA is
looking forward to a Phase II study with an enhanced resveratrol product, based on the earlier study results from the well published
Turner et al. Alzheimer&rsquo;s study. In April 2021, we submitted our first grant application to the NIA for full funding of a
Phase II trial in Mild Cognitive Impairment (MCI) and early Alzheimer&rsquo;s disease. The Phase II trial was designed to focus
on 3 areas: 1) safety and tolerability; 2) pharmacokinetics and pharmacodynamics, measuring of responses from 2 different doses vs.
placebo; and 3) measuring of effect on multiple biomarkers related to the disease. The application was not accepted but we were
encouraged by the NIA to refine our application and submit again. We have since submitted three grant applications, with budgets of
$20 million or higher, to the NIA for full funding of such Phase II trial but none of those applications were successful. The NIA
scientific review of our Alzheimer&rsquo;s Phase II trial grant application, which is attached as Exhibit 10.38 to the registration
statement of which this prospectus forms a part, shows a total score of 47 which is our best score so far. A score of 40 or below is
necessary for being considered for funding. </FONT> <FONT STYLE="font-size: 8pt"></FONT><FONT STYLE="font-size: 10pt"> After
discussions with the NIA, we have decided to apply, in September of 2024, for a much smaller grant, $2.5 million, for a
Proof-of-Concept study focusing on JOTROL&rsquo;s effect on MCI validated biomarkers. The final study design is not yet determined
but a draft synopsis is described in the section &ldquo;Description of Business&rdquo;. There is</FONT> <FONT STYLE="font-size: 10pt">
no guarantee that this and future grant applications will be successful and therefore the rejection of our future grant application
may significantly delay the Company&rsquo;s plans in connection with MCI and Alzheimer&rsquo;s and may have a significant impact on
the Company&rsquo;s financial performance. </FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company continues to apply
for grants opportunistically and on August 12, 2022, submitted an application for a $10.1 million grant to the Department of Defense
for a Phase II Friedreich&rsquo;s Ataxia study. This study planned to assess the efficacy of JOTROL as a potential treatment for
FA through a randomized, blinded, placebo-controlled clinical trial. On December 30 the Company received notification that the application
was not recommended for funding. The grounds for denial were the weaknesses noted in the peer review summary statement, attached as Exhibit
10.33 to the registration statement of which this prospectus forms a part, specifically concerning clinical impact and research
strategy and feasibility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Since inception, we have operated
with limited human capital, utilizing agreements with academia to get pre-clinical work executed at no cost, negotiating favorable deals
for data already produced for resveratrol (e.g. toxicity studies and Phase II clinical study data), obtaining a full grant from the NIA
for our first clinical trial and building a management and scientific consulting team (consisting of the Scientific Advisory Board and
business advisors) as well as negotiating service agreements with companies to handle CMC, Regulatory work and Clinical trials in
South-East Asia primarily compensated with equity securities of the company. We believe that this compensation method aligns the
management, Scientific Advisory Board members and business advisors&rsquo; interests with the shareholders. We believe that our structure
with a core management team that has experience in the utilization of outside resources makes it possible for us to efficiently execute
several programs simultaneously in a cost-effective way.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For the fiscal years ended December
31, 2023 and 2022, we generated no revenues from product sales and reported net losses of $4,783,689 and $4,957,580
respectively, and negative cash flow from operating activities of $480,953 and $1,248,504, respectively. For the three
months ended March 31, 2024 and 2023, we generated no revenues from product sales and reported net losses of $637,100
and $1,747,250, respectively, and negative cash flow from operating activities of $65,165 and $98,687,
respectively. As noted in our financial statements, as of March 31, 2024, we had an accumulated deficit of $24,216,604.
There is substantial doubt regarding our ability to continue as a going concern as a result of our historical recurring losses and
negative cash flows from operations as well as our dependence on private equity and financings. See &ldquo;Risk Factors&mdash;We have
a history of operating losses, our management has concluded that factors raise substantial doubt about our ability to continue as a going
concern and our auditor has included an explanatory paragraph relating to our ability to continue as a going concern in its audit report
for the fiscal years ended December 31, 2023 and 2022. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Resveratrol</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Resveratrol has been studied
for over 50 years by academic institutions as well as by small and large pharmaceutical companies. The multi-functional mechanisms
of resveratrol are well documented in over 9,000 scientific publications. Several of these publications, including a summary
paper by AY Berman.et al, published in Precision Oncology 2017, point to the issue of the poor bioavailability that has
stopped medical utilization of regular resveratrol and never received regulatory approval for any indication. We believe that the
Phase I study we have conducted indicates that we have resolved the poor bioavailability issue with JOTROL&trade;. Resveratrol (3,4&prime;,5-
trihydroxystilbene) is a nutraceutical that has recently attracted a lot of research attention due to its pharmacological potential.
It is a phytoalexin found in many plants including grapes, peanuts, and berries. Resveratrol was first isolated in Veratrum grandiflorum,
or white hellebore plant, in the 1940&rsquo;s. Stilbene compounds are known for their ability to provide plants with resistance to microbial
and fungal infection. Early research showed that resveratrol was present in large quantities in injured, infected, and ultraviolet-treated
leaves. Processed plant products also contain a significant amount of resveratrol.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Based upon available scientific
literature, it appears that resveratrol is an activator of SIRT1, one of the mammalian forms of the sirtuin family of proteins. SIRT1
deacetylates histones and nonhistone proteins including transcription factors. The SIRT1-regulated pathway affects metabolism, stress
resistance, cell survival, cellular senescence, inflammation/immune function, endothelial functions, and circadian rhythms. Resveratrol
has been documented in scientific literature to activate SIRT1, NrF2, NLR3P inflammasomes and have an epigenetic mechanism and therefore
is predicted to benefit diseases affected by abnormal metabolic control, inflammation, and cell cycle defects. Nonetheless, resveratrol
application is a major challenge for the pharmaceutical industry, due to its poor solubility and bioavailability, as well as adverse
effects, such as severe gastro-intestinal side effects when taken at effective dose levels (over 2,000 mg daily). In this context, studies
have proposed that structural changes in the resveratrol molecule, including glycosylation, alkylation, halogenation, hydroxylation,
methylation, and prenylation could lead to the development of derivatives with enhanced bioavailability and pharmacological activity.
Resveratrol has never been developed with all the necessary steps to achieve an approval as a pharmaceutical product since the existing
natural supplements cannot provide high enough levels of resveratrol in blood plasma to be able to provide a therapeutically effective
dose without generating severe gastro-intestinal side effects. This means that we need to take JOTROL&trade; through the full regulatory
NDA (New Drug Application) requirement to obtain a prescription marketing approval in USA. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> Resveratrol holds a significant
place in Traditional Chinese Medicine (TCM) due to its potent antioxidant and anti-inflammatory properties. In TCM, resveratrol-rich
plants, such as the root of Polygonum cuspidatum (commonly known as Hu Zhang), have been used for centuries to treat a variety of ailments.
The compound is prized for its ability to combat oxidative stress and inflammation, which are underlying factors in many chronic diseases.
This aligns with the TCM principle of restoring balance and harmony within the body to maintain health and prevent disease. Resveratrol&rsquo;s
role in TCM extends to supporting cardiovascular health, boosting immune function, and even exhibiting anti-aging properties, making
it a versatile and valuable component of the medicinal repertoire. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> The growing body of scientific
research on resveratrol has further cemented its importance in TCM by providing a modern understanding of its mechanisms and potential
therapeutic benefits. Studies have shown that resveratrol can modulate various molecular pathways, including those involved in cell survival,
apoptosis, and inflammation, which are crucial in the management of conditions such as cardiovascular diseases, neurodegenerative disorders,
and cancers. This scientific validation supports TCM practitioners in integrating resveratrol into their treatment protocols, enhancing
the credibility and acceptance of traditional remedies. Additionally, the compound&rsquo;s ability to improve metabolic health and its neuroprotective
effects are particularly relevant in addressing the rising prevalence of metabolic syndrome and cognitive decline in aging populations.
As research continues to unveil the full spectrum of resveratrol&rsquo;s benefits, its integration into TCM practices is likely to increase,
further bridging the gap between ancient wisdom and contemporary medicine. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> The Traditional Chinese
Medicine (TCM) market is experiencing several technological trends that are transforming how traditional remedies are developed, delivered,
and integrated with modern healthcare practices. These advancements are helping to increase the efficacy, accessibility, and acceptance
of TCM. Below are some of the key technological trends in the TCM market: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-size: 10pt">a.</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-size: 10pt">Digital
                                            platforms and telemedicine services allow patients to consult with TCM practitioners remotely,
                                            expanding access to TCM treatments. </FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-size: 10pt">b.</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-size: 10pt">Apps
                                            are being developed to help users track their health metrics, manage their treatment plans,
                                            and access personalized TCM advice. </FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-size: 10pt">c.</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-size: 10pt">Using
                                            advanced extraction techniques to concentrate active ingredients from traditional herbs,
                                            resulting in more potent and consistent products. </FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-size: 10pt">d.</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-size: 10pt">Development
                                            of new delivery methods such as transdermal patches, sustained-release capsules, and nanoparticles
                                            to enhance the bioavailability and efficacy of TCM products. </FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> (source Emergn Research,
Global TCM Market, Forecast to 2033). </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JOTROL</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">JOTROL was developed together
with our technology partner Aquanova AG, Darmstadt, Germany. JOTROL is formulated with a unique patented micellar technology
that is projected to increase the bioavailability profile of resveratrol. Manufacturing technology transfers were completed in 2017 and
manufacturing procedures and clinical trial supply manufacturing has been completed at Catalent Pharmaceutical Services, Inc., St Petersburg,
Florida.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">JOTROL is a micellar non-aqueous
solution of resveratrol delivered in a softgel capsule. Each capsule includes 100mg of resveratrol. Pre-clinical trials in mice
and rats were conducted comparing JOTROL&trade; to micronized resveratrol, labeled to have the highest bioavailability in the nutritional
market, to demonstrate that we could achieve a significantly higher bioavailability. Summary details of these studies are included
in the section &ldquo;Description of Business&rdquo;. A Phase I dose finding pharmacokinetic (&ldquo;PK&rdquo;) study in healthy
volunteers was completed during the first half of 2021. The study results met our targeted goals. The results from this study
will be used as a cross-reference for all indications where JOTROL will be used in Phase II and Phase III clinical trials. The
Phase I results and the FDA guidance of cross-referencing is further described in the section &ldquo;Description of Business&rdquo;.
The Company has not discussed the use of cross-referencing in this manner with the FDA or other comparable regulatory authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JOTROL
Intellectual Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a worldwide license, from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell
JOTROL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    CSO, Marshall Hayward and the lead scientist at Aquanova AG, Darius Benham, are the inventors of JOTROL. The patent is
    owned jointly by Aquanova AG and the Company. The application was assigned to Aquanova AG per an executed agreement between Aquanova
    AG and the Company. See additional information in the section titled &ldquo;Description of Business&rdquo;.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aquanova
    AG, a German company, filed an international patent application in Germany on January 29, 2017 entitled &ldquo;Resveratrol
    solubilization product for pharmaceutical purposes&rdquo; (PCT/EP2017/O51659).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    priority date is June 16, 2016 with expiration in 2036 which expiration applies to all territories where that patent is approved.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This patent has been granted in the USA, specific
European countries namely: France, United Kingdom, Switzerland, Italy, Belgium, Netherlands, Ireland, Spain, Sweden, Turkey, Poland,
Denmark, Greece, Hungary and Germany, Japan, Hong Kong and China.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For further details, including patented claims
and payment terms, see the section &ldquo;Description of Business&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Material Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has entered into several material agreements,
including the exclusive, worldwide license, from Aquanova AG to develop, manufacture, distribute and sell JOTROL for the company&rsquo;s
presently only product. Other material agreements have been executed with other entities such as Murdoch Children&rsquo;s Research Institute,
Melbourne Australia and with the National Institute on Aging. We have recently agreed to service agreements for development of our
product in the South-East Asian territory. The agreements are with 3 contracted companies that will handle CMC (Chemistry, Manufacturing,
and Controls), regulatory affairs and clinical trial management. These agreements, which are similar to what we do in the USA, are further
described in the section &ldquo;Other Material Agreements&rdquo;. In addition, we are in active negotiations with Dominant Treasure Health (&ldquo;DTH&rdquo;), a BVI company. DTH has demonstrated to us, through several company introductions, that they have business relationships, either directly or through affiliates, with many South-East Asian pharmaceutical companies as well as companies involved
in distribution and sales of TCM, Traditional Chinese Medicine. We are therefore planning to engage DTH in active business development
in China, Malaysia and Singapore as soon as we have financing in place for their engagement. DTH has already introduced us to 3 Chinese
companies, Beimei Pharma, http://en.beimeiyaoye.com, that specializes in pediatric medications, Sichuan Kelun Pharmaceutical Co., ltd,
a publicly traded company that is part of the Kelun Industrial Group, https://www.kelun.com/, and Tianjin Pharmaceuticals, https://en.pharm.com.cn/,
that advocates the corporate core values of &ldquo;Love, Integrity and Power&rdquo;. TCM products are run in a separate division within
Tianjin. Discussions with all three companies are ongoing. We believe that with DTH&rsquo;s assistance we can co-ordinate and oversee
the work of our Service providers in the territory and more expediently negotiate and finalize an out-license agreement with one or more
pharmaceutical companies in South-East Asia. The Asian market is
very large and hard to penetrate for a small company and we believe that our strategy with these agreements is very cost effective and
have the possibility to accelerate an out-licensing deal in the South-East Asian territories. However, there are no assurances that this
approach will be successful. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Product
Development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our management, Scientific Board
of Advisors and business advisors have extensive experience in regulatory affairs and clinical development of product candidates for
the treatment of rare diseases and Alzheimer&rsquo;s disease. The overall regulatory approval process for product candidates for the
treatment of rare diseases are generally conducted with a smaller number of patients in clinical trials and over a shorter amount
of time than more prevalent diseases. There is a documented pathway to get accelerated FDA approval for a rare disease indication
if there is no existing treatment for the indication, if a product shows efficacy and has a good safety profile. There is also a possibility
of receiving a Priority Review Voucher (PRV) from the FDA upon an approval in pediatric population in a rare disease. One or more of
our programs, such as MPS-I, will be targeting pediatric patients. The voucher entitles the bearer to regulatory review in about six
months rather than the standard ten months. The Food and Drug Administration (FDA) awards a voucher following approval of a treatment
for a neglected disease, rare pediatric disease, or medical countermeasure. Two drugs can receive priority review for each voucher: the
drug winning a voucher for a neglected or rare pediatric disease, and the drug using a voucher for another indication. The voucher may
be sold. For example, a small company might win a voucher for developing a drug for a neglected disease and sell the voucher to a large
company for use on a commercial disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company also plans to
investigate the possibility the use of one or more of the following pathways for the indications that it is targeting: (1) Priority
Review (2) Fast Track (3) Accelerated Approval Pathway and (4) Breakthrough therapy. For detailed descriptions of the foregoing
pathways please see the discussion under &ldquo;Product Development&rdquo; in the section titled &ldquo;Description of
Business&rdquo;. There is however no guarantee that an accelerated pathway will lead to an accelerated FDA review and that a
pediatric approval leads to a PRV. Additionally, there can be no guarantee that the Company can be successful in its plans under any
FDA pathway.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have received quotes from
clinical research organizations (&ldquo;CROs&rdquo;) for Phase II trials in MPS I and Friedreich&rsquo;s ataxia ranging from $2 million
to $5 million per study. Alzheimer&rsquo;s disease trials are larger and more complex with higher associated costs, we
have received quotes ranging between approximately $12 million to $20 million for a Phase II study but we
have not received any quotes for a small and shorter-term Proof-Of-Concept (&ldquo;POC&rdquo;) study in MCI/early-AD patients. We
have not received any quotes for a short POC study in Parkinson&rsquo;s disease either, but we have initiated discussions with the
Michael J. Fox Foundation for possible partial funding of the study. There is no assurance that such funding will be obtained.
We believe that with positive Phase II results, in any of the indications, we may be able to garner strategic partnering
interest for financing of larger Phase III trials. We also intend to seek collaborations with future licensees and marketing
partners, especially in markets outside the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Product Pipeline</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="forms-1a_026.jpg" ALT="" STYLE="height: 177px; width: 639px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The product pipeline represented above assume drawing
upon previous preclinical and clinical data conducted by third parties. This data is available either via public domain or under agreements
with our key partner which are further described in the section titled &ldquo;Description of Business&rdquo;. However, we have not discussed
with the FDA the ability to rely on and reference the data from previous third-party trials, such as the Phase II trial in MCI/Early
Alzheimer&rsquo;s disease conducted by Georgetown University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below provides a historical development timeline:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Product
Development and Commercialization Timelines</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 56%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Milestone</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Target
    Start Date</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 24%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Target
    Completion Date</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identified
    key issue with resveratrol, poor bioavailability, and investigated possible solutions.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Q3
    2015</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completed</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Worldwide
    exclusive agreement with Aquanova AG, Germany, for patented micellar technology.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Q3
    2016</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completed</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
    applications submitted in 2016 and patents have subsequently been issued in USA, in certain European countries, Japan, China
    and Hong Kong.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Q2
    2016</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completed</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-clinical
    studies comparing JOTROL with conventional resveratrol, see section &ldquo;Description of Business&rdquo;.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Q1
    2017</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completed</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Technology
    and data transfer agreement with Murdoch Children&rsquo;s Research Institute, Melbourne, Australia regarding research results and
    information related to Friedreich&rsquo;s Ataxia</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Q3
    2015</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completed</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Technology
    transfer from Aquanova, CMC documentation, and clinical trial supplies manufactured (Catalent)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Q1
    2017</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completed</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orphan
    Drug Designations (&ldquo;ODD&rdquo;) submitted to FDA and ODD received for Friedreich&rsquo;s ataxia</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Q3
    2016</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completed</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Resveratrol
    toxicity study received from major pharmaceutical company</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Q3
    2017</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completed</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human
    bioavailability POC study with JOTROL</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Q3
    2017</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completed</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NIA
    grant application for Phase I study submitted and scientific review triggered full financing, $1.76 million.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Q3
    2019</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completed</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    I study in healthy volunteers initiated in December 2020 and in-man phase concluded in March 2021</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Q3
    2020</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completed</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Pre-clinical mice trial in Parkinson&rsquo;s Disease. </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> Q1 2021 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> Completed </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re-submission
    of</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> NIA grant application for MCI </FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Q4
    2023</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> Completed </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
further information on our business and product detail, see &ldquo;Description of Business&rdquo; section.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For a detailed description of recent developments
of the Company, see &ldquo;Description of Business&mdash;Recent Developments&rdquo; on page 116 of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to execute on our business strategy is subject to a number of risks, which are discussed more fully in the section titled &ldquo;Risk
Factors&rdquo; beginning on page 16. You should carefully consider these risks before making an investment in our common stock. These
risks include, among others, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are early in our development efforts, with a limited operating history, and have no products approved for commercial sale.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have not generated any revenue from product sales to date, have incurred significant net losses since our inception, and expect to
    continue to incur significant net losses for the foreseeable future.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    ability to generate revenue and achieve profitability depends significantly on our ability to achieve several objectives relating
    to the discovery, development and commercialization of our product candidate.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if this offering is successful, we will require substantial additional capital to finance our operations.</FONT></TD></TR>

  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Our substantial amount of indebtedness may adversely affect our
    cash flow and our ability to operate our business, remain in compliance with debt covenants and make payments on our indebtedness.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Our outstanding Secured Note provides our Secured Lender with liens
    on substantially all of our assets, including our intellectual property, and contains financial covenants and other restrictions
    on our actions, which may cause significant risks to our stockholders and may impact our ability to pursue certain transactions and
    operate our business</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are substantially dependent on the success of our product candidate, JOTROL. If we are unable to complete development of,
    obtain approval for and commercialize JOTROL for one or more indications in a timely manner, our business will be harmed.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Our prospects depend upon
    developing product candidate JOTROL for particular indications and possibly discovering, developing other product candidates
    in future programs.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Clinical drug development involves a lengthy and expensive process
    with an uncertain outcome. The clinical trials of our product candidate JOTROL may not demonstrate safety and efficacy to
    the satisfaction of the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) or other comparable foreign regulatory
    authorities or otherwise produce positive results and the results of preclinical studies and early clinical trials may not be predictive
    of future results.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">We have limited resources and are currently focusing the majority of
    our efforts on developing JOTROL for particular indications. As a result, we may fail to capitalize on other indications or
    product candidates that may ultimately have proven to be more profitable.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">We are planning on entering into a Service Agreement with DOMINANT TREASURE HEALTH COMPANY
    LIMITED with respect to strategic services in Asia immediately following the completion of the public offering, the fees payable
    by the Company pursuant to which, are non-refundable and not tied to any milestones or performance, and the foregoing nature of such
    fees, could have a material negative impact on our business, financial condition and operating results.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">We face significant competition, and if our competitors develop and
    market technologies or products more rapidly than we do or that are more effective, safer or less expensive than the product candidates
    we develop, our commercial opportunities will be negatively impacted. In particular, we face competition for patients with MPS-I,
    Friedreich&rsquo;s ataxia, MELAS, Parkinson&rsquo;s Disease, Mild Cognitive Impairment, and early Alzheimer&rsquo;s disease
    from companies that produce drugs to treat such diseases. For more information regarding competition we face, see the section titled
    &ldquo;Business&thinsp;&mdash;&thinsp;Competition.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">We rely on third parties to conduct our preclinical studies, clinical
    trials, and manufacturing and these third parties may not perform satisfactorily.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">If we engage in future acquisitions or strategic partnerships, this
    may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject
    us to other risks. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">We rely on our management team and other key employees, and the
    loss of one or more key employees could harm our business.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">The failure to attract and retain additional qualified personnel
    could prevent us from executing our business strategy.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Once our common stock is
    listed on Nasdaq Capital Market, there can be no assurance that we will be able to comply with Nasdaq Capital Market&rsquo;s
    continued listing standards.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    price of our common stock could be subject to rapid and substantial volatility. As a relatively small-capitalization company with relatively small public
float, we may experience greater stock price volatility, extreme price run-ups, lower trading volume and less liquidity than large-capitalization
companies. Such volatility, including any stock-run up, may be unrelated to our actual or expected operating performance and financial
condition or prospects, making it difficult for prospective investors to assess the rapidly changing value of our common stock. In addition,
if the trading volumes of our common stock are low, persons buying or selling in relatively small quantities may easily influence prices
of our common stock. This low volume of trades could also cause the price of our common stock to fluctuate greatly, with large percentage
changes in price occurring in any trading day session. Holders of our common stock may also not be able to readily liquidate their investment
or may be forced to sell at depressed prices due to low volume trading.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> &#9679; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> As a result of the resale of shares of common stock
    by Selling Stockholders being a large volume of shares and potentially at different pricing after the initial fixed price, there
    is a potential for price volatility or depreciation for investors in the initial public offering </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management has concluded that our historical recurring losses from operations and negative cash flows from operations as well as our
dependence on securing private equity and other financings raise substantial doubt about our ability to continue as a going concern and
our auditor has included an explanatory paragraph relating to our ability to continue as a going concern in its audit reports for the
fiscal years ended December 31, 2023 and 2022. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Implications
of Being an Emerging Growth Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a company with less than $1.235 billion in revenues during our last fiscal year, we qualify as an emerging growth company as defined
in the Jumpstart Our Business Startups Act, or the JOBS Act, enacted in 2012. As an emerging growth company, we expect to take advantage
of reduced reporting requirements that are otherwise applicable to public companies. These provisions include, but are not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">being
    permitted to present only two years of audited financial statements, in addition to any required unaudited interim financial statements,
    with correspondingly reduced &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo;
    disclosure in this prospectus; </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
    being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended;
    </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced
    disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exemptions
    from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute
    payments not previously approved.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may use these provisions until the last day of our fiscal year following the fifth anniversary of the completion of this offering. However,
if certain events occur prior to the end of such five-year period, including if we become a &ldquo;large accelerated filer,&rdquo; our
annual gross revenues exceed $1.235 billion or we issue more than $1.00 billion of non-convertible debt in any three-year
period, we will cease to be an emerging growth company prior to the end of such five-year period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
an emerging growth company, we intend to take advantage of an extended transition period for complying with new or revised accounting
standards as permitted by The JOBS Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that we continue to qualify as a &ldquo;smaller reporting company,&rdquo; as such term is defined in Rule 12b-2 under the
Securities Exchange Act of 1934, as amended, after we cease to qualify as an emerging growth company, certain of the exemptions available
to us as an emerging growth company may continue to be available to us as a smaller reporting company, including: (i) not being required
to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes Oxley Act; (ii) scaled executive compensation disclosures;
and (iii) the requirement to provide only two years of audited financial statements, instead of three years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently incorporated and in good standing in the State of Delaware. Our principal executive offices are located at 1001 North US
Hwy 1, Suite 504, Jupiter, Florida 33477, and our telephone number is (561) 406-6154. Our website address is www.jupiterneurosciences.com.
The information contained on our website is not incorporated by reference into this prospectus, and you should not consider any information
contained on, or that can be accessed through, our website as part of this prospectus or in deciding whether to purchase our common shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Stock Splits </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 25, 2022, our board
of directors and shareholders holding a majority of the voting power of our issued and outstanding voting capital stock approved the
reverse stock split in a ratio of 1-for-2. On January 25, 2022, we filed a certificate of amendment to our Certificate of Incorporation,
as amended (the &ldquo;Certificate of Incorporation&rdquo;), implementing the reverse stock split in a ratio of 1-for-2, effective January
25, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> On June 13, 2024, our
board of directors and shareholders holding a majority of the voting power of our issued and outstanding voting capital stock
approved the forward stock split in a ratio of 15-for-4. On June 14, 2024, we filed a certificate of amendment to our Certificate of
Incorporation, as amended (the &ldquo;Certificate of Incorporation&rdquo;), implementing the stock split in a ratio of 15-for-4,
effective June 14, 2024. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Except as otherwise indicated,
all references to our common stock, share data, per share data and related information has been adjusted for the reverse stock split
ratio of 1-for-2 (&ldquo;Reverse Stock Split&rdquo;) and the subsequent stock split ratio of 15-for-4 (the &ldquo;2024 Forward Stock
Split&rdquo;) as if they had occurred at the beginning of the earliest period presented. The Reverse Stock Split and the
2024 Forward Stock Split, combined each two shares of our outstanding common stock into one share of common stock and then subsequently
split each four shares of our outstanding common stock into fifteen shares of common stock, each without any change in the par value
per share, and the Reverse Stock Split and the 2024 Forward Stock Split correspondingly adjusted, among other things, the exercise
rate of our warrants into our common stock. No fractional shares were issued in connection with the Reverse Stock Split or the 2024
Forward Stock Split, and any fractional shares resulting from the Reverse Stock Split, or the 2024 Forward Stock Split
were rounded up to the nearest whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
    Offering</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 38%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuer:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 60%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter
    Neurosciences, Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
    offered by us: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> 2,750,000
                                            shares of common stock.</P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
    Offering Price:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> We
                                            expect the initial public offering price to be between $4.00 and $5.00 per share. For
                                            purposes of this prospectus, the assumed initial public offering price per share is $4.00,
                                            the low-end of the anticipated public offering price range. The actual offering price
                                            per share will be as determined between the representative and us based on market conditions
                                            at the time of pricing. Therefore, the assumed public offering price used throughout this
                                            prospectus may not be indicative of the final offering price<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT> </P></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 38%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock outstanding before this offering:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 60%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30,126,413
shares of common stock (1)</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock to be outstanding after this offering: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> 32,876,413
                                            shares of common stock</P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital
    stock</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    common stock is common equity and contains no preferences as to other classes of our capital stock. Each share of our common stock
    entitles the holder to one vote on all matters submitted to the vote of the stockholders, including the election of directors. Our
    preferred stock is &ldquo;blank check&rdquo; preferred stock whereby the Board of Directors has authority to determine the powers,
    preferences, rights, qualifications, limitations and restrictions without separate shareholder approval.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 38%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Use of proceeds:</P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    expect to receive net proceeds from this offering of approximately $9,515,000 after deducting estimated underwriting
    discounts and commissions (7% of the gross proceeds of the offering) and after our offering expenses, estimated at $715,000.
    We intend to use a portion of the net proceeds from this offering to repay up to $2,100,000 of principal and estimated
    accrued interest outstanding on the senior secured note issued by the Company to an investor and up to $325,000 to repay the
    related-party notes payable and the Tiberend Convertible Note. We intend to use the balance of the net proceeds from this
    offering as follows: (i) approximately $250,000 to fund R&amp;D activities regarding evaluation of new product
    opportunities; (ii) approximately $150,000 to pay the outstanding annual license fees due to Aquanova AG;
    (iii) approximately $2,300,000 to fund a Proof-of-Concept (Phase I B or Phase II A) clinical trial of our
    product candidate JOTROL in patients with Parkinson&rsquo;s Disease; (iv) $2,300,000 will be allocated for  Service
    Agreements to accelerate business opportunities in South-East Asia; and (v) the remaining for working capital and other general
    corporate purposes. See &ldquo;Use of Proceeds.&rdquo;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk factors:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See &ldquo;Risk
    Factors&rdquo; beginning on page 16 of this prospectus for a discussion of some of the factors you should carefully consider before
    deciding to invest in our common stock.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Listing:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">We have applied to list our common stock on the
    Nasdaq Capital Market under the symbol &ldquo;JUNS.&rdquo; The approval of our listing on the Nasdaq Capital Market is a condition
    of closing this offering.</P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lock-Ups:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    and our directors, officers and shareholders, except for the selling stockholders named in the resale prospectus also forming
    part of this registration statement, have agreed with the Representatives not to offer for sale, issue, sell, contract to sell,
    pledge or otherwise dispose of any of our common stock or securities convertible into common stock for a period of 180 days after
    the date of this prospectus. The underwriters have agreed to waive the lock-up requirement for shares of common stock being sold
    by the selling stockholders named in the resale prospectus also filed as part of this registration statement. See &ldquo;Underwriting&mdash;Lock-Up
    Agreements.&rdquo;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend policy: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We do not anticipate declaring or paying any cash dividends on our common stock following our public offering. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Stock Splits: </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">On January 25, 2022, we obtained approval of our board of directors and shareholders holding a majority of the voting power of our issued and outstanding voting capital stock to conduct a reverse stock split in a ratio of 1-for-2. On January 25, 2022, we filed a certificate of amendment to our Certificate of Incorporation, as amended (the &ldquo;Certificate of Incorporation&rdquo;), implementing the reverse stock split in a ratio of 1-for-2, effective January 25, 2022. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
                                    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> On
                                    June 13, 2024, our board of directors and shareholders holding a majority of the voting power of
                                    our issued and outstanding voting capital stock approved the forward stock split in a ratio of 15-for-4.
                                    On June 14, 2024, we filed a certificate of amendment to our Certificate of Incorporation, as amended
                                    (the &ldquo;Certificate of Incorporation&rdquo;), implementing the stock split in a ratio of 15-for-4,
                                    effective June 14, 2024. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
                                    as otherwise indicated, all references to our common stock, share data, per share data and related
                                    information has been adjusted for the reverse stock split ratio of 1-for-2 (&ldquo;Reverse Stock
                                    Split&rdquo;) and the stock split ratio of 15-for-4 (&ldquo;2024 Forward Stock Split&rdquo;)
                                    as if it had occurred at the beginning of the earliest period presented.</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
    we indicate otherwise, all information in this prospectus:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">give pro forma effect to the Reverse Stock Split and
    the 2024 Forward Stock Split of our outstanding shares of common stock, options and warrants and the corresponding adjustment
    of all common stock price per share and stock option and warrant exercise price data, except for the financial statements and the
    notes thereto;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">is based on 30,126,413  shares of common stock and
    1,626,045 restricted stock units issued and outstanding as of July 12, 2024; </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">excludes
    10,634,107 shares of our common stock issuable upon exercise of outstanding options at a weighted average exercise price of $1.03
    per share as of July 12, 2024;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">excludes
    1,359,375 shares of our common stock issuable upon exercise of outstanding warrants at a weighted average exercise price of $0.80
    per share as of July 12, 2024; and</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">excludes
    approximately 219,555 shares of our common stock issuable upon the conversion of our issued and outstanding convertible notes at
    an average conversion price of $2.80 (70% of the assumed initial public offering price of $4.00).</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SELECTED
HISTORICAL FINANCIAL DATA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table presents
our selected historical financial data for the periods indicated. The selected historical financial data for the years ended December
31, 2023 and 2022 and the balance sheet data as of December 31, 2023 and 2022 are derived from the audited financial statements.
The summary historical financial data for the three months ended March 31, 2024 and 2023 and the balance sheet data as
of March 31, 2024 and March 31, 2023 are derived from our unaudited financial statements.&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historical
results are included for illustrative and informational purposes only and are not necessarily indicative of results we expect in future
periods, and results of interim periods are not necessarily indicative of results for the entire year. The data presented below should
be read in conjunction with, and are qualified in their entirety by reference to, &ldquo;Management&rsquo;s Discussion and Analysis of
Financial Condition and Results of Operations&rdquo; and our financial statements and the notes thereto included elsewhere in this prospectus.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three
    Months Ended</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,<BR>
    2023</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,<BR>
    2022</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    31,<BR>
    2024</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    31,<BR>
    2023</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(unaudited)</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statement
    of Operations Data</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant
    and other revenue</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">233,281</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    expenses</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">954,793</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">942,806</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">98,667</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">267,409</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,915,978</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,722,922</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">472,028</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">780,070</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    operating expenses</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,870,771</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,665,728</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">570,695</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,047,479</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss from
    operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,870,771</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,432,447</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(570,695</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,047,479</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    other income (expense)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(912,918</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,525,133</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(63,405</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(699,771</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income (loss)
    before provision for taxes</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,783,689</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,957,580</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(634,100</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,747,250</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
    tax provisions</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    income (loss)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,783,689</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,957,580</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(634,100</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,747,250</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
    and diluted net loss per share</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.18</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.20</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.02</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.07</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    Sheet Data (at period end)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,478</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">64,431</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,313</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,744</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Working capital
    (deficit) (1)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,743,166</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,190,821</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,962,608</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,484,833</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total assets</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">148,592</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">235,944</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">116,820</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">173,866</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total liabilities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,949,946</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,380,028</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,133,957</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,658,699</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders&rsquo;
    equity (deficit)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,801,354</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,144,084</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,020,137</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,484,833</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT> </TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Working
    capital represents total current assets less total current liabilities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="pp_005"></A>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>An
investment in our securities carries a significant degree of risk. You should carefully consider the following risks, as well as the
other information contained in this prospectus, including our historical financial statements and related notes included elsewhere in
this prospectus, before you decide to purchase our securities. Any one of these risks and uncertainties has the potential to cause material
adverse effects on our business, prospects, financial condition and operating results which could cause actual results to differ materially
from any forward-looking statements expressed by us and a significant decrease in the value of our common stock. Refer to &ldquo;Cautionary
Statement Regarding Forward-Looking Statements.&rdquo;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>We
may not be successful in preventing the material adverse effects that any of the following risks and uncertainties may cause. These potential
risks and uncertainties may not be a complete list of the risks and uncertainties facing us. There may be additional risks and uncertainties
that we are presently unaware of, or presently consider immaterial, that may become material in the future and have a material adverse
effect on us. You could lose all or a significant portion of your investment due to any of these risks and uncertainties.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is a summary of material risks, uncertainties and other factors that could have a material effect on the Company and its operations:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are early in our development efforts, with a limited operating history, and have no products approved for commercial sale.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have not generated any revenue from product sales to date, have incurred significant net losses since our inception, and expect to
    continue to incur significant net losses for the foreseeable future.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    ability to generate revenue and achieve profitability depends significantly on our ability to achieve several objectives relating
    to the discovery, development and commercialization of our product candidate.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if this offering is successful, we will require substantial additional capital to finance our operations.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    substantial amount of indebtedness may adversely affect our cash flow and our ability to operate our business, remain in compliance
    with debt covenants and make payments on our indebtedness.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    outstanding Secured Note provides our Secured Lender with liens on substantially all of our assets, including our intellectual property,
    and contains financial covenants and other restrictions on our actions, which may cause significant risks to our stockholders and
    may impact our ability to pursue certain transactions and operate our business.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are substantially dependent on the success of our product candidate, JOTROL. If we are unable to complete development of,
    obtain approval for and commercialize JOTROL for one or more indications in a timely manner, our business will be harmed.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Our prospects depend upon
    developing product candidate JOTROL for particular indications and possibly discovering, developing other product candidates
    in future programs.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Clinical drug development involves a lengthy and expensive process
    with an uncertain outcome. The clinical trials of our product candidate JOTROL may not demonstrate safety and efficacy to
    the satisfaction of the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) or other comparable foreign regulatory
    authorities or otherwise produce positive results and the results of preclinical studies and early clinical trials may not be predictive
    of future results.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">We have limited resources and are currently focusing the majority of
    our efforts on developing JOTROL for particular indications. As a result, we may fail to capitalize on other indications or
    product candidates that may ultimately have proven to be more profitable.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">We face significant competition, and if our competitors develop and
    market technologies or products more rapidly than we do or that are more effective, safer or less expensive than the product candidates
    we develop, our commercial opportunities will be negatively impacted. In particular, we face competition for patients with MPS-I,
    Friedreich&rsquo;s ataxia, MELAS, Parkinson&rsquo;s Disease, Mild Cognitive Impairment, and early Alzheimer&rsquo;s disease
    from companies that produce drugs to treat such diseases. For more information regarding competition we face, see the section titled
    &ldquo;Business&thinsp;&mdash;&thinsp;Competition.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">We rely on third parties to conduct our preclinical studies, clinical
    trials, and manufacturing and these third parties may not perform satisfactorily.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">If we engage in future acquisitions or strategic partnerships, this
    may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject
    us to other risks. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">We rely on our management team and other key employees, and the
    loss of one or more key employees could harm our business.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">The failure to attract and retain additional qualified personnel
    could prevent us from executing our business strategy.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
    our common stock is listed on Nasdaq Capital Market, there can be no assurance that we will be able to comply with Nasdaq Capital
    Market&rsquo;s continued listing standards.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    price of our common stock could be subject to rapid and substantial volatility. As a relatively small-capitalization company with relatively small public float, we may experience greater stock price volatility, extreme
price run-ups, lower trading volume and less liquidity than large-capitalization companies. Such volatility, including any stock-run up,
may be unrelated to our actual or expected operating performance and financial condition or prospects, making it difficult for prospective
investors to assess the rapidly changing value of our common stock. In addition, if the trading volumes of our common stock are low, persons
buying or selling in relatively small quantities may easily influence prices of our common stock. This low volume of trades could also
cause the price of our common stock to fluctuate greatly, with large percentage changes in price occurring in any trading day session.
Holders of our common stock may also not be able to readily liquidate their investment or may be forced to sell at depressed prices due
to low volume trading.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> &#9679; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> As a result of the resale of shares of common stock
    by Selling Stockholders being a large volume of shares and potentially at different pricing after the initial fixed price, there
    is a potential for price volatility or depreciation for investors in the initial public offering </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Financial Position, Need for Additional Capital and Limited Operating History</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are early in our development efforts, with a limited operating history, and we have no products approved for commercial sale, which may
make it difficult for you to evaluate our current business and likelihood of success and future viability.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an early clinical stage pharmaceutical company with a limited operating history upon which you can evaluate our business and prospects.
We are developing one medication to treat rare diseases (MPS I, Friedreich&rsquo;s ataxia, and MELAS) as well as larger indications,
Parkinson&rsquo;s Disease and Mild Cognitive Impairment / early Alzheimer&rsquo;s disease, which is an unproven and
highly uncertain undertaking and involves a substantial degree of risk. We commenced operations in January 2016, have no products approved
for commercial sale and have not generated any revenue. We initiated and completed our Phase I clinical trial for our sole product candidate,
JOTROL, in March 2021. Since our inception in 2016, we have devoted substantially all of our focus and financial resources to
discovering, identifying and developing our product candidate, JOTROL, including advancing our development program, conducting
a preclinical study of our product candidate and initiating a clinical trial, organizing and staffing our company, business planning,
raising capital and securing related intellectual property rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not yet demonstrated our ability to successfully complete efficacy clinical trials that can lead to a New Drug Application (&ldquo;NDA&rdquo;)
submission, obtain marketing approvals, manufacture a commercial-scale product, or obtain a proposal for any out-licensing or distribution
agreements. As a result, it may be more difficult for investors to accurately predict our likelihood of success and viability than it
could be if we had a longer operating history.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors and risks frequently
experienced by clinical-stage biopharmaceutical companies in rapidly evolving fields. We also may need to transition from a company with
a research and development focus to a company capable of supporting commercial activities. We have not yet demonstrated an ability to
successfully overcome such risks and difficulties, or to make such a transition. If we do not adequately address these risks and difficulties
or successfully make such a transition, our business will suffer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have not generated any revenue from product sales to date, have incurred significant net losses since our inception, and expect to continue
to incur significant net losses for the foreseeable future.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have any products approved for sale, and consequently we have not generated any revenue. We have incurred significant net losses
since our inception and have financed our operations principally through private placements of our common stock. To date, we have not
been profitable and have incurred significant losses and cash flow deficits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For the fiscal years ended December
31, 2023 and 2022, we generated no revenues from product sales and reported net losses of $4,783,689 and $4,957,580 respectively,
and negative cash flow from operating activities of $480,953 and $1,248,504, respectively. For the three months ended March
31, 2024 and 2023, we generated no revenues from product sales and reported net losses of $637,100 and $1,747,250, respectively,
and negative cash flow from operating activities of $65,165 and $98,687, respectively. As noted in our financial statements,
as of March 31, 2024, we had an accumulated deficit of $24,216,604. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
sole product candidate, JOTROL, recently completed Phase I clinical trial that commenced in December 2020. As a result, we expect
that it will be several years, if ever, before we receive approval to commercialize our product and generate revenue from product sales.
Even if we succeed in receiving marketing approval for and commercializing of our approved product candidate, we expect that we will
continue to incur substantial research and development and other expenses in order to discover, develop and market additional potential
products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. The net losses we incur
may fluctuate significantly from quarter to quarter such that a period-to-period comparison of our results of operations may not be a
good indication of our future performance, particularly since we expect our expenses to increase if and when our product candidate progresses
through clinical development as a product candidate in later stages of clinical development generally have higher development costs than
those in earlier stages, primarily due to the increased size and duration of later-stage clinical trials. The size of our future net
losses will depend, in part, on the rate of future growth of our expenses and our ability to have our product candidates approved
for marketing and to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse
effect on our working capital, our ability to fund the development of our product candidate and our ability to achieve and maintain profitability
and the performance of our stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
management has concluded that factors raise substantial doubt about our ability to continue as a going concern and our auditor has included
an explanatory paragraph relating to our ability to continue as a going concern in its audit report for the fiscal years ended December
31, 2023 and 2022. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management has concluded that our historical recurring losses from operations and negative cash flows from operations as well as our
dependence on private equity and other financings raise substantial doubt about our ability to continue as a going concern and our auditor
has included an explanatory paragraph relating to our ability to continue as a going concern in its audit report for the fiscal year
ended December 31, 2023 and 2022. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
financial statements do not include any adjustments that might result from the outcome of this uncertainty. These adjustments would likely
include substantial impairment of the carrying amount of our assets and potential contingent liabilities that may arise if we are unable
to fulfill various operational commitments. In addition, the value of our securities, including common stock issued in this offering,
would be greatly impaired. Our ability to continue as a going concern is dependent upon generating sufficient cash flow from operations
and obtaining additional capital and financing, including funds to be raised in this offering. If our ability to generate cash flow from
operations is delayed or reduced and we are unable to raise additional funding from other sources, we may be unable to continue in business
even if this offering is successful. For further discussion about our ability to continue as a going concern and our plan for future
liquidity, see &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&mdash;Ability to Continue
as a Going Concern.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
ability to generate revenue and achieve profitability depends significantly on our ability to achieve several objectives relating to
the discovery, development and commercialization of our product candidates, if approved.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business depends entirely on the successful discovery, development, regulatory approval and commercialization of product candidates.
We have no products approved for commercial sale and do not anticipate generating any revenue from product sales for the next several
years, if ever. Our ability to generate revenue and achieve profitability depends significantly on our ability, or any future collaborator&rsquo;s
ability, to achieve several objectives, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful
    and timely completion of clinical development of JOTROL research program, and our other future product candidates and programs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    and maintaining relationships with CROs and clinical sites for the clinical development of JOTROL and any other future product
    candidates and programs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    initiation and successful patient enrollment and completion of additional clinical trials on a timely basis;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptable
    frequency and severity of adverse events in the clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    efficacy and safety profiles that are satisfactory to the U.S. Food and Drug Administration (FDA) or any comparable foreign regulatory
    authority for marketing approval;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">timely
    receipt of marketing approvals from applicable regulatory authorities for any product candidates for which we successfully complete
    clinical development;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">complying
    with any required post-marketing approval commitments to applicable regulatory authorities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
    an efficient and scalable manufacturing process for our product candidates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    and maintaining commercially viable supply and manufacturing relationships with third parties that can provide adequate, in both
    amount and quality, products and services to support clinical development and meet the market demand for our product candidate, if
    approved;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful
    commercial launch following any marketing approval, including the development of a commercial infrastructure, whether in-house or
    with one or more collaborators;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    continued acceptable safety profile following any marketing approval of our product candidate;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">commercial
    acceptance of our product candidate by patients, the medical community and third-party payors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfying
    any required post-marketing approval commitments to applicable regulatory authorities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying,
    assessing and developing new product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining,
    maintaining and expanding patent protection, trade secret protection and regulatory exclusivity, both in the United States and internationally;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">protecting
    our rights in our intellectual property portfolio;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">defending
    against third-party infringement claims, if any;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">entering
    into, on favorable terms, any collaboration, licensing or other arrangements that may be necessary or desirable to develop, manufacture
    or commercialize our product candidate;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    coverage and adequate reimbursement by third-party payors for our products and patients&rsquo; willingness to pay in the absence
    of such coverage and adequate reimbursement;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    additional funding to develop and potentially manufacture and commercialize our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">addressing
    any competing therapies and technological and market developments;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">managing
    costs, including any unforeseen costs, that we may incur as a result of nonclinical study or clinical trial delays; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">attracting,
    hiring and retaining qualified personnel including clinical, scientific, management and administrative personnel.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may never be successful in achieving our objectives and, even if we do, we may never generate revenue that is significant or large
enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly
or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to
maintain or further our research and development efforts, raise additional necessary capital, grow our business and continue our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also experience delays in developing a sustainable, reproducible and scalable manufacturing process or transferring that process
to commercial partners, which may prevent us from completing our clinical trials or commercializing our product candidates on a timely
or profitable basis, if at all. Changes in the manufacturing process or facilities will require further comparability analysis and approval
by the FDA before implementation, which could delay our clinical trials and product candidate development, and could require additional
clinical trials, including bridging studies, to demonstrate consistent and continued safety and efficacy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if this offering is successful, we will require substantial additional capital to finance our operations. If we are unable to raise such
capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug
development programs or future commercialization efforts.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of July 12, 2024, we had $2,110 in cash. Based on our current operating plan, we believe that the net proceeds from
this offering, together with our existing cash and cash equivalents and grants from NIH, will be sufficient to fund our operations through
at least the next 24 months. Our estimate as to how long we expect the net proceeds from this offering, together with our existing cash
and cash equivalents, to be able to continue to fund our operations is based on assumptions that may prove to be wrong, and we could
use our available capital resources sooner than we currently expect. Changing circumstances, some of which may be beyond our control,
could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner
than planned.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Developing
pharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain
process that takes years to complete. Our operations have consumed substantial amounts of cash since inception, and we expect our expenses
to increase in connection with our ongoing activities, particularly as we conduct clinical trials of, and seek marketing approval for,
JOTROL as well as develop our proprietary drug delivery platform. Even if one or more of the product candidates that we develop
is approved for commercial sale, we anticipate incurring significant costs associated with sales, marketing, manufacturing and distribution
activities. Our expenses could increase beyond expectations if we are required by the FDA, the European Medicines Agency (EMA) or other
regulatory agencies to perform clinical trials or preclinical studies in addition to those that we currently anticipate. Other unanticipated
costs may also arise. Because the design and outcome of our planned and anticipated preclinical studies and clinical trials are highly
uncertain, we cannot reasonably estimate the actual amount of resources and funding that will be necessary to successfully complete the
development and commercialization of any product candidate we develop. We are not permitted to market or promote JOTROL, or any
other product candidate, before we receive marketing approval from the FDA. Following this offering, we also expect to incur additional
costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in order to continue
our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future capital requirements will depend on may factors, including, but not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, progress, results and costs of researching and developing our product candidates including conducting preclinical studies
    and clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs, timing and outcome of regulatory review of our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number and characteristics of other product candidates that we pursue;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of future activities, including product sales, medical affairs, marketing, manufacturing and distribution, for any of our product
    candidates for which we receive marketing approval;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of manufacturing commercial-grade products and sufficient inventory to support commercial launch;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    revenue, if any, received from commercial sale of our products, should any of our product candidates receive marketing approval;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost and timing of hiring new employees to support our continued growth;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending
    intellectual property-related claims;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effect of competing products that may limit market penetration of our products;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability to establish and maintain collaborations on favorable terms, if at all;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent to which we acquire or in-license other product candidates and technologies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing, receipt and amount of sales of, or milestone payments related to or royalties on, our current or future product candidates,
    if any;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    need to implement additional internal systems and infrastructure, including financial and reporting systems;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    compliance and administrative costs associated with being a public company; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent to which we acquire or invest in businesses, products, or technologies, although we currently have no commitments or agreements
    relating to any of these types of transactions.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
change in the outcome of any of these or other factors with respect to the development of any of our product candidates could significantly
change the costs and timing associated with the development of that product candidate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We
                                            currently plan to use the net proceeds from this offering, together with our existing resources,
                                            to initiate a Phase II clinical trial with JOTROL in patients with Parkinson&rsquo;s
                                            Disease, establish a presence in South-East Asia through service agreements and advancing
                                            the manufacturing of JOTROL clinical trial supplies. in support of activities leading
                                            up to clinical trials in targeted indications. Remaining proceeds will be used
                                            for general research and development activities, working capital and other general corporate
                                            activities. Advancing the development of JOTROL program will require a significant
                                            amount of capital. The net proceeds from this offering, together with our cash and cash equivalents
                                            and grants, will not be sufficient for us to fund our product candidates through the completion
                                            of its development, Phase III clinical trials, entire regulatory approval process and commercialization.
                                            We will need to raise additional capital to fund such activities.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds
for our current or future operating plans. Attempting to secure additional financing may divert our management from our day-to-day activities,
which may adversely affect our ability to develop our product candidates. Our failure to raise capital as and when needed or on acceptable
terms would have a negative impact on our financial condition and our ability to pursue our business strategy, and we may have to delay,
reduce the scope of, suspend or eliminate one or more of our research-stage programs, clinical trials or future commercialization efforts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Raising
additional capital may cause substantial dilution to our stockholders, including purchasers of our securities in this offering,
restrict our operations or require us to relinquish rights to our technologies or product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
such time, if ever, as we can generate substantial revenues, we will be required to obtain further funding through public or private
equity offerings, debt financings, collaborations and licensing arrangements or other sources, which may dilute our stockholders or restrict
our operating activities. Adequate additional financing may not be available to us on acceptable terms, or at all. To the extent
that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted,
and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. Debt financing and preferred
equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions,
such as incurring additional debt, making acquisitions, engaging in acquisition, merger or collaboration transactions, selling or licensing
our assets, making capital expenditures, redeeming our stock, making certain investments, declaring dividends or encumbering our assets
to secure future indebtedness. Such restrictions could adversely impact our ability to conduct our operations and execute our business
plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we raise additional funds through upfront payments or milestone payments pursuant to strategic collaborations, strategic alliances or
marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies,
future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are
unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate
our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise
prefer to develop and market ourselves.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>Our substantial
amount of indebtedness may adversely affect our cash flow and our ability to operate our business, remain in compliance with debt covenants
and make payments on our indebtedness.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">As of
May 31, 2024, we have outstanding indebtedness in the principal amount of $2,217,240 and accrued interest of approximately
$102,000. Our substantial level of indebtedness increases the possibility that we may be unable to generate cash sufficient to
pay, when due, the principal of, interest on or other amounts due with respect to our indebtedness. Our indebtedness could have other
important consequences to you as a stockholder. For example, it could:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">make it more difficult for us to satisfy our obligations with respect
    to our indebtedness and any failure to comply with the obligations of any of our debt instruments, including financial and other
    restrictive covenants, could result in an event of default under the debt instruments;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">make us more vulnerable to adverse changes in general economic,
    industry and competitive conditions and adverse changes in government regulation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">require us to dedicate a substantial portion of our cash flow from
    operations to payments on our indebtedness, thereby reducing the availability of our cash flows to fund working capital, capital
    expenditures, acquisitions and other general corporate purposes;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">limit our flexibility in planning for, or reacting to, changes in
    our business and the industry in which we operate;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">place us at a competitive disadvantage compared to our competitors
    that have less debt; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">limit our ability to borrow additional amounts for working capital,
    capital expenditures, acquisitions, debt service requirements, execution of our business strategy or other purposes.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Any
of the above listed factors could materially adversely affect our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">If
we are at any time unable to generate sufficient cash flow from operations to service our indebtedness when payment is due, we may be
required to attempt to renegotiate the terms of the instruments relating to the indebtedness, seek to refinance all or a portion of the
indebtedness, or obtain additional financing. There can be no assurance that we would be able to successfully renegotiate such terms,
that any such refinancing would be possible or that any additional financing could be obtained on terms that are favorable or acceptable
to us, if at all. Any debt financing that is available could cause us to incur substantial costs and subject us to covenants that significantly
restrict our ability to conduct our business. If we seek to complete additional equity financings, the interests of existing equity holders
may be diluted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>Our outstanding
Secured Note provides our Secured Lender with liens on substantially all of our assets, including our intellectual property, and contains
financial covenants and other restrictions on our actions, which may cause significant risks to our stockholders and may impact our ability
to pursue certain transactions and operate our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On April
11, 2022, we issued a senior secured convertible note (&ldquo;Secured Note&rdquo;) in the principal amount of $1,111,111 to an accredited
investor (&ldquo;Secured Lender&rdquo;). In connection with the issuance of the Secured Note, we entered into a Security Agreement and
Intellectual Property Security Agreement, each dated April 11, 2022 (collectively, &ldquo;Security Agreements&rdquo;), with the Secured
Lender. Pursuant to terms of the Secured Note and Security Agreements, we have granted liens on substantially all of our assets, including
our intellectual property, as collateral, and have agreed to significant covenants, including covenants that materially limit our ability
to take certain actions, including our ability to pay dividends, make certain investments and other payments, incur additional indebtedness,
encumber and dispose of assets and customary events of default, including failure to pay amounts due, breaches of covenants and warranties,
material adverse effect events, certain cross defaults and judgements and insolvency. For example, the Security Agreements contain restrictions
on our ability to purchase or dispose of assets and have other affirmative and negative covenants that impact how we run our business.
A failure to comply with the covenants and other provisions of the Secured Note and Security Agreements, including any failure to make
a payment when required, would generally result in events of default under such instruments. The Security Agreements also provide that
a material adverse change constitutes an event of default. The occurrence of any default will cause the interest rate to increase during
the period of such default, which could permit acceleration of such indebtedness and could result in a material adverse effect on us.
If such indebtedness is accelerated, it would generally also constitute an event of default under our other outstanding indebtedness,
permitting acceleration of a substantial portion of our indebtedness. Any required repayment of our indebtedness as a result of acceleration
or otherwise would lower our current cash on hand such that we would not have those funds available for use in our business or for payment
of other outstanding indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"> On
April 29, 2024, the Company, the Secured Lender and the Chief Executive Officer, Christer Rosen, entered into an amendment in which
Mr. Rosen agreed to exchange 182,898 shares of Common Stock issued to the Secured Lender in exchange for his related party notes
that are due from the Company in an aggregate principal amount of $266,667 increasing the principal amounts of the Secured Notes to
$1,377,778. This amendment removed the convertible option from the Secured Note. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">If we
are unable to make payment on our Secured Note, and the subsequent executed amendments when due, the Secured Lender may foreclose
on and sell the assets securing such indebtedness, which includes substantially all of our property, to satisfy our payment obligations,
which could prevent us from accessing those assets for our business and conducting our business as planned. Our business, financial condition,
prospects and results of operations could be materially adversely affected as a result of any of these events.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
ability to utilize our net operating loss carryforwards and certain other tax attributes to offset future taxable income may be limited.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
net operating loss (NOL) carryforwards may be unavailable to offset future taxable income because of restrictions under U.S. tax law.
Our NOLs generated in tax years ending on or prior to December 31, 2017 are only permitted to be carried forward for 20 taxable years
under applicable U.S. federal tax law, and therefore could expire unused. Under tax legislation commonly referred to as the Tax Cuts
and Jobs Act (Tax Act) as amended by the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), our federal NOLs generated in
tax years beginning after December 31, 2017 may be carried forward indefinitely, but for taxable years beginning after December 31, 2021,
the deductibility of federal NOLs generated in tax years beginning after December 31, 2017 is limited to 80% of our current year taxable
income. It is uncertain if and to what extent various states will conform to the Tax Act. As of December 31, 2023, the Company had federal and state (post-apportioned basis) net operating losses of $19.2
million, as well as federal orphan drug tax credit carryforwards of approximately $0.9 million. Approximately $10.3 million of the foregoing
federal and state NOLs will expire at various dates from 2026 through 2043, if not limited by triggering events prior to such time.&nbsp; </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (Code), if a corporation undergoes an &ldquo;ownership
change&rdquo; (generally defined as a cumulative change in the corporation&rsquo;s ownership by &ldquo;5-percent
shareholders&rdquo; that exceeds 50 percentage points over a rolling three-year period), the corporation&rsquo;s ability to use its pre-change
NOLs and certain other pre-change tax attributes to offset its post-change taxable income may be limited. Similar rules may apply under
state tax laws. We may have experienced such ownership changes in the past, and we may experience ownership changes in the future as
a result of this offering or subsequent shifts in our stock ownership, some of which are outside our control. We have not conducted any
studies to determine annual limitations, if any, that could result from such changes in ownership. Our ability to utilize our NOLs
and certain other tax attributes could be limited by an &ldquo;ownership change&rdquo; as described above and consequently, we may not
be able to utilize a material portion of our NOLs and certain other tax attributes, which could have a material adverse effect on our
cash flows and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to the Discovery, Development and Commercialization of Our Product Candidate</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are substantially dependent on the success of our lead product candidate, JOTROL, which will be undergoing Phase II clinical trials.
If we are unable to complete development of, obtain approval for and commercialize JOTROL for one or more indications in a timely
manner, our business will be harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future success is dependent on our ability to timely and successfully complete clinical trials, obtain marketing approval for and successfully
commercialize JOTROL, our lead product candidate, through distribution deals with larger pharmaceutical companies. We are investing
the majority of our efforts and financial resources in the research and development of JOTROL. We have several pre-clinical trials
and one completed Phase I clinical trial to evaluate the safety and tolerability of JOTROL in healthy volunteers. Subsequent
to this offering, we will prepare for Phase II clinical trials. This will be our first clinical efficacy trial, and
JOTROL has not previously been tested in humans with a specific disease although we can rely on data that exist for resveratrol.
The reason for this is that once JOTROL is ingested the formulation excipients will be separated and it is only the active resveratrol
that will be circulating in blood plasma. JOTROL will require additional clinical development, expansion of manufacturing capabilities,
marketing approval from government regulators, substantial investment and significant marketing efforts to obtain established distributors
before we can generate any revenues from product sales. We are not permitted to market or promote JOTROL, or any other product
candidate, before we receive marketing approval from the FDA and comparable foreign regulatory authorities, and we may never receive
such marketing approvals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
success of JOTROL will depend on several factors, including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    successful and timely completion of our clinical trials of JOTROL; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    initiation and successful patient enrollment and completion of additional clinical trials of JOTROL on a timely basis;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining
    and establishing relationships with CROs and clinical sites for the clinical development of JOTROL; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    frequency and severity of adverse events in clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">demonstrating
    efficacy, safety and tolerability profiles that are satisfactory to the FDA, EMA or any comparable foreign regulatory authority for
    marketing approval;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timely receipt of marketing approvals for JOTROL from applicable regulatory authorities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent of any required post-marketing approval commitments to applicable regulatory authorities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    maintenance of existing or the establishment of new supply arrangements with third-party drug product suppliers and manufacturers
    for clinical development and, if approved, commercialization of JOTROL; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    and maintaining patent protection, trade secret protection and regulatory exclusivity, both in the United States and internationally;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">protecting
    our rights in our intellectual property portfolio;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to expand JOTROL into multiple indications;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to find partners handling all aspects of commercialization;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    successful launch of commercial sales following any marketing approval;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    continued acceptable safety profile following any marketing approval;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    actual market-size, ability to identify patients and the demographics of patients eligible for our product candidates, which may
    be different than expected;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">commercial
    acceptance by patients, the medical community and third-party payors, particularly since the product candidates we develop may be
    novel; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to compete with other therapies.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have control over many of these factors, including certain aspects of clinical development and the regulatory submission process,
potential threats to our intellectual property rights and the manufacturing, marketing, distribution and sales efforts of any future
collaborator. If we are not successful with respect to one or more of these factors in a timely manner or at all, we could experience
significant delays or an inability to successfully commercialize JOTROL, which would materially harm our business. If we do not
receive marketing approvals for JOTROL, we may not be able to continue our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>In
addition to JOTROL, our prospects depend in part upon discovering, developing and commercializing product candidates in future
programs, which may fail or suffer delays that adversely affect their commercial viability.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future operating results are dependent on our ability to successfully develop, obtain regulatory approval for and commercialize product
candidates from our research programs, in addition to our lead product candidate, JOTROL. However, research and development related
to novel therapeutics is inherently risky. A product candidate can unexpectedly fail at any stage of preclinical and/or clinical development.
The historical failure rate for product candidates is high due to risks relating to safety, efficacy, clinical execution, changing standards
of medical care and other unpredictable variables. The results from preclinical testing or early clinical trials of a product candidate
may not be predictive of the results that will be obtained in later stage clinical trials of the product candidate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
success of other product candidates we may develop will depend on many factors, including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">generating
    sufficient data to support the initiation or continuation of clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    regulatory permission to initiate clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">contracting
    with the necessary parties to conduct clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful
    enrollment of patients in, and the completion of, clinical trials on a timely basis;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timely manufacture of sufficient quantities of a product candidate for use in clinical trials; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    events in clinical trials.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we successfully discover and advance any other product candidates into clinical development, their success will be subject to all
of the clinical, regulatory and commercial risks described elsewhere in this &ldquo;Risk Factors&rdquo; section. Accordingly, we cannot
assure you that we will ever be able to discover, develop, obtain regulatory approval of, commercialize or generate significant revenue
from any product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Clinical
drug development involves a lengthy and expensive process with an uncertain outcome. The clinical trials of our product candidate may
not demonstrate safety and efficacy to the satisfaction of the FDA, EMA or other comparable foreign regulatory authorities or otherwise
produce positive results and the results of preclinical studies and early clinical trials may not be predictive of future results. We
may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization
of our product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
lead product candidate, JOTROL, is entering into Phase II clinical trials after completing a Phase I clinical trial in March 2021
and its risk of failure is high. It is impossible to predict when or if JOTROL or any product candidate that we develop will prove
effective or safe in humans or will receive marketing approval. Before obtaining marketing approval from the FDA, EMA or other comparable
foreign regulatory authorities for the sale of our product candidates, we must complete preclinical development and extensive clinical
trials to demonstrate with substantial evidence the safety and efficacy of such product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
testing is expensive, difficult to design and implement, can take many years to complete and its ultimate outcome is uncertain. We cannot
guarantee that any of our clinical trials will be conducted as planned or completed on schedule, or at all. Clinical trials can fail
at any stage of testing and failure may result from a multitude of factors, including, among other things, flaws in study design, dose
selection issues, placebo effects, patient enrollment criteria and failure to demonstrate favorable safety or efficacy traits. The outcome
of preclinical studies and early-stage clinical trials may not be predictive of the success of later clinical trials. For example, our
product candidates may fail to show the desired safety and efficacy in clinical development despite positive results in preclinical studies
or having successfully advanced through initial clinical trials. We may also discover that the half-life of our product candidates renders
them unsuitable for the therapeutic applications we have chosen. As a result, we cannot assure you that any clinical trials that we conduct
will demonstrate consistent or adequate efficacy and safety to support marketing approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after
achieving promising results in preclinical testing and earlier-stage clinical trials, and we cannot be certain that we will not face
similar setbacks. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies
that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed
to obtain marketing approval of their drugs. Furthermore, the failure of any of our product candidates to demonstrate safety and efficacy
in any clinical trial could negatively impact the perception of our other product candidates and/or cause the FDA or other regulatory
authorities to require additional testing before approving any of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have experienced delays in completing our clinical trial and may experience additional delays in initiating or completing additional
clinical trials. We may also experience numerous unforeseen events during, or as a result of,
clinical trials that could delay or prevent receipt of marketing approval or our ability to commercialize our product candidates, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">receipt
    of feedback from regulatory authorities that requires us to modify the design of our clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
    trial observations or results that require us to modify the design of our clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">negative
    or inconclusive clinical trial results that may require us to conduct additional clinical trials or abandon certain drug development
    programs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    approval from one or more institutional review boards (IRB);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of patients required for clinical trials being larger than anticipated, enrollment in these clinical trials being slower than
    anticipated or participants dropping out of these clinical trials at a higher rate than anticipated;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    failure or delay in reaching an agreement with CROs and clinical trial sites, the terms of which can be subject to extensive negotiation
    and may vary significantly among different CROs and trial sites;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    suspension or termination of our clinical trials for various reasons, including non-compliance with regulatory requirements or a
    finding that our product candidates have undesirable side effects or other unexpected characteristics or risks;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    to clinical trial protocol;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
    sites deviating from trial protocol or dropping out of a trial;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of clinical trials of our product candidates being greater than anticipated;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates being
    insufficient or inadequate;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subjects
    experiencing severe or unexpected drug-related adverse selection of clinical end points that require prolonged periods of clinical
    observation or analysis of the resulting data;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    facility manufacturing our product candidates or any of their components being ordered by the FDA or comparable foreign regulatory
    authorities to temporarily or permanently shut down due to violations of current good manufacturing practice (cGMPs), regulations
    or other applicable requirements, or infections or cross-contaminations of product candidates in the manufacturing process;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    changes to our manufacturing process that may be necessary or desired;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party
    clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials
    on our anticipated schedule or consistent with the clinical trial protocol, good clinical practices (GCP) or other regulatory requirements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party
    contractors not performing data collection or analysis in a timely or accurate manner;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party
    contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities for violations
    of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all
    of the data produced by such contractors in support of our marketing applications; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulators
    revising the requirements for approving our product candidates.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate,
if we are unable to successfully complete clinical trials of our product candidates or other testing in a timely manner, if the results
of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may incur unplanned costs,
be delayed in seeking and obtaining marketing approval, if we receive such approval at all, receive more limited or restrictive marketing
approval, be subject to additional post-marketing testing requirements or have the drug removed from the market after obtaining marketing
approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
in the future, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time
and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships
to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial
relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study.
The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical
trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of
our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the
denial of marketing approval of one or more of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects
of our product candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed.
Moreover, our product development costs will also increase if we experience delays in preclinical studies or clinical trials or in obtaining
marketing approvals. We do not know whether any of our preclinical studies or clinical trials will begin as planned, will need to be
restructured or will be completed on schedule, or at all. We may also determine to change the design or protocol of one or more of our
clinical trials, which could result in increased costs and expenses and/or delays. Any delays in completing our clinical trials will
increase our costs, slow down our product candidates development and approval process and jeopardize our ability to commence product
sales and generate revenues.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, many of the factors that cause, or lead to, termination or suspension of, or a delay in the commencement or completion of,
clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Any delays to our clinical
trials that occur as a result could shorten any period during which we may have the exclusive right to commercialize our product candidates
and our competitors may be able to bring products to market before we do, and the commercial viability of our product candidates could
be significantly reduced. Any of these occurrences may harm our business, financial condition and prospects significantly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have entered into a Service Agreements with the Selling Stockholders with respect to services to be provided by the Selling Stockholders
to us in Asia for the development of our product in the South-East Asian territory immediately following the completion of the public
offering, the shares issued by us in advance pursuant to which, are non-forfeitable and not tied to any milestones or performance, and
the foregoing nature of such advanced share issuance, could have a material negative impact on our business, financial condition and
operating results.</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into service agreements for development of our product in the South-East Asian territory. The agreements are with three
contracted companies, namely, Longevity Technology Group Limited, Regis Healthcare Group Limited, and Optimized Wellness Limited (collectively,
the &ldquo;Selling Stockholders&rdquo;) that will handle CMC (Chemistry, Manufacturing, and Controls), regulatory affairs and clinical
trial management, respectively. As consideration for these services, on June 3, 2024, the Company issued 1,162,500 shares of common stock
(&ldquo;Issued Shares&rdquo;) to each of the Selling Stockholders with a fair market value of $1.33 per share (3,487,500 shares in aggregate,
with an aggregate fair market value of $4,638,375), as pre-payment for three years of services. The Issued Shares are non-forfeitable
and are not based on performance by the Selling Stockholders or milestones that must be reached by the Selling Stockholders. Accordingly,
if the Selling Stockholders fail to perform, or underperform, under their service agreements with the Company, the Selling Stockholders
would still be entitled to the Issued Shares and the Company would not be entitled to a return of the Issued Shares. Accordingly, the
Company may be in a position where it issued shares to the Selling Stockholders under the service agreements even if the Selling Stockholders
failed to perform, or underperform, without any ability to have the shares forfeited to the Company. The requirement by the Company to
issue the Issued Shares under the service agreements, regardless of any milestones or performance by Selling Stockholders, and the non-forfeiture
nature of such Issued Shares could have a material negative impact on our business, financial condition and operating results.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>We are planning on
entering into a Strategic Service Agreement with DOMINANT TREASURE HEALTH COMPANY LIMITED with respect to strategic services in
Asia immediately following the completion of the public offering, the fees payable by the Company pursuant to which, are non-refundable
and not tied to any milestones or performance, and the foregoing nature of such fees, could have a material negative impact on our business,
financial condition and operating results.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company has negotiated and
plans on entering into a Strategic Service Agreement with DOMINANT TREASURE HEALTH COMPANY LIMITED (&ldquo;Strategic Services
Partner&rdquo;), immediately following the completion of the public offering, to provide services to advance the business objectives
of the Company in China and Southeast Asia. As consideration for these services, the Company will utilize $2,300,000
(the &ldquo;Fees&rdquo;) of the offering proceeds, subject to the successful completion of an offering of $10,000,000 or greater.
The Fees are non-refundable and are not based on performance by the Strategic Services Partner or milestones that must be reached
by the Strategic Services Partner. Accordingly, if the Strategic Services Partner fails to perform, or underperforms, under the Strategic
Service Agreement, the Company would still be obligated to pay the Fees and would not be entitled for any return of the Fees. Accordingly,
the Company may be in a position where it is required to pay the Fees to the Strategic Services Partner under the Strategic Service Agreement
even if the Strategic Services Partner fails to perform, or underperforms, without any ability to get its money back. The requirement
by the Company to pay the Fees under the Strategic Service Agreement, regardless of any milestones or performance by Strategic Services
Partner, and the non-refundable nature of such Fees could have a material negative impact on our business, financial condition and operating
results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
product candidates may cause serious adverse events, toxicities or other undesirable side effects when used alone or in combination
with other approved products or investigational new drugs that may result in a safety profile that could prevent regulatory approval,
prevent market acceptance, limit their commercial potential or result in significant negative consequences.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are developing a novel biologically active small molecule for neurological disorders. As a result, there is uncertainty as to the safety
profile of the product candidates we are developing. In addition, our product candidates may be used in combination with
certain other therapies which may have undesirable side effects. If our product candidates are associated with undesirable side effects
or have unexpected characteristics in preclinical studies or clinical trials when used alone or in combination with other approved products
or investigational new drugs we may need to interrupt, delay or abandon their development or limit development to more narrow uses or
subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from
a risk-benefit perspective. Treatment-related side effects could also affect patient recruitment or the ability of enrolled subjects
to complete the trial or result in potential product liability claims. Any of these occurrences may prevent us from achieving or maintaining
market acceptance of the affected product candidates and may harm our business, financial condition and prospects significantly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
in our ongoing and planned clinical trials may in the future suffer other serious adverse events or other side effects not observed in
our preclinical studies or previous clinical trials. JOTROL or other product candidates may be used in pediatric populations for
which safety concerns may be particularly scrutinized by regulatory agencies. In addition, if JOTROL is studied in combination
with other therapies, it may exacerbate adverse events associated with the therapy. Patients treated with JOTROL or our other
product candidates may also be undergoing other therapies which can cause side effects or adverse events that are unrelated to our product
candidates but may still impact the success of our clinical trials. The inclusion of critically ill patients in our clinical trials may
result in deaths or other adverse medical events due to other therapies or medications that such patients may be using or due to the
gravity of such patients&rsquo; illnesses. For example, it is expected that some of the patients enrolled in our JOTROL clinical
trial will die or experience major clinical events either during the course of our clinical trials or after participating in such trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
further serious adverse events or other side effects are observed in any of our current or future clinical trials, we may have difficulty
recruiting patients to the clinical trials, patients may drop out of our trials, or we may be required to abandon the trials or our development
efforts of that product candidate altogether. We, the FDA, EMA, other comparable regulatory authorities or an IRB may suspend clinical
trials of a product candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to unacceptable
health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic
promise in early-stage trials have later been found to cause side effects that prevented their further development. Even if the side
effects do not preclude the product candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit
market acceptance due to its tolerability versus other therapies. Any of these developments could materially harm our business, financial
condition and prospects. Further, if any of our product candidates obtains marketing approval, toxicities associated with such product
candidates previously not seen during clinical testing may also develop after such approval and lead to a requirement to conduct additional
clinical safety trials, additional contraindications, warnings and precautions being added to the drug label, significant restrictions
on the use of the product or the withdrawal of the product from the market. We cannot predict whether our product candidates will cause
toxicities in humans that would preclude or lead to the revocation of regulatory approval based on preclinical studies or early-stage
clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and the results
of our clinical trials may not satisfy the requirements of the FDA, EMA or other comparable foreign regulatory authorities.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will be required to demonstrate with substantial evidence through well-controlled clinical trials that our product candidates are safe
and effective for use in a diverse population before we can seek marketing approvals for their commercial sale. Success in preclinical
studies and early-stage clinical trials does not mean that future clinical trials will be successful. For instance, we do not know whether
JOTROL will perform in current or future clinical trials as JOTROL has performed in preclinical studies or earlier clinical
trials. Product candidates in clinical trials may fail to demonstrate sufficient safety and efficacy to the satisfaction of the FDA,
EMA and other comparable foreign regulatory authorities despite having progressed through preclinical studies. Regulatory authorities
may also limit the scope of later-stage trials until we have demonstrated satisfactory safety, which could delay regulatory approval,
limit the size of the patient population to which we may market our product candidates, or prevent regulatory approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
some instances, there can be significant variability in safety and efficacy results between different clinical trials of the same product
candidates due to numerous factors, including changes in trial protocols, differences in size and type of the patient populations,
differences in and adherence to the dose and dosing regimen and other trial protocols and the rate of dropout among clinical trial participants.
Patients treated with our product candidates may also be undergoing other therapies and may be using other approved products or investigational
new drugs, which can cause side effects or adverse events that are unrelated to our product candidates. As a result, assessments of efficacy
can vary widely for a particular patient, and from patient to patient and site to site within a clinical trial. This subjectivity can
increase the uncertainty of, and adversely impact, our clinical trial outcomes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not know whether any clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety sufficient to obtain
approval to market any of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we experience delays or difficulties in the enrollment and/or maintenance of patients in clinical trials, our regulatory submissions
or receipt of necessary marketing approvals could be delayed or prevented.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient
number of eligible patients to participate in these trials to such trial&rsquo;s conclusion as required by the FDA, EMA or other comparable
foreign regulatory authorities. Patient enrollment is a significant factor in the timing of clinical trials. Our ability to enroll eligible
patients may be limited or may result in slower enrollment than we anticipate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may encounter difficulties in identifying and enrolling subjects with a stage of disease appropriate for our planned clinical trials
and monitoring such subjects adequately during and after treatment. We may not be able to initiate or continue clinical trials if we
are unable to locate a sufficient number of eligible subjects to participate in the clinical trials required by the FDA or comparable
foreign regulatory authorities. In addition, the process of finding and diagnosing subjects may prove costly. Further, the treating physicians
in our clinical trials may also use their medical discretion in advising patients enrolled in our clinical trials to withdraw from our
studies to try alternative therapies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect patient enrollment to be affected because our competitors have ongoing clinical trials for programs that are under development
for the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials could instead
enroll in clinical trials of our competitors&rsquo; programs. Patient enrollment for our current or any future clinical trials may be
affected by other factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">size
    and nature of the patient population;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">perceived
    risks and benefits of novel, unproven approaches;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">severity
    of the disease under investigation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">availability
    and efficacy of approved drugs for the disease under investigation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient
    eligibility criteria for the trial in question as defined in the protocol;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">perceived
    risks and benefits of the product candidates under study;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinicians&rsquo;
    and patients&rsquo; perceptions as to the potential advantages of the product candidates being studied in relation to other
    available therapies, including any new products that may be approved or other product candidates being investigated for the indications
    we are investigating;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient
    referral practices of physicians;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability to monitor patients adequately during and after treatment;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    activities of key opinion leaders (KOLs) and patient advocacy groups;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">proximity
    and availability of clinical trial sites for prospective patients; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    risk that patients enrolled in clinical trials will drop out of the trials before completion or, because they may have an advanced
    disease, will not survive the full terms of the clinical trials.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or may require us to abandon
one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product
candidates and jeopardize our ability to obtain marketing approval for the sale of our product candidates. Furthermore, even if we are
able to enroll a sufficient number of patients for our clinical trials, we may have difficulty maintaining participation in our clinical
trials through the treatment and any follow-up periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have limited resources and are currently focusing the majority of our efforts on developing JOTROL for particular indications.
As a result, we may fail to capitalize on other indications or product candidates that may ultimately have proven to be more profitable.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently focusing the majority of our resources and efforts on developing JOTROL. As a result, because we have limited resources,
we may forgo or delay the pursuit of opportunities for other indications or with other product candidates that may have greater commercial
potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial drugs or profitable market opportunities.
Our spending on current and future research and development activities for JOTROL may not yield any commercially viable products.
If we do not accurately evaluate the commercial potential or target markets for JOTROL, we may relinquish valuable rights to our
product candidates or programs through collaboration, licensing or other strategic arrangements in cases in which it would have been
more advantageous for us to retain sole development and commercialization rights to such product candidates or program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
face significant competition and if our competitors develop and market technologies or products more rapidly than we do or that are more
effective, safer or less expensive than the products we develop, our commercial opportunities will be negatively impacted.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong
emphasis on proprietary and novel products and product candidates. Our competitors have developed, are developing or may develop products,
product candidates and processes competitive with our product candidate. Any product candidates that we successfully develop and commercialize
will compete with existing therapies and new therapies that may become available in the future. We believe that a significant number
of products are currently under development, and may become commercially available in the future, for the treatment of conditions for
which we may attempt to develop product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have competitors both in the United States and internationally, including major multinational pharmaceutical companies, established biotechnology
companies, specialty pharmaceutical companies, emerging and start-up companies, universities and other research institutions. We also
compete with other organizations to recruit management, scientists and clinical development personnel, which could negatively affect
our level of expertise and our ability to execute our business plan. We will also face competition in establishing clinical trial sites,
enrolling subjects for clinical trials and in identifying and in-licensing new product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to face competition from existing products and products in development for each of our programs. Many of these current and potential
competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources and commercial
expertise than we do. Large pharmaceutical and biotechnology companies, in particular, have extensive experience in clinical testing,
obtaining regulatory approvals, recruiting patients and manufacturing biotechnology products. These companies also have significantly
greater research and marketing capabilities than we do and may also have products that have been approved or are in late stages of development,
and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical and
biotechnology companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds
that could make the product candidates that we develop obsolete. Smaller or early-stage companies may also prove to be significant competitors,
particularly through collaborative arrangements with large and established companies, as well as in acquiring technologies complementary
to, or necessary for, our programs. As a result of all of these factors, our competitors may succeed in obtaining approval from the FDA,
EMA or other comparable foreign regulatory authorities or in discovering, developing and commercializing products in our field before
we do.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective,
have fewer side effects, are more convenient, have a broader label, are marketed more effectively, are more widely reimbursed or are
less expensive than any products that we may develop. Our competitors also may obtain marketing approval from the FDA, EMA or other comparable
foreign regulatory authorities for their products more rapidly than we may obtain approval for ours, which could result in our competitors
establishing a strong market position before we are able to enter the market. Even if the product candidates we develop achieve marketing
approval, they may be priced at a significant premium over competitive products if any have been approved by then, resulting in reduced
competitiveness. Technological advances or products developed by our competitors may render our technologies or product candidates obsolete,
less competitive or not economical. If we are unable to compete effectively, our opportunity to generate revenue from the sale of our
products we may develop, if approved, could be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Interim,
topline and preliminary data from our clinical trials that we announce or publish may change as more patient data become available and
are subject to audit and verification procedures that could result in material changes in the final data.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may publicly disclose preliminary, interim or topline data from our clinical trials, such as the interim data from our
Phase I clinical trial of JOTROL. These interim updates are based on a preliminary analysis of then-available data, and the results
and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular
study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have
received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ
from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have
been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final
data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution
until the final data are available. In addition, we may report interim analyses of only certain endpoints rather than all endpoints.
Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially
change as patient enrollment continues and more patient data become available. Adverse changes between interim data and final data could
significantly harm our business and prospects. Further, additional disclosure of interim data by us or by our competitors in the future
could result in volatility in the price of our securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses
or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability
or commercialization of the particular product candidates or product and our company in general. In addition, the information we choose
to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others
may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. If the preliminary
or topline data that we report differ from late, final or actual results, or if others, including regulatory authorities, disagree with
the conclusions reached, our ability to obtain approval for, and commercialize, JOTROL or any other product candidates may be
harmed, which could harm our business, financial condition, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be successful in our efforts to develop our proprietary drug delivery platform to build a pipeline of indications.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
key element of our strategy is to leverage our proprietary drug delivery platform and our ability to expand our pipeline of indications.
We are leveraging our proprietary drug delivery platform and capabilities to create precision medicines for neurological disorders with
high levels of unmet need. Although our research and development efforts to date have resulted in a pipeline product candidate JOTROL,
this product candidate may not be safe and effective. In addition, although we expect that our proprietary drug delivery platform
will allow us to develop a diverse pipeline across multiple therapeutic areas, we may not prove to be successful at doing so. Furthermore,
we may also find that the uses of our proprietary drug delivery platform are limited because alternative uses of our therapeutics prove
not to be safe or effective. Even if we are successful in building our pipeline, JOTROL may not be suitable for clinical development,
including as a result of being shown to have harmful side effects or other characteristics that indicate that they are unlikely to receive
marketing approval or achieve market acceptance. Further, because our product candidate and development programs are based on our proprietary
drug delivery platform, adverse developments with respect to one of our programs may have a significant adverse impact on the actual
or perceived likelihood of success and value of our other programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies. Our future success will
depend in part on our ability to maintain a competitive position with our approach. If we fail to stay at the forefront of technological
change in utilizing our proprietary drug delivery platform to create and develop product candidates, we may be unable to compete effectively.
Our competitors may render our approach obsolete or limit the commercial value of our product candidates, by advances in existing technological
approaches or the development of new or different approaches, potentially eliminating the advantages in our drug delivery process that
we believe we derive from our research approach and proprietary technologies. By contrast, adverse developments with respect to other
companies that attempt to use a similar approach to our approach may adversely impact the actual or perceived value of our proprietary
drug delivery platform and potential of our product candidates. If any of these events occur, we may be forced to abandon our development
efforts for a program or programs, which would have a material adverse effect on our business and could potentially cause us to cease
operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may develop JOTROL and potentially other programs in combination with other therapies, which would expose us to additional risks.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may develop JOTROL and potentially other programs, in combination with one or more currently approved therapies or therapies in
development. Patients may not be able to tolerate JOTROL or any other product candidates in combination with other therapies or
dosing of JOTROL in combination with other therapies may have unexpected consequences. Even if any of our product candidates were
to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject
to the risks that the FDA, EMA or other comparable foreign regulatory authorities could revoke approval of the therapy used in combination
with any of our product candidates, or safety, efficacy, manufacturing or supply issues could arise with these existing therapies. In
addition, it is possible that existing therapies with which our product candidates are approved for use could themselves fall out of
favor. This could result in the need to identify other combination therapies for our product candidates or our own products being removed
from the market or being less successful commercially.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also evaluate our product candidates in combination with one or more other therapies that have not yet been approved for marketing
by the FDA, EMA or comparable foreign regulatory authorities. We will not be able to market and sell any product candidates in
combination with any such unapproved therapies that do not ultimately obtain marketing approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the FDA, EMA or other comparable foreign regulatory authorities do not approve or revoke their approval of these other therapies, or
if safety, efficacy, commercial adoption, manufacturing or supply issues arise with the therapies we may choose to evaluate in combination
with JOTROL or any other product candidate, we may be unable to obtain approval of or successfully market any one or all of the
product candidates we develop.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
if the third-party providers of therapies or therapies in development used in combination with our product candidates are unable
to produce sufficient quantities for clinical trials or for commercialization of our product candidate, or if the cost of combination
therapies are prohibitive, our development and commercialization efforts would be impaired, which would have an adverse effect on our
business, financial condition, results of operations and growth prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
manufacture of drugs is complex, and our third-party manufacturers may encounter difficulties in production. If any of our third-party
manufacturers encounter such difficulties, our ability to provide adequate supply of our product candidates for clinical trials
or our products for patients, if approved, could be delayed or prevented.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing
drugs, especially in large quantities, is complex and may require the use of innovative technologies. Each lot of an approved drug product
must undergo thorough testing for identity, strength, quality, purity and potency. Manufacturing drugs requires facilities specifically
designed for and validated for this purpose, as well as sophisticated quality assurance and quality control procedures. Slight deviations
anywhere in the manufacturing process, including filling, labeling, packaging, storage and shipping and quality control and testing,
may result in lot failures or product recalls. When changes are made to the manufacturing process, we may be required to provide preclinical
and clinical data showing the comparable quality and efficacy of the products before and after such changes. If our third-party manufacturers
are unable to produce sufficient quantities for clinical trials or for commercialization as a result of these challenges, or otherwise,
our development and commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition,
results of operations and growth prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
product candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors and others in the medical
community necessary for commercial success.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if our product candidates receive regulatory approval, they may not gain adequate market acceptance among physicians, patients, third-party
payors and others in the medical community. The degree of market acceptance of any of our approved product candidates will depend on
a number of factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    efficacy and safety profile as demonstrated in clinical trials compared to alternative treatments;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing of market introduction of the product candidates as well as competitive products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    clinical indications for which a product candidate is approved;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on the use of product candidates in the labeling approved by regulatory authorities, such as boxed warnings or contraindications
    in labeling, or a risk evaluation and mitigation strategy, if any, which may not be required of alternative treatments and competitor
    products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential and perceived advantages of our product candidates over alternative treatments;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of treatment in relation to alternative treatments;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    availability of an approved product candidate for use as a combination therapy;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">relative
    convenience and ease of administration;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    willingness of the target patient population or their caregivers to try new therapies and of physicians to prescribe these therapies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    availability of coverage and adequate reimbursement by third-party payors, including government authorities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients&rsquo;
    willingness to pay for these therapies in the absence of such coverage and adequate reimbursement;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effectiveness of sales and marketing efforts;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">support
    from KOLs and patient advocacy groups;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unfavorable
    publicity relating to our product candidates; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    approval of other new therapies for the same indications.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our product candidates are approved but do not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors
and patients, we may not generate or derive sufficient revenue from that product candidate and our financial results could be negatively
impacted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
patient population suffering from MPS I, Friedreich&rsquo;s ataxia, and MELAS is small and has not been established with precision. If
the actual number of patients is smaller than we estimate, our revenue and ability to achieve profitability may be adversely affected.
Because the target patient populations of our programs are small and the addressable patient population may be even smaller, we must
be able to successfully identify patients and capture a significant market share to achieve profitability and growth.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MPS
I, Friedreich&rsquo;s ataxia, and MELAS are rare, genetic neuromuscular disorders. We estimate that MPS I occurs in approximately one
in every 100,000 live births and that the patient population is approximately 2,000 to 3,000 in the United States and approximately 4,000
in Europe. Friedreich&rsquo;s ataxia has a higher incidence of approximately 1 in every 50,000 live births. We estimate there are between
5,000 and 6,000 patients with Friedreich&rsquo;s ataxia in the United States, with slightly higher patient population estimated in Europe.
MELAS is one of the most common mitochondrial diseases, with an estimated incidence of 1 in 4000.We estimate that there are approximately
80,000 patients with MELAS in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
estimates of the size of these patient populations are based on published studies. Given the small number of patients who have the diseases
that we are targeting, it is critical to our ability to grow and become profitable that we continue to successfully identify patients
with these rare diseases. The effort to identify patients with diseases we seek to treat is in early stages, and we cannot accurately
predict the number of patients for whom treatment might be possible. Various factors may decrease the market size of our product and
product candidates, including the severity of the disease, patient demographics and the response of patients&rsquo; immune systems to
our product candidates. If the results of these studies or our analysis of them do not accurately reflect the relevant patient population,
our assessment of the market may be inaccurate, making it difficult or impossible for us to meet our revenue goals, or to obtain and
maintain profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the potentially addressable patient population for each of our product candidates may be limited or may not be amenable to treatment
with our product candidates, and new patients may become increasingly difficult to identify or gain access to, which would adversely
affect our results of operations and our business. Further, even if we obtain significant market share for our product candidates, because
the potential target populations are very small, we may never achieve profitability despite obtaining such significant market share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Any
product candidates we develop may become subject to unfavorable third-party coverage and reimbursement practices, as well as pricing
regulations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
availability and extent of coverage and adequate reimbursement by third-party payors including government health administration authorities,
private health coverage insurers, managed care organizations and other third-party payors is essential for most patients to be able to
afford expensive treatments. The initial targets in our pipeline are indications with small patient populations. For product candidates
that are designed to treat smaller patient populations to be commercially viable, the reimbursement for such product candidates must
be higher, on a relative basis, to account for the lack of volume. Accordingly, we will need to implement a coverage and reimbursement
strategy for any approved product candidate that accounts for the smaller potential market size.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of any of our product candidates that receive marketing approval will depend substantially, both in the United States and internationally,
on the extent to which the costs of such product candidates will be covered and reimbursed by third-party payors. If reimbursement is
not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even
if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient
to realize an adequate return on our investment. Coverage and reimbursement may impact the demand for, or the price of, any product candidate
for which we obtain marketing approval. If coverage and reimbursement are not available or reimbursement is available only to limited
levels, we may not successfully commercialize any product candidate for which we obtain marketing approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. In the United States,
for example, principal decisions about reimbursement for new products are typically made by the Centers for Medicare &amp; Medicaid Services
(CMS), an agency within the U.S. Department of Health and Human Services (HHS). CMS decides whether and to what extent a new product
will be covered and reimbursed under Medicare, and private third-party payors often follow CMS&rsquo;s decisions regarding coverage and
reimbursement to a substantial degree. However, one third-party payor&rsquo;s determination to provide coverage for a product candidate
does not assure that other payors will also provide coverage for the product candidate or at the same level of reimbursement. As a result,
the coverage determination process is often time-consuming and costly. This process will require us to provide scientific and clinical
support for the use of our products to each third-party payor separately, with no assurance that coverage and adequate reimbursement
will be applied consistently or obtained in the first instance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increasingly,
third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the
prices charged for medical products. Further, such payors are increasingly challenging the price, examining the medical necessity and
reviewing the cost effectiveness of medical product candidates. There may be especially significant delays in obtaining coverage and
reimbursement for newly approved drugs. Third-party payors may limit coverage to specific product candidates on an approved list, known
as a formulary, which might not include all FDA-approved drugs for a particular indication. We may need to conduct expensive pharmaco-economic
studies to demonstrate the medical necessity and cost effectiveness of our products. Nonetheless, our product candidates may not be considered
medically necessary or cost effective. We cannot be sure that coverage and reimbursement will be available for any product that we commercialize
and, if reimbursement is available, what the level of reimbursement will be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outside
the United States, the commercialization of therapeutics is generally subject to extensive governmental price controls and other market
regulations, and we believe the increasing emphasis on cost containment initiatives in Europe, Canada and other countries has and will
continue to put pressure on the pricing and usage of therapeutics such as our product candidates. In many countries, particularly the
countries of the European Union (EU), medical product prices are subject to varying price control mechanisms as part of national health
systems. In these countries, pricing negotiations with governmental authorities can take considerable time after a product receives marketing
approval. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares
the cost-effectiveness of our product candidate to other available therapies. In general, product prices under such systems are substantially
lower than in the United States. Other countries allow companies to fix their own prices for products but monitor and control company
profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge
for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared
with the United States and may be insufficient to generate commercially reasonable revenue and profits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to establish or sustain coverage and adequate reimbursement for any product candidates from third-party payors, the adoption
of those products and sales revenue will be adversely affected, which, in turn, could adversely affect the ability to market or sell
those product candidates, if approved. Coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable
coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage
policies and reimbursement rates may be implemented in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
business entails a significant risk of product liability and if we are unable to obtain sufficient insurance coverage, such inability
could have an adverse effect on our business and financial condition. If product liability lawsuits are brought against us, we may incur
substantial liabilities and may be required to limit commercialization of our products.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business exposes us to significant product liability risks inherent in the development, testing, manufacturing and marketing of therapeutic
treatments. We currently have product liability insurance that we believe is appropriate for our stage of development and may need to
obtain higher levels prior to marketing any of our product candidates, if approved. Any insurance we have or may obtain may not provide
sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly
expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product
liability claims that could have an adverse effect on our business and financial condition. Also, our insurance policies may have various
exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded
by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not
have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle
us to indemnification against losses, such indemnification may not be available or adequate should any claim arise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be sued if any of our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical
testing, manufacturing, marketing, or sale post-approval. Any such product liability claims may include allegations of defects in manufacturing,
defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability, or a breach of warranties. Claims
could also be asserted under state consumer protection laws. If we cannot successfully defend ourselves against product liability claims,
we may incur substantial liabilities or be required to limit testing and commercialization of our products. Even successful defense would
require significant financial and management resources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regardless
of the merits or eventual outcome, liability claims may result in:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in the development of our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA,
    EMA or other regulatory authority investigation of the safety and effectiveness of our products, our manufacturing processes and
    facilities or our marketing programs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreased
    or interrupted demand for our products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">injury
    to our reputation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal
    of clinical trial participants and inability to continue clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiation
    of investigations by regulators;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    to defend the related litigation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    diversion of management&rsquo;s time and our resources;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial
    monetary awards to trial participants or patients;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    recalls, withdrawals or labeling, marketing, or promotional restrictions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss
    of revenue;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exhaustion
    of any available insurance and our capital resources; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inability to commercialize any products.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Regulatory Approval and Other Legal Compliance Matters</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
regulatory approval processes of the FDA, EMA and other comparable foreign regulatory authorities are lengthy, time consuming and inherently
unpredictable. If we are ultimately unable to obtain regulatory approval of our product candidates, we will be unable to generate product
revenue and our business will be substantially harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates are and will continue to be subject to extensive governmental regulations relating to, among other things, research,
testing, development, manufacturing, safety, efficacy, approval, recordkeeping, reporting, labeling, storage, packaging, advertising
and promotion, pricing, marketing and distribution of drugs. Rigorous preclinical testing and clinical trials and an extensive regulatory
approval process must be successfully completed in the United States and in many foreign jurisdictions before a new drug can be approved
for marketing. Obtaining approval by the FDA, EMA and other comparable foreign regulatory authorities is costly, unpredictable, typically
takes many years following the commencement of clinical trials and depends upon numerous factors, including the type, complexity and
novelty of the product candidates involved. In addition, approval policies, regulations or the type and amount of clinical data necessary
to gain approval may change during the course of a product candidate&rsquo;s clinical development and may vary among jurisdictions, which
may cause delays in the approval or the decision not to approve an application. Regulatory authorities have substantial discretion in
the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional
preclinical, clinical or other data. Even if we eventually complete clinical testing and receive approval for our product candidates,
the FDA, EMA and other comparable foreign regulatory authorities may approve our product candidates for a more limited indication or
a narrower patient population than we originally requested or may impose other prescribing limitations or warnings that limit the product&rsquo;s
commercial potential. We have not submitted for, or obtained, regulatory approval for any product candidate, and it is possible that
none of our product candidates will ever obtain regulatory approval. Further, development of our product candidates and/or regulatory
approval may be delayed for reasons beyond our control. We cannot provide any assurance that any product candidates we may develop
will progress through required clinical testing and obtain the regulatory approvals necessary for us to begin selling them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not conducted, managed or completed large-scale or pivotal clinical trials nor managed the regulatory approval process with the
FDA or any other regulatory authority. Applications for our product candidates could fail to receive regulatory approval for many reasons,
including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA, EMA or other comparable foreign regulatory authorities may disagree with the design, implementation or results of our clinical
    trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA, EMA or other comparable foreign regulatory authorities may determine that our product candidates are not safe and effective,
    are only moderately effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude our
    obtaining marketing approval or prevent or limit commercial use;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    population studied in the clinical trial may not be sufficiently broad or representative to assure efficacy and safety in the full
    population for which we seek approval;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA, EMA or other comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies
    or clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be unable to demonstrate to the FDA, EMA or other comparable foreign regulatory authorities that our product candidate&rsquo;s
    risk-benefit ratio for its proposed indication is acceptable;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA, EMA or other comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and
    specifications or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    approval policies or regulations of the FDA, EMA or other comparable foreign regulatory authorities may significantly change in a
    manner rendering our clinical data insufficient for approval.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
lengthy approval process, as well as the unpredictability of the results of clinical trials, may result in our failing to obtain regulatory
approval to market any of our product candidates, which would significantly harm our business, results of operations and prospects. Any
delay or failure in seeking or obtaining required approvals would have a material and adverse effect on our ability to generate revenue
from any particular product candidates we are developing and for which we are seeking approval. Furthermore, any regulatory approval
to market a drug may be subject to significant limitations on the approved uses or indications for which we may market, promote and advertise
the drug or the labeling or other restrictions. In addition, the FDA has the authority to require a Risk Evaluation and Mitigation Strategy
(REMS) plan as part of approving an NDA, or after approval, which may impose further requirements or restrictions on the distribution
or use of an approved drug. These requirements or restrictions might include limiting prescribing to certain physicians or medical centers
that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients
to enroll in a registry. These limitations and restrictions may significantly limit the size of the market for the drug and affect reimbursement
by third-party payors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also subject to numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing
and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process varies among countries, and
generally includes all of the risks associated with FDA and EMA approval described above as well as risks attributable to the satisfaction
of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval may differ from that required to obtain
FDA approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
FDA, EMA and other comparable foreign regulatory authorities may not accept data from trials conducted in locations outside of their
jurisdiction.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ongoing clinical trials are being undertaken in the United States. We may choose to conduct additional clinical trials internationally.
The acceptance of study data by the FDA, EMA or other comparable foreign regulatory authority from clinical trials conducted outside
of their respective jurisdictions may be subject to certain conditions. In cases where data from United States clinical trials are intended
to serve as the basis for marketing approval in the foreign countries outside the United States, the standards for clinical trials and
approval may be different. There can be no assurance that any United States or foreign regulatory authority would accept data from trials
conducted outside of its applicable jurisdiction. If the FDA, EMA or any applicable foreign regulatory authority does not accept such
data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan,
and which may result in our product candidates not receiving approval or clearance for commercialization in the applicable jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Obtaining
and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining
regulatory approval of our product candidates in other jurisdictions.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or
maintain regulatory approval in any other jurisdiction. For example, even if the FDA or EMA grants marketing approval of a product candidate,
comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion and reimbursement
of the product candidate in those countries. However, a failure or delay in obtaining regulatory approval in one jurisdiction may have
a negative effect on the regulatory approval process in others. Approval procedures vary among jurisdictions and can involve requirements
and administrative review periods different from those in the United States, including additional preclinical studies or clinical trials
as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions
outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction.
In some cases, the price that we intend to charge for our products is also subject to approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
foreign regulatory approvals and establishing and maintaining compliance with foreign regulatory requirements could result in significant
delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we or any
future collaborator fail to comply with the regulatory requirements in international markets or fail to receive applicable marketing
approvals, our target market will be reduced and our ability to realize the full market potential of our potential product candidates
will be harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
regulatory approval processes for product candidates that target rare diseases, including MPS I, Friedreich&rsquo;s ataxia, and MELAS
are uncertain.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the lack of precedent, broad discretion of regulatory authorities, and a multitude of unique factors that impact the regulatory approval
process, the likelihood of the approval of any of our product candidates that target rare diseases, such as MPS I, Friedreich&rsquo;s
ataxia, and MELAS is uncertain, and we may not be able to anticipate, prepare for or satisfy requests or requirements from regulatory
authorities, including completing and submitting planned Investigational New Drug (IND) and new drug applications (NDA) for our product
candidates, in a timely manner, or at all. For example, MPS I is a rare disease for which there is only one FDA approved therapeutics.
In addition, no therapies are currently approved for  MELAS in the United States or the EU. Further,
the FDA may determine, after evaluation of our data and analyses, that such data and analyses do not support an NDA submission, filing
or approval. Due to this lack of predictability, we may not have the resources necessary to meet regulatory requirements and successfully
complete a potentially protracted, expensive and wide-ranging approval process for commercialization of product candidates for rare diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if our product candidates receive regulatory approval, they will be subject to significant post-marketing regulatory requirements and
oversight.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
regulatory approvals that we may receive for our product candidates will require the submission of reports to regulatory authorities
and on-going surveillance to monitor the safety and efficacy of the product candidate, may contain significant limitations related to
use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study
or risk management requirements and regulatory inspection. For example, the FDA may require a REMS in order to approve our product candidates,
which could entail requirements for a medication guide, physician training and communication plans or additional elements to ensure safe
use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or foreign
regulatory authorities approve our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event
reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive
and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports,
registration, as well as on-going compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval. In addition,
manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA
and other regulatory authorities for compliance with cGMP regulations and standards. If we or a regulatory agency discover previously
unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facilities where
the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including
requiring recall or withdrawal of the product from the market or suspension of manufacturing. In addition, failure to comply with FDA,
EMA and other comparable foreign regulatory requirements may subject our company to administrative or judicially imposed sanctions, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in or the rejection of product approvals;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on the products, manufacturers or manufacturing process;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">warning
    or untitled letters;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">civil
    and criminal penalties;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
    or withdrawal of regulatory approvals;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    seizures, detentions or import bans;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">voluntary
    or mandatory product recalls and publicity requirements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">total
    or partial suspension of production; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposition
    of restrictions on operations, including costly new manufacturing requirements.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates, if approved, and
generate revenue. Furthermore, non-compliance by us or any future collaborator with regulatory requirements, including safety monitoring
and with requirements related to the development of products for the pediatric population can also result in significant financial penalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be able to obtain orphan drug designation or obtain or maintain orphan drug exclusivity for our product candidates and, even
if we do, that exclusivity may not prevent the FDA, EMA or other comparable foreign regulatory authorities, from approving competing
products.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
authorities in some jurisdictions, including the United States and the EU, may designate drugs for relatively small patient populations
as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare
disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States,
or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing
the drug will be recovered from sales in the United States. However, there can be no assurances that we will be able to obtain orphan
designations for our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical
trial costs, tax advantages and user-fee waivers. In addition, if a product that has orphan drug designation subsequently receives the
first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity. Orphan drug
exclusivity in the United States provides that the FDA may not approve any other applications, including a full NDA, to market the same
drug for the same indication for seven years, except in limited circumstances. The applicable exclusivity period is 10 years in Europe.
The European exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan drug designation or if
the drug is sufficiently profitable so that market exclusivity is no longer justified.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
submitted a request to FDA and received orphan drug designation for Friedreich&rsquo;s ataxia. We intend to seek orphan drug designation
for JOTROL in MPS I and may seek orphan drug designation for other product candidates. Even if we obtain orphan drug designation
for a product candidate, we may not be able to obtain or maintain orphan drug exclusivity for that product candidate. We may not be the
first to obtain marketing approval of any product candidate for which we have obtained orphan drug designation for the orphan-designated
indication due to the uncertainties associated with developing pharmaceutical products. In addition, exclusive marketing rights in the
United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the
FDA later determines that the request for designation was materially defective or if we are unable to ensure that we will be able to
manufacture sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we
obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different
drugs with different active moieties may be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently
approve the same drug with the same active moiety for the same condition if the FDA concludes that the later drug is clinically superior
in that it is shown to be safer, more effective or makes a major contribution to patient care or the manufacturer of the product with
orphan exclusivity is unable to maintain sufficient product quantity. Orphan drug designation neither shortens the development time or
regulatory review time of a drug nor gives the product candidate any advantage in the regulatory review or approval process or entitles
the product candidate to priority review.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Where
appropriate, we plan to secure approval from the FDA or comparable foreign regulatory authorities through the use of accelerated registration
pathways. If we are unable to obtain such approval, we may be required to conduct additional preclinical studies or clinical trials beyond
those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even
if we receive accelerated approval from the FDA, if our confirmatory trials do not verify clinical benefit, or if we do not comply with
rigorous post-marketing requirements, the FDA may seek to withdraw accelerated approval.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
possible, we plan to pursue accelerated development strategies in areas of high unmet need. We may seek an accelerated approval pathway
for our one or more of our product candidates. Under the accelerated approval provisions in the Federal Food, Drug, and Cosmetic Act,
and the FDA&rsquo;s implementing regulations, the FDA may grant accelerated approval to a product candidate designed to treat a serious
or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the product
candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit.
The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease,
such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory
measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure
of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible
morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit.
The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct
therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated
approval is usually contingent on the sponsor&rsquo;s agreement to conduct, in a diligent manner, additional post-approval confirmatory
studies to verify and describe the drug&rsquo;s clinical benefit. If such post-approval studies fail to confirm the drug&rsquo;s clinical
benefit, the FDA may withdraw its approval of the drug.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to seeking such accelerated approval, we will seek feedback from the FDA and will otherwise evaluate our ability to seek and receive
such accelerated approval. There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue
or submit an NDA for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no
assurance that after subsequent FDA feedback we will continue to pursue or apply for accelerated approval or any other form of expedited
development, review or approval, even if we initially decide to do so. Furthermore, if we decide to submit an application for accelerated
approval or under another expedited regulatory designation (e.g., breakthrough therapy designation), there can be no assurance that such
submission or application will be accepted or that any expedited development, review or approval will be granted on a timely basis, or
at all. The FDA or other comparable foreign regulatory authorities could also require us to conduct further studies prior to considering
our application or granting approval of any type. A failure to obtain accelerated approval or any other form of expedited development,
review or approval for our product candidate would result in a longer time period to commercialization of such product candidate, could
increase the cost of development of such product candidate and could harm our competitive position in the marketplace.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may face difficulties from changes to current regulations and future legislation.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Existing
regulatory policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval
of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation
or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements
or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval
that we may have obtained, and we may not achieve or sustain profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative
or executive action, either in the United States or abroad. For example, certain policies of the current U.S. administration may impact
our business and industry, which could impose significant burdens on, or otherwise materially delay, the FDA&rsquo;s ability to engage
in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and
approval of marketing applications. It is difficult to predict how current and future legislation, executive actions, and litigation,
including the executive orders referenced below, will be implemented, and the extent to which they will impact our business, our clinical
development, and the FDA&rsquo;s and other agencies&rsquo; ability to exercise their regulatory authority, including FDA&rsquo;s pre-approval
inspection and timely review of any regulatory filings or applications we submit to the FDA. If these executive actions impose constraints
on FDA&rsquo;s ability to engage in oversight and implementation activities in the normal course or constraints on our business operations,
including operations of our contractors, our business may be negatively impacted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, in March 2010, the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation
Act of 2010 (collectively, the ACA), was passed, which substantially changed the way healthcare is financed by both the government and
private insurers, and continues to significantly impact the U.S. pharmaceutical industry. Since its enactment, there have been judicial
and Congressional challenges to certain aspects of the ACA. For example, various portions of the ACA are currently undergoing legal and
constitutional challenges in the United States Supreme Court. Although the Supreme Court has not yet ruled on the constitutionality of
the ACA, on January 28, 2021, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021
through May 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructs
certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among
others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary
barriers to obtaining access to health insurance coverage through Medicaid or the ACA. We cannot predict how the Supreme Court will rule
on these challenges, how future litigation will impact our business, or what other healthcare measures and regulations will ultimately
be implemented at the federal or state level or the effect of any future legislation or regulation may have on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. These changes included
aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, effective April 1, 2013, which will remain in effect
through 2030. In January 2013, President Obama signed into law the American
Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several providers, and increased the statute of
limitations period for the government to recover overpayments to providers from three to five years. These laws may result in additional
reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for our drugs, if approved,
and accordingly, our financial operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
there has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products,
which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other
things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform
government program reimbursement methodologies for drug products. For example, in May 2019, CMS issued a final rule to allow Medicare
Advantage Plans the option of using step therapy for Part B drugs beginning January 1, 2020. This final rule codified CMS&rsquo;s policy
change that was effective January 1, 2019. At the federal level, the Trump administration used several means to propose or implement
drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, in 2020, HHS and
CMS issued various rules that are expected to impact, among others, price reductions from pharmaceutical manufacturers to plan sponsors
under Part D, fee arrangements between pharmacy benefit managers and manufacturers, manufacturer price reporting requirements under the
Medicaid Drug Rebate Program, including regulations that affect manufacturer-sponsored patient assistance programs subject to pharmacy
benefit manager accumulator programs and Best Price reporting related to certain value-based purchasing arrangements. Multiple lawsuits
have been brought against the HHS challenging various aspects of the rules. In January 2021, the Biden administration issued a &ldquo;regulatory
freeze&rdquo; memorandum that directs department and agency heads to review new or pending rules of the prior administration. It is unclear
whether these new regulations will be withdrawn or when they will become fully effective under the Biden administration. The impact of
these lawsuits as well as legislative, executive, and administrative actions of the Biden administration on us and the pharmaceutical
industry as a whole is unclear.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product
pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure
and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We are unable
to predict the future course of federal or state healthcare legislation in the United States directed at broadening the availability
of healthcare and containing or lowering the cost of healthcare. These and any further changes in the law or regulatory framework that
reduce our revenue or increase our costs could also have a material and adverse effect on our business, financial condition and results
of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage
criteria and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from
Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment
measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product
candidates. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legislative
and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for biotechnology
products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations
will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition,
increased scrutiny by Congress of the FDA&rsquo;s approval process may significantly delay or prevent marketing approval, as well as
subject us to more stringent product labeling and post-marketing testing and other requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
regulatory framework for privacy and personal information security issues worldwide is rapidly evolving and is likely to remain uncertain
for the foreseeable future. The U.S. federal and various state, local and foreign government bodies and agencies have adopted or are
considering adopting laws and regulations limiting, or laws and regulations regarding, the collection, distribution, use, disclosure,
storage, security and other processing of personal information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the collection and use of health data and other personal data is governed in the EU by the General Data Protection Regulation (GDPR),
which extends the geographical scope of EU data protection law to entities and operations outside of the EU under certain conditions
and imposes substantial obligations upon companies and new rights for individuals, and by certain EU Member State-level legislation.
Failure to comply with the GDPR may result in fines up to &euro;20,000,000 or up to 4% of the total worldwide annual turnover of the
preceding financial year, whichever is higher, and other administrative penalties. The GDPR may increase our responsibility and liability
in relation to personal data that we may process, and we may be required to put in place additional measures in an effort to comply with
the GDPR and with other laws and regulations in the EU, including those of EU Member States, relating to privacy and data protection.
This may be onerous and if our efforts to comply with GDPR or other applicable EU laws and regulations are not successful, or are perceived
to be unsuccessful, it could adversely affect our business in the EU. Further, the European Court of Justice (ECJ) invalidated the EU-U.S.
Privacy Shield, which had enabled the transfer of personal data from the EU to the U.S. for companies that had self-certified to the
Privacy Shield in July 2020. The ECJ decision also raised questions about the continued validity of one of the primary alternatives to
the EU-U.S. Privacy Shield, namely the European Commission&rsquo;s Standard Contractual Clauses, and EU regulators have issued additional
guidance regarding considerations and requirements that we and other companies must consider and undertake when using the Standard Contractual
Clauses. Although the EU has presented a new draft set of contractual clauses, at present, there are few, if any, viable alternatives
to the EU-U.S. Privacy Shield and the Standard Contractual Clauses. To the extent that we were to rely on the EU-U.S. or Swiss-U.S. Privacy
Shield programs, we will not be able to do so in the future, and the ECJ&rsquo;s decision and other regulatory guidance or developments
otherwise may impose additional obligations with respect to the transfer of personal data from the EU and Switzerland to the U.S., each
of which could restrict our activities in those jurisdictions, limit our ability to provide our products and services in those jurisdictions,
or increase our costs and obligations and impose limitations upon our ability to efficiently transfer personal data from the EU and Switzerland
to the U.S.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the exit of the United Kingdom (UK) from the EU, often referred to as Brexit, has created uncertainty with regard to data protection
regulation in the UK. Specifically, the UK exited the EU on January 1, 2020, subject to a transition period that ended December 31, 2020.
Under the post-Brexit Trade and Cooperation Agreement between the EU and the UK, the UK and EU have agreed that transfers of personal
data to the UK from EEA member states will not be treated as &lsquo;restricted transfers&rsquo; to a non-EEA country for a period of
up to four months from January 1, 2021, plus a potential further two-month extension (the &ldquo;Extended Adequacy Assessment Period&rdquo;).
Although the current maximum duration of the Extended Adequacy Assessment Period is six months, it may end sooner, for example, in the
event that the European Commission adopts an &lsquo;adequacy decision&rsquo; in respect of the UK, or the UK amends the UK GDPR and/or
makes certain changes regarding data transfers under the UK GDPR/Data Protection Act 2018 without the consent of the EU (unless those
amendments or decisions are made simply to keep relevant UK laws aligned with the EU&rsquo;s data protection regime). If the European
Commission does not adopt an &lsquo;adequacy decision&rsquo; in respect of the UK prior to the expiry of the Extended Adequacy Assessment
Period, from that point onwards the UK will be an &lsquo;inadequate third country&rsquo; under the GDPR and transfers of personal data
from the EEA to the UK will require a &lsquo;transfer mechanism&rsquo; such as the Standard Contractual Clauses. The UK has implemented
legislation similar to the GDPR, referred to as the UK GDPR, which provides for fines of up to the greater of &pound;17.5 million or
4% of global turnover. As of January 1, 2021, the UK is a &ldquo;third country&rdquo; under the GDPR, and the relationship between the
UK and EU in relation to aspects of data protection law in the medium and longer term remains unclear, including with respect to cross-border
data transfers and the role of the UK Information Commissioner&rsquo;s Office with respect to the EU, which exposes us to further compliance
risk. We may incur liabilities, expenses, costs, and other operational losses relating to the GDPR, the UK GDPR, and other laws and regulations
in the EU and UK relating to privacy and data protection, including those of applicable EU Member States in connection with any measures
we take to comply with them. Finally, state and foreign laws may apply generally to the privacy and security of information we maintain,
and may differ from each other in significant ways, thus complicating compliance efforts and potentially requiring us to undertake additional
measures to comply with them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, there are a broad variety of data protection laws and regulations that may apply to our activities such as state data
breach notification laws, state personal data privacy laws (for example, the California Consumer Privacy Act of 2018 (CCPA)), state health
information privacy laws, and federal and state consumer protection laws. A range of enforcement agencies exist at both the state and
federal levels that can enforce these laws and regulations. For example, the CCPA requires covered businesses that process personal information
of California residents to disclose their data collection, use and sharing practices. Further, the CCPA provides California residents
with new data privacy rights (including the ability to opt out of certain disclosures of personal data), imposes new operational requirements
for covered businesses, provides for civil penalties for violations as well as a private right of action for data breaches and statutory
damages (that is expected to increase data breach class action litigation and result in significant exposure to costly legal judgements
and settlements). Aspects of the CCPA and its interpretation and enforcement remain uncertain. In addition, it is anticipated that the
CCPA will be expanded on January 1, 2023, when the California Privacy Rights Act of 2020 (CPRA) becomes operative. The CPRA will, among
other things, give California residents the ability to limit use of certain sensitive personal information, further restrict the use
of cross-contextual advertising, establish restrictions on the retention of personal information, expand the types of data breaches subject
to the CCPA&rsquo;s private right of action, provide for increased penalties for CPRA violations concerning California residents under
the age of 16, and establish a new California Privacy Protection Agency to implement and enforce the new legislation. Although there
are limited exemptions for clinical trial data under the CCPA, the CCPA and other similar laws could impact our business activities,
depending on their interpretation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
the GDPR, CCPA, CRPA and other laws, regulations and other obligations relating to privacy and data protection imposing new and relatively
burdensome obligations, and with substantial uncertainty over the interpretation and application of these and other obligations, we may
face challenges in addressing their requirements and making necessary changes to our policies and practices, and may incur significant
costs and expenses in an effort to do so. Additionally, if third parties we work with, such as vendors or service providers, violate
applicable laws or regulations or our policies, such violations may also put our or our customers&rsquo; data at risk and could in turn
have an adverse effect on our business. Any failure or perceived failure by us or our service providers to comply with our applicable
policies or notices relating to privacy or data protection, our contractual or other obligations to third parties, or any of our other
legal obligations relating to privacy or data protection, may result in governmental investigations or enforcement actions, litigation,
claims and other proceedings, harm our reputation, and could result in significant liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Inadequate
funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel,
prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from
performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding
levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes.
Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the U.S. Securities
and Exchange Commission (SEC) and other government agencies on which our operations may rely, including those that fund research and
development activities is subject to the political process, which is inherently fluid and unpredictable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disruptions
at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies,
which would adversely affect our business. For example, in recent years, including in 2018 and 2019, the U.S. government shut down several
times and certain regulatory agencies, such as the FDA and the SEC, had to furlough critical employees and stop critical activities.
If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory
submissions, which could have a material adverse effect on our business. Further, upon completion of this offering and in our operations
as a public company, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in
order to properly capitalize and continue our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
relationships with healthcare professionals, clinical investigators, CROs and third-party payors in connection with our current and future
business activities may be subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, government
price reporting, and health information privacy and security laws, which could expose us to significant losses, including, among other
things, criminal sanctions, civil penalties, contractual damages, exclusion from governmental healthcare programs, reputational harm,
administrative burdens and diminished profits and future earnings.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
providers and third-party payors play a primary role in the recommendation and prescription of any product candidates for which we obtain
marketing approval. Our current and future arrangements with healthcare professionals, clinical investigators, CROs, third-party payors
and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business
or financial arrangements and relationships through which we research, as well as market, sell and distribute our products for which
we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations may include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering,
    receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the
    referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under
    a federal healthcare program such as Medicare and Medicaid;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal false claims laws, including the civil False Claims Act, which can be enforced by private citizens through civil whistleblower
    or qui tam actions, and civil monetary penalties laws, prohibit individuals or entities from, among other things, knowingly presenting,
    or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement
    to avoid, decrease or conceal an obligation to pay money to the federal government;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), prohibits, among other things, executing or attempting
    to execute a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
    as amended by the Health Information Technology for Economic and Clinical Health Act (HITECH) and their implementing regulations,
    also imposes obligations, including mandatory contractual terms, on covered entities, which are health plans, healthcare clearinghouses,
    and certain health care providers, as those terms are defined by HIPAA, and their respective business associates and their subcontractors,
    with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 48; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Physician Payments Sunshine Act requires applicable manufacturers of covered drugs, devices, biologics and medical supplies
    for which payment is available under Medicare, Medicaid or the Children&rsquo;s Health Insurance Program, with specific exceptions,
    to annually report to CMS information regarding payments and other transfers of value to physicians, defined to include doctors,
    dentists, optometrists, podiatrists and chiropractors, and teaching hospitals as well as information regarding ownership and investment
    interests held by physicians and their immediate family members. Beginning in 2022, reporting obligations with respect to covered
    recipients will be expanded to include physician assistants, nurse practitioners, clinical nurse specialists, certified registered
    nurse anesthetists and anesthesiologist assistants, and certified nurse midwives for payments and transfers of value made during
    the previous year; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">analogous
    state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements
    and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers;
    state laws that require pharmaceutical companies to comply with the pharmaceutical industry&rsquo;s voluntary compliance guidelines
    and the relevant compliance regulations promulgated by the federal government and may require drug manufacturers to report information
    related to payments and other transfers of value to physicians and other healthcare providers, marketing expenditures, or drug pricing;
    state and local laws that require the registration of pharmaceutical sales and medical representatives; state laws that govern the
    privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often
    are not preempted by HIPAA, thus complicating compliance efforts.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Efforts
to ensure that our current and future business arrangements with third parties will comply with applicable healthcare and data privacy
laws and regulations will involve substantial ongoing costs, and may require us to undertake or implement additional policies or measures.
We may face claims and proceedings by private parties, and claims, investigations and other proceedings by governmental authorities,
relating to allegations that our business practices do not comply with current or future statutes, regulations or case law involving
applicable fraud and abuse or other healthcare laws and regulations, and it is possible that courts or governmental authorities may conclude
that we have not complied with them, or that we may find it necessary or appropriate to settle any such claims or other proceedings.
In connection with any such claims, proceedings, or settlements, we may be subject to significant penalties, including civil, criminal
and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government funded healthcare
programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished
profits and future earnings and the curtailment or restructuring of our operations. Defending against any such actions can be costly,
time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against
any such actions that may be brought against us, our business may be impaired. Further, if any of the physicians or other healthcare
providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to
criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage
in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to the risk that our employees, independent contractors, consultants, commercial collaborators, principal investigators,
CROs, suppliers and vendors may engage in misconduct or other improper activities. Misconduct by these parties could include failures
to comply with FDA regulations, provide accurate information to the FDA, comply with federal and state health care fraud and abuse laws
and regulations, accurately report financial information or data or disclose unauthorized activities to us. In particular, research,
sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent
fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range
of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct
by these parties could also involve the improper use of information obtained in the course of clinical trials, which could result in
regulatory sanctions and serious harm to our reputation. We will adopt a code of conduct, which will become effective as of the date
of the effectiveness of the registration statement of which this prospectus forms a part, but it is not always possible to identify and
deter misconduct by these parties, and the precautions we take to detect and prevent this activity may not be effective in controlling
unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from
a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending
ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant
penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation
in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages,
reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 49; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur
costs that could have a material adverse effect on our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the
handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable
materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract
with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these
materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting
damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines
and penalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we maintain workers&rsquo; compensation insurance to cover us for costs and expenses, we may incur due to injuries to our employees resulting
from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain
insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal
of hazardous and flammable materials, including chemicals and biological materials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations.
These current or future laws and regulations may impair our research, development or commercialization efforts. Failure to comply with
these laws and regulations also may result in substantial fines, penalties or other sanctions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
business activities may be subject to the U.S. Foreign Corrupt Practices Act and similar anti-bribery and anti-corruption laws of other
countries in which we operate, as well as U.S. and certain foreign export controls, trade sanctions, and import laws and regulations.
Compliance with these legal requirements could limit our ability to compete in foreign markets and subject us to liability if we violate
them.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business activities are subject to the U.S. Foreign Corrupt Practices Act of 1977, as amended (FCPA), the U.S. domestic bribery statute
contained in 18 U.S.C. &sect; 201, the U.S. Travel Act, and similar anti-bribery or anti-corruption laws, regulations or rules of other
countries in which we operate. These laws generally prohibit companies and their employees, agents, representatives, business partners,
and third-party intermediaries from, directly or indirectly, offering, promising, giving or authorizing others to give anything of value,
either directly or indirectly, to recipients in the public or private sector in order to influence official action or otherwise obtain
or retain business. Our business is heavily regulated and therefore involves significant interaction with public officials, including
officials of non-U.S. governments. Additionally, in many other countries, hospitals are owned and operated by the government, and doctors
and other hospital employees would be considered foreign officials under the FCPA. Recently, the SEC and DOJ have increased their FCPA
enforcement activities with respect to biotechnology and pharmaceutical companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
sometimes leverage third parties to assist with the conduct of our business abroad. We, our employees, agents, representatives, business
partners and our third-party intermediaries may have direct or indirect interactions with officials and employees of government agencies
or state-owned or affiliated entities and may be held liable for the corrupt or other illegal activities of these employees, agents,
representatives, business partners or third-party intermediaries even if we do not explicitly authorize such activities. We cannot assure
you that all of our employees, agents, representatives, business partners and third-party intermediaries will not take actions in violation
of applicable law for which we may be ultimately held responsible. As we increase our international sales and business, our risks under
these laws may increase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 50; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
laws also require that we make and keep books and records that accurately and fairly reflect the transactions of the corporation and
to devise and maintain an adequate system of internal accounting controls and compliance procedures designed to prevent violations of
anti-corruption laws. There is no certainty that all of our employees, agents, representatives, business partners and third-party intermediaries,
or those of our affiliates, will comply with applicable laws and regulations, for which we may be ultimately held responsible.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Violations
of these laws and regulations could result in whistleblower complaints, fines, severe civil or criminal sanctions, settlements, prosecution,
enforcement actions, damages, adverse media coverage, investigations, loss of export privileges, disgorgement, and other remedial measures
and prohibitions on the conduct of our business including our ability to offer our products in one or more countries. Responding to any
investigation or action will likely result in a materially significant diversion of management&rsquo;s attention and resources and significant
defense costs and other professional fees. As a general matter, investigations, enforcement actions and sanctions could damage our reputation,
our brand, our international activities, our ability to attract and retain employees and our business, prospects, operating results and
financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our products may be subject to U.S. and foreign export controls, trade sanctions and import laws and regulations. Governmental
regulation of the import or export of our products, or our failure to obtain any required import or export authorization for our products,
when applicable, could harm our international sales and adversely affect our revenue. Compliance with applicable regulatory requirements
regarding the export of our products may create delays in the introduction of our products in international markets or, in some cases,
prevent the export of our products to some countries altogether. Furthermore, U.S. export control laws and economic sanctions prohibit
the shipment of certain products and services to countries, governments, and persons targeted by U.S. sanctions. If we fail to comply
with export and import regulations and such economic sanctions, penalties could be imposed, including fines and/or denial of certain
export privileges. Moreover, any new export or import restrictions, new legislation or shifting approaches in the enforcement or scope
of existing regulations, or in the countries, persons, or products targeted by such regulations, could result in decreased use of our
products by, or in our decreased ability to export our products to, existing or potential customers with international operations. Any
decreased use of our products or limitation on our ability to export or sell our products would likely adversely affect our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Employee Matters, Managing Our Growth and Other Risks Related to Our Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
success is highly dependent on our ability to attract and retain highly skilled executive officers and employees.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
succeed, we must recruit, retain, manage and motivate qualified clinical, scientific, technical and management personnel, and we face
significant competition for experienced personnel. We are highly dependent on the principal members of our management and scientific
and medical staff, particularly Marshall Hayward, our Co-Founder and Chief Scientific Officer. If we do not succeed in attracting and retaining qualified personnel, particularly
at the management level, it could adversely affect our ability to execute our business plan and harm our operating results. In particular,
the loss of one or more of our executive officers could be detrimental to us if we cannot recruit suitable replacements in a timely manner.
We do not maintain &ldquo;key person&rdquo; insurance for any of our executives or other employees. We could in the future have difficulty
attracting and retaining experienced personnel and may be required to expend significant financial resources in our employee recruitment
and retention efforts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of the other biotechnology companies that we compete against for qualified personnel have greater financial and other resources, different
risk profiles and a longer history in the industry than we do. They also may provide higher compensation, more diverse opportunities
and better prospects for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what
we have to offer. If we are unable to continue to attract and retain high-quality personnel, the rate and success at which we can discover,
develop and commercialize our product candidates will be limited and the potential for successfully growing our business will be harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 51; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
we rely on our scientific founders and other scientific and clinical advisors and consultants to assist us in formulating our research,
development and clinical strategies. These advisors and consultants are not our employees and may have commitments to, or consulting
or advisory contracts with, other entities that may limit their availability to us. In addition, these advisors and consultants typically
will not enter into non-compete agreements with us. If a conflict of interest arises between their work for us and their work for another
entity, we may lose their services. Furthermore, our advisors may have arrangements with other companies to assist those companies in
developing products or technologies that may compete with ours. In particular, if we are unable to maintain consulting relationships
with our scientific founders or if they provide services to our competitors, our development and commercialization efforts will be impaired
and our business will be significantly harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are unable to establish sales or marketing capabilities or enter into agreements with third parties to sell or market our product
candidates, we may not be able to successfully sell or market our product candidates that obtain regulatory approval.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently do not have and have never had a marketing or sales team. In order to commercialize any product candidates, if approved, we
must build marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to
perform these services for each of the territories in which we may have approval to sell or market our product candidates. We may not
be successful in accomplishing these required tasks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Establishing
an internal sales or marketing team with technical expertise and supporting distribution capabilities to commercialize our product candidates
will be expensive and time-consuming and will require significant attention of our executive officers to manage. Any failure or delay
in the development of our internal sales, marketing and distribution capabilities could adversely impact the commercialization of any
of our product candidates that we obtain approval to market, if we do not have arrangements in place with third parties to provide such
services, which is our preferred marketing and sales strategy, on our behalf. Alternatively, if we choose to collaborate, either globally
or on a territory-by-territory basis, with third parties that have direct sales forces and established distribution systems, either to
augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems, we will be required
to negotiate and enter into arrangements with such third parties relating to the proposed collaboration and such arrangements may prove
to be less profitable than commercializing the product on our own. If we are unable to enter into such arrangements when needed, on acceptable
terms, or at all, we may not be able to successfully commercialize any of our product candidates that receive regulatory approval, or
any such commercialization may experience delays or limitations. If we are unable to successfully commercialize our approved product
candidates, either on our own or through collaborations with one or more third parties, our future product revenue will suffer, and we
may incur significant additional losses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>In
order to successfully implement our plans and strategies, we will need to grow the size of our organization, and we may experience difficulties
in managing this growth.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of January 3, 2023, we had a total of 4 full-time employees, 1 full-time consultant and 7 part-time consultants
plus our 6 Scientific Advisory Board members. Of these, 10 were primarily engaged in research or product development and clinical activities.
In order to successfully implement our development and commercialization plans and strategies, and as we transition into operating as
a public company, we expect to hire additional managerial, operational, sales, marketing, financial and other personnel, as reflected
in our organization chart represented in our Operation and Organization section. Future growth would impose significant added responsibilities
on members of management, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying,
    recruiting, integrating, maintaining and motivating additional employees;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">managing
    our internal development efforts effectively, including the clinical, FDA, EMA and other comparable foreign regulatory agencies&rsquo;
    review process for JOTROL and any other product candidates, while complying with any contractual obligations to contractors
    and other third parties we may have; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">improving
    our operational, financial and management controls, reporting systems and procedures.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 52; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future financial performance and our ability to successfully develop and, if approved, commercialize JOTROL and other product
candidates will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert a
disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing
these growth activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors
and consultants to provide certain services, including key aspects of our research and development, clinical development and manufacturing.
We cannot assure you that the services of independent organizations, advisors and consultants will continue to be available to us on
a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced
activities or if the quality or accuracy of the services provided by third-party service providers is compromised for any reason, our
clinical trials may be extended, delayed or terminated, and we may not be able to obtain marketing approval of JOTROL and any
other product candidates or otherwise advance our business. We cannot assure you that we will be able to manage our existing third-party
service providers or find other competent outside contractors and consultants on economically reasonable terms, or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are not able to effectively expand our organization by hiring new employees and/or engaging additional third-party service providers,
we may not be able to successfully implement the tasks necessary to further develop and commercialize JOTROL and other product
candidates and, accordingly, may not achieve our research, development and commercialization goals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
computer systems, or those of any of our CROs, manufacturers, other contractors or consultants or potential future collaborators, may
fail or suffer security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of our proprietary
or confidential data, employee data, or personal data, which could result in additional costs, loss of revenue, significant liabilities,
harm to our brand and material disruption of our operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
the implementation of security measures in an effort to protect systems that store our information, given their size and complexity and
the increasing amounts of information maintained on our internal information technology systems, and those of our third-party CROs, other
contractors (including sites performing our clinical trials) and consultants, these systems are potentially vulnerable to breakdown or
other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war and telecommunication
and electrical failures, as well as security breaches from inadvertent or intentional actions by our employees, contractors, consultants,
business partners, and/or other third parties, or from cyber-attacks by malicious third parties (including supply chain cyber attacks
or the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability
and threaten the confidentiality, integrity and availability of information), which may compromise our system infrastructure or lead
to the loss, destruction, alteration, prevention of access to, disclosure, or dissemination of, or damage or unauthorized access to,
our data (including trade secrets or other confidential information, intellectual property, proprietary business information, and personal
information) or data that is processed or maintained on our behalf, or other assets, which could result in financial, legal, business
and reputational harm to us. For example, in 2019, one our CROs experienced a cybersecurity breach which resulted in unauthorized access
to certain of our preclinical data. We have received phishing attacks, and companies have, in general, experienced an increase in phishing
and social engineering attacks from third parties, and the increase in remote working further
increases security threats. To the extent that any disruption or security incident were to result in any loss, destruction, unavailability,
alteration, disclosure, or dissemination of, or damage or unauthorized access to, our applications, any other data processed or maintained
on our behalf or other assets, or for it to be believed or reported that any of these occurred, we could incur liability, financial harm
and reputational damage and the development and commercialization of our product candidates could be delayed. We cannot assure you that
our data protection efforts and our investment in information technology, or the efforts or investments of CROs, consultants or other
third parties, will prevent significant breakdowns or breaches in systems or other cyber incidents that cause loss, destruction, unavailability,
alteration or dissemination of, or damage or unauthorized access to, our data and other data processed or maintained on our behalf or
other assets that could have a material adverse effect upon our reputation, business, operations or financial condition. For example,
if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our programs and
the development of our product candidates could be delayed. In addition, the loss of clinical trial data for our product candidates could
result in delays in our marketing approval efforts and significantly increase our costs to recover or reproduce the data. Further, any
such event that leads to loss, damage, or unauthorized access to, or use, alteration, or disclosure or dissemination of, personal information,
including personal information regarding our clinical trial subjects or employees, could harm our reputation directly, compel us to comply
with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, and otherwise
subject us to liability under laws and regulations that protect the privacy and security of personal information, which could result
in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 53; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notifications
and follow-up actions related to a security incident could impact our reputation and cause us to incur significant costs, including legal
expenses and remediation costs. For example, the loss of clinical trial data from completed or future clinical trials could result in
delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the lost data. We expect to incur
significant costs in an effort to detect and prevent security incidents, and we may face increased costs and requirements to expend substantial
resources in the event of an actual or perceived security incident. We also rely on third parties to manufacture our product candidates,
and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any
disruption or security incident were to result in any loss, destruction, or alteration of, or damage or unauthorized access to, our data
or other information that is processed or maintained on our behalf, or inappropriate disclosure of or dissemination of any such information,
we could be exposed to litigation and governmental investigations, the further development and commercialization of our product candidates
could be delayed, and we could be subject to significant fines or penalties for any noncompliance with certain state, federal and/or
international privacy and security laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
insurance policies may not be adequate to compensate us for the potential losses arising from any such disruption in or, failure or security
breach of our systems or third-party systems where information important to our business operations or commercial development is stored.
In addition, such insurance may not be available to us in the future on economically reasonable terms, or at all. Further, our insurance
may not cover all claims made against us and could have high deductibles in any event, and defending a suit, regardless of its merit,
could be costly and divert management attention.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
operations are vulnerable to interruption by fire, earthquakes, power loss, telecommunications failure, terrorist activity, pandemics
and other events beyond our control, which could harm our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
facilities are located in Jupiter, Florida. We have not undertaken a systematic analysis of the potential consequences to our business
and financial results from a major flood, blizzard, fire, earthquake, power loss, terrorist activity, pandemics or other disasters and
do not have a recovery plan for such disasters. In addition, we do not carry sufficient insurance to compensate us for actual losses
from interruption of our business that may occur, and any losses or damages incurred by us could harm our business. Also, our contract
development and manufacturing organizations&rsquo; (CDMOs) and suppliers&rsquo; facilities are located in multiple locations where other
natural disasters or similar events which could severely disrupt our operations, could expose us to liability and could have a material
adverse effect on our business. The occurrence of any of these business disruptions could seriously harm our operations and financial
condition and increase our costs and expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 54; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>A
variety of risks associated with marketing our product candidates internationally could materially adversely affect our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may seek regulatory approval of our product candidates outside of the United States and, accordingly, we expect that we will be subject
to additional risks related to operating in foreign countries if we obtain the necessary approvals, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">differing
    regulatory requirements and reimbursement regimes in foreign countries;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unexpected
    changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">economic
    weakness, including inflation, or political instability in particular foreign economies and markets;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance
    with tax, employment, immigration and labor laws for employees living or traveling abroad;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign
    taxes, including withholding of payroll taxes;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign
    currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to
    doing business in another country;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties
    staffing and managing foreign operations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">workforce
    uncertainty in countries where labor unrest is more common than in the United States;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    liability under the FCPA or comparable foreign regulations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">challenges
    enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect
    intellectual property rights to the same extent as the United States;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">production
    shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">business
    interruptions resulting from geo-political actions, including war and terrorism.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
and other risks associated with our international operations may materially adversely affect our ability to attain or maintain profitable
operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
certificate of incorporation, as amended, and amended and restated bylaws provides that state or federal court located
within the state of Delaware will be the sole and exclusive forum for substantially all disputes between us and our shareholders, which
could limit its stockholders&rsquo; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or other
employees.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
IX of our certificate of incorporation, as amended, and Section 7.4 of our amended and restated bylaws provides that &ldquo;unless
the corporation consents in writing to the selection of an alternative forum, the sole and exclusive forum for (i) any derivative
action or proceeding brought on behalf of the Corporation, (ii) any action asserting a claim of breach of a fiduciary duty owed by any
director, officer or other employee of the Corporation to the Corporation or the Corporation&rsquo;s stockholders, (iii) any action asserting
a claim arising pursuant to any provision of the DGCL, or (iv) any action asserting a claim governed by the internal affairs doctrine
shall be a state or federal court located in the county in which the principal office of the corporation in the State of Delaware is
established, in all cases subject to the court&rsquo;s having personal jurisdiction over the indispensable parties named as defendants.
Notwithstanding the foregoing, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created
by the Exchange of 1934, as amended, the Securities Act of 1933, as amended, or any claim for which the federal courts have exclusive
or concurrent jurisdiction.&rdquo; Therefore, the exclusive forum provision in our certificate of incorporation, as amended, and our
amended and restated bylaws will not relieve us of our duty to comply with the federal securities laws and the rules and regulations
thereunder, and shareholders will not be deemed to have waived our compliance with these laws, rules and regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 32.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 55; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
exclusive forum provision may limit a shareholder&rsquo;s ability to bring a claim in a judicial forum of its choosing for disputes with
us or our directors, officers or other employees, which may discourage lawsuits against us or our directors, officers or other employees.
In addition, shareholders who do bring a claim in the state or federal court in the State of Delaware could face additional litigation
costs in pursuing any such claim, particularly if they do not reside in or near Delaware. The state or federal court of the State of
Delaware may also reach different judgments or results than would other courts, including courts where a shareholder would otherwise
choose to bring the action, and such judgments or results may be more favorable to us than to our shareholders. However, the enforceability
of similar exclusive forum provisions in other companies&rsquo; certificates of incorporation have been challenged in legal proceedings,
and it is possible that a court could find this type of provision to be inapplicable to, or unenforceable in respect of, one or more
of the specified types of actions or proceedings. If a court were to find the exclusive forum provision contained in our certificate
of incorporation, as amended, and our amended and restated bylaws to be inapplicable or unenforceable in an action, we
might incur additional costs associated with resolving such action in other jurisdictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>By
purchasing common stock in this offering, you are bound by the fee-shifting provision contained in our amended and restated
bylaws, which may discourage you to pursue actions against us and could discourage shareholder lawsuits that might otherwise
benefit the Company and its shareholders.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
7.4 of our amended and restated bylaws provides that &ldquo;[i]f any action is brought by any party against another party, relating
to or arising out of these Bylaws, or the enforcement hereof, the prevailing party shall be entitled to recover from the other party
reasonable attorneys&rsquo; fees, costs and expenses incurred in connection with the prosecution or defense of such action.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">Our
amended and restated bylaws provide that for this section, the term &ldquo;attorneys&rsquo; fees&rdquo; or &ldquo;attorneys&rsquo; fees
and costs&rdquo; m<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">eans the fees and expenses of counsel to
the Company and any other parties asserting a claim subject to Section 7.4 of the amended and restated bylaws, which may include printing,
photocopying, duplicating and other expenses, air freight charges, and fees billed for law clerks, paralegals and other persons not admitted
to the bar but performing services under the supervision of an attorney, and the costs and fees incurred in connection with the enforcement
or collection of any judgment obtained in any such proceeding.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
adopted the fee-shifting provision to eliminate or decrease nuisance and frivolous litigation. We intend to apply the fee-shifting provision
broadly to all actions except for&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">claims
brought under the Exchange Act and Securities Act<FONT STYLE="background-color: white">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="background-color: white">&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no set level of recovery required to be met by a plaintiff to avoid payment under this provision. Instead, whoever is the prevailing
party is entitled to recover the reasonable attorneys&rsquo; fees, costs and expenses incurred in connection with the prosecution or
defense of such action. Any party who brings an action, and the party against whom such action is brought under Section 7.4 of our amended
and restated bylaws, which could include, but is not limited to former and current shareholders, Company directors, officers, affiliates,
legal counsel, expert witnesses and other parties, are subject to this provision. Additionally, any party who brings an action, and the
party against whom such action is brought under Section 7.4 of our amended and restated bylaws, which could include, but is not limited
to former and current shareholders, Company directors, officers, affiliates, legal counsel, expert witnesses and other parties, would
be able to recover fees under this provision.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event you initiate or assert a claims against us, in accordance with the dispute resolution provisions contained in our amended
and restated Bylaws, and you do not, in a judgment prevail, you will be obligated to reimburse us for all reasonable costs and expenses
incurred in connection with such claim, including, but not limited to, reasonable attorney&rsquo;s fees and expenses and costs of appeal,
if any. <FONT STYLE="background-color: white">Additionally, this provision in Section 7.4 of our amended and restated bylaws could
discourage shareholder lawsuits that might otherwise benefit the Company and its shareholders.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE
FEE SHIFTING PROVISION CONTAINED IN THE AMENDED AND RESTATED BYLAWS IS NOT INTENDED TO BE DEEMED A WAIVER BY ANY HOLDER OF COMMON
STOCK OF THE COMPANY&rsquo;S COMPLIANCE WITH THE U.S. FEDERAL SECURITIES LAWS AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER. THE
FEE SHIFTING PROVISION CONTAINED IN THE AMENDED AND RESTATED BYLAWS DO NOT APPLY TO CLAIMS BROUGHT UNDER THE EXCHANGE ACT AND
SECURITIES ACT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Intellectual Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
success depends on our ability to protect our intellectual property and our proprietary technologies.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends in part on our ability to obtain and maintain patent protection and trade secret protection for our product
candidates, proprietary technologies and their uses as well as our ability to operate without infringing upon the proprietary rights
of others. We generally seek to protect our proprietary position by filing patent applications in the United States and abroad related
to our product candidates, proprietary technologies and their uses that are important to our business. We also seek to protect our proprietary
position by acquiring or in-licensing relevant issued patents or pending applications from third parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending
patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until,
patents issue from such applications, and then only to the extent the issued claims cover the technology. There can be no assurance that
our patent applications or the patent applications of our licensor will result in additional patents being issued or that issued patents
will afford sufficient protection against competitors with similar technology, nor can there be any assurance that the patents issued
will not be infringed, designed around or invalidated by third parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before
various patent offices or in courts. The degree of future protection for our and our licensor&rsquo;s proprietary rights is uncertain.
Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage.
These uncertainties and/or limitations in our ability to properly protect the intellectual property rights relating to our product candidates
could have a material adverse effect on our financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 56; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Presently,
we have a worldwide license for use of JOTROL from Aquanova AG, the patent holder of a micellar technology (&ldquo;NovaSol<SUP>TM</SUP>).
Aquanova AG, a German company, filed an international patent on January 29, 2017 entitled &ldquo;Resveratrol solubilization product for
pharmaceutical purposes&rdquo; (PCT/EP2017/O51659). The patent in jointly owned by the Company and Aquanova AG. The priority date of
the patent was June 16, 2016 with expiration in 2036. The patent has been examined by the International Preliminary Examining Authority
of the Patent Cooperation Treaty (PCT), and 15 claims of this patent are deemed Novel, have an Inventive Step, and have Industrial Applicability.
In accordance with the Patent Cooperation Treaty&rsquo;s procedures and with this favorable examination report, this patent has been
granted in USA, specific EU countries, Japan, China and Hong Kong.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our license agreement with
Aquanova AG is our most important agreement and critical to maintain as long as JOTROL remains our main and only product. A loss of this
agreement will cause the Company a delay in its plans and would cause the Company to seek out other similar licensing agreements. Accordingly,
the loss of this agreement will have a material adverse effect on our business.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential
future collaborators will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties
include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and
    other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent
    application, and partial or complete loss of patent rights in the relevant jurisdiction;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patent
    applications may not result in any patents being issued;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patents
    may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive
    advantage;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing
    technologies, may seek or may have already obtained patents that will limit, interfere with or eliminate our ability to make, use
    and sell our potential product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
    may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection
    both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide
    health concerns; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">countries
    other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign
    competitors a better opportunity to create, develop and market competing product candidates.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent prosecution process is also expensive and time-consuming, and we and our licensor may not be able to file and prosecute all necessary
or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially
advantageous. It is also possible that we or our licensor will fail to identify patentable aspects of our research and development output
before it is too late to obtain patent protection.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of
our research and development output, such as our employees, outside scientific collaborators, CROs, third-party manufacturers, consultants,
advisors and other third parties, any of these parties may breach such agreements and disclose such output before a patent application
is filed, thereby jeopardizing our ability to seek patent protection.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates
might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with
sufficient rights to exclude others from commercializing products similar or identical to ours.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 57; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent
our competitors from commercializing similar or identical product candidates would be adversely affected.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been
the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability and commercial value of our
patent rights are highly uncertain. Our pending and future patent applications and those of our licensor may not result in patents being
issued which protect our product candidates or which effectively prevent others from commercializing competitive product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted
after issuance. Even if patent applications we own or in-license currently or in the future issue as patents, they may not issue in a
form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise
provide us with any competitive advantage. Any patents that we own or in-license may be challenged or circumvented by third parties or
may be narrowed or invalidated as a result of challenges by third parties. Consequently, we do not know whether our product candidates
will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent
our patents or the patents of our licensors by developing similar or alternative technologies or products in a non-infringing manner
which could materially adversely affect our business, financial condition, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents or the patents of our
licensor may be challenged in the courts or patent offices in the United States and abroad. We may be subject to a third-party pre-issuance
submission of prior art to the USPTO, or become involved in opposition, derivation, revocation, reexamination, post-grant review (PGR)
and <I>inter partes</I> review (IPR), or other similar proceedings challenging our owned patent rights. An adverse determination in any
such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our patent rights, allow
third parties to commercialize our product candidates and compete directly with us, without payment to us, or result in our inability
to manufacture or commercialize products without infringing third-party patent rights. Moreover, our patents or the patents of our licensor
may become subject to post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge our priority of
invention or other features of patentability with respect to our patents and patent applications and those of our licensor. Such challenges
may result in loss of patent rights, loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which
could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration
of the patent protection of our product candidates. Such proceedings also may result in substantial cost and require significant time
from our scientists and management, even if the eventual outcome is favorable to us. In addition, if the breadth or strength of protection
provided by our patents and patent applications or the patents and patent applications of our licensor is threatened, regardless of the
outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Intellectual
property rights do not necessarily address all potential threats to our competitive advantage.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations
and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
    may be able to develop products that are similar to our product candidates but that are not covered by the claims of the patents
    that we own or license;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    or our licensor or collaborators might not have been the first to make the inventions covered by the patent applications that we
    own or license;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 58; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    or our licensor or collaborators might not have been the first to file patent applications covering certain of our inventions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
    may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual
    property rights;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
    is possible that the pending patent applications we own or license will not lead to issued patents;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    competitors might conduct research and development activities in countries where we do not have patent rights and then use the information
    learned from such activities to develop competitive products for sale in our major commercial markets;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may not develop additional proprietary technologies that are patentable;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    patents of others may have an adverse effect on our business; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third-party may subsequently file a
    patent covering such intellectual property.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Should
any of these events occur, it could significantly harm our business, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third
parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our
developmental and commercialization efforts.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends in part on avoiding infringement of the patents and proprietary rights of third parties. However, our research,
development and commercialization activities may be subject to claims that we infringe or otherwise violate patents or other intellectual
property rights owned or controlled by third parties. Other entities may have or obtain patents or proprietary rights that could limit
our ability to make, use, sell, offer for sale or import our product candidates and products that may be approved in the future, or impair
our competitive position. There is a substantial amount of litigation, both within and outside the United States, involving patent and
other intellectual property rights in the biopharmaceutical industry, including patent infringement lawsuits, oppositions, reexaminations,
IPR proceedings and PGR proceedings before the USPTO and/or corresponding foreign patent offices. Numerous third-party U.S. and foreign
issued patents and pending patent applications exist in the fields in which we are developing product candidates. There may be third-party
patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the
use or manufacture of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the biopharmaceutical industry expands and more patents are issued, the risk increases that our product candidates may be subject to
claims of infringement of the patent rights of third parties. Because patent applications are maintained as confidential for a certain
period of time, until the relevant application is published, we may be unaware of third-party patents that may be infringed by commercialization
of any of our product candidates, and we cannot be certain that we were the first to file a patent application related to a product candidate
or technology. Moreover, because patent applications can take many years to issue, there may be currently-pending patent applications
that may later result in issued patents that our product candidates may infringe. In addition, identification of third-party patent rights
that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents,
incomplete databases and the difficulty in assessing the meaning of patent claims. There is also no assurance that there is not prior
art of which we are aware, but which we do not believe is relevant to our business, which may, nonetheless, ultimately be found to limit
our ability to make, use, sell, offer for sale or import our products that may be approved in the future, or impair our competitive position.
In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Any
claims of patent infringement asserted by third parties would be time consuming and could:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">result
    in costly litigation that may cause negative publicity;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">divert
    the time and attention of our technical personnel and management;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 59; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cause
    development delays;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">prevent
    us from commercializing any of our product candidates until the asserted patent expires or is held finally invalid or not infringed
    in a court of law;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
    us to develop non-infringing technology, which may not be possible on a cost-effective basis;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject
    us to significant liability to third parties; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
    us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all, or which
    might be non-exclusive, which could result in our competitors gaining access to the same technology.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
no third-party has asserted a claim of patent infringement against us as of the date of this prospectus, others may hold proprietary
rights that could prevent our product candidates from being marketed. These claims could be alleged to cover JOTROL in certain
treatment indications. While we believe that these patents are difficult to enforce and that we would have valid defenses to these claims
of patent infringement, we cannot be certain that we would prevail in any dispute and we cannot be certain how an adverse determination
would affect our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is possible that a third party may assert a claim of patent infringement directed at any of our product candidates. Any patent-related
legal action against us claiming damages and seeking to enjoin commercial activities relating to our products, treatment indications,
or processes could subject us to significant liability for damages, including treble damages if we were determined to willfully infringe,
and require us to obtain a license to manufacture or market our product candidates. Defense of these claims, regardless of their merit,
would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. We cannot
predict whether we would prevail in any such actions or that any license required under any of these patents would be made available
on commercially acceptable terms, if at all. Moreover, even if we or our future strategic partners were able to obtain a license, the
rights may be nonexclusive, which could result in our competitors gaining access to the same intellectual property. In addition, we cannot
be certain that we could redesign our product candidates, treatment indications, or processes to avoid infringement, if necessary. Accordingly,
an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from
developing and commercializing our product candidates, which could harm our business, financial condition and operating results. In addition,
intellectual property litigation, regardless of its outcome, may cause negative publicity and could prohibit us from marketing or otherwise
commercializing our product candidates and technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parties
making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have
substantially greater resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual
property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by
disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse
effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial
condition and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 60; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may in the future pursue invalidity proceedings with respect to third-party patents. The outcome following legal assertions of invalidity
is unpredictable. Even if resolved in our favor, these legal proceedings may cause us to incur significant expenses and could distract
our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results
of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be
negative, it could have a substantial adverse effect on the price of our common stock. Such proceedings could substantially increase
our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities.
We may not have sufficient financial or other resources to conduct such proceedings adequately. Some of these third parties may be able
to sustain the costs of such proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting
from the initiation and continuation of patent proceedings could compromise our ability to compete in the marketplace. If we do not prevail
in the patent proceedings the third parties may assert a claim of patent infringement directed at our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
pharmaceutical companies, biotechnology companies, and academic institutions may have patents and patent applications potentially relevant
to our business. We may find it necessary or prudent to obtain licenses to such patents from such third-party intellectual property holders,
for example, in order to avoid infringing these third-party patents. We may also require licenses from third parties for certain technologies
for use with future product candidates. We may be unable to acquire or in-license any compositions, methods of use, processes or other
third-party intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing and
acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies may pursue
strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established
companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization
capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also
may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return
on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain
the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which
could have a material adverse effect on our business, financial condition, results of operations, and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be involved in lawsuits to protect or enforce our patents or our licensor&rsquo;s patents, which could be expensive, time consuming
and unsuccessful. Further, our issued patents or our licensor&rsquo;s patents could be found invalid or unenforceable if challenged in
court.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors
may infringe our intellectual property rights. To prevent infringement or unauthorized use, we may be required to file infringement claims,
which can be expensive and time-consuming. In addition, in a patent infringement proceeding, a court may decide that a patent we own
or in-license is not valid, is unenforceable and/or is not infringed. If we or any of our potential future collaborators were to initiate
legal proceedings against a third-party to enforce a patent directed at one of our product candidates, the defendant could counterclaim
that our patent or the patent of our licensor is invalid and/or unenforceable in whole or in part. In patent litigation in the United
States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include
an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, lack of sufficient written
description, non-enablement, or obviousness-type double patenting. Grounds for an unenforceability assertion could include an allegation
that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during
prosecution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
parties may also raise similar invalidity claims before the USPTO or patent offices abroad, even outside the context of litigation. Such
mechanisms include re-examination, PGR, IPR, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition
proceedings). The outcome following legal assertions of invalidity and/or unenforceability is unpredictable. With respect to the validity
question, for example, we cannot be certain that there is no invalidating prior art, of which we, our licensor, and the patent examiners
are unaware during prosecution. There is also no assurance that there is not prior art of which we are aware, but which we do not believe
affects the validity or enforceability of a claim in our patents and patent applications or the patents and patent applications of our
licensor, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. If a third-party were to prevail
on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our
technology or proprietary drug delivery platform, or any product candidates that we may develop. Such a loss of patent protection would
have a material adverse impact on our business, financial condition, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 61; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if the breadth or strength of protection provided by our patents and patent applications or the patents and patent applications
of our licensor is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or
future product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant
expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public
announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors
perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or
proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future
sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings
adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because
of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings
could compromise our ability to compete in the marketplace. Furthermore, because of the substantial amount of discovery required in connection
with intellectual property litigation or other legal proceedings relating to our intellectual property rights, there is a risk that some
of our confidential information could be compromised by disclosure during this type of litigation or other proceedings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the issuance of a patent does not give us the right to practice the patented invention. Third parties may have blocking patents
that could prevent us from marketing our own patented product and practicing our own patented technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Intellectual
property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common shares to decline.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the course of any intellectual property litigation, there could be public announcements of the initiation of the litigation as well as
results of hearings, rulings on motions, and other interim proceedings in the litigation. If securities analysts or investors regard
these announcements as negative, the perceived value of our existing products, programs or intellectual property could be diminished.
Accordingly, the market price of shares of our common stock may decline. Such announcements could also harm our reputation or the market
for our future products, which could have a material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Derivation
proceedings may be necessary to determine priority of inventions, and an unfavorable outcome may require us to cease using the related
technology or to attempt to license rights from the prevailing party.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivation
proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions
with respect to our patents or patent applications or those of our licensor. An unfavorable outcome could require us to cease using the
related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party
does not offer us a license on commercially reasonable terms. Our defense of derivation proceedings may fail and, even if successful,
may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with such
proceedings could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue
our research programs, license necessary technology from third parties or enter into development or manufacturing partnerships that would
help us bring our product candidates to market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 62; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Changes
in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect
our product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
is the case with other pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining
and enforcing patents in the pharmaceutical industry involve a high degree of technological and legal complexity. Therefore, obtaining
and enforcing pharmaceutical patents is costly, time consuming and inherently uncertain. Changes in either the patent laws or in the
interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property and may increase
the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. We cannot
predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. In addition, Congress or other
foreign legislative bodies may pass patent reform legislation that is unfavorable to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available
in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard
to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents,
once obtained. Depending on decisions by the U.S. Congress, the U.S. federal courts, the USPTO, or similar authorities in foreign jurisdictions,
the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or
to enforce our existing patent and the patents we might obtain or license in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also be subject to claims that former employees or other third parties have an ownership interest in our patents or other intellectual
property. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending
any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Such an outcome could have
a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial
costs and distraction to management and other employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Patent
terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents
have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally
20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection
it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open
to competition from competitive products. Given the amount of time required for the development, testing and regulatory review of new
product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a
result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical
to ours.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we do not obtain patent term extension for our product candidates, our business may be materially harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depending
upon the timing, duration and specifics of FDA marketing approval of our product candidates, one or more of our U.S. patents or those
of our licensor may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act
of 1984 (Hatch-Waxman Amendments). The Hatch- Waxman Amendments permit a patent restoration term of up to five years as compensation
for patent term lost during product development and the FDA regulatory review process. A maximum of one patent may be extended per FDA
approved product as compensation for the patent term lost during the FDA regulatory review process. A patent term extension cannot extend
the remaining term of a patent beyond a total of 14 years from the date of product approval and only those claims covering such approved
drug product, a method for using it or a method for manufacturing it may be extended. Patent term extension may also be available in
certain foreign countries upon regulatory approval of our product candidates. However, we may not be granted an extension because of,
for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing
to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than
we request. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request,
our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly
materially. Further, if this occurs, our competitors may take advantage of our investment in development and trials by referencing our
clinical and preclinical data and launch their product earlier than might otherwise be the case.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 63; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be able to protect our intellectual property rights throughout the world.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing,
prosecuting and defending patents in all countries throughout the world would be prohibitively expensive, and our intellectual property
rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some
foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently,
we may not be able to prevent third parties from practicing our inventions in all countries outside the United States or from selling
or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies
in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing
products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products
may compete with our product candidates, and our patents, the patents of our licensors, or other intellectual property rights may not
be effective or sufficient to prevent them from competing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The
legal systems of many foreign countries do not favor the enforcement of patents and other intellectual property protection, which could
make it difficult for us to stop the infringement of our patents or our licensor&rsquo;s patents or marketing of competing products in
violation of our proprietary rights. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs
and divert our efforts and attention from other aspects of our business, could put our patents or the patents of our licensors at risk
of being invalidated or interpreted narrowly and our patent applications or the patent applications of our licensor at risk of not issuing
and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or
other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights
around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition,
many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent
owner may have limited remedies, which could materially diminish the value of such patent. If we are forced to grant a license to third
parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition,
results of operations and prospects may be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Obtaining
and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements
imposed by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance
with these requirements.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodic
maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the USPTO
and various foreign patent offices at various points over the lifetime of our patents and/or applications and those of our licensors.
We have systems in place to remind us to pay these fees, and we rely on our outside patent annuity service to pay these fees when due.
Additionally, the USPTO and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and
other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply,
and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to
the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or
patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur,
it could have a material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 64; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest
and our business may be adversely affected.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to use registered or unregistered trademarks or trade names to brand and market ourselves and our products. Our trademarks or
trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not
be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or
customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our
ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark
infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered
trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names,
then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce or protect our proprietary
rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result
in substantial costs and diversion of resources and could adversely affect our financial condition or results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we rely on the protection of our trade secrets, including unpatented know-how, technology and other proprietary information
to maintain our competitive position. Although we have taken steps to protect our trade secrets and unpatented know-how, including entering
into confidentiality agreements with third parties, and confidential information and inventions agreements with employees, consultants
and advisors, we cannot provide any assurances that all such agreements have been duly executed, and any of these parties may breach
the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies
for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming,
and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect
trade secrets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
third parties may still obtain this information or may come upon this or similar information independently, and we would have no right
to prevent them from using that technology or information to compete with us. If any of these events occurs or if we otherwise lose protection
for our trade secrets, the value of this information may be greatly reduced, and our competitive position would be harmed. If we do not
apply for patent protection prior to such publication or if we cannot otherwise maintain the confidentiality of our proprietary technology
and other confidential information, then our ability to obtain patent protection or to protect our trade secret information may be jeopardized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be subject to claims that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into and may enter in the future into non-disclosure and confidentiality agreements to protect the proprietary positions
of third parties, such as outside scientific collaborators, CROs, third-party manufacturers, consultants, advisors, potential partners,
lessees of shared multi-company property and other third parties. We may become subject to litigation where a third-party asserts that
we or our employees inadvertently or otherwise breached the agreements and used or disclosed trade secrets or other information proprietary
to the third parties. Defense of such matters, regardless of their merit, could involve substantial litigation expense and be a substantial
diversion of employee resources from our business. We cannot predict whether we would prevail in any such actions. Moreover, intellectual
property litigation, regardless of its outcome, may cause negative publicity and could prohibit us from marketing or otherwise commercializing
our product candidates and technology. Failure to defend against any such claim could subject us to significant liability for monetary
damages or prevent or delay our developmental and commercialization efforts, which could adversely affect our business. Even if we are
successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team
and other employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 65; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parties
making claims against us may be able to sustain the costs of complex intellectual property litigation more effectively than we can because
they have substantially greater resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual
property litigation, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties
resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise additional
funds or otherwise have a material adverse effect on our business, operating results, financial condition and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used
or disclosed alleged confidential information or trade secrets of their former employers.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
is common in the pharmaceutical industry, in addition to our employees, we engage the services of consultants to assist us in the development
of our product candidates. Many of these consultants, and many of our employees, were previously employed at, or may have previously
provided or may be currently providing consulting services to, other pharmaceutical companies including our competitors or potential
competitors. We may become subject to claims that we, our employees or a consultant inadvertently or otherwise used or disclosed trade
secrets or other information proprietary to their former employers or their former or current clients. Litigation may be necessary to
defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual
property rights or personnel, which could adversely affect our business. Even if we are successful in defending against these claims,
litigation could result in substantial costs and be a distraction to our management team and other employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
rights to develop and commercialize our technology and product candidates may be subject, in part, to the terms and conditions of licenses
granted to us by others.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into a license agreement with Aquanova AG, a German company, pursuant to which we have acquired the exclusive right to certain
patents and patent applications in micellar technologies that revolutionizes the bioavailability profile of resveratrol to treat certain
rare diseases and Alzheimer&rsquo;s disease by eliminating the severe gastro-intestinal side effects experienced at effective dose levels
of resveratrol. We may enter into additional license agreements in the future with others to advance our research or allow commercialization
of product candidates. These and other licenses may not provide exclusive rights to use such intellectual property and technology in
all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and products in the
future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, subject to the terms of any such license agreements, we may not have the right to control the preparation, filing, prosecution,
maintenance, enforcement, and defense of patents and patent applications covering the technology that we license from third parties.
In such an event, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced,
and defended in a manner consistent with the best interests of our business. If our licensor fails to prosecute, maintain, enforce, and
defend such patents, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated,
and our right to develop and commercialize any of our products that are subject of such licensed rights could be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
licensor may have relied on third-party consultants or collaborators or on funds from third parties such that our licensor are not the
sole and exclusive owners of the patents we in-licensed. If other third parties have ownership rights to our in-licensed patents, they
may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could
have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is possible that we may be unable to obtain additional licenses at a reasonable cost or on reasonable terms, if at all. Even if we are
able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In
that event, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods
for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial
basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our
business, financial condition, results of operations, and prospects significantly. We cannot provide any assurances that third-party
patents do not exist which might be enforced against our current technology, manufacturing methods, product candidates, or future methods
or products resulting in either an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation
on our part to pay royalties and/or other forms of compensation to third parties, which could be significant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 66; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise
experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disputes
may arise between us and our licensor or potential licensors regarding intellectual property subject to a license agreement, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope of rights granted under the license agreement and other interpretation-related issues;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the
    licensing agreement;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    right to sublicense patents and other rights to third parties;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    diligence obligations under the license agreement and what activities satisfy those diligence obligations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    right to transfer or assign the license;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors
    and us and our partners; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    priority of invention of patented technology.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the agreements under which we license intellectual property or technology from third parties are complex, and certain provisions
in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may
arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what
we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect
on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we
have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be
unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business,
financial conditions, results of operations, and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
spite of our best efforts, our licensor or potential licensors might conclude that we have materially breached our license agreements
and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize products and technology
covered by these license agreements. If these in-licenses are terminated, or if the underlying patents fail to provide the intended exclusivity,
competitors would have the freedom to seek regulatory approval of, and to market, products identical to ours. This could have a material
adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 67; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
patent protection and patent prosecution for some of our product candidates may be dependent on third parties.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we normally seek to obtain the right to control prosecution, maintenance and enforcement of the patents relating to our product candidates,
there may be times when the filing and prosecution activities for patents relating to our product candidates are controlled by our licensor,
potential licensors or collaboration partners. If any of our licensor, potential licensors or collaboration partners fail to prosecute,
maintain and enforce such patents and patent applications in a manner consistent with the best interests of our business, including by
payment of all applicable fees for patents covering our product candidates, we could lose our rights to the intellectual property or
our exclusivity with respect to those rights, our ability to develop and commercialize those product candidates may be adversely affected
and we may not be able to prevent competitors from making, using and selling competing products. In addition, even where we have the
right to control patent prosecution of patents and patent applications we have licensed to and from third parties, we may still be adversely
affected or prejudiced by actions or inactions of our licensees, our licensors and their counsel that took place prior to the date upon
which we assumed control over patent prosecution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Intellectual
property discovered through government funded programs may be subject to federal regulations such as &ldquo;march-in&rdquo; rights, certain
reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and
limit our ability to contract with non-U.S. manufacturers.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have patent applications, in addition to the in-licensed patent from Aquanova AG, that were generated through the use of U.S. government
funding or grants, and may acquire or license in the future intellectual property rights that have been generated through the use of
U.S. government funding or grants. Pursuant to the Bayh-Dole Act of 1980, the U.S. government has certain rights in inventions developed
with government funding. These U.S. government rights include a non-exclusive, non-transferable, irrevocable worldwide license to use
inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require
us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third-party if it determines that:
(1) adequate steps have not been taken to commercialize the invention; (2) government action is necessary to meet public health or safety
needs; or (3) government action is necessary to meet requirements for public use under federal regulations (also referred to as &ldquo;march-in
rights&rdquo;). If the U.S. government exercised its march-in rights in our future intellectual property rights that are generated through
the use of U.S. government funding or grants, we could be forced to license or sublicense intellectual property developed by us or that
we license on terms unfavorable to us, and there can be no assurance that we would receive compensation from the U.S. government for
the exercise of such rights. The U.S. government also has the right to take title to these inventions if the grant recipient fails to
disclose the invention to the government or fails to file an application to register the intellectual property within specified time
limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance
with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying any
of these inventions or produced through the use of any of these inventions be manufactured substantially in the United States. This preference
for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property
can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would
be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially
feasible. This preference for U.S. industry may limit our ability to contract with non-U.S. product manufacturers for products covered
by such intellectual property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Dependence on Third Parties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
rely, and expect to continue to rely, on third parties to conduct our clinical trials and those third parties may not perform satisfactorily,
including failing to meet deadlines for the completion of such trials, research and studies, which may harm our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have the ability to independently conduct our clinical trials. We currently rely on third parties, such as CROs, clinical data
management organizations, medical institutions and clinical investigators, to conduct our current and planned clinical trials of JOTROL
and we expect to continue to rely upon third parties to conduct additional clinical trials for JOTROL and other product candidates.
Third parties have a significant role in the conduct of our clinical trials and the subsequent collection and analysis of data. These
third parties are not our employees, and except for remedies available to us under our agreements with such third parties, we have limited
ability to control the amount or timing of resources that any such third-party will devote to our clinical trials.  The third parties we rely on for these services may also have relationships
with other entities, some of which may be our competitors. Some of these third parties may terminate their engagements with us at any
time. If we need to enter into alternative arrangements with a third-party, it would delay our drug development activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 68; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
reliance on these third parties for such drug development activities will reduce our control over these activities but will not relieve
us of our regulatory responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted
in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with GCP standards,
regulations for conducting, recording and reporting the results of clinical trials to assure that data and reported results are reliable
and accurate and that the rights, integrity and confidentiality of trial participants are protected. The EMA also requires us to comply
with similar standards. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, principal
investigators and trial sites. If we or any of our CROs fail to comply with applicable GCP requirements, the clinical data generated
in our clinical trials may be deemed unreliable and the FDA, EMA or comparable foreign regulatory authorities may require us to perform
additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory
authority, such regulatory authority will determine that any of our clinical trials substantially comply with GCP regulations. In addition,
our clinical trials must be conducted with product produced under current cGMP regulations. Our failure to comply with these regulations
may require us to repeat clinical trials, which would delay the marketing approval process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in
accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing
approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product
candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also expect to rely on third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part
of our distributors could delay clinical development or marketing approval of our product candidates or commercialization of our products,
producing additional losses and depriving us of potential product revenue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
contract with third parties for the production of our product candidates for preclinical studies and, in the case of JOTROL, our
ongoing clinical trial, and expect to continue to do so for additional clinical trials and ultimately for commercialization. This reliance
on third parties increases the risk that we will not have sufficient quality and quantities of our product candidates or such quantities
at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently have the infrastructure or internal capability to manufacture supplies of our product candidates for use in development
and commercialization. We rely, and expect to continue to rely, on third-party manufacturers for the production of our product candidates
for preclinical studies and clinical trials under the guidance of members of our organization. We are presently relying on a single third-party
manufacturer and are presently evaluating a second source alternative manufacturer. Changing our third-party manufacturer could result
in delays in our manufacturing supply chain which could delay or otherwise impact our development of JOTROL and result in increased
costs related to JOTROL. We do not have long-term supply agreements, and we purchase our required drug product on a purchase order
basis, which means that aside from any binding purchase orders we have from time to time, our supplier could cease supplying to us or
change the terms on which it is willing to continue supplying to us at any time. If we were to experience an unexpected loss of supply
of JOTROL or any other product candidates for any reason, whether as a result of manufacturing, supply or storage issues or otherwise,
we could experience delays, disruptions, suspensions or terminations of, or be required to restart or repeat, any pending or ongoing
clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 69; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to continue to rely on third-party manufacturers for the commercial supply of any of our product candidates for which we obtain
marketing approval. We may be unable to maintain or establish required agreements with third-party manufacturers or to do so on acceptable
terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional
risks, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    failure of the third-party to manufacture our product candidates according to our schedule and specifications, or at all, including
    if our third-party contractors give greater priority to the supply of other products over our product candidates or otherwise do
    not satisfactorily perform according to the terms of the agreements between us and them;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    termination or nonrenewal of arrangements or agreements by our third-party contractors at a time that is costly or inconvenient for
    us;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    breach by the third-party contractors of our agreements with them;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    failure of third-party contractors to comply with applicable regulatory requirements, including cGMPs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    failure of the third-party to manufacture our product candidates according to our specifications;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or active drug or placebo not being
    properly identified;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
    supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or of drug supplies not being distributed
    to commercial vendors in a timely manner, resulting in lost sales; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    misappropriation of our proprietary information, including our trade secrets and know-how.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have complete control over all aspects of the manufacturing process of our CDMOs and are dependent on these CDMOs for compliance
with cGMP regulations for manufacturing both active pharmaceutical ingredients (API) and finished drug products. We are in the process
of developing our supply chain for each of our product candidates and intend to put in place framework agreements under which CDMOs will
generally provide us with necessary quantities of API and drug product on a project-by-project basis based on our development needs.
As we advance our product candidates through development, we will consider our lack of redundant supply for the API and drug product
for each of our product candidates to protect against any potential supply disruptions. However, we may be unsuccessful in putting in
place such framework agreements or protecting against potential supply disruptions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party
manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside of the United States. If our
CDMOs cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA,
EMA or others, they will not be able to secure and/or maintain marketing approval for their manufacturing facilities. In addition, we
do not have control over the ability of our CDMOs to maintain adequate quality control, quality assurance and qualified personnel. If
the FDA, EMA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates
or if it withdraws any such approval in the future, we will need to find alternative manufacturing facilities, and those new facilities
would need to be inspected and approved by FDA, EMA or comparable regulatory authority prior to commencing manufacturing, which would
significantly impact our ability to develop, obtain marketing approval for or market our product candidates, if approved. Our failure,
or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us,
including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls
of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect
supplies of our product candidates or drugs and harm our business and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current and anticipated future dependence upon others for the manufacture of our product candidates may adversely affect our future profit
margins and our ability to commercialize any product candidates that receive marketing approval on a timely and competitive basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 70; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
reliance on third parties may require us to share our trade secrets, which increases the possibility that a competitor will discover
them or that our trade secrets will be misappropriated or disclosed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we currently rely on third parties in the course of our business, we may share our proprietary technology and confidential information,
including trade secrets, with them. We seek to protect our proprietary technology, in part, by entering into confidentiality agreements,
and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements
with our collaborators, advisors, employees and consultants prior to beginning research or disclosing proprietary information. These
agreements typically limit the rights of the third parties to use or disclose our confidential information. Despite the contractual provisions
employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that
such trade secrets become known by our competitors, are intentionally or inadvertently incorporated into the technology of others or
are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade
secrets and despite our efforts to protect our trade secrets, a competitor&rsquo;s discovery of our proprietary technology and confidential
information or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our
business, financial condition, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause
us to incur debt or assume contingent liabilities, and subject us to other risks.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may evaluate various acquisition opportunities and strategic partnerships, including licensing or acquiring complementary
products, intellectual property rights, technologies or businesses. Any potential acquisition or strategic partnership may entail numerous
risks, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased
    operating expenses and cash requirements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    assumption of additional indebtedness or contingent liabilities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    issuance of our equity securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">assimilation
    of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new
    personnel;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    diversion of our management&rsquo;s attention from our existing programs and initiatives in pursuing such a strategic merger or acquisition;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">retention
    of key employees, the loss of key personnel and uncertainties in our ability to maintain key business relationships;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks
    and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing
    products or product candidates and marketing approvals; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition
    or even to offset the associated acquisition and maintenance costs.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if we undertake acquisitions or pursue partnerships in the future, we may issue dilutive securities, assume or incur debt obligations,
incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 71; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we decide to establish collaborations, but are not able to establish those collaborations on commercially reasonable terms, we may have
to alter our development and commercialization plans.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
drug development programs and the potential commercialization of our product candidates will require substantial additional cash to fund
expenses. We may seek to selectively form collaborations to expand our capabilities, potentially accelerate research and development
activities and provide for commercialization activities by third parties. In addition, we intend to explore strategic partnering and
collaboration opportunities to out-license rights to our research programs and drug candidates for indications in which we are unlikely
to pursue development and commercialization. In parallel, we will also evaluate select external opportunities to strategically expand
our portfolio. Any of these relationships may require us to incur non-recurring and other charges, increase our near- and long-term expenditures,
issue securities that dilute our existing stockholders, or disrupt our management and business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
would face significant competition in seeking appropriate collaborators and the negotiation process is time-consuming and complex. Whether
we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&rsquo;s
resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&rsquo;s evaluation of a
number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA, EMA or
comparable foreign regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing
and delivering such product candidate to patients, the potential of competing drugs, the existence of uncertainty with respect to our
ownership of intellectual property and industry and market conditions generally. The potential collaborator may also consider alternative
product candidates or technologies for similar indications that may be available to collaborate on and whether such collaboration could
be more attractive than the one with us for our product candidate. Further, we may not be successful in our efforts to establish a collaboration
or other alternative arrangements for product candidates because they may be deemed to be at too early of a stage of development for
collaborative effort and third parties may not view them as having the requisite potential to demonstrate safety and efficacy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted
in a reduced number of potential future collaborators. Even if we are successful in entering into a collaboration, the terms and conditions
of that collaboration may restrict us from entering into future agreements on certain terms with potential collaborators.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
and when we seek to enter into collaborations, we may not be able to negotiate collaborations on a timely basis, on acceptable terms,
or at all. If we are unable to do so, we may have to curtail the development of a product candidate, reduce or delay its development
program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing
activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to
increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which
may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our
product candidates or bring them to market and generate product revenue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may enter into collaborations with third parties for the development and commercialization of product candidates. If those collaborations
are not successful, we may not be able to capitalize on the market potential of these product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we enter into any collaboration arrangements with any third parties, we will likely have limited control over the amount and timing of
resources that our collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate
revenues from these arrangements will depend on our collaborators&rsquo; abilities and efforts to successfully perform the functions
assigned to them in these arrangements. Collaborations involving our product candidates would pose numerous risks to us, including the
following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    have significant discretion in determining the efforts and resources that they will apply to, and the manner in which they perform
    their obligations under, these collaborations and may not perform their obligations as expected;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 72; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may deemphasize or not pursue development and commercialization of our product candidates or may elect not to continue or renew development
    or commercialization programs based on clinical trial results, changes in the collaborators&rsquo; strategic focus, including as
    a result of a business combination or sale or disposition of a business unit or development function, or available funding or external
    factors such as an acquisition that diverts resources or creates competing priorities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product
    candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates
    if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under
    terms that are more economically attractive than ours;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    collaborator with marketing and distribution rights to multiple products may not commit sufficient resources to the marketing and
    distribution of our product relative to other products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may grant exclusive rights to our collaborators that would prevent us from collaborating with others;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may not properly obtain, maintain, defend or enforce our intellectual property rights or may use our proprietary information and
    intellectual property in such a way as to invite litigation or other intellectual property related proceedings that could jeopardize
    or invalidate our proprietary information and intellectual property or expose us to potential litigation or other intellectual property
    related proceedings;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes
    may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization
    of our product candidates or that result in costly litigation or arbitration that diverts management attention and resources;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborations
    may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization
    of the applicable product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaboration
    agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may not provide us with timely and accurate information regarding development progress and activities under the collaboration or
    may limit our ability to share such information, which could adversely impact our ability to report progress to our investors and
    otherwise plan our own development of our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may own or co-own intellectual property covering our products that results from our collaborating with them, and in such cases, we
    would not have the exclusive right to develop or commercialize such intellectual property; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    collaborator&rsquo;s sales and marketing activities or other operations may not be in compliance with applicable laws resulting in
    civil or criminal proceedings.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also collaborate with a network of experts who advise and support our development efforts. In the future, such experts may not collaborate
with us which could affect our ability to develop our product candidates and proprietary delivery platform as such experts potentially
provide us with access to ideas to address the needs of muscle diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 73; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to This Offering and Ownership of Our Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Once
our common stock is listed on the Nasdaq Capital Market, there can be no assurance that we will be able to comply with Nasdaq
Capital Market&rsquo;s continued listing standards.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Prior to this offering, there
has been no public market for shares of our common stock. As a condition to consummating this offering, our common stock offered in this
prospectus must be listed on the Nasdaq Capital Market or another national securities exchange. Accordingly, in connection with the filing
of the registration statement of which this prospectus forms a part, we have applied to list our common stock on the Nasdaq Capital Market
under the symbol &ldquo;JUNS.&rdquo; Assuming that our common stock is listed and after the consummation of this offering,
there can be no assurance any broker will be interested in trading our common stock. Therefore, it may be difficult to sell your
shares of common stock if you desire or need to sell them. Our underwriters are not obligated to make a market in our common stock, and
even if it makes a market, it can discontinue market making at any time without notice. Neither we nor the underwriters can provide any
assurance that an active and liquid trading market in our common stock will develop or, if developed, that such market will continue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Once our common stock is approved for listing
on the Nasdaq Capital Market, there is no guarantee that we will be able to maintain such listing for any period of time by perpetually
satisfying Nasdaq Capital Market&rsquo;s continued listing requirements. Our failure to continue to meet these requirements may result
in our common stock being delisted from Nasdaq Capital Market.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
price of our common stock could be subject to rapid and substantial volatility.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been instances of extreme stock price run-ups followed by rapid price declines and strong stock price volatility with recent initial
public offerings, especially among those with relatively smaller public floats. As a relatively small-capitalization company with relatively
small public float, we may experience greater stock price volatility, extreme price run-ups, lower trading volume and less liquidity
than large-capitalization companies. In particular, the common stock may be subject to rapid and substantial price volatility, low volumes
of trades and large spreads in bid and ask prices. Such volatility, including any stock-run up, may be unrelated to our actual or expected
operating performance and financial condition or prospects, making it difficult for prospective investors to assess the rapidly changing
value of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if the trading volumes of our common stock are low, persons buying or selling in relatively small quantities may easily influence
prices of our common stock. This low volume of trades could also cause the price of our common stock to fluctuate greatly, with large
percentage changes in price occurring in any trading day session. Holders of our common stock may also not be able to readily liquidate
their investment or may be forced to sell at depressed prices due to low volume trading. Broad market fluctuations and general economic
and political conditions may also adversely affect the market price of our common stock. As a result of this volatility, investors may
experience losses on their investment in our common stock. A decline in the market price of our common stock also could adversely affect
our ability to sell additional shares or common stock or other securities and our ability to obtain additional financing in the future.
No assurance can be given that an active market in our common stock will develop or be sustained. If an active market does not develop,
holders of our common stock may be unable to readily sell the common stock they hold or may not be able to sell their common stock at
all.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
market price of our common stock may be volatile, and you could lose all or part
of your investment.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 30.6pt; background-color: white">We cannot predict the prices at which our common stock will trade. The
initial public offering price of our common stock will be determined by negotiations between us and the underwriters and may not bear
any relationship to the market price at which our common stock will trade after this offering or to any other established criteria of
the value of our business and prospects, and the market price of our common stock following this offering may fluctuate substantially
and may be lower than the initial public offering price. The market price of our common stock following this offering will depend on a
number of factors, including those described in this &ldquo;Risk Factors&rdquo; section, many of which are beyond our control and may
not be related to our operating performance. In addition, the limited public float of our common stock following this offering will tend
to increase the volatility of the trading price of our common stock. The stock market in general, and pharmaceutical and biotechnology
companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to
the operating performance of these companies. These fluctuations could cause you to lose all or part of your investment in our common
stock, since you might not be able to sell your shares at or above the price you paid in this offering. Factors that could cause fluctuations
in the market price of our common stock include, but are not limited to, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 30.6pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing and results of preclinical studies and clinical trials of our product candidates, those conducted by third parties or those
    of our competitors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    success of competitive products or announcements by potential competitors of their product development efforts;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    actions with respect to our products or our competitors&rsquo; products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated changes in our growth rate relative to our competitors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    or legal developments in the United States and other countries;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
    or disputes concerning patent applications, issued patents or other proprietary rights;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 74; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    recruitment or departure of key personnel;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    by us or our competitors of significant acquisitions, strategic collaborations, joint ventures, collaborations or capital commitments;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fluctuations
    in the valuation of companies perceived by investors to be comparable to us;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">market
    conditions in the pharmaceutical and biotechnology sector;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the structure of healthcare payment systems;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">share
    price and volume fluctuations attributable to inconsistent trading volume levels of our shares;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcement
    or expectation of additional financing efforts;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
    of our common stock by us, our insiders or our other stockholders;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expiration
    of market stand-off or lock-up agreements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    impact of any natural disasters or public health emergencies; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    economic, political, industry and market conditions.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
realization of any of the above risks or any of a broad range of other risks, including those described in this &ldquo;Risk Factors&rdquo;
section, could have a dramatic and adverse impact on the market price of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp; </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>As
a result of the resale of shares of common stock by Selling Stockholders being a large volume of shares and potentially at different
pricing after the initial fixed price, there is a potential for price volatility or depreciation for investors in the initial public
offering.</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Resale Prospectus, we are registering the resale of an aggregate of 3,600,000 shares of common stock, which shares of common stock
will be available for immediate resale in the public market. Sales of substantial amounts of our shares of common stock such as these
resale shares could cause the market price of our shares of common stock to decrease significantly. The offering price of the shares
of common stock in the initial public offering has been determined by negotiations between the Company and the underwriter. The Selling
Stockholders may sell the resale shares at prevailing market prices or privately negotiated prices after close of the initial public
offering and listing of our common stock on Nasdaq. Therefore, the offering prices of the initial public offering and resale offering
could differ. As a result, the purchasers in the resale offering could pay more or less than the offering price in the primary offering.
The resale of shares of common stock by the Selling Stockholders after the completion of the initial public offering could have the effect
of depressing the market price for our common stock. As a result of the resale of shares of common stock of the Selling Stockholders
being a large volume of shares and potentially at different pricing after the initial fixed price, there is a potential for price volatility
or depreciation for investors in the initial public offering.</FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
securities or industry analysts do not publish research or reports, or if they publish adverse or misleading research or reports, regarding
us, our business or our market, our stock price and trading volume could decline.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our common stock will be influenced by the research and reports that securities or industry analysts publish about
us, our business or our market. We do not currently have and may never obtain research coverage by securities or industry analysts. If
no or few securities or industry analysts commence coverage of us, the stock price would be negatively impacted. In the event we obtain
securities or industry analyst coverage, if any of the analysts who cover us issue adverse or misleading research or reports regarding
us, our business model, our intellectual property, our stock performance or our market, or if our operating results fail to meet the
expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish
reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume
to decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating
results to fall below expectations or our guidance.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
quarterly and annual operating results may fluctuate significantly in the future, which makes it difficult for us to predict our future
operating results. From time to time, we may enter into license or collaboration agreements or strategic partnerships with other companies
that include development funding and significant upfront and milestone payments and/or royalties, which may become an important source
of our revenue. These upfront and milestone payments may vary significantly from period to period and any such variance could cause a
significant fluctuation in our operating results from one period to the next.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 75; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we measure compensation cost for stock-based awards made to employees at the grant date of the award, based on the fair value
of the award as determined by our board of directors, and recognize the cost as an expense over the employee&rsquo;s requisite service
period. As the variables that we use as a basis for valuing these awards change over time, including, after the closing of this offering,
our underlying stock price and stock price volatility, the magnitude of the expense that we must recognize may vary significantly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
our operating results may fluctuate due to a variety of other factors, many of which are outside of our control and may be difficult
to predict, including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing and cost of, and level of investment in, research and development activities relating to our current product candidates and
    any future product candidates and research-stage programs, which will change from time to time;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to enroll patients in clinical trials and the timing of enrollment;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of manufacturing our current product candidates and any future product candidates, which may vary depending on FDA, EMA or other
    comparable foreign regulatory authority guidelines and requirements, the quantity of production and the terms of our agreements with
    manufacturers;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenditures
    that we will or may incur to acquire or develop additional product candidates and technologies or other assets;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing and outcomes of clinical trials for JOTROL and any of our other possible future product candidates, or competing product
    candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    need to conduct unanticipated clinical trials or trials that are larger or more complex than anticipated;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">competition
    from existing and potential future products that compete with JOTROL and any of our other future product candidates or programs,
    and changes in the competitive landscape of our industry, including consolidation among our competitors or partners;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    delays in regulatory review or approval of JOTROL or any of our other product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    level of demand for JOTROL and any of our other product candidates, if approved, which may fluctuate significantly and be
    difficult to predict;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    risk/benefit profile, cost and reimbursement policies with respect to our product candidates, if approved, and existing and potential
    future products that compete with JOTROL and any of our other product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to commercialize JOTROL and any of our other product candidates, if approved, inside and outside of the United States,
    either independently or working with third parties;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to establish and maintain collaborations, licensing or other arrangements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to adequately support future growth;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    unforeseen business disruptions that increase our costs or expenses;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">future
    accounting pronouncements or changes in our accounting policies; and </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    changing and volatile global economic and political environment. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 76; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
cumulative effect of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results.
As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past
results as an indication of our future performance. This variability and unpredictability could also result in our failing to meet the
expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations
of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below
the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could
occur even when we have met any previously publicly stated guidance we may provide.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters
subject to stockholder approval.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of June 14, 2024, our
executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned approximately
53% our common stock and, upon the closing of this offering, that same group will beneficially own approximately 40% of
our outstanding common stock (based on the number of shares of common stock and restricted stock awards outstanding as of June 14,
2024 assuming no exercise of outstanding options and no purchases of shares in this offering by any of this group), in each case
assuming the exercise of all outstanding options and warrants into shares of our common stock immediately prior to the closing of this
offering. These stockholders, acting together, may be able to control matters requiring stockholder approval. For example, they may be
able to control elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other
major corporate transactions. This concentration of ownership control may delay, discourage or prevent a change of control, including
unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders,
entrench our management and board of directors or delay or prevent a merger, consolidation, takeover or other business combination involving
us that other stockholders may desire. The interests of this group of stockholders may not always coincide with your interests or the
interests of other stockholders and they may act in a manner that advances their best interests and not necessarily those of other stockholders,
including seeking a premium value for their common stock, and might affect the prevailing market price for our common stock.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
common stock may be subject to the &ldquo;penny stock&rdquo; rules in the future.
It may be more difficult to resell securities classified as &ldquo;penny stock.&rdquo;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock may be subject to &ldquo;penny stock&rdquo; rules (generally defined as non-exchange traded stock with a per-share price
below $5.00) in the future. While our common stock will not be considered &ldquo;penny stock&rdquo; following this offering since they
will be listed on the Nasdaq Capital Market, if we are unable to maintain that listing and our common stock is no longer listed
on the Nasdaq Capital Market, unless we maintain a per-share price above $5.00, our common stock will become &ldquo;penny
stock.&rdquo; These rules impose additional sales practice requirements on broker-dealers that recommend the purchase or sale of penny
stocks to persons other than those who qualify as &ldquo;established customers&rdquo; or &ldquo;accredited investors.&rdquo; For example,
broker-dealers must determine the appropriateness for non-qualifying persons of investments in penny stocks. Broker-dealers must also
provide, prior to a transaction in a penny stock not otherwise exempt from the rules, a standardized risk disclosure document that provides
information about penny stocks and the risks in the penny stock market. The broker-dealer also must provide the customer with current
bid and offer quotations for the penny stock, disclose the compensation of the broker-dealer and its salesperson in the transaction,
furnish monthly account statements showing the market value of each penny stock held in the customer&rsquo;s account, provide a special
written determination that the penny stock is a suitable investment for the purchaser, and receive the purchaser&rsquo;s written agreement
to the transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 77; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
remedies available to an investor in &ldquo;penny stocks&rdquo; may include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
If a &ldquo;penny stock&rdquo; is sold to the investor in violation of the requirements listed above, or other federal or states securities
laws, the investor may be able to cancel the purchase and receive a refund of the investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
If a &ldquo;penny stock&rdquo; is sold to the investor in a fraudulent manner, the investor may be able to sue the persons and firms
that committed the fraud for damages.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
requirements may have the effect of reducing the level of trading activity, if any, in the secondary market for a security that becomes
subject to the penny stock rules. The additional burdens imposed upon broker-dealers by such requirements may discourage broker-dealers
from effecting transactions in our securities, which could severely limit the market price and liquidity of our securities. These requirements
may restrict the ability of broker-dealers to sell our common stock and may affect your ability to resell our common
stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
brokerage firms will discourage or refrain from recommending investments in penny stocks. Most institutional investors will not invest
in penny stocks. In addition, many individual investors will not invest in penny stocks due, among other reasons, to the increased financial
risk generally associated with these investments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
these reasons, penny stocks may have a limited market and, consequently, limited liquidity. We can give no assurance at what time, if
ever, our common stock will not be classified as a &ldquo;penny stock&rdquo; in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
the benefits of any proposed acquisition do not meet the expectations of investors, stockholders or financial analysts, the market price
of our Common Stock may decline.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the benefits of any proposed acquisition do not meet the expectations of investors or securities analysts, the market price of our Common
Stock prior to the closing of the proposed acquisition may decline. The market values of our Common Stock at the time of the proposed
acquisition may vary significantly from their prices on the date the acquisition target was identified.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, broad market and industry factors may materially harm the market price of our Common Stock irrespective of our operating performance.
The stock market in general has experienced price and volume fluctuations that have often been unrelated or disproportionate to the operating
performance of the particular companies affected. The trading prices and valuations of these stocks, and of our securities, may not be
predictable. A loss of investor confidence in the market for retail stocks or the stocks of other companies which investors perceive
to be similar to us could depress our stock price regardless of our business, prospects, financial conditions or results of operations.
A decline in the market price of our securities also could adversely affect our ability to issue additional securities and our ability
to obtain additional financing in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Changes
in accounting principles and guidance, or their interpretation, could result in unfavorable accounting charges or effects, including
changes to our previously filed financial statements, which could cause our stock price to decline.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
prepare our financial statements in accordance with GAAP. These principles are subject to interpretation by the SEC and various bodies
formed to interpret and create appropriate accounting principles and guidance. A change in these principles or guidance, or in their
interpretations, may have a significant effect on our reported results and retroactively affect previously reported results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 78; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>As
an &ldquo;emerging growth company&rdquo; under the JOBS Act, we are permitted to rely on exemptions from certain disclosure requirements.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
qualify as an &ldquo;emerging growth company&rdquo; under the JOBS Act. As a result, we are permitted to, and intend to, rely on exemptions
from certain disclosure requirements. For so long as we are an emerging growth company, we will not be required to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">have
    an auditor report on our internal control over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">comply
    with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation
    or a supplement to the auditors&rsquo; report providing additional information about the audit and the financial statements (i.e.,
    an auditor discussion and analysis);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submit
    certain executive compensation matters to stockholder advisory votes, such as &ldquo;say-on-pay&rdquo; and &ldquo;say-on-frequency&rdquo;;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclose
    certain executive compensation related items such as the correlation between executive compensation and performance and comparisons
    of the chief executive officer&rsquo;s compensation to median employee compensation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, Section 102 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period
provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an emerging
growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.
We have elected to take advantage of the benefits of this extended transition period. Our financial statements may therefore not be comparable
to those of companies that comply with such new or revised accounting standards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will remain an emerging growth company until the earliest to occur of: (i) the end of the first fiscal year in which our annual gross
revenue is $1.235 billion or more; (ii) the end of the fiscal year in which the market value of our common shares that are held
by non-affiliates is at least $700.0 million as of the last business day of our most recently completed second fiscal quarter; (iii)
the date on which we have, during the previous three-year period, issued more than $1.0 billion in non-convertible debt; and (iv) the
end of the fiscal year during which the fifth anniversary of this offering occurs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
such time, however, we cannot predict if investors will find our securities less attractive because we may rely on these exemptions.
If some investors find our securities less attractive as a result, there may be a less active trading market for our securities and the
price of our securities may be more volatile.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are unable to implement and maintain effective internal control over financial reporting in the future, investors may lose confidence
in the accuracy and completeness of our financial reports and have an adverse effect on the value of our securities.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company, we would be required to maintain internal control over financial reporting and to report any material weaknesses in
such internal control. Further, we will be required to report any changes in internal controls on a quarterly basis. In addition, we
would be required to furnish a report by management on the effectiveness of internal control over financial reporting pursuant to Section
404 of the Sarbanes-Oxley Act. We will design, implement, and test the internal controls over financial reporting required to comply
with these obligations. If we identify material weaknesses in our internal control over financial reporting, if we are unable to comply
with the requirements of Section 404 in a timely manner or assert that our internal control over financial reporting is effective, or
if our independent registered public accounting firm is unable to express an opinion as to the effectiveness of its internal control
over financial reporting when required, investors may lose confidence in the accuracy and completeness of our financial reports and the
value of our securities could be negatively affected. We also could become subject to investigations by the Commission or other regulatory
authorities, which could require additional financial and management resources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 79; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>As
an emerging growth company, our auditor will not be required to attest to the effectiveness of our internal controls.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
independent registered public accounting firm will not be required to attest to the effectiveness of our internal control over financial
reporting while we are an emerging growth company. This means that the effectiveness of our financial operations may differ from our
peer companies in that they may be required to obtain independent registered public accounting firm attestations as to the effectiveness
of their internal controls over financial reporting and we are not. While our management will be required to attest to internal control
over financial reporting and we will be required to detail changes to our internal controls on a quarterly basis, we cannot provide assurance
that the independent registered public accounting firm&rsquo;s review process in assessing the effectiveness of our internal controls
over financial reporting, if obtained, would not find one or more material weaknesses or significant deficiencies. Further, once we cease
to be an emerging growth company and cease to be a smaller reporting company (as described below), we will be subject to independent
registered public accounting firm attestation regarding the effectiveness of our internal controls over financial reporting. Even if
management finds such controls to be effective, our independent registered public accounting firm may decline to attest to the effectiveness
of such internal controls and issue a qualified report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
believe we will be considered a smaller reporting company and will be exempt from certain disclosure requirements, which could make our
Common Stock less attractive to potential investors.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rule
12b-2 of the Exchange Act defines a &ldquo;smaller reporting company&rdquo; as an issuer that is not an investment company, an asset-backed
issuer, or a majority-owned subsidiary of a parent that is not a smaller reporting company and that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">had
    a public float of less than $250 million as of the last business day of its most recently completed second fiscal quarter, computed
    by multiplying the aggregate worldwide number of shares of its voting and non-voting common equity held by non-affiliates by the
    price at which the common equity was last sold, or the average of the bid and asked prices of common equity, in the principal market
    for the common equity; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    the case of an initial registration statement under the Securities Act, or the Exchange Act of 1934, as amended, which we refer to
    as the Exchange Act, for shares of its common equity, had a public float of less than $250 million as of a date within 30 days of
    the date of the filing of the registration statement, computed by multiplying the aggregate worldwide number of such shares held
    by non-affiliates before the registration plus, in the case of a Securities Act registration statement, the number of such shares
    included in the registration statement by the estimated public offering price of the shares; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    the case of an issuer whose public float as calculated under paragraph (1) or (2) of this definition was zero or whose public float
    was less than $700 million, had annual revenues of less than $100 million during the most recently completed fiscal year for which
    audited financial statements are available.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a smaller reporting company, we will not be required and may not include a Compensation Discussion and Analysis section in our proxy
statements; we will provide only two years of financial statements; and we need not provide the table of selected financial data. We
also will have other &ldquo;scaled&rdquo; disclosure requirements that are less comprehensive than issuers that are not smaller reporting
companies which could make our Common Stock less attractive to potential investors, which could make it more difficult for our stockholders
to sell their shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Upon
becoming a public company, we will incur significant increased costs as a result of operating as a public company, and our management
will be required to devote substantial time to new compliance initiatives.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
becoming a public company, we will incur significant legal, accounting and other expenses that we did not incur as a private company.
In addition, the Sarbanes-Oxley Act has imposed various requirements on public companies including requiring establishment and maintenance
of effective disclosure and financial controls. Our management and other personnel will need to devote a substantial amount of time to
these compliance initiatives. Moreover, these rules and regulations have increased and will continue to increase our legal and financial
compliance costs and will make some activities more time-consuming and costly. For example, we expect that these rules and regulations
may make it more difficult and more expensive for us to obtain directors&rsquo; and officers&rsquo; liability insurance, which could
make it more difficult for us to attract and retain qualified members of our board of directors. We cannot predict or estimate the amount
of additional costs we will incur as a public company or the timing of such costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 80; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Sarbanes-Oxley Act requires, among other things, that we maintain effective internal control over financial reporting and disclosure
controls and procedures. In particular, we must perform system and process evaluation and testing of our internal control over financial
reporting to allow management to report on the effectiveness of our internal control over financial reporting, as required by Section
404 of the Sarbanes-Oxley Act. In addition, we will be required to have our independent registered public accounting firm attest to the
effectiveness of our internal control over financial reporting the later of our second annual report on Form 10-K or the first annual
report on Form 10-K following the date on which we are no longer an emerging growth company or a smaller reporting company. Our compliance
with Section 404 of the Sarbanes-Oxley Act will require that we incur substantial accounting expense and expend significant management
efforts. We currently do not have an internal audit group, and we will need to hire additional accounting and financial staff with appropriate
public company experience and technical accounting knowledge. If we are not able to comply with the requirements of Section 404 in a
timely manner, or if we or our independent registered public accounting firm identify deficiencies in our internal control over financial
reporting that are deemed to be material weaknesses, the value of our securities could decline and we could be subject to sanctions or
investigations by the SEC or other regulatory authorities, which would require additional financial and management resources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to successfully implement our business plan and comply with Section 404 requires us to be able to prepare timely and accurate
financial statements. We expect that we will need to continue to improve existing, and implement new operational and financial systems,
procedures and controls to manage our business effectively. Any delay in the implementation of, or disruption in the transition to, new
or enhanced systems, procedures or controls, may cause our operations to suffer and we may be unable to conclude that our internal control
over financial reporting is effective and to obtain an unqualified report on internal controls from our auditors as required under Section
404 of the Sarbanes-Oxley Act. This, in turn, could have an adverse impact on value of our securities, and could adversely affect our
ability to access the capital markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
management team will have immediate and broad discretion over the use of the net proceeds from this offering and we may use the net proceeds
in ways with which you disagree.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The
                                            net proceeds from this offering will be immediately available to our management to use at
                                            their discretion. We currently intend to use a portion of the net proceeds from this offering
                                            to repay up to $2,100,000 of principal and estimated accrued interest outstanding
                                            on the senior secured note issued by the Company to an investor and up to $325,000 to
                                            repay the related-party notes principal and interest and the Tiberend Convertible Note principal
                                            and interest. We intend to use the balance of the net proceeds from this offering as
                                            follows: (i) approximately $250,000 to fund R&amp;D activities regarding evaluation
                                            of new product opportunities; (ii) approximately $150,000 to pay the outstanding
                                            annual license fees due to Aquanova AG; (iii) approximately $2,300,000 to
                                            fund a Proof-of-Concept (Phase I B or Phase II A) clinical trial of our product
                                            candidate JOTROL in patients with Parkinson&rsquo;s Disease; (iv) $2,300,000
                                            will be allocated for Service Agreements to accelerate business opportunities in South-East
                                            Asia; and (v) $2,090,000 working capital and other general corporate purposes. See &ldquo;Use
                                            of Proceeds.&rdquo; Notwithstanding, our management will have significant discretion and
                                            flexibility in applying the net proceeds of this offering. You will be relying on the judgment
                                            of our management with regard to the use of these net proceeds, and you will not have the
                                            opportunity, as part of your investment decision, to assess whether the proceeds are being
                                            used appropriately. It is possible that the net proceeds will be invested in a way that does
                                            not yield a favorable, or any, return for us or our stockholders. The failure of our management
                                            to use such funds effectively could have a material adverse effect on our business, prospects,
                                            financial condition, and results of operation.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>You
will experience immediate and substantial dilution as a result of this offering and may experience additional dilution in the future.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
will incur immediate and substantial dilution as a result of this offering. After giving effect to the sale by us of up to 2,750,000
shares of common stock offered in this offering, at a public offering price of $4.00 per share, the low-end of the anticipated
public offering price range set forth on the cover page of this prospectus, and after deducting the underwriters&rsquo; discounts
and commissions and other estimated offering expenses payable by us, investors in this offering can expect an immediate dilution of approximately
$3.75 per share, or 93.75%, at the assumed public offering price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 81; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Shares
eligible for future sale may adversely affect the market.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, certain of our stockholders may be eligible to sell all or some of their shares of common stock by means of ordinary brokerage
transactions in the open market pursuant to Rule 144 promulgated under the Securities Act, subject to certain limitations. In general,
pursuant to Rule 144, non-affiliate stockholders may sell freely after six months, subject only to the current public information requirement.
Affiliates may sell after six months, subject to the Rule 144 volume, manner of sale (for equity securities), current public information,
and notice requirements. Of the approximately 30,126,413  shares of our common stock and 1,626,045 restricted stock units
outstanding as of July 7, 2024, 3,600,000 shares are tradable without restrictions defined in the Resale Prospectus. Given the limited trading of our common stock, resale of even a small number of shares of our common stock pursuant to Rule
144 or an effective registration statement may adversely affect the market price of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Anti-takeover
provisions contained in our certificate of incorporation, as amended, and amended and restated bylaws, as well as provisions
of Delaware law, could impair a takeover attempt.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s certificate of incorporation, as amended, and amended and restated bylaws contain provisions that could
have the effect of delaying or preventing changes in control or changes in our management without the consent of our board of directors.
These provisions include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of the board of directors
    or the resignation, death, or removal of a director, which prevents stockholders from being able to fill vacancies on our board of
    directors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability of our board of directors to determine whether to issue shares of our preferred stock and to determine the price and other
    terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly
    dilute the ownership of a hostile acquirer;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limiting
    the liability of, and providing indemnification to, our directors and officers;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">providing
    that a special meeting of the stockholders may only be called by a majority of the board of directors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">providing
    that directors may be removed prior to the expiration of their terms by the affirmative vote of the holders of not less than two-thirds
    (2/3) of the voting power of the issued and outstanding stock entitled to vote; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">advance
    notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters
    to be acted upon at a stockholders&rsquo; meeting, which may discourage or deter a potential acquirer from conducting a solicitation
    of proxies to elect the acquirer&rsquo;s own slate of directors or otherwise attempting to obtain control of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
provisions, alone or together, could delay hostile takeovers and changes in control of the Company or changes in our board of directors
and management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
provision of our certificate of incorporation, as amended, or amended and restated bylaws or Delaware law that has the
effect of delaying or deterring a change in control could limit the opportunity for our security holders to receive a premium for their
securities and could also affect the price that some investors are willing to pay for our securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be subject to securities litigation, which is expensive and could divert management attention.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price of our common stock may be volatile and, in the past, companies that have experienced volatility in the market price of
their stock have been subject to securities class action litigation. This risk is especially relevant for us because biotechnology companies
have experienced significant stock price volatility in recent years and we may be the target of this type of litigation in the future.
Securities litigation against us could result in substantial costs and divert our management&rsquo;s attention from other business concerns,
which could seriously harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 82; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have never paid dividends on our common stock and have no plans to do so in the future.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of shares of our common stock are entitled to receive such dividends as may be declared by our board of directors. To date, we have paid
no cash dividends on our shares of common stock and we do not expect to pay cash dividends on our common stock in the foreseeable future.
We intend to retain future earnings, if any, to provide funds for operations of our business. Therefore, any return investors in our
common stock may have will be in the form of appreciation, if any, in the market value of their shares of common stock. See &ldquo;Dividend
Policy.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
will indemnify and hold harmless our officers and directors to the maximum extent permitted by Delaware law.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
certificate of incorporation provide that we will indemnify and hold harmless our officers and directors against claims arising from
our activities, to the maximum extent permitted by Delaware law. If we were called upon to perform under our indemnification obligations,
then the portion of our assets expended for such purpose would reduce the amount otherwise available for our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ar_001"></A>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate that the net proceeds to us from the sale of the common stock in this offering will be approximately $9,515,000
based upon an assumed initial public offering price of $4.00 per share (which is the low-end of the anticipated public
offering price range set forth on the cover page of this prospectus), and after deducting the estimated underwriting discounts
and commissions and estimated offering expenses payable by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">Each $1.00 increase (decrease)
in the assumed initial public offering price of $4.00 per share would increase (decrease) the net proceeds to us from this offering
by $2.52 million, assuming the number of shares of 2,750,000 offered by us remains the same, and after deducting the estimated
underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of 1.0 million
shares in the number of shares offered by us would increase (decrease) the net proceeds to us from this offering by approximately $3.67
million, assuming the assumed initial public offering price of $4.00 per share, the low-end of the anticipated public offering
price range set forth on the cover page of this prospectus, remains the same, and after deducting the estimated underwriting discounts
and commissions and estimated offering expenses payable by us. We do not expect that a change in the initial public offering price or
the number of shares by these amounts would have a material effect on our uses of the proceeds from this offering, although it may accelerate
the time at which we will need to seek additional capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 83; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal purposes of this offering are to obtain additional capital to support our operations, establish a public market for our common
stock and facilitate our future access to the public capital markets. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="background-color: white"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt"><FONT STYLE="background-color: white">We
intend to use no more than $2,425,000 of the net proceeds of this offering to repay:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 22.65pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2,066,667
                                            <FONT STYLE="background-color: white">of principal and approximately $10,000 of accrued
                                            interest outstanding on the senior secured note (&ldquo;Secured Note&rdquo;). As of July
                                            12, 2024, $1,377,778 in principal and approximately $10,000 of accrued interest
                                            is outstanding on the Secured Note. In accordance with the terms of the Secured Note, $
                                            2,066,667 (150% of the sum  of the original principal amount of $1,111,111 and additional
                                            assumed debt of $266,667) is to be repaid. The Secured Note bears interest at 10% per
                                            annum, payable as described in the Secured Note and has an amended maturity date on
                                            August 11, 2024; </FONT></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 22.65pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$153,333
                                            <FONT STYLE="background-color: white">of principal and approximately $9,000 of accrued interest
                                            outstanding on several</FONT> notes <FONT STYLE="background-color: white">outstanding as
                                            of July 12, 2024 which were issued to Christer Rosen, the CEO of the Company and Alison Silva,
                                            the President and Chief Business Officer of the Company. The notes bear interest at 3.0%
                                            per annum, payable as described in the note and </FONT>is payable upon demand<FONT STYLE="background-color: white">;
                                            and</FONT></FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 22.65pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$150,000
                                            <FONT STYLE="background-color: white">of principal and approximately $10,000 of accrued interest
                                            outstanding on long-term c</FONT>onvertible notes <FONT STYLE="background-color: white">(&ldquo;Tiberend
                                            Note&rdquo;) outstanding on July 12, 2024. The Tiberend Note bears interest at 5.0% per annum,
                                            compounded quarterly and is </FONT>convertible upon election of the holder upon a qualified
                                            financing of at least $5,000,000 into shares of common stock equal to 70% of the per share
                                            price of the equity issued in the qualified financing. The Tiberend Note is also convertible
                                            upon the completion of an IPO by the Company into shares of common stock equal to 70% of
                                            the per share price of the equity issued in connection with the IPO. In both cases the Holder
                                            can elect to receive the principal and accrued interest instead of converting the note and
                                            we believe that the holder will elect for repayment in cash.</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">We currently intend to use
the balance of the net proceeds from this offering, together with our existing resources, as follows:&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately
    $250,000 to fund R&amp;D activities regarding evaluation of new product opportunities; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">approximately $150,000 pay the outstanding
    annual license fees due to Aquanova AG;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximately
    $2,300,000</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> to fund a Proof-of-Concept (Phase
    I B or Phase II A) clinical trial of our product candidate JOTROL in patients with Parkinson&rsquo;s Disease; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> approximately $2,300,000 will be allocated for a
    Strategic Service Agreement to accelerate business activities in South-East Asia; and </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    remainder to fund general research and development activities, working capital and other general corporate activities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions. As
of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon
the completion of this offering or the amounts that we will actually spend on the uses set forth above. We believe opportunities may
exist from time to time to expand our current business through licenses or acquisitions of, or investments in, complementary businesses,
products or technologies. While we have no current agreements, commitments or understandings for any specific licenses, acquisitions
or investments at this time, we may use a portion of the net proceeds for these purposes, subject to applicable regulatory restrictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on our current operating plan, we believe that the net proceeds from this offering, together with our existing cash and cash equivalents,
will be sufficient to fund our operations through at least the next 24 months. However, the net proceeds from this offering, together
with our cash and cash equivalents, will not be sufficient for us to fund our product candidate through the completion of its development,
Phase III clinical trials, entire regulatory approval process and commercialization. We will need to raise additional capital to fund
such activities. It is difficult to predict the cost and timing required to complete development and obtain regulatory approval of, and
commercialize, our product candidates due to, among other factors,  uncertainty regarding the scope and design of clinical trials required to obtain regulatory approval for our product
candidates, the rate of subject enrollment in our clinical trials, filing requirements with various regulatory agencies, clinical trial
results, the actual costs of manufacturing, supplying and commercializing our product candidates and other factors outside of our control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management will have broad discretion over the use of the net proceeds from this offering. The amounts and timing of our expenditures
will depend upon numerous factors including the results of our research and development efforts, the timing, cost and success of preclinical
studies and any ongoing clinical trials or clinical trials we may commence in the future, the timing of regulatory submissions, our ability
to obtain additional financing, the amount of cash obtained through future collaborations, if any, and any unforeseen cash needs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending
their uses, we plan to invest the net proceeds of this offering in short- and intermediate-term, interest-bearing obligations, investment-grade
instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government, subject to applicable regulatory restrictions.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 84; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ar_002"></A>DIVIDEND
POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not declared or paid any cash dividends on our capital stock since our inception. We currently intend to retain future earnings,
if any, and do not anticipate paying any cash dividends in the foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ar_003"></A> CAPITALIZATION </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows our capitalization as of March 31, 2024: </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
    an actual basis;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
                                            a pro forma basis to give effect to:</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)&nbsp;&nbsp;the exchange of 182,898 shares of common stock by the Senior Secured Note holder and agreement to forfeit all rights to all additional
    future shares from the Company that would become due upon a qualified offering, including the ability to convert the
    outstanding principal and interest to common stock, for assuming $266,667 of the CEO&rsquo;s related party notes. The additional
    assumed debt would be considered 10% original issued discount secured notes and have similar terms to the Senior Secured Notes of
    $1,111,111, including a repayment equal to <FONT STYLE="background-color: white">150% of the assumed debt</FONT>. The transaction
reduced the Company&rsquo;s derivative liability associated with the conversion feature and additional variable stock owed to the holder
upon a qualified financing by approximately $637,000 from $1,542,000 to $905,000.</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"> (2)&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the issuance by the Company on June 3, 2024 of 1,162,500 shares of common stock to each of Optimize Wellness Limited,
Regis Healthcare Group Limited, and Longevity Technology Group Limited (collectively, &ldquo;Selling Stockholders&rdquo;) with a fair
market value of $1.33 per share (3,487,500 shares in aggregate, with an aggregate fair market value of $4,638,375), as pre-payment for
3 years of services, which is recognized as a prepaid expense and amortized over the service period of which, approximately $128,844 has
been amortized and $4,509,531 remains as a prepaid expense as of July 12, 2024;</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)&nbsp;&nbsp;the sale of 112,500  shares of common stock to the Selling Stockholders for $1.33 per share on June 3, 2024, with each
    Selling Stockholder purchasing 37,500  shares of common stock; each</FONT> </P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
                                            a pro forma as adjusted basis to reflect:</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)&nbsp;&nbsp;the (a) sale of 2,750,000 shares by us in this offering at an assumed price to the public of $4.00 per share (which is the low-end of the anticipated public offering price range set
forth on the cover page of this prospectus), resulting in net
    proceeds to us of $7,090,000 after deducting (i) $1,485,000 in estimated underwriting discounts and commissions and estimated
    offering expenses payable by us; (ii) the repayment of the principal of $2,066,667 (150% of the sum of original principal amount
    of $1,111,111 and additional assumed debt of $266,667) and accrued interest of $10,000 outstanding on the senior secured
    note issued by the Company to the investor in the amount of approximately $2,100,000; (iii) repayment amount of the aggregate principal of $153,333 and approximately $9,000 of accrued interest on notes
issued to Christer Rosen, the Chief Executive Officer of the Company and Alison Silva, President and Chief Business Officer of the Company;
and (iv) the repayment of the principal amount of $150,000 and $10,000 of accrued interest on the long term convertible notes, and (b)
the elimination of the Company&rsquo;s remaining derivative liability of approximately $905,000 as a result of these debt payoffs; and</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)&nbsp;&nbsp;the automatic conversion of approximately $527,650 of principal and $87,104 of accrued interest on convertible promissory notes held
    by twelve investors into 219,555 shares of common stock.</FONT> </P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
derived this table from, and it should be read in conjunction with and is qualified in its entirety by reference to, our historical and
unaudited pro forma consolidated financial statements and the accompanying notes included elsewhere in this prospectus. You should
also read this table in conjunction with &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of March 31, 2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Actual</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Pro forma</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Pro forma as Adjusted (1)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">(unaudited)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; padding-bottom: 2.5pt">Cash</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="width: 14%; border-bottom: Black 2.5pt double; text-align: right"> 8,313 </TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="width: 14%; border-bottom: Black 2.5pt double; text-align: right"> 157,938 </TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="width: 14%; border-bottom: Black 2.5pt double; text-align: right"> 7,247,938 </TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Convertible notes payable, net of discount of $0, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1,643,746 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 532,635 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"><P STYLE="margin: 0"> - </P> </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Senior Secured Note Payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 1,377,778 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Note payable, related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 428,479 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 161,812 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Long Term Convertible Notes Payable, net of discount of $38,301 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 106,712 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 106,712 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Stockholders&rsquo; equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Common stock, $0.0001 par value; 125,000,000 shares authorized and 26,526,405  shares issued and outstanding on an actual basis, 30,126,413 shares issued
    and outstanding on a pro forma basis, and 33,095,960 shares issued and outstanding on a pro forma as
    adjusted basis.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 2,652 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 3,012 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 3,309 </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Preferred stock, $0.0001 par value 5,000,000 shares authorized and 0 shares issued and outstanding, respectively.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 18,193,815 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 24,216,604 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 34,859,378 </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Accumulated income (deficit)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"> (24,216,604 </P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (23,708,308 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (24,287,339 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total stockholders&rsquo; equity (deficit)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (6,020,137 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (723,841 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 10,575,348 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total capitalization</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (6,126,849 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (830,553 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 10,575,348 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each $1.00 increase (decrease) in the assumed initial
public offering price of $4.00 per share (which is the low-end of the anticipated public offering price range set forth on
the cover page of this prospectus) would increase (decrease) the net proceeds to us from this offering by $2.52 million, assuming
the number of shares of 2,750,000 offered by us, as set forth on the cover page of this prospectus, remains the same, and after
deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase
(decrease) of 1.0 million shares in the number of shares offered by us would increase (decrease) the net proceeds to us from this offering
by approximately $3.67 million, assuming the assumed initial public offering price of $4.00 per share (which is the
low-end of the anticipated public offering price range set forth on the cover page of this prospectus) remains the same, and after
deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.</P>
</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 85; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    number of shares of common stock to be outstanding after the offering is based on 26,526,405, which
    is the number of shares outstanding on March 31, 2024, and excludes:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> 10,566,607 <FONT STYLE="font-size: 10pt">shares of
    our common stock issuable upon exercise of outstanding options at a weighted average exercise price of $1.02
    per share as of March 31, 2024; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> 1,359,375
                                    shares of our common stock issuable upon exercise of outstanding warrants at a weighted average exercise
                                    price of $0.80 per share as of March 31, 2024; </P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-size: 10pt">excludes 219,555</FONT> <FONT STYLE="font-size: 10pt">
    shares of our common stock issuable upon the conversion of our issued and outstanding convertible notes at an average conversion
    price of $2.80. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ar_004"></A>MARKET
PRICE FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Market
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock is not currently
listed on any national securities exchange market or quoted on the OTC Markets. We have applied to list our common stock on the Nasdaq
Capital Market under the symbol &ldquo;JUNS.&rdquo; There is no assurance that our listing application will be approved by the Nasdaq
Capital Market. The approval of our listing on the Nasdaq Capital Market is a condition of closing this offering.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Holders
of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 17, 2024, there were approximately 48 record holders of our common stock. The number of record holders does not
include beneficial owners of common stock whose shares are held in the names of banks, brokers, nominees or other fiduciaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not paid any cash dividends on our common stock and do not currently anticipate paying cash dividends in the foreseeable future.
We intend to retain future earnings, if any, for reinvestment in the development and expansion of our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Historical
Common Equity Transactions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"> Name </TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Date </TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Type </TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"> Type of Award </TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Quantity </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Price </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"> Additional </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; text-align: left"> Christer Ros&eacute;n, our Chief Executive Officer </TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center"> January 01, 2016 </TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: center"> Issued </TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: left"> Common Stock </TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right"> 11,250,000 </TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 6%; text-align: right"> 53.33 </TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 9%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Christer Ros&eacute;n, our Chief Executive Officer </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> January 01, 2016 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Incentive Stock Option; Common Stock </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 225,000 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.01 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Alexander Ros&eacute;n, our Chief Administrative Officer </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> January 01, 2016 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Incentive Stock Option; Common Stock </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 56,250 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.01 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Dr. Claes Wahlestedt, MD, Ph.D., a member of our Science Advisory Board </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> January 01, 2016 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 225,000 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.01 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Claude Volmar, a consultant </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> January 01, 2016 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 56,250 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.01 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Ian Baker-Finch., a consultant </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> January 01, 2016 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 168,750 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.01 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Jacob Uittenbogaard, our former Chief Financial Officer </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> January 01, 2016 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Incentive Stock Option; Common Stock </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 225,000 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.01 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Marshall Hayward, Ph.D., our Chief Scientific Officer </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> January 01, 2016 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Incentive Stock Option; Common Stock </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 225,000 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.01 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Peter Colabuono, a consultant </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> January 01, 2016 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 112,500 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.01 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Thomas Liquard, a consultant </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> January 01, 2016 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 112,500 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.01 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> The shares were subsequently forefeited on January 1, 2016 </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Dr. Claes Wahlestedt, MD, Ph.D., a member of our Science Advisory Board </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> January 04, 2016 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Issued </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 2,757,352 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 13.07 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Jacob Uittenbogaard, our former Chief Financial Officer </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> January 04, 2016 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Issued </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 551,471 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 2.67 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Marshall Hayward, Ph.D., our Chief Scientific Officer </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> January 04, 2016 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Issued </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 2,205,885 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 10.40 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Shaun P. Brothers, Ph.D., a member of our Science Advisory Board </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> January 04, 2016 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Issued </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 1,541,914 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 7.73 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 86; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"> Name </TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Date </TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Type </TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"> Type of Award </TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Quantity </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Price </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"> Additional </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; text-align: left"> David Sinclair, an advisor </TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center"> April 06, 2016 </TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: center"> Granted </TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: left"> Non-qualified Stock Option; Common Stock </TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right"> 225,000 </TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 6%; text-align: right"> 0.01 </TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 9%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Li-Huei Tsai, a member of our Science Advisory Board </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> June 01, 2016 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 135,000 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Raymond Scott Turner, MD, Ph.D., a member of our Science Advisory Board </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> August 01, 2016 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 135,000 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Gene Spotlight, Inc. </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> September 30, 2016 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Issued </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 312,502 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Peter Elliott, Ph.D., a member of our Science Advisory Board </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> October 17, 2016 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 135,000 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Gene Spotlight, Inc. </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> October 17, 2016 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Issued </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 125,002 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Natalie McNamee, a consultant </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> December 19, 2016 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 225,000 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Gene Spotlight, Inc. </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> January 25, 2017 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Issued </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 187,500 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Ulf Wiinberg, an advisor </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> January 27, 2017 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Issued </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 187,500 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Ulf Wiinberg, an advisor </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> January 31, 2017 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 135,000 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Robert Roath, an advisor </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> November 17, 2017 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 135,000 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Gene Spotlight, Inc. </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> December 21, 2017 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Issued </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 112,500 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Gino Cortopassi, an advisor </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> February 14, 2018 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 135,000 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Christer Ros&eacute;n, our Chief Executive Officer </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> May 08, 2018 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Issued </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 225,000 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.01 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Upon an exercise of an incentive stock option </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Alexander Ros&eacute;n, our Chief Administrative Officer </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> May 08, 2018 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Issued </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 56,250 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.01 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Upon an exercise of an incentive stock option </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Jacob Uittenbogaard, our former Chief Financial Officer </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> May 09, 2018 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Issued </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 225,000 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.01 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Upon an exercise of an incentive stock option </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Robert Roath </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> June 01, 2018 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Issued </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 157,083 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.64 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Upon his conversion of a promissory note </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Robert Roath </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> June 20, 2018 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Issued </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 135,000 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Upon an exercise of a non-qualified stock option </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Frank Behnam, an advisor </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> October 01, 2018 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 84,375 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Michio Harano, an advisor </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> October 01, 2018 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 84,375 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Robert Roath, an advisor </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> October 01, 2018 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 84,375 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Ulf Wiinberg, an advisor </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> October 01, 2018 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 84,375 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Alison Silva, our President and Chief Business Officer </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> December 13, 2018 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Incentive Stock Option; Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 225,000 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> John Ditton, an advisor </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> December 13, 2018 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Incentive Stock Option; Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 135,000 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Such stock options were forfeited on January 15, 2022 (90 days following his resignation as a director
    of the Company) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Alexander Ros&eacute;n, our Chief Administrative Officer </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> January 24, 2019 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Incentive Stock Option; Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 569,775 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.74 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Christer Ros&eacute;n, our Chief Executive Officer </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> January 24, 2019 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Incentive Stock Option; Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 811,811 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.74 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Dr. Claes Wahlestedt, MD, Ph.D., a member of our Science Advisory Board </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> January 24, 2019 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 84,937 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.74 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Jacob Uittenbogaard, our former Chief Financial Officer </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> January 24, 2019 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Incentive Stock Option; Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 113,598 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.74 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Shaun Brothers, a member of our Science Advisory Board </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> January 24, 2019 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 77,441 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.74 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> David Sinclair, an advisor </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> May 15, 2019 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Forfeited </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 225,000 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.01 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Peter Colabuono, a consultant </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> September 09, 2019 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Forfeited </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 112,500 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.01 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Michio Harano, an advisor </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> October 01, 2018 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Forfeited </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 84,375 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Gino Cortopassi, an advisor </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> October 17, 2019 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Forfeited </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 135,000 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Natalie McNamee, a consultant </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> October 24, 2019 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Forfeited </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 225,000 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Dr. Rudolph Tanzi, a member of our Science Advisory Board </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> November 06, 2019 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 225,000 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Alalia Pty Ltd ATF McNamee Family Trust </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> December 19, 2019 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Warrant; Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 1,249,998 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Alexander Ros&eacute;n, our Chief Administrative Officer </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> February 01, 2020 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Incentive Stock Option; Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 168,750 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Christer Ros&eacute;n, our Chief Executive Officer </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> February 01, 2020 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Incentive Stock Option; Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 506,250 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Dr. Claes Wahlestedt, MD, Ph.D., a member of our Science Advisory Board </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> February 01, 2020 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 135,000 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Claude Volmar, a consultant </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> February 01, 2020 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 67,500 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Jacob Uittenbogaard, our former Chief Financial Officer </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> February 01, 2020 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 168,750 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Li-Huei Tsai, Ph.D., a member of our Science Advisory Board </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> February 01, 2020 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Incentive Stock Option; Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 67,500 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Marshall Hayward, Ph.D., our Chief Scientific Officer </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> February 01, 2020 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 393,750 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Raymond Scott Turner, MD, Ph.D., a member of our Science Advisory Board </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> February 01, 2020 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 135,000 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Charbel Moussa, MBBS, Ph.D., a member of our Science Advisory Board </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> April 21, 2020 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 90,000 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 87; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold"> Name </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold"> Date </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold"> Type </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold"> Type of Award </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold"> Quantity </TD><TD STYLE="font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold"> Price </TD><TD STYLE="font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold"> Additional </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; text-align: left"> Mark Dant, an advisor </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 10%"> April 21, 2020 </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 7%"> Granted </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 11%; text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 6%; text-align: right"> 90,000 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 6%; text-align: right"> 0.80 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 9%"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Robert Roath </TD><TD> &nbsp; </TD>
    <TD> May 19, 2020 </TD><TD> &nbsp; </TD>
    <TD> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 126,251 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Upon his conversion of a promissory note </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Joel Norman Goldberg Trust #1, Dated 04/15/2003 </TD><TD> &nbsp; </TD>
    <TD> June 23, 2020 </TD><TD> &nbsp; </TD>
    <TD> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 156,251 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Joel Norman Goldberg Trust #1, Dated 04/15/2003 </TD><TD> &nbsp; </TD>
    <TD> June 23, 2020 </TD><TD> &nbsp; </TD>
    <TD> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Warrant; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 234,375 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Andrew C. Matthiesen Trust, Dated 12/03/1998 </TD><TD> &nbsp; </TD>
    <TD> June 23, 2020 </TD><TD> &nbsp; </TD>
    <TD> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 156,251 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Andrew C. Matthiesen Trust, Dated 12/03/1998 </TD><TD> &nbsp; </TD>
    <TD> June 23, 2020 </TD><TD> &nbsp; </TD>
    <TD> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Warrant; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 234,375 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Joel Norman Goldberg Trust #1, Dated 04/15/2003 </TD><TD> &nbsp; </TD>
    <TD> June 23, 2020 </TD><TD> &nbsp; </TD>
    <TD> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 78,123 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> For services rendered by Joel Norman Goldberg to the Company </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Andrew C. Matthiesen Trust, Dated 12/03/1998 </TD><TD> &nbsp; </TD>
    <TD> June 23, 2020 </TD><TD> &nbsp; </TD>
    <TD> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 78,123 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> For services rendered by Andrew C. Matthiesen to the Company </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Dencam Living Trust </TD><TD> &nbsp; </TD>
    <TD> June 29, 2020 </TD><TD> &nbsp; </TD>
    <TD> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 156,251 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Dencam Living Trust </TD><TD> &nbsp; </TD>
    <TD> June 29, 2020 </TD><TD> &nbsp; </TD>
    <TD> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Warrant; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 234,375 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Dencam Living Trust </TD><TD> &nbsp; </TD>
    <TD> June 29, 2020 </TD><TD> &nbsp; </TD>
    <TD> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 78,123 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> For services rendered by Robert Faerber to the Company </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> WKJP, LLC </TD><TD> &nbsp; </TD>
    <TD> July 15, 2020 </TD><TD> &nbsp; </TD>
    <TD> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 156,251 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> WKJP, LLC </TD><TD> &nbsp; </TD>
    <TD> July 15, 2020 </TD><TD> &nbsp; </TD>
    <TD> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Warrant; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 234,375 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> WKJP, LLC </TD><TD> &nbsp; </TD>
    <TD> July 15, 2020 </TD><TD> &nbsp; </TD>
    <TD> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 78,123 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> For services rendered by Jeffery W. Krol to the Company </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Joel Norman Goldberg Trust #1, Dated 04/15/2003 </TD><TD> &nbsp; </TD>
    <TD> August 20, 2020 </TD><TD> &nbsp; </TD>
    <TD> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 669,645 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.15 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Dencam Living Trust </TD><TD> &nbsp; </TD>
    <TD> August 20, 2020 </TD><TD> &nbsp; </TD>
    <TD> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 167,411 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.15 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> WKJP, LLC </TD><TD> &nbsp; </TD>
    <TD> August 20, 2020 </TD><TD> &nbsp; </TD>
    <TD> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 502,233 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.15 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Arthur Kirsch, a consultant </TD><TD> &nbsp; </TD>
    <TD> October 01, 2020 </TD><TD> &nbsp; </TD>
    <TD> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 150,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Gene Spotlight, Inc. </TD><TD> &nbsp; </TD>
    <TD> December 29, 2020 </TD><TD> &nbsp; </TD>
    <TD> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 375,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Gene Spotlight, Inc. </TD><TD> &nbsp; </TD>
    <TD> December 29, 2020 </TD><TD> &nbsp; </TD>
    <TD> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Warrant; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 75,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Robert S. Roath Revocable Trust </TD><TD> &nbsp; </TD>
    <TD> February 19, 2021 </TD><TD> &nbsp; </TD>
    <TD> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 11,373 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Upon his conversion of a promissory note </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Dana Eschenburg Perez, our former Chief Financial Officer </TD><TD> &nbsp; </TD>
    <TD> March 01, 2021 </TD><TD> &nbsp; </TD>
    <TD> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Incentive Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 135,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Robert S. Roath </TD><TD> &nbsp; </TD>
    <TD> March 05, 2021 </TD><TD> &nbsp; </TD>
    <TD> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 84,375 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Upon an exercise of a non-qualified stock option </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Alexander Ros&eacute;n, our Chief Administrative Officer </TD><TD> &nbsp; </TD>
    <TD> June 01, 2021 </TD><TD> &nbsp; </TD>
    <TD> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Incentive Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 168,750 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 2.16 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Dana Eschenburg Perez, our former Chief Financial Officer </TD><TD> &nbsp; </TD>
    <TD> June 01, 2021 </TD><TD> &nbsp; </TD>
    <TD> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Incentive Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 193,125 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 2.16 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Tiberend Strategic Advisors, a consultant </TD><TD> &nbsp; </TD>
    <TD> June 15, 2021 </TD><TD> &nbsp; </TD>
    <TD> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 56,250 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 2.16 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> W. Dalton Deitrich III, an advisor </TD><TD> &nbsp; </TD>
    <TD> June 22, 2021 </TD><TD> &nbsp; </TD>
    <TD> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 67,500 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 2.16 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Dencam Living Trust </TD><TD> &nbsp; </TD>
    <TD> August 30, 2021 </TD><TD> &nbsp; </TD>
    <TD> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 234,375 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Upon the exercise of a warrant </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Alison Silva, our President and Chief Business Officer </TD><TD> &nbsp; </TD>
    <TD> September 01, 2021 </TD><TD> &nbsp; </TD>
    <TD> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Incentive Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 281,250 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 2.16 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Gene Spotlight, Inc. </TD><TD> &nbsp; </TD>
    <TD> September 09, 2021 </TD><TD> &nbsp; </TD>
    <TD> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 75,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Upon the exercise of a warrant </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Joel Norman Goldberg Trust #1, Dated 04/15/2003 </TD><TD> &nbsp; </TD>
    <TD> September 28, 2021 </TD><TD> &nbsp; </TD>
    <TD> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 234,375 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Upon the exercise of a warrant </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> WKJP, LLC </TD><TD> &nbsp; </TD>
    <TD> September 29, 2021 </TD><TD> &nbsp; </TD>
    <TD> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 234,375 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Upon the exercise of a warrant </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Andrew C. Matthiesen Trust, Dated 12/03/1998 </TD><TD> &nbsp; </TD>
    <TD> September 30, 2021 </TD><TD> &nbsp; </TD>
    <TD> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 234,375 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Upon the exercise of a warrant </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Nicholas Hemmerly, a member of our Board of Directors </TD><TD> &nbsp; </TD>
    <TD> October 01, 2021 </TD><TD> &nbsp; </TD>
    <TD> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 67,500 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 2.16 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Allison W. Brady, a member of our Board of Directors </TD><TD> &nbsp; </TD>
    <TD> October 01, 2021 </TD><TD> &nbsp; </TD>
    <TD> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 67,500 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 2.16 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Julie Kampf, a member of our Board of Directors </TD><TD> &nbsp; </TD>
    <TD> October 01, 2021 </TD><TD> &nbsp; </TD>
    <TD> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 67,500 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 2.16 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> John Ditton, an advisor </TD><TD> &nbsp; </TD>
    <TD> October 01, 2021 </TD><TD> &nbsp; </TD>
    <TD> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 67,500 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 2.16 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Such stock options were forfeited on January 15, 2022 (90 days following his resignation as a director
    of the Company) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Holger Weis, a member of our Board of Directors </TD><TD> &nbsp; </TD>
    <TD> October 01, 2021 </TD><TD> &nbsp; </TD>
    <TD> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 67,500 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 2.16 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Arthur Kirsch, a consultant </TD><TD> &nbsp; </TD>
    <TD> October 01, 2021 </TD><TD> &nbsp; </TD>
    <TD> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 46,875 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 2.16 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Frank Behnam, CEO of Aquanova AG </TD><TD> &nbsp; </TD>
    <TD> December 01, 2021 </TD><TD> &nbsp; </TD>
    <TD> Cancelled </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 84,375 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> Issued on October 2018 </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Aquanova AG </TD><TD> &nbsp; </TD>
    <TD> December 01, 2021 </TD><TD> &nbsp; </TD>
    <TD> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 84,375 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 2.16 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Pursuant to the terms of the Debt Forgiveness and Exchange Agreement. subject to vesting terms set
    forth in the non-qualified stock option </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> An accredited investor </TD><TD> &nbsp; </TD>
    <TD> April 11, 2022 </TD><TD> &nbsp; </TD>
    <TD> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 514,403 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 2.16 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> In connection with the issuance of a senior secured convertible note with a principal amount of $1,111,111
    to an accredited investor; as additional consideration to the investor for lending $1,000,000 to the Company </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> June 1, 2021 Option Grant to Alexander Ros&eacute;n, our Chief Administrative Officer </TD><TD> &nbsp; </TD>
    <TD> July 14, 2022 </TD><TD> &nbsp; </TD>
    <TD> Amendment </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Incentive Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 168,750 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> June 1, 2021 Option Grant to Dana Eschenburg Perez, our former Chief Financial Officer </TD><TD> &nbsp; </TD>
    <TD> July 14, 2022 </TD><TD> &nbsp; </TD>
    <TD> Amendment </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Incentive Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 193,125 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> August 1, 2021 Option Grant to Dana Eschenburg Perez, our former Chief Financial Officer </TD><TD> &nbsp; </TD>
    <TD> July 14, 2022 </TD><TD> &nbsp; </TD>
    <TD> Amendment </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Incentive Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 193,125 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> June 22, 2021 Option Grant to W. Dalton Dietrich III, an advisor </TD><TD> &nbsp; </TD>
    <TD> July 14, 2022 </TD><TD> &nbsp; </TD>
    <TD> Amendment </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 67,500 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> September 1, 2021 Option Grant to Alison D. Silva, our President and Chief Business Officer </TD><TD> &nbsp; </TD>
    <TD> July 14, 2022 </TD><TD> &nbsp; </TD>
    <TD> Amendment </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Incentive Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 281,250 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 88; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Type</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Type
    of Award</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantity</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christer Ros&eacute;n,
    our Chief Executive Officer</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 21, 2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted stock</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">476,070</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.33</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The restricted
    stock award was issued in exchange for forgiveness of $634,760 of accrued compensation</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marshall Hayward, our Chief
    Scientific Officer</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 21, 2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted stock</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">399,401</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.33</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The restricted stock award
    was issued in exchange for forgiveness of $532,535 of accrued compensation</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jacob Uittenbogaard, our former
    Chief Financial Officer</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 21, 2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted stock</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">93,367</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.33</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The restricted stock award
    was issued in exchange for forgiveness of $124,490 of accrued compensation</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alexander Ros&eacute;n, our
    Chief Administrative Officer</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 21, 2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted stock</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">96,607</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.33</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The restricted stock award
    was issued in exchange for forgiveness of $128,810 of accrued compensation</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dana Eschenburg Perez, our
    former Chief Financial Officer</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 21, 2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted stock</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,125</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.33</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The restricted stock award
    was issued in exchange for forgiveness of $13,500 of accrued compensation</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Claes Wahlestedt, MD, Ph.D.,
    a member of our Science Advisory Board</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 21, 2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted stock</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46,620</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.33</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The restricted stock award
    was issued in exchange for forgiveness of $62,160 of accrued compensation</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shaun Brothers, a member of
    our Science Advisory Board</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 21, 2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted stock</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44,820</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.33</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The restricted stock award
    was issued in exchange for forgiveness of $59,760 of accrued compensation</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 1, 2021 Option Grant
    to Nicholas Hemmerly, a member of our Board of Directors</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 25, 2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-qualified Stock Option;
    Common Stock</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">67,500</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.33</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 1, 2021 Option Grant
    to Allison W. Brady, a member of our Board of Directors</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 25, 2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-qualified Stock Option;
    Common Stock</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">67,500</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.33</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 1, 2021 Option Grant
    to Julie Kampf, a member of our Board of Directors</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 25, 2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-qualified Stock Option;
    Common Stock</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">67,500</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.33</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 1, 2021 Option Grant
    to Holger Weis, a member of our Board of Directors</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 25, 2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-qualified Stock Option;
    Common Stock</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">67,500</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.33</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 1, 2021 Option Grant
    to Arthur Kirsch, a consultant</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 25, 2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-qualified Stock Option;
    Common Stock</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46,875</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.33</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 1, 2021 Option Grant
    to Aquanova AG</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 01, 2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-qualified Stock Option;
    Common Stock</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">193,125</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.33</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Senior secured note investor</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 10, 2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42,867</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.16</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For consideration of an amendment
    to postpone the amortization of principle and interest one month to November 11, 2022</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Senior secured note investor</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 10, 2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">128,598</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.16</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For consideration of an amendment
    to postpone the amortization of principle and interest three months to February 11, 2023</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Saleem Elmasri, CPA, our Chief
    Financial Officer</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 01, 2023</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-qualified Stock Option;
    Common Stock</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">562,500</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.33</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An employee and consultants</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 01, 2023</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-qualified Stock Option;
    Common Stock</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">562,500</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.33</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Various employees and executives
    as part of their accrued compensation forgiveness</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 29, 2023</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-qualified Stock Option;
    Common Stock</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,353,777</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.33</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christer
    Ros&eacute;n, our Chief Executive Officer</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    13, 2023</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">113,637</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.88</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
    an exercise of an incentive stock option</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Various employees and executives
    as part of their accrued compensation forgiveness</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    18,</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2023</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-qualified Stock Option;
    Restricted Stock</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,618,545</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.33</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Various
    employees and executives as part of their accrued compensation forgiveness</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    18, 2023</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-qualified
    Stock Option; Common Stock</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">289,296</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.33</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    consultant</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    24, 2024</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-qualified
    Stock Option; Common Stock</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">180,000</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.33</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dana
    Eschenburg Perez, our former Chief Financial Officer</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    15, 2024</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-qualified
    Stock Option; Restricted Stock</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,500</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.33</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dana
    Eschenburg Perez, our former Chief Financial Officer</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    15, 2024</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-qualified
    Stock Option; Common Stock</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49,605</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.33</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    consultant</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    17, 2024</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-qualified
    Stock Option; Common Stock</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">67,500</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.33</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The above issuances/sales were
made pursuant to an exemption from registration as set forth in Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D
promulgated under the Securities Act.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ar_005"></A>DILUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If you invest in our common stock
in this offering, your interest will be diluted to the extent of the difference between the assumed public offering price per share of
common stock and the pro forma net tangible book value per share of our common stock immediately after this offering.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
net tangible book value of our common stock as of March 31, 2024 was ($6,020,137) or approximately ($0.23)
per share. Net tangible book value per share represents our total tangible assets of $116,820 less our total liabilities of
$6,136,957 for a tangible book value $6,020,137, divided by the number of issued and outstanding shares of common stock,
26,526,405<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT> </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
tangible book value dilution per share of common stock to new investors represents the difference between the amount per share of common
stock paid by purchasers in this offering and the pro forma net tangible book value per share of our common stock immediately after the
completion of this offering. After giving effect to (i) issuance by the Company of 219,555 shares of our common stock issuable upon
the conversion of our issued and outstanding convertible notes at an average conversion price of $2.80 per share, or an aggregate of
$614,754, (ii) the issuance by the Company on June 3, 2024 of 1,162,500 shares of common stock to each of Optimize Wellness Limited,
Regis Healthcare Group Limited, and Longevity Technology Group Limited (collectively, &ldquo;Selling Stockholders&rdquo;) with a fair
market value of $1.33 per share (3,487,500 shares in aggregate, with an aggregate fair market value of $4,638,375), as pre-payment for
3 years of services, which is recognized as a prepaid expense and amortized over the service period of which, approximately $128,844
has been amortized and $4,509,531 remains as a prepaid expense as of July 12, 2024;(iii) the sale of 112,500 shares of common stock to
the Selling Stockholders for $1.33 per share on June 3, 2024, with each Selling Stockholder purchasing 37,500 shares of common stock,
(iv) the repayment of the principal of $2,066,667 (150% of the sum of original principal amount of $1,111,111 and additional assumed
debt of $266,667) and accrued interest of $10,000 outstanding on the senior secured note issued by the Company to the investor in the
amount of approximately $2,100,000, (v) repayment amount of the principal of $153,333 and $9,000 of accrued interest on notes issued
to Christer Rosen, the Chief Executive Officer of the Company and Alison Silva, the President and Chief Business Officer of the Company,
(vi) the repayment of the principal amount of $150,000 and $10,000 of accrued interest on the long term convertible notes, (vii) elimination
of derivative liabilities of $1,542,000 associated with the conversion feature and additional variable stock owed to a debt holder upon
a qualified financing due to the forfeiture of the additional variable stock owed and debt payoff, and (viii) the issuance and sale of
2,750,000 shares of common stock in this offering at the assumed public offering price of $4.00 per share and after deducting
estimated underwriting discounts and commissions and estimated offering expenses, our pro forma net tangible book value as of March
31, 2024 would have been $8,168,148 or approximately $0.25 per share. This represents an immediate
increase in net tangible book value of $0.48 per share to existing stockholders and an immediate dilution in net tangible book
value of $3.75 per share to purchasers of shares in this offering, as illustrated in the following table:</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left">Assumed public offering price per share</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.00</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Net tangible book value per share as of March 31, 2024 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> (0.23 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Increase in net tangible book value per share attributable to new investors</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.48</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Less: pro forma net tangible book value per share after giving effect to the offering</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.25</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Immediate dilution in net tangible book value per share to new investors</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.75</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 89; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table sets forth,
as of March 31, 2024, the assumed number of shares of common stock purchased from us, the total consideration paid to us and the
average price per share paid by existing stockholders and to be paid by new investors purchasing common stock in this offering, after
giving pro forma effect to the new investors in this offering at the public offering price of $4.00 per share (which is the
low-end of the anticipated public offering price range set forth on the cover page of this prospectus), together with the total consideration
paid an average price per share paid by each of these groups, before deducting underwriting discounts and commissions and estimated offering
expenses.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares Purchased</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total Consideration</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Average <BR> Price</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percent</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percent</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">per Share</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; font-size: 10pt; text-align: left">Existing stockholders</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right"> 26,526,405 </TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right"> 80.2 </TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">%</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">18,133,815</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right"> 52.6 </TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">%</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right"> 0.68 </TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Issuance of shares to Selling Stockholders in advance for services to be
    rendered by Selling Stockholders to the Company </TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"> 3,487,500 </TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"> 10.5 </TD><TD STYLE="font-size: 10pt; text-align: left"> % </TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"> $ </TD><TD STYLE="font-size: 10pt; text-align: right"> 4,638,375 </TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"> 13.4 </TD><TD STYLE="font-size: 10pt; text-align: left"> % </TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"> $ </TD><TD STYLE="font-size: 10pt; text-align: right"> 1.33 </TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"> Issuance of shares to Selling Stockholders for cash consideration </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 112,500 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 0.3 </TD><TD STYLE="font-size: 10pt; text-align: left"> % </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> $ </TD><TD STYLE="font-size: 10pt; text-align: right"> 149,625 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 0.4 </TD><TD STYLE="font-size: 10pt; text-align: left"> % </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> $ </TD><TD STYLE="font-size: 10pt; text-align: right"> 1.33 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"> Convertible promissory notes conversion into shares of common stock </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 219,555 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 0.7 </TD><TD STYLE="font-size: 10pt; text-align: left"> % </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> $ </TD><TD STYLE="font-size: 10pt; text-align: right"> 614,754 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 1.7 </TD><TD STYLE="font-size: 10pt; text-align: left"> % </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> $ </TD><TD STYLE="font-size: 10pt; text-align: right"> 2.80 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.5pt">New investors</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">2,750,000</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"> 8.3 </TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">%</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">11,000,000</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"> 31.9 </TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">%</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">4.00</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">Total</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"> 33,095,960 </TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">100.0</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">%</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"> 34,474,467 </TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">100.0</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">%</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"> 1.04 </TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The
foregoing discussion and tables above do not give effect to the dilution that would result from (i) 1,359,375  shares of our common
stock issuable upon the exercise of our issued and outstanding warrants at an average exercise price of $0.80  per share;
(ii) 10,634,107 shares of our common stock issuable upon the exercise of our issued and outstanding options at an average exercise
price of $1.03 per share; and (iii) <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,626,045 shares of
common stock issuable upon the exercise of our issued and outstanding restricted stock units.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ar_006"></A>DESCRIPTION
OF BUSINESS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Unless
the context otherwise requires, &ldquo;JNS,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; or &ldquo;the Company&rdquo;
refers to Jupiter Neurosciences, Inc., a Delaware corporation.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Business
Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Jupiter Neurosciences, Inc.
(the &ldquo;Company&rdquo;) is a clinical stage research and development pharmaceutical company located in Jupiter, Florida. The Company
incorporated in Delaware in January 2016. The Company has developed a unique resveratrol platform product targeting treatment of neuro-inflammation.
The product, called JOTROL, has many potential indications of use for rare diseases, which of we primarily are targeting Mucopolysaccharidoses
Type 1, Friedreich&rsquo;s Ataxia, and MELAS. In the larger disease areas, we are primarily targeting Parkinson&rsquo;s Disease and
Mild Cognitive Impairment/early Alzheimer&rsquo;s disease. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The Company has recently
completed preclinical activities in a validated mouse model of Parkinson&rsquo;s Disease (PD) at the University of Miami. The model of
PD that was used mimics many aspects of the disease utilizing a unilateral injection of a neurotoxin precursor that elicits nigral cell
loss, striatal dopamine loss and behavior deficits similar to physiological characteristics of human disease. We believe that results
from this trial indicates that PD might be the best target for treatment and financial opportunity among the multiple indications where
JOTROL<SUP></SUP> might play a role. The trial design and outcomes are further described in this section, see JNS115. On
May 23, 2024 the US Senate unanimously passed the <B>National Plan to End Parkinson&rsquo;s Act</B>, the first-ever federal legislation
dedicated to ending Parkinson&rsquo;s disease. A cross-country strategy to end Parkinson&rsquo;s and atypical parkinsonism has the potential
to: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dramatically
    increase federal research funding; </FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Develop
    more effective pathways for treatments and cures; </FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Improve
    early diagnosis; </FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Spark
    new and improved models for patient care; </FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Create
    standards and measures to prevent Parkinson&rsquo;s disease; </FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
    health disparities in diagnosis, treatment and clinical trial participation and </FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enhance
    public awareness of the disease.</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to follow the various opportunities closely with a particular focus on seeking available funding to to accelerate research
and development JOTROL&rsquo;s Parkinson&rsquo;s Disease indication. However, there is no assurance that such funding will ever become
available or be awarded to the Company.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> We have over the past
2 years received a strong interest in JOTROL from various Asian organizations. We believe that this interest has been triggered, in part,
by (i) resveratrol becoming commonly used in Asian herbal medicines as a therapeutic strategy as described in available scientific literature
published by PubMed Central: PMCID: PMC7498443 (September 2020), (ii) Hong Kong&rsquo;s and China&rsquo;s recent approval of the patent
for JOTROL, (iii) China releasing a list of approximately 120 rare disease indications issued jointly by five national bodies, including
the National Health Commission, Ministry of Science and Technology, Ministry of Industry and Information Technology, State Drug Administration,
and State Administration of Traditional Chinese Medicine (May 2018), that we believe JOTROL can be applicable as a treatment for MPS-1
and MELAS in this population and (iv) recent publications regarding JOTROL in the Journal of Alzheimer&rsquo;s Disease and AAPS Open
(Journal of Alzheimer&rsquo;s Disease 86 (2022) 173&ndash;190 February 2022; Kemper et al. AAPS Open June 2022). (v) the projected increase
of the TCM market due to several factors which of one is reformulation of existing compounds. Our Chairman &amp; CEO, Christer Ros&eacute;n,
presented in person, our company&rsquo;s status and pipeline at the BIOHK 2023 in Hong Kong in September of 2023. The presentation led
to several follow-on meetings, and we have therefore recently agreed to service agreements in the areas of CMC (Chemistry, Manufacturing,
and Controls), regulatory affairs and clinical trial management. These agreements are with companies that, we believe, have the knowledge and network in the South-East Asian market to accelerate steps that is needed to have a product that can have treatment value
in the territory. In addition, we are in active negotiations with Dominant Treasure Health (&ldquo;DTH&rdquo;), a BVI company. DTH has demonstrated to us through several company introductions that they have business relationships, either directly or through affiliates, with many South-East Asian pharmaceutical companies as well as companies involved
in distribution and sales of TCM, Traditional Chinese Medicine. We are therefore planning to engage DTH in active business development
in China, Malaysia and Singapore as soon as we have financing in place for their engagement. DTH has already introduced us to 3 Chinese
companies, Beimei Pharma, http://en.beimeiyaoye.com, that specializes in pediatric medications, Sichuan Kelun Pharmaceutical Co., ltd,
a publicly traded company that is part of the Kelun Industrial Group, https://www.kelun.com/, and Tianjin Pharmaceuticals, https://en.pharm.com.cn/,
that advocates the corporate core values of &ldquo;Love, Integrity and Power&rdquo;. TCM products are run in a separate division within
Tianjin. Discussions with all three companies are ongoing. We believe that with DTH&rsquo;s assistance we can co-ordinate and oversee
the work of our Service providers in the territory and more expediently negotiate and finalize an out-license agreement with one or more
pharmaceutical companies in South-East Asia. The agreements are
further described in the section &ldquo;Other Material Agreements&rdquo;. The Asian market is very large and hard to penetrate for a
small company and we believe that our strategy with these agreements have the possibility
to accelerate an out-licensing deal in the South-East Asian territories. However, there are no assurances that this approach will be
successful. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 90; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that a high dose
of resveratrol is needed for therapeutic effects. Currently available resveratrol products are associated with severe gastrointestinal
(GI) side effects at the dose levels we believe are needed. Our belief is based on available scientific literature, preclinical trial
results conducted in mice and rats, and previously conducted human trials with resveratrol. We believe that JOTROL, based on the
results from our Phase I trial, see section &ldquo;Description of Business&rdquo;, has the potential to deliver a therapeutically effective
dose of resveratrol in the blood stream without causing gastrointestinal (GI) side effects. Based on our pre-clinical and Phase I study
results, we expect that JOTROL will resolve &ldquo;the major obstacle of resveratrol&rsquo;s poor bioavailability&rdquo; as discussed
in AY Berman&rsquo;s summary article in the Journal of Precision Oncology (AY Berman, 2017). Based on our own preclinical studies we
believe that resveratrol has the ability to cross the blood-brain barrier. In studies conducted in Friedreich&rsquo;s ataxia (FA)
and Alzheimer&rsquo;s disease (AD) patients, resulted in positive effects on oxidative stress, inflammation, and mitochondrial function.
The FA study was concluded in Australia by Murdoch Children&rsquo;s Research Institute in 2015 (Yiu et al.). The AD study was conducted
in 2015 by the Alzheimer&rsquo;s Disease Cooperative Study with Professor Raymond Turner, MD, Ph.D., Georgetown, as principal investigator
(Turner et al.). Both studies have been published in scientific journals and further described in the section &ldquo;Description of Business&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In 2020, we received approval
for full funding, $1.76 million, for our Phase I study from the National Institute on Aging (&ldquo;NIA&rdquo;). Since there were unanticipated
higher costs, mostly due to COVID-19 related additional procedures during the Phase I trial, a supplemental grant of $233,281 was submitted
to the NIA in December of 2021. We were awarded the supplemental grant on April 7, 2022. In the NIA scientific review summary statement
of our Phase I study application, it is stated that the NIA is looking forward to a Phase II study with an enhanced resveratrol
product, based on the earlier study results from the well published Turner et al. Alzheimer&rsquo;s study. In April 2021, we submitted
our first grant application to the NIA for full funding of a Phase II trial in Mild Cognitive Impairment (MCI) and early
Alzheimer&rsquo;s disease. The Phase II trial was designed to focus on 3 areas: 1) safety and tolerability; 2) pharmacokinetics
and pharmacodynamics, measuring of responses from 2 different doses vs. placebo; and 3) measuring of effect on multiple biomarkers related
to the disease. The application was not accepted but we were encouraged by the NIA to refine our application and submit again. We
have since submitted 3 grant applications, with budgets of $20 million or higher, to the NIA for full funding of such Phase II trial
but none of those applications were successful. The NIA scientific review of our Alzheimer&rsquo;s Phase II trial grant application,
which is attached as Exhibit 10.38 to the registration statement of which this prospectus forms a part, shows a total score of 47 which
is our best score so far. A score of 40 or below is necessary for being considered for funding. After discussions with the NIA, we have
decided to apply, in September of 2024, for a much smaller grant, $2.5 million, for a Proof-of-Concept study focusing on JOTROL&rsquo;s
effect on validated biomarker. The final study design is not yet determined but a draft synopsis is described in the section
&ldquo;Description of Business&rdquo;. There is no guarantee that this and future grant applications will be successful and therefore
the rejection of our future grant application may significantly delay the Company&rsquo;s plans in connection with MCI and Alzheimer&rsquo;s
and may have a significant impact on the Company&rsquo;s financial performance. Further, the Company may never receive any future grants
or costs savings. The Company continues to apply for grants opportunistically and on August 12, 2022, submitted a $10.1 million grant
to the Department of Defense for a Phase II Friedreich&rsquo;s Ataxia study. This study planned to assess the efficacy of JOTROL
as a potential treatment for FA through a randomized, blinded, placebo-controlled clinical trial. On December 30 the Company received
notification that the application was not recommended for funding. The grounds for denial were the weaknesses noted in the peer review
summary statement, attached as Exhibit 10.33 to the registration statement of which this prospectus forms a part, specifically
concerning clinical impact and research strategy and feasibility. Reata Pharmaceuticals has recently received an approval for their
product, Omaveloxolone, for treatment of Friedreich&rsquo;s ataxia. After the FDA approval was achieved by Reata Biogen announced that
it has agreed to purchase Reata for $7.3 billion in cash. The approval of Omaveloxolone and the resources of Biogen will make it hard
to find patients for a FA clinical study in USA and therefore we have reduced the focus on this indication decided while exploring the
possibility of conducting a Phase II trial in Europe and/or Australia. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
inception, we have operated with limited human capital, utilizing agreements with academia to get pre-clinical work executed at no cost,
negotiating favorable deals for data already produced for resveratrol (e.g. toxicity studies and Phase II clinical study data), obtaining
a full grant from the NIA for our first clinical trial and building a management and scientific consulting team (consisting of
the Scientific Advisory Board and business advisors) as well as negotiating service agreements with companies to handle CMC, regulatory
work and clinical trials in South-East Asia primarily compensated with equity securities of the company. We believe that this compensation
method aligns the management, Scientific Advisory Board members and business advisors&rsquo; interests with the shareholders.
We believe that our structure with a core management team that has experience in the utilization of outside resources makes it possible
for us to efficiently execute several programs simultaneously in a cost-effective way. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Resveratrol</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Resveratrol has been studied
for over 50 years by academic institutions as well as by small and large pharmaceutical companies. The multi-functional mechanisms
of resveratrol are well documented in over 9,000 scientific publications. Several of these publications, including a summary
paper by AY Berman.et al, published in Precision Oncology 2017, point to the issue of the poor bioavailability that has stopped
medical utilization of regular resveratrol and never received regulatory approval for any indication. We believe the Phase I study
we have conducted indicates that we have resolved the poor bioavailability issue with JOTROL&trade;. Resveratrol (3,4&prime;,5- trihydroxystilbene)
is a nutraceutical that has recently attracted a lot of research attention due to its exciting pharmacological potential. It is a phytoalexin
found in many plants including grapes, peanuts, and berries. Resveratrol was first isolated in Veratrum grandiflorum, or white hellebore
plant, in the 1940&rsquo;s. Stilbene compounds are known for their ability to provide plants with resistance to microbial and fungal
infection. Early research showed that resveratrol was present in large quantities in injured, infected, and ultraviolet-treated leaves.
Processed plant products also contain a significant amount of resveratrol.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Based upon available scientific
literature, it appears that resveratrol is an activator of SIRT1, one of the mammalian forms of the sirtuin family of proteins. SIRT1
deacetylates histones and nonhistone proteins including transcription factors. The SIRT1-regulated pathway affects metabolism, stress
resistance, cell survival, cellular senescence, inflammation/immune function, endothelial functions, and circadian rhythms. Resveratrol
has been documented in scientific literature to activate SIRT1, NrF2, NLR3P inflammasomes and have an epigenetic mechanism and therefore
is predicted to benefit diseases affected by abnormal metabolic control, inflammation, and cell cycle defects. Nonetheless, resveratrol
application is a major challenge for the pharmaceutical industry, due to its poor solubility and bioavailability, as well as adverse
effects, such as severe gastro-intestinal side effects when taken at effective dose levels (over 2,000 mg daily). In this context, studies
have proposed that structural changes in the resveratrol molecule, including glycosylation, alkylation, halogenation, hydroxylation,
methylation, and prenylation could lead to the development of derivatives with enhanced bioavailability and pharmacological activity.
Resveratrol has never been developed with all the necessary steps to achieve an approval as a pharmaceutical product since the existing
natural supplements cannot provide high enough levels of resveratrol in blood plasma to be able to provide a therapeutically effective
dose without generating severe gastro-intestinal side effects. This means that we need to take JOTROL through the full regulatory
NDA (New Drug Application) requirement to obtain a prescription marketing approval in the USA. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Resveratrol
holds a significant place in Traditional Chinese Medicine (TCM) due to its potent antioxidant and anti-inflammatory properties. In TCM,
resveratrol-rich plants, such as the root of Polygonum cuspidatum (commonly known as Hu Zhang), have been used for centuries to treat
a variety of ailments. The compound is prized for its ability to combat oxidative stress and inflammation, which are underlying factors
in many chronic diseases. This aligns with the TCM principle of restoring balance and harmony within the body to maintain health and
prevent disease. Resveratrol&rsquo;s role in TCM extends to supporting cardiovascular health, boosting immune function, and even exhibiting
anti-aging properties, making it a versatile and valuable component of the medicinal repertoire.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 91; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
growing body of scientific research on resveratrol has further cemented its importance in TCM by providing a modern understanding of
its mechanisms and potential therapeutic benefits. Studies have shown that resveratrol can modulate various molecular pathways, including
those involved in cell survival, apoptosis, and inflammation, which are crucial in the management of conditions such as cardiovascular
diseases, neurodegenerative disorders, and cancers. This scientific validation supports TCM practitioners in integrating resveratrol
into their treatment protocols, enhancing the credibility and acceptance of traditional remedies. Additionally, the compound&rsquo;s ability
to improve metabolic health and its neuroprotective effects are particularly relevant in addressing the rising prevalence of metabolic
syndrome and cognitive decline in aging populations. As research continues to unveil the full spectrum of resveratrol&rsquo;s benefits, its
integration into TCM practices is likely to increase, further bridging the gap between ancient wisdom and contemporary medicine.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Traditional Chinese Medicine (TCM) market is experiencing several technological trends that are transforming how traditional remedies
are developed, delivered, and integrated with modern healthcare practices. These advancements are helping to increase the efficacy, accessibility,
and acceptance of TCM. Below are some of the key technological trends in the TCM market:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Digital
                                            platforms and telemedicine services allow patients to consult with TCM practitioners remotely,
                                            expanding access to TCM treatments. </FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Apps
                                            are being developed to help users track their health metrics, manage their treatment plans,
                                            and access personalized TCM advice. </FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Using
                                            advanced extraction techniques to concentrate active ingredients from traditional herbs,
                                            resulting in more potent and consistent products. </FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Development
                                            of new delivery methods such as transdermal patches, sustained-release capsules, and nanoparticles
                                            to enhance the bioavailability and efficacy of TCM products. </FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(source
Emergn Research, Global TCM Market, Forecast to 2033).</FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JOTROL</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">JOTROL was developed together
with our technology partner Aquanova AG, Darmstadt, Germany. JOTROL&trade; is formulated with a unique patented micellar technology
that is projected to increase the bioavailability profile of resveratrol. Manufacturing technology transfers were completed in 2017 and
manufacturing procedures and clinical trial supply manufacturing has been completed at Catalent Pharmaceutical Services, Inc., St Petersburg,
Florida.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">JOTROL is a micellar
non-aqueous solution of resveratrol delivered in a softgel capsule. Each capsule includes 100mg of resveratrol. Pre-clinical trials in
mice and rats were conducted comparing JOTROL to micronized resveratrol, labeled to have the highest bioavailability in the nutritional
market, to demonstrate that we could achieve a significantly higher bioavailability. Summary details of these studies are included in
the section &ldquo;Description of Business&rdquo;. A Phase I dose finding pharmacokinetic (&ldquo;PK&rdquo;) study in healthy volunteers
was completed during the first half of 2021. The study results met our targeted goals. The results from this study will be used as a
cross-reference for all indications where JOTROL will be used in Phase II and Phase III clinical trials. The Phase I results and
the FDA guidance of cross-referencing is further described in the section &ldquo;Description of Business&rdquo;. The Company has not
discussed the use of cross-referencing in this manner with the FDA or other comparable regulatory authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDA cross-reference guidance states:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Investigational New Drug Applications
(INDs)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The information below is Excerpted
from page 4 of the guidance document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">E. Cross References to other
INDs</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At times, IND submissions
are supported by a cross-reference to another IND [21 CFR 312.23(b)]. The utility of the electronic IND submission will be further increased
if all reference materials are supplied with the IND submission. You should handle these files in the same manner as other electronic
files submitted to the IND. For example, you should generate the files from electronic source files rather than from scanned paper documents
if at all possible. If the electronic source file is not available, we will accept a scanned copy. You should describe the file format
and organization of these files as described in this guidance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If an electronic IND or other
form of documentation already exists in CBER, and the appropriate letters of authorization are supplied, the IND review team will be
granted access to those documents. If the files you choose to reference have been provided in electronic format, you should include the
main folder name in which the document resides in place of the volume number required under 21 CFR 312.23(b). You should provide copies
of the appropriate letters of authorization in the admin folder of the submission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There is however no guarantee
that FDA will approve our planned use of cross-referencing.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 92; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JOTROL
Intellectual Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have a worldwide license, from Aquanova AG, the
patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    CSO, Marshall Hayward and the lead scientist at Aquanova AG, Darius Benham, are the inventors of JOTROL. The patent is
    owned jointly by Aquanova AG and the Company and the application was assigned to Aquanova AG per an executed agreement
    between Aquanova AG and the Company.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aquanova
    AG, a German company, filed an international patent application in Germany on January 29, 2017 entitled &ldquo;Resveratrol
    solubilization product for pharmaceutical purposes&rdquo; (PCT/EP2017/O51659).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">The priority date is June 16, 2016 with expiration in 2036
    which expiration date applies to all territories.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This patent has been granted in USA, specific European
countries, Japan, China and Hong Kong.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The specific European countries are: France, UK,
Switzerland, Italy, Belgium, Netherlands, Ireland, Spain, Sweden, Turkey, Poland, Denmark, Greece, Hungary and Germany.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The approved claims of the patents, formulation
and method of use, are as stated in issued US patent #10,780,056:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1. A solubilization product consisting of<B><I>:
</I></B>resveratrol; an emulsifying agent mixture of polysorbate 80 and polysorbate 20; at least one medium-chain triglyceride (MCT);
and tocopherol or mixed tocopherols, wherein the solubilization product is for use as a pharmaceutical product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2. The solubilization product according to claim
1, characterized in that: the fractional amount of the&nbsp;resveratrol&nbsp;is in the range of 3% by weight to 15% by weight, or in
the range of 5% by weight to 10% by weight, or is 10% by weight.<BR></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3. The solubilization product according to claim
1, characterized in that: the fractional amount of the emulsifying agent mixture of polysorbate 20 and polysorbate 80 is in the range
of approximately 65% by weight to approximately 95% by weight, or in the range of approximately 70% by weight to approximately 92% by
weight, or is approximately 71.8% by weight.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">4. The solubilization product according to claim
1, characterized in that: the fractional amount of the at least one medium-chain triglyceride is in the range of at least approximately
2% by weight to approximately 8% by weight, or in the range of approximately 3% by weight to approximately 5% by weight, or is approximately
4.5% by weight.<BR></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5. The solubilization product according to claim
1, characterized in that: the fractional amount of the tocopherol or the mixed tocopherols is in the range of approximately 3% by weight
to approximately 6% by weight, or is approximately 5.25% by weight.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">6. The solubilization product according to claim
1, characterized in that: the solubilization product has micelles wherein a distribution of diameters of the micelles ranges from approximately
1 nm to approximately 25 nm.<BR></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">7. The solubilization product according to claim
1, characterized in that: a turbidity of the solubilization product is less than 50 FNU, measured by scattered light measurement with
infrared light according to the provisions of the ISO 7027 standard at a 1:50 dilution of the solubilization product in water.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">8. The solubilization product according to claim
1, characterized in that: a turbidity of the solubilization product after 24 hours of storage at room temperature and pH 7 is less than
50 FNU, measured by scattered light measurement with infrared light according to the provisions of the ISO 7027 standard at a 1:50 dilution
of the solubilization product in water.<BR></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">9. The solubilization product according to claim
1, characterized in that: a turbidity of the solubilization product after 1 hour of storage at 37.degree. C. and pH 1.1 is less than
50 FNU, measured by scattered light measurement with infrared light according to the provisions of the ISO 7027 standard at a 1:50 dilution
of the solubilization product in water.<BR></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">10. The solubilization product according to claim
1, wherein the solubilization product is for use in the treatment of Alzheimer&rsquo;s disease, Friedreich&rsquo;s ataxia and other Ataxia related
diseases, lysosomal diseases, cancer, diabetes, atherosclerosis, heart diseases, arthritis or autoimmune diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">11. The solubilisation product according to claim
1, wherein the solubilization product is for use in a method for the treatment of Alzheimer&rsquo;s disease, Friedreich&rsquo;s ataxia and other
Ataxia related diseases, lysosomal diseases, cancer, diabetes, atherosclerosis, heart diseases, arthritis or autoimmune diseases, characterized
in that: the solubilization product is administered orally, in an amount corresponding to at least 200 mg&nbsp;resveratro<B><I>l</I></B>&nbsp;per
day.<BR></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">12. A capsule filled with the solubilisation product
according to claim 1, characterized in that: the capsule is provided as a soft gelatin capsule, a hard gelatin capsule, a soft gelatin-free
capsule, or a hard gelatin-free capsule.<BR></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">13. A method for the treatment of Alzheimer&rsquo;s
disease, Friedreich&rsquo;s ataxia and other Ataxia related diseases, lysosomal diseases, cancer, diabetes, atherosclerosis, heart diseases,
arthritis or autoimmune diseases, comprising: providing a solubilization product consisting of&nbsp;resveratrol<B><I>,</I></B>&nbsp;an
emulsifying agent mixture of polysorbate 80 and polysorbate 20, at least one medium-chain triglyceride (MCT), and tocopherol or mixed
tocopherols; and orally administering the solubilization product to a patient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">14. The method according to claim 13, characterized
in that: the solubilization product is contained in a capsule; and the capsule is provided as a soft gelatin capsule, a hard gelatin
capsule, a soft gelatin-free capsule, or a hard gelatin-free capsule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 93; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>License Agreement with Aquanova AG</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
license agreement with Aquanova AG is our most important agreement and critical to maintain as long as JOTROL remains our main
and only product. A loss of this agreement will cause the Company a delay in its plans and would cause the Company to seek out other
similar licensing agreements. Accordingly, the loss of this agreement will have a material adverse effect on our business. The agreement
provides us with a worldwide exclusivity for utilization of the patents granted and pending. The following are the material terms of
the agreement a including the fees we agreed to pay in consideration for this exclusivity:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Type
    of agreement: Exclusive Global Development and Licensing agreement</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Execution
    and termination: Executed September 15, 2016 to be terminated upon the latter or the patent expiration or ten years subsequent to
    the first commercial sale of product in each territory.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upfront
    fee of $20,000.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
    license fee of $75,000 until first product approval in a territory.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
    are three territories defined, USA, Europe and Asia.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$200,000
    in milestone payment upon first regulatory approval in a territory.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$200,000
    in milestone payment upon first regulatory approval in the second territory.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$200,000
    in milestone payment upon first regulatory approval in the third territory.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    annual $75,000 license fee is replaced with a 5% royalty fee, based on net sales in each territory, upon first regulatory approval
    in any of the 3 areas.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    party can decide to instead of the 5% royalty fee have the Company pay Aquanova AG $3 million within 180 days of the first regulatory
    approval leading to a reduced royalty payment to 1.5% for the life of the agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">The termination provisions under our license agreement
with Aquanova AG are as follows:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination
    provisions and penalties.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-indent: -0.25in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination
    for Material Uncured Breach:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-indent: -0.25in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either
    party shall have the right to terminate the agreement in the event the other party has materially breached or defaulted in the performance
    of any of its obligations thereunder, and if such breach or default is not corrected or within sixty (60) days after the breaching
    party receives written notice identifying such breach, or if a cure (other than any payment) is not possible in such sixty (60) day
    period, such longer period (not exceeding 120 days) during which the breaching party is diligently pursuing a cure. If the parties
    cannot agree on a product schedule for three products in a row either party shall have the right to terminate the agreement. For
    the avoidance of doubt, a party&rsquo;s decision to terminate a clinical trial pursuant to Section 3.04(c) of the agreement will
    not be deemed to be a material breach of its obligations thereunder. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-indent: -0.25in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination
    for Insolvency; Retention of License:</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.25in">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9632;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">If voluntary or involuntary proceedings by or against a party are instituted in bankruptcy under
  any insolvency law, or a receiver of custodian is appointed for such party, or proceedings are instituted by or against such party
  for corporate reorganization or the dissolution of such party, which proceedings, if involuntary, shall not have been dismissed within
  ninety (90) days after the date of filing, or if such party makes an assignment for the benefit of creditors, or substantially all
  of the assets of such party are seized or attached and not released within ninety (90) days thereafter, the other party may immediately
  terminate the agreement effective upon notice of such termination. Notwithstanding the bankruptcy of a party, or the impairment of
  performance by a party of its obligations under the agreement as a result of bankruptcy or insolvency of such party, and subject to
  such other party&rsquo;s rights to terminate the agreement for reasons other than bankruptcy or insolvency as expressly provided in
  the agreement, the other party shall be entitled to retain the licenses under the terms and conditions granted therein, and otherwise
  in accordance with Section 365(n) of the United States Bankruptcy Code.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 94; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></P>
                                                         <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    Effect of Termination:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.25in">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in">&#9632;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Accrued Obligations:</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1.75in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Termination of the agreement or for any reason shall not release and party thereto from any liability
  which, at the time of such termination, nor preclude either party from pursuing any rights and remedies it may have thereunder or at
  law or in equity which accrued or are based upon any event occurring prior to such termination.</TD></TR>
</TABLE>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9632;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Return of Materials:</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1.75in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Upon any termination of the agreement, each party shall promptly return to the other party all materials,
  know-how and other tangible confidential information received from the other party (except one copy of which may be retained by legal
  counsel for archival purposes); except that if the agreement is terminated with respect to a product only, each party shall so return
  confidential information relating exclusively to the product.</TD></TR>
</TABLE>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9632;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Reversion of Rights</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1.75in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Upon any ending of the agreement, all licenses granted by a party to the other party shall be terminated
  and the rights therein shall revert to the licensor party.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
description of the foregoing agreement as set forth above is qualified in its entirety to the full agreement as attached as Exhibit 10.16
to the registration statement of which this prospectus forms a part.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
signing the licensing agreement on September 15, 2016, the Company paid the upfront fee of $20,000 and one year of the annual $75,000
licensing fee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 1, 2021, the Company and Aquanova AG entered into a Debt Forgiveness and Exchange Agreement, dated as of December 1, 2021, pursuant
to which $225,000 of the $281,250 of indebtedness under the licensing agreement with Aquanova was forgiven in exchange for (i) the payment
by the Company to Aquanova of $125,000 in cash, (ii) the issuance by the Company of a convertible promissory note in the amount of $100,000
to Aquanova, and (iii) the issuance by the Company of an option to purchase 22,500 shares of common stock of the Company at an exercise
price of $2.16  per share, subject to vesting of 5,625 shares on December 1, 2021, 469 shares per month thereafter
for 35 months and 460 shares on the month thereafter (36<SUP>th</SUP> month). </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2023, $150,000 was included
in Accounts payable and accrued expenses on the Balance Sheet. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to pay the outstanding annual licensing fees with proceeds from this offering.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 95; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Other
                                            Material Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Agreement with Murdoch Children&rsquo;s Research
Institute (MCRI). The material terms of this agreement are as follows:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Type
    of agreement: Global Development and Licensing agreement</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executed
    September 1, 2015.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
    schedule:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    upfront payment.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$100,000
    per territory (US, European Union and Japan are the defined territories) upon first received marketing approval.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Royalty:
    1.5% of net product sales. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination
    Date</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
    agreement is terminated earlier the term of the agreement shall commence on the effective date and shall continue until the expiration
    of the Royalty Term in each country in the Territory with respect to the Product</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.25in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination
    provisions &amp; penalties</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-indent: -0.25in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination
    for material uncured breach</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-indent: -0.25in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9632;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">120
    day cure period</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-indent: -0.25in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination
    for insolvency; retention of license</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effects
    of termination</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-indent: -0.25in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    obligations not released </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9632;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Return
    of materials</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9632;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    Murdoch terminates the agreement, the license granted to Jupiter Neurosciences by Murdoch will immediately terminate</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9632;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Royalties
    will not terminate unless Jupiter terminates the agreement and will have no obligation to pay any amount to Murdoch which accrues
    after the effective date of termination (termination for material uncured breach). </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
description of the foregoing agreement as set forth above is qualified in its entirety to the full agreement as attached as Exhibit 10.18
to the registration statement of which this prospectus forms a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been no payments made by the Company to date under this agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement
with major pharmaceutical company (restricted by confidentiality agreement):</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Type
    of agreement: Data access to resveratrol toxicology studies by a letter of reference.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Execution
    and termination: May 2<SUP>nd</SUP>, 2017, can only be terminated due to a material breach of the contract.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Access
    to resveratrol toxicology studies performed at Charles River Laboratories. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    payments associated with this agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement
with the National Institute on Aging (NIA). The material terms of this agreement are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Type
    of Agreement: Federal Grant # 1R44AG067907-01A1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term:
    September 30, 2020 through May 31, 2022.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    Safety and Pharmacokinetics of JOTROL for Alzheimer&rsquo;s Disease.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount
    of grant award: $1,764,270, fully paid to the company.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Supplemental grant award: $233,281 fully paid to the
    company.</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company&rsquo;s obligation was to perform a Phase I pharmacokinetics study and subsequently report the findings of the study. This
    is further described in the <B>JOTROL Phase I Pharmacokinetic (&ldquo;PK&rdquo;) and Safety Study </B>section in this document.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company has no more obligations left to be executed per the grant specifications. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no termination or penalty provisions under this agreement, the agreement terminated by its terms on May 31, 2022. The description
of the grant agreement with the NIA as set forth above is qualified in their entirety to the full grant agreement as attached
as Exhibit 10.17 to the registration statement of which this prospectus forms a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 96; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December of 2021 the Company submitted a grant
for supplemental funding of $233,281 of our Phase I study due to unanticipated costs, mostly due to COVID-19. We received and were awarded
this grant on April 7, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B>Recent Service Agreements &ndash; South-East
Asia</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 3, 2024 the Company entered into three service agreements with companies that we believe can assist us in accelerating business
opportunities in South-East Asia. A summary of each agreement is below and the full agreements are attached to this
document.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <B><I>CRO Services Agreement</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> CRO Services <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement
between Jupiter Neurosciences, Inc. (&ldquo;JN&rdquo;) and OPTIMIZE WELLNESS LIMITED (&ldquo;CRO&rdquo;) a company incorporated in
Hong Kong whose office located at ROOM 401, On Hong Commercial Building, 145 Hennessy Road, Wan Chai, Hong Kong.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Territory
is China (including Hong Kong), Malaysia and Singapore.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CRO shall provide services including, not limited to or inclusive of, the following:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide
                                            JN with strategic guidance regarding pharmaceutical products clinical trial environment in
                                            the Territory;</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide
                                            and guide JN with a clinical strategy to possibly obtain a regulatory approval in several
                                            countries in the Territory. </FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Propose
                                            priority of indications for an accelerated approval path;</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
                                            up and execute of all aspects of clinical trials to be performed;</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assist
                                            and coordinate with any professional advisors, such as Key Opinion Leaders, in the clinical
                                            field.</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment for the Services is a pre-payment of 1,162,500 common shares of common stock, for 3 years
of services. No cash payment to be received by CMC from
JN.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CRO
committed to purchase 37,500 common shares for $50,000, $1.33 per share, from JN in conjunction
with signing of the agreement.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either
Party may terminate this Agreement without liability if:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JN
                                            fails to complete an Initial Public Offering of at least US$10 million gross proceeds on
                                            or before March 31, 2025; or</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            petition is presented for the winding up or liquidation of the other Party, or anything analogous
                                            thereto occurs in respect of the other Party; or</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            any of the Parties are deemed to be involved in any illegal activities.</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Agreement can be terminated at any time as long as this is agreed to by both parties.</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> The description of the CRO Services Agreement
as set forth above is qualified in its entirety to the full agreement as attached as Exhibit 10.35 to the registration statement of which
this prospectus forms a part. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <B><I>Regulatory Service Agreement</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
Services Agreement between Jupiter Neurosciences, Inc (&ldquo;JN&rdquo;) and Regis Healthcare Group Limited (&ldquo;RSC&rdquo;),&nbsp;with
address (CCS Trustees Limited, Mandar House, 3rd Floor, Johnson&rsquo;s Ghut, Tortola, British Virgin Islands)</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Territory
is China (including Hong Kong), Malaysia and Singapore.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RSC  shall provide services including, not limited to or inclusive of, the following:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide
                                            JN with strategic guidance regarding pharmaceutical products regulatory environment in the
                                            Territory;</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide
                                            and guide JN with a regulatory strategy to possibly obtain a regulatory approval in the Territory.
                                            </FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Propose
                                            priority of indications for an accelerated approval path;</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Monitor
                                            regulatory changes within the Territory so JN and its partners can adapt its business strategy;</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Participate
                                            in any required regulatory inspections that might be triggered by local and other authorities;</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assist
                                            and coordinate with any professional advisors in the regulatory field.</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment for the Services is a pre-payment of 1,162,500 common shares of common stock, for 3 years
of services. No cash payment to be received by CMC from
JN.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RSC
committed to purchase 37,500 common shares for $50,000, $1.33 per share, from JN
in conjunction with signing of the agreement.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either
Party may terminate this Agreement without liability if:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JN
                                            fails to complete an Initial Public Offering of at least US$10 million gross proceeds on
                                            or before March 31, 2025; or</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            petition is presented for the winding up or liquidation of the other Party, or anything analogous
                                            thereto occurs in respect of the other Party; or</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            any of the Parties are deemed to be involved in any illegal activities.</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Agreement can be terminated at any time as long as this is agreed to by both parties.</FONT> </TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
description of the Regulatory Services Agreement as set forth above is qualified in its entirety to the full agreement as attached as
Exhibit 10.36 to the registration statement of which this prospectus forms a part.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Product
Services Agreement</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product
Services Agreement between Jupiter Neurosciences, Inc (&ldquo;JN&rdquo;) and Longevity Technology Group Limited (&ldquo;CMC&rdquo;) a
company incorporated in British Virgin Islands whose office registered at CCS Trustees Limited, Mandar House, 3rd Floor, Johnson&rsquo;s
Ghut, Tortola, British Virgin Islands.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Territory
is China (including Hong Kong) Malaysia and Singapore</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CMC
shall provide services including, not limited to or inclusive of, the following:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide
    JN with strategic guidance regarding pharmaceutical product manufacturing in the Territory;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide
    and guide JN with all aspects of technology transfer needs. </FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluation
    of best manufacturing sites and companies to use for product manufacturing;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oversee
    all work and execution of tech transfers between Aquanova, JN and designated manufacturers in the Territory;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluate
    and propose best packaging and distribution channels for finished goods;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oversee
    any required regulatory inspections that might be triggered by local and other authorities;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assist
    and coordinate with any professional advisors in the CMC field.</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
for the Services is a pre-payment of 1,162,500 common shares of common stock, for 3 years of services. No cash payment to be received
by CMC from JN.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CMC
committed to purchase 37,500 common shares for $50,000, $1.33 per share, from JN in conjunction with signing of the agreement.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either
Party may terminate this Agreement without liability if:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JN
    fails to complete an Initial Public Offering of at least US$10 million gross proceeds on or before March 31, 2025; or</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    petition is presented for the winding up or liquidation of the other Party, or anything analogous thereto occurs in respect of the
    other Party; or</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    any of the Parties are deemed to be involved in any illegal activities.</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Agreement can be terminated at any time as long as this is agreed to by both parties.</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
description of the Product Services Agreement as set forth above is qualified in its entirety to the full agreement as attached as Exhibit
10.37 to the registration statement of which this prospectus forms a part.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> </P>

<!-- Field: Page; Sequence: 97; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B>Proposed Agreement with Dominant Treasure Health</B> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"> We are planning to engage Dominant Treasure Health
(&ldquo;DTH&rdquo;), a BVI company. DTH will be active in business development in China, Malaysia and Singapore as soon as we have financing
in place for their engagement. DTH has already introduced us to three Chinese companies, Beimei Pharma, http://en.beimeiyaoye.com, that specializes
in pediatric medications, Sichuan Kelun Pharmaceutical Co., ltd, a publicly traded company that is part of the Kelun Industrial Group,
https://www.kelun.com/, and Tianjin Pharmaceuticals, https://en.pharm.com.cn/, that advocates the corporate core values of &ldquo;Love,
Integrity and Power&rdquo;. TCM products are run in a separate division within Tianjin. Discussions with all three companies are ongoing.
We believe that with DTH&rsquo;s assistance we can co-ordinate and oversee the work of our Service providers in the territory and more
expediently negotiate and finalize an out-license agreement with one or more pharmaceutical companies in South-East Asia. However, there
are no guarantees that this approach will be successful. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
proposed terms with DTH are as follows.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement
    will be for three years from signing.</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company is projected to pay $2.3 million for the services. Final payment terms to be decided but it is expected that a majority and
    possibly all to be an up-front payment.</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DTH
    will receive a success fee of 5% of any upfront payments and milestone payments from agreements made with companies within the territory.
    </FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DTH
    will receive 5% of any royalty agreements made with companies within the territory.</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    Joint Steering Committee will be established between the two parties.</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either
Party may terminate this Agreement without liability if:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company fails to complete a public listing raising at least US$10 million of gross proceeds on or before March 31, 2025; or</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    petition is presented for the winding up or liquidation of the other Party, or anything analogous thereto occurs in respect of the
    other Party.</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    any of the Parties are deemed to be involved in any illegal activities.</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement can be terminated at any time if the Parties mutually agree to do so.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><B>Senior Secured Note</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">On
April 11, 2022, the Company entered into a securities purchase agreement (the &ldquo;Purchase Agreement&rdquo;) with an accredited investor
for the sale of the Company&rsquo;s convertible notes. Pursuant to the terms of the Purchase Agreement, on April 11, 2022, the Company
received aggregate gross proceeds of $1,000,000 and issued (i) a 10% Original Issue Discount Senior Secured Convertible Note in the principal
amount of $1,111,111.11 (the &ldquo;Note&rdquo;) and (ii) 514,403  shares of common stock, par value $0.0001
per share (the &ldquo;Shares&rdquo;), of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><B><I>The
Note</I></B>. The aggregate principal amount of the Note is $1,111,111.11, and the Company received gross proceeds of $1,000,000 after
giving effect to the original issue discount of 10%. The Note bears interest at a rate of 10% per year, payable monthly in arrears, and
mature 12 months from issuance. A &ldquo;Qualified Offering&rdquo; is a debt or equity financing for the account of the Company or any
of its subsidiaries in which shares of common stock, or securities, directly or indirectly, convertible into or exchangeable or exercisable
for shares of common stock are issued, which financing results in cumulative aggregate proceeds to the Company of at least $3,000,000.
The principal and interest on the Note will be amortized on a straight-line basis at 110% of the principal amount commencing sixth months
after the closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"> Upon
an Event of Default and after a Qualified Offering, the principal and interest are convertible at any time at the option of the holder
into shares of the Company&rsquo;s common stock at a conversion price equal to 30% discount to the lowest closing price of the common
stock for the 20 prior trading days; provided, however, <FONT STYLE="background-color: white">the holder will not have the right to convert
any portion of the Note, to the extent that after giving effect to the conversion, the holder, together with its affiliates, would beneficially
own in excess of 4.99% of the number of shares of the Company&rsquo;s common stock outstanding immediately after giving effect to its
conversion. The holder may increase or decrease its ownership limitation to any percentage not exceeding 9.99% upon 61 days prior written
notice to the Company</FONT>. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"> The
Company will have the right at any time to redeem in cash all or a portion of the Note at 120% (or 125% on or after the first six months
from the closing; provided, however, if interest due and payable on January 31, 2023 is not paid in full, 130% on or after the first
six months from the closing) of the principal amount thereof plus any unpaid accrued interest to the date of repayment. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"> The
Company will be required to offer to prepay in cash the aggregate principal amount of the Note at 120% (or 125% on or after the first
six months from the closing; provided, however, if interest due and payable on January 31, 2023 is not paid in full, 130% on or after
the first six months from the closing) of the principal amount thereof plus any unpaid accrued interest to the date of repayment, on
the sale of all or substantially all of the assets of the Company and its subsidiaries, upon a Change of Control (as defined in the Note),
or on a Qualified Offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"> Upon
an Event of Default (as defined therein) interest shall accrue at 1 1/2% per month and the 125% (or 130% if interest due and payable
on January 31, 2023 is not paid in full) of principal and interest through maturity shall be due and payable. At the holder&rsquo;s option
the holder shall be entitled to be paid in cash or after the Qualified Offering (as defined in the Purchase Agreement) common stock with
the conversion price of the common stock equal to a 30% discount to the lowest closing price of the common stock for the 20 prior trading
days. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">On
October 10, 2022, the Note was amended to postpone the commencement of the amortization amount from October 11, 2022 to November 11,
2022. On November 10, 2022, the Note was amended to postpone the commencement of the amortization from November 11, 2022 to February
11, 2023 and payable in three monthly installments. As consideration for the amendment, an additional 42,867 shares of common
stock were issued to the accredited investor on October 10, 2022 and 128,599  shares issued to the accredited
investor on November 10, 2022. On January 13, 2023, the Note was amended to delay the interest payment due and payable on January 11,
2023 to the earlier of (i) January 31, 2023 and (ii) the closing of a Qualified Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"> On
February 6, 2023, the Note was amended to postpone the commencement of the principle to February 28, 2023. On March 6, 2023, the Note
was amended to postpone the commencement of the principal from February 11, 2023 to May 31, 2023. The Company and the note holder agreed
to a repayment plan on past due interest. In addition, the Company agreed to prepay in cash the aggregate principal amount of the Note
of 120% (or 137.5% on or after the first six months from closing) plus any accrued interest on the sale of all the assets of the Company
and its subsidiaries, upon the Change of Control, or on a Qualified Offering. Upon default of the Note the Company agrees to pay 137.5%
of the outstanding note principal, and accrued interest through maturity and all liquidation damages. As a result of the material modification,
the incremental fair value of the modified derivative was classified as a debt extinguishment. Due to the extension of the maturity date
of the convertible note, the fair value of the derivative liability increased. This resulted in the Company recording a loss on extinguishment
of debt of $670,419. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"> On
September 22, 2023, the Note was amended to postpone the commencement of the principle to December 31, 2023. The Company and the note
holder agreed to a repayment plan on past due interest. In addition, the Company agreed to prepay in cash the aggregate principal amount
of the Note of 120% (or 150% on or after the first six months from closing) plus any accrued interest on the sale of all the assets of
the Company and its subsidiaries, upon the Change of Control, or on a Qualified Offering. Upon default of the Note the Company agrees
to pay 150% of the outstanding note principal, and accrued interest through maturity and all liquidation damages. In addition, upon closing
the Note holder will receive 175% stock coverage. As a result of the material modification, the incremental fair value of the modified
derivative was classified as a debt extinguishment. Due to the extension of the maturity date of the convertible note, the fair value
of the derivative liability increased. This resulted in the Company recording a loss on extinguishment of debt of $217,527. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B><I>The Shares</I></B>. In
connection with the issuance of the Note, the Company issued 514,403  shares of Common Stock to the holder with a fair market
value of $2.16  per share (aggregate value of $1,111,111) as additional consideration for the holder lending $1,000,000 to the
Company. The 514,403  have a relatively fair value of $310,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Purchase Agreement related to
the Note was amended to provide that upon closing, the purchaser will receive 175% coverage (i.e. the face amount of the Note,
i.e., $1,111,111.11 divided by the lesser of (i) the price/share of the last issuance of solely common stock (including options) of the
Company, i.e., $5.00/share or (ii) the price per share of common stock (or if units are issued in the Qualified Offering, the price of
units sold in the Qualified Offering), in shares of common stock of the Company (or if units are issued in the Qualified Offering, units).
The number of shares to be received at closing shall be determined by using clause (i) above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In light of the foregoing, the
holder shall receive an additional number of shares of common stock, such that it shall have received the number of shares of common
stock of the aggregate value of $1,111,111 divided by the lesser of (i) the price/share of the last issuance of solely common stock (including
options) of the Company, i.e., $5.00/share or (ii) the price per share of common stock (or if units are issued in the Qualified Offering,
the price of units sold in the Qualified Offering), in shares of common stock of the Company (or if units are issued in the Qualified
Offering, units) (&ldquo;Share True Up&rdquo;). The Share True-Up was forfeited in the April 29, 2024 agreement. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><B><I>Ancillary
Agreements</I></B>. In connection with the Company&rsquo;s obligations under the Note, the Company entered into a security agreement
and intellectual property security agreement with the holder, pursuant to which the Company granted a security interest on all assets
of the Company, including all intellectual property of the Company, for the benefit of the holders, to secure the Company&rsquo;s obligations
under the Note and the other transaction documents. In addition, the holder was granted piggyback registration rights for the shares
of common stock issued under the Purchase Agreement and shares of common stock issuable upon conversion of the Note (collectively,
&ldquo;Registrable Securities&rdquo;). At any time while there are any Registrable Securities of holder outstanding, if the Company proposes
to register any of its securities either for its own account or for the account of other security holders (other than a registration
statement relating solely to employee benefit plans on Form S-8 or a Commission Rule 145 transaction on Form S-4), the holder is entitled
to include its Registrable Securities in the registration. Notwithstanding, the Company and underwriters in an underwritten registration
may exclude some or all of the Registrable Securities from the underwritten registration if the underwriters believe that including the
Registrable Securities would adversely affect the underwritten offering.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">At
any time within the 12 months closing, upon any issuance by the Company or any of its subsidiaries of debt or common stock or common
stock equivalents for cash consideration, indebtedness or a combination of units thereof, other than in an underwritten public offering
(a &ldquo;Subsequent Financing&rdquo;), the investor will have the right to participate up to its investment amount in the Note, but
not more than 25% of the Subsequent Financing, on the same terms, conditions and price provided for in the Subsequent Financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Until the Company has consummated
a Qualified Offering which results in a listing of the Common Stock onto a national securities exchange, if the Company engages in any
future financing transactions with a third-party investor, if the holder determines that the terms of the subsequent investment are preferable
in any respect to the terms of the securities of the Company issued to the Holder pursuant to the terms of the Purchase Agreement, the
holder will have the right to amend and restate such securities to include the preferable term or terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The descriptions of the Securities
Purchase Agreement, the Note, the Security Agreement, and the Intellectual Property Security Agreement as set forth above is qualified
in their entirety to the full Securities Purchase Agreement, the Note, the Security Agreement, and the Intellectual Property Security
Agreement as attached as Exhibits 10.25, 10.26, 10.27, and 10.28 to the registration statement of which this prospectus
forms a part.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Agreements
with the purpose to expand and accelerate business in South-East Asia</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into 3 Service agreements with companies that specialize in CMC (Longevity Technology Group Limited), Regulatory
Affairs (Regis Healthcare Group Limited) and Clinical Trials (Optimize Wellness Limited) in the South-East Asian territory. The Company
was able to negotiate similar terms with all the companies, besides the specific tasks that needs to be performed.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
key aspects of these agreements are as follows.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
                                            of the companies purchased 10,000 shares for $5 per share (prior to forward split) from the
                                            Company.</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
                                            of the companies committed to 36 months of services against a pre-payment of 310,000 shares
                                            (prior to forward split) in the Company. This represents payment in full for the duration
                                            of the agreement (no cash to be paid out by the Company).</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Territory
                                            is limited to China (including Hong Kong), Malaysia and Singapore.</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            is no recourse for the Company in case the service providers don&rsquo;t perform according
                                            to the scheduled requirements.</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either
Party may terminate this Agreement without liability if:-</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JN
                                            fails to complete a public listing raising at least $10 million of gross proceeds on or before
                                            March 31, 2025; or</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            petition is presented for the winding up or liquidation of the other Party, or anything analogous
                                            thereto occurs in respect of the other Party.</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            any of the Parties are deemed to be involved in any illegal activities.</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
                                            Agreement can also be terminated at any time if the Parties mutually agree to do so.</FONT> </TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 98; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Product
Development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management, Scientific Board of Advisors and business advisors have extensive experience in regulatory affairs and clinical development
of product candidates for the treatment of rare diseases and Alzheimer&rsquo;s disease. The overall regulatory approval process for product
candidates for the treatment of rare diseases are generally conducted with a smaller number of patients in clinical trials and
over a shorter amount of time than more prevalent diseases. There is a documented pathway to get accelerated FDA approval for a rare
disease indication if there is no existing treatment for the indication, if a product shows efficacy and has a good safety profile. There
is also a possibility of receiving a Priority Review Voucher (PRV) from the FDA upon an approval in pediatric population in a rare disease.
One or more of our programs, such as MPS-I, will be targeting pediatric patients. The voucher entitles the bearer to regulatory review
in about six months rather than the standard ten months. The Food and Drug Administration (FDA) awards a voucher following approval of
a treatment for a neglected disease, rare pediatric disease, or medical countermeasure. Two drugs can receive priority review for each
voucher: the drug winning a voucher for a neglected or rare pediatric disease, and the drug using a voucher for another indication. The
voucher may be sold. For example, a small company might win a voucher for developing a drug for a neglected disease and sell the voucher
to a large company for use on a commercial disease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are four specific approval pathways applicable for rare disease indication. We will be evaluating and most likely applying for one or
more of these when we get closer in the FDA approval process. These include the following pathways for the indications that it is targeting:
(1) Priority Review (2) Fast Track (3) Accelerated Approval Pathway and (4) Breakthrough therapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Priority
Review</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Priority
Review was authorized in 1992 by the Prescription Drug User Fee Act (PDUFA) which created the two-tiered FDA drug review system (standard
v. priority). This pathway shortens application review from 10 months (standard) to 6 months (priority). The FDA determines if a drug
receives a standard or priority review, although sponsors may request a priority review. Priority review is granted if a new drug would
result in a significant improvement in safety and effectiveness compared to existing therapies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Fast
Track</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drugs
for the treatment of serious conditions that address an unmet medical need receive an expedited review. The purpose of this pathway is
to get important new drugs to patent earlier, for conditions such as Alzheimer&rsquo;s disease, epilepsy, depression, and multiple sclerosis.
Any drug being developed to treat or prevent a condition with no current therapy is prioritized. If there are available therapies, the
new drug must:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Show
    superior efficacy;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Avoid
    serious side effects of the available therapy;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Decrease
    clinically significant toxicity of an available therapy; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
    an emerging or anticipated public health need</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fast
Track designation should come at the time of submission and be requested by the manufacturer, although it can be requested at any time
in the approval process. Once in the Fast Track pathway, there are more frequent meetings with the FDA to discuss the development plan
and appropriate data needed to support drug approval. Drugs in the Fast Track pathway are also eligible for accelerated approval and
priority review if relevant criteria are met.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Accelerated
Approval Pathway</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized
in 1992 and updated in 2012, this pathway is applied to new therapies that treat serious or life- threatening conditions for which there
is an unmet medical need and have a &ldquo;clinically meaningful&rdquo; outcome. Drugs that are eligible for this pathway must be reasonably
likely to improve a surrogate endpoint if a standard endpoint would require long-term evaluation. If given conditional approval, the
sponsor must conduct post-marketing clinical trials to ensure endpoints are met. If the standard endpoints are not met, the FDA can withdraw
approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Breakthrough
Therapy</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
designation is designed to expedite the development and review of drugs that are intended to treat serious conditions and preliminary
clinical evidence indicates that the drug may demonstrate substantial improvement over available therapies on clinically significant
endpoints.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is however no guarantee that an accelerated pathway will lead to an accelerated FDA review and that a pediatric approval leads to a PRV.
Additionally, there can be no guarantee that the Company can be successful in its plans under any FDA pathway.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have received quotes from clinical research organizations (&ldquo;CROs&rdquo;) for Phase II trials in MPS I and Friedreich&rsquo;s ataxia
ranging from $2 Million - $5 Million per study. Alzheimer&rsquo;s disease trials are larger and more complex with higher associated costs,
we have received quotes ranging between ~$12 million to ~$20 million for our planned Phase II study. We believe
that with positive Phase II results we may be able to garner strategic partnering interest for financing of larger Phase III trials.
We also intend to seek collaborations with future licensees and marketing partners, especially in markets outside the United States.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 99; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below provides our historical development timeline:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Product
Development and Commercialization Timelines</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 54%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Milestone</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Target Start Date</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Target Completion Date</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Identified key issue with resveratrol, poor bioavailability, and investigated possible solutions.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">Q3 2015</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">Completed</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Worldwide exclusive agreement with Aquanova AG, Germany, for patented micellar technology.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">Q3 2016</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">Completed</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Patent applications submitted in 2016 and patents have subsequently been issued in USA, Certain
    European countries, Japan, China and Hong Kong.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">Q2 2016</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">Completed</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Pre-clinical studies comparing JOTROL with conventional resveratrol, see section &ldquo;Description
    of Business&rdquo;. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Q1 2017</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">Completed</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Technology and data transfer agreement with Murdoch Children&rsquo;s Research Institute,
    Melbourne, Australia regarding research results and information related to Friedreich&rsquo;s Ataxia</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">Q3 2015</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">Completed</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Technology</FONT><FONT STYLE="font-size: 10pt"> transfer from Aquanova, CMC documentation,
    and clinical trial supplies manufactured (Catalent)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">Q1 2017</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">Completed</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Orphan Drug Designations (&ldquo;ODD&rdquo;) submitted to FDA and ODD received for Friedreich&rsquo;s ataxia</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">Q3 2016</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">Completed</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Resveratrol toxicity study received from major pharmaceutical company </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">Q3 2017</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">Completed</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Human bioavailability POC study with JOTROL</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">Q3 2017</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">Completed</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">NIA grant application for Phase I study submitted and scientific review triggered full financing, $1.76 million.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">Q3 2019</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">Completed</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Phase I study in healthy volunteers initiated in December 2020 and in-man phase concluded in March 2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">Q3 2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">Completed</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> Pre-clinical study in Parkinson&rsquo;s Disease </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> Q1 2022 </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> Completed </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">NIA grant application submission, $26.5 Million, for Phase II study for Mild Cognitive Impairment
    (MCI) </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">Q1 2023</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-size: 10pt">Completed</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> Resubmission of grant application to NIA for MCI trial </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Q4 2023 </P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-size: 10pt">Completed</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JOTROL
early Pre-clinical studies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
company initially conducted pre-clinical studies in mice and rats to demonstrate JOTROL&rsquo;s difference in bioavailability
compared with resveratrol. These studies were the basis for our MPS I IND application to the FDA for approval to conduct a Phase I trial.
IND, #132145, approval for the study was received by the FDA in Q1 of 2018. The Company conducted two such pre-clinical studies, one
conducted in mice, containing 48 subjects and one conducted in rats, containing 18 subjects. A recent pre-clinical study in Parkinson&rsquo;s
Disease is further described in the section &ldquo; <B>JNS115 Parkinson&rsquo;s Disease project&rdquo;.</B> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summary
of the results:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Trial
in Mice</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter
Neurosciences, Inc. conducted study 2015-3021-007 (AMP429) where mice (N=12 per group) were administered 4 treatments: micronized (commercial)
resveratrol as an aqueous suspension at 50 mg/kg; the API (resveratrol is the Active Pharmaceutical Ingredient) used to prepare the JOTROL
formula as an aqueous suspension at 50 mg/kg; and JOTROL, marked as JOT-101, (micelles loaded at 5% resveratrol) at 50 mg/kg
and 25 mg/kg resveratrol (data on file). The different formulations acted as internal comparison controls. Blood was drawn, plasma prepared,
and tissue samples were collected for further tests. Blood samples were collected at 0.25, 0.5, 1, and 4 hr post dose. Pharmacokinetic
parameters were determined and shown in the table below. The JOTROL micellar form is a predecessor/prototype formula in a series,
and while it is not the final JOTROL formulation, it does show proof of concept.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Table
1. PK Summary of Study 2015-3021-007 (AMP429) where Mice Were Administered 4 Resveratrol Treatments.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">dose</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tmax</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cmax</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gr1/Grx</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AUClast</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tlast</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clast</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">t1/2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vz_obs/F</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cl_obs/F</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Group_ID</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">mg/kg</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">hr</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ng/mL</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ratio</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">hr*ng/mL</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">hr</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ng/mL</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">hr</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">mL/kg</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">mL/hr/kg</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gr1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 3%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 3%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.25</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 3%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1423</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 3%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 3%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">762</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 3%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 3%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">122</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 3%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NC</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 3%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NC</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 3%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NC</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gr2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.25</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">84.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.9</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">175</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.37</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.84</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">337069</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">277678</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gr3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.25</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">137</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">201</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49.0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NC</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NC</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NC</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gr4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.25</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">350</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">155</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30.0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NC</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NC</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NC</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="16" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NC:
    not calculated due to the lack of terminal slope</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gr1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD COLSPAN="9" STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JOTROL
                                            micellar form</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gr2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD COLSPAN="9" STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JOTROL
                                            Raw API</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gr3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD COLSPAN="9" STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mega
                                            Resveratrol (micronized solid form)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gr4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD COLSPAN="9" STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted
                                            JOT-101 micellar form</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">The
headings in the above Table 1, have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Group
                                            ID: this heading contains the name of each of the 4 treatment groups.</FONT></TD></TR><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dose
                                            mg/kg: this heading denotes the applicable dose of resveratrol administered to each of the
                                            treatment groups.</FONT></TD></TR>
                                                                                                                                                                                                                                                                                        <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Tmax
                                            hr: this heading denotes the time at which the maximal concentration of resveratrol was measured
                                            in the plasma.</P></TD></TR>
                                                                                                                                                                                                                                                                                        <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Cmax
                                            ng/mL: this heading contains the concentration of resveratrol in plasma at a given Tmax.</FONT></TD></TR>
                                                                                                                                                                                                                                                                                        <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Gr1/Grx
                                            Ratio: this heading denotes the ratio of the other treatment groups compared to Group 1.</P></TD></TR>
                                                                                                                                                                                                                                                                                        <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AUClast
                                            hr*ng/mL: this heading denotes the area under the curve metric in the terminal phase.</FONT></TD></TR>
                                                                                                                                                                                                                                                                                        <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tlast
                                            hr: this heading denotes the last timepoint used.</FONT></TD></TR>
                                                                                                                                                                                                                                                                                        <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clast
                                            ng/ML: this heading sets forth the concentration at final timepoint.</FONT></TD></TR>
                                                                                                                                                                                                                                                                                        <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">t1/2
                                            hr: this heading sets fort the time measured while the resveratrol is in the body.</FONT></TD></TR>
                                                                                                                                                                                                                                                                                        <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vz_obs/F
                                            ml/kg: this heading sets forth the apparent volume of distribution.</FONT></TD></TR>
                                                                                                                                                                                                                                                                                        <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Cl_obs/F
                                            mL/hr/kg: this heading sets forth when the resveratrol totally leaves the body.</P></TD></TR>
                                                                                                                                                                                                                                                                                        </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
units for each measurement are listed below the metric name.</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Cmax comparisons
are shown in the figure below. Ratios based on Cmax for Gr2, Gr3, and Gr4 ranged from 4 to 16.9 and, when based on AUC, ranged from 4
to 5, indicating at least a 4 fold increase in bioavailability with the JOT-101 (JOTROL) micellar form. Cmax values are plotted below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
1. Cmax comparisons in mouse study 2015-3021-007 (AMP429). </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comparison
to the human data below suggests that mice absorb resveratrol faster than humans; and although this data is limited, the actual Cmax
value may not have been captured, as 15 minutes may, in fact, be past the concentration peak in mice. This possibility is supported by
the observation that the &ldquo;half dose&rdquo; of JOT101 (JOTROL) showed a higher Cmax at 15 minutes than megaresveratrol, although
the 4 hour AUC for the half dose is a bit lower than megaresveratrol &ndash; suggesting that absorption between the two formulations
poorly correlates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trial
in Rats</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD ROWSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 45%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><IMG SRC="img_001.jpg" ALT="" STYLE="height: 248px; width: 240px"></P>
                                                                                                   <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></P>
                                                                                <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
                                                                                <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></P>
                                                                                <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 55%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter
                                            Neurosciences, Inc. conducted a PK study in rats: Study 2016-3021-008 (AMP446). After acclimatization
                                            in the animal facility for at least 5 days, male CD rats with an average body weight of ~200g
                                            received 50 mg/kg resveratrol as JOTROL, marked as JOT-101, a form of fully synthetic
                                            resveratrol (NovaSol resveratrol) (data on file). This is the formula described in the patent.
                                            The control article, Megaresveratrol, is a commercially available micronized form of resveratrol.
                                            The compound was handled in the dark.</FONT></P>
                                                                                <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
                                                                                <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug
                                            was administered by gavage (N=9 per group). Blood was removed from the jugular vein at 10,
                                            20, 30 minutes, then 1, 2, 4, 6, 8, and 12 hr post dose. At 24 hr, trunk blood, heart, sc
                                            fat, and brain was collected. Plasma was separated and analyzed for resveratrol by LC-MS/MS
                                            using (Resveratrol-C6) as an internal standard.</FONT></P>
                                                                                <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
                                                                                <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
                                                                                <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>
                                                                                <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></P>
                                                                                <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></P>
                                                                                <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Table
2. PK Summary of study 2015-3021-008 (AMP446) where rats were administered 2 resveratrol treatments.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">dose</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tmax</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cmax</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gr3A/GrxA</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AUCall</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">t1/2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vz_obs/F</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cl_obs/F</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Group_ID</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">mg/kg</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">hr</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ng/mL</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ratio</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">hr*ng/mL</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">hr</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">mL/kg</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">mL/hr/kg</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gr2A</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 4%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 4%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.389</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 4%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">340</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 4%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 4%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1062</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 4%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.37</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 4%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">93209</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 4%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">47731</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gr3A</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.167</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2423</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2543</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.19</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36642</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23053</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gr2A</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mega
    Resveratrol</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gr3A</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JOTROL
    micellar form</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
headings in the above Table 2, have the following meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Group
  ID: this heading contains the name of each of the 4 treatment groups.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dose
  mg/kg: this heading denotes the applicable dose of resveratrol administered to each of the treatment groups.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tmax
  hr: this heading denotes the time at which the maximal concentration of resveratrol was measured in the plasma.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cmax
  ng/mL: this heading contains the concentration of resveratrol in plasma at a given Tmax.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gr3A/GrxA
  ratio: this heading denotes the ratio of the other treatment groups compared to Group 3.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AUCall
  hr*ng/mL: this heading denotes the area under the curve metric using all data points.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">t1/2
  hr: this heading sets fort the time measure when the resveratrol is in the body.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vz_obs/F
  mL/kg: this heading sets forth the apparent volume of distribution.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cl_obs/F
  mL/hr/kg: this heading sets forth when the resveratrol totally leaves the body.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
units for each measurement are listed below the metric name.</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> A 7 fold
increase in Cmax and a 2.4 fold increase in AUC were observed.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
2: Cmax comparisons in rats, and drug concentration in plasma over time (AMP446)</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT><IMG SRC="form1-a_026.jpg" ALT="" STYLE="height: 289px; width: 214px"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><IMG SRC="forms1-a_005.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 100; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Resveratrol has demonstrated promise as a potent
SIRT1 activator acting on various anti-Alzheimer&rsquo;s disease (&ldquo;AD&rdquo;) related pathways</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We partnered with the University of Miami, by
executing a Material Transfer Agreement (MTA) attached to this document as Exhibit 10.21, that conducted several studies in 3xTd-mice
that targeted various Alzheimer&rsquo;s biomarkers, including mitochondrial biogenesis that is useful for mitochondrial targeted diseases.
Results of those studies are in the illustrations below. The studies have recently been presented at several Alzheimer&rsquo;s Disease
conference events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="forms1-a_006.jpg" ALT="" STYLE="height: 357px; width: 575px"><FONT STYLE="font-size: 10pt"></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Resveratrol
regulates neuro-inflammation and induces adaptive immunity in Alzheimer&rsquo;s disease. We hypothesize that equimolar concentrations
of JOTROL, compared to non-formulated resveratrol, will result in greater brain exposure to resveratrol and more efficacious responses
on Alzheimer&rsquo;s disease biomarkers, allowing for a reduction in dose regimen.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 101; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Acute
treatment shows a positive effect of JOTROL on AD-related pathology in aged AD mice</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="forms-1a_007.jpg" ALT="" STYLE="height: 278px; width: 575px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A p-value of less than .05 is generally accepted
as statistically significant by regulatory authorities, such as the FDA.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
results led to a grant application to the NIA for funding of a Phase I PK trial. The grant, in the amount of $1.76 Million, was
approved on September 30, 2020. The Phase I trial started in late December 2020 and was completed in the first half of 2021. The final
study report has been completed and will shortly be published on clinicaltrials.gov. Supplemental funding of $233,281 was approved and
awarded on April 7, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>JOTROL Phase I Pharmacokinetic (&ldquo;PK&rdquo;)
and Safety Study</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">DESIGN / EXECUTION &ndash;
    Single Ascending Dose (&ldquo;SAD&rdquo;) with Food Effect</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">3- arm</FONT><FONT STYLE="font-size: 10pt">
    ascending dose (@200, 500, 700 mg), 24 subjects up to 75 years of age; food effect arm of 16 subjects)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Safety; blood plasma and
    urine collection out to 32 hours post dose</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">At 200 mg = A; at 500 mg = B; at 700 mg = C; at 500
    mg with food = D (these are the different arms of the PK study)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Measure resveratrol and
    3 key metabolites (2 glucuronides and one sulfate)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Completed 21 subjects first
arm A, 16 subjects second arm B, 18 subjects dosed 3rd arm C. Food effect arm 14 subjects D</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Covid-19 reduced enrollment.</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">PK observations (blood plasma)
    consistent with expectations; Target of an average C-Max level above 300ng/ml was achieved without causing any severe treatment
    adverse events.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">No treatment emergent
    serious adverse events, see Phase 1 Safety Conclusions per final report</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">High variability in bioavailability
    that can be adjusted patient by patient; will continue evaluation with Population PK in indication specific trials</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Plasma Cmax targets can
    be achieved without approaching the FDA stipulated AUC limit (2100 ng*hr/ml)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 102; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Study
results</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="forms-1a_008.jpg" ALT="" STYLE="height: 245px; width: 625px"><FONT STYLE="font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Earlier performed clinical studies in patient populations
that we have used to set a targeted C-Max level, 300ng/ml, of resveratrol in blood plasma are the MCRI, Friedreich&rsquo;s Ataxia study
(2 X 1 g and 2 X 2.5 g daily dose of resveratrol) published by Yiu et al. and Turner et al. Alzheimer disease study (dose escalation
with 500mg &ndash; 2g daily). In both trials it was shown that only the highest doses generated any positive therapeutic effect. The
associated PK results shows that at the highest dose in the Alzheimer&rsquo;s study there was an average of ~ 200ng/ml at Cmax of resveratrol
in the blood plasma and in the Friedreich&rsquo;s ataxia there was an average of ~ 260 ng/ml at Cmax of resveratrol in the blood plasma.
Our conclusions are that a result of ~ 300 ng/ml at Cmax, without generating any severe adverse events, is most likely a therapeutically
effective dose and the targeted level of resveratrol in blood plasma for all applications that we have identified. Our Phase I PK study
shows JOTROL (500mg) had a mean C-Max level of 454 ng/ml without generating any serious Treatment Emergent Adverse Events (TEAEs)
and therefore we achieved our own target results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">Phase 1 Safety Conclusions per final report:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">There were no deaths, serious,
or severe treatment emergent adverse events (&ldquo;TEAEs&rdquo;) reported. One (1) subject was withdrawn from the study due to
TEAE: Subject No. 07 was withdrawn due to TEAE of Sars-Cov-2 Test Positive and the study drug was interrupted for 2 subjects due to TEAEs:
Subject Nos. 02 and 03 due to TEAE of Covid-19. Subject No. 04 was withdrawn due to non-TEAE back pain, which commenced prior to study
drug administration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">A total of 25 TEAEs were
reported by 15 of the 24 subjects who received any amount of study drug. Nine (9) TEAEs were reported by 7 of the 21 subjects who received
Treatment A, 4 TEAEs were reported by 4 of the 16 subjects who received Treatment B, 6 TEAEs were reported by 6 of the 18 subjects who
received Treatment C, and 6 TEAEs were reported by 6 of the 15 subjects who received Treatment D. The number of subjects who reported
TEAEs was not notably different between the Treatments A, B, and C. No clear trend was observed with number of TEAEs reported with increasing
doses of resveratrol. Although the number of TEAEs were not notably different between Treatment B (fasting) and Treatment D (fed), there
was a slight difference in the proportion of subjects who reported TEAEs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The most commonly reported
TEAEs during this study were in the System Organ Class (&ldquo;SOC&rdquo;) of nervous system disorders, with somnolence reported
by 7 (29.2%) subjects, and headache reported by 5 (20.8%) subjects. Three (3) subjects contracted Covid-19 during the course of the study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Of the 25 TEAEs reported,
23 were graded as mild and 2 were graded as moderate. None were graded as severe. Moderate TEAEs were reported by 1 subject (Subject
No. 02) after receiving Treatment A (Covid-19) and 1 subject (Subject No. 15) after receiving Treatment C (syncope).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Of the 25 TEAEs reported,
the relationship of 13 TEAEs was judged as possibly related, 8 as remotely related, and 4 as unrelated. Somnolence (6 [25%] subjects;
8 events) and headache (4 [16.7%] subjects; 4 events) were the most frequent events judged to be possibly related.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Three (3) subjects reported
CS laboratory abnormalities that led to TEAEs. The TEAEs &ldquo;White Blood Cells Urine&rdquo; reported by Subject No. 03, &ldquo;Alanine
Aminotransferase Increased&rdquo; reported by Subject No. 05, and &ldquo;Haemoglobin Decreased&rdquo; reported by Subject No. 20 were
mild in severity and were remotely related to the study drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">One (1) subject reported
CS vital sign abnormality that led to a TEAE. Subject No. 21 reported &ldquo;Blood Pressure Increased&rdquo; which was mild in severity
and remotely related to the study drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">There were no clinically
significant changes in ECG and no TEAEs related to ECG was reported during the study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">After obtaining the results from the Phase I study,
showing that we achieved a Cmax level of over 300 ng/ml of resveratrol without generating any severe adverse events, we applied for additional
funding from the NIA for a Phase II trial in MCI/early AD as well as moving forward with preparations of protocols and IND submissions
for Friedreich&rsquo;s ataxia and MCI/early AD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 103; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MARKET
OVERVIEW</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rare
(Orphan) Diseases</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Orphan Drug Act defines an orphan disease as
a disease which affects less than 200,000 people in the United States. Other countries in the world have similar laws to recognize diseases
which affect small populations. There are only treatments for about 600 out of 7,000 rare diseases. Many of these rare diseases
are very serious and life threatening, generating a large economic burden as illustrated in the pie chart below. Under the Orphan Drug
Act there are incentives and benefits available to companies that develop an orphan disease product. This may include certain R&amp;D
tax benefits, reduced or waiver of FDA filing fees, 7 &ndash; 10 years of exclusivity, an accelerated approval process, the possible
receipt of a transferable Priority Revue Voucher (present value ~ $50 M) and favorable product price reimbursement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pricing structure is very different between approved
treatments for orphan diseases vs. non-orphan. The average price for a product treating an orphan disease is over $150,000 per year/per
patient (source: Evaluate Pharma).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="forms-1a_009.jpg" ALT="" STYLE="height: 468px; width: 575px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 104; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Relevant Market Size</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our relevant market size is the annual revenue
that we could attain if we owned 100% market share of the diseases treated by our product, if approved. The global Alzheimer&rsquo;s
disease market is very large, as evidenced by the Alzheimer&rsquo;s Association&rsquo;s 2020 annual report stating Alzheimer&rsquo;s
disease has impacted 5.7 million Americans. However, we believe it is premature for us to calculate a relevant market
size for Alzheimer&rsquo;s disease.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
assumed relevant  market size in the rare disease indications is calculated as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of patients, in countries with drug reimbursement plans, who are affected with our targeted rare disease pipeline products:
    Approximately 82,000 patients</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">The amount these patients might be willing to spend on
    an annual basis on our products, if reimbursed (price projected to be 50% of the average $150,804 US orphan drug price according
    to Evaluate Pharma market report 2020): $75,000.</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">With these assumptions, our relevant market size in rare
    diseases: $6 billion</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market size in United States for our targeted rare disease applications is as follows for each indication:, price source: Evaluate
Pharma 2020:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Friedreich&rsquo;s
ataxia:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">~
    5000 patients in USA</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9632;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average
    price for presently sold rare disease medications: ~$360 K per year/per patient </FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9632;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumed
    JOTROL price: ~$75 K per year/per patient</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9632;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Relative
    market size: $375M</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MPS
I: </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">~
    2000 patients in the USA</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average
                                            price for the present rare disease medication (Aldurazyme): ~$600 K per year/per
                                            patient</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JOTROL
price: ~$75 K per year/per patient</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Relative
    market size: $150 M</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MELAS:
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">~
    80,000 patients in USA</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average
    price for rare disease medication: $150 K per year/per patient </FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JOTROL
price: ~$75 K per year/per patient</FONT></P></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Relative
                                            market size: ~$6 B</FONT></P></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
source for the average pricing information above is Evaluate Pharma 2020 and published patient support sites, such as Friedreich&rsquo;s
Ataxia Research Alliance (FARA), www.curefa.org. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Alzheimer&rsquo;s
Disease</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alzheimer&rsquo;s
is a progressive, neurodegenerative disease and the most common cause of dementia. Alzheimer&rsquo;s disease is not a normal part
of aging.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
National Institutes of Health (NIH) defines dementia as &ldquo;a loss of thinking, remembering, and reasoning skills that interferes
with a person&rsquo;s daily life and activities&rdquo;. Other forms include frontotemporal degeneration, dementia with Lewy bodies,
and vascular and mixed dementias.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">According to Alzheimer&rsquo;s Association&rsquo;s
2020 annual report Alzheimer&rsquo;s disease has impacted 5.7 million Americans and that it costs the US $277 billion each year, excluding
the cost of &ldquo;unpaid time and effort of the people, mostly women, who are caring for spouses, parents, siblings, and friends with
dementia.&rdquo; The Association explained, &ldquo;In 2017, 16 million Americans provided an estimated 18.4 billion hours of unpaid care
in the form of physical, emotional and financial support &ndash; a contribution to the nation valued at $232.1 billion.&rdquo; Any product
that delays the onset of severe Alzheimer&rsquo;s disease will represent a significant savings to society.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><IMG SRC="form1-a_027.jpg" ALT="" STYLE="height: 332px; width: 650px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Parkinson&rsquo;s
Disease</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parkinson&rsquo;s
disease (PD) occurs when&nbsp;<B>brain cells that make dopamine, a chemical that coordinates movement, stop working or die</B>. Because
PD can cause tremor, slowness, stiffness, and walking and balance problems, it is called a &ldquo;movement disorder.&rdquo; But constipation,
depression, memory problems and other non-movement symptoms also can be part of Parkinson&rsquo;s. PD is a lifelong and progressive disease,
which means that symptoms slowly worsen over time.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
experience of living with Parkinson&rsquo;s over the course of a lifetime is&nbsp;unique to each person. As symptoms and progression vary from
person to person, neither you nor your doctor can predict which symptoms you will get, when you will get them or how severe they will
be. Even though broad paths of similarity are observed among individuals with PD as the disease progresses, there is no guarantee you
will experience what you see in others.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimates
suggest that Parkinson&rsquo;s affects nearly 1 million people in the United States&nbsp;and&nbsp;more than 6 million people worldwide,
source Michael J Fox Foundation.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>


<!-- Field: Page; Sequence: 105; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Product
Pipeline</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-1a_026.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The product pipeline represented above assume drawing
upon previous preclinical and clinical data conducted by third parties. This data is available either via public domain or under agreements
with our key partner which are further described in the section titled &ldquo;Description of Business&rdquo;. The Company has not discussed
with the FDA its ability to rely on and reference data from previous third-party trials, such as the Phase II trial in MCI/early
Alzheimer&rsquo;s disease, conducted by Georgetown University.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note:
</B>The Company has designated the different indications with project numbers, JNS101 &ndash; JNS115. The same JOTROL product
is planned to be used in all indications although the number of capsules might vary and be indication specific.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JNS101
Friedreich&rsquo;s ataxia direct to Phase II</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JNS101
is a project utilizing JOTROL, specifically designed to treat Friedreich&rsquo;s Ataxia.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Friedreich&rsquo;s
Ataxia (FA) is a rare inherited disease that causes damage to the nervous system as well as mobility dysfunctions. FA usually begins
in childhood and leads to impaired muscle coordination (ataxia) which worsens over time. It is caused by a defect (mutation) in a gene
labeled FXN. Friedreich&rsquo;s ataxia is recessive, meaning it only occurs in someone who inherits two defective copies of the gene,
one from each parent. Although rare, FA is the most common form of hereditary ataxia, affecting about 1 in 50,000 people in the United
States. EU5 (5 largest European countries) alone has approximately the same amount of FA patients as there are in USA. As of 2020 there
are still no approved treatments available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Murdoch Children&rsquo;s Research Institute (MCRI),
which we have a licensing agreement with, conducted a clinical trial in 27 human subjects where 24 completed the study, resulting
in that a high daily dose (5 grams) of nutritional grade trans-resveratrol  had statistically different positive results, see
p-values for 5 g daily dosing in the table below, on established Friedreich&rsquo;s Ataxia measurements. Key markers, such as FARS
Score and measurements of hearing and speech parameters were included in these positive results. The results indicate that an effective
dose of resveratrol is expected to be a meaningful treatment for patients with Friedreich&rsquo;s Ataxia. The data from the
MCRI study was used in pre-IND meetings with the FDA discussing our Phase II study and was also referenced in our application for orphan
drug designation (ODD). The ODD, request #17-5978, was granted to us by the FDA on August 16, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The MCRI study is widely published, Eppie
M. Yiu et al., and below is a summary table of the results including the demonstrated issue with gastro-intestinal side effects at a
higher dose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
p-value (or probability value) is used to determine if the outcome of an experiment is statistically significant. A low p-value means
that there is a very low likelihood that this outcome was a result of luck or is a random occurrence.&nbsp; A high p-value means that
assuming the null hypothesis is true, this outcome was very likely.&nbsp;&nbsp;Generally, a p value less than 0.05 (or 5% odds of the
event being random) is regarded as statistically significant.&nbsp;&nbsp;The lower the P value, the less chance that the comparison is
a random outcome.&nbsp;&nbsp;The FDA follows these accepted measures of statistical probability in the evaluation of significant results
in preclinical experimental outcomes and for clinical trials.&nbsp; In general, if a primary endpoint in a Phase III/Pivotal trial gets
a p-value below 0.05 there is a good possibility, unless there are simultaneous safety issues, that a product may receive approval from
the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The below graph representing results of two different doses of resveratrol in
the same patient population. Comparisons are made from the patients baseline and was not placebo controlled. There is a clear difference
between the 1gram daily dosing vs the 5gram daily dosing in p-values in all areas measured. There is also a clear difference in adverse
events, primarily GI related between the 2 doses. Our target is to replicate the results of the 5 gram results in a placebo controlled
study with the low side effect results from the 1 gram dosing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="forms-1a_012.jpg" ALT="" STYLE="height: 414px; width: 575px"><FONT STYLE="font-size: 10pt"></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 106; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="forms-1a_013.jpg" ALT="" STYLE="height: 353px; width: 575px"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JNS102
Phase II trial for MPS I</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JNS102
is utilizing JOTROL for treatment of Lysosomal Storage disease areas whereas MPS Type I is the first target.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Mucopolysaccharidosis
Type 1 (MPS I)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MPS
I is divided into three subtypes based on severity of symptoms. All three types result from an absence of, or insufficient levels of,
the enzyme alpha-L-iduronidase. Children who have parents with MPS I will carry the defective gene.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MPS
I patients are presently treated with an Enzyme Replacement Therapy (ERT) named Aldurazyme. This requires a weekly infusion of 4 hours
per event and cost over $500,000 per year per patient. The ERT is effective in significantly prolonging life however since the
ERT does not penetrate the Blood Brain Barrier, Ears, Eyes and Joints, it leaves the patients with a gradually worsening quality of life
including loss of hearing, blindness and severe arthritis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> JNS102 is targeting the specific areas that
ERT cannot treat, with JOTROL&trade; treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JNS102
Phase II Clinical Trial</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Preclinical studies conducted at University of Miami in MPS I mice
    results showed that a high dose of resveratrol increased the alpha-L-iduronidase which is the critical enzyme that is too low in
    these patients.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">IND application for Phase I study was approved by the FDA and the
    clinical trial is completed. Results documented in the section <B>JOTROL Phase I Pharmacokinetic (&ldquo;PK&rdquo;) and Safety
    Study</B>. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-size: 10pt">3.</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Final study details and start
    to be determined by consultation with the FDA and supportive additional financing. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 107; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Primary
    endpoint:</U></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">Safety, tolerability and PK/PD
values</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 4.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="forms-1a_014.jpg" ALT="" STYLE="height: 195px; width: 625px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT> </TD>
    <TD COLSPAN="3" STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Secondary
    endpoints to include (subject to FDA acceptance)</U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Improvement
    in 6-minute walk distance</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forced
    vital capacity</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biomarkers,
    such as alpha-L-iduronidase levels</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">iv.</P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify">MPS I validated pain survey</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JNS107
</B><FONT STYLE="font-style: normal; font-weight: normal">Phase II trial</FONT> <B>for MELAS Syndrome</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JNS107
is utilizing JOTROL as the product to treat MELAS Syndrome.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MELAS
(Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes) syndrome is a rare disorder that begins in childhood, usually
between two and fifteen years of age, and mostly affects the nervous system and muscles. The most common early symptoms are seizures,
recurrent headaches, loss of appetite, and recurrent vomiting. Stroke-like episodes with temporary muscle weakness on one side of the
body (hemiparesis) may also occur and this can lead to altered consciousness, vision and hearing loss, loss of motor skills, and intellectual
disability. MELAS is caused by mutations in mitochondrial DNA. Pre-clinical trials performed with mice at University of Miami showed
that JOTROL&trade; increased mitochondrial biogenesis in the liver with 70% and in the brain with 30%, which is expected to lead to an
increase in the mitochondria levels in MELAS patients and thereby show positive patient outcomes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signs
&amp; Symptoms</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Symptoms
of MELAS syndrome usually begin between the ages of two and fifteen years, but delayed onset cases have also been reported in people
aged fifteen to forty years and older. In approximately 75 percent of cases, onset of the disorder occurs before the age of 20 years.
Symptoms and physical findings associated with MELAS syndrome vary greatly among affected individuals. The distinguishing feature in
MELAS syndrome is the recurrence of stroke-like episodes. It is currently thought that the deficiency of a compound called nitric oxide
in the small blood vessels of the brain may be responsible for the stroke-like episodes. Short stature and hearing loss may be present
and fatigue and difficulty tolerating exercise may be early symptoms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Affected
Populations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MELAS
syndrome is a rare disorder that affects males and females in equal numbers. Although rare, MELAS syndrome is probably the most common
type of mitochondrial myopathy caused by mutations in mtDNA. Some researchers believe that mitochondrial myopathies may go unrecognized
and underdiagnosed in the general population, making it difficult to determine the true frequency of disorders like MELAS syndrome.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 108; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Opportunity
for JNS107</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximately
80,000 patients in the USA</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumptions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Projected
    treatment cost per patient in USA: ~ $75,000 per year</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,000
    patients treated with JOTROL = ~ $3.75 B per year product</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    addition, positive clinical trial results might be applicable for other Mitochondrial diseases</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 65.75pt; text-align: justify; text-indent: -65.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JNS108
Mild Cognitive Impairment/early Alzheimer&rsquo;s Disease</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 65.75pt; text-align: justify; text-indent: -22.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">We will be utilizing JOTROL
in our applications for investigating treatment of various segments of Alzheimer&rsquo;s disease of which MCI/early AD is the initial
target. If any NIA grant application is successful, we will have the funding to conduct a Phase II trial in MCI/early Alzheimer&rsquo;s
Disease. Our failure to obtain such a grant will most likely result in delays of this project and the need to raise additional
capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Early-stage
Alzheimer&rsquo;s (mild)&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Later stages of Alzheimer&rsquo;s
are very difficult to reverse and therefore it is important to start treatment of Alzheimer&rsquo;s in the earliest possible stage so
the individuals can continue living normal lives and maintain their independence.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
the early stage of Alzheimer&rsquo;s, a person may function independently. He or she may still drive, work and be participate in social
activities. Despite this, the person may feel as if he or she is having memory lapses, such as forgetting familiar words or the location
of everyday objects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Symptoms
may not be widely apparent at this stage, but family and close friends may take notice and a doctor would be able to identify symptoms
using certain diagnostic tools.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
difficulties include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify; text-indent: -22.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Coming
    up with the right word or name.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remembering
    names when introduced to new people.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Having
    difficulty performing tasks in social or work settings.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forgetting
    material that was just read.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Losing
    or misplacing a valuable object.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Experiencing
    increased trouble with planning or organizing.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">This is the Alzheimer&rsquo;s
disease patient category that we will include in our proposed Phase II clinical trial with the final objective of showing that JOTROL
has the potential of slowing and/or possibly stopping the progression of this disease. The effect of JOTROL treatment, in the
Phase II trial, will primarily be measured through several biomarkers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Economic
burden of Alzheimer&rsquo;s disease on society in USA is generating a very large opportunity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to Alzheimer&rsquo;s Association&rsquo;s 2020 annual report Alzheimer&rsquo;s disease has impacted 5.7 million Americans and that it
costs the US $277 billion each year, excluding the cost of &ldquo;unpaid time and effort of the people, mostly women, who are caring
for spouses, parents, siblings, and friends with dementia.&rdquo; The Association explained, &ldquo;In 2017, 16 million Americans provided
an estimated 18.4 billion hours of unpaid care in the form of physical, emotional and financial support &ndash; a contribution to the
nation valued at $232.1 billion.&rdquo; Any product that delays the onset of severe Alzheimer&rsquo;s disease should represent
a significant savings to society.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JNS108
Phase II Clinical Trial for MCI/early Alzheimer&rsquo;s Disease</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0; text-align: justify">National Institute on Aging (&ldquo;NIA&rdquo;)
financed our Phase I study with $1.76 million through grant 1R44AG067907-01A1. Since there were unanticipated higher costs, mostly due
to Covid-19 related additional procedures during the Phase I trial, a supplemental grant of $233,281 was submitted to the NIA in December
of 2021. We were awarded the supplemental grant on April 7, 2022. In April 2021, we submitted our first grant application to the
NIA for full funding of a Phase II trial in Mild Cognitive Impairment (MCI) and early Alzheimer&rsquo;s disease. The Phase
II trial was designed to focus on 3 areas: 1) safety and tolerability; 2) pharmacokinetics and pharmacodynamics, measuring of
responses from 2 different doses vs. placebo; and 3) measuring of effect on multiple biomarkers related to the disease. The application
was not accepted but we were encouraged by the NIA to refine our application and submit again. We have since submitted 3 grant applications,
with budgets of $20 M or higher, to the NIA for full funding of such Phase II trial but none of those applications were successful. The NIA scientific review of our Alzheimer&rsquo;s Phase II trial grant application, which is attached as Exhibit
10.38 to the registration statement of which this prospectus forms a part, shows a total score of 47 which is our best score so far. A
score of 40 or below is necessary for being considered for funding. After
discussions with the NIA, we have decided to apply, in September of 2024, for a much smaller grant, $2.5 million, for a Proof of Concept
study focusing on JOTROL&rsquo;s effect on validated biomarker. The final study design is not yet determined but a draft synopsis is
described below. There is however no guarantee that we will ever receive NIA grant funding for this project. A delay
or rejection of this funding will cause a delay in this program and most likely requiring additional financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> The proposed Phase II trial is utilizing published
information from the earlier Turner et al Phase II trial, completed in 2015 with 119 patients with early Alzheimer&rsquo;s disease who
were treated with 4 different doses of resveratrol. The study was conducted by Professor Raymond Turner, MD. at Georgetown University,
a member of our Scientific Advisory Board, as the Principal Investigator. Dr. Turner is the Principal Investigator of our proposed Phase
II trial. The study tried 500mg, 1000mg, 1500mg and 2000mg daily doses with each dose taken by the patients over 13 weeks. Only the highest
dose of 2000mg (2 X 1g per day) showed positive results on biomarkers which lead to the conclusion that this study was most likely underdosed
for achieving the best therapeutic effect. PK analysis showed that the average C-Max of resveratrol in the blood on the highest dose
was 181 ng/ml, which is far from the target of 300ng/ml that we believe is needed for reaching therapeutic effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 109; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Based on the recent Scientific Review received
from NIA. Our team of scientists in the Alzheimer&rsquo;s field, Professors Raymond Turner, MD, Ph.D. and Charbel
Moussa, Ph.D. from Georgetown University, Rudolph Tanzi, Ph.D. Harvard and Li-Huei Tsai, Ph.D. MIT are assisting in designing
our POC study to address and explore several biomarkers and areas where the trial results can guide us to a follow-on Phase II
trial, if approved to do so by the FDA, that might generate meaningful outcomes for MCI/early AD patients. The Company has not discussed
its ability to rely on and reference the Phase II trial conducted by Georgetown with the FDA nor has it discussed the design of the
planned POC study in MCI patients with the FDA. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JOTROL
MCI POC STUDY SYNOPSIS (DRAFT)</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title:</B></FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 68%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            phase II, randomized, double-blind, study to assess the safety and efficacy of JOTROL (micellar
                                            resveratrol solubilisation formulation) in early Alzheimer&rsquo;s Disease (AD) patients</FONT> </P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Study
    Description:</B></FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
                                            study seeks to assess the safety and blood biomarker assessed efficacy of JOTROL (resveratrol)
                                            in patients with MCI/early AD. Approximately 40 patients would be enrolled at 2 study centers
                                            in the United States. Patients will be randomized into one of two active treatment arms to
                                            receive JOTROL 500 (resveratrol) mg BID or conventional resveratrol 500 mg BID. Treatment
                                            duration will be 3 months. There is no placebo group.</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    hypothesize that JOTROL will be safe and tolerable in individuals with MCI/early AD, and that key biomarkers will show evidence of
    efficacy.</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    blood draw-biomarker assays will be evaluated pretreatment, at 0.5 months, 1 month, 2 months, and 3 months of treatment, and a 1-month
    post treatment evaluation (safety follow-up and biomarker assessment).</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Objectives:</B></FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            determine the safety and efficacy of JOTROL for neuroinflammation and biomarkers of MCI/early
                                            AD.</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primary
    Objective:</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.15in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    To assess safety and tolerability of JOTROL in AD-MCI patients by monitoring adverse events (AEs) and serious adverse events (SAEs)
    and assessing their relationship to the study drug. Tolerability will be measured by subjects&rsquo; ability to remain on treatment.
    Overall tolerability of the drug will be defined as fewer than 25% discontinuations due to drug-related AEs and SAEs</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.15in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    Early efficacy indicator(s) will be Abeta40, Abeta42, Abeta40/42 ratio, total tau, p-tau181, p-tau217, nfl, GFAP, and ApoE genotype
    or proteotypeptau231, MMP9, IL6 and FGF2. </FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Secondary
    Objectives:</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.15in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    To assess population pharmacokinetics (Pop PK) in the ITT population. </FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.15in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    To measure the effect of JOTROL on biochemical markers for AD, neurodegeneration, vascular damage, metabolic effects, and neuroinflammation</FONT> </P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Endpoints:</B></FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primary
                                            Endpoint:</FONT> </P>
                                                         <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.15in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    Assessment of safety/tolerability by monitoring AEs and SAEs, assessing their potential relationship to the study drug and Abeta
    40/42 ratio.</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Secondary
    Endpoints:</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.15in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    Additional experimental biomarkers such as total tau, p-tau181, p-tau 217, nfl, GFAP, and ApoE genotype or proteotypeptau231, MMP9,
    IL6 and FGF2.</FONT> </P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Study
    Population:</B></FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximately
                                            40 male or female subjects between 55 and 85 years of age with a diagnosis of MCI/early AD
                                            to be enrolled. MCI/early AD patients should be amyloid positive (by PET, if available
                                            in the patient background) with an AD/MCI clinical diagnosis.</FONT> </P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Phase:</B></FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                            II</FONT> </P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description
    of Sites/Facilities Enrolling Participants:</B></FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximately
                                            2 study centers in the USA. Study sites will be determined by competitive selection of interested
                                            and eligible ADCS sites - with experienced study coordinators, raters, and site PIs</FONT> </P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description
    of Study Intervention:</B></FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subjects
                                            will be randomized 1:1 to receive 500 mg bid (1g/day) resveratrol as JOTROL; or 500 mg bid
                                            conventional resveratrol</FONT> </P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Participant
    Duration:</B></FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treatment
                                            phase will be 3 months with a one month follow up safety visit and safety monitoring over
                                            a 6-month period to ensure that patients have no long lasting treatment related effects.</FONT> </P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 110; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JNS115
Parkinson&rsquo;s Disease project</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will be utilizing JOTROL<SUP></SUP> in our application for investigating a treatment for Parkinson&rsquo;s Disease (PD).</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Michael J Fox Foundation, that we have used as the primary source for disease related information, has been informed about our activities
and pre-clinical results and are guiding us on how to apply for further research grants from their organization. There is however no
guarantee that we will obtain any grants and therefore we are planning to use proceeds from this offering to conduct a Phase IIA trial.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are multiple Symptoms for PD and those can vary from person to person affected by PD. Here are some of the most common Symptoms.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Motor
Symptoms</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">People
are usually more familiar with the motor (movement) symptoms of Parkinson&rsquo;s disease (PD). These signs are noticeable from the outside
and are used by doctors to make a diagnosis. The three &ldquo;cardinal&rdquo; motor symptoms of PD are:<BR>
&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stiffness</B>&nbsp;(rigidity):
                                            muscle stiffness detected by a doctor on examination</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Slowness</B>&nbsp;(bradykinesia):
                                            decrease in spontaneous and voluntary movement; may include slower walking, less arm swinging
                                            while walking, or decreased blinking or facial expression</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Resting
                                            tremor</B>: a rhythmic, involuntary shaking that occurs in a finger, hand or limb when it&rsquo;s
                                            relaxed and disappears during voluntary movement</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Non-motor
Symptoms</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-motor
(non-movement) symptoms sometimes are called&nbsp;<B>the &ldquo;invisible&rdquo; symptoms of Parkinson&rsquo;s</B>&nbsp;because you can&rsquo;t see
them from the outside. These common symptoms can affect almost every body system, occur any time in the course of disease (even before
motor symptoms or diagnosis) and differ in severity from person to person. Non-motor symptoms can significantly impact quality of life
for people with Parkinson&rsquo;s and their families. They may include:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Autonomic
Dysfunction</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parkinson&rsquo;s
can affect the automatic/involuntary functions that our bodies perform.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Constipation</B>:
                                            decreased or difficult-to-pass bowel movements</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Low
                                            blood pressure</B>&nbsp;(orthostatic hypotension): decrease in blood pressure when changing
                                            positions, such as standing from sitting, which can cause lightheadedness, dizziness or fainting</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sexual
                                            problems</B>: erectile dysfunction in men; decreased libido or pain in women</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sweating
                                            problems</B>: excessive perspiration, even when not hot or anxious</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Urine
                                            problems</B>: frequent urination, involuntary loss of urine (incontinence) or difficulty
                                            emptying the bladder&nbsp;</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> </P>

<!-- Field: Page; Sequence: 111; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Medication
and Treatments</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
available therapies can treat some symptoms, people with Parkinson&rsquo;s urgently need better treatments to improve quality of life and slow
or stop disease progression.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are several approved medications for Motor Symtoms but none of them alone or in combination can stop progression of the disease.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dopamine
                                            Replacement Therapy: levodopa/carbidopa</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adenosine
                                            Receptor Antagonist</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amantadine</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anticholinergic
                                            Medications</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Catechol-O-methyltransferase
                                            (COMT) Inhibitors</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Decarboxylase
                                            Inhibitor</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dopamine
                                            Agonists</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Monoamine
                                            Oxidase (MAO) B Inhibitors</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Researchers
are appreciating what patients have long known: non-motor symptoms of Parkinson&rsquo;s can be debilitating and difficult to treat. While scientists
work on new therapies, doctors use what is on the market today to help manage these symptoms.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Preclinical
results leading to encouraging of JOTROL possibly being a treatment for PD</U></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recently completed preclinical activities in a validated mouse model of Parkinson&rsquo;s Disease (PD) at the University of Miami.
The model of PD that was used mimics many aspects of the disease utilizing a unilateral injection of a neurotoxin precursor that elicits
nigral cell loss, striatal dopamine loss and behavior deficits similar to physiological characteristics of human disease. The PD model
(MPTP unilateral infusion into 2 sites along the nigrostriatal pathway) displayed significant motor deficits which were attenuated by
treatment with JOTROL<SUP>&trade;</SUP>. Most importantly, MPTP-infused (PD model mice) treated with either 25 mg/kg (low dose) or 50
mg/kg (high dose) did not significantly differ from healthy controls, suggesting that JOTROL<SUP></SUP> treatment is able to mediate
various motor dysfunctions to the point that those PD model mice function comparable to healthy, non-PD (wild-type, Sham surgery) controls.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-infused
MPTP mice were tested as well to demonstrate a clear comparison. The MPTP treated mice were tested with a placebo product, 25 mg of JOTROL<SUP>
</SUP>and 50mg of JOTROL<SUP></SUP>. 3 key areas were evaluated, grip strength, rotarod time and rotarod speed. Results are presented
below.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SHAM columns are healthy mice while the MTPT columns are mice induced to have Parkinson&rsquo;s Disease. The MTPT vehicle is a placebo
dose.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-1a_016.jpg" ALT="" STYLE="height: 185.25pt; width: 202.5pt"></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> </P>

<!-- Field: Page; Sequence: 112; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"> <IMG SRC="forms-1a_017.jpg" ALT="" STYLE="height: 216.75pt; width: 213pt"> </TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"> <IMG SRC="forms-1a_18.jpg" ALT="" STYLE="height: 212.25pt; width: 235.5pt"> </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s Conclusion of the trial is that JOTROL has the possibility of being neuroprotective in PD patients and to further explore
this we have decided to use a part of the proceeds from this offering to conduct a clinical Phase II A, or alternatively a smaller Phase I B study, depending on cost and FDA recommendations and IND approval, to target
results that can give indications that JOTROL has the potential of being beneficial as an adjunct treatment in the disease<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
</FONT></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The study, subject to approval by the FDA, is projected to be with 30 individuals diagnosed with PD (stage TBD)</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Randomize
30 individuals 1:1:1 into JOTROL 200mg, JOTROL 500mg versus placebo)</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug
administration and study duration:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taken
orally, by mouth, twice daily, for 24 weeks (6 months)</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Study
Objectives:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primary
                                            Objectives &ndash;Safety and Pharmacokinetics</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Secondary
                                            Objectives &ndash;Biomarker and Target Engagement (TBD)</FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exploratory
                                            Objectives &ndash;TBD</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
final study design, protocol, IND submission and execution of the trial will be led by our SAB member Dr. Charbel Moussa, Associate Professor
of Neurology at Georgetown University Medical Center. Since March 2015, Dr. Moussa has served as the director of Translational Neurotherapeutics
Program at Georgetown University Medical Center. Since January 2018, Dr. Moussa has served as the Principal Investigator of the Lewy
Body Disease Association (LBDA) Research Center of Excellence at Georgetown University Medical Center. Since March 2015, Dr. Moussa has
served as Clinical Research Director at the Parkinson&rsquo;s Foundation Center of Excellence.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 113; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Competitive
Analysis</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is an overview of JNS&rsquo;s competitors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
companies, including the largest pharma companies in the world, are competitors in some of the disease areas for which we are developing
treatments for through our various projects. We will compete with both small and large companies in each indication we are pursuing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are a multiple of companies, both smaller biotech&rsquo;s as well as large pharmaceutical companies, that are working on solutions for
the same indications that we are pursuing. There is no assurance that we will be able to compete with these companies even if
our product gets approved in an indication.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Competition
in Rare Diseases</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are several companies that are targeting the same rare diseases as us. Below is description of a selection of those companies that we
see as our closest competitors. However, it is possible that another company, that is not listed below, can potentially have a successful
product approved before us and have a more effective treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>MPS
-1 </U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sanofi
                                            Genzyme: Aldurazyme is an Enzyme Replacement Therapy that has been in the market for nearly
                                            20 years and is the standard of care. </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RegenexBio:
                                            RGX-111 is a gene therapy which is intended to deliver a functional copy of the &alpha;-L-iduronidase
                                            (IDUA) gene to the central nervous system. </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sigilon
                                            Therapeutics, Inc.: SIG-005 contains a human cell line genetically modified with a non-viral
                                            vector designed to express human a-L-iduronidase (IDUA), an enzyme which is missing or defective
                                            in patients with MPS-1. IND application to start Phase I is submitted to the FDA.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            are other companies, such as Sangamo Therapeutics, Inc., that has sought to produce gene
                                            editing products, but no positive results have been published so far. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Friedreich&rsquo;s
ataxia, there is now one approved treatment for the disease. </U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reata
                                            Pharmaceuticals, Inc.: Omaveloxolone, brand name SKYCLARYS, went through two
                                            Phase II and one Pivotal trial. Reata submitted an NDA to the FDA in early 2022 that
                                            led to an approval during the first half of 2023. Based on the MCRI study results
                                            with resveratrol we believe that we have the possibility of showing that JOTROL can
                                            be more effective than Omaveloxolone in several areas, such as oxidative stress, hearing
                                            and speech. However, with Biogen&rsquo;s recent acquisition of Reata ($7.3 Billion), and
                                            their strength in marketing and distribution, it will be very hard to find patients for a
                                            study in USA since they most likely will be prescribed SKYCLARYS.
                                            Therefore, we expect to conduct future studies in Europe and Australia where it will most
                                            likely take several years before SKYCLARYS is approved. </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Minoryx
                                            Therapeutics: MIN-102, Leriglitazone selective PPAR gamma agonist, Phase II (Proof of Concept)
                                            trial completed.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Larimar
                                            Therapeutics, Inc.: CTI-1601 is a recombinant fusion protein intended to deliver human frataxin
                                            into the mitochondria of patients with Friedreich&rsquo;s ataxia. Phase I trial in process.&nbsp;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>MELAS,
there is no existing approved treatment for the disease. </U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclerion
                                            Therapeutics, Inc.: CY643 is in Phase 1B. In addition to safety, the study will assess the
                                            impact of short-term CY6463 treatment on biomarkers of mitochondrial dysfunction, brain perfusion,
                                            neurodegeneration, and cognition.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abliva
                                            AB: KL1333 has been evaluated in both healthy volunteers and in patients and has been granted
                                            orphan drug designation in both the United States and Europe. Abliva kicked off a
                                            registrational Phase 2/3 study in December 2022.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Competition
in Alzheimer&rsquo;s Disease</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are several companies that are targeting treatment for Alzheimer&rsquo;s disease. Below is a selection of those companies that we see
as our closest competitors. However, it is possible that another company, that is not listed below, can potentially have a successful
product approved before us and have a more effective treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biogen:
                                            Aduhelm is a drug that you get once a month through a needle in the vein (IV) as an infusion.
                                            You may need to take it for the rest of your life. Aduhelm targets a key sign of Alzheimer&rsquo;s
                                            disease: plaques of a protein called amyloid-beta, which builds up in the&nbsp;brain&nbsp;and
                                            can lead to the death of neurons. Aduhelm was approved by the FDA but has since received
                                            a lot of re-imbursement resistance and therefore has had a very low market penetration.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eli
                                            Lilly: Donanemab, an investigational antibody that targets a modified form of beta amyloid
                                            called N3pG has received an FDA Breakthrough Therapy designation.&nbsp;Lilly&rsquo;s Phase
                                            2 trial, TRAILBLAZER-ALZ, studied the efficacy and safety of donanemab in patients with early,
                                            symptomatic AD. Lilly&nbsp;intends to submit a biologics license application (BLA) for donanemab
                                            under the accelerated approval pathway later this year based on data from TRAILBLAZER-ALZ. The
                                            safety, tolerability and efficacy of donanemab are also being evaluated in the ongoing randomized,
                                            placebo-controlled, double-blind, multi-center Phase 3 study. This product was very recently
                                            approved by the FDA and the estimated price of the product is $32,000 per year. </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cognition
                                            Therapeutics: CT1812&nbsp;is a first-in-class, orally dosed and highly brain penetrant small
                                            molecule that is being assessed as a treatment for mild-to-moderate Alzheimer&rsquo;s disease.
                                            Received approximately $164 million in grants from the NIA for their development of CT1812.
                                            CT1812 is presently in Phase II.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
                                            Life Sciences: SIGMACEPTOR&trade;&nbsp;Discovery Platform produces therapeutic candidates
                                            designed to activate SIGMAR1, a novel pathway designed to target chronic central nervous
                                            system (CNS) conditions with genomic precision. Anavex 2-73 is presently in Phase III.</FONT></TD></TR><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> 5. </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> Eisai
                                            and Biogen: &nbsp;A panel of expert advisers on June 6, 2023 unanimously agreed that a late-stage
                                            trial of Eisai&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4523.T)&nbsp;and
                                            Biogen&rsquo;s&nbsp;(BIIB.O)&nbsp;Alzheimer&rsquo;s drug, Leqembi, verified the benefit of the treatment
                                            for those at an early stage of the disease, clearing the way for a traditional U.S. approval.
                                            All six advisers on the panel voted in favor of Leqembi for treatment of the mind-wasting
                                            illness. Regular approval by Food and Drug Administration is likely to expand Medicare payment
                                            for the treatment. The price of the drug is set to $26,000 per year.</FONT> </TD></TR>
                                                                                                                                                   </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 114; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Competition
in Parkinson&rsquo;s Disease. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are products that are FDA approved for treatment of Parkinson&rsquo;s Disease, but it has been many years since there has been any breakthrough
of an additionally effective treatment. No product exist that completely stops the progression of the disease.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Approved
Dopamine Replacement Therapy for PD Motion Symptoms: levodopa/carbidopa</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Examples:&nbsp;<B>Sinemet,&nbsp;</B>Dhivy<B>,*&nbsp;</B>Duopa<B>,*&nbsp;</B>Inbrija<B>,*
Parcopa,&nbsp;</B>Rytary<B>*, Stalevo (levodopa/carbidopa and entacapone)</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Levodopa
was approved for Parkinson&rsquo;s in the late 1960s and is the most commonly prescribed drug for Parkinson&rsquo;s. It is absorbed in the intestine
and the brain converts it to dopamine, which is the brain chemical that powers normal movement but decreases in Parkinson&rsquo;s disease (PD).</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carbidopa
prevents levodopa from turning into dopamine before it gets to the brain and limits levodopa&rsquo;s side effects, such as nausea and vomiting.
In the United States, the combination of immediate-release levodopa and carbidopa is commonly referred to by the brand name Sinemet.
A controlled-release form also is available, as is a capsule (Rytary) that combines both immediate and extended-release levodopa in one.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Levodopa/carbidopa
can be taken alone or with other Parkinson&rsquo;s medications. It comes in a pill, a dissolvable tablet (Parcopa) and a gel (Duopa). The gel
is infused directly into the small intestine, where levodopa is absorbed.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pros</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the majority of patients, especially people with mild symptoms, levodopa significantly improves motor symptoms. Typically, the medication
remains effective as long as you need it, but since Parkinson&rsquo;s symptoms gradually progress over time, you may need to increase your
dose or change how often you take it.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cons
and Complications</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
first starting levodopa, the most common potential side effects are nausea and vomiting. If these occur, doctors usually recommend taking
the medication with a small carbohydrate snack, such as crackers or toast, or adding extra carbidopa (Lodosyn). Other possible side effects
include drowsiness, low blood pressure (which can cause lightheadedness or dizziness) or hallucinations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Competitive
Advantages</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that we are positioned to outperform competitors for the following reasons:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe that the focus on a new product based
on resveratrol with higher bioavailability, JOTROL, will enable us to utilize the same product for several indications, subject
to FDA&rsquo;s approval. We believe that this enables us to have several opportunities to obtain a regulatory approval in case we are
able to show efficacy and safety acceptable to regulatory agencies for one or more of our targeted indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> JOTROL is an oral product based on a natural
compound. Oral delivery of medications is a physician and patient preferred treatment compared with injections and infusions and we
expect that our product will have an attractive and affordable price point for reimbursors and patients. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are building a close relationship with Key
Opinion Leaders (KOL&rsquo;s) and patient organizations to facilitate a better understanding of patient needs and thereby design trials
targeting solutions to those needs as long as these targets are acceptable to the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The natural product resveratrol is well studied with
over 14,000 scientific publications to date. Published scientific papers, such as AY Berman.et al, indicate that a highly bioavailable
product generating less GI side effects may have application in a number of indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 115; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Based upon available scientific literature, it
appears that resveratrol is an activator of SIRT1, one of the mammalian forms of the sirtuin family of proteins. SIRT1 deacetylates histones
and nonhistone proteins including transcription factors. The SIRT1-regulated pathway affects metabolism, stress resistance, cell survival,
cellular senescence, inflammation/immune function, endothelial functions, and circadian rhythms. Resveratrol has been documented in scientific
literature to activate SIRT1, NrF2, NLR3P inflammasomes and have an epigenetic mechanism and therefore is predicted to benefit diseases
affected by abnormal metabolic control, inflammation, and cell cycle defects. Nonetheless, resveratrol application is a major challenge
for the pharmaceutical industry, due to its poor solubility and bioavailability, as well as adverse effects, such as severe gastro-intestinal
side effects when taken at effective dose levels (over 2,000 mg daily). In this context, studies have proposed that structural changes
in the resveratrol molecule, including glycosylation, alkylation, halogenation, hydroxylation, methylation, and prenylation could lead
to the development of derivatives with enhanced bioavailability and pharmacological activity. Resveratrol has never been developed with
all the necessary steps to achieve an approval as a pharmaceutical product since the existing natural supplements cannot provide high
enough levels of resveratrol in blood plasma to be able to provide a therapeutically effective dose without generating severe gastro-intestinal
side effects. This means that we need to take JOTROL through the full regulatory NDA (New Drug Application) requirement to obtain
a marketing approval. We were able to receive, through a confidential agreement from a major pharmaceutical company, a chronic toxicology
study performed with resveratrol, in two different species, that was referenced in our approved Phase I IND application submitted to
the FDA. The study was conducted by Charles River Laboratories.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Possible
out-licensing for Asian markets is being considered as it may reduce risk and cost of product development in those markets that requires
confirming trials in an Asian population, while generating income through milestones and royalty agreements, see &ldquo;Recent Developments&rdquo;
regarding further developments and strategy in the Asian market. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Marketing
and Commercialization Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently have no plans to implement the commercialization
of our product JOTROL but expect to either out-license JOTROL to one or more companies that has such commercialization capability in
place. We may consider at any time a complete exit through any proposed acquisition of our company. In case no acceptable M&amp;A offer
is presented we might consider marketing and distributing JOTROL in the USA for the rare disease market only and have companies
with large sales organizations distribute our product for the larger indications. All international distributions will most likely be
out licensed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The marketing and sales of orphan drugs can be
relatively fast and effective. We believe, based on discussions with organizations such as the EveryLife Foundation an approval of a drug for a rare disease is efficiently communicated through social media to Key Opinion Leaders
(KOL), patient advocacy groups and directly to patients, which may reduce marketing costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are already using information regarding our
development progress through KOL&rsquo;s and the respective patient organizations that exist for each indication.  We have also initiated a collaboration with several patient organizations such as the FARA
organization, www.curefa.org, the National MPS Society, UMDF, www.umdf.org, and the EveryLife Foundation in USA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have been approached by several large and mid-size
pharmaceutical companies discussing future collaborations once we have more clinical data available. We will try to utilize
this interest by out-licensing primarily the Asian territories while waiting to conduct out-licensing in USA and Europe until after Phase
II results are obtained.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have participated in several industry trade shows, such as Biotech Showcase, BIO USA, LSX World, World Orphan Congress, World Symposium
for LSD, BIO Hong Kong 2023 and many others. We plan to continue to participate in those conferences as well as, post IPO, conferences
targeting presentations by publicly traded companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Operation
and Organization</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are, and plan to stay, primarily a virtual organization utilizing partnership arrangements for certain functions including but not limited
to our R&amp;D, clinical trial work, regulatory affairs and product manufacturing. A core organization is in place and will be expanded
handling Strategy, Project Management, Clinical trial Management, Regulatory Affairs, Finance and Business Development. We believe that
our core management team structure has proven experience in utilizing outside resources which allows us to efficiently execute several
programs simultaneously in what we believe to be a very cost-effective way.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 116; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<!-- Field: Split-Segment; Name: Sp_001 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is an organization chart representing the key staff and planned additions to be employed in the near term (* mark part-time consultants).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="forms1-a_025.jpg" ALT="" STYLE="height: 424px; width: 670px"><FONT STYLE="font-size: 10pt"></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NIA Supplemental Grant Funding</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December of 2021 the Company submitted
a grant for supplemental funding of $233,281 of our Phase I study due to unanticipated costs, mostly due to COVID-19. We received and
were awarded this grant on April 7, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>Senior Secured Note</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On April
11, 2022, the Company entered into a securities purchase agreement (the &ldquo;Purchase Agreement&rdquo;) with an accredited investor
for the sale of the Company&rsquo;s convertible notes. Pursuant to the terms of the Purchase Agreement, on April 11, 2022, the Company
received aggregate gross proceeds of $1,000,000 and issued (i) a 10% Original Issue Discount Senior Secured Convertible Note in the principal
amount of $1,111,111.11 (the &ldquo;Note&rdquo;) and (ii) 514,403  shares of common stock, par value $0.0001
per share (the &ldquo;Shares&rdquo;), of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><B><I>The
Note</I></B>. The aggregate principal amount of the Note is $1,111,111.11, and the Company received gross proceeds of $1,000,000 after
giving effect to the original issue discount of 10%. The Note bears interest at a rate of 10% per year, payable monthly in arrears, and
mature 12 months from issuance. A &ldquo;Qualified Offering&rdquo; is a debt or equity financing for the account of the Company or any
of its subsidiaries in which shares of common stock, or securities, directly or indirectly, convertible into or exchangeable or exercisable
for shares of common stock are issued, which financing results in cumulative aggregate proceeds to the Company of at least $8,000,000.
The principal and interest on the Note will be amortized on a straight-line basis at 110% of the principal amount commencing sixth
months after the closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Upon
an Event of Default and after a Qualified Offering, the principal and interest are convertible at any time at the option of the holder
into shares of the Company&rsquo;s common stock at a conversion price equal to 30% discount to the lowest closing price of the common
stock for the 20 prior trading days; provided, however, <FONT STYLE="background-color: white">the holder will not have the right to
convert any portion of the Note, to the extent that after giving effect to the conversion, the holder, together with its affiliates,
would beneficially own in excess of 4.99% of the number of shares of the Company&rsquo;s common stock outstanding immediately after giving
effect to its conversion. The holder may increase or decrease its ownership limitation to any percentage not exceeding 9.99% upon 61
days prior written notice to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Company will have the right at any time to redeem in cash all or a portion of the Note at 120% (or 125% on or after the first six months
from the closing; provided, however, if interest due and payable on January 31, 2023 is not paid in full, 130% on or after the first
six months from the closing) of the principal amount thereof plus any unpaid accrued interest to the date of repayment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Company will be required to offer to prepay in cash the aggregate principal amount of the Note at 120% (or 125% on or after the first
six months from the closing; provided, however, if interest due and payable on January 31, 2023 is not paid in full, 130% on or after
the first six months from the closing) of the principal amount thereof plus any unpaid accrued interest to the date of repayment, on
the sale of all or substantially all of the assets of the Company and its subsidiaries, upon a Change of Control (as defined in the Note),
or on a Qualified Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Upon
an Event of Default (as defined therein) interest shall accrue at 1 1/2% per month and the 125% (or 130% if interest due and payable
on January 31, 2023 is not paid in full) of principal and interest through maturity shall be due and payable. At the holder&rsquo;s
option the holder shall be entitled to be paid in cash or after the Qualified Offering (as defined in the Purchase Agreement) common
stock with the conversion price of the common stock equal to a 30% discount to the lowest closing price of the common stock for the 20
prior trading days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 10, 2022, the Note was amended to postpone the commencement of the amortization amount from October 11, 2022 to November 11,
2022. On November 10, 2022, the Note was amended to postpone the commencement of the amortization from November 11, 2022 to February
11, 2023 and payable in three monthly installments. As consideration for the amendment, an additional 11,431 shares of common stock were
issued to the accredited investor on October 10, 2022 and 34,293 shares issued to the accredited investor on November 10, 2022. On January
13, 2023, the Note was amended to delay the interest payment due and payable on January 11, 2023 to the earlier of (i) January 31, 2023
and (ii) the closing of a Qualified Offering.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.5in; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 6, 2023, the Note was amended to postpone the commencement of the principle to February 28, 2023. On March 6, 2023, the Note
was amended to postpone the commencement of the principal from February 11, 2023 to May 31, 2023. The Company and the note holder agreed
to a repayment plan on past due interest. In addition, the Company agreed to prepay in cash the aggregate principal amount of the Note
of 120% (or 137.5% on or after the first six months from closing) plus any accrued interest on the sale of all the assets of the Company
and its subsidiaries, upon the Change of Control, or on a Qualified Offering. Upon default of the Note the Company agrees to pay 137.5%
of the outstanding note principal, and accrued interest through maturity and all liquidation damages. As a result of the material modification,
the incremental fair value of the modified derivative was classified as a debt extinguishment. Due to the extension of the maturity date
of the convertible note, the fair value of the derivative liability increased. This resulted in the Company recording a loss on extinguishment
of debt of $670,419.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.5in; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 22, 2023, the Note was amended to postpone the commencement of the principle to December 31, 2023. The Company and the note
holder agreed to a repayment plan on past due interest. In addition, the Company agreed to prepay in cash the aggregate principal amount
of the Note of 120% (or 150% on or after the first six months from closing) plus any accrued interest on the sale of all the assets of
the Company and its subsidiaries, upon the Change of Control, or on a Qualified Offering. Upon default of the Note the Company agrees
to pay 150% of the outstanding note principal, and accrued interest through maturity and all liquidation damages. In addition, upon closing
the Note holder will receive 175% stock coverage. As a result of the material modification, the incremental fair value of the modified
derivative was classified as a debt extinguishment. Due to the extension of the maturity date of the convertible note, the fair value
of the derivative liability increased. This resulted in the Company recording a loss on extinguishment of debt of $217,527.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B><I>The Shares</I></B>. In
connection with the issuance of the Note, the Company issued 514,403  shares of Common Stock to the holder with a fair market
value of $2.16  per share (aggregate value of $1,111,111) as additional consideration for the holder len<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ding
$1,000,000 to the Company. The 514,403  shares have a relatively fair value of $310,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Purchase Agreement related to the Note was amended to provide that upon closing, the purchaser will receive 175% coverage (i.e.
the face amount of the Note, i.e., $1,111,111.11 divided by the lesser of (i) the price/share of the last issuance of solely common stock
(including options) of the Company, i.e., $5.00/share or (ii) the price per share of common stock (or if units are issued in the Qualified
Offering, the price of units sold in the Qualified Offering), in shares of common stock of the Company (or if units are issued in the
Qualified Offering, units). The number of shares to be received at closing shall be determined by using clause (i) above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
light of the foregoing, the holder shall receive an additional number of shares of common stock, such that it shall have received the
number of shares of common stock of the aggregate value of $1,111,111 divided by the lesser of (i) the price/share of the last issuance
of solely common stock (including options) of the Company, i.e., $5.00/share or (ii) the price per share of common stock (or if units
are issued in the Qualified Offering, the price of units sold in the Qualified Offering), in shares of common stock of the Company (or
if units are issued in the Qualified Offering, units) (&ldquo;Share True Up&rdquo;). The True-Up Shares have been forfeited as a result
of the April 29, 2024 agreement. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><B><I>Ancillary
Agreements</I></B>. In connection with the Company&rsquo;s obligations under the Note, the Company entered into a security agreement
and intellectual property security agreement with the holder, pursuant to which the Company granted a security interest on all assets
of the Company, including all intellectual property of the Company, for the benefit of the holders, to secure the Company&rsquo;s obligations
under the Note and the other transaction documents. In addition, the holder was granted piggyback registration rights for the shares
of common stock issued under the Purchase Agreement and shares of common stock issuable upon conversion of the Note (collectively,
&ldquo;Registrable Securities&rdquo;). At any time while there are any Registrable Securities of holder outstanding, if the Company proposes
to register any of its securities either for its own account or for the account of other security holders (other than a registration
statement relating solely to employee benefit plans on Form S-8 or a Commission Rule 145 transaction on Form S-4), the holder is entitled
to include its Registrable Securities in the registration. Notwithstanding, the Company and underwriters in an underwritten registration
may exclude some or all of the Registrable Securities from the underwritten registration if the underwriters believe that including the
Registrable Securities would adversely affect the underwritten offering.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">At
any time within the 12 months closing, upon any issuance by the Company or any of its subsidiaries of debt or common stock or common
stock equivalents for cash consideration, indebtedness or a combination of units thereof, other than in an underwritten public
offering (a &ldquo;Subsequent Financing&rdquo;), the investor will have the right to participate up to its investment amount in the Note,
but not more than 25% of the Subsequent Financing, on the same terms, conditions and price provided for in the Subsequent Financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Until the Company has consummated
a Qualified Offering which results in a listing of the Common Stock onto a national securities exchange, if the Company engages in any
future financing transactions with a third-party investor, if the holder determines that the terms of the subsequent investment are preferable
in any respect to the terms of the securities of the Company issued to the Holder pursuant to the terms of the Purchase Agreement, the
holder will have the right to amend and restate such securities to include the preferable term or terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The descriptions of the Securities
Purchase Agreement, the Note, the Security Agreement, and the Intellectual Property Security Agreement as set forth above is qualified
in their entirety to the full Securities Purchase Agreement, the Note, the Security Agreement, and the Intellectual Property Security
Agreement as attached as Exhibits 10.25, 10.26, 10.27, and 10.28 to the registration statement of which this prospectus
forms a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Research Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">On July 1, 2022, the Company entered into a research
agreement with the University of Miami to conduct a preclinical study to evaluate the effect of JOTROL in Parkinson&rsquo;s Disease models.
The cost of the research agreement activities, to be paid by the Company, is $72,844. Jupiter Neurosciences owns any intellectual property
generated from the research. The agreement is for 1 year from the start date, July 1, 2022. Either the Company or University of Miami
may terminate this agreement upon thirty (30) days written notice for any reason. In the event of such termination, both the Company
and University of Miami shall take all reasonable steps to cancel further costs in connection with this agreement. The Company and University
of Miami will be entitled to reimbursement for costs and non-cancelable obligations incurred prior to effective day of the termination,
not to exceed the total amount of the project. The description of the foregoing agreement as set forth above is qualified in its entirety
to the full agreement as attached as Exhibit 10.29 to the registration statement of which this prospectus forms a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amendment
to Stock Options Awards</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 14, 2022, ten stock option awards were amended to reduce the exercise price of the option awards from $2.16 to $1.33  per share, pursuant to a Board of Directors&rsquo; resolution. Pursuant to the resolution, $5.00 per share was identified
as the fair market value of the Company&rsquo;s common stock when considering recent market conditions and evaluating historical purchases
of common stock for cash.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Increase
in Reserved Shares under 2021 Equity Incentive Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 19, 2022, the Board of Directors executed a Unanimous Written Consent to increase the 2021 Equity Incentive Plan from a pool of
1,125,000  shares to a pool of 1,710,000  shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Restricted
Stock Awards for Salary Forgiveness</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 21, 2022, the Board of Directors executed a Unanimous Written Consent relating to the forgiveness of $1,556,010 of accrued salaries
for executives and two consultants. Subsequently, each executive and consultant executed a Debt Forgiveness and Release Agreement with
the Company. In consideration for the salary forgiveness, the Company awarded restricted stock awards with a fair market value of $1.33
 per share, totaling 1,167,011  shares. The restricted stock awards vest 100% on the first business
day following the expiration of a lock-up period after the Company&rsquo;s common stock is listed for trading on NASDAQ, NYSE, or NYSE
American.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 29, 2023, the Board of Directors executed a Unanimous Written Consent relating to the forgiveness of accrued compensation for
executives, consultants, and board members in the amount of $4,189,626. In exchange for the forgiveness of the accrued compensation the
Company agreed to a cash bonus of $583,214 to be paid upon the occurrence of a successful IPO. In addition, the Company agreed to issue
an aggregate of 2,353,665 stock options with an exercise price of $1.33 and an aggregate of 1,399,833 restricted stock units with a grant date value of $1.33 in exchange for the aggregate forgiveness
of compensation in the amount of $4,189,626.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 18, 2023, the Board of Directors executed a Unanimous Written Consent relating to the forgiveness of the $583,214 cash bonus
granted in the September 29, 2023 forgiveness in exchange for 338,899 stock options with an exercise price of $1.33 and an aggregate of 226,203 restricted stock units with a grant date value of $1.33.</FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B>Amendments to Convertible Promissory Notes</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
January 2024, the Company and all Note holders agreed to amend and extend the maturity date of their notes to December 31, 2024. The
holders waived any default under the original notes prior to the amendment date. With the amendments the applicable interest rate increased to 10% effective from January 1, 2024.</FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 117; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recent
Developments</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Asian
Business Development Activities</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Chairman &amp; CEO, Christer Ros&eacute;n, presented in person, our company&rsquo;s status and pipeline at the BIOHK 2023 in Hong
Kong in September of 2023. The presentation led to several follow-on meetings, and we have recently agreed to service agreements in
the areas of CMC (Chemistry, Manufacturing, and Controls), regulatory affairs and clinical trial management. These agreements are
with companies that, we believe, have the knowledge and network in the South-East Asian market. The agreements are further described
in the section &ldquo;Other Material Agreements&rdquo;. In addition, we are in active negotiations with Dominant Treasure Health
(&ldquo;DTH&rdquo;), a BVI company. DTH has demonstrated to us, through several company introductions, that they have business
relationships, either directly or through affiliates, with many South-East Asian
pharmaceutical companies as well as companies involved in distribution and sales of TCM, Traditional Chinese Medicine. We are
therefore planning to engage DTH in active business development in China, Malaysia and Singapore as soon as we have financing in
place for their engagement. DTH has already introduced us to 3 Chinese companies, Beimei Pharma, http://en.beimeiyaoye.com, that
specializes in pediatric medications, Sichuan Kelun Pharmaceutical Co., ltd, a publicly traded company that is part of the Kelun
Industrial Group, https://www.kelun.com/, and Tianjin Pharmaceuticals, https://en.pharm.com.cn/, that advocates the corporate core
values of &ldquo;Love, Integrity and Power&rdquo;. TCM products are run in a separate division within Tianjin. Discussions with all
three companies are ongoing. We believe that with DTH&rsquo;s assistance we can co-ordinate and oversee the work of our Service
providers in the territory and more expediently negotiate and finalize an out-license agreement with one or more pharmaceutical
companies in South-East Asia. The Asian market is very large and hard to penetrate for a small company and we believe that our
strategy with these agreements have the possibility to accelerate an out-licensing deal in the South-East Asian territories.
However, there are no assurances that this approach will be successful.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
rationale for the strong approach into the South-East Asian market is:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Background:
Asian countries are not accepting pharmaceutical products to be sold without clinical trial approvals based on trials conducted in an
Asian population</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company&rsquo;s strategy is to partner with organizations in the territory that can execute
                                            much more efficiently than trying to manage the process from USA.</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            have already received interest for our JOTROL product in the Asian market since resveratrol
                                            is listed as a Traditional Chinese Medicine.</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            need for a set up that can service this market is imperative for success.</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strategic
                                            collaboration agreements have been executed to facilitate an expedited execution of an out-licensing
                                            agreement with one or more Chinese or other SE Asian pharmaceutical companies.</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company is too small, both financially as well as internal manpower, to manage developments
                                            in the territory. </FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company has a history of poor financial status and not being able to fulfill commitments
                                            and finalize clinical studies.</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
                                            utilizing equity as service payments, the company believes that it can get projects finalized
                                            without any significant cash outflow. </FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            service agreements are therefore designed to be a win for both parties, assuming an increase
                                            in equity value, in case clinical studies and out-licensing activities will be successful
                                            in the territory. </FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Amendments
to</I></B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I> Senior Secured Convertible Note
&ndash; Postpone Commencement of Amortization Amount</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 29, 2024, the Company, the Holder of the Note II and the CEO entered into an amendment in which the CEO agrees to exchange 182,898
shares issued to the Holder in exchange for his related party notes that accrued interest at 3% that are due from the Company in an aggregate
principal amount of $266,667 and the Holder agreed to forfeit all rights to all additional future shares from the Company that would
of become due upon a qualified offering. In addition, the Holder agreed to extend the note maturity date to August 11, 2024. The note
shall be designated as a 10% original issued discount secured note (&ldquo;Senior Secured Note&rdquo;) moving forward. The note and interest
will become due and payable upon the earliest of the maturity date or upon the occurrence of a qualified event.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
descriptions of the Amendments as set forth above are qualified in their entirety to the full Amendment and subsequent Amendments
as attached as Exhibits 10.31 and 10.32 to the registration statement of which this prospectus forms a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>Elimination of Derivative Liability</I></B> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 29, 2024, the Company, the senior secured note investor, and the CEO entered into an amendment in which the CEO agreed to exchange
685,867 shares issued to the Holder in exchange for his related party notes that accrued interest at 3% that are due from the Company
in an aggregate principal amount of $266,667 and the Holder agreed to forfeit all rights to all additional future shares from the Company
that would of become due upon a qualified offering and the convertible feature of the note, resulting in a reduction of derivative liabilities from $1,543,109 as of March 31, 2024 to approximately $905,000. In addition, the Holder agreed to extend
the note maturity date to August 11, 2024. The note shall be designated as a 10% original issued discount secured note (&ldquo;Senior Secured
Note&rdquo;) moving forward. The note and interest will become due and payable upon the earliest of the maturity date or upon the occurrence
of a qualified event.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>Stock Issuances</I></B> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 3, 2024, the Company entered into a three 36-month service agreement with three different entities. Upon the closing of these
agreements, the Company issued an aggregate of 3,487,500 shares of common stock, 1,162,500 of shares of common stock for each entity
with a fair market value of $1.33 per share, for services to be rendered. The shares issued are free from any restriction as a pre-payment in full for the 36 months of services to be provided. The
aforementioned shares will be registered upon an IPO as long as an IPO happens no later than March 31, 2025. In addition, each of
the entities agreed to purchase 37,500 shares each of the Company&rsquo;s common stock at a price of $1.33 per share prior to the
occurrence of the IPO. Either party is able to terminate the respective agreement with no liability upon the occurrence of i) the
Company failing to raise at least $10 million in gross proceeds from an IPO prior to May 31, 2025, ii) if either party is involved
in any illegal activity or iii) at any time as long as both parties agree to it.</FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Legal
Proceedings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we are involved in various legal proceedings arising from the normal course of business activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white">On
July 19, 2022, Tiberend Strategic Advisors (&ldquo;Tiberend&rdquo;), an entity that the Company had previously engaged as a communications
and investor relations firm, filed a summons for civil action in the District Court of Southern Florida against the Company alleging
non-payment by the Company under a services agreement (the &ldquo;Services Agreement&rdquo;) with Tiberend in the amount of $130,400.
Additionally, Tiberend was seeking an $19,600 in legal fees. Tiberend and the Company elected to take this to arbitration
and at that time both parties agreed that Tiberend will be issued a convertible note of $150,000 that will be converted
into shares of the Company, immediately after an IPO is completed, based on the share value in an IPO. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white">Other
than the foregoing, we are not presently a party to any litigation the outcome of which, we believe, if determined adversely to us,
would individually or taken together have a material adverse effect on our business, operating results, cash flows or financial condition.
Defending such proceedings is costly and can impose a significant burden on management and employees. The results of any current or future
litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of
defense and settlement costs, diversion of management resources, and other factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Facilities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
corporate headquarters are located at 1001 North US Hwy 1, Suite 504, Jupiter, Florida 33477, where we lease approximately 1,206 rentable
square feet of office space. This lease expires on May 31, 2026. Terms of the office lease provide for a base rent payment of $3,783
per month and a share of the buildings operating expenses such as taxes and maintenance of $476 per month. In September 2021, we added
an additional office located at 127 Main Street, Boston, Massachusetts, 02129, for 120 rentable square feet of office space for our Boston
based employees and scientist to utilize as necessary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We believe that these facilities are adequate for our current and near-term future
needs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 60pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2024, we had a total of 4 full-time employees, 1 full-time consultant and 7 part-time consultants plus our 6 Scientific
Advisory Board members. Of these, 10 were primarily engaged in research or product development and clinical activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 118; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ar_007"></A>MANAGEMENT&rsquo;S
DISCUSSION AND ANALYSIS OF<BR>
FINANCIAL CONDITION AND RESULTS OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">References
in this prospectus to &ldquo;we,&rdquo; &ldquo;us&rdquo; or the &ldquo;Company&rdquo; refer to Jupiter Neurosciences, Inc. The following
discussion and analysis of the Company&rsquo;s financial condition and results of operations should be read in conjunction with the financial
statements and the notes thereto contained elsewhere in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Business
Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt; text-align: justify; text-indent: 0.5in">Jupiter Neurosciences, Inc.
(the &ldquo;Company&rdquo;) is a clinical stage research and development pharmaceutical company located in Jupiter, Florida. The Company
incorporated in Delaware in January 2016. The Company has developed a unique resveratrol platform product primarily targeting
treatment of neuro-inflammation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt; text-align: justify; text-indent: 0.5in">The product, called JOTROL,
has many potential indications of use for rare diseases, which of we primarily are targeting Mucopolysaccharidoses Type 1, Friedreich&rsquo;s
ataxia and MELAS. In the larger disease areas, we are primarily targeting Parkinson&rsquo;s Disease and Mild Cognitive
Impairment/early Alzheimer&rsquo;s disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has recently completed preclinical activities in a validated mouse model of Parkinson&rsquo;s Disease (PD) at the University
of Miami. The model of PD that was used mimics many aspects of the disease utilizing a unilateral injection of a neurotoxin
precursor that elicits nigral cell loss, striatal dopamine loss and behavior deficits similar to physiological characteristics of
human disease. We believe that results from this trial indicates that PD might be the best target for treatment among the multiple
indications where JOTROL<SUP></SUP> might play a role. The trial design and outcomes are further described section
&ldquo;Description of Business&rdquo;. On May 23, 2024 the US Senate unanimously passed the <B>National
Plan to End Parkinson&rsquo;s Act</B>, the first-ever federal legislation dedicated to ending Parkinson&rsquo;s disease. A cross-country
strategy to end Parkinson&rsquo;s and atypical parkinsonism has the potential to:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dramatically
    increase federal research funding; </FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Develop
    more effective pathways for treatments and cures; </FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Improve
    early diagnosis; </FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Spark
    new and improved models for patient care; </FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Create
    standards and measures to prevent Parkinson&rsquo;s disease; </FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
    health disparities in diagnosis, treatment and clinical trial participation and </FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enhance
    public awareness of the disease.</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to follow the various opportunities closely with a particular focus on seeking available funding to to accelerate research
and development JOTROL&rsquo;s Parkinson&rsquo;s Disease indication. However, there is no assurance that such funding will ever become
available or be awarded to the Company.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have over the past 2 years received a strong interest in JOTROL from various Asian organizations. We believe that this interest has been
triggered, in part, by (i) resveratrol becoming commonly used in Asian herbal medicines as a therapeutic strategy as described in available
scientific literature published by PubMed Central: PMCID: PMC7498443 (September 2020), (ii) Hong Kong&rsquo;s and China&rsquo;s recent
approval of the patent for JOTROL, (iii) China releasing a list of approximately 120 rare disease indications issued jointly by five
national bodies, including the National Health Commission, Ministry of Science and Technology, Ministry of Industry and Information Technology,
State Drug Administration, and State Administration of Traditional Chinese Medicine (May 2018), that we believe JOTROL can be applicable
as a treatment for MPS-1 and MELAS in this population and (iv) recent publications regarding JOTROL in the Journal of Alzheimer&rsquo;s
Disease and AAPS Open (Journal of Alzheimer&rsquo;s Disease 86 (2022) 173&ndash;190 February 2022; Kemper et al. AAPS Open June 2022).
(v) the projected increase of the TCM market due to several factors which of one is reformulation of existing compounds. Our Chairman
&amp; CEO, Christer Ros&eacute;n, presented in person, our company&rsquo;s status and pipeline at the BIOHK 2023 in Hong Kong in September
of 2023. The presentation led to several follow-on meetings, and we have therefore recently agreed to service agreements in the areas
of CMC (Chemistry, Manufacturing, and Controls), regulatory affairs and clinical trial management. These agreements are with companies
that, we believe, have the knowledge and network in the South-East Asian market to accelerate steps that is needed to have
a product that can have treatment value in the territory. In addition, we are planning to use some of the IPO proceeds to engage a partner
in business development in the South-East Asian market since we believe that this will increase the potential of an out-licensing deal
within the near future. The agreements are further described in the section &ldquo;Other Material Agreements&rdquo;. In addition, we are in active negotiations with Dominant Treasure Health
(&ldquo;DTH&rdquo;), a BVI company. DTH has demonstrated to us, through several company introductions, that they have business relationships, either directly or through affiliates, with many South-East Asian pharmaceutical
companies as well as companies involved in distribution and sales of TCM, Traditional Chinese Medicine. We are therefore planning to engage
DTH in active business development in China, Malaysia and Singapore as soon as we have financing in place for their engagement. DTH has
already introduced us to 3 Chinese companies, Beimei Pharma, http://en.beimeiyaoye.com, that specializes in pediatric medications, Sichuan
Kelun Pharmaceutical Co., ltd, a publicly traded company that is part of the Kelun Industrial Group, https://www.kelun.com/, and Tianjin
Pharmaceuticals, https://en.pharm.com.cn/, that advocates the corporate core values of &ldquo;Love, Integrity and Power&rdquo;. TCM products
are run in a separate division within Tianjin. Discussions with all three companies are ongoing. We believe that with DTH&rsquo;s assistance
we can co-ordinate and oversee the work of our Service providers in the territory and more expediently negotiate and finalize an out-license
agreement with one or more pharmaceutical companies in South-East Asia. The Asian market
is very large and hard to penetrate for a small company and we believe that our strategy with these agreements have the possibility to accelerate an out-licensing deal in the South-East Asian territories. However, there are no
assurances that this approach will be successful.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 119; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt; text-align: justify; text-indent: 0.5in">We believe that a high dose
of resveratrol is needed for therapeutic effects. Currently available resveratrol products are associated with severe gastrointestinal
(GI) side effects at the dose levels we believe are needed. Our belief is based on available scientific literature, preclinical trial
results conducted in mice and rats, and previously conducted human trials with resveratrol. We believe that JOTROL, based on the results
from our Phase I trial, see section &ldquo;Description of Business&rdquo;, has the potential to deliver a therapeutically effective dose
of resveratrol in the blood stream without causing gastrointestinal (GI) side effects. Based on our pre-clinical and Phase I study results,
we expect that JOTROL will resolve &ldquo;the major obstacle of resveratrol&rsquo;s poor bioavailability&rdquo; as discussed in
AY Berman&rsquo;s summary article in the Journal of Precision Oncology (AY Berman, 2017). Based on our own preclinical studies we believe
that resveratrol has the ability to cross the blood-brain barrier. In studies conducted in Friedreich&rsquo;s ataxia (FA) and
Alzheimer&rsquo;s disease (AD) patients, resulted in positive effects on oxidative stress, inflammation, and mitochondrial function.
The FA study was concluded in Australia by Murdoch Children&rsquo;s Research Institute in 2015 (Yiu et al.). The AD study was conducted
in 2015 by the Alzheimer&rsquo;s Disease Cooperative Study with Professor Raymond Turner, MD, Ph.D., Georgetown, as principal investigator
(Turner et al.). Both studies have been published in scientific journals and further described in the section &ldquo;Description of Business&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt; text-align: justify; text-indent: 0.5in">In 2020, we received
approval for full funding, $1.76 million, for our Phase I study from the National Institute on Aging (&ldquo;NIA&rdquo;). Since
there were unanticipated higher costs, mostly due to Covid-19 related additional procedures during the Phase I trial, a supplemental
grant of $233,281 was submitted to the NIA in December of 2021. We were awarded the supplemental grant on April 7, 2022. In the NIA
scientific review summary statement of our Phase I study application, it is stated that the NIA is looking forward to a Phase
II study with an enhanced resveratrol product, based on the earlier study results from the well published Turner et al.
Alzheimer&rsquo;s study. In April 2021, we submitted our first grant application to the NIA for full funding of a
Phase II trial in Mild Cognitive Impairment (MCI) and early Alzheimer&rsquo;s disease. The Phase II trial was designed to
focus on 3 areas: 1) safety and tolerability; 2) pharmacokinetics and pharmacodynamics, measuring of responses from 2 different
doses vs. placebo; and 3) measuring of effect on multiple biomarkers related to the disease The application was not accepted but
we were encouraged by the NIA to refine our application and submit again. We have since submitted 3 grant applications, with budgets
of $20 million or higher, to the NIA for full funding of such Phase II trial but none of those applications were successful. The NIA
scientific review of our Alzheimer&rsquo;s Phase II trial grant application, which is attached as Exhibit 10.38 to the registration
statement of which this prospectus forms a part, shows a total score of 47 which is our best score so far. A score of 40 or below is
necessary for being considered for funding. After discussions with the NIA, we have decided to apply, in September of 2024, for a
much smaller grant, $2.5 million, for a Proof of Concept study focusing on JOTROL&rsquo;s effect on validated biomarker. The final
study design is not yet determined but a draft synopsis is described in the section &ldquo;Description of Business&rdquo;.
There is no guarantee that this and future grant applications will be successful and therefore the rejection of our future grant
application may significantly delay the Company&rsquo;s plans in connection with MCI and Alzheimer&rsquo;s and may have a
significant impact on the Company&rsquo;s financial performance. Further, the Company may never receive any future grants or costs
savings. The Company continues to apply for grants opportunistically and on August 12, 2022, submitted a $10.1 million grant to the
Department of Defense for a Phase II Friedreich&rsquo;s Ataxia study. This study planned to assess the efficacy of JOTROL as
a potential treatment for FA through a randomized, blinded, placebo-controlled clinical trial. On December 30 the Company received
notification that the application was not recommended for funding. The grounds for denial were the weaknesses noted in the peer
review summary statement, attached as Exhibit 10.34 to the registration statement of which this prospectus forms a part,
specifically concerning clinical impact and research strategy and feasibility. Reata Pharmaceuticals has recently received an
approval for their product, Omaveloxolone, for treatment of Friedreich&rsquo;s ataxia. After the FDA approval was achieved by Reata,
Biogen announced that it has agreed to purchase Reata for $7.3 billion in cash. The approval of Omaveloxolone will make it hard to
find patients for a FA clinical study in USA and therefore we have decided to explore the possibility of conducting a Phase II trial
in Europe and/or Australia. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
inception, we have operated with limited human capital, utilizing agreements with academia to get pre-clinical work executed at no cost,
negotiating favorable deals for data already produced for resveratrol (e.g. toxicity studies and Phase II clinical study data), obtaining
a full grant from the NIA for our first clinical trial and building a management and scientific consulting team (consisting of
the Scientific Advisory Board and business advisors) as well as negotiating service agreements with companies to handle CMC, Regulatory
work and Clinical trials in South-East Asia primarily compensated with equity securities of the company. We believe that this compensation
method aligns the management, Scientific Advisory Board members and business advisors&rsquo; interests with the shareholders. We believe
that our structure with a core management team that has experience in the utilization of outside resources makes it possible for us to
efficiently execute several programs simultaneously in a cost-effective way.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 120; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Resveratrol</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Resveratrol has been studied
for over 50 years by academic institutions as well as by small and large pharmaceutical companies. The multi-functional mechanisms
of resveratrol are well documented in over 9,000 scientific publications. Several of these publications, including a summary
paper by AY Berman.et al, published in Precision Oncology 2017, point to the issue of the poor bioavailability that has stopped
medical utilization of regular resveratrol and never received regulatory approval for any indication. We believe that the Phase
I study we have conducted indicates that we have resolved the poor bioavailability issue with JOTROL. Resveratrol (3,4&prime;,5-
trihydroxystilbene) is a nutraceutical that has recently attracted a lot of research attention due to its pharmacological potential.
It is a phytoalexin found in many plants including grapes, peanuts, and berries. Resveratrol was first isolated in Veratrum grandiflorum,
or white hellebore plant, in the 1940&rsquo;s. Stilbene compounds are known for their ability to provide plants with resistance to microbial
and fungal infection. Early research showed that resveratrol was present in large quantities in injured, infected, and ultraviolet-treated
leaves. Processed plant products also contain a significant amount of resveratrol.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Based upon available scientific
literature, it appears that resveratrol is an activator of SIRT1, one of the mammalian forms of the sirtuin family of proteins. SIRT1
deacetylates histones and nonhistone proteins including transcription factors. The SIRT1-regulated pathway affects metabolism, stress
resistance, cell survival, cellular senescence, inflammation/immune function, endothelial functions, and circadian rhythms. Resveratrol
has been documented in scientific literature to activate SIRT1, NrF2, NLR3P inflammasomes and have an epigenetic mechanism and therefore
is predicted to benefit diseases affected by abnormal metabolic control, inflammation, and cell cycle defects. Nonetheless, resveratrol
application is a major challenge for the pharmaceutical industry, due to its poor solubility and bioavailability, as well as adverse
effects, such as severe gastro-intestinal side effects when taken at effective dose levels (over 2,000 mg daily). In this context, studies
have proposed that structural changes in the resveratrol molecule, including glycosylation, alkylation, halogenation, hydroxylation,
methylation, and prenylation could lead to the development of derivatives with enhanced bioavailability and pharmacological activity.
Resveratrol has never been developed with all the necessary steps to achieve an approval as a pharmaceutical product since the existing
natural supplements cannot provide high enough levels of resveratrol in blood plasma to be able to provide a therapeutically effective
dose without generating severe gastro-intestinal side effects. This means that we need to take JOTROL&trade; through the full regulatory
NDA (New Drug Application) requirement to obtain a prescription marketing approval in the USA. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Resveratrol
holds a significant place in Traditional Chinese Medicine (TCM) due to its potent antioxidant and anti-inflammatory properties. In TCM,
resveratrol-rich plants, such as the root of Polygonum cuspidatum (commonly known as Hu Zhang), have been used for centuries to treat
a variety of ailments. The compound is prized for its ability to combat oxidative stress and inflammation, which are underlying factors
in many chronic diseases. This aligns with the TCM principle of restoring balance and harmony within the body to maintain health and
prevent disease. Resveratrol&rsquo;s role in TCM extends to supporting cardiovascular health, boosting immune function, and even exhibiting
anti-aging properties, making it a versatile and valuable component of the medicinal repertoire.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
growing body of scientific research on resveratrol has further cemented its importance in TCM by providing a modern understanding of
its mechanisms and potential therapeutic benefits. Studies have shown that resveratrol can modulate various molecular pathways, including
those involved in cell survival, apoptosis, and inflammation, which are crucial in the management of conditions such as cardiovascular
diseases, neurodegenerative disorders, and cancers. This scientific validation supports TCM practitioners in integrating resveratrol
into their treatment protocols, enhancing the credibility and acceptance of traditional remedies. Additionally, the compound&rsquo;s ability
to improve metabolic health and its neuroprotective effects are particularly relevant in addressing the rising prevalence of metabolic
syndrome and cognitive decline in aging populations. As research continues to unveil the full spectrum of resveratrol&rsquo;s benefits, its
integration into TCM practices is likely to increase, further bridging the gap between ancient wisdom and contemporary medicine.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> </P>

<!-- Field: Page; Sequence: 121; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Traditional Chinese Medicine (TCM) market is experiencing several technological trends that are transforming how traditional remedies
are developed, delivered, and integrated with modern healthcare practices. These advancements are helping to increase the efficacy, accessibility,
and acceptance of TCM. Below are some of the key technological trends in the TCM market:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Digital
                                            platforms and telemedicine services allow patients to consult with TCM practitioners remotely,
                                            expanding access to TCM treatments. </FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Apps
                                            are being developed to help users track their health metrics, manage their treatment plans,
                                            and access personalized TCM advice. </FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k.</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Using
                                            advanced extraction techniques to concentrate active ingredients from traditional herbs,
                                            resulting in more potent and consistent products. </FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Development
                                            of new delivery methods such as transdermal patches, sustained-release capsules, and nanoparticles
                                            to enhance the bioavailability and efficacy of TCM products. </FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(source
Emergn Research, Global TCM Market, Forecast to 2033).</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JOTROL</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">JOTROL was developed together
with our technology partner Aquanova AG, Darmstadt, Germany. JOTROL is formulated with a unique patented micellar technology
that is projected to increase the bioavailability profile of resveratrol. Manufacturing technology transfers were completed in 2017 and
manufacturing procedures and clinical trial supply manufacturing has been completed at Catalent Pharmaceutical Services, Inc., St Petersburg,
Florida.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">JOTROL is a micellar non-aqueous
solution of resveratrol delivered in a softgel capsule. Each capsule includes 100mg of resveratrol. Pre-clinical trials in mice and rats
were conducted comparing JOTROL to micronized resveratrol, labeled to have the highest bioavailability in the nutritional market,
to demonstrate that we could achieve a significantly higher bioavailability. Summary details of these studies are included in the section
&ldquo;Description of Business&rdquo;. A Phase I dose finding pharmacokinetic (&ldquo;PK&rdquo;) study in healthy volunteers was completed
during the first half of 2021. The study results met our targeted goals. The results from this study will be used as a cross-reference
for all indications where JOTROL will be used in Phase II and Phase III clinical trials. The Phase I results and the FDA guidance
of cross-referencing is further described in the section &ldquo;Description of Business&rdquo;. The Company has not discussed the use
of cross-referencing in this manner with the FDA or other comparable regulatory authorities.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial
Position</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 60pt">For the fiscal years ended December
31, 2023 and 2022, we generated no revenues from product sales and reported net losses of $4,783,689 and $4,957,580
respectively, and negative cash flow from operating activities of $480,953 and $1,248,504, respectively. For the three
months ended March 31, 2024 and 2023, we generated no revenues from product sales and reported net losses of $637,100
and $1,747,250, respectively, and negative cash flow from operating activities of $65,165 and $98,687,
respectively. As noted in our financial statements, as of March 31, 2024, we had an accumulated deficit of $24,216,604.
There is substantial doubt regarding our ability to continue as a going concern as a result of our historical recurring losses and
negative cash flows from operations as well as our dependence on private equity and financings. See &ldquo;Risk Factors&mdash;We have
a history of operating losses, our management has concluded that factors raise substantial doubt about our ability to continue as a going
concern and our auditor has included an explanatory paragraph relating to our ability to continue as a going concern in its audit report
for the fiscal years ended December 31, 2023 and 2022. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 60pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 122; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results
of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>Three</I></B> <B><I> Months Ended March
31, 2024 Compared to Three Months Ended March 31, 2023 </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Revenue and Federal Awards</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There was no revenue from product
sales during the three months ended March 31, 2024 or 2023 as we are focused on research and development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We intend to apply for additional
federal grants through the Small Business Innovation and Research programs through the National Institute of Health (&ldquo;NIH&rdquo;).
In April 2021, we submitted our first grant application to the NIA for full funding of a Phase II trial in Mild Cognitive Impairment
(MCI) and early Alzheimer&rsquo;s disease. The Phase II trial was designed to focus on 3 areas: 1) safety and tolerability; 2) pharmacokinetics
and pharmacodynamics, measuring of responses from 2 different doses vs. placebo; and 3) measuring of effect on multiple biomarkers related
to the disease. The application was not accepted but we were encouraged by the NIA to refine our application and submit again. We
have since submitted 3 grant applications, with budgets of $20 M or higher, to the NIA for full funding of such Phase II trial but none
of those applications were successful. After discussions with the NIA, we have decided to apply, in September of 2024, for a much smaller
grant, $2.5 million, for a Proof of Concept study focusing on JOTROL&rsquo;s effect on validated biomarker. The final study design is
not yet determined but a draft synopsis is described in the section &ldquo;Description of Business&rdquo;. There is no guarantee
that this and future grant applications will be successful and therefore the rejection of our future grant application may significantly
delay the Company&rsquo;s plans in connection with MCI and Alzheimer&rsquo;s and may have a significant impact on the Company&rsquo;s
financial performance. We intend to apply for Phase IIB for clinical trial related to Orphan diseases. Phase IIB grants may fund 50%
of clinical trial expenses over three years, not to exceed approximately $2,500,000 per year for a maximum of three years. However, those
limits may be adjusted annually at the discretion of the Small Business Administration. We recognize there is no guarantee of future
federal grant funding and that might have an impact on our possibility to conclude our planned MCI/early Alzheimer&rsquo;s disease project.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Research and Development Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Research and development (&ldquo;R&amp;D&rdquo;)
expenses were $98,667 for the three months ended March 31, 2024 compared to $267,409 for the three
months ended March 31, 2023. The decrease is primarily due to the reduction of employee salaries beginning in December
2023. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 123; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">R&amp;D expenses related to the
federal grant were segregated in the chart of accounts from non-federal award costs. At this time, we are not tracking R&amp;D expenses
per indication as all of the R&amp;D expenses incurred to date related to JOTROL, which is the platform product used in each indication
defined in our product pipeline. Costs will be segregated amongst the different indications beginning next fiscal year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, the probability
of success for JOTROL will depend on numerous factors, including manufacturing capability, satisfactory results in follow on clinical
trials, regulatory approvals and commercial viability. See &ldquo;Risk Factors&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>General and Administrative Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">General and administrative expenses
were $472,028 for the three months ended March 31, 2024 compared to $780,070 for the three months
ended March 31, 2023. The decrease is primarily due to the reduction of employee salaries beginning in December
2023. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Loss
on Extinguishment of</I></B></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I> </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>Debt and (Loss)/Gain</I></B> <B><I> on
Change in Fair Value of Derivative Liability</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2023, the Senior Secured Convertible Note were amendment several times with materially different economics thus requiring for
the recording of debt as an extinguishment and re-recording the debt with the amended terms. This resulted
in a loss on extinguishment of debt in the three month period ended March 31, 2023 of $670,419. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2024 and 2023 the variable conversion options embedded in our convertible notes was marked to market and the change
in fair value of the derivative was recorded as a loss of $37,711 and a gain of $18,628, in the three month periods ended March 31,
2024 and 2023, respectively. 2 </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Interest Expense</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Interest expense is primarily
attributable to interest expense associated with our previously outstanding notes payable, convertible notes payable and related amortization
of the debt discount, notes payable to Chief Executive Officer, Christer Ros&eacute;n, and interest expense on our corporate credit card.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>Gain on forgiveness of accrued compensation</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> In March 2024, the former
CFO of the Company, Dana Escherburg Perez agreed to exchange $100,000 in accrued compensation in exchange for 49,605 options to purchase
common stock and 7,500 restricted stock units. The options to purchase common stock have a strike price of $1.33. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Year Ended December 31, 2023 Compared
to Year Ended December 31, 2022 </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Revenue and Federal Awards</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There was no revenue from product
sales during the twelve months ended December 31, 2023 or 2022 as we are focused on research and development. The revenue
for the twelve months ended December 31, 2022 consisted of federal grant income of $233,281 for award number R44AG067907-01A1
for a Phase I dose finding pharmacokinetics (&ldquo;PK&rdquo;) study. The study will be foundational for all indications where our product
candidate will be used for Phase II and Phase III clinical trials.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Research
and Development Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development (&ldquo;R&amp;D&rdquo;) expenses were $954,793 for the twelve months ended December 31, 2023 compared to
$942,806 for the twelve months ended December 31, 2022. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 124; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">R&amp;D expenses related to the
federal grant were segregated in the chart of accounts from non-federal award costs. At this time, we are not tracking R&amp;D expenses
per indication as all of the R&amp;D expenses incurred to date related to JOTROL, which is the platform product used in each indication
defined in our product pipeline. Costs will be segregated amongst the different indications beginning next fiscal year.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, the probability
of success for JOTROL will depend on numerous factors, including manufacturing capability, satisfactory results in follow on clinical
trials, regulatory approvals and commercial viability. See &ldquo;Risk Factors&rdquo;.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>General
and Administrative Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses were $2,915,978 for the twelve months ended December 31, 2023 compared to $2,722,922
for the twelve months ended December 31, 2022. The increase relates to general consulting, accountancy, legal and public relation
services related to preparing the Company for the public offering.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Interest Expense</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Interest expense is primarily
attributable to interest expense associated with our previously outstanding notes payable, convertible notes payable, notes payable to
Chief Executive Officer, Christer Ros&eacute;n, and interest expense on our corporate credit card.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Gain
on Change in Fair Value of Derivative Liability</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023 </FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and 2022 and at each
quarter end during the years, the variable conversion options embedded in our convertible notes was marked to market and the
change in fair value of the derivative was recorded as a gain of $148,751 and $262,514, in the twelve month periods ended December
31, 2023 and 2022, respectively. </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Loss
on Extinguishment of Debt</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2022 and 2023, the Senior Secured Convertible Note was amendment several times with materially different economics thus requiring for
the recording of debt as an extinguishment and re-recording the debt with the amended terms. This resulted in a loss on extinguishment
of debt in the twelve month period ended December 31, 2023 and 2022 of $887,946 and $1,047,410, respectively.</FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 125; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity
and Capital Resources; Plan of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of March 31, 2024,
we had cash and cash equivalents of $8,313. Our cash equivalents are held in high yield savings account. Since inception, we have
incurred net losses and negative cash flows from operations. On March 31, 2024, we had an accumulated deficit of $24,216,604. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 42.85pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have historically financed
our operations primarily through the sale of common stock and convertible debt. On April 11, 2022, we issued a senior secured convertible
note in the principal amount of $1,111,111 in exchange for $1,000,000 as described above under &ldquo;Description of Business &ndash;
Recent Developments.&rdquo; As of July 12, 2024, we had cash and cash equivalents of $2,110. We believe that our existing
cash and cash equivalents will be sufficient to fund our planned operations for the next 1 month from the date of this prospectus without
the proceeds from this offering. Management expects operating losses to continue for the foreseeable future. As we continue to incur
losses, a transition to profitability is dependent upon the successful development, approval and commercialization of our drug candidate
and the achievement of a level of revenues adequate to support our cost structure. We will continue to require additional capital to
develop our drug candidate and fund operations for the foreseeable future. We may seek to raise capital through private or public equity
or debt financings, collaborative or other arrangements with other companies, or through other sources of financing. Adequate additional
funding may not be available to us on acceptable terms, or at all.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 42.85pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
failure to raise capital as and when needed could have a negative impact on our financial condition and our ability to pursue our business
strategies. We anticipate that we will need to raise substantial additional capital, the requirements of which will depend on many factors,
including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, rate of progress and costs of our drug delivery, preclinical development activities, laboratory testing and clinical trials
    for our drug candidate;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number and scope of clinical programs we decide to pursue;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope and costs of manufacturing development and commercial manufacturing activities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent to which we acquire or in-license other drug candidate and technologies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost, timing and outcome of regulatory review of our drug candidate;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost and timing of establishing sales and marketing capabilities, if of our drug candidate receives marketing approval;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of preparing, filing and prosecuting patent applications, obtaining, maintaining and enforcing our intellectual property rights
    and defending intellectual property-related claims;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to establish and maintain collaborations on favorable terms, if at all;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support
    the development of our drug candidate;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs associated with being a public company; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost associated with commercializing our drug candidate, if it receives marketing approval.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing into which
we enter may impose upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or
additional debt, pay dividends, repurchase our common stock, make certain investments and engage in certain merger, consolidation or
asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our
stockholders. If we are unable to raise additional funds when needed, we may be required to delay, reduce, or terminate some or all of
our development programs and clinical trials. We may also be required to sell or license to other parties rights to develop or commercialize
our drug candidate that we would prefer to retain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 42.85pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 126; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&ldquo;Risk Factors&rdquo; for additional risks associated with our capital requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 42.85pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Cash
Flows for the Years Ended December 31, 2023 and 2022 </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows a summary of our cash flows for the years ended December 31, 2023 and 2022. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Fiscal Years Ended <BR> December 31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> 2023 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> 2022 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left">Net cash from operating activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"> (480,953 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"> (1,248,504 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net cash used in investing activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> 445,000 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> 982,333 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">Net increase (decrease) in cash</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> (35,953 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> (266,171 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Cash - beginning of the period</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Cash - end of the period</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"> 28,478 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"> 64,431 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Net
Cash from Operating Activities:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
used in operating activities during the year ended December 31, 2023 decreased $767,551 from December 31, 2022 mainly attributable
to an increase of $443,828 in stock-based compensation, $636,171 in accrued compensation, and $221,160 in accounts
payable and accrued expenses, offset by a $587,015 in changes associated with debt (amortization of debt discounts, loss on extinguishment
of debt, and gain/loss on change in fair value of derivative liabilities). </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Net
Cash Provided by Financing Activities:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
flows provided by financing activities for the year ended December 31, 2022 decreased $537,33 from the year ended December 31,
2022 due to a reduction in investment proceeds from issuance of convertible notes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 127; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><B><I>Cash Flows for the Three
Months Ended March 31, 2024 and 2023 </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table shows a summary
of our cash flows for the nine months ended September 30, 2023 and 2022. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Nine Months Ended September
    30,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> 2023 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> 2022 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Net cash from operating activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"> (65,165 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"> (98,687 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net cash used in investing activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> 45,000 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> 50,000 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Net increase (decrease) in cash</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> (20,165 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> (48,687 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Cash - beginning of the period</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 28,478 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 64,431 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Cash - end of the period</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"> 8,313 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"> 15,744 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Net Cash from Operating Activities:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Cash used in operating activities
during the three months ended March 31, 2024 decreased $33,522 from March 31, 2023 mainly attributable to an decrease
in net loss of $1,073,150 and a decrease of $300,122 in accrued compensation, and $112,177 in accounts payable and accrued
expenses, offset by a $610,738 in increases as a result of changes associated with debt (amortization of debt discounts, loss
on extinguishment of debt, and gain/loss on change in fair value of derivative liabilities). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Net Cash Provided by Financing Activities:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Cash flows provided by financing
activities for the three months ended March 31, 2024 decreased $5,000 from March 31, 2023. The financing
activity during the periods relate to proceeds from notes from related parties or sale of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Off-balance
sheet financing arrangements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no obligations, assets or liabilities which would be considered off-balance sheet arrangements. We do not participate in transactions
that create relationships with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which
would have been established for the purpose of facilitating off-balance sheet arrangements. We have not entered into any off-balance
sheet financing arrangements, established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased
any non-financial assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 128; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Asian
Business Development Activities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company initiated business development activities in the Asian region beginning in October of 2021. The Company has a strong strategic
interest in accelerating the drug development and potential commercialization efforts of JOTROL in this market. Our Chairman
&amp; CEO, Christer Ros&eacute;n, presented in person, our company&rsquo;s status and pipeline at the BIOHK 2023 in Hong Kong in September
of 2023. The presentation led to several follow-on meetings, and we have recently agreed to service agreements in the areas of business
development, CMC (Chemistry, Manufacturing, and Controls), regulatory affairs and clinical trial management. These agreements are further
described in the section &ldquo;Other Material Agreements&rdquo;. In addition, we are in active negotiations with Dominant Treasure Health (&ldquo;DTH&rdquo;), a BVI company. DTH has demonstrated to us, through several company introductions, that they have business relationships, either directly or through affiliates, with many South-East Asian pharmaceutical companies as well as companies involved
in distribution and sales of TCM, Traditional Chinese Medicine. We are therefore planning to engage DTH in active business development
in China, Malaysia and Singapore as soon as we have financing in place for their engagement. DTH has already introduced us to 3 Chinese
companies, Beimei Pharma, http://en.beimeiyaoye.com, that specializes in pediatric medications, Sichuan Kelun Pharmaceutical Co., ltd,
a publicly traded company that is part of the Kelun Industrial Group, https://www.kelun.com/, and Tianjin Pharmaceuticals, https://en.pharm.com.cn/,
that advocates the corporate core values of &ldquo;Love, Integrity and Power&rdquo;. TCM products are run in a separate division within
Tianjin. Discussions with all three companies are ongoing. We believe that with DTH&rsquo;s assistance we can co-ordinate and oversee
the work of our Service providers in the territory and more expediently negotiate and finalize an out-license agreement with one or more
pharmaceutical companies in South-East Asia. The Asian market is very large and hard to penetrate for a small company
and we believe that our strategy with these agreements is very cost effective and have the possibility to accelerate an out-licensing
deal in the South-East Asian territories. However, there are no assurances that this approach will be successful. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
agreements executed are very similar in nature that include an equity investment in our company by the other party and in turn the company
issued equity in form of common shares, in lieu of cash, for 3 years of services from each company.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
company believes these agreements to be favorable for both parties based on the cash position of the company and the need for these activities
to be executed and enabling the possibility of a one or more out-licesning agreements in the territory.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contractual
obligations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have any long-term capital lease obligations, operating lease obligations or long-term liabilities, except as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 30, 2021, the Company executed a lease agreement for office space in Jupiter, Florida. The term of the lease is sixty-one months
commencing May 1, 2021 rent free until June 1, 2021. Fixed annual rent amounts are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%; margin-left: 0.5in">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">Lease Period</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Annual Fixed Rent</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 68%">6/1/2021-5/31/2022</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: right">45,396</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">6/1/2022-5/31/2023</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">46,758</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">6/1/2023-5/31/2024</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">48,158</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">6/1/2024-5/31/2025</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">49,608</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">6/ l/2025-5/31/2026</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">51,096</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 129; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>Senior Secured Note</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On April
11, 2022, the Company entered into a securities purchase agreement (the &ldquo;Purchase Agreement&rdquo;) with an accredited investor
for the sale of the Company&rsquo;s convertible notes. Pursuant to the terms of the Purchase Agreement, on April 11, 2022, the Company
received aggregate gross proceeds of $1,000,000 and issued (i) a 10% Original Issue Discount Senior Secured Convertible Note in the principal
amount of $1,111,111.11 (the &ldquo;Note&rdquo;) and (ii) 514,403  shares of common stock, par value $0.0001
per share (the &ldquo;Shares&rdquo;), of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><B><I>The
Note</I></B>. The aggregate principal amount of the Note is $1,111,111.11, and the Company received gross proceeds of $1,000,000 after
giving effect to the original issue discount of 10%. The Note bears interest at a rate of 10% per year, payable monthly in arrears, and
mature 12 months from issuance. A &ldquo;Qualified Offering&rdquo; is a debt or equity financing for the account of the Company or any
of its subsidiaries in which shares of common stock, or securities, directly or indirectly, convertible into or exchangeable or exercisable
for shares of common stock are issued, which financing results in cumulative aggregate proceeds to the Company of at least $8,000,000.
The principal and interest on the Note will be amortized on a straight-line basis at 110% of the principal amount commencing sixth
months after the closing. On October 10, 2022, the Note was amended to postpone the commencement of the amortization amount from October
11, 2022 to November 11, 2022. On November 10, 2022, the Note was amended to postpone the commencement of the amortization from November
11, 2022 to February 11, 2023 and payable in three monthly installments. As consideration for the amendment, an additional 11,431 shares
of common stock were issued to the accredited investor on October 10, 2022 and 34,293 shares issued to the accredited investor on November
10, 2022. On January 13, 2023, the Note was amended to delay the interest payment due and payable on January 11, 2023 to the earlier
of (i) January 31, 2023 and (ii) the closing of a Qualified Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Upon
an Event of Default and after a Qualified Offering, the principal and interest are convertible at any time at the option of the holder
into shares of the Company&rsquo;s common stock at a conversion price equal to 30% discount to the lowest closing price of the common
stock for the 20 prior trading days; provided, however, <FONT STYLE="background-color: white">the holder will not have the right to
convert any portion of the Note, to the extent that after giving effect to the conversion, the holder, together with its affiliates,
would beneficially own in excess of 4.99% of the number of shares of the Company&rsquo;s common stock outstanding immediately after giving
effect to its conversion. The holder may increase or decrease its ownership limitation to any percentage not exceeding 9.99% upon 61
days prior written notice to the Company</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Company will have the right at any time to redeem in cash all or a portion of the Note at 120% (or 125% on or after the first six months
from the closing; provided, however, if interest due and payable on January 31, 2023 is not paid in full, 130% on or after the first
six months from the closing) of the principal amount thereof plus any unpaid accrued interest to the date of repayment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Company will be required to offer to prepay in cash the aggregate principal amount of the Note at 120% (or 125% on or after the first
six months from the closing; provided, however, if interest due and payable on January 31, 2023 is not paid in full, 130% on or after
the first six months from the closing) of the principal amount thereof plus any unpaid accrued interest to the date of repayment,
on the sale of all or substantially all of the assets of the Company and its subsidiaries, upon a Change of Control (as defined in the
Note), or on a Qualified Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Upon
an Event of Default (as defined therein) interest shall accrue at 1 1/2% per month and the 125% (or 130% if interest due and payable
on January 31, 2023 is not paid in full) of principal and interest through maturity shall be due and payable. At the holder&rsquo;s
option the holder shall be entitled to be paid in cash or after the Qualified Offering (as defined in the Purchase Agreement) common
stock with the conversion price of the common stock equal to a 30% discount to the lowest closing price of the common stock for the 20
prior trading days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> </P>

<!-- Field: Page; Sequence: 130; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.5in; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 6, 2023, the Note was amended to postpone the commencement of the principle to February 28, 2023. On March 6, 2023, the Note
was amended to postpone the commencement of the principal from February 11, 2023 to May 31, 2023. The Company and the note holder agreed
to a repayment plan on past due interest. In addition, the Company agreed to prepay in cash the aggregate principal amount of the Note
of 120% (or 137.5% on or after the first six months from closing) plus any accrued interest on the sale of all the assets of the Company
and its subsidiaries, upon the Change of Control, or on a Qualified Offering. Upon default of the Note the Company agrees to pay 137.5%
of the outstanding note principal, and accrued interest through maturity and all liquidation damages. As a result of the material modification,
the incremental fair value of the modified derivative was classified as a debt extinguishment. Due to the extension of the maturity date
of the convertible note, the fair value of the derivative liability increased. This resulted in the Company recording a loss on extinguishment
of debt of $670,419.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.5in; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 22, 2023, the Note was amended to postpone the commencement of the principle to December 31, 2023. The Company and the note
holder agreed to a repayment plan on past due interest. In addition, the Company agreed to prepay in cash the aggregate principal amount
of the Note of 120% (or 150% on or after the first six months from closing) plus any accrued interest on the sale of all the assets of
the Company and its subsidiaries, upon the Change of Control, or on a Qualified Offering. Upon default of the Note the Company agrees
to pay 150% of the outstanding note principal, and accrued interest through maturity and all liquidation damages. In addition, upon closing
the Note holder will receive 175% stock coverage. As a result of the material modification, the incremental fair value of the modified
derivative was classified as a debt extinguishment. Due to the extension of the maturity date of the convertible note, the fair value
of the derivative liability increased. This resulted in the Company recording a loss on extinguishment of debt of $217,527.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>The Shares</I></B>. In
connection with the issuance of the Note, the Company issued 514,403  shares of Common Stock to the holder with a fair market
value of $2.16  per share (aggregate value of $1,111,111) as additional consideration for the holder lending $1,000,000 to the
Company. The 514,403  shares have a relatively fair value of $310,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Purchase Agreement related
to the Note was amended to provide that upon closing, the purchaser will receive 133.33% coverage (i.e. the face amount of the Note,
i.e., $1,111,111.11 divided by the lesser of (i) the price/share of the last issuance of solely common stock (including options) of the
Company, i.e., $5.00/share or (ii) the price per share of common stock (or if units are issued in the Qualified Offering, the price of
units sold in the Qualified Offering), in shares of common stock of the Company (or if units are issued in the Qualified Offering, units).
The number of shares to be received at closing shall be determined by using clause (i) above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In light of the foregoing, the
holder shall receive an additional number of shares of common stock, such that it shall have received the number of shares of common
stock of the aggregate value of $1,111,111 divided by the lesser of (i) the price/share of the last issuance of solely common stock (including
options) of the Company, i.e., $5.00/share or (ii) the price per share of common stock (or if units are issued in the Qualified Offering,
the price of units sold in the Qualified Offering), in shares of common stock of the Company (or if units are issued in the Qualified
Offering, units) (&ldquo;Share True Up&rdquo;). The Share True Up was forfeited as a result of the April 29, 2024 agreement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><B><I>Ancillary
Agreements</I></B>. In connection with the Company&rsquo;s obligations under the Note, the Company entered into a security agreement
and intellectual property security agreement with the holder, pursuant to which the Company granted a security interest on all assets
of the Company, including all intellectual property of the Company, for the benefit of the holders, to secure the Company&rsquo;s obligations
under the Note and the other transaction documents. In addition, the holder was granted piggyback registration rights for the shares
of common stock issued under the Purchase Agreement and shares of common stock issuable upon conversion of the Note (collectively,
&ldquo;Registrable Securities&rdquo;). At any time while there are any Registrable Securities of holder outstanding, if the Company proposes
to register any of its securities either for its own account or for the account of other security holders (other than a registration
statement relating solely to employee benefit plans on Form S-8 or a Commission Rule 145 transaction on Form S-4), the holder is entitled
to include its Registrable Securities in the registration. Notwithstanding, the Company and underwriters in an underwritten registration
may exclude some or all of the Registrable Securities from the underwritten registration if the underwriters believe that including the
Registrable Securities would adversely affect the underwritten offering.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 131; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">At
any time within the 12 months closing, upon any issuance by the Company or any of its subsidiaries of debt or common stock or common
stock equivalents for cash consideration, indebtedness or a combination of units thereof, other than in an underwritten public offering
(a &ldquo;Subsequent Financing&rdquo;), the investor will have the right to participate up to its investment amount in the Note, but
not more than 25% of the Subsequent Financing, on the same terms, conditions and price provided for in the Subsequent Financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Until the Company has consummated
a Qualified Offering which results in a listing of the Common Stock onto a national securities exchange, if the Company engages in any
future financing transactions with a third-party investor, if the holder determines that the terms of the subsequent investment are preferable
in any respect to the terms of the securities of the Company issued to the Holder pursuant to the terms of the Purchase Agreement, the
holder will have the right to amend and restate such securities to include the preferable term or terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The descriptions of the Securities
Purchase Agreement, the Note, the Security Agreement, and the Intellectual Property Security Agreement as set forth above is qualified
in their entirety to the full Securities Purchase Agreement, the Note, the Security Agreement, and the Intellectual Property Security
Agreement as attached as Exhibits 10.25, 10.26, 10.27, and 10.28 to the registration statement of which this prospectus forms
a part.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
Payable, related party</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
payable, related party, to </FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the CEO totaled $428,479
and $383,479 as of March 31, 2024 and December 31, 2023, respectively. The note bears interest at 3% per
year and is payable upon demand. Accrued interest was $14,329 and $11,220 as of March 31, 2024 and December 31, 2023, respectively. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
payable, related party, to an employee totaled $25,000 and $0 </FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
of March 31, 2024 and December 31, 2023. The note bears interest at 3% per year and is payable upon demand. Accrued interest
was $912 and $723 as of March 31, 2024 and December 31, 2023, respectively. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2020, $100,000 of principal plus accrued interest of $1,001, owed to the CEO, was converted to 84,168 shares of common at $3.00 per share which was the estimated fair value of the common stock based on recent sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Related Party Transactions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2020, the CEO forgave $536,314 of accrued compensation which has been reflected as additional paid in capital on the statement of stockholders&rsquo;
deficit due to the related party nature of the transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Accrued compensation includes
partially accrued salaries to executives since inception. Since inception, executive salaries have been paid in cash when the Company<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">&rsquo;s
cash flow has permitted such payment. During 2020, the Company began paying salaries at 50% of the respective employment agreements.
As of September 2021, the Company began paying full salaries. During the first quarter of 2022, the Company returned to paying partial
salaries in an effort to conserve cash outflows in an effort to conserve cash outflows. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 21, 2022, the Board of Directors executed a Unanimous Written Consent relating to the forgiveness of $1,556,010 of accrued salaries
for executives and two consultants. Subsequently, each executive and consultant executed a Debt Forgiveness and Release Agreement with
the Company. In consideration for the salary forgiveness, the Company awarded restricted stock awards with a fair market value of $1.33 per share, totaling 1,167,011 restricted shares. The restricted stock awards vest 100% on the
first business day following the expiration of a lock-up period after the Company&rsquo;s common stock is listed for trading on NASDAQ,
NYSE, or NYSE American.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 29, 2023, the Board of Directors executed a Unanimous Written Consent relating to the forgiveness of accrued compensation for
executives, consultants, and board members in the amount of $4,189,626. In exchange for the forgiveness of the accrued compensation the
Company agreed to a cash bonus of $583,214 to be paid upon the occurrence of a successful IPO. In addition, the Company agreed to issue
an aggregate of 2,353,665 stock options with an exercise price of $1.33 and an aggregate of 1,399,833 restricted stock units with a grant
date value of $1.33 in exchange for the aggregate forgiveness of compensation in the amount of $4,189,626.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 18, 2023, the Board of Directors executed a Unanimous Written Consent relating to the forgiveness of the $583,214 cash bonus
granted in the September 29, 2023 forgiveness in exchange for 338,899 stock options with an exercise price of $1.33 and an aggregate of 226,203 restricted stock units with a grant date value of $1.33.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2024 and December 31, 2023, $92,125 and $67,750 were due to a Company wholly owned by the Company&rsquo;s Chief Financial
Officer, who also is an option holder. The amount is included in accrued compensation.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Included in accounts payable
and accrued expenses as of March 31, 2024 and December 31, 2023 are the following related party balances, respectively:
expense reports due to employees $76,995 and $49,214 and annual license fee due to Aquanova AG totaling $168,750 and $150,000. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 132; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B>Recent Developments</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> <B><I>Notes Payable,
related party</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"> April
29, 2024, the Company, the Holder of the Note II and the CEO entered into an amendment in which the CEO agrees to exchange 685,869 shares
issued to the Holder in exchange for his related party notes that accrued interest at 3% that are due from the Company in an aggregate
principal amount of $266,667 and the Holder agreed to forfeit all rights to all additional future shares from the Company that would
of become due upon a qualified offering and the conversion feature of the note. In addition, the Holder agreed to extend the note maturity
date to August 11, 2024. The note shall be designated as a 10% original issued discount secured note (&ldquo;Senior Secured Note&rdquo;)
moving forward. The note and interest will become due and payable upon the earliest of the maturity date or upon the occurrence of a
qualified event. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>Share Issuances</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> On June 3, 2024, the Company
issued 1,162,500 shares of common stock to each of Optimize Wellness Limited, Regis Healthcare Group Limited, and Longevity Technology
Group Limited (collectively, &ldquo;Selling Stockholders&rdquo;) with a fair market value of $1.33 per share (3,487,500 shares in aggregate,
with an aggregate fair market value of $4,638,375), as pre-payment for 3 years of services. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> On June 3, 2024, the Company
sold 112,500 shares of common stock to the Selling Stockholders for $1.33 per share, with each Selling Stockholder purchasing 37,500
shares of common stock. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Critical
Accounting Policies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use
of Estimates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements and related disclosures in conformity with accounting principles generally accepted in the United
States of America (&ldquo;GAAP&rdquo;) requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and income and expenses during
the periods reported. Actual results could materially differ from those estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Federal
Contract Revenue</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes federal contract revenue from the NIH Award in the period in which the allowable research and development expenses
are incurred, and receivables associated with this revenue are included within federal contract revenue receivable on our balance sheets.
This revenue is not within the scope of Accounting Standards Codification (ASC) 606 &ndash; Revenue from contracts with customers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
and Development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. Costs for certain development activities, such as clinical trials, are recognized based
on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, monitoring visits, clinical site
activations, or information provided to us by our vendors with respect to their actual costs incurred. Payments for these activities
are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the
financial statements as prepaid or accrued research and development expense, as the case may be. Total research and development costs
for the fiscal years ended December 31, 2023 and 2022 were $954,73 and $942,806, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock-Based
Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based compensation in accordance with the provisions of Accounting Standards Codification (ASC) Topic 718,
Compensation&mdash;Stock Compensation, or ASC 718, which requires the recognition of expense related to the fair value of stock-based
awards in the statements of operations. For stock options issued to employees, non-employees and members of our board of directors for
their services on our board of directors, the Company estimates the grant-date fair value of options using the Black-Scholes option pricing
model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of
the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates, and,
for grants prior to our initial public offering, the value of the common stock. For awards subject to time-based vesting, the Company
recognized stock-based compensation expense, on a straight-line basis over the requisite service period, which is generally the vesting
term of the award. As of December 31, 2022 and 2021, stock-based compensation expense totaled $2,310,761 and $1,302,495
respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Clinical
Trial Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the process of preparing our financial statements, the Company is required to estimate expenses resulting from obligations under
contracts with vendors, clinical research organizations and consultants and under clinical site agreements in connection with conducting
clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result
in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company&rsquo;s
objective is to reflect the appropriate trial expenses in the financial statements by matching those expenses with the period in which
services are performed and efforts are expended. The Company accounts for these expenses according to the progress of the trial as measured
by patient progression and the timing of various aspects of the trial. The Company determines accrual estimates based on estimates of
services received and efforts expended that take into account discussion with applicable personnel and outside service providers as to
the progress or state of consummation of trials. During the course of a clinical trial, the Company adjusts the clinical expense recognition
if actual results differ from its estimates. The Company makes estimates of the accrued expenses as of each balance sheet date based
on the facts and circumstances known at that time. The clinical trial accruals are dependent upon the timely and accurate reporting of
contract research organizations and other third-party vendors. Although the Company does not expect the estimates to be materially different
from amounts actually incurred, understanding of the status and timing of services performed relative to the actual status and timing
of services performed may vary and may result in reporting amounts that are too high or too low for any particular period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 133; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Convertible
Notes with Embedded Derivative Liabilities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into convertible notes, some of which contain variable conversion options, whereby the outstanding principal and
accrued interest may be converted, by the holder, into common shares at a fixed discount to the price of the common stock at or around
the time of conversion upon certain trigger events. The Company evaluates all its financial instruments to determine if those contracts
or any potential embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC
815-10 <I>&ndash; Derivative and Hedging &ndash; Contract in Entity&rsquo;s Own Equity</I>. This accounting treatment requires that the
carrying amount of any derivatives be recorded at fair value at issuance and marked-to-market at each balance sheet date. In the event
that the fair value is recorded as a liability, as is the case with the Company, the change in the fair value during the period is recorded
as either other income or expense. Upon conversion, exercise or repayment, the respective derivative liability is marked to fair value
at the conversion, repayment, or exercise date and then the related fair value amount is reclassified to other income or expense as part
of gain or loss on debt extinguishment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ar_008"></A>MANAGEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the names and ages of the members of our Board of Directors and our executive officers and the positions held
by each. Our Board of Directors elects our executive officers annually by majority vote. Each director&rsquo;s term continues until his
or her successor is elected or qualified at the next annual meeting, unless such director earlier resigns or is removed. In addition,
the following table sets forth the names and ages of the members of our Science Advisory Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 31.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 6%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: top; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 38%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Positions
    Held </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 18%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Initial
    Term of</B><BR>
    <B>Office</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Executive
    Officers and Directors</U></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christer
                                            Ros&eacute;n</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    of Board, Chief Executive Officer and Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    1, 2016</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Saleem
    Elmasri, CPA</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer and Secretary</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    1, 2023</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marshall
    Hayward, Ph.D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Scientific Officer and Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    1, 2016</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alexander
    Ros&eacute;n</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Administrative Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    1, 2016</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alison
    D. Silva</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President,
    Chief Business Officer, and Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    30, 2018</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nicholas
    H. Hemmerly</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    </FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8, 2021</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Julie
    Kampf</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    8, 2021</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> Allison W. Brady </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> 51 </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"> Independent Director </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> September 8, 2021 </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holger
    Weis</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    8, 2021</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Scientific
    Advisory Board</U></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Claes Wahlestedt, MD, Ph.D. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
    of Science Advisory Board</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    1, 2016</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shaun
    P. Brothers, Ph.D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
    of Science Advisory Board</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    1, 2016</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-size: 10pt">Rudolph Tanzi Ph.D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 6%"> <FONT STYLE="font-size: 10pt">64</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 38%"><FONT STYLE="font-size: 10pt">Member of Science Advisory Board</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%"><FONT STYLE="font-size: 10pt">November 1, 2019</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Li-Huei Tsai, Ph.D. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-size: 10pt">62</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Member of Science Advisory Board</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">June 1, 2016</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Raymond Scott Turner, MD, Ph.D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-size: 10pt">63</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Member of Science Advisory Board</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">August 1, 2016</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Charbel Moussa, MBBS, Ph.D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-size: 10pt">50</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Member of Science Advisory Board</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">April 21, 2020</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 38%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter
    Elliott, Ph.D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
    of Science Advisory Board</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    17, 2016</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dalton
    Dietrich, Ph.D</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
    of Science Advisory Board</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    22, 2021</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 134; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biographical
information concerning our directors and executive officers listed above is set forth below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Executive
Officers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Christer
Ros&eacute;n.</I></B> Mr. Ros&eacute;n is our Co-Founder and has served as our Chief Executive Officer and Chairman of our Board of Directors
since January 1, 2016. From 1997 through May 2015, Mr. Ros&eacute;n founded and served as the Chief Executive Officer and Chairman of
EffRx Pharmaceuticals. Mr. Ros&eacute;n together with Marshall Hayward, our Chief Scientific Officer, held the same position at EffRx,
invented, developed and received FDA and EU approvals of a drug treating osteoporosis, Binosto<SUP>&reg;</SUP>. Binosto<SUP>&reg;</SUP>
is distributed in several parts of the world and gave Mr. Ros&eacute;n a full insight in all the aspects of pharmaceutical development,
regulatory paths and distribution. Mr. Ros&eacute;n is a graduate of Malmo Trade Schools/Lund University, Sweden, with a degree in Computer
Sciences in 1971.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Saleem
Elmasri, CPA. </I></B> Mr. Elmasri&nbsp;has served as our Chief Financial Officer and Secretary since&nbsp;January 1, 2023. From September
2020 to December 2022, he served as a Principal at Titan Advisory Services LLC, a boutique advisory firm focused on providing collaborative
and customized financial operations and CFO services to early-stage companies. From September 2020 to April 2021, Mr. Elmasri was a consultant
to DLA LLC, a professional services firm providing clients internal audit, accounting advisory, and corporate finance services. From
June 2019 to August 2020, he was Managing Director at DLA LLC. From September 2007 to March 2018, Mr. Elmasri worked as Senior Director
for Pine Hill Group LLC, a boutique accounting and transaction advisory firm, From March 2018 to June 2019, he worked as Senior Director
for Pine Hill Group LLC, a boutique accounting and transaction advisory firm. From September 2007 to March 2018, Mr. Elmasri worked as
Senior Manager for PricewaterhouseCoopers LLP, a Big-4 Accounting and Global Professional Services firm. Mr. Elmasri is a CPA and seasoned
business professional who has a passion for delivering meaningful and measurable value to clients through practical solutions. He has
over 15 years of experience in financial and management consulting. Mr. Elmasri began his career at PricewaterhouseCoopers and worked
on several of the firm&rsquo;s Fortune 500 clients, primarily focused on the Life Sciences and Pharmaceutical industry. From PwC, he
transitioned to lead advisory practices at boutique consulting firms, specializing in transaction and complex accounting advisory. Mr.
Elmasri received B.S. degrees in Accounting and Finance from Rutgers University in 2007.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Marshall
Hayward, Ph.D. </I></B>Dr. Hayward is one of our Co-Founders, serves as our Chief Scientific Officer, and is a member of our Board of
Directors since January 1, 2016. Since May 2013, Dr. Hayward has served as the managing member of Marshall Hayward Associates LLC. From
September 2003 to May 2013, Dr. Hayward served as the Chief Scientific Officer of EffRx Pharmaceuticals where he was instrumental in
all aspects of the development and approvals of the Binosto&reg; product. Dr. Hayward received a Ph.D. in Biochemistry from the University
of Illinois at Urbana-Champaign in 1982 and did postdoctoral work there in molecular biology. Dr. Hayward received a B.S. degree (in
Biochemistry with High Honor) from the Honors College of Michigan State University in 1977. Dr. Hayward does not hold, and has not previously
held, any directorships in any reporting companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Alexander
Ros&eacute;n.</I></B> Mr. Ros&eacute;n is a Co-Founder and our Chief Administrative Officer and has been with Jupiter Neurosciences,
Inc. since its inception. Previously, Mr. Ros&eacute;n held the position of Head of Administration at X-Vax Technology, Inc. from November
2020 to June 2021. From February 2019 to November 2020, Mr. Ros&eacute;n served as the Controller at X-Vax Technology, Inc. Mr. Ros&eacute;n
attended Halmstad University, Sweden from 2009 - 2012. Mr. Ros&eacute;n does not hold, and has not previously held, any directorships
in any reporting companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 135; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Alison
D. Silva.</I></B> Alison Silva, who has been a member of our Board of Directors since 2018, has now expanding her role to include President
and Chief Business Officer since September 1, 2021. Previously, Ms. Silva was the Chief Executive Officer of Cotinga Pharmaceuticals,
formerly Critical Outcome Technologies, from July 2016 through August 2021. She continues to serve on the Board of Directors of Cotinga
Pharmaceuticals since 2015, and management consultant to several organizations, including EMA Wellness and The Orphan Group. Before joining
Cotinga, Alison co-founded The Microbiome Company in 2013, later rebranded to Synlogic Therapeutics, where she served as Executive Vice
President and Chief Operating Officer until June 2016. Other relevant positions include co-founder and Vice President, Development at
Marina Biotech; co-founder and Director at The Orphan Group; Director, Drug Development at Cequent Pharmaceuticals; COO at SLA Pharma;
and various other positions in biotech and pharma. Ms. Silva obtained her undergraduate degree in Biologyfrom Clark University in 2001
and her graduate degree from the University of Massachusetts Medical Center in 2002. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Independent
Directors </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Allison
W. Brady. </I></B>Ms. Brady has served as an independent director at Jupiter Neurosciences, Inc. since September 8, 2021. She serves
on the board of Gene Spotlight, Inc., where she is co-founder, a non-profit dedicated to raising money to sponsor medical research for
rare diseases, since April 2011. Since 2016, Ms. Brady has served on the Board of Advisors at University of Pennsylvania&rsquo;s
school of Social Policy &amp; Practice and is currently the Fundraising Chair of its Power of Penn campaign. Ms. Brady received a BAS
from University of Pennsylvania in 1993. She also received a PR Strategy Certificate in 2021 from Cornell University. Ms. Brady does
not hold, and has not previously held, any directorships in any reporting companies. Gene Spotlight is presently the largest outside
investor in the Company. Ms. Brady does not hold, and has not previously held, any directorships in any reporting companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Nicholas
H. Hemmerly.</I></B> Mr. Hemmerly has served as an independent director at Jupiter Neurosciences, Inc. since September 8, 2021. Mr. Hemmerly
has been Managing Director and Co- Head of Investment Banking for Clear Street LLC since June 2023. Mr. Hemmerly
has over 18 years of investment banking experience with broad transactional experience having completed approximately $25 billion of
debt and equity transactions. Prior to joining Clear Street Mr. Hemmerly was Head of Investment Banking at Bridgeway Capital
Partners, a merchant banking firm, From March 2016 to February 2020 Mr. Hemmerly was the Director, Head of Life Sciences at PricewaterhouseCoopers
LLC where he led U.S. M&amp;A and capital raising in the life sciences space with a focus on specialty and generic pharmaceuticals as
well as healthcare consumer products and contract manufacturing. Prior to PwC from June 2014 to March 2016, Mr. Hemmerly was a Vice President
at Jefferies LLC with a focus on executing M&amp;A and financing transactions within the pharmaceutical and life sciences sectors. Prior
experience includes investment banking roles in JPMorgan Chase &amp; Co.&rsquo;s Healthcare Group as well as JMP Securities LLC&rsquo;s
Healthcare Group. Mr. Hemmerly began his investment banking career as an analyst with Wachovia Securities. Mr. Hemmerly also serves
as an independent director for Liberty Star Uranium &amp; Metals Corp. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Julie
Kampf.</I></B> Ms. Kampf has served as an independent director at Jupiter Neurosciences, Inc. since September 8, 2021. Ms. Kampf is currently
a Director and CEO of JBK Associates International an Executive Search firm focused on the Life Science Industry, which she founded in
2003. Ms. Kampf is also currently a Director at Marizyme, Inc. a Florida-based Biotech Company. Ms. Kampf has significant not-for-profit
board and advisory committee experience having served on Howard University&rsquo;s School of Communications Board of Visitors, where
she helped launch an entrepreneurial incubator and established an award for student entrepreneurs. Deeply committed to enhancing the
careers and well-being of other women, Ms. Kampf was president of the 1,750-member HBA (Healthcare Businesswomen&rsquo;s Association)
Metro Chapter, where she co-founded a successful mentoring program. Ms. Kampf has received numerous awards, including having been recognized
as one of New Jersey&rsquo;s Best 50 Women in Business, an Enterprising Woman of The Year, an Ernst &amp; Young Entrepreneurial Winning
Woman and a Brava Smart CEO Winner. In 2013 and 2009, Julie was recognized as one of the PharmaVoice 100 &lsquo;most inspiring people
in the Life Science Industry&rsquo;. Ms. Kampf received a B.A. in Political Science from the University of Rhode Island in 1983. Ms.
Kampf does not hold, and has not previously held, any directorships in any reporting companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 136; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Holger
Weis</I></B>. Mr. Weis has served as an independent director at Jupiter Neurosciences, Inc. since September 8, 2021. Since December 2020,
he has served as a Director, member of Audit and Compensation Committees as Alaunos Therapeutics, Inc. He is the principal of
Weis Advisors, Inc., a company that provides consulting services to life science companies, since founding the company in April 2018.
Between December 2011 and April 2018, Mr. Weis served many roles at DemeRx, Inc. including COO, CFO, President as well as a Consultant.
From August 2010 to November 2011 Mr. Weis served as CFO for EnSA Holdings, LLC. Prior to his time at EnSA Holdings, LLC. Mr. Weis served
as Vice President &amp; CFO, Secretary and Treasurer at NovaVision, Inc. from January 2006 to August 2010. Prior to that, he served as
the Chief Financial Officer &amp; Treasurer of GMP Companies, Inc., a company that develops and commercializes pharmaceutical, medical
device and diagnostic technologies, from 2000 to 2005. Earlier in his career, Mr. Weis served as a Senior Manager at Ernst &amp; Young,
a multinational professional services company, from 1986 to 2000. Mr. Weis received a Bachelor of Business Administration in Accounting
from the University of Georgia in 1985 and is a Certified Public Accountant. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Scientific
Advisory Board</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
want to emphasize that our SAB members and Business Advisors take a very active role in our company and specific projects. This is one
important reason how a company with our small staff can execute so many different pipeline projects effectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Shaun
P. Brothers, Ph.D. </I></B>Dr. Brothers has served as a member of our Scientific Advisory Board and our Consulting VP of Scientific Research
since January 1, 2016. Dr. Brothers is an expert reviewer for molecular probes and drug discovery in neuroscience NIH study sections.
Since June 2017, Dr. Brothers has served as an Associate Professor at the University of Miami, Miller School of Medicine. Since June
2016, Dr. Brothers has served as Director at Sylvester Cancer Center Molecular Therapeutics Shares Resource at University of Miami, Miller
School of Medicine. From March 2011 through May 2017, Dr. Brothers served as an Assistant Professor at the University of Miami, Miller
School of Medicine. Since September 2012, Dr. Brothers has served as Director of Pharmacology at Epigenetix Inc. From 2016 through 2018,
Dr. Brothers served as Director Preclinical Research at DemeRx, Inc. From October 2006 to March 2011, Dr. Brothers served as a researcher
at Scripps Research Institute in Jupiter, Florida. Dr. Brothers has also co-founded 2 biotech companies. Dr. Brothers received an MBA
from West Texas A&amp;M University in 2019, Ph.D. in physiology and pharmacology from Oregon Health and Science University in 2006, and
Bachelor of Science degree in Microbiology from Oregon State University in 2000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Dalton
Dietrich, Ph.D. </I></B>Dr. Dietrich has served as a member of our Scientific Advisory Board since June 22, 2021. Dr. Dietrich currently
is the Scientific Director at The Miami Project to Cure Paralysis and the Kinetic Concepts Distinguished Chair in Neurosurgery at the
University of Miami Miller School of Medicine which is where he has been since 1997. Dr. Dietrich also currently serves as the Senior
Associate Dean for Discovery Science at the University of Miami Miller School of Medicine and Co-Director of the Institute for Neural
Engineering at the University of Miami. Between 1995 to 1997 Dr. Dietrich served as Vice-Chairman for Basic Science in the Department
of Neurology at the University of Miami. He attained the rank of Professor in 1993. In 1981, Dr. Dietrich joined the Department of Neurology
at the University of Miami with a joint appointment in Cell Biology and Anatomy. Dr Dietrich has published over 375 refereed journal
articles, 75 book chapters and 4 books. His published work has been cited over 38,000 times. He has been listed by the Institute of Scientific
Information as a &ldquo;Highly Cited Researcher&rdquo;, placing him in the top 0.5% of all scientists based on the impact his research
has made on other scientists. Dr. Dietrich received his Ph.D. in Anatomy from the Medical College of Virginia in 1979 and completed a
postdoctoral fellowship in the Department of Pharmacology at Washington University, St. Louis, MO in 1981.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 137; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->135<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Peter
Elliott, Ph.D. </I></B>Dr. Elliott has served as a member of our Scientific Advisory Board since October, 2016. Since 2009, Dr. Elliott
has served as a consultant to the pharmaceuticals industry. From 2005 to 2009, Dr. Elliott served as Senior Vice President of R&amp;D
at Sirtris Pharmaceuticals. As part of work from his teams at Sirtris, three SIRT1 activators entered clinical development, SRT501, SRT2104
and SRT2379. He was also an integral part of the road-show to take Sirtris public with a successful IPO in 2007, leading to it being
purchased by GSK in 2008 for $720 million. From 2001 to 2005, Dr. Elliott served as Executive Vice President of Product Development at
CominatoRx leading efforts in 8 Phase II programs in inflammation and oncology. From 1996 to 2001, Dr. Elliott served as Vice President
of Pharmacology and Development at ProScript which was acquired by LeukoSite, and ultimately Millennium where he co-developed the multiple
myeloma drug, Velcade&copy; and PS-519 for stroke. From 1993 to 1996, Dr. Elliott served as Associate Director of Pharmacology at Alkermes.
From 1988 to 1993, Dr. Elliott served as Group &amp; Research Leader at Glaxo Group Research where he led a number of CNS programs focusing
on movement disorders, neurodegeneration as well as pain. Dr. Elliott received a B.Sc. in Pharmacology from London University and a Ph.D.
in Psychopharmacology from Cambridge University.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Charbel
Moussa, MBBS, Ph.D.</I></B> Dr. Moussa has served as a member of our Scientific Advisory Board since April, 2020. Since July 2017, Dr.
Moussa has served as an Associate Professor of Neurology at Georgetown University Medical Center. Since March 2015, Dr. Moussa has served
as the director of Translational Neurotherapeutics Program at Georgetown University Medical Center. Since January 2018, Dr. Moussa has
served as the Principal Investigator of the Lewy Body Disease Association (LBDA) Research Center of Excellence at Georgetown University
Medical Center. Since March 2015, Dr. Moussa has served as Clinical Research Director at the Parkinson&rsquo;s Foundation Center of Excellence.
Since August 2016, Dr. Moussa has served as Director of Neurosciences Grand Rounds at Georgetown University Medical Center. Dr. Moussa
received a Bachelor of Medicine, Bachelor of Surgery (MBBS), and Doctor of Philosophy (Ph.D) in Biomedical Sciences from the University
of Sydney Australia in 1996 and 2002, respectively. Dr. Moussa has expertise in geriatric neurology with a special focus on movement
and memory disorders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Rudolph
Tanzi Ph.D. </I></B>Dr. Tanzi has served as the Co-Chairman of our Scientific Advisory Board since November, 2019. Since 2013, Dr. Tanzi
has served as the Vice-Chair of Neurology and Director of the Genetics and Aging Research Unit at Massachusetts General Hospital. Since
2008, Dr. Tanzi has also served as the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard Medical School. Dr. Tanzi received
his B.S. (microbiology) and B.A. (history) at the University of Rochester in 1980 and his Ph.D. (neurobiology) at Harvard Medical School
in 1990. In his research achievements, Dr. Tanzi served on the team that was the first to find a disease gene ((Huntington&rsquo;s disease)
using human genetic markers, helping to launch the field of neurogenetics. He later co-discovered all three early-onset familial Alzheimer&rsquo;s
disease genes and identified several others as leader of the Cure Alzheimer&rsquo;s Fund Alzheimer&rsquo;s Genome Project. He also co-discovered
the Wilson&rsquo;s disease gene and several other neurological disease genes. Most recently, he and his team used Alzheimer&rsquo;s genes
and human stem cells to create what the New York Times coined, &ldquo;Alzheimer&rsquo;s-in-a-Dish&rdquo;. This is a three-dimensional
human stem cell-derived neural culture system that is considered to be the first true model of Alzheimer&rsquo;s disease, recapitulating
both pathological hallmarks of Alzheimer&rsquo;s disease: plaques and tangles. The model has made drug screening for Alzheimer&rsquo;s
disease 10 times cheaper and 10 times faster. Dr. Tanzi has developed novel therapeutics for Alzheimer&rsquo;s disease including gamma
secretase modulators and metal chaperones (PBT; Prana) aimed at lowering plaque and tangle pathology. Both have been entered into clinical
trials for Alzheimer&rsquo;s patients. Dr. Tanzi is also very active in the areas of integrative medicine and applications to brain health.
In this regard, along with Dr. Deepak Chopra, Dr. Tanzi co-directs the Self-Directed Biological Transformation Initiative (SBTI) aimed
at exploring and quantifying the effects of lifestyle interventions on neuroplasticity and epigenetics.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Tanzi has published over 500 research papers and has received the highest awards in his field, including the Metropolitan Life Foundation
Award, Potamkin Prize, Ronald Reagan Award, Silver Innovator Award, and many others. He was named to TIME magazine&rsquo;s 2015 list
of TIME100 Most Influential People in the World, and received the Smithsonian American Ingenuity Award, the top national award for invention
and innovation. He co-authored the popular trade books &ldquo;Decoding Darkness&rdquo;, New York Times best seller, &ldquo;Super Brain&rdquo;,
and international best seller &ldquo;Super Genes&rdquo; with Dr. Deepak Chopra. He was named by GQ magazine as a Rock Star of Science,
and in his spare time, has played keyboards with the band Aerosmith. With singer, Chris Mann, he also composed the beautiful ballad,
&ldquo;Remember Me&rdquo;, which honors Alzheimer&rsquo;s patients, and is being used to raise funds for Alzheimer&rsquo;s research at
the Cure Alzheimer&rsquo;s Fund, for which, Dr. Tanzi serves as Chair of the Cure Alzheimer&rsquo;s Fund Research Consortium.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 138; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->136<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Li-Huei
Tsai, Ph.D.</I></B> Dr. Tsai has served as a member of our Scientific Advisory Board since June, 2016. Since May 2006, Dr. Tsai has served
as the Director of the Picower Institute for Learning and Memory at the Massachusetts Institute of Technology, a Picower Professor of
Neuroscience, and an Associate Member of the Broad Institute. From 1994 to May 2006, Dr. Tsai served as an Assistant Professor of Pathology
at Harvard Medical School and was promoted to tenure Professor at Harvard in 2002. From 1997 to 2013, Dr. Tsai served as an Investigator
of the Howard Hughes Medical Institute from 1997 to 2013. Dr. Tsai is also a Fellow of the American Association for the Advancement of
Science, a member of the National Academy of Medicine, and an Academician of the Academia Sinica in Taiwan. Dr. Tsai obtained a Ph.D.
from University of Texas Southwestern Medical Centre in Dallas, Texas in 1990 and postdoctoral training at Cold Spring Harbor Laboratories
and Massachusetts General Hospital from 1990 to 1994.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Raymond
Scott Turner, MD, Ph.D. </I></B>Dr. Turner has served as a member of our Scientific Advisory Board since August, 2016. Since April 2020,
Dr. Turner has served as the Vice Chair for Clinical Research, Department of Neurology at Georgetown University Medical Center. Since
July 2008, Dr. Turner has served as a Professor at the Department of Neurology and the Director of the Memory Disorders Program, Department
of Neurology at Georgetown University Medical Center. From March 2007 to July 2008, Dr. Turner served as the Associate Chair in the Department
of Neurology, University of Michigan at Ann Arbor, Michigan. From October 2003 to July 2008, Dr. Turner served as Associate Professor
in the Department of Neurology, University of Michigan. From July 1995 to October 2003, Dr. Turner served as Assistant Professor in the
Department of Neurology, University of Michigan. From September 2002 to July 2008, Dr. Turner served as Chief of Neurology Service at
VA Ann Arbor Healthcare System in Ann Arbor, Michigan. From July 1995 to July 2008, Dr. Turner served as Attending Neurologist and Research
Scientist, Geriatric Research Education and Clinical Center at VA Ann Arbor Healthcare System in Ann Arbor, Michigan. Dr. Turner received
a Bachelor of Science degree in microbiology/molecular biology from Clemson University in 1979. Dr. Turner obtained a Ph.D. in pharmacology
and an MD from Emory University in 1984 and 1988, respectively, and completed his internship, residency, and fellowship at the University
of Pennsylvania, Philadelphia in 1992. Dr. Turner has received numerous prestigious awards, including a fellowship from the Howard Hughes
Medical Institute and a Paul Beeson Scholarship. Dr. Turner serves as a reviewer for granting agencies and biomedical journals, has published
more than seventy peer-reviewed paper, editorials, and book chapters, as well as lectures widely. He became board-certified in Psychiatry
and Neurology in 1993.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Dr.
Claes Wahlestedt, MD, Ph.D. </I></B>Dr. Wahlestedt has served as the Co-Chairman of our Scientific Advisory Board and our Consulting
Chief Medical Officer since January 1, 2016. From January 1, 2016 through October 1, 2021, he previously served as a member of our Board
of Directors. Dr. Wahlestedt is a renowned scientist throughout the pharmaceutical industry. Since March 2011, Dr. Wahlestedt has served
as the Leonard M. Miller Professor &amp; Associate Dean for Therapeutic Innovation at the University of Miami Miller School of Medicine.
From 2005 to March 2011, Dr. Wahlestedt was the founding Professor and Director of Neuroscience at The Scripps Research Institute in
Florida. From 1997 to 2005, Dr. Wahlestedt was the Professor and Department Chair at Karolinska Institute in Stockholm, Sweden. Dr. Wahlestedt
was the Director of Worldwide Genomics for Pharmacia between 1997 to 2004. From 1994 to 1997, Dr. Wahlestedt was a faculty member at
McGill University. From 1993 to 1997, Dr. Wahlestedt directed the research and development team for Astra-Zeneca Research Centre in Montreal,
Canada. From 1989 to 1993, Dr. Wahlestedt was the Assistant Professor of the Department of Neurology and Neurosciences at Cornell University
Medical College in New York, NY. Dr. Wahlestedt has also co-founded 2 other biotech companies, including CuRNA, Inc. and Epigenetix,
Inc. Dr. Wahlestedt is a graduate of Lund University, Sweden with a M.D. in Medicine and Ph.D. in Pharmacology in 1986 and 1987, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Business
Advisors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 139; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->137<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Ulf
Wiinberg.</I></B> Mr. Wiinberg is an experienced healthcare industry professional who has served on the boards of several healthcare
industry associations. Since April 2017, Mr. Wiinberg has had the position of Chief Executive Officer at X-VAX Technology, Inc. From
June 2008 to December 2014, Mr. Wiinberg served as the Chief Executive Officer at Lundbeck, a pharmaceutical company specialized in psychiatric
and neurological disorders. Mr. Wiinberg served as President of the European pharma business at Wyeth from June 2005 to May 2008. At
Wyeth, Mr. Wiinberg also served as President of the global consumer health care business from 2002 to 2005. From 1997 to 2002, Mr. Wiinberg
served as Managing Director at Wyeth UK and Ireland. Ulf is presently a non-executive member of the board of Alfa Laval AB, Agenus Inc
and at the Belgian pharmaceutical company UCB. He is also chairman of the board of Sigrid Therapeutics AB, Chairman of the Board at Hansa
Biopharma as well as CEO and chairman of the board of Ulf Wiinberg Consulting &amp; Invest AB.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Arthur
Kirsch.</I> <FONT STYLE="font-weight: normal">Mr. Kirsch has advised the Company since June 2020 on a variety of financial and strategic
initiatives. Previously he was a Senior Advisor and Head of Global Healthcare at GCA Global from 2005 to 2019, an investment bank providing
strategic M&amp;A and capital markets advice for growth companies. From 1994 to 2004 he was Head of Research for Vector Securities with
over 200 companies under coverage and later became Head of Capital Markets that acquired by Prudential Securities. From 1990 to 1993
Mr. Kirsch was CEO OF Natwest Markets the investment banking division of Natwest Bank in the U.K. He began his career at Drexel Burnham
where he was an Executive Vice President running the global equity division as well as being on the Executive Committee. Mr. Kirsch has
served on the Board of Kadmon since 2019, a publicly traded bio pharmaceutical company where he serves on the Audit Committee. He also
serves on the board of Liquidia Technologies a public nano technology healthcare company as well as being the Chairman of the Audit Committee.
Mr. Kirsch received his B.A. in Finance from the University of Rhode Island and an M.B.A. from Bernard M. Baruch College.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Mark
Dant. </I><FONT STYLE="font-weight: normal">Mr. Dant, EveryLife Foundation for Rare Diseases Board Chair, is a parent advocate and retired
Carrolton, Texas Police Department Chief of Police. Mark and his wife Jeanne are the parents of Ryan, who is 33 years old and the longest
treated person in the world with MPS I. Mark and Jeanne spearheaded the funding for the first MPS Enzyme Replacement Therapy, Aldurazyme,
through their Foundation, the Ryan Foundation. In partnership with Dr. Emil Kakkis, Mr. Dant and his family were also key advocates speaking
to the FDA about the importance and significant impact of ERT for the treatment of mucopolysaccharidoses. In 2009, Mr. Dant and his family
successfully championed Congress to pass the Ryan Dant Health Care Opportunity Act, H.R. 1441-111.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborating
Partners</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our philosophy and strategy are to utilize strong
established outside partners. These strategic partnerships have enabled the Company to operate with a relatively small management
team resulting in a low fixed overhead cost. This strategy enables us to utilize resveratrol&rsquo;s multi-functional effects
quickly and effectively by adding new partners for each project we want to pursue. Below are our present key partners as well as supporting
organizations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 43pt; text-align: justify">
<IMG SRC="form1-a_028.jpg" ALT="" STYLE="height: 19px; width: 81px">Catalent is the world&rsquo;s #1 drug development, delivery and supply partner. Catalent has helped thousands of innovators by optimizing
and manufacturing thousands of pharmaceutical, biologic, consumer health and beauty products utilizing their superior innovative drug
delivery technologies to improve their value to patients and consumers. Catalent is our JOTROL product manufacturer. The material
terms of our agreement with Catalent are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signing
    Date</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
                                            16, 2020</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-indent: -0.25in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination
  Date</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
                                            completion of project</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-indent: -0.25in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination
  Provisions &amp; Penalties</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either
                                            party may terminate project or any portion at any time by providing 30 days written notice.
                                            </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Catalent
                                            reserves the right to project cancellation fees</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-indent: -0.25in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees
  Payable Under the Agreement</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepayment
                                            1 - $33,000</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepayment
                                            2 - $58,000</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepayment
                                            3 - $64,100</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Project
                                            completed and fully paid by the Company</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt 0 0.5in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of this agreement is attached as Exhibit 10.19 to the registration statement of which this prospectus forms a part.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt 0 0.5in; text-align: justify; text-indent: 0pt"><IMG SRC="forms-1a_019.jpg" ALT="" STYLE="float: left; height: 63px; width: 61px">
Evolva discovers and provides innovative, high-value, sustainable ingredients, with an emphasis on health, wellness and nutrition. Evolva
is our API supplier. We deal with Evolva on a basis of purchase orders for resveratrol needed for JOTROL manufacturing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 43pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 43pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 140; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->138<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 43pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt 0 0.5in; text-align: justify"><IMG SRC="forms-1a_020.jpg" ALT="" STYLE="float: left; height: 45px; width: 173px">
Murdoch Children&rsquo;s Research Institute (MCRI) is the largest child research institute in Australia. We have a worldwide exclusive
license on all its research and know-how in Friedreich&rsquo;s ataxia. A description of the terms of this agreement is included on
page 93 hereof. A copy of this agreement is attached as Exhibit 10.18 to the registration statement of which this prospectus forms a
part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 43pt; text-align: justify; text-indent: -0.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 43pt; text-align: justify; text-indent: -0.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt 0 0.5in; text-align: justify"><IMG SRC="forms-1a_021.jpg" ALT="|Users|JOT123|Desktop|JOT Pictuures|FARA logo.png" STYLE="float: left; height: 22px; width: 89px">The
Friedreich&rsquo;s Ataxia Research Alliance (FARA) is a national, public, 501(c)(3), non-profit, tax-exempt organization dedicated to
the pursuit of scientific research leading to treatments and a cure for Friedreich&rsquo;s Ataxia. We work closely with FARA <FONT STYLE="letter-spacing: -0.15pt">in
a supporting role in</FONT> all aspects of upcoming clinical trial for FA. Although we do not have any formal written or
verbal agreement with FARA, FARA as the patient organization for Friedreich&rsquo;s Ataxia, has in the past been willing to provide input to
clinical trial protocols, KOL and patient connections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt 0 0.5in; text-align: justify"><IMG SRC="forms-1a_022.jpg" ALT="A picture containing logo&#10;&#10;Description automatically generated" STYLE="float: left; height: 58px; width: 98px">Syneos
Health has helped to develop of commercialize a large amount of <FONT STYLE="letter-spacing: -0.15pt">all new </FONT>drugs approved by
the FDA and by the EMA over the last five years. Syneos conducted our Phase I PK study at their Miami clinical site. Syneos has completed,
signed and issued the final Clinical Study Report. The material terms of our agreement with Syneos are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signing
  Date</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
                                            15, 2020</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination
  Date</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
                                            receipt of Phase I final study report</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination
  provisions &amp; penalties</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement
                                            may be terminated or postponed by either party, without cause upon a 30 day prior termination
                                            or postponement notice. </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either
                                            party may terminate if the authorization and approval to perform the Study is withdrawn by
                                            the applicable regulatory agency having jurisdiction over the Study</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            emergence of any unanticipated significant safety issues with the study design</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination
                                            for breach</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination
                                            for bankruptcy</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effects
                                            on termination or postponement</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cooperation</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            rights affected</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees
  Payable Under Agreement</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
                                            Budget of $815,866</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">Final
                                            cost of $858,289 which has been fully paid</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of this agreement is attached as Exhibit 10.20 to the registration statement of which this prospectus forms a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt 0 0.5in; text-align: justify"><IMG SRC="forms-1a_023.jpg" ALT="Logo, company name&#10;&#10;Description automatically generated" STYLE="float: left; height: 83px; width: 146px">
Our company was started based on resveratrol research at University of Miami. Two of our Co-Founders, Professor Claes Wahlestedt,
MD, Ph.D. &amp; Associate Professor Shaun Brothers, Ph.D., MBA, were conducting those studies and are actively involved in all
our R&amp;D activities. Several pre-clinical projects with our product have been conducted at UM under a material transfer agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0pt; margin-bottom: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
material terms of our material transfer agreement with the University of Miami are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Type
    of agreement: Material Transfer Agreement</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UM
    is using JOTROL in pre-clinical studies that can be grant financed. UM obtains and keep the grants while the Company has the exclusive
    rights to all data and results from such studies. No payments are due to any of the parties.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
    Date</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    5, 2017</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-indent: -0.25in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination
    Date</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    4, 2019</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-indent: -0.25in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination
    provisions &amp; penalties</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either
    party may terminate the agreement upon 30 days written notice. Upon termination, recipient and recipient organization agree to return
    or destroy the material, at the providing organization&rsquo;s request.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of this agreement is attached as Exhibit 10.21 to the registration statement of which this prospectus forms a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 43pt; text-align: justify"><IMG SRC="forms1-a_024.jpg" ALT="Icon&#10;&#10;Description automatically generated" STYLE="float: left; height: 41px; width: 67px">
Technical Resources International, Inc. (TRI) is experienced in the successful design and implementation of regulatory strategies to
optimize product development pathways. By employing highly qualified staff, some of whom were previously at the FDA, TRI is able
to deliver a portfolio of regulatory and medical writing services to address the needs of every clinical research project. The material
terms of our agreement with TRI, as amended, are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signing
    Date</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    24, 2021</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination
    Date</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 144px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    end term designated</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination
    provisions &amp; penalties</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 144px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either
    party may terminate the agreement without cause at any time during the term of the agreement upon 30 days prior written notice to
    the other party. Either party may terminate this agreement for material breach upon 10 days written notice specifying the nature
    of the breach, if such breach has not been substantially cured within the 10 day period. Either party may terminate this agreement
    immediately upon provision of written notice if the other party becomes insolvent or files for bankruptcy. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$216.32/hour
    which may increase up to 4% per year </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 144px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$250
    Publishing fee for each submission</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 144px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$20K
    retainer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9632;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
    75% of retainer is fulfilled, invoice for replenishment of retainer will be due</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of this agreement is attached as Exhibit 10.22 to the registration statement of which this prospectus forms a part. Additionally,
a copy of the amendment to this agreement is attached as Exhibit 10.23 to the registration statement of which this prospectus forms a
part.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 141; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->139<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Family
Relationships</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no family relationships among any of our directors or executive officers, except that Christer Ros&eacute;n, our Chief Executive
Officer, is the father of Alexander Ros&eacute;n, our Chief Administrative Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Involvement
in Certain Legal Proceedings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
executive officer, member of the board of directors or control person of our Company has been involved in any legal proceeding listed
in Item 401(f) of Regulation S-K in the past 10 years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Board
Committees and Director Independence</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to this offering, there has been no public market for our common stock. Our common stock is not currently listed on any national securities
exchange market or quoted on the OTC Markets. We have applied to list our common stock on the Nasdaq Capital Market. In order
to list our common stock on the Nasdaq Capital Market, we are required to comply with the Nasdaq Capital Market standards relating to
corporate governance, requiring, among other things, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    majority of our Board of Directors to consist of &ldquo;independent directors&rdquo; as defined by the applicable rules and regulations
    of the Nasdaq Capital Market;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    compensation of our executive officers to be determined, or recommended to the Board of Directors for determination, by independent
    directors constituting a majority of the independent directors of the Board in a vote in which only independent directors participate
    or by a Compensation Committee comprised of at least two independent directors as well as composed entirely of independent directors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That
    director nominees to be selected, or recommended to the Board of Directors for selection, by independent directors constituting a
    majority of the independent directors of the Board in a vote in which only independent directors participate or by a nomination committee
    comprised of at least two independent directors as well as composed entirely of independent directors; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Establishment
    of an audit committee with at least three independent directors as well as composed entirely of independent directors, where at least
    one of the independent directors qualifies as an audit committee financial expert under SEC rules and as a financially sophisticated
    audit committee member under the Nasdaq Capital Market rules.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For purposes of the audit committee
composition requirements, we must have at least one independent director on our audit committee at the time of listing on the Nasdaq
Capital Market, at least two independent directors within 90 days of listing on the Nasdaq Capital Market and at least three independent
directors within one year of listing on the Nasdaq Capital Market, where at least one of the independent directors qualifies as an audit
committee financial expert under SEC rules and as a financially sophisticated audit committee member under the Nasdaq Capital Market
rule. In accordance with Rule 5615(b)(1), since we are listing in connection with our initial public offering, we are permitted to phase
in our compliance with the independent committee requirements set forth in Rules 5605(d)(2) (for purposes of the compensation committee)
and Rules 5605(e)(1)(B) (for purposes of the nominating committee) on the same schedule as we are permitted to phase in our compliance
with the independent audit committee requirement pursuant to Rule 10A-3(b)(1)(iv)(A) under the Act. Accordingly, we are permitted to
phase in the compensation committee and nominating committee composition requirements as follows: (1) one member must satisfy the independence
requirement at the time of listing; (2) a majority of members must satisfy the independence requirement within 90 days of listing; and
(3) all members must satisfy the independence requirement within one year of listing. Furthermore, a Company listing in connection with
its initial public offering shall have twelve months from the date of listing to comply with the majority independent board requirement
in Rule 5605(b). The foregoing is referred to herein as the &ldquo;Independence Composition Requirements.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 142; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->140<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company&rsquo;s Board
of Directors has affirmatively determined that currently three of its seven directors, including, Christer Ros&eacute;n, Marshall
Hayward, Ph.D., and Alison D. Silva, are non-independent directors of the Company and four of its seven directors, namely
Nicholas H. Hemmerly, Julie Kampf, Allison W. Brady, and Holger Weis, are independent directors of the Company. Therefore, a majority
of the members of our Board of Directors are independent. Currently, the Company&rsquo;s audit committee consists of three independent
directors, namely Holger Weis, Allison W. Brady and Nicholas Hemmerly. Currently, the Company&rsquo;s compensation committee consists
of three independent directors, namely Nicholas H. Hemmerly, Julie Kampf and Allison W. Brady. Currently, the Company&rsquo;s nominating
committee consists of three independent director, namely Julie Kampf, Holger Weis and Nicholas H. Hemmerly. Mr. Weis qualifies
as an audit committee financial expert under SEC rules and as a financially sophisticated audit committee member under the Nasdaq Capital
Market rules.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Board
Leadership Structure and Board&rsquo;s Role in Risk Oversight</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not separated the positions of Chairman of the Board and Chief Executive Officer. Christer Ros&eacute;n has served as our Chairman
of the Board of Directors and Chief Executive Officer since January 1, 2016. We believe that combining the positions of Chairman and
Chief Executive Officer allows for focused leadership of our organization which benefits us in our relationships with investors, customers,
suppliers, employees and other constituencies. We believe that consolidating the leadership of the Company under Mr. Ros&eacute;n is
the appropriate leadership structure for our Company and that any risks inherent in that structure are balanced by the oversight of our
other independent directors on our Board. However, no single leadership model is right for all companies and at all times. The Board
recognizes that depending on the circumstances, other leadership models, such as the appointment of a lead independent director, might
be appropriate. Accordingly, the Board may periodically review its leadership structure. In addition, following the completion of the
offering, the Board will hold executive sessions in which only independent directors are present.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board is generally responsible for the oversight of corporate risk in its review and deliberations relating to our activities. Our principal
source of risk falls into two categories, financial and product commercialization. The audit committee oversees management of financial
risks; our Board regularly reviews information regarding our cash position, liquidity and operations, as well as the risks associated
with each. The Board regularly reviews plans, results and potential risks related to our business. The Board is also expected to oversee
risk management as it relates to our compensation plans, policies and practices for all employees including executives and directors,
particularly whether our compensation programs may create incentives for our employees to take excessive or inappropriate risks which
could have a material adverse effect on the Company.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Committees
of the Board of Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Audit
Committee</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have established an audit committee (&ldquo;Audit Committee&rdquo;), which consists of three independent directors, Holger Weis, Allison
W. Brady and Nicholas Hemmerly. Mr. Weis is the chair of the Audit Committee. Mr. Weis qualifies as an audit committee financial
expert under SEC rules and as a financially sophisticated audit committee member under the Nasdaq Capital Market rules. Our Audit Committee
adopted a written charter, a copy of which is posted on the Corporate Governance section of our website, at www.jupiterneurosciences.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 143; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->141<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Audit Committee is authorized to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approve
    and retain the independent auditors to conduct the annual audit of our financial statements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">review
    the proposed scope and results of the audit;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">review
    and pre-approve audit and non-audit fees and services;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">review
    accounting and financial controls with the independent auditors and our financial and accounting staff;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">review
    and approve transactions between us and our directors, officers and affiliates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recognize
    and prevent prohibited non-audit services;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
    procedures for complaints received by us regarding accounting matters; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">oversee
    internal audit functions, if any.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Compensation
Committee</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have established a compensation committee (&ldquo;Compensation Committee&rdquo;), which consists of three independent directors, Nicholas
H. Hemmerly, Julie Kampf and Allison Brady. Mr. Hemmerly is the chair of the Compensation Committee. Our Compensation Committee adopted
a written charter, a copy of which is posted on the Corporate Governance section of our website, at www.jupiterneurosciences.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Compensation Committee is authorized to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">review
    and determine the compensation arrangements for management;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
    and review general compensation policies with the objective to attract and retain superior talent, to reward individual performance
    and to achieve our financial goals;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">administer
    our incentive compensation and benefit plans and purchase plans;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">oversee
    the evaluation of the Board of Directors and management; and</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">review
    the independence of any compensation advisers.</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Nominating
and Corporate Governance Committee</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have established a nominating and corporate governance committee (&ldquo;Nominating and Corporate Governance Committee&rdquo;), which
consists of three independent directors, Julie Kampf, Holger Weis and Nicholas H. Hemmerly. Ms. Kampf is the chair of the Nominating
and Corporate Governance Committee. Our Nominating and Corporate Governance Committee adopted a written charter, a copy of which is posted
on the Nominating and Corporate Governance Committee section of our website, at www.jupiterneurosciences.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
functions of the Nominating and Corporate Governance Committee, among other things, include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying
    individuals qualified to become board members and recommending director;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">nominees
    and board members for committee membership;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
    and recommending to our board corporate governance guidelines;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">review
    and determine the compensation arrangements for directors; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    the evaluation of our board of directors and its committees and management.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Compensation
Committee Interlocks and Insider Participation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of our executive officers currently serves, or in the past year has served, as a member of the Board of Directors or Compensation Committee
of any entity that has one or more executive officers on our Board of Directors or Compensation Committee. For a description of transactions
between us and members of our Compensation Committee and affiliates of such members, please see &ldquo;Certain Relationships and Related
Party Transactions&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 144; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->142<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Code
of Ethics</B></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has adopted a Code of Ethics and Business Conduct that applies to all of its directors, officers (including our principal executive
officer, principal financial officer, principal accounting officer or controller, and any person performing similar functions) and employees.
The Code of Ethics and Business Conduct is available on our website at www.jupiterneurosciences.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Limitation
on Liability and Indemnification of Officers and Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
certificate of incorporation provides that our officers and directors will be indemnified by us to the fullest extent authorized by Delaware
law, as it now exists or may in the future be amended. In addition, our certificate of incorporation provides that our directors will
not be personally liable for monetary damages to us for breaches of their fiduciary duty as directors, except to the extent such exemption
from liability or limitation thereof is not permitted by the Delaware General Corporation Law (&ldquo;DGCL&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
certificate of incorporation also permits us to maintain insurance on behalf of any officer, director or employee for any liability arising
out of his or her actions, regardless of whether Delaware law would permit such indemnification. We have purchased a policy of directors&rsquo;
and officers&rsquo; liability insurance that insures our officers and directors against the cost of defense, settlement or payment of
a judgment in some circumstances and insures us against our obligations to indemnify our officers and directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
provisions may discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. These provisions
also may have the effect of reducing the likelihood of derivative litigation against officers and directors, even though such an action,
if successful, might otherwise benefit us and our stockholders. Furthermore, a stockholder&rsquo;s investment may be adversely affected
to the extent we pay the costs of settlement and damage awards against officers and directors pursuant to these indemnification provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that these provisions and the insurance are necessary to attract and retain talented and experienced officers and directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ar_009"></A>EXECUTIVE
COMPENSATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
Compensation Table</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table provides
information regarding the compensation we paid during fiscal years ended December 31, 2023 and 2022 to our chief executive
officer (principal executive officer), chief scientific officer, former chief financial officer, chief administrative officer and chief
business officer. We refer to these individuals as our &ldquo;named executive officers.&rdquo;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Name and Position</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Year</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Salary
    <SUP>(9)</SUP> <SUP> </SUP>($)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Bonus <SUP>(8) </SUP>($)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Stock<BR>
    Awards<BR>
    ($)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Option<BR>
    Awards<BR>
    ($) <SUP>(7)</SUP> </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Non-<BR>
    Equity<BR>
    Incentive<BR>
    Plan<BR>
    Compensation<BR>
    ($)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Non-<BR>
    qualified<BR>
    Deferred<BR>
    Compensation<BR>
    Earnings<BR>
    ($)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>All<BR>
    Other<BR>
    Compensation<BR>
    ($) <SUP>(8)</SUP> </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Total<BR>
    ($)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 29%"><FONT STYLE="font-size: 10pt">Christer Ros&eacute;n</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: center"> <FONT STYLE="font-size: 10pt">2023</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"> <FONT STYLE="font-size: 10pt">336,000</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"> <FONT STYLE="font-size: 10pt">(1)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"> 0<FONT STYLE="font-size: 10pt"></FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"> <FONT STYLE="font-size: 10pt">(1)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"> <FONT STYLE="font-size: 10pt">9,722</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"> <FONT STYLE="font-size: 10pt">345,722</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-size: 10pt">2022</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">420,000</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">(1)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">(1)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">13,035</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">433,035</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Marshall Hayward</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-size: 10pt">2023</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">268,800</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">(2)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">(2)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">268,800</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Chief Scientific Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-size: 10pt">2022</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">336,000</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">(2)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">(2)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">11,485</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">347,485</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Dana Eschenburg Perez</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-size: 10pt">2023</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">(3)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">(3)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-size: 10pt">former Chief Financial Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> <FONT STYLE="font-size: 10pt">2022</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"> <FONT STYLE="font-size: 10pt">270,000</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <FONT STYLE="font-size: 10pt">(3)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <FONT STYLE="font-size: 10pt">(3)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"> <FONT STYLE="font-size: 10pt">32,849</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"> <FONT STYLE="font-size: 10pt">302,849</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Alexander Ros&eacute;n</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-size: 10pt">2023</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">192,000</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">(4)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">(4)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">9,722</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">201,722</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Chief Administrative Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-size: 10pt">2022</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">240,000</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">(4)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">(4)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">36,000</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">276,000</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Alison Silva</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-size: 10pt">2023</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">240,000</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">(5)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">(5)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">192,500</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">5,804</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">438,304</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Chief Business Officer &amp; President</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-size: 10pt">2022</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">275,000</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">(5)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">(5)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">-</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">36,000</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">311,000</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> Saleem Elmasri </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> 2023 </P>
</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> $ </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 200,000 </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> (5) </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> $ </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> (5) </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> $ </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> $ </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 589,500 </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> $ </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> $ </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> $ </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> $ </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 789,500 </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> Chief Financial Officer </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> 2022 </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> $ </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> (6) </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> $ </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> (6) </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> $ </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> $ </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> $ </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> $ </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> $ </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> $ </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christer Ros&eacute;n has served as our Chief Executive Officer since January 1, 2016.</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            2022, Mr. Ros&eacute;n was paid $420,000 and agreed to defer receipt of
                                            $273,000 of salary. The deferred compensation is recorded in accrued compensation
                                            as of December 31, 2022. No interest was accrued or due on the deferred compensation for
                                            2022. </FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            2023, Mr. Ros&eacute;n agreed to defer all salary compensation and to
                                            reduce his salary to $84,000 beginning on October 1, 2023. The deferred compensation
                                            is recorded in accrued compensation as of December 31, 2023. No interest was
                                            accrued or due on the deferred compensation for </FONT> 2023. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 21,
2022, Mr. Ros&eacute;n agreed to forgive $634,760 of earned compensation in exchange for 476,070 restricted stock awards.
On September 29, 2023, Mr. Ros&eacute;n agreed to forgive $1,433,938 of earned compensation in exchange for 710,344 options to
purchase common stock, 430,181 restricted stock units, and $179,242 to be paid out as a bonus upon an IPO. The options to purchase
common stock have a strike price of $1.33. On December 18, 2023 the restricted stock units issued on September 29, 2023 were
cancelled and reissued as part of an additional forgiveness, whereby, Mr. Ros&eacute;n agreed to forgive the $179,242 of accrued
bonus in exchange for 88,909 options to purchase common stock and an additional 67,215 restricted stock units (total of 497,392 restricted stock units). The options to
purchase common stock have a strike price of $1.33. </FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 145; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->143<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Marshall Hayward has served as our Chief Scientific Officer since January 1, 2016.</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">During
                                            2022, Mr. Hayward was paid $336,000 and agreed to defer receipt of $218,400
                                            of salary. The deferred compensation is recorded in accrued compensation
                                            as of December 31, 2022. No interest was accrued or due on the deferred compensation
                                            for 2022. </FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"> &nbsp; </FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">During
                                            2023, Mr. Hayward agreed to defer all salary compensation and to
                                            reduce his salary to $67,200 beginning on October 1, 2023. The deferred compensation
                                            is recorded in accrued compensation as of December 31, 2023. No interest was
                                            accrued or due on the deferred compensation for </FONT> 2023. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">On July 21, 2022, Mr. Hayward agreed to forgive $532,529 of earned
compensation in exchange for 399,401 restricted stock awards. On September 29, 2023, Mr. Hayward agreed to forgive
$1,123,727 of earned compensation in exchange for 556,672 options to purchase common stock, 337,118 restricted stock units, and
$140,466 to be paid out as a bonus upon an IPO. The options to purchase common stock have a strike price of $1.33. On December 18,
2023 the restricted stock units issued on September 29, 2023 were cancelled and reissued as part of an additional forgiveness,
whereby, Mr. Hayward agreed to forgive the $140,466 of accrued bonus in exchange for 69,675 options to purchase common stock and an
additional 52,676 restricted stock units (total of 389,794 restricted stock units). The options to purchase common stock have a strike price of $1.33. </FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Dana Eschenburg Perez had served as our Chief Financial Officer from June 1, 2021 until resigning on December 31, 2022.</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">During
                                            2022, Ms. Perez was paid $270,000 and agreed to defer receipt of $141,750 of salary. The deferred
                                            compensation is recorded in accrued compensation as of December 31, 2022. No
                                            interest was accrued or due on the deferred compensation for 2022.</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0">On
                                            July 21, 2022, Ms. Perez agreed to forgive $13,500 of earned compensation in exchange
                                            for 10,125 restricted stock awards. On March 15, 2024, Ms. Perez agreed to forgive
                                            $100,000 of accrued compensation in exchange for 49,605 options to purchase common stock
                                            and 7,500 restricted stock units, The options to purchase common stock have a strike price
                                            of $1.33. </P>
<P STYLE="margin-top: 0; margin-bottom: 0"></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">(4)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0">Alexander Ros&eacute;n has served as our Chief Administrative Officer since January 1, 2016.</P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0">During 2022,
                                            Mr. Ros&eacute;n was paid $240,000 and agreed to defer receipt of $126,00
                                            of salary. The deferred compensation is recorded in accrued compensation as
                                            of December 31, 2022. No interest was accrued or due on the deferred compensation
                                            for 2022. </P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0">During 2023,
                                            Mr. Ros&eacute;n agreed to defer all salary compensation and to reduce his
                                            salary to $48,000 beginning on October 1, 2023. The deferred compensation is recorded
                                            in accrued compensation as of December 31, 2023. No interest was accrued or
                                            due on the deferred compensation for 2023. </P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"> &nbsp; </P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0">On July 21,
                                            2022, Mr. Ros&eacute;n agreed to forgive $<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">128,810
                                            of earned compensation in exchange for 96,608 restricted stock awards.
                                            On September 29, 2023, Mr. Ros&eacute;n agreed to forgive $477,382 of earned compensation
                                            in exchange for 234,998 options to purchase common stock, 142,316 restricted stock units, and
                                            $59,298 to be paid out as a bonus upon an IPO. The options to purchase common stock have
                                            a strike price of $1.33. On December 18, 2023 the restricted stock units issued on September
                                            29, 2023 were cancelled and reissued as part of an additional forgiveness, whereby, Mr. Ros&eacute;n
                                            agreed to forgive the $59,298 of accrued bonus in exchange for 29,415 options to purchase common
                                            stock and an additional 29,415 restricted stock units (total of 164,553 restricted stock units). The options to purchase common stock have a strike
                                            price of $1.33. </FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">(5)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0">Alison Silva has served as our Chief Business Officer and President since <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 1, 2021.</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            2022, Ms. Silva was paid $240,000 and agreed to defer receipt of $170,000 of salary.
                                            The deferred compensation is recorded in accrued compensation as of December 31,
                                            2022. No interest was accrued or due on the deferred compensation for 2022. </FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            2023, Ms. Silva agreed to defer all salary compensation of salary and to reduce
                                            her salary to $60,000 beginning on October 1, 2023. The deferred compensation is recorded
                                            in accrued compensation as of December 31, 2023. No interest was accrued or
                                            due on the deferred compensation for 2023. </FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> &nbsp; </FONT></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> On September
                                                                              29, 2023, Ms. Silva agreed to forgive $317,774 of earned compensation in exchange for 157,418 options to purchase common stock,
                                                                              95,333 restricted stock units, and $39,722 to be paid out as a bonus upon an IPO. On December 18, 2023 the restricted stock units
                                                                              issued on September 29, 2023 were cancelled and reissued as part of an additional forgiveness, whereby, Ms. Silva agreed to forgive
                                                                              the $39,722 of accrued bonus in exchange for 19,703 options to purchase common stock and an additional 14,895 restricted stock units (total of 110,227 restricted stock units). The options to
                                                                              purchase common stock have a strike price of $1.33. </FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> (6) </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"> Saleem Elmasri
                                            has served as our Chief Financial Officer and President since January 1, 2023. </P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"> &nbsp; </P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"> During 2023,
                                            Mr. Elmasri agreed to defer all salary compensation and to reduce his salary to $250,000
                                            beginning on February 1, 2023, and further reduced to $60,000 beginning on October 1, 2023.
                                            The deferred compensation is recorded in accrued compensation as of December 31, 2023. No
                                            interest was accrued or due on the deferred compensation for 2023. </P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"> &nbsp; </P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"> On September
                                            29, 2023, Mr. Elmasri agreed to forgive $164,720 of earned compensation in exchange for 81,599
                                            options to purchase common stock, 49,417 restricted stock units, and $45,000 to be paid out
                                            as a bonus upon an IPO. The options to purchase common stock have a strike price of $1.33.
                                            On December 18, 2023 the restricted stock units issued on September 29, 2023 were cancelled
                                            and reissued as part of an additional forgiveness, whereby, Mr. Elmasri agreed to forgive
                                            the $45,000 of accrued bonus in exchange for 22,320 options to purchase common stock and
                                            an additional 16,875 restricted stock units (total of 66,292 restricted stock units). The
                                            options to purchase common stock have a strike price of $1.33. </P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">(7)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">This amount reflects the
    aggregate grant-date fair value of stock awards computed in accordance with FASB ASC Topic 718. See Note 9 &ndash; Stockholders&rsquo;
    Deficit &ndash; Stock Options, of the audited December 31, 2023 financial statements.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">(8)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">This amount represents health insurance premiums and medical reimbursements paid by the Company.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">(9)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">There is no amount of salary or bonus earned in a given fiscal year in the table that is not calculable through the latest practicable date.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Employ<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ment
Agreements</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into employment agreements with certain of its officers and employees. These employment agreements are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Employment
Agreement with Christer Rosen, dated as of September 1, 2021.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
C. Rosen&rsquo;s agreement provides that he will serve as the Chief Executive Officer of the Company and provides that he will be paid
an annual base salary of $420,000. Commencing with the Company&rsquo;s 2021 fiscal year, Mr. C. Rosen is eligible to receive an annual
cash bonus, with the target amount of the bonus equal to 50% of the base salary in the year to which the bonus relates, and the actual
amount of the bonus may be greater or less than the target amount, and will ultimately be determined by the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> <I>Amended Employment
Agreement with Christer Rosen, dated as of December 18, 2023</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> Mr. C. Rosen&rsquo;s employment
agreement was amended on December 18, 2023. The amendment reduces Mr. C. Rosen&rsquo;s annual base salary from $420,000 to $84,000, effective
retrospectively to October 1, 2023, until the time that the Company has raised additional capital from the sale of its securities in
the amount of $1,500,000 (the &ldquo;Reduction Period&rdquo;). Upon the expiration of the Reduction Period, the base salary shall be
adjusted to be 105% the original base salary. The remainder of the original agreement shall remain in full force. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Employment
Agreement with Alexander Rosen, dated as of June 1, 2021.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Mr. A. Rosen&rsquo;s agreement
provides that he will serve as the Chief Administrative Officer of the Company, that he will be paid an annual base salary of $240,000
and that he will be issued an option to acquire 337,500 shares of Common Stock, pursuant to a separate option
agreement. 25% of the options are vested upon issuance, with the balance to vest in equal monthly installments over the following 36
months, and the option has a 10 year term. The exercise price for the shares of common stock is $1.33 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing
with the Company&rsquo;s 2021 fiscal year, Mr. A. Rosen is eligible to receive an annual cash bonus, with the target amount of the bonus
equal to 30% of the base salary in the year to which the bonus relates, and the actual amount of the bonus may be greater or less than
the target amount, and will ultimately be determined by the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Amended
Employment Agreement with Alexander Rosen, dated as of December 18, 2023</I></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
A. Rosen&rsquo;s employment agreement was amended on December 18, 2023. The amendment reduces Mr. A. Rosen&rsquo;s annual base salary from
$240,000 to $48,000, effective retrospectively to October 1, 2023, until the time that the Company has raised additional capital from
the sale of its securities in the amount of $1,500,000 (the &ldquo;Reduction Period&rdquo;). Upon the expiration of the Reduction Period,
the base salary shall be adjusted to be 105% the original base salary. The remainder of the original agreement shall remain in full force.</FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 146; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->144<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Employment
Agreement with Alison Silva, dated as of September 1, 2021.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms.
Silva&rsquo;s agreement provides that she will serve as the President and Chief Business Officer of the Company and that she will be
paid an annual base salary of $300,000, provided that, for the first 6 months that the agreement is in effect, Ms. Silva will work on
a part time basis at a maximum of 25 hours per week and her salary will be 50% of the amount above (i.e., based on a $150,000 annual
salary). After this 6 month period, Ms. Silva will work full time for the Company. The agreement also provides that Ms. Silva will be
issued an option to acquire 562,500 shares of Common Stock, pursuant to a separate option agreement. 25% of
the options are vested upon issuance, with the balance to vest in equal monthly installments over the following 36 months, and the option
has a 10 year term. The exercise price for the shares of common stock is $1.33 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing
with the Company&rsquo;s 2021 fiscal year, Ms. Silva is eligible to receive an annual cash bonus, with the target amount of the bonus
equal to 30% of the base salary in the year to which the bonus relates, and the actual amount of the bonus may be greater or less than
such target amount, and will ultimately be determined by the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> <I>Amended Employment
Agreement with Alison Silva, dated as of December 18, 2023</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> <I>&nbsp;</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <I></I>Ms.
A. Silva&rsquo;s employment agreement was amended on December 18, 2023. The amendment reduces Ms. A. Silva&rsquo;s annual base salary
from $300,000 to $60,000, effective retrospectively to October 1, 2023, until the time that the Company has raised additional capital
from the sale of its securities in the amount of $1,500,000 (the &ldquo;Reduction Period&rdquo;). Upon the expiration of the Reduction
Period, the base salary shall be adjusted to be 105% the original base salary. The remainder of the original agreement shall remain in
full force. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Employment
Agreement with Marshall Hayward, dated as of September 1, 2021.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Hayward&rsquo;s agreement provides that he will serve as the Chief Scientific Officer of the Company and that he will be paid an annual
base salary of $336,000. Commencing with the Company&rsquo;s 2021 fiscal year, Mr. Hayward is eligible to receive an annual cash bonus,
with the target amount of the bonus equal to 30% of the base salary in the year to which the bonus relates, and the actual amount of
the bonus may be greater or less than such target amount, and will ultimately be determined by the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> <I>Amended Employment
Agreement with Marshall Hayward, dated as of December 18, 2023</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> <I>&nbsp;</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> Mr.
M. Hayward&rsquo;s employment agreement was amended on December 18, 2023. The amendment reduces Mr. M. Hayward&rsquo;s annual base salary
from $336,000 to $67,200, effective retrospectively to October 1, 2023, until the time that the Company has raised additional capital
from the sale of its securities in the amount of $1,500,000 (the &ldquo;Reduction Period&rdquo;). Upon the expiration of the Reduction
Period, the base salary shall be adjusted to be 105% the original base salary. The remainder of the original agreement shall remain in
full force. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Provisions
applicable to all of the employment agreements.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the employment agreements described above has a term of 3 years, which will be automatically extended for one or more additional terms
of 1 year each unless either party provides notice to the other party of their desire to not so renew the term at least 30 days prior
to the expiration of the then-current term. Each of the agreements is &ldquo;at will,&rdquo; meaning that either party may terminate
the employment at any time and for any reason, subject to the provisions of the applicable agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
executive is entitled to fringe benefits consistent with the practices of the Company, and to the extent the Company provides similar
benefits to the Company&rsquo;s executive officers, and is entitled to be reimbursed for all reasonable and necessary out-of-pocket business,
entertainment and travel expenses incurred in connection with the performance of their duties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 147; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->145<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
agreement may be terminated by the Company at any time, either with or without &ldquo;Cause&rdquo;, and by the applicable executive any
time, either with or without &ldquo;Good Reason&rdquo;. For all of the executives other than Ms. Silva, &ldquo;Cause&rdquo; is defined
as (i) violation of any material written rule or policy of the Company for which violation any employee may be terminated pursuant to
the written policies of the Company reasonably applicable to an executive employee; (ii) misconduct by the applicable executive to the
material detriment of the Company; (iii) the applicable executive conviction (by a court of competent jurisdiction, not subject to further
appeal) of, or pleading guilty to, a felony; (iv) the applicable executive&rsquo;s gross negligence in the performance of their duties
and responsibilities to the Company as described in the agreement; or the applicable executive&rsquo;s material failure to perform their
duties and responsibilities to the Company as described in the agreement (other than any such failure resulting from their incapacity
due to physical or mental illness or any such failure subsequent to the applicable executive delivered a notice of termination without
Cause by the Company or delivering a notice of termination for Good Reason to the Company), in either case after written notice from
the Board to the applicable executive of the specific nature of such material failure and such executive&rsquo;s failure to cure such
material failure within 10 days following receipt of such notice</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
Ms. Silva, &ldquo;Cause&rdquo; is defined as (i) a material violation of any material written rule or policy of the Company for which
a material violation by any employee may be terminated pursuant to the written policies of the Company reasonably applicable to an executive
employee, after written notice from the Board to Ms. Silva of the specific nature of such material violation and Ms. Silva&rsquo;s failure
to cure such material violation within 30 days following receipt of such notice (ii) Ms. Silva&rsquo;s conviction (by a court of competent
jurisdiction, not subject to further appeal) of, or pleading guilty to, a felony involving fraud, dishonesty or other moral turpitude;
(iii) Ms. Silva&rsquo;s gross negligence in the performance of her material duties and responsibilities to the Company as described in
the agreement after written notice from the Board to Ms. Silva of the specific nature of such gross negligence and Ms. Silva&rsquo;s
failure to cure such gross negligence within 30 days following receipt of such notice; or (iv) Ms. Silva&rsquo;s material failure to
perform her duties and responsibilities to the Company as described in the agreement (other than any such failure resulting from the
her incapacity due to physical or mental illness or any such failure subsequent Ms. Silva being delivered a notice of termination without
Cause by the Company or delivering a notice of termination for Good Reason to the Company), in either case after written notice from
the Board to Ms. Silva of the specific nature of such material failure and Ms. Silva&rsquo;s failure to cure such material failure within
30 days following receipt of such notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
all of the executives other than Ms. Silva, &ldquo;Good Reason&rdquo; is defined as (i) at any time following a Change of Control (as
defined below), a material diminution by the Company of compensation and benefits (taken as a whole) provided to the applicable executive
immediately prior to a Change of Control; (ii) reduction in base salary or target or maximum bonus, other than as part of an across-the-board
reduction in salaries of management personnel; (iii) the relocation of the applicable executive&rsquo;s principal executive office to
a location more than 50 miles further from their principal executive office immediately prior to such relocation; or (iv) a material
breach by the Company of any of the terms and conditions of the agreement which the Company fails to correct within 10 days after the
Company receives written notice from the applicable executive of such violation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
Ms. Silva, &ldquo;Good Reason&rdquo; is defined as (i) at any time following a Change of Control, a material diminution by the Company
of title, authority, responsibility, compensation and/or benefits provided to Ms. Silva immediately prior to a Change of Control; (ii)
any reduction in base salary or target or maximum bonus, other than as part of an across-the-board reduction in salaries of management
personnel; (iii) the relocation of the Ms. Silva&rsquo;s principal executive office to a location more than 25 miles further from the
her principal executive office immediately prior to such relocation; (iv) a material breach by the Company of any of the terms and conditions
of the agreement which the Company fails to correct within 10 days after the Company receives written notice from Ms. Silva of such violation;
or (iv) a material diminution, at any time, in Ms. Silva&rsquo;s title, role, authority and/or responsibilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
&ldquo;Change of Control&rdquo; will be deemed to have occurred if, after the effective date of the applicable agreement, (i) the beneficial
ownership (as defined in Rule 13d-3 under the Exchange Act) of securities representing more than 50% of the combined voting power of
the Company is acquired by any &ldquo;person&rdquo; as defined in sections 13(d) and 14(d) of the Exchange Act (other than the Company,
any subsidiary of the Company, or any trustee or other fiduciary holding securities under an employee benefit plan of the Company), (ii)
the merger or consolidation of the Company with or into another corporation where the shareholders of the Company, immediately prior
to the consolidation or merger, would not, immediately after the consolidation or merger, beneficially own (as such term is defined in
Rule 13d-3 under the Exchange Act), directly or indirectly, shares representing in the aggregate 50% or more of the combined voting power
of the securities of the corporation issuing cash or securities in the consolidation or merger (or of its ultimate parent corporation,
if any) in substantially the same proportion as their ownership of the Company immediately prior to such merger or consolidation, or
(iii) the sale or other disposition of all or substantially all of the Company&rsquo;s assets to an entity, other than a sale or disposition
by the Company of all or substantially all of the Company&rsquo;s assets to an entity, at least 50% of the combined voting power of the
voting securities of which are owned directly or indirectly by shareholders of the Company, immediately prior to the sale or disposition,
in substantially the same proportion as their ownership of the Company immediately prior to such sale or disposition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 148; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->146<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company terminates any executive&rsquo;s employment for &ldquo;Cause&rdquo;, or the applicable executive terminates their employment
without &ldquo;Good Reason&rdquo;, then the Company will pay to the applicable executive any unpaid base salary and benefits then owed
or accrued, and any unreimbursed expenses, any unvested portion of any equity granted to the applicable executive under the agreement
or any other agreements with the Company will immediately be forfeited as of the termination date without any further action of the parties;
and all of the parties&rsquo; rights and obligations under the applicable agreement cease, other than such rights or obligations which
arose prior to the termination date or in connection with such termination, and subject to those provisions which survive the termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company terminates the applicable executive&rsquo;s employment without &ldquo;Cause&rdquo;, or the applicable executive terminates
their employment with &ldquo;Good Reason&rdquo;, the Company will pay to the applicable executive any base salary and benefits then owed
or accrued and any unreimbursed expenses; the Company will pay to the applicable executive an amount in cash equal to the target annual
performance bonus for which they would have been eligible with respect to the year in which termination of their employment occurs multiplied
by a portion of the year for which the agreement was in place; the Company will continue to pay to the applicable executive the base
salary that would have been paid to them for the following 12 month period, assuming that the agreement and the term had remained in
effect; any equity grant already made to the applicable executive will, to the extent not already vested, be deemed automatically vested;
and all of the parties&rsquo; rights and obligations under the agreement cease, other than such rights or obligations which arose prior
to the termination date or in connection with such termination, and subject to those provisions which survive the termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the agreements also provides for certain &ldquo;gross-up payments&rdquo; being payable to the applicable executive if it is determined
that any payment or benefit provided to the executive under the agreement or otherwise, whether or not in connection with a Change of
Control would constitute an &ldquo;excess parachute payment&rdquo; within the meaning of section 280G of the Internal Revenue Code of
1986, as amended (the &ldquo;Code&rdquo;), such that the payment would be subject to an excise tax under section 4999 of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the agreements contains customary confidentiality provisions, and customary provisions relating to intellectual property created by
the executive (i.e., a &ldquo;work-made-for-hire&rdquo; provision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the agreements also contains a customary non-solicitation provision, wherein the executive agrees that they shall not, directly or
indirectly solicit or discuss with any employee of Company the employment of such Company employee by any other commercial enterprise
other than Company, nor recruit, attempt to recruit, hire or attempt to hire any such Company employee on behalf of any commercial enterprise
other than Company, provided that this provision does not prohibit the executive from undertaking a general recruitment advertisement
provided that the foregoing is not targeted towards any person identified above, or from hiring, employing or engaging any such person
who responds to such general recruitment advertisement. This provision applies for 1 year for Ms. Silva and for 3 years for all of the
other executives under their respective agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the agreements also contains a customary non-compete provision, wherein the executive agrees that they will not, directly or indirectly:
(i) engage in any other business, association or relationship of any kind with any business which provides, in whole or in part, the
same or similar services and/or products offered by Company as part of its existing or developing businesses which directly or indirectly
competes with Company; nor (ii) solicit or accept, or induce any person to reduce goods or services to Company, or in any manner assist
others in the solicitation, acceptance, or inducement of, any business transactions with Company&rsquo;s existing and prospective clients,
accounts, suppliers and/or other persons or entities with whom Company has had business relationships (or whom Company had specifically
identified for a prospective business relationship). This provision applies for 6 months for Ms. Silva and for 9 months for all of the
other executives under their respective agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the agreements contains a &ldquo;Blue Pencil&rdquo; provision, wherein if a court of competent jurisdiction determines that any of
the non-solicit or non-compete provisions are unenforceable, the court may substitute an enforceable restriction in place of any restriction
deemed unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 149; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->147<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the agreements is governed by Florida law, and contains customary representations and warranties and other miscellaneous provisions.
Each of the employment agreements were amended on September 29, 2021, to cure certain typographical errors in the agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
descriptions of the employment agreements as set forth above are qualified in their entirety to the full employment agreements as attached
as Exhibits 10.2 through 10.11 to the registration statement of which this prospectus forms a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consulting
Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 31, 2022, the Company entered into a Master Services Agreement with Titan Advisory Services LLC (&ldquo;Titan&rdquo;) pursuant
to which the Titan will provide certain services to the Company (the &ldquo;MSA&rdquo;). The MSA provides that the specific services
(the &ldquo;Services&rdquo;) will be described in separate Scopes of Work (&ldquo;SOW&rdquo;) which will constitute a part of the MSA.
The term of the MSA continues until 30 days after either party notifies the others that it desires to terminate the MSA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Services, which commenced on January 1, 2023, are to be provided by Saleem Elmasri, and include Mr. Elmasri serving as the Chief Financial
Officer of the Company, and having the following responsibilities: (i) overall financial strategy implementation and execution; (ii)
overseeing forecasts and budgeting; (iii) overseeing the Company&rsquo;s finance/accounting department; (iv) financial reporting; and
(v) overseeing tax compliance. Separately, Mr. Elmasri has also been named as the Secretary of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
MSA agreement provides that the Company shall pay Titan a monthly fee in the amount of $25,000 (annual fee in aggregate of $300,000 per
year) and that Mr. Elmasri will be issued an option to acquire 562,500  shares of Common Stock, pursuant to
a separate option agreement. 25% of the options are vested upon issuance, with the balance to vest in equal quarterly installments over
the following 24 months, and the option has a 10 year term. The exercise price for the shares of common stock will be, $1.33. The options will accelerate and vest immediately upon an merger, acquisition or other transaction that will be deemed
a change of control of the Company. Titan and Mr. Elmasri will be eligible to participate in additional incentive equity or cash compensation
alongside the Company&rsquo;s other executives, at the sole discretion of the Company. Any additional resources used by Titan to provide
the Services, subject to prior approval by the Company, will be billed to the Company at between $150 and $250 per hour, and the Company
has also agreed to reimburse Titan for all reasonable out-of-pocket expenses that Titan incurs in providing the Services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
MSA includes a customary confidentiality provision for the benefit of the Company, and also includes a non-solicitation provision pursuant
to which each party agrees that during the term of the MSA and for a period of one year thereafter, neither party will, without the prior
written consent of the other, engage in any way, employ, hire, or otherwise do business with any employee or former employee of the other
party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
MSA provides that the Company will be solely responsible for the contents of the information it provides to Titan in connection with
the MSA, and the Company makes customary representations and warranties regarding such information. The Company also agreed in the MSA
to indemnify Titan, its principals, employees and representatives, from and against any claims, losses, damages or any other liability
arising from or as a result of (i) Titan performing the Services or any other services requested by the Company, (ii) any claim by the
Company or any third party of any misrepresentation or reliance on any information resulting from the Services; (iii) any claim by the
Company or any third party or governmental agency brought under the federal securities laws or other statutes, state statute, or common
law, or otherwise, or (iv) any claim by the Company or any third party in connection with the sale or issuance of any shares of the Company&rsquo;s
stock, or other equity or debt of the Company. The maximum liability of Titan that may arise out of the Services is limited to the total
fees paid to Titan for a particular SOW, unless Titan is found to be grossly negligent in its duties or acts with willful misconduct.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
MSA contains customary miscellaneous provisions, including a no-assignment provision, and an agreement to submit any disputes to mediation,
or thereafter to arbitration if the mediation is not successful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
description of the MSA as set forth above is qualified in its entirety to the full MSA as attached as Exhibit 10.33 to the registration
statement of which this prospectus forms a part.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> On January 31, 2023, Titan
agreed to reduce the monthly fee to $20,000 per month until the time that the Company has raised additional capital from the sale of
its securities in the amount of $1,500,000 </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> On December 18, 2023, Titan
agreed to reduce the monthly fee to $5,000 per month, effective retrospectively to October 1, 2023, until the time that the Company has
raised additional capital from the sale of its securities in the amount of $1,500,000 (the &ldquo;Reduction Period&rdquo;). Upon the
expiration of the Reduction Period, the base salary shall be adjusted to be 105% the original base salary. The remainder of the original
agreement shall remain in full force. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Director
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 8, 2021, the Company entered into Independent Director Agreements with each of Allison Brady, Holger Weis, Julie
Kampf and Nick Hemmerly (each, a &ldquo;Director&rdquo;) relating to their service as independent directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to each of the agreements,
the Director agreed to serve as an independent director of the Company and to perform the duties consistent with such position. In addition,
pursuant to their respective agreements, Ms. Brady agreed to serve as a member of the Compensation Committee and Audit Committee;
Mr. Weis agreed to serve as a member of the Nomination Committee and the Chairman of the Audit Committee; Ms. Kampf agreed
to serve as a member of the Compensation Committee and as Chairman of the Nomination Committee of the Board; and Mr. Hemmerly agreed
to serve as Chairman of the Compensation Committee as well as a member of the Audit Committee and Nominating Committee.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the Directors confirmed that the Director is independent (as such term has been construed under Delaware law with respect to directors
of Delaware corporations and the OTC Markets, the NASDAQ Stock Exchange and the New York Stock Exchange). Each Director also confirmed
that, to their knowledge, (a) that Director does not possess material business, close personal relationships or other affiliations, or
any history of any such material business, close personal relationships or other affiliations, with the Company&rsquo;s significant equity
or debt holders or any of their respective corporate affiliates that would cause that Director to be unable to (i) exercise independent
judgment based on the best interests of the Company or (ii) make decisions and carry out that Director&rsquo;s responsibilities as a
director of the Company, in each case in accordance with the terms of the Company&rsquo;s governing documents and applicable law, and
(b) that they have no existing relationship or affiliation of any kind with any entity that the applicable Director knows to be a competitor
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the agreements continues until the earliest of (a) such time as the Director resigns or is removed in accordance with the Company&rsquo;s
governing documents, and (b) the death of the Director.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors are compensated as follows under their respective agreements:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each of the Directors will
be paid $30,000 annually for their service as directors, to be paid $7,500 each calendar quarter, with the amount for any partial calendar
quarter being appropriately prorated. In addition, the Company agreed that, on October 1, 2021, the Company will issue to each Director
an option to acquire up to 67,500 shares of the Common Stock at an exercise price of $1.33 per share,
which options will vest ratably over 36 months subject to the applicable Director continuing to serve as a director of the Company during
such period. The option grants were made pursuant to an Option Award Agreement as attached to each of their respective agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 150; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->148<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the applicable agreements provide that the Directors will be compensated as follows in connection with their service on Committees
of the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms.
    Brady: For as long as Ms. Brady serves as a member of the Compensation Committee, Ms. Brady will be paid $5,000 annually to be paid
    $1,250 each calendar quarter, with the amount for any partial calendar quarter being appropriately prorated.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">For as long as Ms. Brady serves as a member
    of the Audit Committee, Ms. Brady will be paid $5,000 annually to be paid $1,250 each calendar quarter, with the amount for any partial
    calendar quarter being appropriately prorated.</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Weis:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 5%">&#9675;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    as long as Mr. Weis serves as Chairman of the Audit Committee, Mr. Weis will be paid $10,000 annually to be paid $2,500 each calendar
    quarter, with the amount for any partial calendar quarter being appropriately prorated.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9675;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    as long as Mr. Weis serves as a member of the Nominating Committee, Mr. Weis will be paid $4,000 annually to be paid $1,000 each
    calendar quarter, with the amount for any partial calendar quarter being appropriately prorated.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms.
    Kampf:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 5%">&#9675;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    as long as Ms. Kampf serves as a member of the Compensation Committee, Ms. Kampf will be paid $5,000 annually to be paid $1,250 each
    calendar quarter, with the amount for any partial calendar quarter being appropriately prorated.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9675;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    as long as Ms. Kampf serves as Chairman of the Nominating Committee, Ms. Kampf will be $7,500 annually to be paid $1,875 each calendar
    quarter, with the amount for any partial calendar quarter being appropriately prorated.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Hemmerly:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 5%">&#9675;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    as long as Mr. Hemmerly serves as a member of the Audit Committee, Mr. Hemmerly will be paid $5,000 annually to be paid $1,250
    each calendar quarter, with the amount for any partial calendar quarter being appropriately prorated.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9675;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    as long as Mr. Hemmerly serves as Chairman of the Compensation Committee, Mr. Hemmerly will be $10,000 annually to be paid $2,500
    each calendar quarter, with the amount for any partial calendar quarter being appropriately prorated.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9675;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">For as long as Mr. Hemmerly serves as a member of the
    Nominating Committee, Mr. Hemmerly will be paid $4,000 annually to be paid $1,000 each calendar quarter, with the amount for any
    partial calendar quarter being appropriately prorated.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the agreements contains customary confidentiality provisions, and customary provisions relating to intellectual property created by
the executive (i.e., a &ldquo;work-made-for-hire&rdquo; provision. Each of the agreements is governed by Delaware law and contains customary
representations and warranties and other miscellaneous provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
descriptions of the agreements with the Directors as set forth above are qualified in their entirety to the full agreements as attached
as Exhibits 10.12 through 10.15 to the registration statement of which this prospectus forms a part.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 151; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->149<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<!-- Field: Split-Segment; Name: Sp_002 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Elements
of Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Christer Ros&eacute;n, Marshall
Hayward, Dana Eschenburg Perez, Alexander Ros&eacute;n, and Alison Silva were provided with the following primary elements of compensation
in 2023 and 2022: </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Base
Salary</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Christer Ros&eacute;n, Marshall
Hayward, Dana Eschenburg Perez, Alexander Ros&eacute;n, and Alison Silva received a fixed base salary in an amount determined
by the Board of Directors based on a number of factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    nature, responsibilities and duties of the officer&rsquo;s position; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    officer&rsquo;s expertise, demonstrated leadership ability and prior performance; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    officer&rsquo;s salary history and total compensation, including annual cash bonuses and long-term incentive compensation; and </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    competitiveness of the market for the officer&rsquo;s services. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Christer Ros&eacute;n, Marshall
Hayward, Dana Eschenburg Perez, Alexander Ros&eacute;n, and Alison Silva base salary for 2023 and 2022 is listed in &ldquo;Summary
Compensation Table.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stock
Awards</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 1, 2023, the Company granted non-qualified stock option to purchase 562,500 shares of Common Stock to Saleem Elmasri, CPA, as
Chief Financial Officer, at an exercise price of $1.33 per share.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
did not grant any other stock awards to our directors or executive officers in fiscal year 2023 other than those related to the compensation
forgiveness as listed in the &ldquo;Summary Compensation Table.&rdquo;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 21, 2022, the Company issued 476,070 restricted stock shares, pursuant to a restricted stock award, to
Christer Ros&eacute;n, our Chief Executive Officer, at a fair market value of $1.33. The restricted stock award
was issued in exchange for forgiveness of $634,760 of accrued compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 21, 2022, the Company issued 399,401 restricted stock shares, pursuant to a restricted stock award, to
Marshall Hayward, our Chief Scientific Officer, at a fair market value of $1.33. The restricted stock award
was issued in exchange for forgiveness of $532,535 of accrued compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 21, 2022, the Company issued 96,607 restricted stock shares, pursuant to a restricted stock award, to
Alexander Ros&eacute;n, our Chief Administrative Officer, at a fair market value of $1.33. The restricted stock
award was issued in exchange for forgiveness of $128,810 of accrued compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 21, 2022, the Company issued 10,125 restricted stock shares, pursuant to a restricted stock award, to Dana
Eschenburg Perez, our former Chief Financial Officer, at a fair market value of $1.33. The restricted stock
award was issued in exchange for forgiveness of $13,500 of accrued compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stock
Option Grants</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2021, we granted stock
options to (i) purchase a total of 135,000 shares of our common stock to Dana Eschenburg Perez at an exercise price of $1.33
per share that vests 1/36 monthly, (ii) purchase a total of 193,125 shares of our common stock to Dana Eschenburg Perez at
an exercise price of $1.33 per share that vests 1/36 monthly with 25% immediately vested, (iii) purchase a total
of 168,750 shares of our common stock to Alexander Ros&eacute;n at an exercise price of $1.33
per share that vests 1/36 monthly with 25% immediately vested, (iv) purchase a total of 281,250 shares
of our common stock to Alison Silva at an exercise price of $1.33 per share that vests 1/36 monthly with 25%
immediately vested.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> On January 1, 2023, the
Company granted non-qualified stock option to purchase 562,500 of Common Stock to Saleem Elmasri, CPA, as Chief Financial Officer,
at an exercise price of $1.33 per share. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Other
Benefits</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In fiscal year 2022 and 2021,
Christer Ros&eacute;n, Marshall Hayward, Dana Eschenburg Perez, Alexander Ros&eacute;n, and Alison Silva were reimbursed healthcare expenses.
The amounts paid to Christer Ros&eacute;n, Marshall Hayward, Dana Eschenburg Perez, Alexander Ros&eacute;n, and Alison Silva in 2023
and 2022 in respect of these benefits is reflected above in the &ldquo;Summary Compensation Table&rdquo; section under the
&ldquo;All Other Compensation&rdquo; heading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Compensation
Discussion and Analysis</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities
Authorized for Issuance Under Equity Compensation Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information, as of December 31, 2023, with respect to our compensation plans under which common stock
on a post-reverse split basis is authorized for issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 152; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->150<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Equity
Compensation Plan Information</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: justify">Plan Category</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Number of securities to be issued upon exercise of outstanding options, warrants and rights<BR> (A)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Weighted-average exercise price of outstanding options, warrants and rights<BR> (B)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in Column A)<BR> (C)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif; width: 34%; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity compensation plans approved by stockholders</FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2016 Equity Incentive Plan <SUP>(1)</SUP></I></FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"> 6,167,679 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"> 0.80 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"> 2,269,821 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>2021
                                            Equity Incentive Plan <SUP>(2)</SUP></I></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 270,000 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 1.33 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 1,440,000 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif; text-align: justify"> 2023 Equity Incentive Plan<SUP>(3)</SUP> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 1,873,545 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 1.33 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 2,139,240 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><I>Equity compensation plans not approved by stockholders</I></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 5,308,303 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-style: normal; font-weight: normal">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 1.20 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    options to purchase an aggregate of 8,437,500 shares of common stock issued to officers and employees and consultants for
    services provided to the Company at exercise price not less than 100% of the fair market value of the Company&rsquo;s common stock
    on the date the stock award is granted.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>&nbsp;</SUP>Represents
    options to purchase an aggregate of 1,710,000 shares of common stock issued to officers and employees and consultants for
    services provided to the Company at exercise price not less than 100% of the fair market value of the Company&rsquo;s common stock
    on the date the stock award is granted.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> (3) </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> Represents options to purchase an aggregate of 4,012,785
    shares of common stock issued to officers and employees and consultants for services provided to the Company at an exercise price
    not less than 100% of the fair market value of the Company&rsquo;s common stock on the date the stock award is granted </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s stockholders approved
the 2016 Equity Incentive Plan (&ldquo;2016 Plan&rdquo;) on January 4, 2016. Under the 2016 Plan, as modified, 8,437,500
shares of common stock are authorized for issuance to employees, officers, directors, consultants. The 2016 Plan authorizes the
grant of nonqualified stock options and incentive stock options, restricted stock awards, restricted stock units, stock appreciation
rights, under the 2016 Plan. The Company does not intend to make any grants under the 2016 Plan as the Company has adopted the 2021
Equity Incentive Plan (&ldquo;2021 Plan&rdquo;) referred to herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board of Directors and stockholders of the
Company approved the 2021 Plan on September 17, 2021. Under the 2021 Plan, 1,125,000 shares of common stock are authorized for
issuance to employees, directors and independent contractors (except those performing services in connection with the offer or sale of
the Company&rsquo;s securities in a capital raising transaction, or promoting or maintaining a market for the Company&rsquo;s securities)
of the Company or its subsidiaries. The 2021 Plan authorizes equity-based and cash-based incentives for participants. On July 22, 2022,
the Board of Directors increased the shares authorized in the 2021 Equity Incentive Plan, increasing the plan to 1,710,000.
The Company does not intend to make any grants under the 2021 Plan as the Company has adopted the 2023 Equity Incentive Plan (&ldquo;2021
Plan&rdquo;) referred to herein. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> The Board of Directors and stockholders of the Company approved the 2023 Plan on October 4, 2023. Under the 2023
Plan, 4,012,785 shares of common stock are authorized for issuance to employees, directors and independent contractors (except those performing
services in connection with the offer or sale of the Company&rsquo;s securities in a capital raising transaction, or promoting or maintaining
a market for the Company&rsquo;s securities) of the Company or its subsidiaries. There were 2,139,240 shares available for award as of
July 10, 2024 under the 2023 Plan. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2023
</B></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Equity Incentive Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Overview</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Board of Directors and shareholders holding a majority of the Company&rsquo;s voting capital approved and adopted the 2024 Equity
Incentive Plan (the &ldquo;2024 Plan&rdquo;) on October 4, 2023, respectively. The 2023 Plan authorizes the issuance
of up to an aggregate maximum of 4,012,785 shares of the common stock, subject to adjustment as described in the 2023 Plan.
The 2023 Plan shall be administered by the Board or one or more committees appointed by the Board or another committee (&ldquo;Administrator&rdquo;).
The Administrator, in its discretion, selects the individuals to whom awards may be granted, the time or times at which such awards are
granted, and the terms of such awards. The 2023 Plan authorizes the Company to grant stock options, stock appreciation rights,
restricted shares, restricted share unit, cash awards, other awards, and performance-based awards. Awards may be granted to the Company&rsquo;s
officers, employees, directors and consultants.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purpose of 2023 Plan is to promote the success of the Company and to increase stockholder value by providing an additional means
through the grant of awards to attract, motivate, retain and reward selected employees and other eligible persons. The Board may, at
any time, terminate or, from time to time, amend, modify or suspend this 2023 Plan, in whole or in part. To the extent then required
by applicable law or any applicable stock exchange or required under the Internal Revenue Code to preserve the intended tax consequences
of the 2023 Plan, or deemed necessary or advisable by the Board, the 2023 Plan and any amendment to the 2023 Plan
shall be subject to stockholder approval. Unless earlier terminated by the Board, the 2023 Plan will terminate ten years from
the date of adoption.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 153; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->151<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Authorized
Shares</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
total of 4,012,785 shares of the Company&rsquo;s common stock are authorized for issuance pursuant to the 2023 Plan. Subject
to adjustment as provided in the 2023 Plan, the maximum aggregate number of shares that may be issued under the 2023 Plan
will be cumulatively increased on January 1, 2024 and on each subsequent January 1, by a number of shares equal to the smaller
of (i) 3% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (ii) an amount
determined by the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
if any award issued pursuant to the 2023 Plan expires or becomes exercisable without having been exercised in full, is surrendered
pursuant to an exchange program, as provided in the 2023 Plan, or, with respect to restricted stock, restricted stock units (&ldquo;RSUs&rdquo;),
performance units or performance shares, is forfeited to or repurchased by the Company due to the failure to vest, the unpurchased shares
(or for awards other than stock options or stock appreciation rights the forfeited or repurchased shares) which were subject thereto
will become available for future grant or sale under the 2023 Plan (unless the 2023 Plan has terminated). With respect
to stock appreciation rights, only shares actually issued pursuant to a stock appreciation right will cease to be available under the
2023 Plan; all remaining shares under stock appreciation rights will remain available for future grant or sale under the 2023
Plan (unless the 2023 Plan has terminated). Shares that have actually been issued under the 2023 Plan under any award
will not be returned to the 2023 Plan and will not become available for future distribution under the 2023 Plan; provided,
however, that if shares issued pursuant to awards of restricted stock, restricted stock units, performance shares or performance units
are repurchased by the Company or are forfeited to the Company due to the failure to vest, such shares will become available for future
grant under the 2023 Plan. Shares used to pay the exercise price of an award or to satisfy the tax withholdings related to an
award will become available for future grant or sale under the 2023 Plan. To the extent an award under the 2023 Plan is
paid out in cash rather than shares, such cash payment will not result in reducing the number of shares available for issuance under
the 2023 Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing and, subject to adjustment as provided in the 2023 Plan, the maximum number of shares that may be issued upon the
exercise of incentive stock options will equal the aggregate share number stated above, plus, to the extent allowable under Section 422
of the Internal Revenue Code of 1986, as amended, and regulations promulgated thereunder, any shares that become available for issuance
under the 2023 Plan in accordance with the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Plan
Administration</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board or one or more committees appointed by the Board will administer the 2023 Plan. In addition, if the Company determines it
is desirable to qualify transactions under the 2023 Plan as exempt under Rule 16b-3 of the Securities Exchange Act of 1934, as
amended, such transactions will be structured with the intent that they satisfy the requirements for exemption under Rule 16b-3. Subject
to the provisions of the 2023 Plan, the administrator has the power to administer the 2023 Plan and make all determinations
deemed necessary or advisable for administering the 2023 Plan, including the power to determine the fair market value of the Company&rsquo;s
common stock, select the service providers to whom awards may be granted, determine the number of shares covered by each award, approve
forms of award agreements for use under the 2023 Plan, determine the terms and conditions of awards (including the exercise price,
the time or times at which the awards may be exercised, any vesting acceleration or waiver or forfeiture restrictions and any restriction
or limitation regarding any award or the shares relating thereto), construe and interpret the terms of the 2023 Plan and awards
granted under it, prescribe, amend and rescind rules relating to the 2023 Plan, including creating sub-plans and modify or amend
each award, including the discretionary authority to extend the post-termination exercisability period of awards (provided that no option
or stock appreciation right will be extended past its original maximum term), and to allow a participant to defer the receipt of payment
of cash or the delivery of shares that would otherwise be due to such participant under an award. The administrator also has the authority
to allow participants the opportunity to transfer outstanding awards to a financial institution or other person or entity selected by
the administrator and to institute an exchange program by which outstanding awards may be surrendered or cancelled in exchange for awards
of the same type which may have a higher or lower exercise price or different terms, awards of a different type or cash, or by which
the exercise price of an outstanding award is increased or reduced. The administrator&rsquo;s decisions, interpretations and other actions
are final and binding on all participants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 154; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->152<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Eligibility</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Awards
under the 2023 Plan, other than incentive stock options, may be granted to employees (including officers) of the Company or a
subsidiary, members of the Company&rsquo;s Board, or consultants engaged to render bona fide services to the Company or a subsidiary.
Incentive stock options may be granted only to employees of the Company or a subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stock
Options</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
options may be granted under the 2023 Plan. The exercise price of options granted under the 2023 Plan generally must at
least be equal to the fair market value of the Company&rsquo;s common stock on the date of grant. The term of each option will be as
stated in the applicable award agreement; provided, however, that the term may be no more than 10 years from the date of grant. The administrator
will determine the methods of payment of the exercise price of an option, which may include cash, shares or other property acceptable
to the administrator, as well as other types of consideration permitted by applicable law. After the termination of service of an employee,
director or consultant, they may exercise their option for the period of time stated in their option agreement. In the absence of a specified
time in an award agreement, if termination is due to death or disability, the option will remain exercisable for 12 months. In all other
cases, in the absence of a specified time in an award agreement, the option will remain exercisable for three months following the termination
of service. An option may not be exercised later than the expiration of its term. Subject to the provisions of the 2023 Plan,
the administrator determines the other terms of options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stock
Appreciation Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
appreciation rights may be granted under the 2023 Plan. Stock appreciation rights allow the recipient to receive the appreciation
in the fair market value of the Company&rsquo;s common stock between the exercise date and the date of grant. Stock appreciation rights
may not have a term exceeding 10 years. After the termination of service of an employee, director or consultant, they may exercise their
stock appreciation right for the period of time stated in their stock appreciation right agreement. In the absence of a specified time
in an award agreement, if termination is due to death or disability, the stock appreciation rights will remain exercisable for 12 months.
In all other cases, in the absence of a specified time in an award agreement, the stock appreciation rights will remain exercisable for
three months following the termination of service. However, in no event may a stock appreciation right be exercised later than the expiration
of its term. Subject to the provisions of the 2023 Plan, the administrator determines the other terms of stock appreciation rights,
including when such rights become exercisable and whether to pay any increased appreciation in cash or with shares of the Company&rsquo;s
common stock, or a combination thereof, except that the per share exercise price for the shares to be issued pursuant to the exercise
of a stock appreciation right will be no less than 100% of the fair market value per share on the date of grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Restricted
Stock</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
stock may be granted under the 2023 Plan. Restricted stock awards are grants of shares of the Company&rsquo;s common stock that
vest in accordance with terms and conditions established by the administrator. The administrator will determine the number of shares
of restricted stock granted to any employee, director or consultant and, subject to the provisions of the 2023 Plan, will determine
the terms and conditions of such awards. The administrator may impose whatever conditions to vesting it determines to be appropriate
(for example, the administrator may set restrictions based on the achievement of specific performance goals or continued service to the
Company); provided, however, that the administrator, in its sole discretion, may accelerate the time at which any restrictions will lapse
or be removed. Recipients of restricted stock awards generally will have voting and dividend rights with respect to such shares upon
grant without regard to vesting, unless the administrator provides otherwise. Shares of restricted stock that do not vest are subject
to the Company&rsquo;s right of repurchase or forfeiture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Restricted
Stock Units</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RSUs
may be granted under the 2023 Plan. RSUs are bookkeeping entries representing an amount equal to the fair market value of one
share of the Company&rsquo;s common stock. Subject to the provisions of the 2023 Plan, the administrator determines the terms
and conditions of RSUs, including the vesting criteria and the form and timing of payment. The administrator may set vesting criteria
based upon the achievement of Company-wide, divisional, business unit or individual goals (including continued employment or service),
applicable federal or state securities laws or any other basis determined by the administrator in its discretion. The administrator,
in its sole discretion, may pay earned RSUs in the form of cash, in shares of the Company&rsquo;s common stock or in some combination
thereof. Notwithstanding the foregoing, the administrator, in its sole discretion, may accelerate the time at which any vesting requirements
will be deemed satisfied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 155; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->153<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Performance
Units and Performance Shares</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Performance
units and performance shares may be granted under the 2023 Plan. Performance units and performance shares are awards that will
result in a payment to a participant only if performance goals established by the administrator are achieved or the awards otherwise
vest. The administrator will establish performance objectives or other vesting criteria in its discretion, which, depending on the extent
to which they are met, will determine the number or the value of performance units and performance shares to be paid out to participants.
The administrator may set performance objectives based on the achievement of Company-wide, divisional, business unit or individual goals
(including continued employment or service), applicable federal or state securities laws or any other basis determined by the administrator
in its discretion. After the grant of a performance unit or performance share, the administrator, in its sole discretion, may reduce
or waive any performance criteria or other vesting provisions for such performance units or performance shares. Performance units shall
have an initial dollar value established by the administrator on or prior to the grant date. Performance shares shall have an initial
value equal to the fair market value of the Company&rsquo;s common stock on the grant date. The administrator, in its sole discretion,
may pay earned performance units or performance shares in the form of cash, in shares or in some combination thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Non-Employee
Directors</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2023 Plan provides that all non-employee directors will be eligible to receive all types of awards (except for incentive stock
options) under the 2023 Plan. The 2023 Plan includes a maximum limit of $750,000 of equity awards that may be granted to
a non-employee director in any fiscal year, increased to $1,500,000 in connection with his or her initial service. For purposes of this
limitation, the value of equity awards is based on the grant date fair value (determined in accordance with accounting principles generally
accepted in the United States). Any equity awards granted to a person for their services as an employee, or for their services as a consultant
(other than as a non-employee director), will not count for purposes of the limitation. The maximum limit does not reflect the intended
size of any potential compensation or equity awards to the Company&rsquo;s non-employee directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Non-transferability
of Awards</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
the administrator provides otherwise, the 2023 Plan generally does not allow for the transfer of awards and only the recipient
of an award may exercise an award during their lifetime. If the administrator makes an award transferrable, such award will contain such
additional terms and conditions as the administrator deems appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Certain
Adjustments</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of certain changes in the Company&rsquo;s capitalization, to prevent diminution or enlargement of the benefits or potential
benefits available under the 2023 Plan, the administrator will adjust the number and class of shares that may be delivered under
the 2023 Plan or the number, and price of shares covered by each outstanding award and the numerical share limits set forth in
the 2023 Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Dissolution
or Liquidation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of the Company&rsquo;s proposed liquidation or dissolution, the administrator will notify participants as soon as practicable
and all awards will terminate immediately prior to the consummation of such proposed transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 156; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->154<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Merger
or Change in Control</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2023 Plan provides that in the event of the Company&rsquo;s merger with or into another corporation or entity or a &ldquo;change
in control&rdquo; (as defined in the 2023 Plan), each outstanding award will be treated as the administrator determines, including,
without limitation, that (i) awards will be assumed, or substantially equivalent awards will be substituted, by the acquiring or succeeding
corporation (or an affiliate thereof) with appropriate adjustments as to the number and kind of shares and prices; (ii) upon written
notice to a participant, that the participant&rsquo;s awards will terminate upon or immediately prior to the consummation of such merger
or change in control; (iii) outstanding awards will vest and become exercisable, realizable or payable, or restrictions applicable to
an award will lapse, in whole or in part, prior to or upon consummation of such merger or change in control and, to the extent the administrator
determines, terminate upon or immediately prior to the effectiveness of such merger or change in control; (iv) (A) the termination of
an award in exchange for an amount of cash or property, if any, equal to the amount that would have been attained upon the exercise of
such award or realization of the participant&rsquo;s rights as of the date of the occurrence of the transaction (and, for the avoidance
of doubt, if as of the date of the occurrence of the transaction the administrator determines in good faith that no amount would have
been attained upon the exercise of such award or realization of the participant&rsquo;s rights, then such award may be terminated by
the Company without payment) or (B) the replacement of such award with other rights or property selected by the administrator in its
sole discretion; or (v) any combination of the foregoing. The administrator will not be obligated to treat all awards, all awards a participant
holds, or all awards of the same type, similarly. In the event that awards (or portion thereof) are not assumed or substituted for in
the event of a merger or change in control, the participant will fully vest in and have the right to exercise all of their outstanding
options and stock appreciation rights, including shares as to which such awards would not otherwise be vested or exercisable, all restrictions
on restricted stock and RSUs will lapse and, with respect to awards with performance-based vesting, all performance goals or other vesting
criteria will be deemed achieved at 100% of target levels and all other terms and conditions met, in all cases, unless specifically provided
otherwise under the applicable award agreement or other written agreement between the participant and the Company or any of the Company&rsquo;s
subsidiaries or parents, as applicable. If an option or stock appreciation right is not assumed or substituted in the event of a merger
or change in control, the administrator will notify the participant in writing or electronically that the option or stock appreciation
right will be exercisable for a period of time determined by the administrator in its sole discretion and the vested option or stock
appreciation right will terminate upon the expiration of such period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
awards granted to an outside director, the outside director will fully vest in and have the right to exercise all of their outstanding
options and stock appreciation rights, all restrictions on restricted stock and RSUs will lapse and, for awards with performance-based
vesting, unless specifically provided for in the award agreement, all performance goals or other vesting criteria will be deemed achieved
at 100% of target levels and all other terms and conditions met.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Clawback</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Awards
will be subject to any Company clawback policy that the Company is required to adopt pursuant to the listing standards of any national
securities exchange or association on which the Company&rsquo;s securities are listed or as is otherwise required by the Dodd-Frank Wall
Street Reform and Consumer Protection Act or other applicable laws. The administrator also may specify in an award agreement that the
participant&rsquo;s rights, payments or benefits with respect to an award will be subject to reduction, cancellation, forfeiture or recoupment
upon the occurrence of certain specified events. The Board may require a participant to forfeit, return or reimburse the Company all
or a portion of the award or shares issued under the award, any amounts paid under the award and any payments or proceeds paid or provided
upon disposition of the shares issued under the award in order to comply with such clawback policy or applicable laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Amendment
and Termination</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
administrator has the authority to amend, suspend or terminate the 2023 Plan provided such action does not impair the existing
rights of any participant. The 2023 Plan automatically will terminate on October 4, 2023, unless it is terminated sooner.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 157; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->155<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Director
Compensation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Other
than as set forth in the table and described more fully below, we did not pay any compensation or make any equity awards or non-equity
awards to any of our non-employee directors during fiscal years 2023 and 2022. Directors may be reimbursed for travel and
other expenses directly related to their activities as directors. Directors who also serve as employees receive no additional compensation
for their service as directors. During fiscal years 2023 and 2022, Christer Ros&eacute;n, our Chief Executive Officer,
Marshall Hayward, our Chief Sciences Officer, and Alison Silva, our President and Chief Business Officer, were each a member of our board
of directors, as well as an employee, and received no additional compensation for their services as a director. See the section titled
&ldquo;Executive Compensation&rdquo; for more information about the compensation for Christer Ros&eacute;n, Marshall Hayward, and Alison
Silva for fiscal years 2023 and 2022. The following table presents the total compensation for each person who served as
a non-employee director during fiscal years 2023 and 2022. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Name</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Compensation<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Stock Awards<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">Option</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">Awards<BR> ($)</P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total <BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Nicholas H. Hemmerly (1)(2) </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> 2023<SUP>(2)</SUP> </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"> 49,000 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"> 49,000 </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: center"> 2022 </TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right"> 49,000 </TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 10%; text-align: right"> - </TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 10%; text-align: right"> - </TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 10%; text-align: right"> 49,000 </TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Julie Kampf (1)(3) </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> 2023<SUP>(3)</SUP> </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"> 42,500 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 42,500 </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> 2022 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"> 42,500 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 42,500 </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Holger Weis (1)(4) </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> 2023<SUP>(4)</SUP> </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"> 44,000 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 44,000 </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> 2022 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"> 44,000 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 44,000 </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Alison W. Brady (1)(5) </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> 2023<SUP>(5)</SUP> </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"> 40,000 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 40,000 </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> 2022 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"> 40,000 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 40,000 </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    designated, these directors joined our Board of Directors on September 8, 2021. Each member received compensation as defined in their
    Director Agreement and denoted below. </FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT> </TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            2022, Mr. Hemmerly agreed to defer all salary compensation. The deferred compensation is
                                            recorded in accrued compensation as of December 31, 2022. No interest was accrued or due
                                            on the deferred compensation for 2022.</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    2023, Mr. Hemmerly agreed to defer all cash compensation of salary. The deferred compensation is recorded in accrued compensation
    as of December 31, 2023. No interest was accrued or due on the deferred compensation for 2023.</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    September 29, 2023, Mr. Hemmerly agreed to forgive $78,400 of earned compensation in exchange for 116,513 options to purchase common
    stock, 88,200 restricted stock units, and $19,600 to be paid out as a bonus upon an IPO. The options to purchase common stock have
    a strike price of $1.33 per share. On December 18, 2023 the restricted stock units issued on September 29, 2023 were cancelled and
    reissued as part of an additional forgiveness, whereby, Mr. Hemmerly agreed to forgive the $19,600 of accrued bonus in exchange for
    9,724 options to purchase common stock and an additional 7,350 restricted stock units (total of 95,550 restricted stock units). The
    restricted stock units have a fair market value of $1.33 per unit. The options to purchase common stock have a strike price of $1.33
    per share.</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT> </TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            2022, Ms. Kampf agreed to defer all salary compensation. The deferred compensation is recorded
                                            in accrued compensation as of December 31, 2022. No interest was accrued or due on the deferred
                                            compensation for 2022.</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    2023, Ms. Kampf agreed to defer all cash compensation of salary. The deferred compensation is recorded in accrued compensation as
    of December 31, 2023. No interest was accrued or due on the deferred compensation for 2023.</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    September 29, 2023, Ms. Kampf agreed to forgive $68,000 of earned compensation in exchange for 101,058 options to purchase common
    stock, 76,500 restricted stock units, and $17,000 to be paid out as a bonus upon an IPO. The options to purchase common stock have
    a strike price of $1.33 per share. On December 18, 2023 the restricted stock units issued on September 29, 2023 were cancelled and
    reissued as part of an additional forgiveness, whereby, Ms. Kampf agreed to forgive the $17,000 of accrued bonus in exchange for
    8,501 options to purchase common stock and an additional 6,375 restricted stock units (total of 82,875 restricted stock units). The
    restricted stock units have a fair market value of $1.33 per unit. The options to purchase common stock have a strike price of $1.33
    per share.</FONT> </P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT> </TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            2022, Mr. Weis agreed to defer all salary compensation. The deferred compensation is recorded
                                            in accrued compensation as of December 31, 2022. No interest was accrued or due on the deferred
                                            compensation for 2022.</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    2023, Mr. Weis agreed to defer all cash compensation of salary. The deferred compensation is recorded in accrued compensation as
    of December 31, 2023. No interest was accrued or due on the deferred compensation for 2023.</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    September 29, 2023, Mr. Weis agreed to forgive $70,400 of earned compensation in exchange for 104,624 options to purchase common
    stock, 79,200 restricted stock units, and $17,600 to be paid out as a bonus upon an IPO. The options to purchase common stock have
    a strike price of $1.33 per share. On December 18, 2023 the restricted stock units issued on September 29, 2023 were cancelled and
    reissued as part of an additional forgiveness, whereby, Mr. Hemmerly agreed to forgive the $17,600 of accrued bonus in exchange for
    8,730 options to purchase common stock and an additional 6,600 restricted stock units (total of 85,800 restricted stock units). The
    restricted stock units have a fair market value of $1.33 per unit. The options to purchase common stock have a strike price of $1.33
    per share.</FONT> </P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT> </TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            2022, Ms. Brady agreed to defer all salary compensation. The deferred compensation is recorded
                                            in accrued compensation as of December 31, 2022. No interest was accrued or due on the deferred
                                            compensation for 2022.</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    2023, Ms. Brady agreed to defer all cash compensation of salary. The deferred compensation is recorded in accrued compensation as
    of December 31, 2023. No interest was accrued or due on the deferred compensation for 2023.</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    September 29, 2023, Ms. Brady agreed to forgive $64,000 of earned compensation in exchange for 95,113 options to purchase common
    stock, 72,000 restricted stock units, and $16,000 to be paid out as a bonus upon an IPO. The options to purchase common stock have
    a strike price of $1.33 per share. On December 18, 2023 the restricted stock units issued on September 29, 2023 were cancelled and
    reissued as part of an additional forgiveness, whereby, Mr. Hemmerly agreed to forgive the $16,000 of accrued bonus in exchange for
    9,724 options to purchase common stock and an additional 6,000 restricted stock units (total of 78,000 restricted stock units). The
    restricted stock units have a fair market value of $1.33 per unit. The options to purchase common stock have a strike price of $1.33
    per share.</FONT> </P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the effectiveness of the registration statement of which this prospectus forms a part, we did not have a formal policy to compensate
our non-employee directors. Immediately prior to the effectiveness of the registration statement of which this prospectus forms a part,
we intend to implement a formal policy pursuant to which our non-employee directors will be eligible to receive the following cash retainers
and equity awards. The retainers will be payable in four equal installments in each calendar quarter and will payable within 5 business
days of the end of each calendar quarter, and with such amount for any partial calendar quarter being appropriately prorated. The foregoing
compensation arrangement will be set forth in independent director agreements entered into or to be entered into which each independent
director.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Annual Retainer for Board Membership</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 78%; text-align: left">Annual service on the board of directors</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right">30,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Additional Annual Retainer for Committee Membership</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Annual service as member of the audit committee (other than chair)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Annual service as chair of the audit committee</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Annual service as member of the compensation committee (other than chair)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Annual service as chair of the compensation committee</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Annual service as member of the nominating and corporate governance committee (other than chair)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Annual service as chair of the nominating and corporate governance committee</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7,500</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 158; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->156<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
policy will provide (as codified in the independent director agreements) that each non-employee director elected to our board of directors
after the effectiveness of this registration statement of which this prospectus forms a part, upon initial election to our board of directors,
will be granted an option to acquire up to 18,000 shares of the Common Stock at an exercise price of $5.00 per share (subject
to customary adjustments), which options shall vest ratably over 36 months subject to the director continuing to serve as a director
of the Company during such period, pursuant to the Option Award Agreement. During the term of the independent director agreements, the
Company shall reimburse each director for all reasonable out-of-pocket expenses incurred by the director in attending any in-person meetings,
provided that the director complies with the generally applicable policies, practices and procedures of the Company for submission of
expense reports, receipts or similar documentation of such expenses. Any reimbursements for allocated expenses (as compared to out-of-pocket
expenses of the director in excess of $500.00) must be approved in advance by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Executive
Compensation Philosophy</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors determines the compensation given to our executive officers in their sole determination. Our Board of Directors reserves
the right to pay our executives or any future executives a salary, and/or issue them shares of common stock issued in consideration for
services rendered and/or to award incentive bonuses which are linked to our performance, as well as to the individual executive officer&rsquo;s
performance. This package may also include long-term stock based compensation to certain executives, which is intended to align the performance
of our executives with our long-term business strategies. Additionally, while our Board of Directors has not granted any performance
base stock options to date, the Board of Directors reserves the right to grant such options in the future, if the Board in its sole determination
believes such grants would be in the best interests of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Incentive
Bonus</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors may grant incentive bonuses to our executive officers and/or future executive officers in its sole discretion, if
the Board of Directors believes such bonuses are in the Company&rsquo;s best interest, after analyzing our current business objectives
and growth, if any, and the amount of revenue we are able to generate each month, which revenue is a direct result of the actions and
ability of such executives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Long-Term,
Stock Based Compensation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to attract, retain and motivate executive talent necessary to support the Company&rsquo;s long-term business strategy we may award
our executives and any future executives with long-term, stock-based compensation in the future, at the sole discretion of our Board
of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 159; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->157<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ar_010"></A>SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the number of shares of and percent of the Company&rsquo;s common stock beneficially owned as of July 12,
2024, by all directors, our named executive officers, our directors and executive officers as a group, and persons or groups known by
us to own beneficially 5% or more of our common stock, immediately prior to this Offering, and immediately after the closing of this
offering, as adjusted to reflect the assumed sale of 2,750,000 shares of common stock.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The business address of each
of the beneficial owners listed below is c/o Jupiter Neurosciences, Inc., 1001 North US Hwy 1, Suite 504, Jupiter, Florida 33477.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> Name of Beneficial Owner </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Amount and Nature of Beneficial
    Ownership </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1.5pt solid"> Pre- Closing Percentage of Class (1) </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Post- Closing Amount and Nature
    of Beneficial Ownership </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1.5pt solid"> Post- Closing Percentage of Class (1) </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"> Directors and Executive Officers </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 49%; text-align: left"> Christer Ros&eacute;n (2) </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 12,571,758 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 41.7 </TD><TD STYLE="width: 1%; text-align: left"> % </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 12,571,758 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 38.2 </TD><TD STYLE="width: 1%; text-align: left"> % </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Marshall Hayward, Ph.D. (3) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 3,625,382 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 12.0 </TD><TD STYLE="text-align: left"> % </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 3,625,382 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 11.0 </TD><TD STYLE="text-align: left"> % </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Saleem Elmasri (4) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 666,420 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2.2 </TD><TD STYLE="text-align: left"> % </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 666,420 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2.0 </TD><TD STYLE="text-align: left"> % </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Alison D. Silva (5) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 870,871 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2.9 </TD><TD STYLE="text-align: left"> % </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 870,871 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2.6 </TD><TD STYLE="text-align: left"> % </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Nicholas H. Hemmerly (6) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 193,737 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT> </TD><TD STYLE="text-align: left"> % </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 193,737 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT> </TD><TD STYLE="text-align: left"> % </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Julie Kampf (7) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 176,993 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT> </TD><TD STYLE="text-align: left"> % </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 176,993 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT> </TD><TD STYLE="text-align: left"> % </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Allison W. Brady (8) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 170,659 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT> </TD><TD STYLE="text-align: left"> % </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 170,659 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT> </TD><TD STYLE="text-align: left"> % </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Alexander Ros&eacute;n (9) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,624,546 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 5.4 </TD><TD STYLE="text-align: left"> % </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,624,546 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 4.9 </TD><TD STYLE="text-align: left"> % </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Holger Weis (10) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 180,855 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT> </TD><TD STYLE="text-align: left"> % </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 180,855 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT> </TD><TD STYLE="text-align: left"> % </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Dana Eschenburg Perez (11) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 387,855 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1.3 </TD><TD STYLE="text-align: left"> % </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 387,855 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1.2 </TD><TD STYLE="text-align: left"> % </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> All directors and officers as a group (10 persons) (12) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 20,469,076 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 67.9 </TD><TD STYLE="text-align: left"> % </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 20,469,076 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 62.3 </TD><TD STYLE="text-align: left"> % </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"> Principal Shareholders (more than 5%): </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Dr. Claes Wahlestedt, M.D., Ph.D. (13) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 3,318,583 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 11.0 </TD><TD STYLE="text-align: left"> % </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 3,318,583 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 10.1 </TD><TD STYLE="text-align: left"> % </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Shaun Brothers (14) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2,025,553 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 6.7 </TD><TD STYLE="text-align: left"> % </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2,025,553 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 6.2 </TD><TD STYLE="text-align: left"> % </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">* less than 1%</FONT> </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            pre-closing percentages in the table have been calculated on the basis of treating as outstanding
                                            for a particular person, all shares of our capital stock outstanding on July 12, 2024. The
                                            post-closing percentages in the table have been calculated on the basis of treating as outstanding
                                            for a particular person, all shares of our capital stock outstanding on July 12, 2024, plus
                                            the assumed sale of 2,750,000 common stock in this Offering. On July 12, 2024, there were
                                            30,126,413 shares of our common stock and restricted stock awards outstanding. To calculate
                                            a stockholder&rsquo;s percentage of beneficial ownership, we include in the numerator and
                                            denominator the common stock outstanding, restricted stock awards outstanding and all shares
                                            of our common stock issuable to that person in the event of the exercise of outstanding warrants
                                            and other derivative securities owned by that person which are exercisable within 60 days
                                            of July 12, 2024. Common stock warrants and derivative securities held by other stockholders
                                            are disregarded in this calculation. Therefore, the denominator used in calculating beneficial
                                            ownership among our stockholders may differ. Unless we have indicated otherwise, each person
                                            named in the table has sole voting power and sole investment power for the shares listed
                                            opposite such person&rsquo;s name.</FONT> </P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    shares issuable upon options to acquire 2,003,678 shares of common stock exercisable within 60 days of July 12, 2024.</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT>&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 160; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->158<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    shares issuable upon options to acquire 1,245,098 shares of common stock exercisable within 60 days of July 12, 2024.</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    shares issuable upon options to acquire 666,420 shares of common stock exercisable within 60 days of July 12, 2024.</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    shares issuable upon options to acquire 870,871 shares of common stock exercisable within 60 days of July 12, 2024.</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6) </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    shares issuable upon options to acquire 193,737 shares of common stock exercisable within 60 days of July 12, 2024.</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    shares issuable upon options to acquire 176,993 shares of common stock exercisable within 60 days of July 12, 2024.</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    shares issuable upon options to acquire 170,659 shares of common stock exercisable within 60 days of July 12, 2024.</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    shares issuable upon options to acquire 1,171,688 shares of common stock exercisable within 60 days of July 12, 2024.</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    shares issuable upon options to acquire 180,855 shares of common stock exercisable within 60 days of July 12, 2024.</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
                                            shares issuable upon options to acquire 377,730 shares of common stock exercisable within
                                            60 days of July 12, 2024.</FONT> </P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    Christer Ros&eacute;n, Marshall Hayward, Ph.D., Saleem Elmasri, Alison D. Silva, Nicholas H. Hemmerly, Julie Kampf, Allison W. Brady,
    Alexander Ros&eacute;n, Dana Eschenburg Perez, and Holger Weis.</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13) </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    shares issuable upon options to acquire 514,609 shares of common stock exercisable within 60 days of July 12, 2024.</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14) </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    shares issuable upon options to acquire 326,319 shares of common stock exercisable within 60 days of July 12, 2024.</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ar_011"></A>CERTAIN
RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Policies
and Procedures for Related Party Transactions</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Item 404 of SEC Regulation S-K, a related person transaction is any actual or proposed transaction, arrangement or relationship or series
of similar transactions, arrangements or relationships, including those involving indebtedness not in the ordinary course of business,
to which we or our subsidiaries were or are a party, or in which we or our subsidiaries were or are a participant, in which the amount
involved exceeded or exceeds the lesser of $120,000 or one percent of the average of our total assets at year-end for the last two completed
fiscal years and in which any of our directors, nominees for director, executive officers, beneficial owners of more than 5% of any class
of our voting securities (a &ldquo;significant shareholder&rdquo;), or any member of the immediate family of any of the foregoing persons,
had or will have a direct or indirect material interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize that transactions between us and any of our directors or executives or with a third party in which one of our officers, directors
or significant shareholders has an interest can present potential or actual conflicts of interest and create the appearance that our
decisions are based on considerations other than the best interests of our Company and stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 161; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->159<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee of the Board of Directors is charged with responsibility for reviewing, approving and overseeing any transaction between
the Company and any related person (as defined in Item 404 of Regulation S-K), including the propriety and ethical implications of any
such transactions, as reported or disclosed to the Audit Committee by the independent auditors, employees, officers, members of the Board
of Directors or otherwise, and to determine whether the terms of the transaction are not less favorable to us than could be obtained
from an unaffiliated party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time we engage in transactions with related parties. The following is a summary of the related party transactions for the fiscal
years ended December 31, 2023 and 2022 requiring disclosure pursuant to Item 404 of Regulation S-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
Payable, related party</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Notes payable, related party, to the CEO totaled $403,479 and $358,479
as of March 31, 2024 and December 31, 2023, respectively. The note bears interest at 3% per year and is payable upon demand. Accrued interest
was $14,329 and $11,308 as of March 31, 2024 and December31, 2023. See Note 7 &ndash; Stockholders&rsquo; Deficit &ndash; Stock Options
for details related to issuance of common stock pursuant to the exercise of options in exchange of $100,000 of principal owed to the CEO
on the notes payable, related party. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Note payable, related party, to an employee totaled $25,000 as of March
31, 2024 and December 31, 2023, respectively. The note bears interest at 3% per year and is payable upon demand. Accrued interest was
$912 and $723, as of December 31, 2023 and 2022, respectively. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During 2020, $100,000 of
principle plus accrued interest of $1,001, owed to the CEO, was converted to 126,251 shares of
common at $3.00 per share which was the estimated fair value of the common stock based on recent sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> On April 29, 2024, the Company, the Holder of the Note II and the CEO entered
into an amendment in which the CEO agrees to exchange 685,867 shares issued to the Holder in exchange for his related party notes that
accrued interest at 3% that are due from the Company in an aggregate principal amount of $266,667 and the Holder agreed to forfeit all
rights to all additional future shares from the Company that would of become due upon a qualified offering and the conversion feature
of the note. In addition, the Holder agreed to extend the note maturity date to August 11, 2024. The note shall be designated as a 10%
original issued discount secured note (&ldquo;Senior Secured Note&rdquo;) moving forward. The note and interest will become due and payable
upon the earliest of the maturity date or upon the occurrence of a qualified event. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Related Party Transactions </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2020, the CEO forgave $536,314 of accrued compensation which has been reflected as additional paid in capital on the statement of stockholders&rsquo;
deficit due to the related party nature of the transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
compensation includes partially accrued salaries to executives since inception. Since inception, executive salaries have been paid
in cash when the Company&rsquo;s cash flow has permitted such payment. During 2020, the Company began paying salaries at 50% of the
respective employment agreements. As of September 2021, the Company began paying full salaries. During the first quarter of 2022,
the Company returned to paying partial salaries in an effort to conserve cash outflows and by November 2022 the Company stopped
paying salaries 100% in an effort to conserve cash outflows. On July 21, 2022, the Company entered into a Forgiveness and Release
Agreement with these executives and two consultants, who also are shareholders&rsquo;, to forgive accrued salary and consulting fees
in the amount of $1,556,010. The executives and consultants received 1,167,386 restricted common stock awards, priced at $1.33,
based on the last purchase price of common stock, in exchange for the forgiveness of salaries. See Note 7 for details related to the
issuances On September 29, 2023, various employees and board members agreed to forgive accrued compensation in the amount of
$4,189,626. In exchange for the forgiveness of the accrued compensation the Company agreed to a cash bonus of 50% of the remaining
accrued compensation for each individual. This resulted in an accrual for cash bonuses of $513,013 for employees and an accrual of
$70,200 to the board members, to be paid upon the occurrence of a successful IPO. In addition, the Company agreed to issue an
aggregate of 2,353,665 stock options with an exercise price of $1.33 and an aggregate of 1,399,834 restricted stock units with a
grant date value of $1.33 in exchange for the aggregate forgiveness of compensation in the amount of
$4,189,626. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 29, 2023, the Board of Directors executed a Unanimous Written Consent relating to the forgiveness of accrued compensation
for executives, consultants, and board members in the amount of $4,189,626. In exchange for the forgiveness of the accrued
compensation the Company agreed to a cash bonus of 583,214 to be paid upon the occurrence of a successful IPO. In addition, the
Company agreed to issue an aggregate of 2,353,665 stock options with an exercise price of $1.33 and an aggregate of 1,399,834
restricted stock units with a grant date value of $1.33 in exchange for the aggregate forgiveness of compensation in the amount of
$4,189,626.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 16, 2023, the Board of Directors executed a Unanimous Written Consent relating to the forgiveness of the $583,214 cash
bonus granted in the September 29, 2023 forgiveness in exchange for 338,899 stock options with an exercise price of $1.33 and an
aggregate of 226,203 restricted stock units with a grant date value of $1.33.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2024, $92,125 was due to a Company wholly owned by the Company&rsquo;s Chief Financial Officer, who also is an option
holder. The amount is included in accrued compensation on the balance sheet.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included
in accounts payable and accrued expenses as of March 31, 2024 and December 31, 2023 are the following related party
balances, respectively: expense reports due to employees $76,995 and $49,214 and annual license fee due to Aquanova AG totaling
$168,750 and $150,000. See Notes 4 and 8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Director
Independence</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have applied to list our common stock on the Nasdaq Capital Market. In order to list our common stock on the Nasdaq Capital Market,
we are required to comply with the Nasdaq Capital Market standards relating to corporate governance, requiring, among other things, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    majority of our Board of Directors to consist of &ldquo;independent directors&rdquo; as defined by the applicable rules and regulations
    of the Nasdaq Capital Market;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    compensation of our executive officers to be determined, or recommended to the Board of Directors for determination, by independent
    directors constituting a majority of the independent directors of the Board in a vote in which only independent directors participate
    or by a Compensation Committee comprised of at least two independent directors as well as composed entirely of independent directors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That
    director nominees to be selected, or recommended to the Board of Directors for selection, by independent directors constituting a
    majority of the independent directors of the Board in a vote in which only independent directors participate or by a nomination committee
    comprised of at least two independent directors as well as composed entirely of independent directors; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 162; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->160<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Establishment
    of an audit committee with at least three independent directors as well as composed entirely of independent directors, where at least
    one of the independent directors qualifies as an audit committee financial expert under SEC rules and as a financially sophisticated
    audit committee member under the Nasdaq Capital Market rules.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
applicable rules of the Nasdaq Capital Market, a director will only qualify as an &ldquo;independent director&rdquo; if, in the opinion
of the listed company&rsquo;s board of directors, that person does not have a relationship that would interfere with the exercise of
independent judgment in carrying out the responsibilities of a director. In order to be considered independent for purposes of Rule 10A-3,
a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the
board of directors, or any other board committee, accept, directly or indirectly, any consulting, advisory, or other compensatory fee
from the listed company or any of its subsidiaries or otherwise be an affiliated person of the listed company or any of its subsidiaries.
For purposes of the audit committee composition requirements, we must have at least one independent director on our audit committee at
the time of listing on the Nasdaq Capital Market, at least two independent directors within 90 days of listing on the Nasdaq Capital
Market and at least three independent directors within one year of listing on the Nasdaq Capital Market, where at least one of the independent
directors qualifies as an audit committee financial expert under SEC rules and as a financially sophisticated audit committee member
under the Nasdaq Capital Market rule. In accordance with Rule 5615(b)(1), since we are listing in connection with our initial public
offering, we are permitted to phase in our compliance with the independent committee requirements set forth in Rules 5605(d)(2) (for
purposes of the compensation committee) and Rules 5605(e)(1)(B) (for purposes of the nominating committee) on the same schedule as we
are permitted to phase in our compliance with the independent audit committee requirement pursuant to Rule 10A-3(b)(1)(iv)(A) under the
Act. Accordingly, we are permitted to phase in the compensation committee and nominating committee composition requirements as follows:
(1) one member must satisfy the independence requirement at the time of listing; (2) a majority of members must satisfy the independence
requirement within 90 days of listing; and (3) all members must satisfy the independence requirement within one year of listing. Furthermore,
a Company listing in connection with its initial public offering shall have twelve months from the date of listing to comply with the
majority independent board requirement in Rule 5605(b). The foregoing is referred to herein as the &ldquo;Independence Composition Requirements.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s Board of Directors has affirmatively determined that currently three of its seven directors, including, Christer Ros&eacute;n,
Marshall Hayward, Ph.D., and Alison D. Silva, are non-independent directors of the Company and four of its seven directors, namely Nicholas
H. Hemmerly, Julie Kampf, Allison W. Brady, and Holger Weis, are independent directors of the Company. Therefore, a majority of the members
of our Board of Directors are independent. Currently, the Company&rsquo;s audit committee consists of three independent directors, namely
Holger Weis, Allison W. Brady and Nicholas Hemmerly. Currently, the Company&rsquo;s compensation committee consists of three independent
directors, namely Nicholas H. Hemmerly, Julie Kampf and Allison W. Brady. Currently, the Company&rsquo;s nominating committee consists
of three independent directors, namely Julie Kampf, Holger Weis and Nicholas H. Hemmerly. Mr. Weis qualifies as an audit committee
financial expert under SEC rules and as a financially sophisticated audit committee member under the Nasdaq Capital Market rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ar_012"></A>UNDERWRITING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the terms and conditions set forth in the underwriting agreement between us and the underwriters named below, for which Revere
Securities LLC, is acting as the representative (the &ldquo;representative&rdquo;), we have agreed to sell to the underwriters,
and each underwriter has severally agreed to purchase, the number of shares of our common stock listed next to its name in the following
table:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1.5pt solid">Underwriter</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>of
                                            Shares</B></FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"> Revere Securities LLC</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> 2,750,000 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the underwriting agreement, the underwriters are committed to purchase all of the shares offered by this prospectus, if the underwriters buy any of such shares.
The underwriters&rsquo; obligation to purchase the shares is subject to satisfaction of certain conditions, including, among others,
the continued accuracy of representations and warranties made by us in the underwriting agreement, delivery of legal opinions and the
absence of any material changes in our assets, business or prospects after the date of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters initially propose to offer our common stock directly to the public at the public offering price set forth on the front cover
page of this prospectus and to certain dealers at such offering price less a concession not to exceed $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per share. After the initial public offering of the shares of our common stock, the offering price and other selling terms may be changed
by the underwriters. Sales of shares of our common stock made outside the United States may be made by affiliates of certain of the underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Discounts
and Commissions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the per share and total underwriting discounts and commissions we will pay to the underwriters. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per
    Share</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
    offering price</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting
    discounts and commissions to be paid by us (1)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds,
    before expenses, to us</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    underwriters will receive an underwriting discount equal to 7.0% (+1.0% in expenses for a total of 8.0%) on shares sold in
    this offering.</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 163; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->161<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to reimburse the representative for accountable legal expenses and other out-of-pocket expenses, roadshow expenses and cost
of background checks incurred by the </FONT>representative in connection with the offering, in an estimated amount not to exceed $175,000. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate that the total expenses of the offering payable by us, excluding underwriting discounts and commissions, will be approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Right
of First Refusal</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have granted Revere Securities LLC the right, subject to FINRA Rule&nbsp;5110(g)(5), for a period of 9 months following
the successful completion of this offering, (a) to act as financial advisor for certain dispositions,
acquisitions, exchange or tender offers, or mergers, consolidations or other business combinations; (b) to act as sole book-runner, sole
manager, sole placement agent or sole agent with respect to financings or refinancing of indebtedness; or (c) to act as sole book-running
manager, sole underwriter or sole placement agent for any public offering (including at-the-market facility) or private placement or
any other capital-raising financing of equity, equity-linked or debt securities using an underwriter or placement agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stabilization</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In accordance with Regulation&nbsp;M
under the Exchange Act, the underwriters may engage in any of the activities written below that stabilize, maintain or otherwise affect
the price of our common stock. The underwriters are prohibited from conducting any short sale activity in the underlying security including,
but not limited to, sales of shares in excess of the number of shares the underwriters are obligated to purchase and/or conducting any
naked short sale activity.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT>&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stabilizing transactions permit bids to purchase the
    underlying security as long as the stabilizing bids do not exceed a specific maximum price.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">In passive market making, market makers in our common
    stock who are underwriters or prospective underwriters may, subject to limitations, make bids for or purchase shares of our common
    stock until the time, if any, at which a stabilizing bid is made.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 164; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->162<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
activities</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> may have the effect of raising or maintaining
the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result
of these activities, the price of our common stock may be higher than the price that might otherwise exist in the open
market. These transactions may be effected on the Nasdaq Capital Market or otherwise and, if commenced, may be discontinued at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
we nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions
described above may have on the price of our common stock. In addition, neither we nor any of the underwriters make any representation
that the representative will engage in these stabilizing transactions or that any transaction, once commenced, will not be discontinued
without notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indemnification</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have agreed to indemnify the underwriters against specified liabilities,
including liabilities under the Securities Act, and to contribute to payments the underwriters may be required to make in respect thereof.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Discretionary
Accounts</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters have informed us that they do not expect to make sales to accounts over which they exercise discretionary authority in excess
of 5% of the shares of our common stock being offered in this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Determination
of the Public Offering Price</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to this offering, there has been no public market for shares of our common stock. The public offering price will be as determined through
negotiations between us and the representative. In addition to prevailing market conditions, the factors considered in determining the
public offering price included the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    information included in this prospectus and otherwise available to the representative;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    valuation multiples of publicly traded companies that the representative believes to be comparable to us;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    financial information;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    prospects and the history and the prospectus of the industry in which we compete;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    assessment of our management, its past and present operations, and the prospects for, and timing of, our future revenues;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    present state of our development; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    above factors in relation to market values and various valuation measures of other companies engaged in activities similar to ours.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock-Up
<I>Agreements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed that for a period of 180 days after the closing of this offering, we and any of our successors will not, without the
prior written consent of the representative, which may be withheld or delayed in the representative&rsquo;s sole discretion:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">offer,
    issue, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any
    option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">enter
    into any swap or other arrangement that transfers to another entity, in whole or in part, any of the economic consequences of ownership
    of any of our common stock or such other securities, whether any such transaction described above is to be settled by delivery of
    shares of our capital stock or such other securities, in cash or otherwise; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">file
    with the SEC a registration statement under the Securities Act relating to, any shares of our common stock or any securities convertible
    into or exercisable or exchangeable for common stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of our directors, executive officers, convertible note holders, and all holders of our outstanding common stock as of the effective
date of this registration statement, has entered into lock-up agreements with the representative prior to the commencement of this offering
pursuant to which each of these persons or entities has agreed that, for a period ending 180 days after the date of this prospectus,
none of them will, without the prior written consent of the representative (which may be withheld or delayed in the representative&rsquo;s
sole discretion):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offer,
    pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract
    to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, or file (or
    participate in the filing of) a registration statement with the Securities and Exchange Commission in respect of, any shares of Common
    Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock (including without limitation,
    shares of Common Stock which may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations
    of the Securities and Exchange Commission and securities which may be issued upon exercise of a stock option or warrant);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enter
    into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the shares
    of, whether any such transaction is to be settled by delivery of shares of Common Stock or such other securities, in cash or otherwise;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Make
    any demand for or exercise any right with respect to, the registration of any shares of Common Stock or any security convertible
    into or exercisable or exchangeable for shares of Common Stock;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Publicly
    announce an intention to effect any transaction specified above.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Relationships</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
representative and its affiliates may provide various advisory, investment and commercial banking and other services to us in the ordinary
course of business, for which they may receive customary fees and commissions. The representative may in the future provide us and our
affiliates with investment banking and financial advisory services for which it may in the future receive customary fees. The representative
may release, or authorize us to release, as the case may be, the Lock-Up Securities subject to the lock-up agreements described above
in whole or in part at any time with or without notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Electronic
Distribution</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
prospectus in electronic format may be made available on the websites maintained by one or more of the underwriters or selling
group members, if any, participating in the offering. The representative may allocate a number of shares to the
underwriters and selling group members, if any, for sale to their online brokerage account holders. Any such allocations
for online distributions will be made by the representative on the same basis as other allocations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Listing
on The Nasdaq Capital Market</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is not currently listed on any national securities exchange market or quoted on the OTC Markets. We have applied to list
our common stock on the Nasdaq Capital Market under the symbol &ldquo;JUNS.&rdquo; There is no assurance that our listing application
will be approved by the Nasdaq Capital Market. The approval of our listing on the Nasdaq Capital Market is a condition of closing this
offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 165; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->163<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Offer Restrictions Outside the United States</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus does not constitute an offer to sell to, or a solicitation of an offer to buy from, anyone in any country or jurisdiction
(i) in which such an offer or solicitation is not authorized, (ii) in which any person making such offer or solicitation is not qualified
to do so or (iii) in which any such offer or solicitation would otherwise be unlawful. No action has been taken that would, or is intended
to, permit a public offer of the shares of common stock or possession or distribution of this prospectus or any other offering or publicity
material relating to the shares of common stock in any country or jurisdiction (other than the United States) where any such action for
that purpose is required. Accordingly, each underwriter has undertaken that it will not, directly or indirectly, offer or sell any shares
of common stock or have in its possession, distribute or publish any prospectus, form of application, advertisement or other document
or information in any country or jurisdiction except under circumstances that will, to the best of its knowledge and belief, result in
compliance with any applicable laws and regulations and all offers and sales of shares of common stock by it will be made on the same
terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Australia</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus is not a disclosure document under Chapter 6D of the Australian Corporations Act, has not been lodged with the Australian
Securities and Investments Commission and does not purport to include the information required of a disclosure document under Chapter
6D of the Australian Corporations Act. Accordingly, (i) the offer of the securities under this prospectus is only made to persons to
whom it is lawful to offer the securities without disclosure under Chapter 6D of the Australian Corporations Act under one or more exemptions
set out in section 708 of the Australian Corporations Act, (ii) this prospectus is made available in Australia only to those persons
as set forth in clause (i) above, and (iii) the offeree must be sent a notice stating in substance that by accepting this offer, the
offeree represents that the offeree is such a person as set forth in clause (i) above, and, unless permitted under the Australian Corporations
Act, agrees not to sell or offer for sale within Australia any of the securities sold to the offeree within 12 months after its transfer
to the offeree under this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Canada</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors,
as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted
clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale
of the securities must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements
of applicable securities laws. Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies
for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies
for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&rsquo;s
province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&rsquo;s
province or territory for particulars of these rights or consult with a legal advisor. Pursuant to section 3A.3 of National Instrument
33-105 Underwriting Conflicts (NI 33-105), the underwriter is not required to comply with the disclosure requirements of NI33-105 regarding
underwriter conflicts of interest in connection with this offering.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>China</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information in this document does not constitute a public offer of the securities, whether by way of sale or subscription, in the People&rsquo;s
Republic of China (the &ldquo;PRC&rdquo;) (excluding, for purposes of this paragraph, Hong Kong Special Administrative Region, Macau
Special Administrative Region and Taiwan). The securities may not be offered or sold directly or indirectly in the PRC to legal or natural
persons other than directly to &ldquo;qualified domestic institutional investors.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 166; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->164<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>European
Economic Area &mdash; Belgium, Germany, Luxembourg and Netherlands</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information in this document has been prepared on the basis that all offers of securities will be made pursuant to an exemption under
the Directive 2003/71/EC (&ldquo;Prospectus Directive&rdquo;), as implemented in Member States of the European Economic Area (each, a
&ldquo;Relevant Member State&rdquo;), from the requirement to produce a prospectus for offers of securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
offer to the public of securities has not been made, and may not be made, in a Relevant Member State except pursuant to one of the following
exemptions under the Prospectus Directive as implemented in that Relevant Member State:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    legal entities that are authorized or regulated to operate in the financial markets or, if not so authorized or regulated, whose
    corporate purpose is solely to invest in securities;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    any legal entity that has two or more of (i) an average of at least 250 employees during its last fiscal year; (ii) a total balance
    sheet of more than &euro;43,000,000 (as shown on its last annual unconsolidated or consolidated financial statements) and (iii) an
    annual net turnover of more than &euro;50,000,000 (as shown on its last annual unconsolidated or consolidated financial statements);</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    fewer than 100 natural or legal persons (other than qualified investors within the meaning of Article 2(1)(e) of the Prospectus Directive)
    subject to obtaining the prior consent of our Company or any underwriter for any such offer; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no such offer of securities shall
    result in a requirement for the publication by our Company of a prospectus pursuant to Article 3 of the Prospectus Directive.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>France</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
document is not being distributed in the context of a public offering of financial securities (offre au public de titres financiers)
in France within the meaning of Article L.411-1 of the French Monetary and Financial Code (Code mon&eacute;taire et financier) and Articles
211-1, et seq. of the General Regulation of the French Autorit&eacute; des march&eacute;s financiers (&ldquo;AMF&rdquo;). The securities
have not been offered or sold and will not be offered or sold, directly or indirectly, to the public in France.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
document and any other offering material relating to the securities have not been, and will not be, submitted to the AMF for approval
in France and, accordingly, may not be distributed or caused to distributed, directly or indirectly, to the public in France.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
offers, sales and distributions have been and shall only be made in France to (i) qualified investors (investisseurs qualifi&eacute;s)
acting for their own account, as defined in and in accordance with Articles L.411-2-II-2&deg; and D.411-1 to D.411-3, D.744-1, D.754-1
and D.764-1 of the French Monetary and Financial Code and any implementing regulation and/or (ii) a restricted number of non-qualified
investors (cercle restreint d&rsquo;investisseurs non-qualifi&eacute;s) acting for their own account, as defined in and in accordance
with Articles L.411-2-II-2&deg; and D.411-4, D.744-1, D.754-1 and D.764-1 of the French Monetary and Financial Code and any implementing
regulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Article 211-3 of the General Regulation of the AMF, investors in France are informed that the securities cannot be distributed (directly
or indirectly) to the public by the investors otherwise than in accordance with Articles L.411-1, L.411-2, L.412-1 and L.621-8 to L.621-8-3
of the French Monetary and Financial Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ireland</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information in this document does not constitute a prospectus under any Irish laws or regulations and this document has not been filed
with or approved by any Irish regulatory authority as the information has not been prepared in the context of a public offering of securities
in Ireland within the meaning of the Irish Prospectus (Directive 2003/71/EC) Regulations 2005 (the &ldquo;Prospectus Regulations&rdquo;).
The securities have not been offered or sold, and will not be offered, sold or delivered directly or indirectly in Ireland by way of
a public offering, except to (i) qualified investors as defined in Regulation 2(l) of the Prospectus Regulations and (ii) fewer than
100 natural or legal persons who are not qualified investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 167; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->165<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Israel</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities offered by this prospectus have not been approved or disapproved by the Israeli Securities Authority (the &ldquo;ISA&rdquo;),
nor have such securities been registered for sale in Israel. The shares may not be offered or sold, directly or indirectly, to the public
in Israel, absent the publication of a prospectus. The ISA has not issued permits, approvals or licenses in connection with the offering
or publishing the prospectus; nor has it authenticated the details included herein, confirmed their reliability or completeness, or rendered
an opinion as to the quality of the securities being offered. Any resale in Israel, directly or indirectly, to the public of the securities
offered by this prospectus is subject to restrictions on transferability and must be effected only in compliance with the Israeli securities
laws and regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Italy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
offering of the securities in the Republic of Italy has not been authorized by the Italian Securities and Exchange Commission (Commissione
Nazionale per le Societ&aacute; e la Borsa, &ldquo;CONSOB&rdquo;) pursuant to the Italian securities legislation and, accordingly, no
offering material relating to the securities may be distributed in Italy and such securities may not be offered or sold in Italy in a
public offer within the meaning of Article 1.1(t) of Legislative Decree No. 58 of 24 February 1998 (&ldquo;Decree No. 58&rdquo;), other
than:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    Italian qualified investors, as defined in Article 100 of Decree No. 58 by reference to Article 34-ter of CONSOB Regulation no. 11971
    of 14 May 1999 (&ldquo;Regulation no. 11971&rdquo;) as amended (&ldquo;Qualified Investors&rdquo;); and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    other circumstances that are exempt from the rules on public offer pursuant to Article 100 of Decree No. 58 and Article 34-ter of
    Regulation No. 11971 as amended.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
offer, sale or delivery of the securities or distribution of any offer document relating to the securities in Italy (excluding placements
where a Qualified Investor solicits an offer from the issuer) under the paragraphs above must be:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">made
    by investment firms, banks or financial intermediaries permitted to conduct such activities in Italy in accordance with Legislative
    Decree No. 385 of 1 September 1993 (as amended), Decree No. 58, CONSOB Regulation No. 16190 of 29 October 2007 and any other applicable
    laws; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    compliance with all relevant Italian securities, tax and exchange controls and any other applicable laws.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
subsequent distribution of the securities in Italy must be made in compliance with the public offer and prospectus requirement rules
provided under Decree No. 58 and the Regulation No. 11971 as amended unless an exception from those rules applies. Failure to comply
with such rules may result in the sale of such securities being declared null and void and in the liability of the entity transferring
the securities for any damages suffered by the investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Japan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities have not been and will not be registered under Article 4, paragraph 1 of the Financial Instruments and Exchange Law of Japan
(Law No. 25 of 1948), as amended (the &ldquo;FIEL&rdquo;), pursuant to an exemption from the registration requirements applicable to
a private placement of securities to Qualified Institutional Investors (as defined in and in accordance with Article 2, paragraph 3 of
the FIEL and the regulations promulgated thereunder). Accordingly, the securities may not be offered or sold, directly or indirectly,
in Japan or to, or for the benefit of, any resident of Japan other than Qualified Institutional Investors. Any Qualified Institutional
Investor who acquires securities may not resell them to any person in Japan that is not a Qualified Institutional Investor, and acquisition
by any such person of securities is conditional upon the execution of an agreement to that effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 168; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->166<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>New Zealand</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">The securities offered hereby have not been offered
or sold, and will not be offered or sold, directly or indirectly in New Zealand and no offering materials or advertisements have been
or will be distributed in relation to any offer of shares in New Zealand, in each case other than:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    persons whose principal business is the investment of money or who, in the course of and for the purposes of their business, habitually
    invest money;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to persons who in all
    the circumstances can properly be regarded as having been selected otherwise than as members of the public;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to persons who are each
    required to pay a minimum subscription price of at least NZ$500,000 for the shares before the allotment of those shares (disregarding
    any amounts payable, or paid, out of money lent by the issuer or any associated person of the issuer); or</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in other circumstances
    where there is no contravention of the Securities Act 1978 of New Zealand (or any statutory modification or reenactment of, or statutory
    substitution for, the Securities Act 1978 of New Zealand).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Portugal</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
document is not being distributed in the context of a public offer of financial securities (oferta p&uacute;blica de valores mobili&aacute;rios)
in Portugal, within the meaning of Article 109 of the Portuguese Securities Code (C&oacute;digo dos Valores Mobili&aacute;rios). The
securities have not been offered or sold and will not be offered or sold, directly or indirectly, to the public in Portugal. This document
and any other offering material relating to the securities have not been, and will not be, submitted to the Portuguese Securities Market
Commission (Comiss&atilde;o do Mercado de Valores Mobili&aacute;rios) for approval in Portugal and, accordingly, may not be distributed
or caused to distributed, directly or indirectly, to the public in Portugal, other than under circumstances that are deemed not to qualify
as a public offer under the Portuguese Securities Code. Such offers, sales and distributions of securities in Portugal are limited to
persons who are &ldquo;qualified investors&rdquo; (as defined in the Portuguese Securities Code). Only such investors may receive this
document and they may not distribute it or the information contained in it to any other person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sweden</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
document has not been, and will not be, registered with or approved by Finansinspektionen (the Swedish Financial Supervisory Authority).
Accordingly, this document may not be made available, nor may the securities be offered for sale in Sweden, other than under circumstances
that are deemed not to require a prospectus under the Swedish Financial Instruments Trading Act (1991:980) (Sw. lag (1991:980) om handel
med finansiella instrument). Any offering of securities in Sweden is limited to persons who are &ldquo;qualified investors&rdquo; (as
defined in the Financial Instruments Trading Act). Only such investors may receive this document and they may not distribute it or the
information contained in it to any other person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Switzerland</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (&ldquo;SIX&rdquo;) or on any
other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards
for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses
under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland.
Neither this document nor any other offering material relating to the securities may be publicly distributed or otherwise made publicly
available in Switzerland.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
this document nor any other offering material relating to the securities have been or will be filed with or approved by any Swiss regulatory
authority. In particular, this document will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial
Market Supervisory Authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
document is personal to the recipient only and not for general circulation in Switzerland.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>United
Arab Emirates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">this document nor the securities
have been approved, disapproved or passed on in any way by the Central Bank of the United Arab Emirates or any other governmental authority
in the United Arab Emirates, nor have we received authorization or licensing from the Central Bank of the United Arab Emirates or any
other governmental authority in the United Arab Emirates to market or sell the securities within the United Arab Emirates. This document
does not constitute and may not be used for the purpose of an offer or invitation. No services relating to the securities, including
the receipt of applications and/or the allotment or redemption of such shares, may be rendered within the United Arab Emirates by our
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
offer or invitation to subscribe for securities is valid or permitted in the Dubai International Financial Centre.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 169; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->167<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>United
Kingdom</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
the information in this document nor any other document relating to the offer has been delivered for approval to the Financial Services
Authority in the United Kingdom and no prospectus (within the meaning of section 85 of the Financial Services and Markets Act 2000, as
amended (&ldquo;FSMA&rdquo;)) has been published or is intended to be published in respect of the securities. This document is issued
on a confidential basis to &ldquo;qualified investors&rdquo; (within the meaning of section 86(7) of FSMA) in the United Kingdom, and
the securities may not be offered or sold in the United Kingdom by means of this document, any accompanying letter or any other document,
except in circumstances which do not require the publication of a prospectus pursuant to section 86(1) FSMA. This document should not
be distributed, published or reproduced, in whole or in part, nor may its contents be disclosed by recipients to any other person in
the United Kingdom.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
invitation or inducement to engage in investment activity (within the meaning of section 21 of FSMA) received in connection with the
issue or sale of the securities has only been communicated or caused to be communicated and will only be communicated or caused to be
communicated in the United Kingdom in circumstances in which section 21(1) of FSMA does not apply to our company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 30.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United Kingdom, this document is being distributed only to, and is directed at, persons (i) who have professional experience in matters
relating to investments falling within Article 19(5) (investment professionals) of the Financial Services and Markets Act 2000 (Financial
Promotions) Order 2005 (&ldquo;FPO&rdquo;), (ii) who fall within the categories of persons referred to in Article 49(2)(a) to (d) (high
net worth companies, unincorporated associations, etc.) of the FPO or (iii) to whom it may otherwise be lawfully communicated (together
&ldquo;relevant persons&rdquo;). The investments to which this document relates are available only to, and any invitation, offer or agreement
to purchase will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document
or any of its contents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="SS_001"></A>SELLING
STOCKHOLDERS</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 3, 2024, the Company entered into a 36-month service agreement with three different non-affiliated entities. Upon the closing of
these agreements, the Company issued an aggregate of 3,487,500 shares of common stock, 1,162,500 of shares of common stock for each entity,
with a fair market value of $1.33 per share. The shares issued are free from any restriction as a pre-payment in full for the 36 months
of services to be provided. In addition, each of the entities agreed to purchase 37,500 shares each of the Company&rsquo;s common stock
at a price of $1.33 per share prior to the occurrence of the initial public offering. The shares of common stock were issued by the Company
to Selling Stockholders under Rule 506(b) of Regulation D promulgated under the Securities Act or Regulation S promulgated under the
Securities Act, as applicable. The shares of common stock being offered by the Selling Stockholders in the Resale Prospectus filed contemporaneously
with this prospectus are those acquired by the Selling Stockholders on June 3, 2024. We are registering the shares of common stock in
the Resale Prospectus in order to permit the Selling Stockholders to offer the shares for resale from time to time following the closing
of the initial public offering and listing on the Nasdaq Capital Market. Except for the ownership of these securities or as otherwise
disclosed below, the Selling Stockholders have not had any position, office, or other material relationship with us or any of our predecessors
or affiliates within the past three years, and based on the information provided to us by the Selling Stockholders, no Selling Stockholder
is a broker-dealer or an affiliate of a broker-dealer.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information with respect to the number of shares of common stock beneficially owned by the Selling Stockholders
named below and as adjusted to give effect to the sale of the shares of common stock offered in the Resale Prospectus. The table lists
the number of shares of common stock beneficially owned by the Selling Stockholders as of the date of this prospectus, the shares of
common stock covered by the Resale Prospectus that may be disposed of by the Selling Stockholders, and the number of shares of common
stock that will be beneficially owned by the Selling Stockholders assuming all of the shares of common stock covered by the Resale Prospectus
are sold.</FONT> </P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of common stock beneficially owned have been determined in accordance with rules promulgated by the SEC, and the information is
not necessarily indicative of beneficial ownership for any other purpose. The information in the table below is current as of the date
of this prospectus. The Selling Stockholders may from time to time offer and
sell pursuant to the Resale Prospectus any or all of the shares of common stock being registered. The Selling Stockholders are under
no obligation to sell all or any portion of such shares of common stock nor are the Selling Stockholders obligated to sell any shares
of common stock immediately upon effectiveness of the Resale Prospectus. All information with respect to share ownership has been furnished
by the Selling Stockholders.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid"> Name </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Shares Beneficially Owned Prior
    to Resale Offering </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percent
    Beneficially Owned Prior to Resale Offering<SUP>(1)</SUP></B></FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Shares to be Resold </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Amount Beneficially Owned After
    Resale Offering </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percent
    Beneficially Owned After Resale Offering<SUP>(1)</SUP></B></FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; text-align: left; padding-bottom: 1.5pt"> Optimize Wellness Limited </TD><TD STYLE="width: 2%; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"> 1,200,000 </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"> 3.65 </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"> % </TD><TD STYLE="width: 2%; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"> 1,200,000 </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"> % </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Regis Healthcare Group Limited </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 1,200,000 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 3.65 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> % </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 1,200,000 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> % </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Longevity Technology Group Limited </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 1,200,000 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 3.65 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> % </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 1,200,000 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> % </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
less than 1%</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on 32,876,413 shares of common stock issued and outstanding immediately after the completion of this underwritten public offering.
    As noted above, for purposes of computing percentage ownership after the resale offering, we have assumed that any shares of common
    stock being offered will be sold in the resale offering.</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ar_013"></A>DESCRIPTION
OF SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are offering 2,750,000 shares of common stock in this offering. The following description of our capital stock is based upon our
amended and restated certificate of incorporation, as amended, our amended and restated bylaws, as amended, and applicable provisions
of law, in each case as currently in effect. This discussion does not purport to be complete and is qualified in its entirety by reference
to our certificate of incorporation, as amended, and our amended and restated bylaws, copies of which are filed with the SEC as exhibits
to the registration statement of which this prospectus is a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Authorized
Capital Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of July 12, 2024, our authorized capital stock consists of (i) 125,000,000 shares of common stock, par value $0.0001 per
share (&ldquo;Common Stock&rdquo;), and (ii) 5,000,000 shares of preferred stock, par value $0.0001 per share (&ldquo;Preferred Stock&rdquo;).
At July 12, we had 30,126,413 shares of Common Stock and Restricted Stock Awards issued and outstanding and no shares of
Preferred Stock issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of July 12, 2024, there were 26 holders of record of our Common Stock and no holders of record of our Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of our common stock are entitled to one vote for each share held on all matters to be voted on by the Company&rsquo;s stockholders.
There shall be no cumulative voting.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 170; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->168<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dividends</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of shares of our common stock are entitled to dividends when and as declared by the Board from funds legally available therefor
if, as and when determined by the Board of Directors of the Company in their sole discretion, subject to provisions of law, and any provision
of the Company&rsquo;s Certificate of Incorporation, as amended from time to time. There are no preemptive, conversion or redemption
privileges, nor sinking fund provisions with respect to the common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Liquidation</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of any voluntary or involuntary liquidation, dissolution or winding up of our affairs, the holders of our common stock will
be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of or provision for
all of our debts and other liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Fully
Paid and Non-assessable</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
outstanding shares of common stock are, and the common stock to be outstanding upon completion of this offering will be, duly authorized,
validly issued, fully paid and non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors shall have the authority to authorize the issuance of the preferred stock from time to time in one or more classes
or series, and to state in the resolution or resolutions from time to time adopted providing for the issuance thereof the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 57pt; text-align: justify; text-indent: -21pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of shares of any series and the designation to distinguish the shares of such series from the shares of all other series;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    voting powers, if any, and whether such voting powers are full or limited in such series;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    redemption provisions, if any, applicable to such series, including the redemption price or prices to be paid;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    dividends, if any, will be cumulative or noncumulative, the dividend rate of such series, and the dates and preferences of dividends
    on such series;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    rights of such series upon the voluntary or involuntary dissolution of, or upon any distribution of the assets of, the Corporation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    provisions, if any, pursuant to which the shares of such series are convertible into, or exchangeable for, shares of any other class
    or classes or of any other series of the same or any other class or classes of stock, or any other security, of the Corporation or
    any other corporation or other entity, and the rates or other determinants of conversion or exchange applicable thereto;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    right, if any, to subscribe for or to purchase any securities of the Corporation or any other corporation or other entity;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    provisions, if any, of a sinking fund applicable to such series; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other relative, participating, optional, or other special powers, preferences or rights and qualifications, limitations, or restrictions
    thereof.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 57pt; text-align: justify; text-indent: -21pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of each class or series of the preferred stock may vary from the shares of any other class or series thereof in any respect. The
Board of Directors may increase the number of shares of the preferred stock designated for any existing class or series by a resolution
adding to such class or series authorized and unissued shares of the preferred stock not designated for any existing class or series
of the preferred stock and the shares so subtracted shall become authorized, unissued and undesignated shares of the preferred stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Anti-Takeover
Effects of Certain Provisions of Our Certificate of Incorporation, as Amended, and Our Amended and Restated Bylaws,
as Amended</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
of our certificate of incorporation, as amended, and our amended and
restated bylaws, as amended (&ldquo;bylaws&rdquo;), could make it more difficult to acquire us by means of a merger, tender offer, proxy
contest, open market purchases, removal of incumbent directors and otherwise. These provisions, which are summarized below, are expected
to discourage types of coercive takeover practices and inadequate takeover bids and to encourage persons seeking to acquire control of
us to first negotiate with us. We believe that the benefits of increased protection of our potential ability to negotiate with the proponent
of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging takeover or acquisition
proposals because negotiation of these proposals could result in an improvement of their terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Removal
of Directors.</I> Our amended and restated bylaws provide that directors may be removed prior to the expiration of their terms
by the affirmative vote of the holders of not less than two-thirds (2/3) of the voting power of the issued and outstanding stock entitled
to vote.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Vacancies</I>.
Our amended and restated bylaws provide the exclusive right of our board of directors to elect a director to fill a vacancy created
by the expansion of the board of directors or the resignation, death, or removal of a director, which prevents stockholders from being
able to fill vacancies on our board of directors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Preferred
Stock. </I>Our certificate of incorporation, as amended, authorizes the issuance of up to 5,000,000 shares of preferred stock
with such rights and preferences as may be determined from time to time by our board of directors in their sole discretion. Our board
of directors may, without stockholder approval, issue series of preferred stock with dividends, liquidation, conversion, voting or other
rights that could adversely affect the voting power or other rights of the holders of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Amendment
of Bylaws.</I> The certificate of incorporation, as amended, and amended and restated bylaws provide that the bylaws may
be altered, amended or repealed by the Board of Directors by an affirmative vote of a majority of the Board of Directors at any regular
meeting of the Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Limitation
of Liability</I>. The certificate of incorporation provides for the limitation of liability of, and providing indemnification to, our
directors and officers;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Special
Stockholders Meeting</I>. The amended and restated bylaws provide that a special meeting of the stockholders may only be called
by a majority of the board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Nominations
of Directors</I>. The amended and restated bylaws provide for advance notice procedures that stockholders must comply with in
order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&rsquo; meeting, which
may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&rsquo;s own slate of directors
or otherwise attempting to obtain control of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exclusive
Forum Provision</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
IX of our certificate of incorporation, as amended, and Section 7.4 of our amended and restated bylaws provide that
&ldquo;[u]nless the corporation consents in writing to the selection of an alternative forum, the sole and exclusive forum for (i) any
derivative action or proceeding brought on behalf of the Corporation, (ii) any action asserting a claim of breach of a fiduciary duty
owed by any director, officer or other employee of the Corporation to the Corporation or the Corporation&rsquo;s stockholders, (iii)
any action asserting a claim arising pursuant to any provision of the DGCL, or (iv) any action asserting a claim governed by the internal
affairs doctrine shall be a state or federal court located in the county in which the principal office of the corporation in the State
of Delaware is established, in all cases subject to the court&rsquo;s having personal jurisdiction over the indispensable parties named
as defendants. Notwithstanding the foregoing, the exclusive forum provision will not apply to suits brought to enforce any liability
or duty created by the Exchange of 1934, as amended, the Securities Act of 1933, as amended, or any claim for which the federal courts
have exclusive or concurrent jurisdiction.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 171; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->169<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
choice of forum provision may limit a bondholder&rsquo;s ability to bring a claim in a judicial forum that it finds favorable for disputes
with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and
employees. Alternatively, a court could find these provisions of our certificate of incorporation, as amended, and our amended
and restated bylaws to be inapplicable or unenforceable in respect of one or more of the specified types of actions or proceedings,
which may require us to incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect
our business and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fee
Shifting Provision</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
7.4 of our amended and restated bylaws provides that &ldquo;[i]f any action is brought by any party against another party, relating
to or arising out of these Bylaws, or the enforcement hereof, the prevailing party shall be entitled to recover from the other party
reasonable attorneys&rsquo; fees, costs and expenses incurred in connection with the prosecution or defense of such action.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
amended and restated bylaws provide that for this section, the term &ldquo;attorneys&rsquo; fees&rdquo; or &ldquo;attorneys&rsquo; fees
and costs&rdquo; means the fees and expenses of counsel to the Company and any other parties asserting a claim subject to Section 7.4
of the amended and restated bylaws, which may include printing, photocopying, duplicating and other expenses, air freight charges, and
fees billed for law clerks, paralegals and other persons not admitted to the bar but performing services under the supervision of an
attorney, and the costs and fees incurred in connection with the enforcement or collection of any judgment obtained in any such proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
adopted the fee-shifting provision to eliminate or decrease nuisance and frivolous litigation. We intend to apply the fee-shifting provision
broadly to all actions except for&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">claims
brought under the Exchange Act and Securities Act<FONT STYLE="background-color: white">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no set level of recovery required to be met by a plaintiff to avoid payment under this provision. Instead, whoever is the prevailing
party is entitled to recover the reasonable attorneys&rsquo; fees, costs and expenses incurred in connection with the prosecution or
defense of such action. Any party who brings an action, and the party against whom such action is brought under Section 7.4 of our amended
and restated bylaws, which could include, but is not limited to former and current shareholders, Company directors, officers, affiliates,
legal counsel, expert witnesses and other parties, are subject to this provision. Additionally, any party who brings an action, and the
party against whom such action is brought under Section 7.4 of our amended and restated bylaws, which could include, but is not limited
to former and current shareholders, Company directors, officers, affiliates, legal counsel, expert witnesses and other parties, would
be able to recover fees under this provision.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event you initiate or assert a claims against us, in accordance with the dispute resolution provisions contained in our amended and
restated bylaws, and you do not, in a judgment prevail, you will be obligated to reimburse us for all reasonable costs and expenses incurred
in connection with such claim, including, but not limited to, reasonable attorney&rsquo;s fees and expenses and costs of appeal, if any.
Additionally, this provision in Section 7.4 of our amended and restated bylaws could discourage shareholder lawsuits that might otherwise
benefit the Company and its shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE
FEE SHIFTING PROVISION CONTAINED IN THE AMENDED AND RESTATED BYLAWS IS NOT INTENDED TO BE DEEMED A WAIVER BY ANY HOLDER OF COMMON
STOCK OF THE COMPANY&rsquo;S COMPLIANCE WITH THE U.S. FEDERAL SECURITIES LAWS AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER.
THE FEE SHIFTING PROVISION CONTAINED IN THE AMENDED AND RESTATED BYLAWS DO NOT APPLY TO CLAIMS BROUGHT UNDER THE EXCHANGE ACT
AND SECURITIES ACT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Transfer Agent </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The transfer agent and registrar
for our Common Stock is Equiniti Trust Company. The transfer agent and registrar&rsquo;s address is 1110 Centre Pointe Curve, Suite 101,
Mendota Heights, Minnesota 55120. The transfer agent&rsquo;s telephone (800) 401-1957.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ar_014"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validity of the securities offered by this prospectus will be passed upon for us by Anthony, Linder &amp; Cacomanolis, 1700 Palm Beach
Lakes Blvd., Suite 820, West Palm Beach, Florida 33401. ArentFox Schiff LLP, Washington, District of Columbia, is acting as counsel
to the underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ar_015"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
balance sheets as of December 31, 2023 and 2022 and the related statement of operations, changes in stockholders&rsquo; equity
and cash flows for the year ended December 31, 2023 and 2022 included in this registration statement and prospectus have been
audited by Assurance Dimensions, independent registered public accounting firm, as indicated in their report with respect thereto, and
have been so included in reliance upon the report of such firm given on their authority as experts in accounting and auditing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ar_016"></A>APPOINTMENT
OF AUDITOR</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 10, 2021, we appointed Assurance Dimensions as our independent registered public accounting firm. Assurance Dimensions audited our
financial statements for the years ended December 31, 2023 and 2022 which have been included in this prospectus and registration
statement. Prior to engaging Assurance Dimensions as our independent registered public accounting firm, we did not have an independent
registered public accounting firm to audit our financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 172; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->170<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ar_017"></A>DISCLOSURE
OF COMMISSION&rsquo;S POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors and officers are indemnified as provided by Delaware law, our certificate of incorporation, as amended, and our amended
and restated bylaws. We have agreed to indemnify each of our directors and certain officers against certain liabilities, including
liabilities under the Securities Act. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to
our directors, officers and controlling persons pursuant to the provisions described above, or otherwise, we have been advised that in
the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.
In the event that a claim for indemnification against such liabilities (other than our payment of expenses incurred or paid by our director,
officer or controlling person in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling
person in connection with the securities being registered, we will, unless in the opinion of our counsel the matter has been settled
by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public
policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ar_018"></A>WHERE
YOU CAN FIND ADDITIONAL INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed with the SEC the registration statement on Form S-1 under the Securities Act for the securities offered by this prospectus.
This prospectus, which is a part of the registration statement, does not contain all of the information in the registration statement
and the exhibits filed with it, portions of which have been omitted as permitted by SEC rules and regulations. For further information
concerning us and the securities offered by this prospectus, we refer to the registration statement and to the exhibits filed with it.
Statements contained in this prospectus as to the content of any contract or other document referred to are not necessarily complete.
In each instance, we refer you to the copy of the contracts and/or other documents filed as exhibits to the registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registration statement on Form S-1, of which this prospectus forms a part, including exhibits, is available at the SEC&rsquo;s website
at <I>http://www.sec.gov</I>. You may also read and copy any document we file with, or furnish to, the SEC at its public reference facilities:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
    Reference Room Office</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100
    F Street, N.E.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Room
    1580</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Washington,
    D.C. 20549</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 31.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may also obtain copies of the documents at prescribed rates by writing to the Public Reference Section of the SEC at 100 F Street, N.E.,
Room 1580, Washington, D.C. 20549. Callers in the United States can also call (202) 551-8090 for further information on the operations
of the public reference facilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 173; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->171<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JUPITER
NEUROSCIENCES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ar_019"></A>INDEX
TO FINANCIAL STATEMENTS</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#as_001">Report
    of Independent Registered Public Accounting Firm </A></FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.75in"> F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#as_002">Balance
    Sheets, as of December 31, 2023 and 2022 (Audited) </A></FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#as_003">Statements&nbsp;of
    Operations for the Years Ended December 31, 2023 and 2022 (Audited) </A></FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#as_004">Statements&nbsp;of
    Changes in Stockholder&rsquo;s Deficit for the Years Ended December 31, 2023 and 2022 (Audited) </A></FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#as_005">Statements&nbsp;of
    Cash Flows for the Years Ended December 31, 2023 and 2022 (Audited) </A></FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#as_006">Notes
    to Financial Statements</A></FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ch_001">Balance
    Sheets as of March 31, 2024 (Unaudited) and December 31, 2023</A> </FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.75in"> F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ch_002">Statements&nbsp;of
    Operations for the Three Months Ended March 31, 2024 and 2023 (Unaudited)</A> </FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ch_003">Statements&nbsp;of
    Stockholder&rsquo;s Deficit for the Three Months Ended March 31, 2024 and 2023 (Unaudited)</A> </FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ch_004">Statements&nbsp;of
    Cash Flows for the Three Months Ended March 31, 2024 and 2023 (Unaudited)</A> </FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ch_005">Condensed&nbsp;Notes
    to Financial Statements</A></FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> F-32 </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 174; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="aud_001.jpg" ALT="" STYLE="height: 75px; width: 650px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="as_001"></A>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Stockholders and Board of Directors of</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter
Neurosciences, Inc</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Opinion
on the Financial Statements</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of Jupiter Neurosciences, Inc, (the Company) as of December 31, 2023 and 2022,
and the related statements of operations, stockholders&rsquo; equity (deficit), cash flows for each of the years in the two-year period
ended December 31, 2023, and the related notes (collectively referred to as the financial statements). In our opinion, the financial
statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the
results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2023, in conformity with
accounting principles generally accepted in the United States of America.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Explanatory
Paragraph &ndash; Going Concern</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note
2 to the financial statements, the Company had a net loss of approximately $4,784,000 and cash used in operating activities of approximately
$481,000 for the year ended December 31, 2023 as well as an accumulated deficit of approximately $23,583,000 as of December 31, 2023.
These factors raise substantial doubt about the Company&rsquo;s ability to continue as a going concern. Management&rsquo;s plans in regard
to these matters are described in Note 2. The financial statements do not include any adjustments that might result from the outcome
of this uncertainty.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basis
for Opinion</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits,
we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion
on the effectiveness of the Company&rsquo;s internal control over financial reporting. Accordingly, we express no such opinion.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Critical
Audit Matters</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated
or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial
statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters
does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit
matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Valuation
of Derivatives</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Description
of the Matter</I></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has issued various debt and equity offerings in the past. Convertible notes have various terms, including a conversion feature.
The Company accounts for derivative instruments in accordance with Accounting Standards Codification 815, Derivatives and Hedging (&ldquo;ASC
815&rdquo;), which establishes accounting and reporting standards for derivative instruments, including certain derivative instruments
embedded in the conversion feature.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
judgment is exercised by the Company in accounting and valuation of the financial instruments by using a Monte Carlo simulation to value
them at inception and on any subsequent valuation dates.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>How
We Addressed the Matter in Our Audit.</I></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary procedures we performed to address this critical audit matter included evaluating all debt instruments, confirmation of significant
balances, reviewing inputs used in the valuation of the derivative instruments, and performing a reasonableness test the accuracy of
the Company&rsquo;s calculations.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="aud_002.jpg" ALT="A black letter and a white background&#10;&#10;Description automatically generated" STYLE="height: 37px; width: 180px"></FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have served as the Company&rsquo;s auditor since 2021</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Margate,
    Florida</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
    11, 2024</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ASSURANCE
DIMENSIONS, LLC</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>also
d/b/a McNAMARA and ASSOCIATES, LLC</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TAMPA
BAY</B>: 4920 W Cypress Street, Suite 102 | Tampa, FL 33607 | Office: 813.443.5048 | Fax: 813.443.5053</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JACKSONVILLE</B>:
4720 Salisbury Road, Suite 223 | Jacksonville, FL 32256 | Office: 888.410.2323 | Fax: 813.443.5053</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ORLANDO:
</B>1800 Pembrook Drive, Suite 300 | Orlando, FL 32810 | Office: 888.410.2323 | Fax: 813.443.5053</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SOUTH
FLORIDA</B>: 2000 Banks Road, Suite 218 | Margate, FL 33063 | Office: 754.800.3400 | Fax: 813.443.5053</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">www.assurancedimensions.com</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Assurance
Dimensions&rdquo; is the brand name under which Assurance Dimensions, LLC including its subsidiary McNamara and Associates, LLC (referred
together as &ldquo;AD LLC&rdquo;) and AD Advisors, LLC (&ldquo;AD Advisors&rdquo;), provide professional services. AD LLC and AD Advisors
practice as an alternative practice structure in accordance with the AICPA Code of Professional Conduct and applicable laws, regulations,
and professional standards. AD LLC is a licensed independent CPA firm that provides attest services to its clients, and AD Advisors provide
tax and business consulting services to their clients. AD Advisors, and its subsidiary entities are not licensed CPA firms.</FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 175; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JUPITER
NEUROSCIENCES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="as_002"></A>BALANCE
SHEETS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, <BR> 2023</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, <BR> 2022</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    Assets:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 64%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,478</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">64,431</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    current assets</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">261</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,232</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    current assets</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,739</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">69,663</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease right of use asset, net</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">116,070</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">162,498</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    asset</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,783</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,783</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    assets</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">148,592</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">235,944</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities
    and Stockholders&rsquo; Deficit</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    Liabilities:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    payable and accrued expenses</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">546,014</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">526,737</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    compensation</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,562,041</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,194,778</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    interest</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">88,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49,730</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    portion of operating lease liability</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48,213</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46,401</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
    notes payable, net of discount of $0, respectively</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,638,760</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,638,760</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
    payable, related party</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">383,479</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">93,479</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative
    liability</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,505,398</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">710,599</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    current liabilities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,771,905</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,260,484</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
    notes payable, net of discount of $43,288</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">106,712</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease liability, net of current portion</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">71,329</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">119,544</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    liabilities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,949,946</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,380,028</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commitments
    and Contingencies (Note 10)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders&rsquo;
    Deficit:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    A preferred stock, par value $0.0001; 5,000,000 shares authorized, nil shares issued and outstanding</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock, par value $0.0001; 125,000,000 shares authorized; 26,526,405 and 26,371,519 issued and outstanding, respectively</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,654</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,637</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    paid in capital</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> 17,778,498 </P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,652,094</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
    deficit</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(23,582,504</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(18,798,815</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    stockholders&rsquo; deficit</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,801,354</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,144,084</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    liabilities and stockholders&rsquo; deficit</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">148,592</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">235,944</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these audited financial statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 176; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JUPITER
NEUROSCIENCES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="as_003"></A>STATEMENTS
OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the Years Ended</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, <BR> 2023</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, <BR> 2022</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal
    contract revenue</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">233,281</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">954,793</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">942,806</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,915,978</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,722,922</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    operating expenses</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,870,771</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,665,728</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    loss</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,870,771</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,432,447</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    Income (Expenses):</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    income</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">482</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">617</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain
    on change in fair value of derivative liability</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">148,751</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">262,514</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    expense</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(218,705</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(740,854</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
    on extinguishment of debt</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(887,946</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,047,410</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    income</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44,500</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    other expenses, net</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(912,918</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,525,133</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,783,689</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,957,580</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss per common share:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
    and diluted</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.18</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.19</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    average number of common shares outstanding:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
    and diluted</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> 26,405,109 </P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,449,675</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these audited financial statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 177; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JUPITER
NEUROSCIENCES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="as_004"></A>STATEMENTS
OF CHANGES IN STOCKHOLDERS&rsquo; DEFICIT<BR>
FOR THE YEARS ENDED DECEMBER 31, 2023 AND 2022</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> Additional </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> Total </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> Common Stock </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> Paid </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> Accumulated </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> Stockholders&rsquo; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> Shares </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> Amount </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> in Capital </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> Deficit </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> Deficit </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 35%"> December 31, 2021 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"> 24,518,640 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> $ </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"> 2,452 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> $ </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"> 8,661,153 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> $ </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"> (13,841,235 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> ) </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> $ </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"> (5,177,630 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> ) </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Stock-based compensation </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 754,751 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 754,751 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Common stock issued with convertible note </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 514,403 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 51 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 309,949 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 310,000 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Issuance of restricted stock for forgiveness of accrued salary </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 1,167,011 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 117 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 1,555,893 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 1,556,010 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Stock issued for amendment to convertible note </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 171,465 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 17 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 370,348 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 370,365 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"> Net operating loss </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> (4,957,580 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> (4,957,580 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"> December 31, 2022 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"> 26,371,519 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"> 2,637 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"> 11,652,094 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"> (18,798,815 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"> (7,144,084 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Stock-based compensation </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 1,198,579 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 1,198,579 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Selling of Common stock </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 41,250 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 4 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 54,996 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 55,000 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Stock issued for exercise of options in exchange for note payable, related party </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 113,636 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 11 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 99,989 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 100,000 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Issuance of restricted stock units for forgiveness of accrued salaries and accrued bonuses </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 2,158,050 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 2,158,050 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Issuance of stock options for forgiveness of accrued salaries and accrued bonuses </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 2,614,790 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 2,614,790 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"> Net operating loss </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> (4,783,689 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> (4,783,689 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> December 31, 2023 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"> 26,526,405 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"> 2,652 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"> 17,778,498 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"> (23,582,504 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> ) </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"> (5,801,354 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> ) </TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these audited financial statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 178; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JUPITER
NEUROSCIENCES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="as_005"></A>STATEMENTS
OF CASH FLOWS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOR
THE YEARS ENDED DECEMBER 31, 2023 AND 2022</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    Flows from Operating Activities:</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 64%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    Loss</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,783,689</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,957,580</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments
    to reconcile net loss to net cash used in operating activities:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain
    on change in fair value of derivative liability</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(148,751</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(262,514</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
    of debt discounts</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,712</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">558,026</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
    of prepaid stock issued for advisor services</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62,500</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
    on extinguishment of debt</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">887,946</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,047,410</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    based compensation</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,198,579</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">754,751</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    in operating assets and liabilities:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Decrease
    in other current assets</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,971</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56,340</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Decrease
    in operating lease right of use asset</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,782</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    in accounts payable and accrued expenses</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">164,881</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(56,279</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    in accrued compensation</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,140,103</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,503,932</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    in accrued interest</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38,270</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43,128</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash used in operating activities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(480,953</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,248,504</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    Flows from Financing Activities:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from convertible notes payable</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">982,333</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from note payable, related parties</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">390,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from sale of common stock</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">55,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash provided by financing activities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">445,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">982,333</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    Change in Cash</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(35,953</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(266,171</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning
    of period</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">64,431</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">330,602</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">End
    of period</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,478</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">64,431</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental
    disclosure of cash flow information:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    paid for interest</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,128</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">81,500</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    paid for income taxes</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
    of Non-Cash Investing and Financing Activities:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discount
    on convertible note payable</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">801,111</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock issued with convertible note payable</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">310,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
    note issued as a settlement of a previously accrued liability</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">150,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    stock issued for forgiveness of accrued salary</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,158,050</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,556,010</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    options issued for forgiveness of accrued salary</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,614,790</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    issued for exercise of options in exchange for note payable, related party</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these audited financial statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 179; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="as_006"></A>Notes
to Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2023 and 2022</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt auto; width: 100%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
1 &ndash; Organization and Description of Business</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter
Neurosciences, Inc. (the &ldquo;Company&rdquo;) is a clinical stage research and development pharmaceutical company located in Jupiter,
Florida. The Company incorporated in Delaware in January 2016. The Company has developed a unique resveratrol platform product primarily
targeting treatment of neuro-inflammation. The product candidate, called JOTROL, has many potential indications of use for rare diseases,
which of we primarily are targeting Mucopolysaccharidoses Type 1, Friedreich&rsquo;s Ataxia, and MELAS. In the larger disease areas,
we are primarily targeting Parkinson&rsquo;s Disease and Mild Cognitive Impairment/early Alzheimer&rsquo;s disease. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 30, 2021, the Company filed a Certificate of Amendment to the Certificate of Incorporation with the State of Delaware to change
its name from Jupiter Orphan Therapeutics, Inc. to Jupiter Neurosciences, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JOTROL
has the potential to deliver a therapeutically effective dose of resveratrol in the blood stream, using a unique patented micellar formulation,
without causing gastrointestinal side effects. We expect JOTROL, based on the results of our Phase I study, will resolve the major
obstacle of resveratrol&rsquo;s poor bioavailability, which has been documented in various scientific articles describing previously
conducted human trials with resveratrol as well as preclinical trial results in mice and rats</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s activities and operations include a project funded by the U.S. National Institute on Aging, an institute of the U.S.
National Institutes of Health (&ldquo;NIH&rdquo;): Safety and Pharmacokinetics of JOTROL for Alzheimer&rsquo;s Disease, Federal
Award Identification Number R44AG067907-01A1 (the &ldquo;Award&rdquo;). The project encompassed a Phase 1 dose finding pharmacokinetics
(&ldquo;PK&rdquo;) study which was completed before December 31, 2021. The award end date was May 31, 2022. This Phase 1 PK study will
be homogeneous for all indications where JOTROL will be used in Phase II and Phase III clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 9, 2020, the Company effected a three-for-one (3:1) forward stock split whereby the Company (i) increased the number of authorized
shares of common stock, $0.0001 par value per share, to 25,000,000 from 5,000,000 and (ii) increased by a ratio of three-for-one (3:1)
the number of retroactively issued and outstanding shares of common stock. Proportional adjustments for the forward stock split were
made to the Company&rsquo;s outstanding stock options, warrants and equity incentive plans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 11, 2021, the Company increased the number of authorized shares of common stock, $0.0001 par value per share, to 45,000,000
from 25,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 25, 2022, the Company effected a one-for-two (1:2) reverse stock split whereby the Company (i) decreased the number of issued
and outstanding shares of common stock, $0.0001 par value per share, from 13,076,608 to 6,538,304 and (ii) decreased by a ratio of one-for
two (1:2) the number of retroactively issued and outstanding shares of common stock. Proportional adjustments for the reverse stock split
were made to the Company&rsquo;s outstanding stock options, warrants and equity incentive plans. All share and per-share data and amounts
have been retroactively adjusted as of the earliest period presented in the financial statements to reflect the reverse stock split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 14, 2024, the Company effected a fifteen-for-four (15:4) forward stock split whereby the Company (i) increased the number
of issued and outstanding shares of common stock, $0.0001 par value per share, to 30,123,405 from 8,033,706 and
(ii) increased by a ratio of fifteen-for-four (15:4) the number of retroactively issued and outstanding shares of common stock. Proportional
adjustments for the forward stock split were made to the Company&rsquo;s outstanding stock options, warrants and equity incentive plans.
All share and per-share data and amounts have been retroactively adjusted as of the earliest period presented in the financial statements
to reflect the forward stock split. In addition, the Company increased the number of authorized shares of common stock, $0.0001 par
value per share, to 125,000,000 from 45,000,000. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 180; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2023 and 2022</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt auto; width: 100%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
2 &ndash; Significant Accounting Policies</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basis
of Accounting and Going Concern</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States
of America (&ldquo;U.S. GAAP&rdquo;). US GAAP contemplates continuation of the Company as a going concern. For the fiscal year ended
December 31, 2023 and 2022, the Company had no revenues from product sales and incurred a net loss of $4,783,689 and $4,957,580, respectively.
Net cash used in operations for years ended 2023 and 2022 was $480,953 and $1,248,504, respectively. As of December 31, 2023, the Company
had a working capital deficit and accumulated deficit of $5,743,166 and $23,582,504, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company plans to finance future operations with proceeds from equity securities, grant awards and strategic collaborations. However,
there is no assurance the Company will be successful. It is the management&rsquo;s opinion that these conditions raise substantial doubt
about the Company&rsquo;s ability to continue as a going concern for a period of at least twelve months from the date of this report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use
of Estimates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Federal
Contract Revenue</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes federal contract revenue from the NIH Award in the period in which the allowable research and development expenses
are incurred, and receivables associated with this revenue are included within federal contract revenue receivable on our balance sheets.
This revenue is not within the scope of Accounting Standards Codification (ASC) 606 &ndash; Revenue from contracts with customers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Federal
Contract Receivable</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal
contract receivable represents amounts due to us under the NIH Award for valid expenditures expected to be reimbursed to us under the
terms of the NIH contract.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cash</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. As
of December 31, 2023 and December 31, 2022, the Company invested a portion of cash balances in a high yield savings account, which are
included as cash equivalents on the balance sheets. As of December 31, 2023 and December 31, 2022, the cash balances did not exceed the
FDIC limit of $250,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Current Assets and Prepaid Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
current assets and prepaid expenses generally represent payments made for goods or services to be received within one year and are expensed
as the related benefit is received.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 181; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2023 and 2022</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt auto; width: 100%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
2 &ndash; Significant Accounting Policies, continued</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
and Development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. Costs for certain development activities, such as clinical trials, are recognized based
on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, monitoring visits, clinical site
activations, or information provided to us by our vendors with respect to their actual costs incurred. Payments for these activities
are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the
financial statements as prepaid or accrued research and development expense, as the case may be. Total research and development costs
for the years ended December 31, 2023, and 2022 were $954,793 and $942,806, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Income
Taxes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis
of our assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws
on deferred taxes, if any, applied during the years in which temporary differences are expected to be settled, is reflected in the financial
statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence,
it is more likely than not that some, or all, of the deferred tax assets will not be realized. The effect on deferred tax assets and
liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted. As of December 31, 2023 and
2022, the Company concluded that a full valuation allowance is necessary for the net deferred tax assets. The Company had no material
amounts recorded for uncertain tax positions, interest or penalties in the accompanying financial statements. The Company is subject
to taxation in the U.S. Our tax years for 2021 and forward are subject to examination by tax authorities. The Company is not currently
under examination by any tax authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Loss
Per Share of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common
stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of
securities, such as convertible preferred stock, convertible notes payable, warrants, stock options, and unvested restricted stock, which
would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable
to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net
loss exists, dilutive shares are not included in the calculation. As of December 31, 2023, there were 1,359,375 warrants outstanding,
1,618,537 restricted stock units and 10,336,882 stock options and 14 convertible notes payable, which are convertible into restricted
fully-paid and non-assessable shares of the Company&rsquo;s common stock or units of common stock and warrants to purchase common stock,
if units are offered in the Initial Public Offering equal to the indebtedness divided by 70% of the offering price paid per share of
at which the IPO is made. Such securities are considered dilutive securities which were excluded from the computation since the effect
is anti-dilutive. As of December 31, 2022, there were 1,359,375 warrants outstanding and 6,682,560 stock options and 13 convertible notes
payable, which are convertible into restricted fully-paid and non-assessable shares of the Company&rsquo;s common stock or units of common
stock and warrants to purchase common stock, if units are offered in the Initial Public Offering equal to the indebtedness divided by
70% of the offering price paid per share of at which the IPO is made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 182; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2023 and 2022</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt auto; width: 100%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
2 &ndash; Significant Accounting Policies, continued</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock-Based
Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based compensation in accordance with the provisions of Accounting Standards Codification (&ldquo;ASC&rdquo;)
Topic 718, Compensation&mdash;Stock Compensation, or ASC 718, which requires the recognition of expense related to the fair value of
stock-based awards in the statements of operations. For stock options issued to employees, non-employees and members of our board of
directors, the Company estimates the grant-date fair value of options using the Black-Scholes option pricing model. The use of the Black-Scholes
option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility
of the common stock consistent with the expected life of the option, risk-free interest rates, and, for grants prior to our initial public
offering, the value of the common stock. For awards subject to time-based vesting, the Company recognized stock-based compensation expense,
on a straight-line basis over the requisite service period, which is generally the vesting term of the award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Clinical
Trial Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the process of preparing our financial statements, the Company is required to estimate expenses resulting from obligations under
contracts with vendors, clinical research organizations and consultants and under clinical site agreements in connection with conducting
clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result
in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company&rsquo;s
objective is to reflect the appropriate trial expenses in the financial statements by matching those expenses with the period in which
services are performed and efforts are expended. The Company accounts for these expenses according to the progress of the trial as measured
by patient progression and the timing of various aspects of the trial. The Company determines accrual estimates based on estimates of
services received and efforts expended that take into account discussion with applicable personnel and outside service providers as to
the progress or state of consummation of trials. During the course of a clinical trial, the Company adjusts the clinical expense recognition
if actual results differ from its estimates. The Company makes estimates of the accrued expenses as of each balance sheet date based
on the facts and circumstances known at that time. The clinical trial accruals are dependent upon the timely and accurate reporting of
contract research organizations and other third-party vendors. Although the Company does not expect the estimates to be materially different
from amounts actually incurred, understanding of the status and timing of services performed relative to the actual status and timing
of services performed may vary and may result in reporting amounts that are too high or too low for any particular period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair
Value of Financial Instruments and Fair Value Measurements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures its financial assets and liabilities in accordance with US GAAP. For certain financial instruments, including cash and
cash equivalents, accounts receivable, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their
short maturities. Amounts recorded for notes payable, net of discount, and loans payable also approximate fair value because current
interest rates available for debt with similar terms and maturities are substantially the same.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows accounting guidance for financial assets and liabilities. This standard defines fair value, provides guidance for measuring
fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all
other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related
to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income
approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement
cost).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 183; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2023 and 2022</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt auto; width: 100%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
2 &ndash; Significant Accounting Policies, continued</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair
Value of Financial Instruments and Fair Value Measurements, continued</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into six broad
levels. The following is a brief description of those three levels:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2: Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets
or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us,
which reflect those that a market participant would use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table represents the Company&rsquo;s financial instruments that are measured at fair value on a recurring basis at each reporting
period for each fair value hierarchy level:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative
    Liability 12/31/2023</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative
    Liability 12/31/2022</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    I</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    II</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48%; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    III</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 22%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,505,398</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 22%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">710,599</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,505,398</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">710,599</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also
see Note 5 - Convertible Debt and Derivative Liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Derivative
Instruments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
Topic 815, Derivatives and Hedging (&ldquo;ASC Topic 815&rdquo;), establishes accounting and reporting standards for derivative instruments
and for hedging activities by requiring that all derivatives be recognized in the balance sheet and measured at fair value. Gains or
losses resulting from changes in the fair value of derivatives are recognized in earnings. On the date of conversion or payoff of debt,
the Company records the fair value of the conversion shares, removes the fair value of the related derivative liability, removes any
discounts and records a net gain or loss on debt extinguishment. On January 1, 2020 the Company adopted ASU 2017-11 under which down-round
Features in Financial Instruments will no longer cause derivative treatment. The Company applies the modified prospective method of adoption.
There were no cumulative effects on adoption.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 184; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2023 and 2022</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt auto; width: 100%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
2 &ndash; Significant Accounting Policies, continued</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Convertible
Notes with Embedded Derivative Liabilities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into convertible notes, some of which contain variable conversion options, whereby the outstanding principle and
accrued interest may be converted, by the holder, into common shares at a fixed discount to the price of the common stock at or around
the time of conversion upon certain trigger events. The Company evaluates all its financial instruments to determine if those contracts
or any potential embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC
815-10 <I>&ndash; Derivative and Hedging &ndash; Contract in Entity&rsquo;s Own Equity</I>. This accounting treatment requires that the
carrying amount of any derivatives be recorded at fair value at issuance and marked-to-market at each balance sheet date. In the event
that the fair value is recorded as a liability, as is the case with the Company, the change in the fair value during the period is recorded
as either other income or expense. Upon conversion, exercise or repayment, the respective derivative liability is marked to fair value
at the conversion, repayment, or exercise date and then the related fair value amount is reclassified to other income or expense as part
of gain or loss on debt extinguishment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Leases</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2016, the Financial Accounting Standards Board (&ldquo;FASB&rdquo;) issued ASU 2016-02, Leases (Topic 842). The updated guidance
requires lessees to recognize lease assets and lease liabilities for most operating leases. In addition, the updated guidance requires
that lessors separate lease and non-lease components in a contract in accordance with the new revenue guidance in ASC 606.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease ROU assets represents the right to use the leased asset for the lease term and operating lease liabilities are recognized based
on the present value of future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit
rate, the Company use an incremental borrowing rate based on the information available at the adoption date in determining the present
value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included
in general and administrative expenses in the statements of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recent
Accounting Pronouncements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has reviewed the FASB issued ASU accounting pronouncements and interpretations thereof that have effectiveness dates during the
periods reported and in future periods. The Company has carefully considered the new pronouncements that alter previous generally accepted
accounting principles and do not believe that any new or modified principles will have a material impact on the Company&rsquo;s reported
financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company&rsquo;s
financial management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging
&ndash; Contracts in Entity&rsquo;s Own Equity (Subtopic 815-40) &ndash; Accounting for Convertible Instruments and Contracts in an Entity&rsquo;s
Own Equity. The ASU simplifies accounting for convertible instruments by removing major separation models required under current GAAP.
Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded
conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative
scope exception, which will permit more equity contracts to qualify for the exceptions. The ASU also simplifies the diluted net income
per share calculation in certain areas. The new guidance is effective for fiscal years beginning after December 15, 2023, including interim
periods within those fiscal years, and early adoption is permitted. The Company is currently evaluating the impact of the adoption of
the standard on the financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
other newly issued accounting pronouncements but not yet effective have been deemed immaterial or nonapplicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 185; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2023 and 2022</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt auto; width: 100%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
3 &ndash; Related Party Transactions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s Chief Executive Officer (CEO) has loaned the Company working capital since inception. The balance of the loans to the
CEO as of December 31, 2023 and December 31, 2022 was $358,479 and $93,479, respectively. The loan is due on demand and accrues interest
at 3% per year. Accrued interest relating to the loan was $11,308 and $6,184 as of December 31, 2023 and December 31, 2022, respectively,
and is included in accrued interest on the accompanying balance sheets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, an employee has loaned the Company $25,000. The balance of the loan as of December 31, 2023, was $25,000.
The loan is due on demand and accrues interest at 3% per year. Accrued interest related to the loan was $723 as of December 31, 2023,
and is included in accrued interest on the accompanying balance sheet.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
compensation includes partially accrued salaries to executives since inception. Since inception, executive salaries have been paid in
cash when the Company&rsquo;s cash flow has permitted such payment. During 2020, the Company began consistently paying salaries at 50%
of the salaries reflected in the respective employment agreements. As of September 2021, the Company began paying full salaries. Throughout
2022, the Company returned to paying partial salaries and by November 2022 the Company stopped paying salaries 100% in an effort to conserve
cash.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 29, 2023, various employees and board members agreed to forgive accrued compensation in the amount of $4,189,626. In exchange
of the forgiveness the Company issued an aggregate of 2,353,661 stock options with an exercise price of $1.33 and an aggregate of 1,399,834
restricted stock units with a grant date value of $1.33 in exchange for the aggregate forgiveness of compensation in the amount of $4,189,626.
Additionally the Company agreed to a bonus of $513,013 for the employees and a bonus of $70,200 to the board members, to be paid upon
the occurrence of a successful IPO in exchange for the forgiveness of the afore mentioned accrued compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 18, 2023, various employees and board members agreed to amend the accrued compensation debt forgiveness dated September 29,
2023. Pursuant to the amendment the cash bonuses of $513,013 for the employees and a bonus of $70,200 to the board members agreed to
on September 29, 2023, were forgiven, and no cash will be paid upon a successful IPO. In addition, the options issued in connection with
the forgiveness dated September 29, 2023, have been amended to vest fully on the effective date of the new amendment. In addition, the
restricted stock unit issued in connection with the forgiveness dated September 29, 2023, were terminated and replaced with 1,399,834
restricted stock units that vest upon the earlier occurrence of the initial public offering or a change of control of the Company. In
exchange of the forgiveness of the accrued bonuses the Company issued an aggregate of 289,294 stock options with an exercise price of
$1.33 and an aggregate of 218,704 restricted stock units with a grant date value of $1.33 in exchange for the aggregate forgiveness of
compensation in the amount of $583,213.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 6 &ndash; Stockholders&rsquo; Deficit &ndash; Stock Options for details related to issuance of common stock pursuant to the exercise
of options in exchange of $100,000 of principal owed to the CEO on the notes payable, related party.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
4 &ndash; Accounts Payable and Accrued Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
payable and accrued expenses consisted of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2023</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2022</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    payable</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 22%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">189,495</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 22%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">187,032</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professional
    fees</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">174,053</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">230,880</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">License
    fee</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">150,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">75,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative expenses</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,466</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33,825</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    accounts payable and accrued expenses</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">546,014</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">526,737</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, $67,750 was due to a Company wholly owned by the Company&rsquo;s Chief Financial Officer, who also is an option
holder. The amount is included in accrued compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 186; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2023 and 2022</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt auto; width: 100%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
4 &ndash; Accounts Payable and Accrued Expenses, continued</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
compensation of $1,562,041 and $4,194,778 as of December 31, 2023 and 2022, respectively, includes accrued salaries and accrued health
insurance benefits to executives since inception and board fees. Since inception, executive salaries have been paid in cash when
the Company&rsquo;s cash flow has permitted such payment. During 2020, the Company began consistently paying salaries at 50% of the salaries
reflected in the respective employment agreements. As of September 1, 2021, the Company began paying full salaries. Throughout 2022,
the Company returned to paying partial salaries and by November 2022 the Company stopped paying salaries 100% in an effort to conserve
cash. Starting the fourth quarter of 2023 the Company&rsquo;s executives agreed to reduce their salaries with 80% until an initial public
offering. See Note 3 &ndash; Related Party Transactions for details related to forgiveness of accrued compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
5 &ndash; Convertible Debt and Derivative Liability</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Convertible
Debt I</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between
August and December 2021, the Company executed twelve convertible promissory notes (&ldquo;Notes I&rdquo;) for $527,650 in proceeds with
a maturity date of July 31, 2022, and interest rate of 1%. The Notes I will automatically convert into equity securities on the first
business day following effectiveness of an initial public offering of common stock with the Securities and Exchange Commission (&ldquo;IPO&rdquo;).
Upon IPO, the outstanding principle of the Notes I and all unpaid accrued interest will automatically convert into a number of restricted
fully paid and non-assessable shares of common stock, or units of common stock and warrants to purchase common stock if units are offered
to the public in the IPO, equal to the indebtedness divided by 70% of the offering price paid per share at which the IPO is made. For
the avoidance of doubt, in the event the IPO is not declared effective prior to the maturity date, none of the indebtedness shall convert
or be convertible into shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the time of execution, the Company recorded a debt discount of $257,650 based on the fair value of the embedded conversion feature of
Notes I, which was amortized into interest expense over term of Notes I, each with a maturity date of July 31, 2022. On August 6, 2022,
the Notes I were amended to extend the maturity date to January 31, 2023, and increase the interest rate to 5%. All other terms remain
the same as previously stated in Notes I. The impact of the amendment is prospective and increased accrued interest by $23,072 and is
included in accrued interest on the accompanying balance sheet. On February 2, 2023, the Notes I were amended to extend the maturity
date to December 31, 2023. The amendments were accounted for as a modification and not an extinguishment of debt, therefore there was
no gain recorded in the statement of operations. See Note 10 &ndash; Subsequent Events for details related to amendment to the
Notes I subsequent to December 31, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Convertible
Debt II</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Note -</B> On April 11, 2022, the Company entered into a securities purchase agreement with an accredited investor (the &ldquo;Holder&rdquo;).
Pursuant to the terms of the securities purchase agreement, the Company received aggregate gross proceeds of $1,000,000, less loan origination
costs of $22,667, and issued a (i) 10% original issue discount senior secured convertible note (the &ldquo;Note II&rdquo;) in the principal
amount of $1,111,111 and (ii) 514,403 shares of common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
II matures 12 months from issuance and bears interest at 10% per annum, payable monthly in arrears. A &ldquo;Qualified Offering&rdquo;
is a debt or equity financing for the account of the Company or any of its subsidiaries in which shares of common stock, or securities,
directly or indirectly, convertible into or exchangeable or exercisable for shares of common stock are issued, which financing results
in cumulative aggregate proceeds to the Company of at least $8,000,000. The principal and interest on the Note II will be amortized on
a straight-line basis at 110% of the principal amount commencing sixth months after the closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 187; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2023 and 2022</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt auto; width: 100%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
5 &ndash; Convertible Debt and Derivative Liability, continued</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Convertible
Debt II, continued</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
an Event of Default and after a Qualified Offering, the principal and interest are convertible at any time at the option of the Holder
into shares of the Company&rsquo;s common stock at a conversion price equal to 30% discount to the lowest closing price of the common
stock for the 20 prior trading days; provided, however, the Holder will not have the right to convert any portion of Note II, to the
extent that after giving effect to the conversion, the Holder, together with its affiliates, would beneficially own in excess of 4.99%
of the number of shares of the Company&rsquo;s common stock outstanding immediately after giving effect to its conversion. The Holder
may increase or decrease its ownership limitation to any percentage not exceeding 9.99% upon 61 days prior written notice to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will have the right at any time to redeem in cash all or a portion of Note II at 120% (or 125% on or after the first six months
from the closing) of the principal amount thereof plus any unpaid accrued interest to the date of repayment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will be required to offer to prepay in cash the aggregate principal amount of Note II at 120% (or 125% on or after the first
six months from the closing) of the principal amount thereof plus any unpaid accrued interest to the date of repayment, on the sale of
all or substantially all of the assets of the Company and its subsidiaries, upon a Change of Control (as defined in Note II), or on a
Qualified Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
an Event of Default (as defined therein) interest shall accrue at 1 1/2% per month and the 125% of principal and interest through maturity
shall be due and payable. At the Holder&rsquo;s option the Holder shall be entitled to be paid in cash or after the Qualified Offering
(as defined in the Purchase Agreement) common stock with the conversion price of the common stock equal to a 30% discount to the lowest
closing price of the common stock for the 20 prior trading days.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 10, 2022, Note II was amended to postpone the commencement of the principal payments from October 11, 2022 to November 11, 2022.
As consideration for the amendment, an additional 42,867 shares of common stock were issued to the Holder on October 10, 2022,
valued at 1/12<SUP>th</SUP> of the original 514,403 shares issued at commencement of Note II.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 10, 2022, Note II was amended to postpone the commencement of the principle from November 11, 2022 to February 11, 2023 and
payable in three monthly installments. An additional 128,599 shares of common stock were issued to the Holder on November 10, 2022, value
at 1/4<SUP>th</SUP> of the original 514,403 shares issued at commencement of Note II.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 6, 2023, Note II was amended to postpone the commencement of the principle to February 28, 2023. On March 6, 2023, Note II was
amended to postpone the commencement of the principal from February 11, 2023 to May 31, 2023. The Company and the noteholder agreed to
a repayment plan on past due interest. In addition, the Company agreed to prepay in cash the aggregate principal amount of the Note II
of 120% (or 137.5% on or after the first six months from closing) plus any accrued interest on the sale of all the assets of the Company
and its subsidiaries, upon the Change of Control, or on a Qualified Offering. Upon default of Note II, the Company agrees to pay 137.5%
of the outstanding note principal, and accrued interest through maturity and all liquidation damages. As a result of the material modification,
the incremental fair value of the modified derivative was classified as a debt extinguishment. Due to the extension of the maturity date
of the convertible note, the fair value of the derivative liability increased. This resulted in the Company recording a loss on extinguishment
of debt of $670,419.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 188; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2023 and 2022</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt auto; width: 100%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
5 &ndash; Convertible Debt and Derivative Liability, continued</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Convertible
Debt II, continued</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 22, 2023, Note II was amended to postpone the commencement of the principle to December 31, 2023. The Company and the noteholder
agreed to a repayment plan on past due interest. In addition, the Company agreed to prepay in cash the aggregate principal amount of
the Note II of 120% (or 150% on or after the first six months from closing) plus any accrued interest on the sale of all the assets of
the Company and its subsidiaries, upon the Change of Control, or on a Qualified Offering. Upon default of Note II, the Company agrees
to pay 150% of the outstanding note principal and accrued interest through maturity and all liquidation damages. In addition, upon closing
the Note Holder will receive 175% stock coverage. As a result of the material modification, the incremental fair value of the modified
derivative was classified as a debt extinguishment. Due to the extension of the maturity date of the convertible note, the fair value
of the derivative liability increased. This resulted in the Company recording a loss on extinguishment of debt of $217,527. See Note
10 &ndash; Subsequent Events for details related to amendment to the Note II subsequent to December 31, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
Shares</I></B> - In connection with the issuance of Note II, the Company issued 514,403 shares of Common Stock to the Holder with
a fair market value of $2.16 per share (aggregate value of $1,111,111) as additional consideration for the Holder lending $1,000,000
to the Company. The 514,403 shares have a relative fair value of $310,000. See <I>Derivative Liability Pursuant to Convertible
Debt</I> in the following section. If the price per share in a Qualified Offering is less than $2.16, the Holder shall receive an additional
number of shares of common stock, such that it shall have received the number of shares of common stock of the aggregate value of $1,111,111
divided by the price per share in the Qualified Offering, (&ldquo;Share True Up&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Ancillary
Agreements</I></B> - In connection with the Company&rsquo;s obligations under Note II, the Company entered into a security agreement
and intellectual property security agreement with the holder, pursuant to which the Company granted a security interest on all assets
of the Company, including all intellectual property of the Company, for the benefit of the Holders, to secure the Company&rsquo;s obligations
under Note II and the other transaction documents. In addition, the Holder was granted piggyback registration rights for the shares of
common stock issued under the Purchase Agreement and shares of common stock issuable upon conversion of Note II (collectively, &ldquo;Registrable
Securities&rdquo;). At any time while there are any Registrable Securities of Holder outstanding, if the Company proposes to register
any of its securities either for its own account or for the account of other security Holders (other than a registration statement relating
solely to employee benefit plans on Form S-8 or a Commission Rule 145 transaction on Form S-4), the Holder is entitled to include its
Registrable Securities in the registration. Notwithstanding, the Company and underwriters in an underwritten registration may exclude
some or all of the Registrable Securities from the underwritten registration if the underwriters believe that including the Registrable
Securities would adversely affect the underwritten offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
any time within the 12 months closing, upon any issuance by the Company or any of its subsidiaries of debt or common stock or common
stock equivalents for cash consideration, indebtedness or a combination of units thereof, other than in an underwritten public offering
(a &ldquo;Subsequent Financing&rdquo;), the Holder will have the right to participate up to its investment amount in Note II, but not
more than 25% of the Subsequent Financing, on the same terms, conditions and price provided for in the Subsequent Financing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the securities purchase agreement, the Company received aggregate gross proceeds of $1,000,000, less loan origination
costs of $22,667, and issued a (i) 10% original issue discount senior secured convertible note (the &ldquo;Note II&rdquo;) in the principle
amount of $1,111,111 and (ii) 514,403 shares of common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 189; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2023 and 2022</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt auto; width: 100%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
5 &ndash; Convertible Debt and Derivative Liability, continued</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Convertible
Debt III</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 1, 2023, the Company issued a convertible promissory note (the &ldquo;Note III&rdquo;) with a principal amount of $150,000 as part
of a settlement agreement with an investor relations firm. Note III matures on February 28, 2026 and accrues interest at 5% annually
which compounds quarterly. Note III is convertible upon election of the holder upon a qualified financing of at least $5,000,000 into
shares of common stock equal to 70% of the per share price of the equity issued in the qualified financing. Note III is also convertible
upon the completion of an IPO by the Company into shares of common stock equal to 70% of the per share price of the equity issued in
connection with the IPO. In both cases the Holder can elect to receive the principal and accrued interest instead of converting the note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, $143,761 is included in interest expense for the combined convertible Notes I, II and III on the accompanying
statements of operations. During the year ended December 31, 2022, $114,193 is included in interest expense for the combined convertible
Note I and II on the accompanying statements of operations. As of December 31, 2023 the balance of the combined convertible promissory
Note I, II and III was $1,745,472, net of the debt discount and loan origination costs of $43,288.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Derivative
Liability Pursuant to Convertible Debt</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the issuance of the Notes, the Company determined that the terms of Notes contain an embedded conversion option to be
accounted for as a derivative liability due to the Holder having the potential to gain value upon IPO. Accordingly, under the provisions
of ASC 815-40 &ndash;<I>Derivatives and Hedging &ndash; Contracts in an Entity&rsquo;s Own Stock</I>, the embedded conversion option
contained in Notes was accounted for as derivative liability and debt discount at the date of issuance and has been adjusted to fair
value through earnings at each reporting date. The fair value of the embedded conversion option was determined using the Monte Carlo
valuation model.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the issuance of Notes I, on the initial measurement date of September 2021, the fair value of the embedded conversion
option of $257,650 was recorded as derivative liability and debt discount to be amortized into interest expense over the terms of the
Notes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the issuance of Note II, on the initial measurement date of April 2022, the fair value of the embedded conversion option
of $346,000 and the fair value of the Share True Up of $34,000 was recorded as derivative liability and a debt discount to be amortized
into interest expense over the term of Note II. An additional discount of $421,111 was recorded on the initial measurement date for the
10% original issue discount of $111,111 and the relative fair value of the allocation of proceeds to the 514,403 shares of common
stock issued, valued at $310,000, to be amortized into interest expense over the term of Note II.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, the derivative liabilities were revalued and a $887,946 adjustment was recorded as a loss on extinguishment
of debt to other expense reflected in the accompanying statements of operations. The Company also recorded a $148,751, adjustment as
a gain on the change in the fair value of the derivative liability for the year ended December 31, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 190; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2023 and 2022</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt auto; width: 100%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
5 &ndash; Convertible Debt and Derivative Liability, continued</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Derivative
Liability Pursuant to Convertible Debt, continued</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the derivative liability of Notes I, Note II and Note III was estimated using the Monte Carlo Valuation model at issuance
and each reporting period with the following assumptions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
    I</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
    I</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
    II</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
    I &amp; II</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
    III</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
    I, II &amp; III</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>August
    2, 2021 - September 15, 2021 (Issuance)</B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
                                            1, 2021 (Issuance) -</B></FONT></P>
                                                                                <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
                                            31, 2021</B></FONT></P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>April
                                            11, 2022</B></FONT></P>
                                                                                <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Issuance)</B></FONT></P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
                                            31,</B></FONT></P>
                                                                                <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2022</B></FONT></P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
                                            1, 2023<BR></B></FONT></P>
                                                                                <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Issuance)</B></FONT></P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
                                            31,</B></FONT></P>
                                                                                <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2023</B></FONT></P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
    Rate</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1
                                            - 0.88</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.66
                                            - 0.58</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.12</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.25</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.25</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">82</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">140</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">95</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">90</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">90</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">90</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    rate</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.07</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.09</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.85</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.70</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.70</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Probability
    of IPO</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of activity of the derivative liability pertaining to the Notes is presented below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative
    Liability</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 74%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at December 31, 2021</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 22%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">351,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
    value at issuance April 11, 2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">380,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
    value on date of amendment, net</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">242,113</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
    value change</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(262,514</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at December 31, 2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">710,599</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
    value at issuance March 1, 2023</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">55,604</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
    value on date of amendment, net</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">887,946</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
    value change</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(148,751</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at December 31, 2023</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,505,398</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
6 &ndash; Stockholders&rsquo; Deficit</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Common
Stock</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue 125,000,000 shares of common stock and 5,000,000 shares of preferred stock. The Company had 26,426,405
shares of common stock issued and outstanding as of December 31, 2023. There was no preferred stock issued and outstanding as of December
31, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> The Company is authorized to issue
125,000,000 shares of common stock and 5,000,000 shares of preferred stock. The Company had 26,371,519 shares of common stock issued
and outstanding as of December 31, 2022. There was no preferred stock issued and outstanding as of December 31, 2022. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 191; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2023 and 2022</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt auto; width: 100%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
6 &ndash; Stockholders&rsquo; Deficit, continued</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stock
Options</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company grants stock awards to officers, employees, directors, and other key persons pursuant to its 2021 Equity Incentive Plan (&ldquo;the
Plan&rdquo;). During the years ended December 31, 2023 and 2022, the Company granted employees, consultants, board members and advisors,
options to acquire 3,767,955 and 0, respectively, shares of common stock with an exercise prices ranging from $0.80 - $2.16 per share. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2023 and 2022, the Company recognized stock-based compensation of $1,198,579 and $754,751, respectively,
related to vested stock options. There was $1,046,670 of unvested stock options expense as of December 31, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> On July 14, 2022, ten option agreements
were amended to reduce the exercise price from $2.16 to $1.33. As result of the modification, the options were evaluated to determine
the incremental fair value change of the modification and an additional stock-based compensation cost of $50,998 was recorded for the
options vested during the period ended December 31, 2022 and an additional $48,626 of unvested stock options will be recognized through
December 2024. Stock-based compensation for the twelve months ended December 31, 2022 is inclusive of the modification expense. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 1, 2023, the Company granted non-qualified stock option to purchase 562,500 shares of Common Stock to our Chief Financial Officer,
at an exercise price of $1.33 per share. The option had a grant date fair value of $589,500.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 1, 2023, the Company granted non-qualified stock option to purchase an aggregate of 562,500 shares of Common Stock to an employee
and consultants, at an exercise price of $1.33 per share. The options had an aggregate grant date fair value of $589,900. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 29, 2023, the company granted non-qualified stock options to purchase an aggregate of 2,353,665 shares of common stock to various
employees and executives as part of their accrued compensation forgiveness. The options have an exercise price of $1.33 per share. The
options had an aggregate grant date fair value of $2,323,181.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 13, 2023, the CEO elected to exercise options to purchase 113,632 shares of common stock at an exercise price of $0.88 in exchange
for $100,000 of principal owed on the CEO&rsquo;s note payable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 18, 2023, the company granted non-qualified stock options to purchase an aggregate of 289,294 shares of common stock to various
employees and executives as part of their accrued bonus compensation forgiveness. The options have an exercise price of $1.33 per share.
The options had an aggregate grant date fair value of $291,609.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 192; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2023 and 2022</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt auto; width: 100%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
6 &ndash; Stockholders&rsquo; Deficit, continued</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stock
Options, continued</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of activity for the years ended December 31, 2023 and 2022, respectively, is presented below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Options</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise Price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Contractual Term (Years)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate Intrinsic Value</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; font-weight: bold">Outstanding as of December 31, 2021</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right"> 6,885,060 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 11%; text-align: right"> 0.97 </TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">7.41</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">2,478,622</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Forfeited</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (202,500 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 0.98 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Outstanding as of December 31, 2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 6,682,560 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.89 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.40</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,376,725</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 3,767,955 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> (113,633 </TD><TD STYLE="text-align: left"> ) </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0.88 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Forfeited</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">Outstanding as of December 31, 2023</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 10,336,883 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 1.00 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 6.91 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,316,119</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Exercisable as of December 31, 2023</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 9,424,826 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 1.00 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6.76</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,276,119</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Exercisable as of December 31, 2022</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 5,798,228 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 0.78 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6.14</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,367,222</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarized information about employee stock options outstanding as of December 31, 2023:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Outstanding Options</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Vested Options</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercise Price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number Outstanding at December 31, 2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Remaining Life</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number Exercisable at December 31, 2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weighted
Average Remaining Life</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right"> 0.01 </TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right"> 675,000 </TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">2.51</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right">180,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">2.51</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"> 0.74 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 1,657,560 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.57</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">442,017</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.57</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 2,783,243 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">722,197</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.62</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 5,164,830 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.51</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,154,073</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.92</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"> 2.16 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 56,250 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7.96</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">15,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7.71</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 10,336,883 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6.91</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,513,287</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6.76</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 193; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2023 and 2022</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt auto; width: 100%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
6 &ndash; Stockholders&rsquo; Deficit, continued</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Warrants</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the Company&rsquo;s warrant activity for the years ended December 31, 2023:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of Shares</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    Average Exercise Price per Share</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted Average Remaining</FONT></P>
                                                                                <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Life (Years)</FONT></P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    as of December 31, 2021</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,359,375</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.80</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.31</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    as of December 31, 2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,359,375</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.80</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.98</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    as of December 31, 2023</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,359,375</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.80</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.64</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Restricted
Stock Units</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 29, 2023, the Company issued an aggregate of 1,399,834 restricted stock units with a grant date value of $1.33 in exchange
for the forgiveness of accrued compensation. Pursuant to the amendment dated December 18, 2023, the restricted stock units shall vest
on the on earlier event of either the occurrence of an initial public offering or in the event of change of control of the Company. The
restricted stock units have an aggregate grant date fair value of $1,866,445.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 18, 2023, the Company terminated 1,399,834 restricted stock units and issued an aggregate of 1,618,537 restricted stock units
with a grant date value of $1.33 in exchange for the forgiveness of accrued compensation. The restricted stock units shall vest on the
earlier event of either the occurrence of an initial public offering or in the event of change of control of the Company. The restricted
stock units have an aggregate grant date fair value of $2,158,050.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
7 &ndash; Concentrations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s grant revenues and grant receivables are from the NIH Award. The Company expects to maintain the relationship with the
NIH.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 194; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2023 and 2022</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt auto; width: 100%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
8 &ndash; Income Taxes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2023 and 2022, a reconciliation of the total provision for income taxes after applying the U.S. federal
statutory rate of 21% to income before provision for income taxes to the reported provision for income taxes are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"> 2023 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"> 2022 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"> Federal </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"> 21.00 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> % </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"> 21.00 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> % </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> State </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 2.55 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> % </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 2.37 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> % </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Nondeductible expenses </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> -3.85 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> % </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> -3.87 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> % </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Change in valuation allowance </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> -19.70 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> % </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> -19.51 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> % </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Effective tax rate </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>A
summary of the Company&rdquo;s deferred tax assets is as follows:</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"> <B>2023</B> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"> <B>2022</B> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"> U.S Federal and State net operating loss </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"> 2,429,544 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"> 1,341,184 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Stock based compensation </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 1,031,860 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 803,365 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Accrued salaries </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 395,899 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 1,057,019 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Orphan drug credit </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 924,171 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 882,669 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Derivative liability </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 370,572 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 180,101 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> Other </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> 392,486 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> 337,915 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Total net deferred tax assets </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 5,544,532 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 4,602,252 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Valuation allowance </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> (5,544,532 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> (4,602,252 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Total Deferred Tax Asset </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the Company had federal and state (post-apportioned basis) net operating losses (&ldquo;NOLs&rdquo;) of $18.6 million,
as well as federal orphan drug tax credit carryforwards of approximately $0.9 million. Approximately $10.0 million of the foregoing federal
and state NOLs will expire at various dates from 2026 through 2043, if not limited by triggering events prior to such time. Under the
provisions of the Internal Revenue Code, changes in ownership of the Company, in certain circumstances, would limit the amount of federal
NOLs that can be utilized annually in the future to offset taxable income. In particular, Section 382 of the Internal Revenue Code (&ldquo;Section
382&rdquo;) imposes limitations on an entity&rsquo;s ability to use NOLs upon certain changes in ownership. If the Company is limited
in its ability to use its NOLs in future years in which it has taxable income, then the Company will pay more taxes than if it were otherwise
able to fully utilize its NOLs. The Company may experience ownership changes in the future as a result of subsequent shifts in ownership
of the Company&rsquo;s capital stock that the Company cannot predict or control that could result in further limitations being placed
on the Company&rsquo;s ability to utilize its federal NOLs.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
valuation allowance, if needed, reduces deferred tax assets to the amount expected to be realized. When determining the amount of net
deferred tax assets that are more likely than not to be realized, the Company assesses all available positive and negative evidence.
This evidence includes, but is not limited to, prior earnings history, expected future earnings, carry-back and carry-forward periods
and the feasibility of ongoing tax strategies that could potentially enhance the likelihood of the realization of a deferred tax asset.
The weight given to the positive and negative evidence is commensurate with the extent the evidence may be objectively verified. As such,
it is generally difficult for positive evidence regarding projected future taxable income, exclusive of reversing taxable temporary differences,
to outweigh objective negative evidence of recent financial reporting losses. Based on these criteria and the relative weighting of both
the positive and negative evidence available, management continues to maintain a full valuation allowance against its net deferred tax
assets.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 195; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2023 and 2022</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt auto; width: 100%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
9 &ndash; Commitments and Contingencies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Legal
Matters</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, claims are made against the Company in the ordinary course of business, which could result in litigation. Claims and associated
litigation are subject to inherent uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties or
injunctions prohibiting the Company from selling one or more products or engaging in other activities. The occurrence of an unfavorable
outcome in any specific period could have a material adverse effect on the Company&rsquo;s results of operations for that period or future
periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 19, 2022, Tiberend Strategic Advisors (&ldquo;Tiberend&rdquo;), an entity that the Company had previously engaged as a communications
and investor relations firm, filed a summons for civil action in the District Court of Southern Florida against the Company alleging
non-payment by the Company under a services agreement (the &ldquo;Services Agreement&rdquo;) with Tiberend in the amount of $130,400.
The Company and Tiberend entered into a full settlement and release agreement in exchange for a $150,000 convertible promissory note
in March 2023. See Note 5 &ndash; Convertible Debt and Derivative Liability &ndash; Convertible Debt III for details associated with
the note issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Office
Lease</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 1, 2021 the Company entered into an 61 month operating lease for office space for a base rent of $3,783 subject to a 3% yearly escalation.
The Company adopted ASC Topic 842, Leases upon inception of the lease. As of December 31, 2023, the Company&rsquo;s Operating lease right-of-use
asset, net (ROU) is $116,070 and total lease liability is $119,542 based on an incremental borrowing rate of 0.81% at lease inception.
As of December 31, 2022, the Company&rsquo;s Operating lease right-of-use asset, net (ROU) is $162,498 and total lease liability is $165,945
based on an incremental borrowing rate of 0.81% at lease inception.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease right-of-use asset (&ldquo;ROU&rdquo;) is summarized below:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 64%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
    lease ROU</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">236,009</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">236,009</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
    accumulated reduction</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(119,939</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(73,511</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Balance
    of ROU, net</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">116,070</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">162,498</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease liability related to the ROU asset is summarized below:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
    lease liability</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">236,009</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">236,009</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reduction
    of lease liability</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(116,467</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(70,064</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">119,542</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">165,945</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum lease liability payments under non-cancelable operating lease at December 31, 2023 are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">47574</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49,004</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49,004</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,476</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,476</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,290</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,290</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">120,770</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">168,344</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less:
    imputed interest</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,228</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,399</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    lease liabilities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">119,542</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">165,945</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    operating lease liabilities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48,213</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46,401</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-current
    operating lease liabilities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">71,329</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">119,544</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    lease liabilities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">119,542</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">165,945</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 196; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2023 and 2022</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt auto; width: 100%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
9 &ndash; Commitments and Contingencies, continued</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Office
Lease, continued</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 1, 2021, the Company entered into a month-to-month lease for office space in Charlestown, MA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rental
expenses of $20,844 and $20,845 for the year ended December 31, 2023 and 2022, respectively, is included in general and administrative
expenses on the accompanying statement of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Consulting
Agreements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes various consultants and advisors for clinical research, scientific advisory services and business strategies. Each consultant
has an executed agreement in place defining term, compensation, duties, confidentiality, intellectual property. The majority of the agreements
have a 2-year term. Agreements are evaluated for renewal upon expiration. Bonus provisions are at the discretion of the Company&rsquo;s
Board of Directors and are granted on an individual agreement basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes various consultants and advisors for clinical research, scientific advisory services and business strategies. Each consultant
has an executed agreement in place defining term, compensation, duties, confidentiality, intellectual property. The majority of the agreements
have a 2-year term. Agreements are evaluated for renewal upon expiration. Bonus provisions are at the discretion of the Company&rsquo;s
Board of Directors and are granted on an individual agreement basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Executive
Employment Agreements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s standard executive employment agreements have a stated term of six years. Per the agreements, employees are eligible
for a discretionary annual performance bonus, determined by the Board of Directors. If the Company terminates an employee without cause,
the employee is entitled to a pro-rated pay out of the annual performance bonus based on days worked in the fiscal year, severance of
twelve months of the base salary, and automatic vesting of unvested equity grants. If the employee terminates with good reason, as defined
in the employment contract, the employee is entitled to automatic vesting of unvested equity grants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2020, the Company began consistently paying salaries at 50% of the salaries reflected in the respective employment agreements. As of
September 2021, the Company began paying full salaries. Throughout 2022, the Company returned to paying partial salaries and by October
2023 the company stopped paying 100% in an effort to conserve cash. See Note 3 &ndash; Related Party Transactions for details related
to forgiveness of accrued compensation during the year ended December 31, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 18, 2023, various employees agreed to reduce their annual base salary to 20% of their original base salary effective October
1, 2023 until the time the Company raises additional capital from securities in the amount of $1,500,000 (the &ldquo;Reduction Period&rdquo;).
Upon the expiration of the Reduction Period, the bases salaries shall adjust to be 105% of their original base salary as set forth in
their original agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 197; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2023 and 2022</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt auto; width: 100%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
9 &ndash; Commitments and Contingencies, continued</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Licensing
and Royalty Agreements - </I>Aquanova AG</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 15, 2016 the Company entered into a Development, Collaboration and License Agreement (&ldquo;License Agreement&rdquo;) with
Aquanova AG, a German company in the field of development, manufacturing and selling of colloidal formulas. The License Agreement resulted
in the creation of the pharmaceutic product, JOTROL. The License Agreement is in effect until product launch, which is undeterminable
at this time. The Chief Scientific Officer of the Company and the CEO of Aquanova are the joint inventors of JOTROL. Aquanova
is assignee on the patents in the United States, the European Union, China and Japan whereas the Company is obligated to maintain the
patents. The agreement grants ownership to the Company for regulatory approvals and the sole and exclusive worldwide right to develop,
manufacture and commercialize all products, including JOTROL. Aquanova is granted the exclusive license to conduct formulation
development and manufacturing. The agreement also defines fees owed to Aquanova for product and formulation development and licensing
of the products. The Company is required to pay Aquanova an annual license fee of $75,000 upon acceptance of the product formulation
by both parties, with the license fee requirement ending in the year of marketing authorization approval (&ldquo;MMA&rdquo;) in a single
territory. MMA has not yet been received as of the period ended December 31, 2023. As of December 31, 2023 and December 31, 2022, $150,000
and $75,000 of accrued license fees are included in accounts payable and accrued expenses on the balance sheet, respectively. Upon receipt
of approval of the MMA in each territory (e.g United States, European Union, China, Japan), the Company will pay $200,000 to Aquanova
per territory an MMA approval is received, up to a max of $600,000. The Company shall pay Aquanova a royalty of 5% of net sales in each
territory through the later of ten years after the first commercial sale, the first date there is no valid claim within the Aquanova
patent rights, or the date of expiration of the MMA in each territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
mutual agreement, the Company can pay a one-time royalty of $3,000,000 within 180 days of United States marketing approval, with subsequent
royalty payments reduced to 1.25%, in accordance with the terms set forth above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Murdoch
Children&rsquo;s Research Institute</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 1, 2015 the Company entered into a Global Development and License Agreement (&ldquo;License Agreement II&rdquo;) with Murdoch
Children&rsquo;s Research Institute (&ldquo;MCRI&rdquo;), an Australian Institute at the Royal Children&rsquo;s Hospital in Australia,
with the know-how in the process of using pharmaceutical grade Resveratrol for the treatment of Freidreich&rsquo;s ataxia. The License
Agreement II is for both parties to work jointly to develop an appropriate delivery system and conduct clinical trials for the purpose
of product approval in the treatment of Friedreich&rsquo;s ataxia and worldwide commercialization by the Company. The License Agreement
II grants an exclusive worldwide license to the Company to use the MCRI know-how for developing, manufacturing and commercializing the
product for proposed treatment for Friedreich&rsquo;s ataxia. MCRI is granted an irrevocable, royalty free, worldwide license to use
the product inventions and patent rights for internal research and development. Upon receipt of approval of the MMA in each territory
(e.g United States, European Union, China, Japan), the Company will pay $100,000 to MCRI per each territory up to a maximum of $300,000.
MMA has not yet been received as of December 31, 2023. The Company shall pay MCRI a royalty of 1.5% of net sales in each territory until
the product is no longer sold in the respective territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 198; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2023 and 2022</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt auto; width: 100%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
9 &ndash; Commitments and Contingencies, continued</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Research
and Development Service Providers</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the services received under the licensing agreements noted above, a substantial portion of the research and development (&ldquo;R&amp;D&rdquo;)
expense included in the statement of operations is incurred pursuant to short term service and consulting agreements with third party
providers for research, development, testing and manufacturing services. The agreements generally provide termination, at any time by
either party without cause, upon a 30-day written notice, unless otherwise disclosed below. There are no pending milestone payments due
as of December 31, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
10 &ndash; Subsequent Events</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluated events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the
evaluation and transactions, the Company did not identify any subsequent events that would have required adjustment or disclosure in
the Financial Statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 24, 2024, the Company granted 180,000 stock options to a consultant with an exercise price of $1.33 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
to December 31, 2023, the Company and all Note I holders agreed to amend and extend the maturity date of their notes to December 31,
2024. The holders waived any default under the original notes prior to the amendment date. With the amendments the applicable interest
rate to Notes I increased to 10% effective from January 1, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
to December 31, 2023, the Company&rsquo;s CEO loaned the Company an additional $109,000. The loans are due on demand and accrues interest
at 3% per year. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> On March 15, 2024, a former executive
agreed to forgive $100,000 of accrued compensation in exchange for 49,605 options to purchase common stock and 7,500 restricted stock
units, The options to purchase common stock have a strike price of $1.33. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> On March 15, 2024, a former executive
agreed to forgive $100,000 of accrued compensation in exchange for 49,605 options to purchase common stock and 7,500 restricted stock
units, The options to purchase common stock have a strike price of $1.33 The Company recorded a gain on the forgiveness of accrued compensation
in the amount of $40,000. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Senior
</I></B></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Secured Note &ndash; Formerly Known
as the Convertible Debt II</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 29, 2024, the Company, the Holder of the Note II and the CEO entered into an amendment in which the CEO agrees to exchange 685,867
shares issued to the Holder in exchange for his related party notes that accrued interest at 3% that are due from the Company in an aggregate
principal amount of $266,667 and the Holder agreed to forfeit all rights to all additional future shares from the Company that would
of become due upon a qualified offering. In addition, the Holder agreed to extend the note maturity date to August 11, 2024. The note
shall be designated as a 10% original issued discount secured note (&ldquo;Senior Secured Note&rdquo;) moving forward. The note
and interest will become due and payable upon the earliest of the maturity date or upon the occurrence of a qualified event .</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Service
Agreements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 3, 2024, the Company entered into a three 36-month service agreement with three different entities. Upon the closing of these agreements,
the Company issued an aggregate of 3,487,500 shares of common stock, 1,162,500 of shares of common stock for each entity. The shares
issued are free from any restriction as a pre-payment in full for the 36 months of services to be provided. The aforementioned shares
will be registered upon an IPO as long as an IPO happens no later than March 31, 2025. In addition, each of the entities agreed to purchase
37,500 shares each of the Company&rsquo;s common stock at a price of $1.33 per share prior to the occurrence of the IPO. These shares
will also be registered upon an IPO as long as an IPO happens no later than March 31, 2025. Either party is able to terminate the
respective agreement with no liability upon the occurrence of i) the Company failing to raise at least $10 million in gross proceeds
from an IPO prior to May 31, 2025, ii) if either party is involved in any illegal activity or iii) at any time as long as both parties
agree to it.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 199; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter
Neurosciences, Inc.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Table
of Contents</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    Statements (unaudited):</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ch_001">Balance Sheets</A> </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ch_002">Statements of Operations</A> </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ch_003">Statements of Changes in Stockholders&rsquo; Deficit</A> </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ch_004">Statements of Cash Flows</A> </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ch_005">Notes to Financial Statements</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">F-33 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
F-50</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 200; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ch_001"></A>JUPITER
NEUROSCIENCES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BALANCE
SHEETS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">March 31, <BR> 2024</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">December 31, <BR> 2023</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">(unaudited)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: center">Assets</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Current Assets:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 64%; padding-left: 10pt">Cash</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">8,313</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">28,478</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Other current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">261</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">261</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 20pt">Total current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8,574</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">28,739</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating lease right of use asset, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">104,463</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">116,070</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Other asset</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">3,783</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">3,783</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 30pt">Total assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">116,820</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">148,592</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: center">Liabilities and Stockholders&rsquo; Deficit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Current Liabilities:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Accounts payable and accrued expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">559,219</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">546,014</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Accrued compensation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 1,640,873 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,562,041</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Accrued interest</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">107,083</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">88,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Current portion of operating lease liability</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">48,673</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">48,213</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Convertible notes payable, net of discount of $0, respectively</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,643,746</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,638,760</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Note payable, related party</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">428,479</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">383,479</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Derivative liability</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">1,543,109</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">1,505,398</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total current liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> 5,971,182 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">5,771,905</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Convertible notes payable, net of discount of $38,301 and $43,288</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">106,712</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">106,712</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Operating lease liability, net of current portion</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">59,063</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">71,329</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> 6,136,957 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">5,949,946</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Commitments and Contingencies (Note 10)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Stockholders&rsquo; Deficit:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Series A preferred stock, par value $0.0001; 5,000,000 shares authorized, nil shares issued and outstanding</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Common stock, par value $0.0001; 125,000,000 shares authorized; 26,526,405
    issued and outstanding</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> 2,652 </P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 2,652 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Additional paid in capital</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 18,193,815 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 17,778,498 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Accumulated deficit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> (24,216,604 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(23,582,504</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 40pt">Total stockholders&rsquo; deficit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> (6,020,137 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(5,801,354</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 30pt">Total liabilities and stockholders&rsquo; deficit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">116,820</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">148,592</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these audited financial statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 201; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ch_002"></A>JUPITER
NEUROSCIENCES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STATEMENTS
OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Unaudited)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">For the Three Months Ended</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">March 31, <BR> 2024</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">March 31, <BR> 2023</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Federal contract revenue</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Expenses:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 64%; text-align: left">Research and development</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">98,667</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">267,409</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">General and administrative</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">472,028</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">780,070</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">570,695</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">1,047,479</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left; padding-bottom: 1.5pt">Operating loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(570,695</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(1,047,479</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Other Income (Expenses):</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Interest income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">62</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">97</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"> (Loss) Gain on change in fair value of derivative liability</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(37,711</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">18,628</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Interest expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(65,756</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(48,077</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Loss on extinguishment of debt</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(670,419</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"> Gain on forgiveness of accrued compensation </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 40,000 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total other expenses, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> (63,405 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(699,771</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"> (634,100 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> ) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">(1,747,250</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt">Net loss per common share:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Basic and diluted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"> (0.02 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"> (0.07 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt">Weighted average number of common shares outstanding:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Basic and diluted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> 26,526,405 </P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"> 26,375,895 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these audited financial statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 202; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ch_003"></A>JUPITER
NEUROSCIENCES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STATEMENTS
OF CHANGES IN STOCKHOLDERS&rsquo; DEFICIT<BR>
FOR THE THREE MONTHS ENDED MARCH 31, 2024 AND 2023</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Common Stock</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">Additional Paid</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">Accumulated</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">Total Stockholders&rsquo;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Shares</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">in Capital</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Deficit</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Deficit</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 35%">December 31, 2023</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"> 26,526,405 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"> 2,625 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"> 17,778,498 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">(23,582,504</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">(5,801,354</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock-based compensation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">355,317</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">355,317</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Issuance of restricted stock units for forgiveness of accrued salary </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 10,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 10,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Issuance of stock options for forgiveness of accrued salary </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 50,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 50,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>

  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Net operating loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> (634,100 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> (634,100 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">March 31, 2024</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"> 26,526,405 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"> 2,625 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"> 18,193,815 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"> (24,216,604 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> ) </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"> (6,020,137 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> ) </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Common Stock</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">Additional Paid</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">Accumulated</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">Total Stockholders&rsquo;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Shares</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">in Capital</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Deficit</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Deficit</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 35%">December 31, 2022</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"> 26,371,519 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"> 2,637 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"> 11,652,094 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">(18,798,815</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">(7,144,084</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock-based compensation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">381,501</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">381,501</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Purchase of common stock</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 18,750 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 2 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 24,998 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">25,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Net operating loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(1,747,250</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(1,747,250</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">March 31, 2023</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"> 26,390,269 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"> 2,639 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"> 12,058,593 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">(20,546,065</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">(8,484,833</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these audited financial statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 203; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ch_004"></A>JUPITER
NEUROSCIENCES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STATEMENTS
OF CASH FLOWS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOR
THE THREE MONTHS ENDED MARCH 31, 2024 AND 2023</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Cash Flows from Operating Activities:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 64%; text-align: left">Net Loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"> (634,100 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> ) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(1,747,250</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"> Loss (Gain) on change in fair value
    of derivative liability</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">37,711</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(18,628</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Amortization of debt discounts</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,986</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,644</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Loss on extinguishment of debt</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">670,419</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"> Gain on forgiveness of accrued compensation </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> (40,000 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Stock based compensation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">355,317</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">381,501</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left">Changes in operating assets and liabilities:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Decrease in other current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,784</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"> (Decrease) increase in operating lease right of use asset</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(199</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">243</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Increase in accounts payable and accrued expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">13,205</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">125,382</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Increase in accrued compensation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">178,832</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">478,954</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Increase in accrued interest</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">19,083</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">7,264</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(65,165</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(98,687</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Cash Flows from Financing Activities:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Proceeds from note payable, related parties</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">45,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">25,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Proceeds from sale of common stock</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">25,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">45,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">50,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Net Change in Cash</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(20,165</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(48,687</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt">Beginning of period</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">28,478</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">64,431</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 2.5pt">End of period</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">8,313</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">15,744</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Supplemental disclosure of cash flow information:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Cash paid for interest</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">28,011</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">28,128</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Cash paid for income taxes</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Schedule of Non-Cash Investing and Financing Activities:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Convertible note issued as a settlement of a previously accrued liability</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">150,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; width: 64%; text-align: left; padding-bottom: 2.5pt"> Restricted stock issued for forgiveness of
    salary </TD><TD STYLE="width: 2%; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="width: 14%; border-bottom: Black 2.5pt double; text-align: right"> 10,000 </TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="width: 14%; border-bottom: Black 2.5pt double; text-align: right"> - </TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"> Stock options issued for forgiveness of salary </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 50,000 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> - </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these audited financial statements</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 204; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR STYLE="clear: both"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ch_005"></A>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
31, 2024 and 2023</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
1 &ndash; Organization and Description of Business</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter
Neurosciences, Inc. (the &ldquo;Company&rdquo;) is a clinical stage research and development pharmaceutical company located in Jupiter,
Florida. The Company incorporated in Delaware in January 2016. The Company has developed a unique resveratrol platform product primarily
targeting treatment of neuro-inflammation. The product candidate, called JOTROL, has many potential indications of use for rare
diseases, which of we primarily are targeting Mucopolysaccharidoses Type 1, Friedreich&rsquo;s Ataxia, and MELAS. In the larger disease
areas, we are primarily targeting Parkinson&rsquo;s Disease and Mild Cognitive Impairment/early Alzheimer&rsquo;s disease</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 30, 2021, the Company filed a Certificate of Amendment to the Certificate of Incorporation with the State of Delaware to change
its name from Jupiter Orphan Therapeutics, Inc. to Jupiter Neurosciences, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JOTROL
has the potential to deliver a therapeutically effective dose of resveratrol in the blood stream, using a unique patented micellar formulation,
without causing gastrointestinal side effects. We expect JOTROL, based on the results of our Phase I study, will resolve the major
obstacle of resveratrol&rsquo;s poor bioavailability, which has been documented in various scientific articles describing previously
conducted human trials with resveratrol as well as preclinical trial results in mice and rats</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s activities and operations include a project funded by the U.S. National Institute on Aging, an institute of the U.S.
National Institutes of Health (&ldquo;NIH&rdquo;): Safety and Pharmacokinetics of JOTROL for Alzheimer&rsquo;s Disease, Federal
Award Identification Number R44AG067907-01A1 (the &ldquo;Award&rdquo;). The project encompassed a Phase 1 dose finding pharmacokinetics
(&ldquo;PK&rdquo;) study which was completed before December 31, 2021. The award end date was May 31, 2022. This Phase 1 PK study will
be homogeneous for all indications where JOTROL will be used in Phase II and Phase III clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 9, 2020, the Company effected a three-for-one (3:1) forward stock split whereby the Company (i) increased the number of authorized
shares of common stock, $0.0001 par value per share, to 25,000,000 from 5,000,000 and (ii) increased by a ratio of three-for-one (3:1)
the number of retroactively issued and outstanding shares of common stock. Proportional adjustments for the forward stock split were
made to the Company&rsquo;s outstanding stock options, warrants and equity incentive plans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 11, 2021, the Company increased the number of authorized shares of common stock, $0.0001 par value per share, to 45,000,000
from 25,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 25, 2022, the Company effected a one-for-two (1:2) reverse stock split whereby the Company (i) decreased the number of issued
and outstanding shares of common stock, $0.0001 par value per share, from 13,076,608 to 6,538,304 and (ii) decreased by a ratio of one-for
two (1:2) the number of retroactively issued and outstanding shares of common stock. Proportional adjustments for the reverse stock split
were made to the Company&rsquo;s outstanding stock options, warrants and equity incentive plans. All share and per-share data and amounts
have been retroactively adjusted as of the earliest period presented in the financial statements to reflect the reverse stock split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 14, 2024, the Company effected a fifteen-for-four (15:4) forward stock split whereby the Company (i) increased the number
of issued and outstanding shares of common stock, $0.0001 par value per share, from 30,123,405 to 8,033,706 and (ii) increased
by a ratio of fifteen-for-four (15:4) the number of retroactively issued and outstanding shares of common stock. Proportional adjustments
for the forward stock split were made to the Company&rsquo;s outstanding stock options, warrants and equity incentive plans. All share
and per-share data and amounts have been retroactively adjusted as of the earliest period presented in the financial statements to reflect
the forward stock split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 205; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
31, 2024 and 2023</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
2 &ndash; Significant Accounting Policies</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basis
of Accounting and Going Concern</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States
of America (&ldquo;U.S. GAAP&rdquo;). US GAAP contemplates continuation of the Company as a going concern. For the three months ended
March 31, 2024 and 2023, the Company had no revenues from product sales and incurred a net loss of $634,100 and $1,747,250, respectively.
Net cash used in operations for three months ended March 31, 2024 and 2023 was $65,165 and $98,687, respectively. As of March 31, 2024,
the Company had a working capital deficit and accumulated deficit of $5,962,608 and $24,216,604, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company plans to finance future operations with proceeds from equity securities, grant awards and strategic collaborations. However,
there is no assurance the Company will be successful. It is the management&rsquo;s opinion that these conditions raise substantial doubt
about the Company&rsquo;s ability to continue as a going concern for a period of at least twelve months from the date of this report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use
of Estimates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Federal
Contract Revenue</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes federal contract revenue from the NIH Award in the period in which the allowable research and development expenses
are incurred, and receivables associated with this revenue are included within federal contract revenue receivable on our balance sheets.
This revenue is not within the scope of Accounting Standards Codification (ASC) 606 &ndash; Revenue from contracts with customers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Federal
Contract Receivable</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal
contract receivable represents amounts due to us under the NIH Award for valid expenditures expected to be reimbursed to us under the
terms of the NIH contract.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cash</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. As
of March 31, 2024 and December 31, 2023, the Company invested a portion of cash balances in a high yield savings account, which are included
as cash equivalents on the balance sheets. As of March 31, 2024 and December 31, 2023, the cash balances did not exceed the FDIC limit
of $250,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Current Assets and Prepaid Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
current assets and prepaid expenses generally represent payments made for goods or services to be received within one year and are expensed
as the related benefit is received.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 206; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
31, 2024 and 2023</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
2 &ndash; Significant Accounting Policies, continued</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
and Development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. Costs for certain development activities, such as clinical trials, are recognized based
on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, monitoring visits, clinical site
activations, or information provided to us by our vendors with respect to their actual costs incurred. Payments for these activities
are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the
financial statements as prepaid or accrued research and development expense, as the case may be. Total research and development costs
for the three months ended March 31, 2024, and 2023 were $98,667 and $267,409, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Income
Taxes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis
of our assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws
on deferred taxes, if any, applied during the years in which temporary differences are expected to be settled, is reflected in the financial
statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence,
it is more likely than not that some, or all, of the deferred tax assets will not be realized. The effect on deferred tax assets and
liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted. As of March 31, 2024 and December
31, 2023, the Company concluded that a full valuation allowance is necessary for the net deferred tax assets. The Company had no material
amounts recorded for uncertain tax positions, interest or penalties in the accompanying financial statements. The Company is subject
to taxation in the U.S. Our tax years for 2021 and forward are subject to examination by tax authorities. The Company is not currently
under examination by any tax authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Loss
Per Share of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common
stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of
securities, such as convertible preferred stock, convertible notes payable, warrants, stock options, and unvested restricted stock, which
would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable
to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net
loss exists, dilutive shares are not included in the calculation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2024, there were 1,359,375 warrants outstanding, 1,626,037 restricted stock units and 10,566,488 stock options
and 14 convertible notes payable, which are convertible into restricted fully-paid and non-assessable shares of the Company&rsquo;s common
stock or units of common stock and warrants to purchase common stock, if units are offered in the Initial Public Offering equal to the
indebtedness divided by 70% of the offering price paid per share of at which the IPO is made. Such securities are considered dilutive
securities which were excluded from the computation since the effect is anti-dilutive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, there were 1,359,375 warrants outstanding, 1,618,537 restricted stock units, and 10,336,882 stock options
and 14 convertible notes payable, which are convertible into restricted fully-paid and non-assessable shares of the Company&rsquo;s common
stock or units of common stock and warrants to purchase common stock, if units are offered in the Initial Public Offering equal to the
indebtedness divided by 70% of the offering price paid per share of at which the IPO is made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 207; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
31, 2024 and 2023</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
2 &ndash; Significant Accounting Policies, continued</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock-Based
Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based compensation in accordance with the provisions of Accounting Standards Codification (&ldquo;ASC&rdquo;)
Topic 718, Compensation&mdash;Stock Compensation, or ASC 718, which requires the recognition of expense related to the fair value of
stock-based awards in the statements of operations. For stock options issued to employees, non-employees and members of our board of
directors, the Company estimates the grant-date fair value of options using the Black-Scholes option pricing model. The use of the Black-Scholes
option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility
of the common stock consistent with the expected life of the option, risk-free interest rates, and, for grants prior to our initial public
offering, the value of the common stock. For awards subject to time-based vesting, the Company recognized stock-based compensation expense,
on a straight-line basis over the requisite service period, which is generally the vesting term of the award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Clinical
Trial Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the process of preparing our financial statements, the Company is required to estimate expenses resulting from obligations under
contracts with vendors, clinical research organizations and consultants and under clinical site agreements in connection with conducting
clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result
in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company&rsquo;s
objective is to reflect the appropriate trial expenses in the financial statements by matching those expenses with the period in which
services are performed and efforts are expended. The Company accounts for these expenses according to the progress of the trial as measured
by patient progression and the timing of various aspects of the trial. The Company determines accrual estimates based on estimates of
services received and efforts expended that take into account discussion with applicable personnel and outside service providers as to
the progress or state of consummation of trials. During the course of a clinical trial, the Company adjusts the clinical expense recognition
if actual results differ from its estimates. The Company makes estimates of the accrued expenses as of each balance sheet date based
on the facts and circumstances known at that time. The clinical trial accruals are dependent upon the timely and accurate reporting of
contract research organizations and other third-party vendors. Although the Company does not expect the estimates to be materially different
from amounts actually incurred, understanding of the status and timing of services performed relative to the actual status and timing
of services performed may vary and may result in reporting amounts that are too high or too low for any particular period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair
Value of Financial Instruments and Fair Value Measurements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures its financial assets and liabilities in accordance with US GAAP. For certain financial instruments, including cash and
cash equivalents, accounts receivable, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their
short maturities. Amounts recorded for notes payable, net of discount, and loans payable also approximate fair value because current
interest rates available for debt with similar terms and maturities are substantially the same.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows accounting guidance for financial assets and liabilities. This standard defines fair value, provides guidance for measuring
fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all
other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related
to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income
approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement
cost).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 208; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
31, 2024 and 2023</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
2 &ndash; Significant Accounting Policies, continued</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair
Value of Financial Instruments and Fair Value Measurements, continued</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into six broad
levels. The following is a brief description of those three levels:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2: Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets
or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us,
which reflect those that a market participant would use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table represents the Company&rsquo;s financial instruments that are measured at fair value on a recurring basis at each reporting
period for each fair value hierarchy level:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Derivative Liability 03/31/2024</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Derivative Liability 12/31/2023</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Level I</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Level II</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: left; padding-bottom: 2.5pt">Level III</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%; border-bottom: Black 2.5pt double; text-align: right">1,543,109</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%; border-bottom: Black 2.5pt double; text-align: right">1,505,398</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">1,543,109</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">1,505,398</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also
see Note 5 - Convertible Debt and Derivative Liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Derivative
Instruments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
Topic 815, Derivatives and Hedging (&ldquo;ASC Topic 815&rdquo;), establishes accounting and reporting standards for derivative instruments
and for hedging activities by requiring that all derivatives be recognized in the balance sheet and measured at fair value. Gains or
losses resulting from changes in the fair value of derivatives are recognized in earnings. On the date of conversion or payoff of debt,
the Company records the fair value of the conversion shares, removes the fair value of the related derivative liability, removes any
discounts and records a net gain or loss on debt extinguishment. On January 1, 2020 the Company adopted ASU 2017-11 under which down-round
Features in Financial Instruments will no longer cause derivative treatment. The Company applies the modified prospective method of adoption.
There were no cumulative effects on adoption.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 209; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
31, 2024 and 2023</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
2 &ndash; Significant Accounting Policies, continued</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Convertible
Notes with Embedded Derivative Liabilities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into convertible notes, some of which contain variable conversion options, whereby the outstanding principle and
accrued interest may be converted, by the holder, into common shares at a fixed discount to the price of the common stock at or around
the time of conversion upon certain trigger events. The Company evaluates all its financial instruments to determine if those contracts
or any potential embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC
815-10 <I>&ndash; Derivative and Hedging &ndash; Contract in Entity&rsquo;s Own Equity</I>. This accounting treatment requires that the
carrying amount of any derivatives be recorded at fair value at issuance and marked-to-market at each balance sheet date. In the event
that the fair value is recorded as a liability, as is the case with the Company, the change in the fair value during the period is recorded
as either other income or expense. Upon conversion, exercise or repayment, the respective derivative liability is marked to fair value
at the conversion, repayment, or exercise date and then the related fair value amount is reclassified to other income or expense as part
of gain or loss on debt extinguishment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Leases</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2016, the Financial Accounting Standards Board (&ldquo;FASB&rdquo;) issued ASU 2016-02, Leases (Topic 842). The updated guidance
requires lessees to recognize lease assets and lease liabilities for most operating leases. In addition, the updated guidance requires
that lessors separate lease and non-lease components in a contract in accordance with the new revenue guidance in ASC 606.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease ROU assets represents the right to use the leased asset for the lease term and operating lease liabilities are recognized based
on the present value of future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit
rate, the Company use an incremental borrowing rate based on the information available at the adoption date in determining the present
value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included
in general and administrative expenses in the statements of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recent
Accounting Pronouncements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has reviewed the FASB issued ASU accounting pronouncements and interpretations thereof that have effectiveness dates during the
periods reported and in future periods. The Company has carefully considered the new pronouncements that alter previous generally accepted
accounting principles and do not believe that any new or modified principles will have a material impact on the Company&rsquo;s reported
financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company&rsquo;s
financial management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging
&ndash; Contracts in Entity&rsquo;s Own Equity (Subtopic 815-40) &ndash; Accounting for Convertible Instruments and Contracts in an Entity&rsquo;s
Own Equity. The ASU simplifies accounting for convertible instruments by removing major separation models required under current GAAP.
Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded
conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative
scope exception, which will permit more equity contracts to qualify for the exceptions. The ASU also simplifies the diluted net income
per share calculation in certain areas. The new guidance is effective for fiscal years beginning after December 15, 2023, including interim
periods within those fiscal years, and early adoption is permitted. The Company adoption of this standard did not have a material impact
on the Company&rsquo;s financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
other newly issued accounting pronouncements that are not yet effective have been deemed immaterial or nonapplicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 210; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
31, 2024 and 2023</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
3 &ndash; Related Party Transactions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2024, the Company&rsquo;s CEO loaned the Company an additional $45,000. The loans are due on demand
and accrues interest at 3% per year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s Chief Executive Officer (CEO) has loaned the Company working capital since inception. The balance of the loans to the
CEO as of March 31, 2024 and December 31, 2023 was $403,479 and $358,479, respectively. The loan is due on demand and accrues interest
at 3% per year. Accrued interest relating to the loan was $14,329 and $11,308 as of March 31, 2024 and December 31, 2023, respectively,
and is included in accrued interest on the accompanying balance sheets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, an employee has loaned the Company $25,000. The balance of the loan as of March 31, 2024 and December
31, 2023, was $25,000. The loan is due on demand and accrues interest at 3% per year. Accrued interest related to the loan was $912 and
$723 as of March 31, 2024 and December 31, 2023, respectively, and is included in accrued interest on the accompanying balance sheet.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
compensation includes partially accrued salaries to executives since inception. Since inception, executive salaries have been paid in
cash when the Company&rsquo;s cash flow has permitted such payment. During 2020, the Company began consistently paying salaries at 50%
of the salaries reflected in the respective employment agreements. As of September 2021, the Company began paying full salaries. Throughout
2022, the Company returned to paying partial salaries and by November 2022 the Company stopped paying salaries 100% in an effort to conserve
cash.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 29, 2023, various employees and board members agreed to forgive accrued compensation in the amount of $4,189,626. In exchange
of the forgiveness the Company issued an aggregate of 2,353,661 stock options with an exercise price of $1.33 and an aggregate of 1,399,834
restricted stock units with a grant date value of $1.33 in exchange for the aggregate forgiveness of compensation in the amount of $4,189,626.
Additionally, the Company agreed to a bonus of $513,013 for the employees and a bonus of $70,200 to the board members, to be paid upon
the occurrence of a successful IPO in exchange for the forgiveness of the afore mentioned accrued compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 18, 2023, various employees and board members agreed to amend the accrued compensation debt forgiveness dated September 29,
2023. Pursuant to the amendment the cash bonuses of $513,013 for the employees and a bonus of $70,200 to the board members agreed to
on September 29, 2023, were forgiven, and no cash will be paid upon a successful IPO. In addition, the options issued in connection with
the forgiveness dated September 29, 2023, have been amended to vest fully on the effective date of the new amendment. In addition, the
restricted stock unit issued in connection with the forgiveness dated September 29, 2023, were terminated and replaced with 1,399,834
restricted stock units that vest upon the earlier occurrence of the initial public offering or a change of control of the Company. In
exchange of the forgiveness of the accrued bonuses the Company issued an aggregate of 289,294 stock options with an exercise price of
$1.33 and an aggregate of 218,704 restricted stock units with a grant date value of $1.33 in exchange for the aggregate forgiveness of
compensation in the amount of $583,213.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 15, 2024, a former executive agreed to forgive $100,000 of accrued compensation in exchange for 49,605 options to purchase common
stock and 7,500 restricted stock units, The options to purchase common stock have a strike price of $1.33 The Company recorded a gain
on the forgiveness of accrued compensation in the amount of $40,000.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 211; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
31, 2024 and 2023</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
4 &ndash; Accounts Payable and Accrued Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
payable and accrued expenses consisted of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2024</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2023</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Accounts payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">208,939</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;189,495</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Professional fees</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">169,617</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">174,053</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">License fee</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">150,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">150,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Credit cards</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">30,663</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">32,466</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total accounts payable and accrued expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">559,219</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">546,014</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2024, $92,125 was due to a Company wholly owned by the Company&rsquo;s Chief Financial Officer, who also is an option holder.
The amount is included in accrued compensation on balance sheet. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
compensation of $1,640,873 and $1,562,041 as of March 31, 2024 and 2023, respectively, includes accrued salaries and health
benefits to executives since inception and board fees. Since inception, executive salaries have been paid in cash when the Company&rsquo;s
cash flow has permitted such payment. During 2020, the Company began consistently paying salaries at 50% of the salaries reflected in
the respective employment agreements. As of September 1, 2021, the Company began paying full salaries. Throughout 2022, the Company returned
to paying partial salaries and by November 2022 the Company stopped paying salaries 100% in an effort to conserve cash. Starting the
fourth quarter of 2023 the Company&rsquo;s executives agreed to reduce their salaries with 80% until an initial public offering. See
Note 3 &ndash; Related Party Transactions for details related to forgiveness of accrued compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
5 &ndash; Convertible Debt and Derivative Liability</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Convertible
Debt I</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between
August and December 2021, the Company executed twelve convertible promissory notes (&ldquo;Notes I&rdquo;) for $527,650 in proceeds with
a maturity date of July 31, 2022, and interest rate of 1%. The Notes I will automatically convert into equity securities on the first
business day following effectiveness of an initial public offering of common stock with the Securities and Exchange Commission (&ldquo;IPO&rdquo;).
Upon IPO, the outstanding principle of the Notes I and all unpaid accrued interest will automatically convert into a number of restricted
fully paid and non-assessable shares of common stock, or units of common stock and warrants to purchase common stock if units are offered
to the public in the IPO, equal to the indebtedness divided by 70% of the offering price paid per share at which the IPO is made. For
the avoidance of doubt, in the event the IPO is not declared effective prior to the maturity date, none of the indebtedness shall convert
or be convertible into shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the time of execution, the Company recorded a debt discount of $257,650 based on the fair value of the embedded conversion feature of
Notes I, which was amortized into interest expense over term of Notes I, each with a maturity date of July 31, 2022. On August 6, 2022,
the Notes I were amended to extend the maturity date to January 31, 2023, and increase the interest rate to 5%. All other terms remain
the same as previously stated in Notes I. The impact of the amendment is prospective and increased accrued interest by $23,072 and is
included in accrued interest on the accompanying balance sheet. On February 2, 2023, the Notes I were amended to extend the maturity
date to December 31, 2023. During January 31, 2024, the Company and all Note I holders agreed to amend and extend the maturity date of
their notes to December 31, 2024. The holders waived any default under the original notes prior to the amendment date. With the amendments
the applicable interest rate to Notes I increased to 10% effective from January 1, 2024. The amendments were accounted for as a modification
and not an extinguishment of debt, therefore there was no gain recorded in the statement of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 212; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
31, 2024 and 2023</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
5 &ndash; Convertible Debt and Derivative Liability, continued</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Convertible
Debt II</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Note -</B> On April 11, 2022, the Company entered into a securities purchase agreement with an accredited investor (the &ldquo;Holder&rdquo;).
Pursuant to the terms of the securities purchase agreement, the Company received aggregate gross proceeds of $1,000,000, less loan origination
costs of $22,667, and issued a (i) 10% original issue discount senior secured convertible note (the &ldquo;Note II&rdquo;) in the principal
amount of $1,111,111 and (ii) 514,403 shares of common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
II matures 12 months from issuance and bears interest at 10% per annum, payable monthly in arrears. A &ldquo;Qualified Offering&rdquo;
is a debt or equity financing for the account of the Company or any of its subsidiaries in which shares of common stock, or securities,
directly or indirectly, convertible into or exchangeable or exercisable for shares of common stock are issued, which financing results
in cumulative aggregate proceeds to the Company of at least $8,000,000. The principal and interest on the Note II will be amortized on
a straight-line basis at 110% of the principal amount commencing sixth months after the closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
an Event of Default and after a Qualified Offering, the principal and interest are convertible at any time at the option of the Holder
into shares of the Company&rsquo;s common stock at a conversion price equal to 30% discount to the lowest closing price of the common
stock for the 20 prior trading days; provided, however, the Holder will not have the right to convert any portion of Note II, to the
extent that after giving effect to the conversion, the Holder, together with its affiliates, would beneficially own in excess of 4.99%
of the number of shares of the Company&rsquo;s common stock outstanding immediately after giving effect to its conversion. The Holder
may increase or decrease its ownership limitation to any percentage not exceeding 9.99% upon 61 days prior written notice to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will have the right at any time to redeem in cash all or a portion of Note II at 120% (or 125% on or after the first six months
from the closing) of the principal amount thereof plus any unpaid accrued interest to the date of repayment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will be required to offer to prepay in cash the aggregate principal amount of Note II at 120% (or 125% on or after the first
six months from the closing) of the principal amount thereof plus any unpaid accrued interest to the date of repayment, on the sale of
all or substantially all of the assets of the Company and its subsidiaries, upon a Change of Control (as defined in Note II), or on a
Qualified Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
an Event of Default (as defined therein) interest shall accrue at 1 1/2% per month and the 125% of principal and interest through maturity
shall be due and payable. At the Holder&rsquo;s option the Holder shall be entitled to be paid in cash or after the Qualified Offering
(as defined in the Purchase Agreement) common stock with the conversion price of the common stock equal to a 30% discount to the lowest
closing price of the common stock for the 20 prior trading days.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 10, 2022, Note II was amended to postpone the commencement of the principal payments from October 11, 2022 to November 11, 2022.
As consideration for the amendment, an additional 42,867 shares of common stock were issued to the Holder on October 10, 2022,
valued at 1/12<SUP>th</SUP> of the original 514,403 shares issued at commencement of Note II.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 10, 2022, Note II was amended to postpone the commencement of the principle from November 11, 2022 to February 11, 2023 and
payable in three monthly installments. An additional 128,599 shares of common stock were issued to the Holder on November 10, 2022, value
at 1/4<SUP>th</SUP> of the original 514,403 shares issued at commencement of Note II.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 213; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
31, 2024 and 2023</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
5 &ndash; Convertible Debt and Derivative Liability, continued</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Convertible
Debt II, continued</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 6, 2023, Note II was amended to postpone the commencement of the principle to February 28, 2023. On March 6, 2023, Note II was
amended to postpone the commencement of the principal from February 11, 2023 to May 31, 2023. The Company and the noteholder agreed to
a repayment plan on past due interest. In addition, the Company agreed to prepay in cash the aggregate principal amount of the Note II
of 120% (or 137.5% on or after the first six months from closing) plus any accrued interest on the sale of all the assets of the Company
and its subsidiaries, upon the Change of Control, or on a Qualified Offering. Upon default of Note II, the Company agrees to pay 137.5%
of the outstanding note principal, and accrued interest through maturity and all liquidation damages. As a result of the material modification,
the incremental fair value of the modified derivative was classified as a debt extinguishment. Due to the extension of the maturity date
of the convertible note, the fair value of the derivative liability increased. This resulted in the Company recording a loss on extinguishment
of debt of $670,419.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 22, 2023, Note II was amended to postpone the commencement of the principle to December 31, 2023. The Company and the noteholder
agreed to a repayment plan on past due interest. In addition, the Company agreed to prepay in cash the aggregate principal amount of
the Note II of 120% (or 150% on or after the first six months from closing) plus any accrued interest on the sale of all the assets of
the Company and its subsidiaries, upon the Change of Control, or on a Qualified Offering. Upon default of Note II, the Company agrees
to pay 150% of the outstanding note principal and accrued interest through maturity and all liquidation damages. In addition, upon closing
the Note Holder will receive 175% stock coverage. As a result of the material modification, the incremental fair value of the modified
derivative was classified as a debt extinguishment. Due to the extension of the maturity date of the convertible note, the fair value
of the derivative liability increased. This resulted in the Company recording a loss on extinguishment of debt of $217,527. See Note
9 &ndash; Subsequent Events for details related to amendment to the Note II subsequent to March 31, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
Shares</I></B> - In connection with the issuance of Note II, the Company issued 514,403 shares of Common Stock to the Holder with
a fair market value of $2.16 per share (aggregate value of $1,111,111) as additional consideration for the Holder lending $1,000,000
to the Company. The 514,403 shares have a relative fair value of $310,000. See <I>Derivative Liability Pursuant to Convertible
Debt</I> in the following section. If the price per share in a Qualified Offering is less than $2.16, the Holder shall receive an additional
number of shares of common stock, such that it shall have received the number of shares of common stock of the aggregate value of $1,111,111
divided by the price per share in the Qualified Offering, (&ldquo;Share True Up&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Ancillary
Agreements</I></B> - In connection with the Company&rsquo;s obligations under Note II, the Company entered into a security agreement
and intellectual property security agreement with the Holder, pursuant to which the Company granted a security interest on all
assets of the Company, including all intellectual property of the Company, for the benefit of the Holders, to secure the
Company&rsquo;s obligations under Note II and the other transaction documents. In addition, the Holder was granted piggyback
registration rights for the shares of common stock issued under the Purchase Agreement and shares of common stock issuable upon
conversion of Note II (collectively, &ldquo;Registrable Securities&rdquo;). At any time while there are any Registrable Securities
of Holder outstanding, if the Company proposes to register any of its securities either for its own account or for the account of
other security Holders (other than a registration statement relating solely to employee benefit plans on Form S-8 or a Commission
Rule 145 transaction on Form S-4), the Holder is entitled to include its Registrable Securities in the </FONT>registration.
Notwithstanding, the Company and underwriters in an underwritten registration may exclude some or all of the Registrable Securities
from the underwritten registration if the underwriters believe that including the Registrable Securities would adversely affect the
underwritten offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 214; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
31, 2024 and 2023</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
5 &ndash; Convertible Debt and Derivative Liability, continued</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Convertible
Debt II, continued</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
any time within the 12 months closing, upon any issuance by the Company or any of its subsidiaries of debt or common stock or common
stock equivalents for cash consideration, indebtedness or a combination of units thereof, other than in an underwritten public offering
(a &ldquo;Subsequent Financing&rdquo;), the Holder will have the right to participate up to its investment amount in Note II, but not
more than 25% of the Subsequent Financing, on the same terms, conditions and price provided for in the Subsequent Financing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the securities purchase agreement, the Company received aggregate gross proceeds of $1,000,000, less loan origination
costs of $22,667, and issued a (i) 10% original issue discount senior secured convertible note (the &ldquo;Note II&rdquo;) in the principle
amount of $1,111,111 and (ii) 514,403 shares of common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Convertible
Debt III</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 1, 2023, the Company issued a convertible promissory note (the &ldquo;Note III&rdquo;) with a principal amount of $150,000 as part
of a settlement agreement with an investor relations firm. Note III matures on February 28, 2026 and accrues interest at 5% annually
which compounds quarterly. Note III is convertible upon election of the holder upon a qualified financing of at least $5,000,000 into
shares of common stock equal to 70% of the per share price of the equity issued in the qualified financing. Note III is also convertible
upon the completion of an IPO by the Company into shares of common stock equal to 70% of the per share price of the equity issued in
connection with the IPO. In both cases the Holder can elect to receive the principal and accrued interest instead of converting the note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2024 and 2023, $46,948 and $34,519, respectively, are included in interest expense for the combined
convertible Notes I, II and III on the accompanying statements of operations. As of March 31, 2024 and December 31, 2023 the balance
of the combined convertible promissory Note I, II and III was $1,750,458 and $1,745,472, respectively, net of the debt discount and loan
origination costs of $38,301 and $43,288, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Derivative
Liability Pursuant to Convertible Debt</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the issuance of the Notes, the Company determined that the terms of Notes contain an embedded conversion option to be
accounted for as a derivative liability due to the Holder having the potential to gain value upon IPO. Accordingly, under the provisions
of ASC 815-40 &ndash;<I>Derivatives and Hedging &ndash; Contracts in an Entity&rsquo;s Own Stock</I>, the embedded conversion option
contained in Notes was accounted for as derivative liability and debt discount at the date of issuance and has been adjusted to fair
value through earnings at each reporting date. The fair value of the embedded conversion option was determined using the Monte Carlo
valuation model.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the issuance of Notes I, on the initial measurement date of September 2021, the fair value of the embedded conversion
option of $257,650 was recorded as derivative liability and debt discount to be amortized into interest expense over the terms of the
Notes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the issuance of Note II, on the initial measurement date of April 2022, the fair value of the embedded conversion option
of $346,000 and the fair value of the Share True Up of $34,000 was recorded as derivative liability and a debt discount to be amortized
into interest expense over the term of Note II. An additional discount of $421,111 was recorded on the initial measurement date for the
10% original issue discount of $111,111 and the relative fair value of the allocation of proceeds to the 514,403 shares of common
stock issued, valued at $310,000, to be amortized into interest expense over the term of Note II.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 215; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
31, 2024 and 2023</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
5 &ndash; Convertible Debt and Derivative Liability, continued</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Derivative
Liability Pursuant to Convertible Debt, continued</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months March 31, 2023, the derivative liabilities were revalued, and a $670,419 adjustment was recorded as a loss on extinguishment
of debt to other expenses reflected in the accompanying statements of operations. The Company also recorded a $(37,711) and $18,628,
adjustment as a (gain) loss on the change in the fair value of the derivative liability for the three months ended March 31, 2024 and
2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the derivative liability of Notes I, Note II and Note III was estimated using the Monte Carlo Valuation model at issuance
and each reporting period with the following assumptions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">NOTE III</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">NOTES I, II &amp; III</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">NOTES I, II &amp; III</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">March
1, 2023<BR> (Issuance)</P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">December 31, <BR> 2023</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">March 31, <BR> 2024</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Dividend Rate</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 34%">Term</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right">0.25</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right">0.25</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right">0.25</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Volatility</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">90</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">90</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">90</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free rate</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4.70</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5.20</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Probability of IPO</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">60</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">60</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">60</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of activity of the derivative liability pertaining to the Notes is presented below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Derivative Liability</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 80%">Balance at December 31, 2022</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;710,599</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Fair value at issuance March 1, 2023</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">55,604</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Fair value on date of amendment, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">887,946</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Fair value change</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(148,751</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">Balance at December 31, 2023</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,505,398</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Fair value change</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">37,711</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance at March 31, 2024</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">1,543,109</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 216; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
31, 2024 and 2023</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
6 &ndash; Stockholders&rsquo; Deficit</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Common
Stock</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue 125,000,000 shares of common stock and 5,000,000 shares of preferred stock. The Company had 26,526,405
shares of common stock issued and outstanding as of March 31, 2024. There was no preferred stock issued and outstanding as of March 31,
2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stock
Options</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company grants stock awards to officers, employees, directors, and other key persons pursuant to its 2021 Equity Incentive Plan (&ldquo;the
Plan&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2024 and 2023, the Company recognized stock-based compensation of $355,317 and $381,501, respectively,
related to vested stock options. There was $874,710 of unvested stock options expense as of March 31, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 1, 2023, the Company granted non-qualified stock option to purchase 562,500 shares of Common Stock to our Chief Financial Officer,
at an exercise price of $1.33 per share. The option had a grant date fair value of $589,500.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 24, 2024, the Company granted 180,000 stock options to a consultant with an exercise price of $1.33 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 217; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
31, 2024 and 2023</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
6 &ndash; Stockholders&rsquo; Deficit, continued</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stock
Options, continued</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of activity for the three months ended March 31, 2024 is presented below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of Options</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    Average Exercise Price</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    Average Contractual Term (Years)</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate
    Intrinsic Value</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 40%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    as of December 31, 2023</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,336,883</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.00</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.41</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,316,119</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">229,605</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.33</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    as of March 31, 2024</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,566,488</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.02</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.72</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,316,119</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable
    as of March 31, 2024</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,779,704</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.99</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.57</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,291,119</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarized information about employee stock options outstanding as of March 31, 2024:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Outstanding Options</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Vested Options</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercise Price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number Outstanding at March 31,
    2024 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Remaining Life</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number Exercisable at March 31,
    2024 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Remaining Life</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right"> 0.01 </TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right"> 675,000 </TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">1.75</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right"> 675,000 </TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">1.75</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"> 0.74 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 1,657,560 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.82</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 1,657,564 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.82</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 2,783,243 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.04</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 2,736,364 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.03</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 5,394,435 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 8.81 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 4,654,526 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 8.82 </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"> 2.16 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 56,250 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7.21</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 56,250 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7.21</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 10,566,488 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 6.74 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 9,779,704 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 6.59 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Warrants</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the Company&rsquo;s warrant activity for the three months ended March 31, 2024:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise Price per Share</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Remaining Life (Years)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; font-weight: bold">Outstanding as of December 31, 2022</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right"> 1,359,375 </TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right"> 0.80 </TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">0.98</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Forfeited</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Outstanding as of December 31, 2023</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 1,359,375 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 0.80 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.64</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Forfeited</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Outstanding as of March 31, 2024</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 1,359,375 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 0.80 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.56</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>


<!-- Field: Page; Sequence: 218; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
31, 2024 and 2023</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
6 &ndash; Stockholders&rsquo; Deficit, continued</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Restricted
Stock Units</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 29, 2023, the Company issued an aggregate of 1,399,834 restricted stock units with a grant date value of $1.33 in exchange
for the forgiveness of accrued compensation. Pursuant to the amendment dated December 18, 2023, the restricted stock units shall vest
on the on earlier event of either the occurrence of an initial public offering or in the event of change of control of the Company. The
restricted stock units have an aggregate grant date fair value of $1,866,445.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 18, 2023, the Company terminated 1,399,384 restricted stock units and issued an aggregate of 1,618,537 restricted stock units
with a grant date value of $1.33 in exchange for the forgiveness of accrued compensation. The restricted stock units shall vest on the
earlier event of either the occurrence of an initial public offering or in the event of change of control of the Company. The restricted
stock units have an aggregate grant date fair value of $2,158,050.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2024, the Company had an aggregate of 1,626,037 restricted stock units outstanding with an aggregate fair value of
$2,195,550. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
7 &ndash; Concentrations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s grant revenues and grant receivables are from the NIH Award. The Company expects to maintain the relationship with the
NIH.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
8 &ndash; Commitments and Contingencies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Legal
Matters</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, claims are made against the Company in the ordinary course of business, which could result in litigation. Claims and associated
litigation are subject to inherent uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties or
injunctions prohibiting the Company from selling one or more products or engaging in other activities. The occurrence of an unfavorable
outcome in any specific period could have a material adverse effect on the Company&rsquo;s results of operations for that period or future
periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 19, 2022, Tiberend Strategic Advisors (&ldquo;Tiberend&rdquo;), an entity that the Company had previously engaged as a communications
and investor relations firm, filed a summons for civil action in the District Court of Southern Florida against the Company alleging
non-payment by the Company under a services agreement (the &ldquo;Services Agreement&rdquo;) with Tiberend in the amount of $130,400.
The Company and Tiberend entered into a full settlement and release agreement in exchange for a $150,000 convertible promissory note
in March 2023. See Note 5 &ndash; Convertible Debt and Derivative Liability &ndash; Convertible Debt III for details associated with
the note issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Office
Lease</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 1, 2021 the Company entered into an 61 month operating lease for office space for a base rent of $3,783 subject to a 3% yearly escalation.
The Company adopted ASC Topic 842, Leases upon inception of the lease. As of March 31, 2024, the Company&rsquo;s Operating lease right-of-use
asset, net (ROU) is $116,070 and total lease liability is $107,736 based on an incremental borrowing rate of 0.81% at lease inception.
As of December 31, 2023, the Company&rsquo;s Operating lease right-of-use asset, net (ROU) is $116,939 and total lease liability is $119,542
based on an incremental borrowing rate of 0.81% at lease inception.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 219; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
31, 2024 and 2023</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
8 &ndash; Commitments and Contingencies, continued</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Office
Lease, continued</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">March 31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Operating lease right-of-use asset (&ldquo;ROU&rdquo;) is summarized below:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 64%; text-align: left">Office lease ROU</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">236,009</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">236,009</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less accumulated reduction</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(131,546</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(119,939</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Balance of ROU, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">104,463</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">116,070</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Operating lease liability related to the ROU asset is summarized below:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Office lease liability</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">236,009</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">236,009</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Reduction of lease liability</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(128,273</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(116,467</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-left: 20pt; padding-bottom: 2.5pt">Total</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">107,736</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">119,542</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum lease liability payments under non-cancelable operating lease at March 31, 2024 and December 31, 2023 are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">2024</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">36,964</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">49,004</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">2025</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">50,476</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">50,476</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">2026</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">21,290</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">21,290</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">108,730</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">120,770</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Less: imputed interest</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(994</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(1,228</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total lease liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">107,736</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">119,542</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Current operating lease liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">48,673</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">48,213</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Non-current operating lease liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">59,063</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">71,329</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total lease liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">107,736</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">119,542</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 1, 2021, the Company entered into a month-to-month lease for office space in Charlestown, MA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rental
expenses of $4,210 and $5,081 for the three months ended March 31, 2024 and 2023, respectively, is included in general and administrative
expenses on the accompanying statement of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Consulting
Agreements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes various consultants and advisors for clinical research, scientific advisory services and business strategies. Each consultant
has an executed agreement in place defining term, compensation, duties, confidentiality, intellectual property. The majority of the agreements
have a 2-year term. Agreements are evaluated for renewal upon expiration. Bonus provisions are at the discretion of the Company&rsquo;s
Board of Directors and are granted on an individual agreement basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes various consultants and advisors for clinical research, scientific advisory services and business strategies. Each consultant
has an executed agreement in place defining term, compensation, duties, confidentiality, intellectual property. The majority of the agreements
have a 2-year term. Agreements are evaluated for renewal upon expiration. Bonus provisions are at the discretion of the Company&rsquo;s
Board of Directors and are granted on an individual agreement basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 220; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
31, 2024 and 2023</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
8 &ndash; Commitments and Contingencies, continued</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Executive
Employment Agreements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s standard executive employment agreements have a stated term of six years. Per the agreements, employees are eligible
for a discretionary annual performance bonus, determined by the Board of Directors. If the Company terminates an employee without cause,
the employee is entitled to a pro-rated pay out of the annual performance bonus based on days worked in the fiscal year, severance of
twelve months of the base salary, and automatic vesting of unvested equity grants. If the employee terminates with good reason, as defined
in the employment contract, the employee is entitled to automatic vesting of unvested equity grants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2020, the Company began consistently paying salaries at 50% of the salaries reflected in the respective employment agreements. As of
September 2021, the Company began paying full salaries. Throughout 2022, the Company returned to paying partial salaries and by October
2023 the company stopped paying 100% in an effort to conserve cash. See Note 3 &ndash; Related Party Transactions for details related
to forgiveness of accrued compensation during the year ended December 31, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 18, 2023, various employees agreed to reduce their annual base salary to 20% of their original base salary effective October
1, 2023 until the time the Company raises additional capital from securities in the amount of $1,500,000 (the &ldquo;Reduction Period&rdquo;).
Upon the expiration of the Reduction Period, the bases salaries shall adjust to be 105% of their original base salary as set forth in
their original agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Licensing
and Royalty Agreements - </I>Aquanova AG</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 15, 2016 the Company entered into a Development, Collaboration and License Agreement (&ldquo;License Agreement&rdquo;) with
Aquanova AG, a German company in the field of development, manufacturing and selling of colloidal formulas. The License Agreement resulted
in the creation of the pharmaceutic product, JOTROL. The License Agreement is in effect until product launch, which is undeterminable
at this time. The Chief Scientific Officer of the Company and the CEO of Aquanova are the joint inventors of JOTROL. Aquanova is assignee
on the patents in the United States, the European Union, China and Japan whereas the Company is obligated to maintain the patents. The
agreement grants ownership to the Company for regulatory approvals and the sole and exclusive worldwide right to develop, manufacture
and commercialize all products, including JOTROL. Aquanova is granted the exclusive license to conduct formulation development and manufacturing.
The agreement also defines fees owed to Aquanova for product and formulation development and licensing of the products. The Company is
required to pay Aquanova an annual license fee of $75,000 upon acceptance of the product formulation by both parties, with the license
fee requirement ending in the year of marketing authorization approval (&ldquo;MMA&rdquo;) in a single territory. MMA has not yet been
received as of the period ended March 24, 2024. As of March 31, 2024 and December 31, 2023, $168,750 and $150,000 of accrued license
fees are included in accounts payable and accrued expenses on the balance sheet, respectively. Upon receipt of approval of the MMA in
each territory (e.g United States, European Union, China, Japan), the Company will pay $200,000 to Aquanova per territory an MMA approval
is received, up to a max of $600,000. The Company shall pay Aquanova a royalty of 5% of net sales in each territory through the later
of ten years after the first commercial sale, the first date there is no valid claim within the Aquanova patent rights, or the date of
expiration of the MMA in each territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
mutual agreement, the Company can pay a one-time royalty of $3,000,000 within 180 days of United States marketing approval, with subsequent
royalty payments reduced to 1.25%, in accordance with the terms set forth above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 221; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
31, 2024 and 2023</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
8 &ndash; Commitments and Contingencies, continued</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Murdoch
Children&rsquo;s Research Institute</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 1, 2015 the Company entered into a Global Development and License Agreement (&ldquo;License Agreement II&rdquo;) with Murdoch
Children&rsquo;s Research Institute (&ldquo;MCRI&rdquo;), an Australian Institute at the Royal Children&rsquo;s Hospital in Australia,
with the know-how in the process of using pharmaceutical grade Resveratrol for the treatment of Freidreich&rsquo;s ataxia. The License
Agreement II is for both parties to work jointly to develop an appropriate delivery system and conduct clinical trials for the purpose
of product approval in the treatment of Friedreich&rsquo;s ataxia and worldwide commercialization by the Company. The License Agreement
II grants an exclusive worldwide license to the Company to use the MCRI know-how for developing, manufacturing and commercializing the
product for proposed treatment for Friedreich&rsquo;s ataxia. MCRI is granted an irrevocable, royalty free, worldwide license to use
the product inventions and patent rights for internal research and development. Upon receipt of approval of the MMA in each territory
(e.g United States, European Union, China, Japan), the Company will pay $100,000 to MCRI per each territory up to a maximum of $300,000.
MMA has not yet been received as of March 24, 2024. The Company shall pay MCRI a royalty of 1.5% of net sales in each territory until
the product is no longer sold in the respective territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Research
and Development Service Providers</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the services received under the licensing agreements noted above, a substantial portion of the research and development (&ldquo;R&amp;D&rdquo;)
expense included in the statement of operations is incurred pursuant to short term service and consulting agreements with third party
providers for research, development, testing and manufacturing services. The agreements generally provide termination, at any time by
either party without cause, upon a 30-day written notice, unless otherwise disclosed below. There are no pending milestone payments due
as of March 31, 2024. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
9 &ndash; Subsequent Events</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluated events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the
evaluation and transactions, the Company did not identify any subsequent events that would have required adjustment or disclosure in
the Financial Statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
to March 31, 2024, the Company&rsquo;s CEO loaned the Company an additional $64,000. The loans are due on demand and accrues interest
at 3% per year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Senior
</I></B></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Secured Note &ndash; Formerly Known
as the Convertible Debt II</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 29, 2024, the Company, the Holder of the Note II and the CEO entered into an amendment in which the CEO agrees to exchange 685,867
shares issued to the Holder in exchange for his related party notes that accrued interest at 3% that are due from the Company in an aggregate
principal amount of $266,667 and the Holder agreed to forfeit all rights to all additional future shares from the Company that would
of become due upon a qualified offering as well as the conversion option. In addition, the Holder agreed to extend the note maturity
date to August 11, 2024. The note shall be designated as a 10% original issued discount secured note (&ldquo;Senior Secured Note&rdquo;)
moving forward. The note and interest will become due and payable upon the earliest of the maturity date or upon the occurrence of a
qualified event.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Service
Agreements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 3, 2024, the Company entered into a three 36-month service agreement with three different entities. Upon the closing of these agreements,
the Company issued an aggregate of 3,487,500 shares of common stock, 1,162,500 of shares of common stock for each entity. The shares
issued are free from any restriction as a pre-payment in full for the 36 months of services to be provided. The aforementioned shares
will be registered upon an IPO as long as an IPO happens no later than March 31, 2025. In addition, each of the entities agreed to purchase
37,500 shares each of the Company&rsquo;s common stock at a price of $1.33 per share prior to the occurrence of the IPO. These shares
will also be registered upon an IPO as long as an IPO happens no later than March 31, 2025. Either party is able to terminate the
respective agreement with no liability upon the occurrence of i) the Company failing to raise at least $10 million in gross proceeds
from an IPO prior to May 31, 2025, ii) if either party is involved in any illegal activity or iii) at any time as long as both parties
agree to it.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 222; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>2,750,000</B> <B> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
of</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<IMG SRC="forms-1a_001.jpg" ALT="" STYLE="height: 173px; width: 580px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JUPITER
NEUROSCIENCES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="forms-1a_029.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="background-color: white"><B>REVERE
SECURITIES</B></FONT> <FONT STYLE="background-color: white"><B> LLC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>__________,
2024 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Through and including &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2024 (the 25<SUP>th</SUP> day after the date of this offering), all dealers effecting transactions in these securities, whether
or not participating in this offering, may be required to deliver a prospectus. This is in addition to a dealer&rsquo;s obligation to
deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 223 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <B>[Alternate Page for
Resale Prospectus]&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>The
information in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration
statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities, and
it is not soliciting an offer to buy these securities, in any jurisdiction where the offer or sale is not permitted.</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>PRELIMINARY
    PROSPECTUS</B></FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>SUBJECT
    TO COMPLETION </B></FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>DATED
    <FONT STYLE="text-transform: uppercase">JULY 12, 2024</FONT></B></FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <IMG SRC="forms-1a_001.jpg" ALT=""> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JUPITER
NEUROSCIENCES, INC.</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3,600,000
Shares of</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus relates to 3,600,000 shares of common stock, par value US$0.0001 per share, of Jupiter Neurosciences, Inc. that may be sold
from time to time by the selling stockholders named in this prospectus (the &ldquo;Selling Stockholders&rdquo;) following the closing
of our initial public offering, described in greater detail in the Public Offering Prospectus (defined below).</FONT> </P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will not receive any of the proceeds from the sale of our common stock by the Selling Stockholders.</FONT> </P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
there is currently no public market established for our securities, the Selling Stockholders will sell at a fixed price of $4.00 per
share, the price at which we sell shares in our public offering pursuant to the registration statement of which this prospectus is a
part. Once, and if, our common stock are listed on the Nasdaq Capital Market and there is an established market for these resale shares,
the Selling Stockholders may sell the resale shares from time to time, at the market price prevailing on the Nasdaq Capital Market at
the time of offer and sale, or at prices related to such prevailing market prices or in negotiated transactions or a combination of such
methods of sale directly or through brokers.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have applied to list our shares of common stock on The Nasdaq Capital Market, which we refer to in this prospectus as &ldquo;Nasdaq&rdquo;
or &ldquo;the Nasdaq Capital Market,&rdquo; under the symbol &ldquo;JUNS&rdquo;. The Nasdaq might not approve such application, and if
our application is not approved, the Company&rsquo;s initial public offering cannot be completed and this resale offering will not proceed.</FONT> </P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
resales of shares of common stock covered by this prospectus shall occur until the shares of common stock sold in our initial public
offering begins trading on The Nasdaq Capital Market. The Selling Stockholders may offer and sell the shares of common stock being offered
by this prospectus from time to time in public or private transactions, or both.
These sales will occur at fixed prices, at market prices prevailing at the time of sale, at prices related to prevailing market prices,
or at negotiated prices. The Selling Stockholders may sell shares to or through underwriters, broker-dealers or agents, who may receive
compensation in the form of discounts, concessions or commissions from the selling stockholders, the purchasers of the shares, or both.
Any participating broker-dealers and any Selling Stockholders who are affiliates of broker-dealers may be deemed to be &ldquo;underwriters&rdquo;
within the meaning of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), and any commissions or discounts given
to any such broker-dealer or affiliates of a broker-dealer may be regarded as underwriting commissions or discounts under the Securities
Act. The Selling Stockholders have informed us that they do not have any agreement or understanding, directly or indirectly, with any
person to distribute their shares of common stock. See &ldquo;Plan of Distribution&rdquo; for a more complete description of the ways
in which the common stock may be sold.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
______________, 2024, the registration statement under the Securities Act&nbsp;of&nbsp;1933 containing this prospectus relating to the
resale offering by the Selling Stockholders and a separate prospectus relating to our initial public offering (the &ldquo;Public Offering
Prospectus&rdquo;) was declared effective by the Securities and Exchange Commission (the &ldquo;SEC&rdquo;). On _____________, 2024,
we closed on the initial public offering of ___________ shares of common stock at the public offering price of $____ per share of common
stock under the Public Offering Prospectus through the underwriter named on the cover page of the Public Offering Prospectus. We received
approximately $____ million in net proceeds from the initial public offering after payment of underwriting discounts and commissions
and estimated expenses of the offering.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &ldquo;emerging growth company&rdquo; under the federal securities laws and, as such, we have elected to comply with certain reduced
public company reporting requirements for this prospectus and future filings. See &ldquo;Prospectus Summary&mdash; Implications of Being
an Emerging Growth Company.&rdquo;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
in our common stock involves a high degree of risk. Before buying any shares, you should carefully read the discussion of the material
risks of investing in our common stock under the heading &ldquo;Risk Factors&rdquo; beginning on page 16 of this prospectus.</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
on the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospectus
dated __________, 2024</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>


<!-- Field: Page; Sequence: 224; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[Alternate
Page for Resale Prospectus]&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THE
OFFERING</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock offered by the Selling Stockholders:</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    prospectus relates to 3,600,000 shares of common stock that may be sold from time to time by the selling stockholders named in this
    prospectus</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock outstanding at commencement of the offering<SUP>(1)</SUP>:</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,876,413
    shares of common stock based on the assumed initial public offering price of $4.00 per share, which is the low-end of the anticipated
    public offering price range set forth on the cover page of the initial public offering prospectus filed contemporaneously with this
    prospectus.</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use
    of proceeds:</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will not receive any proceeds from the sales of outstanding shares of common stock by the selling stockholders.</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
    Factors:</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing
    in our common stock involves a high degree of risk. See &ldquo;Risk Factors&rdquo; beginning on page 16 of this prospectus for a
    discussion of some of the factors you should carefully consider before deciding to invest in our common stock.</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    market and symbol:</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have applied to list our common stock on the Nasdaq Capital Market under the symbol &ldquo;JUNS&rdquo;. We believe that upon the
    completion of the Company&rsquo;s initial public offering, we will meet the standards for listing on The Nasdaq Capital Market. The
    closing of the initial public offering is contingent upon the successful listing of our common stock on the Nasdaq Capital Market.
    This resale offering will not proceed unless the initial public offering is closed.</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The number of shares of common stock outstanding at the commencement of the offering assumes the issuance by us of common stock pursuant
to the initial public offering prospectus filed contemporaneously with this prospectus, is based on 32,876,413 shares of common stock
outstanding as of the date of this prospectus or that may be outstanding before the commencement of the initial public offering, and
excludes:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>


<!-- Field: Page; Sequence: 225 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[Alternate
Page for Resale Prospectus]&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>USE
OF PROCEEDS</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will not receive any of the proceeds from the sale of our common stock by the Selling Stockholders. In addition, the Underwriter will
not receive any compensation from the sale of the common stock by the Selling Stockholders. The Selling Stockholders will receive all
of the net proceeds from the sales of the shares of our common stock offered by them pursuant to this prospectus. We have agreed to bear
the expenses relating to the registration of the common stock for the Selling Stockholders.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>


<!-- Field: Page; Sequence: 226 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[Alternate
Page for Resale Prospectus]&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SELLING
STOCKHOLDERS</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 3, 2024, the Company entered into a three 36-month service agreement with three different entities. Upon the closing of these agreements,
the Company issued an aggregate of 3,487,500 shares of common stock, 1,162,500 of shares of common stock for each entity. The shares
issued are free from any restriction as a pre-payment in full for the 36 months of services to be provided. The aforementioned shares
will be registered upon an IPO as long as an IPO happens no later than March 31, 2025. In addition, each of the entities agreed to purchase
37,500 shares each of the Company&rsquo;s common stock at a price of $1.33 per share prior to the occurrence of the IPO. These shares
will also be registered upon an IPO as long as an IPO happens no later than March 31, 2025. Either party is able to terminate the respective
agreement with no liability upon the occurrence of (i) the Company failing to raise at least $10 million in gross proceeds from an IPO
prior to May 31, 2025, (ii) if either party is involved in any illegal activity or (iii) at any time as long as both parties agree to
it. The shares of common stock were issued by the Company to Selling Stockholders under Rule 506(b) of Regulation D promulgated under
the Securities Act or Regulation S promulgated under the Securities Act, as applicable. The shares of common stock being offered by the
Selling Stockholders in this prospectus are those acquired by the Selling Stockholders on June 3, 2024. We are registering the shares
of common stock in order to permit the Selling Stockholders to offer the shares for resale from time to time following the closing of
the initial public offering and listing on the Nasdaq Capital Market. Except for the ownership of these securities or as otherwise disclosed
below, the Selling Stockholders have not had any position, office, or other material relationship with us or any of our predecessors
or affiliates within the past three years, and based on the information provided to us by the Selling Stockholders, no Selling Stockholder
is a broker-dealer or an affiliate of a broker-dealer.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information with respect to the number of shares of common stock beneficially owned by the Selling Stockholders
named below and as adjusted to give effect to the sale of the shares of common stock offered hereby. The table lists the number of shares
of common stock beneficially owned by the Selling Stockholders as of the date of this prospectus, the shares of common stock covered
by this prospectus that may be disposed of by the Selling Stockholders, and the number of shares of common stock that will be beneficially
owned by the Selling Stockholders assuming all of the shares of common stock covered by this prospectus are sold.</FONT> </P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of common stock beneficially owned have been determined in accordance with rules promulgated by the SEC, and the information is
not necessarily indicative of beneficial ownership for any other purpose. The information in the table below is current as of the date
of this prospectus. The Selling Stockholders may from time to time offer and sell pursuant to this prospectus any or all of the shares
of common stock being registered. The Selling Stockholders are under no obligation to sell all or any portion of such shares of common
stock nor are the Selling Stockholders obligated to sell any shares of common stock immediately upon effectiveness of this prospectus.
All information with respect to share ownership has been furnished by the Selling Stockholders.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid"> Name </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Shares Beneficially Owned Prior
    to Offering </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percent
    Beneficially Owned Prior to Offering<SUP>(1)</SUP></B></FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Shares to be Offered </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Amount Beneficially Owned After
    Offering </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percent
    Beneficially Owned After Offering<SUP>(1)</SUP></B></FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; text-align: left; padding-bottom: 1.5pt"> Optimize Wellness Limited </TD><TD STYLE="width: 2%; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"> 1,200,000 </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"> 3.65 </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"> % </TD><TD STYLE="width: 2%; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"> 1,200,000 </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"> % </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Regis Healthcare Group Limited </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 1,200,000 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 3.65 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> % </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 1,200,000 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> % </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Longevity Technology Group Limited </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 1,200,000 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 3.65 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> % </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 1,200,000 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> % </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
less than 1%</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on 32,876,413 shares of common stock issued and outstanding immediately after the completion of the underwritten public offering.
    As noted above, for purposes of computing percentage ownership after this offering, we have assumed that any shares of common stock
    being offered will be sold in this resale offering.</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>


<!-- Field: Page; Sequence: 227 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[Alternate
Page for Resale Prospectus]&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SELLING
SHAREHOLDERS PLAN OF DISTRIBUTION</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
there is currently no public market established for our securities, the Selling Stockholders will sell at a fixed price of $4.00 per
share, the price at which we sell shares in our public offering pursuant to the registration statement of which this prospectus is a
part. Once, and if, our shares of common stock are listed on the Nasdaq Capital Market and there is an established market for these resale
shares, the Selling Stockholders may sell the resale shares from time to time at the market price prevailing on the Nasdaq Capital Market
at the time of offer and sale, or at prices related to such prevailing market prices or in negotiated transactions or a combination of
such methods of sale directly or through brokers.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Selling Stockholder may use any one or more of the following methods when selling securities:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordinary
    brokerage transactions and transactions in which the broker-dealer solicits purchasers;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">block
    trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block
    as principal to facilitate the transaction;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchases
    by a broker-dealer as principal and resale by the broker-dealer for its account;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    exchange distribution in accordance with the rules of the applicable exchange;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">privately
    negotiated transactions;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">settlement
    of short sales;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    transactions through broker-dealers that agree with the Selling Stockholders to sell a specified number of such securities at a stipulated
    price per security;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">through
    the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    combination of any such methods of sale; or</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other method permitted pursuant to applicable law.</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Selling Stockholders may also sell securities under Rule 144 or any other exemption from registration under the Securities Act, if available,
rather than under this prospectus.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Broker-dealers
engaged by the Selling Stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions
or discounts from the Selling Stockholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser)
in amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction not in
excess of a customary brokerage commission in compliance with Rule 2121 of the Financial Industry Regulatory Authority, Inc. (&ldquo;FINRA&rdquo;);
and in the case of a principal transaction a markup or markdown in compliance with FINRA Rule 2121.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the sale of the securities or interests therein, the Selling Stockholders may enter into hedging transactions with broker-dealers
or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they
assume. The Selling Stockholders may also sell securities short and deliver these securities to close out their short positions, or loan
or pledge the securities to broker-dealers that in turn may sell these securities. The Selling Stockholders may also enter into option
or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the
delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer
or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Selling Stockholders and any broker-dealers or agents that are involved in selling the securities may be deemed to be &ldquo;underwriters&rdquo;
within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers
or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts
under the Securities Act. Each Selling Stockholder has informed us that it does not have any written or oral agreement or understanding,
directly or indirectly, with any person to distribute the securities.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are required to pay certain fees and expenses incurred by us incident to the registration of the securities, but we will not receive
any proceeds from the sale of our shares of common stock. We have agreed to indemnify the Selling Stockholders against certain losses,
claims, damages and liabilities, including liabilities under the Securities Act.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
agreed to keep the registration statement of which this prospectus forms a part effective for a period as shall be required to permit
the investors to complete the offer and sale of their shares, unless the shares may be resold pursuant to Rule 144 promulgated under
the Securities Act. The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable
state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered
or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is
complied with.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously
engage in market making activities with respect to the shares of common stock for the applicable restricted period, as defined in Regulation
M promulgated under the Exchange Act, prior to the commencement of the distribution. In addition, the Selling Stockholders will be subject
to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing
of purchases and sales of the shares of common stock by the Selling Stockholders or any other person. We will make copies of this prospectus
available to the Selling Stockholders and have informed them of the need to deliver a copy of this prospectus to each purchaser at or
prior to the time of the sale (including by compliance with Rule 172 under the Securities Act).</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validity of the shares of common stock covered by this prospectus will be passed upon by&nbsp;Anthony, Linder &amp; Cacomanolis, PLLC,
West Palm Beach, Florida.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>


<!-- Field: Page; Sequence: 228 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3,600,000
Shares of</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <IMG SRC="forms-1a_001.jpg" ALT=""> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JUPITER
NEUROSCIENCES, INC.</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2024</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 229 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART
II</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION
NOT REQUIRED IN PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
    13.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
    Expenses of Issuance and Distribution</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth all expenses to be paid by us, other than estimated underwriting discounts and commissions, in connection
with the offer and sale of common stock by us and the Selling Stockholders. All amounts shown are estimates except for the SEC
registration fee, the Nasdaq Capital Market listing fee and the FINRA filing fee:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">Type</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 82%; text-align: left">SEC Registration Fee</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"> 4,686 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">FINRA Filing Fee</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 5,263 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Nasdaq Capital Market Listing Fee</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 50,000 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Legal Fees and Expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 200,000 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Accounting Fees and Expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 120,000 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Accountable Fees </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 175,000 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Non-Accountable Fees </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 110,000 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Transfer Agent and Registrar&rsquo;s Fees and
    Expenses </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Printing and Engraving Expenses </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 10,000 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Miscellaneous Expense </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> 30,051 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total Expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"> 715,000 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
    14.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indemnification
    of Directors and Officers.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
certificate of incorporation provides that all of our directors, officers, employees and agents shall be entitled to be indemnified by
us to the fullest extent permitted by the Delaware General Corporation Law (the &ldquo;DGCL&rdquo;). Section 145 of the DGCL concerning
indemnification of officers, directors, employees and agents is set forth below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
145. Indemnification of officers, directors, employees and agents; insurance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    corporation shall have power to indemnify any person who was or is a party or is threatened to be made a party to any threatened,
    pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by
    or in the right of the corporation) by reason of the fact that the person is or was a director, officer, employee or agent of the
    corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation,
    partnership, joint venture, trust or other enterprise, against expenses (including attorneys&rsquo; fees), judgments, fines and amounts
    paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person
    acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation,
    and, with respect to any criminal action or proceeding, had no reasonable cause to believe the person&rsquo;s conduct was unlawful.
    The termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or
    its equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner which the person
    reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or
    proceeding, had reasonable cause to believe that the person&rsquo;s conduct was unlawful.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    corporation shall have power to indemnify any person who was or is a party or is threatened to be made a party to any threatened,
    pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact
    that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation
    as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses
    (including attorneys&rsquo; fees) actually and reasonably incurred by the person in connection with the defense or settlement of
    such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the
    best interests of the corporation and except that no indemnification shall be made in respect of any claim, issue or matter as to
    which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery
    or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability
    but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which
    the Court of Chancery or such other court shall deem proper.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 230; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    the extent that a present or former director or officer of a corporation has been successful on the merits or otherwise in defense
    of any action, suit or proceeding referred to in subsections (a) and (b) of this section, or in defense of any claim, issue or matter
    therein, such person shall be indemnified against expenses (including attorneys&rsquo; fees) actually and reasonably incurred by
    such person in connection therewith.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    indemnification under subsections (a) and (b) of this section (unless ordered by a court) shall be made by the corporation only as
    authorized in the specific case upon a determination that indemnification of the present or former director, officer, employee or
    agent is proper in the circumstances because the person has met the applicable standard of conduct set forth in subsections (a) and
    (b) of this section. Such determination shall be made, with respect to a person who is a director or officer at the time of such
    determination, (1) by a majority vote of the directors who are not parties to such action, suit or proceeding, even though less than
    a quorum, or (2) by a committee of such directors designated by majority vote of such directors, even though less than a quorum,
    or (3) if there are no such directors, or if such directors so direct, by independent legal counsel in a written opinion, or (4)
    by the stockholders.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses
    (including attorneys&rsquo; fees) incurred by an officer or director in defending any civil, criminal, administrative or investigative
    action, suit or proceeding may be paid by the corporation in advance of the final disposition of such action, suit or proceeding
    upon receipt of an undertaking by or on behalf of such director or officer to repay such amount if it shall ultimately be determined
    that such person is not entitled to be indemnified by the corporation as authorized in this section. Such expenses (including attorneys&rsquo;
    fees) incurred by former officers and directors or other employees and agents may be so paid upon such terms and conditions, if any,
    as the corporation deems appropriate.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    indemnification and advancement of expenses provided by, or granted pursuant to, the other subsections of this section shall not
    be deemed exclusive of any other rights to which those seeking indemnification or advancement of expenses may be entitled under any
    bylaw, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in such person&rsquo;s official
    capacity and as to action in another capacity while holding such office. A right to indemnification or to advancement of expenses
    arising under a provision of the certificate of incorporation or a bylaw shall not be eliminated or impaired by an amendment to such
    provision after the occurrence of the act or omission that is the subject of the civil, criminal, administrative or investigative
    action, suit or proceeding for which indemnification or advancement of expenses is sought, unless the provision in effect at the
    time of such act or omission explicitly authorizes such elimination or impairment after such action or omission has occurred.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    corporation shall have power to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee
    or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of
    another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and
    incurred by such person in any such capacity, or arising out of such person&rsquo;s status as such, whether or not the corporation
    would have the power to indemnify such person against such liability under this section.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    purposes of this section, references to &ldquo;the corporation&rdquo; shall include, in addition to the resulting corporation, any
    constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate
    existence had continued, would have had power and authority to indemnify its directors, officers, and employees or agents, so that
    any person who is or was a director, officer, employee or agent of such constituent corporation, or is or was serving at the request
    of such constituent corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust
    or other enterprise, shall stand in the same position under this section with respect to the resulting or surviving corporation as
    such person would have with respect to such constituent corporation if its separate existence had continued.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 231; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    purposes of this section, references to &ldquo;other enterprises&rdquo; shall include employee benefit plans; references to &ldquo;fines&rdquo;
    shall include any excise taxes assessed on a person with respect to any employee benefit plan; and references to &ldquo;serving at
    the request of the corporation&rdquo; shall include any service as a director, officer, employee or agent of the corporation which
    imposes duties on, or involves services by, such director, officer, employee or agent with respect to an employee benefit plan, its
    participants or beneficiaries; and a person who acted in good faith and in a manner such person reasonably believed to be in the
    interest of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner &ldquo;not opposed
    to the best interests of the corporation&rdquo; as referred to in this section.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    indemnification and advancement of expenses provided by, or granted pursuant to, this section shall, unless otherwise provided when
    authorized or ratified, continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the
    benefit of the heirs, executors and administrators of such a person.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Court of Chancery is hereby vested with exclusive jurisdiction to hear and determine all actions for advancement of expenses or indemnification
    brought under this section or under any by law, agreement, vote of stockholders or disinterested directors, or otherwise. The Court
    of Chancery may summarily determine a corporation&rsquo;s obligation to advance expenses (including attorneys&rsquo; fees).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
certificate of incorporation also permit us to maintain insurance on behalf of any officer, director or employee for any liability arising
out of his or her actions, regardless of whether Delaware law would permit such indemnification. We have purchased a policy of directors&rsquo;
and officers&rsquo; liability insurance that insures our officers and directors against the cost of defense, settlement or payment of
a judgment in some circumstances and insures us against our obligations to indemnify our officers and directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
provisions may discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. These provisions
also may have the effect of reducing the likelihood of derivative litigation against officers and directors, even though such an action,
if successful, might otherwise benefit us and our stockholders. Furthermore, a stockholder&rsquo;s investment may be adversely affected
to the extent we pay the costs of settlement and damage awards against officers and directors pursuant to these indemnification provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
repeal or amendment of provisions of our certificate of incorporation affecting indemnification rights, whether by our board of directors,
stockholders or by changes in applicable law, or the adoption of any other provisions inconsistent therewith, will (unless otherwise
required by law) be prospective only, except to the extent such amendment or change in law permits us to provide broader indemnification
rights on a retroactive basis, and will not in any way diminish or adversely affect any right or protection existing thereunder with
respect to any act or omission occurring prior to such repeal or amendment or adoption of such inconsistent provision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">also intends to enter into indemnification agreements with its future directors and executive officers. The registrant has
purchased directors&rsquo; and officers&rsquo; liability insurance. The registrant believes that this insurance is necessary to attract
and retain qualified directors and officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons
pursuant to the foregoing provisions, or otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against
public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against
such liabilities (other than the payment of expenses incurred or paid by a director, officer or controlling person in a successful defense
of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being
registered, we will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to the court of
appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act
and will be governed by the final adjudication of such issue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 232; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
    15.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recent
    Sales of Unregistered Securities.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of transactions by us since inception (January 1, 2016) involving registered and unregistered issuances and redemption
of our common equity securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"> Name </TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Date </TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Type </TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"> Type of Award </TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Quantity </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Price </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"> Additional </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; text-align: left"> Christer Ros&eacute;n, our Chief Executive Officer </TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center"> January 01, 2016 </TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: center"> Issued </TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: left"> Common Stock </TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right"> 11,250,000 </TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 6%; text-align: right"> 53.33 </TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 9%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Christer Ros&eacute;n, our Chief Executive Officer </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> January 01, 2016 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Incentive Stock Option; Common Stock </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 225,000 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.01 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Alexander Ros&eacute;n, our Chief Administrative Officer </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> January 01, 2016 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Incentive Stock Option; Common Stock </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 56,250 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.01 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Dr. Claes Wahlestedt, MD, Ph.D., a member of our Science Advisory Board </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> January 01, 2016 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 225,000 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.01 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Claude Volmar, a consultant </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> January 01, 2016 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 56,250 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.01 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Ian Baker-Finch., a consultant </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> January 01, 2016 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 168,750 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.01 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Jacob Uittenbogaard, our former Chief Financial Officer </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> January 01, 2016 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Incentive Stock Option; Common Stock </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 225,000 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.01 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Marshall Hayward, Ph.D., our Chief Scientific Officer </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> January 01, 2016 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Incentive Stock Option; Common Stock </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 225,000 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.01 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Peter Colabuono, a consultant </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> January 01, 2016 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 112,500 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.01 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Thomas Liquard, a consultant </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> January 01, 2016 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Granted </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 112,500 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.01 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> The shares were subsequently forefeited on January 1, 2016 </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Dr. Claes Wahlestedt, MD, Ph.D., a member of our Science Advisory Board </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> January 04, 2016 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Issued </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 2,757,352 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 13.07 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Jacob Uittenbogaard, our former Chief Financial Officer </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> January 04, 2016 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Issued </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 551,471 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 2.67 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Marshall Hayward, Ph.D., our Chief Scientific Officer </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> January 04, 2016 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Issued </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 2,205,885 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 10.40 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Shaun P. Brothers, Ph.D., a member of our Science Advisory Board </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> January 04, 2016 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"> Issued </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 1,541,914 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 7.73 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 233; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold"> Name </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Date </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Type </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold"> Type of Award </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"> Quantity </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"> Price </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold"> Additional </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 13%; text-align: left"> David Sinclair, an advisor </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 14%; text-align: center"> April 06, 2016 </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 10%; text-align: center"> Granted </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 13%; text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 10%; text-align: right"> 225,000 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 10%; text-align: right"> 0.01 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 14%"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Li-Huei Tsai, a member of our Science Advisory Board </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> June 01, 2016 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 135,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Raymond Scott Turner, MD, Ph.D., a member of our Science Advisory Board </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> August 01, 2016 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 135,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Gene Spotlight, Inc. </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> September 30, 2016 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 312,502 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Peter Elliott, Ph.D., a member of our Science Advisory Board </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> October 17, 2016 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 135,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Gene Spotlight, Inc. </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> October 17, 2016 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 125,002 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Natalie McNamee, a consultant </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> December 19, 2016 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 225,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Gene Spotlight, Inc. </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> January 25, 2017 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 187,500 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Ulf Wiinberg, an advisor </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> January 27, 2017 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 187,500 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Ulf Wiinberg, an advisor </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> January 31, 2017 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 135,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Robert Roath, an advisor </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> November 17, 2017 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 135,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Gene Spotlight, Inc. </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> December 21, 2017 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 112,500 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Gino Cortopassi, an advisor </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> February 14, 2018 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 135,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Christer Ros&eacute;n, our Chief Executive Officer </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> May 08, 2018 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 225,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.01 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Upon an exercise of an incentive stock option </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Alexander Ros&eacute;n, our Chief Administrative Officer </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> May 08, 2018 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 56,250 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.01 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Upon an exercise of an incentive stock option </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Jacob Uittenbogaard, our former Chief Financial Officer </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> May 09, 2018 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 225,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.01 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Upon an exercise of an incentive stock option </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Robert Roath </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> June 01, 2018 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 157,083 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.64 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Upon his conversion of a promissory note </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Robert Roath </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> June 20, 2018 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 135,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Upon an exercise of a non-qualified stock option </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Frank Behnam, an advisor </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> October 01, 2018 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 84,375 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Michio Harano, an advisor </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> October 01, 2018 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 84,375 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Robert Roath, an advisor </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> October 01, 2018 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 84,375 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Ulf Wiinberg, an advisor </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> October 01, 2018 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 84,375 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Alison Silva, our President and Chief Business Officer </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> December 13, 2018 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Incentive Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 225,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> John Ditton, an advisor </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> December 13, 2018 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Incentive Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 135,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Such stock options were forfeited on January 15, 2022 (90 days following his resignation as a director
    of the Company) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Alexander Ros&eacute;n, our Chief Administrative Officer </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> January 24, 2019 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Incentive Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 569,775 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.74 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Christer Ros&eacute;n, our Chief Executive Officer </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> January 24, 2019 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Incentive Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 811,811 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.74 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Dr. Claes Wahlestedt, MD, Ph.D., a member of our Science Advisory Board </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> January 24, 2019 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 84,937 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.74 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Jacob Uittenbogaard, our former Chief Financial Officer </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> January 24, 2019 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Incentive Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 113,598 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.74 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Shaun Brothers, a member of our Science Advisory Board </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> January 24, 2019 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 77,441 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.74 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> David Sinclair, an advisor </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> May 15, 2019 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Forfeited </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 225,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.01 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Peter Colabuono, a consultant </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> September 09, 2019 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Forfeited </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 112,500 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.01 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Michio Harano, an advisor </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> October 01, 2018 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Forfeited </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 84,375 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Gino Cortopassi, an advisor </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> October 17, 2019 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Forfeited </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 135,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Natalie McNamee, a consultant </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> October 24, 2019 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Forfeited </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 225,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Dr. Rudolph Tanzi, a member of our Science Advisory Board </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> November 06, 2019 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 225,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Alalia Pty Ltd ATF McNamee Family Trust </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> December 19, 2019 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Warrant; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,249,998 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Alexander Ros&eacute;n, our Chief Administrative Officer </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> February 01, 2020 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Incentive Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 168,750 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Christer Ros&eacute;n, our Chief Executive Officer </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> February 01, 2020 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Incentive Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 506,250 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Dr. Claes Wahlestedt, MD, Ph.D., a member of our Science Advisory Board </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> February 01, 2020 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 135,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Claude Volmar, a consultant </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> February 01, 2020 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 67,500 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Jacob Uittenbogaard, our former Chief Financial Officer </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> February 01, 2020 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 168,750 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Li-Huei Tsai, Ph.D., a member of our Science Advisory Board </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> February 01, 2020 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Incentive Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 67,500 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Marshall Hayward, Ph.D., our Chief Scientific Officer </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> February 01, 2020 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 393,750 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Raymond Scott Turner, MD, Ph.D., a member of our Science Advisory Board </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> February 01, 2020 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 135,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Charbel Moussa, MBBS, Ph.D., a member of our Science Advisory Board </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> April 21, 2020 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 90,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 234; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> Name </TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Date </TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Type </TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"> Type of Award </TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; text-align: center"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Quantity </TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Price </TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"> Additional </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 11%; text-align: left"> Mark Dant, an advisor </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 11%; text-align: center"> April 21, 2020 </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 11%; text-align: center"> Granted </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 11%; text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> &nbsp; </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 90,000 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 8%; text-align: right"> 0.80 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 10%"> &nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Robert Roath </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> May 19, 2020 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 126,251 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Upon his conversion of a promissory note </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Joel Norman Goldberg Trust #1, Dated 04/15/2003 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> June 23, 2020 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 156,251 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Joel Norman Goldberg Trust #1, Dated 04/15/2003 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> June 23, 2020 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Warrant; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 234,375 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Andrew C. Matthiesen Trust, Dated 12/03/1998 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> June 23, 2020 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 156,251 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Andrew C. Matthiesen Trust, Dated 12/03/1998 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> June 23, 2020 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Warrant; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 234,375 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Joel Norman Goldberg Trust #1, Dated 04/15/2003 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> June 23, 2020 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 78,123 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> For services rendered by Joel Norman Goldberg to the Company </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Andrew C. Matthiesen Trust, Dated 12/03/1998 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> June 23, 2020 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 78,123 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> For services rendered by Andrew C. Matthiesen to the Company </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Dencam Living Trust </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> June 29, 2020 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 156,251 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Dencam Living Trust </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> June 29, 2020 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Warrant; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 234,375 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Dencam Living Trust </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> June 29, 2020 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 78,123 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> For services rendered by Robert Faerber to the Company </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> WKJP, LLC </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> July 15, 2020 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 156,251 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> WKJP, LLC </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> July 15, 2020 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Warrant; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 234,375 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> WKJP, LLC </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> July 15, 2020 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 78,123 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> For services rendered by Jeffery W. Krol to the Company </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Joel Norman Goldberg Trust #1, Dated 04/15/2003 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> August 20, 2020 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 669,645 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.15 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Dencam Living Trust </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> August 20, 2020 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 167,411 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.15 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> WKJP, LLC </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> August 20, 2020 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 502,233 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.15 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Arthur Kirsch, a consultant </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> October 01, 2020 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 150,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Gene Spotlight, Inc. </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> December 29, 2020 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 375,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Gene Spotlight, Inc. </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> December 29, 2020 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Warrant; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 75,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Robert S. Roath Revocable Trust </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> February 19, 2021 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 11,373 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Upon his conversion of a promissory note </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Dana Eschenburg Perez, our former Chief Financial Officer </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> March 01, 2021 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Incentive Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 135,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Robert S. Roath </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> March 05, 2021 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 84,375 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Upon an exercise of a non-qualified stock option </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Alexander Ros&eacute;n, our Chief Administrative Officer </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> June 01, 2021 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Incentive Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 168,750 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 2.16 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Dana Eschenburg Perez, our former Chief Financial Officer </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> June 01, 2021 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Incentive Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 193,125 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 2.16 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Tiberend Strategic Advisors, a consultant </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> June 15, 2021 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 56,250 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 2.16 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> W. Dalton Deitrich III, an advisor </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> June 22, 2021 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 67,500 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 2.16 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Dencam Living Trust </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> August 30, 2021 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 234,375 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Upon the exercise of a warrant </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Alison Silva, our President and Chief Business Officer </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> September 01, 2021 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Incentive Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 281,250 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 2.16 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Gene Spotlight, Inc. </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> September 09, 2021 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 75,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Upon the exercise of a warrant </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Joel Norman Goldberg Trust #1, Dated 04/15/2003 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> September 28, 2021 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 234,375 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Upon the exercise of a warrant </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> WKJP, LLC </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> September 29, 2021 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 234,375 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Upon the exercise of a warrant </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Andrew C. Matthiesen Trust, Dated 12/03/1998 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> September 30, 2021 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 234,375 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Upon the exercise of a warrant </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Nicholas Hemmerly, a member of our Board of Directors </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> October 01, 2021 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 67,500 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 2.16 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Allison W. Brady, a member of our Board of Directors </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> October 01, 2021 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 67,500 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 2.16 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Julie Kampf, a member of our Board of Directors </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> October 01, 2021 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 67,500 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 2.16 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> John Ditton, an advisor </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> October 01, 2021 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 67,500 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 2.16 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Such stock options were forfeited on January 15, 2022 (90 days following his resignation as a director
    of the Company) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Holger Weis, a member of our Board of Directors </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> October 01, 2021 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 67,500 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 2.16 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Arthur Kirsch, a consultant </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> October 01, 2021 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 12,500 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 46,875 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 2.16 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Frank Behnam, CEO of Aquanova AG </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> December 01, 2021 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Cancelled </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 84,375 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> Issued on October 2018 </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Aquanova AG </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> December 01, 2021 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 84,375 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 2.16 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Pursuant to the terms of the Debt Forgiveness and Exchange Agreement. subject to vesting terms set
    forth in the non-qualified stock option </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> An accredited investor </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> April 11, 2022 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 514,403 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 2.16 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> In connection with the issuance of a senior secured convertible note with a principal amount of $1,111,111
    to an accredited investor; as additional consideration to the investor for lending $1,000,000 to the Company </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> June 1, 2021 Option Grant to Alexander Ros&eacute;n, our Chief Administrative Officer </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> July 14, 2022 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Amendment </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Incentive Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 168,750 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> June 1, 2021 Option Grant to Dana Eschenburg Perez, our former Chief Financial Officer </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> July 14, 2022 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Amendment </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Incentive Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 193,125 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> August 1, 2021 Option Grant to Dana Eschenburg Perez, our former Chief Financial Officer </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> July 14, 2022 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Amendment </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Incentive Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 193,125 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> June 22, 2021 Option Grant to W. Dalton Dietrich III, an advisor </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> July 14, 2022 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Amendment </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 67,500 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> September 1, 2021 Option Grant to Alison D. Silva, our President and Chief Business Officer </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> July 14, 2022 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Amendment </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Incentive Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 281,250 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 235; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid"> Name </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Date </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Type </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Type of Award </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Quantity </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Price </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Additional </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 15%; text-align: left"> Christer Ros&eacute;n, our Chief Executive Officer </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 10%; text-align: center"> July 21, 2022 </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 10%; text-align: center"> Issued </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 13%; text-align: left"> Restricted stock </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 10%; text-align: right"> 476,070 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 10%; text-align: right"> 1.33 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 16%; text-align: left"> The restricted stock award was issued in exchange for forgiveness of $634,760 of accrued
    compensation </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Marshall Hayward, our Chief Scientific Officer </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> July 21, 2022 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Restricted stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 399,401 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> The restricted stock award was issued in exchange for forgiveness of $532,535 of accrued compensation </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Jacob Uittenbogaard, our former Chief Financial Officer </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> July 21, 2022 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Restricted stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 93,367 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> The restricted stock award was issued in exchange for forgiveness of $124,490 of accrued compensation </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Alexander Ros&eacute;n, our Chief Administrative Officer </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> July 21, 2022 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Restricted stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 96,607 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> The restricted stock award was issued in exchange for forgiveness of $128,810 of accrued compensation </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Dana Eschenburg Perez, our former Chief Financial Officer </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> July 21, 2022 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Restricted stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 10,125 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> The restricted stock award was issued in exchange for forgiveness of $13,500 of accrued compensation </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Claes Wahlestedt, MD, Ph.D., a member of our Science Advisory Board </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> July 21, 2022 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Restricted stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 46,620 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> The restricted stock award was issued in exchange for forgiveness of $62,160 of accrued compensation </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Shaun Brothers, a member of our Science Advisory Board </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> July 21, 2022 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Restricted stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 44,820 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> The restricted stock award was issued in exchange for forgiveness of $59,760 of accrued compensation </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> October 1, 2021 Option Grant to Nicholas Hemmerly, a member of our Board of Directors </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> July 25, 2022 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Amendment </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 67,500 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> October 1, 2021 Option Grant to Allison W. Brady, a member of our Board of Directors </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> July 25, 2022 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Amendment </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 67,500 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> October 1, 2021 Option Grant to Julie Kampf, a member of our Board of Directors </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> July 25, 2022 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Amendment </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 67,500 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> October 1, 2021 Option Grant to Holger Weis, a member of our Board of Directors </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> July 25, 2022 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Amendment </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 67,500 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> October 1, 2021 Option Grant to Arthur Kirsch, a consultant </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> July 25, 2022 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Amendment </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 46,875 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> December 1, 2021 Option Grant to Aquanova AG </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> August 01, 2022 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Amendment </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 193,125 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Senior secured note investor </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> October 10, 2022 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 42,867 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 2.16 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> For consideration of an amendment to postpone the amortization of principle and interest one month
    to November 11, 2022 </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Senior secured note investor </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> November 10, 2022 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 128,598 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 2.16 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> For consideration of an amendment to postpone the amortization of principle and interest three months
    to February 11, 2023 </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Saleem Elmasri, CPA, our Chief Financial Officer </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> January 01, 2023 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 562,500 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> An employee and consultants </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> April 01, 2023 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 562,500 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Various employees and executives as part of their accrued compensation forgiveness </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> September 29, 2023 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2,353,777 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Christer Ros&eacute;n, our Chief Executive Officer </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> November 13, 2023 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 113,637 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.88 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Upon an exercise of an incentive stock option </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Various employees and executives as part of their accrued compensation forgiveness </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> December 18, 2023 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Restricted Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,618,545 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Various employees and executives as part of their accrued compensation forgiveness </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> December 18, 2023 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 289,296 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> A consultant </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> January 24, 2024 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 180,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Dana Eschenburg Perez, our former Chief Financial Officer </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> March 15, 2024 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Restricted Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 7,500 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Dana Eschenburg Perez, our former Chief Financial Officer </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> March 15, 2024 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 49,605 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> A consultant </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> April 17, 2024 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Non-qualified Stock Option; Common Stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 67,500 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.33 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
above issuances/sales were made pursuant to an exemption from registration as set forth in Section 4(a)(2) of the Securities Act and/or
Rule 506 of Regulation D promulgated under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
    16.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibits
    and Financial Statement Schedules</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Exhibits.
    </I>The list of exhibits preceding the signature page of this registration statement is incorporated herein by reference.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 236; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Financial
    Statements.</I> See page F-1 for an index to the financial statements and schedules included in the registration statement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
    17.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Undertakings</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar
as indemnification for liabilities arising under the Securities Act &ldquo;may be permitted to directors, officers and controlling persons
of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC
such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that
a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director,
officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director,
officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel
the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rule
    415 Offering. The undersigned registrant hereby undertakes:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent
    post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set
    forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if
    the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end
    of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b)
    if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set
    forth in the &ldquo;Calculation of Registration Fee&rdquo; table in the effective registration statement.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    include any material information with respect to the plan of distribution not previously disclosed in the registration statement
    or any material change to such information in the registration statement;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That,
    for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed
    to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall
    be deemed to be the initial bona fide offering thereof.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
    termination of the offering.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    undersigned Registrant hereby undertakes that it will:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for
    determining any liability under the Securities Act of 1933, treat the information omitted from the form of prospectus filed as part
    of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant under Rule
    424(b)(1), or (4) or 497(h) under the Securities Act of 1933 as part of this registration statement as of the time the Commission
    declared it effective.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for
    determining any liability under the Securities Act of 1933, treat each post-effective amendment that contains a form of prospectus
    as a new registration statement for the securities offered in the registration statement, and that offering of the securities at
    that time as the initial bona fide offering of those securities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">That, for the purpose of determining liability
under the Securities Act of 1933 to any purchaser, if the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule
424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other
than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the
date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is
part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement
or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first
use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement
or made in any such document immediately prior to such date of first use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 237; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
INDEX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit<BR>
    No.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="ex1-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Underwriting Agreement*</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex3-1.htm" STYLE="-sec-extract: exhibit">Certificate of Incorporation of the Company dated December 30, 2015**</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex3-2.htm" STYLE="-sec-extract: exhibit">Certificate of Validation of the Company dated July 9, 2021 (including Certificate of Amendment to Certificate of Incorporation of the Company)**</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex3-3.htm" STYLE="-sec-extract: exhibit">Certificate of Amendment to Certificate of Incorporation of the Company dated August 30, 2021**</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.4</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1679628/000149315221031850/ex3-4.htm" STYLE="-sec-extract: exhibit">Certificate of Amendment to Certificate of Incorporation of the Company dated November 19, 2021**</A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.5</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1679628/000149315222002313/ex3-5.htm" STYLE="-sec-extract: exhibit">Certificate of Amendment to Certificate of Incorporation of the Company dated January 25, 2022**</A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 3.6 </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <A HREF="ex3-6.htm">Certificate of Amendment to Certificate of Incorporation of the Company dated June 14, 2024*</A> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex3-4.htm" STYLE="-sec-extract: exhibit">Amended and Restated Bylaws**</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="ex5-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Anthony, Linder &amp; Cacomanolis, PLLC*</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex10-1.htm" STYLE="-sec-extract: exhibit">Jupiter Orphan Therapeutics, Inc. 2021 Equity Incentive Plan**&dagger;</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex10-2.htm" STYLE="-sec-extract: exhibit">Employment Agreement, dated as of September 1, 2021, between the Company and Christer Ros&eacute;n **&dagger;</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex10-3.htm" STYLE="-sec-extract: exhibit">Amendment No. 1 to Executive Employment Agreement, dated as of September 29, 2021, between the Company and Christer Ros&eacute;n **&dagger;</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex10-4.htm" STYLE="-sec-extract: exhibit">Employment Agreement, dated as of September 1, 2021, between the Company and Marshall Hayward, Ph.D. **&dagger;</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex10-5.htm" STYLE="-sec-extract: exhibit">Amendment No. 1 to Executive Employment Agreement, dated as of September 29, 2021, between the Company and Marshall Hayward, Ph.D. **&dagger;</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex10-6.htm" STYLE="-sec-extract: exhibit">Employment Agreement, dated as of June 6, 2021, between the Company and Alexander Ros&eacute;n **&dagger;</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex10-7.htm" STYLE="-sec-extract: exhibit">Amendment No. 1 to Executive Employment Agreement, dated as of September 29, 2021, between the Company and Alexander Ros&eacute;n **&dagger;</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex10-8.htm" STYLE="-sec-extract: exhibit">Employment Agreement, dated as of September 1, 2021, between the Company and Alison Silva**&dagger;</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex10-9.htm" STYLE="-sec-extract: exhibit">Amendment No. 1 to Executive Employment Agreement, dated as of September 29, 2021, between the Company and Alison D. Silva **&dagger;</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex10-10.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment
    Agreement, dated as of June 1, 2021, between the Company and Dana Eschenburg Perez **&dagger;</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex10-11.htm" STYLE="-sec-extract: exhibit">Amendment No. 1 to Executive Employment Agreement, dated as of September 29, 2021, between the Company and Dana Eschenburg Perez **&dagger;</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex10-12.htm" STYLE="-sec-extract: exhibit">Independent Director Agreement, dated as of September 8, 2021, between the Company and Nicholas H. Hemmerly**&dagger;</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex10-13.htm" STYLE="-sec-extract: exhibit">Independent Director Agreement, dated as of September 8, 2021, between the Company and Julie Kampf **&dagger;</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex10-14.htm" STYLE="-sec-extract: exhibit">Independent Director Agreement, dated as of September 8, 2021 between the Company and Allison W. Brady **&dagger;</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex10-15.htm" STYLE="-sec-extract: exhibit">Independent Director Agreement, dated as of September 8, 2021, between the Company and Holger Weis **&dagger;</A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1679628/000149315221027617/ex10-16.htm" STYLE="-sec-extract: exhibit">License Agreement with Aquanova AG.**</A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10.17</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1679628/000149315221027617/ex10-17.htm" STYLE="-sec-extract: exhibit">Grant Agreement between Company and National Institute on Aging.**</A><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10.18</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1679628/000149315221027617/ex10-18.htm" STYLE="-sec-extract: exhibit">Agreement between Company and Murdoch Children&rsquo;s Research Institute.**</A><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10.19</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1679628/000149315221027617/ex10-19.htm" STYLE="-sec-extract: exhibit">Manufacturing Agreement between Company and Catalent.**</A><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10.20</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1679628/000149315221027617/ex10-20.htm" STYLE="-sec-extract: exhibit">Agreement between the Company and Syneos Health.**</A><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10.21</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1679628/000149315221027617/ex10-21.htm" STYLE="-sec-extract: exhibit">Material Transfer Agreement between the Company and University of Miami.**</A><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10.22</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1679628/000149315221027617/ex10-22.htm" STYLE="-sec-extract: exhibit">Services Agreement between the Company and Technical Resources International, Inc.**</A><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>
</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10.23</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1679628/000149315221027617/ex10-23.htm" STYLE="-sec-extract: exhibit">Amendment to Services Agreement between the Company and Technical Resources International, Inc.**</A><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10.24</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1679628/000149315221031850/ex10-24.htm" STYLE="-sec-extract: exhibit">Debt Forgiveness and Exchange Agreement, dated as of December 1, 2021, between the Company and Aquanova AG.**</A></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">10.25</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1679628/000149315222011151/ex10-25.htm" STYLE="-sec-extract: exhibit">Securities Purchase Agreement, dated April 11, 2022, between the Company and Puritan Partners LLC**</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">10.26</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1679628/000149315222011151/ex10-26.htm" STYLE="-sec-extract: exhibit">Senior Secured Convertible Promissory Note, dated as of April 11, 2022, issued by the Company in favor of Puritan Partners LLC**</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">10.27</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1679628/000149315222011151/ex10-27.htm" STYLE="-sec-extract: exhibit">Security Agreement, dated April 11, 2022, between the Company and Puritan Partners LLC**</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">10.28</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1679628/000149315222011151/ex10-28.htm" STYLE="-sec-extract: exhibit">Intellectual Property Security Agreement, dated April 11, 2022, between the Company and Puritan Partners LLC**</A></FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> 10.29 </P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1679628/000149315222024119/ex10-30.htm" STYLE="-sec-extract: exhibit">Research Agreement, dated July 1, 2022, between the Company and University of Miami**</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 10.30 </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1679628/000149315222034319/ex10-31.htm" STYLE="-sec-extract: exhibit">Amendment to the Securities Purchase Agreement, dated as of October 10, 2022, between the Company and Puritan Partners LLC**</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 10.31 </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1679628/000149315222034319/ex10-32.htm" STYLE="-sec-extract: exhibit">Second Amendment to the Securities Purchase Agreement, dated as of November 10, 2022, between the Company and Puritan Partners LLC**</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 10.32 </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1679628/000149315223000795/ex10-33.htm" STYLE="-sec-extract: exhibit">Master Services Agreement, dated as of December 27, 2022, between the Company and Titan Advisory Services**&dagger;</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 10.33 </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1679628/000149315223000795/ex10-34.htm" STYLE="-sec-extract: exhibit">Peer Review Summary Statement of FA Grant Application**</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 10.34 </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1679628/000149315223001540/ex10-35.htm" STYLE="-sec-extract: exhibit"> Third Amendment to the Securities Purchase Agreement, dated as of January 13, 2013, between the Company and Puritan Partners LLC*<FONT STYLE="font-family: Times New Roman, Times, Serif">*</FONT> </A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10.35</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"> <A HREF="ex10-35.htm">CRO Services Agreement, dated June 3, 2024, between the Company and Optimize Wellness Limited*</A> </P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10.36</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <A HREF="ex10-36.htm">Regulatory Services Agreement, dated June 3, 2024, between the Company and Regis Healthcare Group Limited*</A> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10.37</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <A HREF="ex10-37.htm">Product Services Agreement, dated June 3, 2024, between the Company and Longevity Technology Group Limited*</A> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10.38</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <A HREF="ex10-38.htm">Scientific Review of Alzheimer&rsquo;s Phase II Trial Grant Application</A> </TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.39</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex10-39.htm">Form of Strategic Services Agreement between the Company and Dominant Treasure Health Company Limited</A></FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.40</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex10-40.htm">Jupiter Neurosciences, Inc. 2023 Equity Incentive Plan*&dagger;</A></FONT> </TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="ex23-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Assurance Dimensions*</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex5-1.htm">Consent
    of Anthony, Linder &amp; Cacomanolis, PLLC (included on Exhibit 5.1) *</A></FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/forms-1.htm#poa_001" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power of Attorney (included on the signature page of the Form S-1 filed on October 12, 2021) **</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">107</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="ex107.htm">Filing Fee Table*</A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Filed herewith</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**Previously
filed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&dagger;
Includes management contracts and compensation plans and arrangements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 238; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="ja_001"></A><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Act of 1933, as amended, the registrant has duly caused this Pre-Effective Amendment No. 18 to Registration
Statement on Form S-1 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Jupiter, Florida, on July
12, 2024. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JUPITER
    NEUROSCIENCES, INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Christer Ros&eacute;n</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christer
    Ros&eacute;n</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
                                            Executive Officer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(principal
    executive officer)</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="arz_001"></A></FONT>Pursuant
to the requirements of the Securities Act, this Pre-Effective Amendment No. 18 to Registration Statement on Form S-1 has been
signed by the following persons in the capacities held on July 12, 2024. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 28%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Position</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Date</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><I>/s/ Christer Ros&eacute;n</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Chairman of the Board, Chief Executive Officer, </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> July 12, 2024 </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Christer Ros&eacute;n</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">and Director (Principal Executive Officer)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><I>/s/ Saleem Elmasri</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Chief Financial Officer and Secretary</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> July 12, 2024 </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Saleem Elmasri, CPA</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Chief Scientific Officer and Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> July 12, 2024 </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Marshall Hayward, Ph.D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">President, Chief Business Officer and Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> July 12, 2024 </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Alison D. Silva</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Independent Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> July 12, 2024 </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Nicholas H. Hemmerly</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Independent Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> July 12, 2024 </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Julie Kampf</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Independent Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> July 12, 2024 </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Allison W. Brady</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Independent Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> July 12, 2024 </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">Holger Weis</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-size: 10pt"><I>/s/ Christer Ros&eacute;n</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt">Christer Ros&eacute;n</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt">Attorney-in-fact*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 239; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



































































































</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ex1-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
1.1</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JUPITER
NEUROSCIENCES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[&#9679;]
SHARES OF COMMON STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNDERWRITING
AGREEMENT</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[________],
2024 </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REVERE
</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECURITIES LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> 560 Lexington Ave., 16<SUP>th</SUP> Floor </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10022 </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
the representative of the several underwriters, if any,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">named
in <U>Schedule I</U> hereto</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned, Jupiter Neurosciences, Inc., a company incorporated under the laws of Delaware (collectively with its subsidiaries, including,
without limitation, all entities disclosed or described in the Registration Statement as being subsidiaries of Jupiter Neurosciences,
Inc., the &ldquo;<U>Company</U>&rdquo;), hereby confirms its agreement (this &ldquo;<U>Agreement</U>&rdquo;) with the several underwriters
(such underwriters, including the Representative (as defined below), the &ldquo;<U>Underwriters</U>&rdquo; and each an &ldquo;<U>Underwriter</U>&rdquo;)
named in <U>Schedule I</U> hereto for which Revere Securities LLC is acting as representative to the several Underwriters (the
&ldquo;<U>Representative</U>&rdquo; and if there are no Underwriters other than the Representative, references to multiple Underwriters
shall be disregarded and the term Representative as used herein shall have the same meaning as &ldquo;Underwriter&rdquo;) on the terms
and conditions set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is understood that the several Underwriters are to make a public offering of the Public Securities as soon as the Representative deems
it advisable to do so. The Public Securities are to be initially offered to the public at the public offering price set forth in the
Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is further understood that you will act as the Representative for the Underwriters in the offering and sale of the Closing Shares in
accordance with this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
I.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DEFINITIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1
<U>Definitions</U>. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms
have the meanings set forth in this Section 1.1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(k).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means with respect to any Person, any other Person that, directly or indirectly through one or more intermediaries, controls or is controlled
by or is under common control with such Person as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>AFS</U>&rdquo;
means ArentFox Schiff LLP with offices located at 1717 K Street NW, Washington, DC 20006.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally
are open for use by customers on such day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Closing Shares pursuant to Section 2.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing
Date</U>&rdquo; means the hour and the date on the Trading Day on which all conditions precedent to (i) the Underwriters&rsquo; obligations
to pay the Closing Purchase Price and (ii) the Company&rsquo;s obligations to deliver the Closing Shares, in each case, have been satisfied
or waived, but in no event later than 10:00 a.m. (New York City time) on the second (2<SUP>nd</SUP>) Trading Day following the date hereof
or at such earlier time as shall be agreed upon by the Representative and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing
Purchase Price</U>&rdquo; shall have the meaning ascribed to such term in Section 2.1(b), which aggregate purchase price shall be net
of the underwriting discounts and commissions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing
Shares</U>&rdquo; shall have the meaning ascribed to such term in Section 2.1(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Company
Auditor</U>&rdquo; means Assurance Dimensions Certified Public Accountants &amp; Associates, with offices located at 2000 Banks Road,
Suite 218, Margate, FL 33063.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Company
Counsel</U>&rdquo; means Anthony L.G., PLLC, with offices located at 625 N. Flagler Drive, Suite 600, West Palm Beach, Florida 33401.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Effective
Date</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(f).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Execution
Date</U>&rdquo; shall mean the date on which the parties execute and enter into this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exempt
Issuance</U>&rdquo; means the issuance of (a) shares of Common Stock or options to employees, officers or directors of the Company pursuant
to any stock or option plan duly adopted or ratified for such purpose by a majority of the non-employee members of the Board of Directors
or a majority of the members of a committee of non-employee directors established for such purpose for services rendered to the Company;
(b) the filing of any registration statement on Form S-8 with respect to the registration of securities to be issued pursuant to any
stock or option plan described in clause (a), and (c) securities issued for conversion of any debt of the Company outstanding on the
date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FINRA</U>&rdquo;
means the Financial Industry Regulatory Authority, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(i).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Indebtedness</U>&rdquo;
means (a) any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the
ordinary course of business), (b) all guaranties, endorsements and other contingent obligations in respect of indebtedness of others,
whether or not the same are or should be reflected in the Company&rsquo;s consolidated balance sheet (or the notes thereto), except guaranties
by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; and (c)
the present value of any lease payments in excess of $50,000 due under leases required to be capitalized in accordance with GAAP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Lock-Up
Agreements</U>&rdquo; means the lock-up agreements that are delivered on the date hereof by each of the Company&rsquo;s officers and
directors and holders of 5% or more of the Company&rsquo;s issued and outstanding Common Stock and Common Stock Equivalents prior to
the consummation of this Offering, in the form of <U>Exhibit A</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Material
Adverse Effect</U>&rdquo; means (i) a material adverse effect on the results of operations, assets, business, prospects or condition
(financial or otherwise) of the Company and the Subsidiaries, taken as a whole or (ii) a material adverse effect on the Company&rsquo;s
ability to perform in any material respect on a timely basis its obligations under any Transaction Document.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Offering</U>&rdquo;
shall have the meaning ascribed to such term in Section 2.1(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Preliminary
Prospectus</U>&rdquo; means, if any, any preliminary prospectus relating to the Securities included in the Registration Statement or
filed with the Commission pursuant to Rule 424(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Prospectus</U>&rdquo;
means the final prospectus filed for the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Prospectus
Supplement</U>&rdquo; means, if any, any supplement to the Prospectus complying with Rule 424(b) of the Securities Act that is filed
with the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Public
Securities</U>&rdquo; means the Closing Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registration
Statement</U>&rdquo; means, collectively, the various parts of the registration statement prepared by the Company on Form S-1 (File No.
333-260183) with respect to the Securities, each as amended as of the date hereof, including the Prospectus and Prospectus Supplement,
if any, the Preliminary Prospectus, if any, and all exhibits filed with or incorporated by reference into such registration statement,
and includes any Rule 462(b) Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(e).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
424</U>&rdquo; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
462(b) Registration Statement</U>&rdquo; means any registration statement prepared by the Company registering additional Public Securities,
which was filed with the Commission on or prior to the date hereof and became automatically effective pursuant to Rule 462(b) promulgated
by the Commission pursuant to the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities</U>&rdquo;
means the Closing Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Shares</U>&rdquo;
means the shares of Common Stock delivered to the Underwriters in accordance with Section 2.1(a)(i).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed
or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock
Exchange OTCQX or OTCQB (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, the Lock-Up Agreements, and any other documents or agreements executed in connection with
the transactions contemplated hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means Equiniti Trust Company, the current transfer agent of the Company, with offices located at 110 Centre Pointe Curve,
Suite 101, Mendota Heights, Minnesota 55120, and any successor transfer agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
II.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURCHASE
AND SALE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1
<U>Closing</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Upon the terms and subject to the conditions set forth herein, the Company agrees to sell in the aggregate [&#9679;] shares of Common
Stock (the &ldquo;<U>Closing Shares</U>&rdquo;), and each Underwriter agrees to purchase, severally and not jointly, at the Closing,
the number of Closing Shares set forth opposite the name of such Underwriter on <U>Schedule I</U> hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The aggregate purchase price for the Closing Shares shall equal the amount set forth opposite the name of such Underwriter on <U>Schedule
I</U> hereto (the &ldquo;<U>Closing Purchase Price</U>&rdquo;). The purchase price for one Closing Share shall be $[&#9679;] (or 93%
of price per Closing Share offered to the public); and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
On the Closing Date, each Underwriter shall deliver or cause to be delivered to the Company, via wire transfer, immediately available
funds equal to such Underwriter&rsquo;s Closing Purchase Price and the Company shall deliver to, or as directed by, such Underwriter
its respective Closing Shares and the Company shall deliver the other items required pursuant to Section 2.3 deliverable at the Closing.
Upon satisfaction of the covenants and conditions set forth in Sections 2.3 and 2.4, the Closing shall occur at the offices of AFS or
such other location as the Company and Representative shall mutually agree. The Public Securities are to be offered initially to the
public at the offering price set forth on the cover page of the Prospectus (the &ldquo;<U>Offering</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2
<U>Reserved</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3
<U>Deliveries</U>. (a) The Company shall deliver or cause to be delivered to each Underwriter (if applicable) the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
At the Closing Date, the Closing Shares, which shares shall be delivered via The Depository Trust Company Deposit or Withdrawal at Custodian
system for the accounts of the several Underwriters;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
At the Closing Date, a legal opinion of Company Counsel addressed to the Underwriters, including, without limitation, a negative assurance
letter; </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
Contemporaneously herewith, a cold comfort letter, addressed to the Underwriters and in form and substance satisfactory in all respects
to the Representative from the Company Auditor dated, respectively, as of the date of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
On the Closing Date, the duly executed and delivered Officer&rsquo;s Certificate, substantially in the form required by <U>Exhibit B
</U>attached hereto;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
On the Closing Date, the duly executed and delivered Secretary&rsquo;s Certificate, substantially in the form required by <U>Exhibit
C</U> attached hereto; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
Contemporaneously herewith, the duly executed and delivered Lock-Up Agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4
<U>Closing Conditions</U>. The respective obligations of each Underwriter hereunder in connection with the Closing are subject to the
following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the accuracy in all material respects when made and on the date in question (other than representations and warranties of the Company
already qualified by materiality, which shall be true and correct in all respects) of the representations and warranties of the Company
contained herein (unless as of a specific date therein);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
all obligations, covenants and agreements of the Company required to be performed at or prior to the date in question shall have been
performed;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
the delivery by the Company of the items set forth in Section 2.3 of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
the Registration Statement shall be effective on the date of this Agreement and at the Closing Date, no stop order suspending the effectiveness
of the Registration Statement shall have been issued and no proceedings for that purpose shall have been instituted or shall be pending
or contemplated by the Commission and any request on the part of the Commission for additional information shall have been complied with
to the reasonable satisfaction of the Representative;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
by the Execution Date, if required by FINRA, the Underwriters shall have received clearance from FINRA as to the amount of compensation
allowable or payable to the Underwriters as described in the Registration Statement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
the Closing Shares have been approved for listing on the Trading Market; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)
prior to and on the Closing Date: (i) there shall have been no material adverse change or development involving a prospective material
adverse change in the condition or prospects or the business activities, financial or otherwise, of the Company from the latest dates
as of which such condition is set forth in the Registration Statement and Prospectus; (ii) no action suit or proceeding, at law or in
equity, shall have been pending or threatened against the Company or any Affiliate of the Company before or by any court or federal or
state commission, board or other administrative agency wherein an unfavorable decision, ruling or finding may materially adversely affect
the business, operations, prospects or financial condition or income of the Company, except as set forth in the Registration Statement
and Prospectus; (iii) no stop order shall have been issued under the Securities Act and no proceedings therefor shall have been initiated
or threatened by the Commission; and (iv) the Registration Statement and the Prospectus and any amendments or supplements thereto shall
contain all material statements which are required to be stated therein in accordance with the Securities Act and the rules and regulations
thereunder and shall conform in all material respects to the requirements of the Securities Act and the rules and regulations thereunder,
and neither the Registration Statement nor the Prospectus nor any amendment or supplement thereto shall contain any untrue statement
of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in light
of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
III.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPRESENTATIONS
AND WARRANTIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
<U>Representations and Warranties of the Company</U>. The Company represents and warrants to the Underwriters as of the Execution Date,
and as of the Closing Date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Subsidiaries</U>. All of the direct and indirect Subsidiaries of the Company are set forth in the Prospectus. The Company owns, directly
or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued
and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive
and similar rights to subscribe for or purchase securities. If the Company has no Subsidiaries, all other references to the Subsidiaries
or any of them in the Transaction Documents shall be disregarded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Organization and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized,
validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power
and authority to own and use its properties and assets and to carry on its business as described in the Prospectus. Neither the Company
nor any Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws
or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in
good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property
owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be,
could not have a Material Adverse Effect and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing
or seeking to revoke, limit or curtail such power and authority or qualification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Authorization; Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions
contemplated by this Agreement and each of the other Transaction Documents to which the Company is a party and otherwise to carry out
its obligations hereunder and thereunder. The execution and delivery of this Agreement and each of the other Transaction Documents by
the Company and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary
action on the part of the Company and no further action is required by the Company, the Board of Directors or the Company&rsquo;s stockholders
in connection herewith or therewith other than in connection with the Required Approvals. This Agreement and each other Transaction Document
to which the Company is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance
with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in
accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization,
moratorium and other laws of general application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws
relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification
and contribution provisions may be limited by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>No Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to
which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby
do not and will not (i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate or articles
of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that
with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or
assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments,
acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument
(evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by
which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict
with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or
governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations),
or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and
(iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Filings, Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any
notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other
Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filing
with the Commission of the Registration Statement, Preliminary Prospectus and Prospectus, (ii) such filings as are required to be made
under applicable state securities laws (collectively, the &ldquo;<U>Required Approvals</U>&rdquo;) and (iii) any filings with The Nasdaq
Stock Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Registration Statement</U>. The Company has filed with the Commission the Registration Statement, including any related Prospectus
or Prospectuses, for the registration of the Securities under the Securities Act, which Registration Statement at each time it was filed
or amended, complied in all material respects with the requirements of the Securities Act and the rules and regulations of the Commission
under the Securities Act. The Registration Statement has been declared effective by the Commission on the date hereof (the &ldquo;<U>Effective
Date</U>&rdquo;). The Company has filed with the Commission a registration under the Exchange Act of its Common Stock; and that registration
has been declared effective by the Commission as of the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Issuance of Securities</U>. The Securities are duly authorized and, when issued and paid for in accordance with the applicable Transaction
Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The holder
of the Securities will not be subject to personal liability by reason of being such holders. The Securities are not and will not be subject
to the preemptive rights of any holders of any security of the Company or similar contractual rights granted by the Company. All corporate
action required to be taken for the authorization, issuance and sale of the Securities has been duly and validly taken. The Securities
conform in all material respects to all statements with respect thereto contained in the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>Capitalization</U>. The capitalization of the Company is as set forth in the Registration Statement. Except as set forth in the
Registration Statement, the Company has not issued any capital stock since March 31, 2024, other than pursuant to the exercise
of employee stock options under the Company&rsquo;s stock option plans and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding
as of the Effective Date. No Person has any right of first refusal, preemptive right, right of participation, or any similar right to
participate in the transactions contemplated by the Transaction Documents. Except as a result of the purchase and sale of the Securities,
there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to,
or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe
for or acquire, any shares of Common Stock or the capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements
by which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents
or the capital stock of any Subsidiary. The issuance and sale of the Securities will not obligate the Company or any Subsidiary to issue
shares of Common Stock or other securities to any Person (other than the Underwriters). There are no outstanding securities or instruments
of the Company or any Subsidiary with any provision that adjusts the exercise, conversion, exchange or reset price of such security or
instrument upon an issuance of securities by the Company or any Subsidiary. There are no outstanding securities or instruments of the
Company or any Subsidiary that contain any redemption or similar provisions, and there are no contracts, commitments, understandings
or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary.
The Company does not have any stock appreciation rights or &ldquo;phantom stock&rdquo; plans or agreements or any similar plan or agreement.
All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable, have
been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation of
any preemptive rights or similar rights to subscribe for or purchase securities. The authorized shares of the Company conform in all
material respects to all statements relating thereto contained in the Registration Statement and the Prospectus. The offers and sales
of the Company&rsquo;s securities were at all relevant times either registered under the Securities Act and the applicable state securities
or Blue Sky laws or, based in part on the representations and warranties of the purchasers, exempt from such registration requirements.
No further approval or authorization of any stockholder, the Board of Directors or others is required for the issuance and sale of the
Securities. There are no stockholders agreements, voting agreements or other similar agreements with respect to the Company&rsquo;s capital
stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company&rsquo;s stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Financial Statements</U>. The financial statements of the Company included in the Registration Statement and Prospectus comply in
all material respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as
in effect at the time of filing. Such financial statements have been prepared in accordance with United States generally accepted accounting
principles applied on a consistent basis during the periods involved (&ldquo;<U>GAAP</U>&rdquo;), except as may be otherwise specified
in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required
by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and
for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements,
to normal, immaterial, year-end audit adjustments. The agreements and documents described in the Registration Statement and the Prospectus,
conform to the descriptions thereof contained therein and there are no agreements or other documents required by the Securities Act and
the rules and regulations thereunder to be described in the Registration Statement or the Prospectus or to be filed with the Commission
as exhibits to the Registration Statement, that have not been so described or filed. Each agreement or other instrument (however characterized
or described) to which the Company is a party or by which it is or may be bound or affected and (i) that is referred to in the Registration
Statement or the Prospectus, or (ii) is material to the Company&rsquo;s business, has been duly authorized and validly executed by the
Company, is in full force and effect in all material respects and is enforceable against the Company and, to the Company&rsquo;s knowledge,
the other parties thereto, in accordance with its terms, except (x) as such enforceability may be limited by bankruptcy, insolvency,
reorganization or similar laws affecting creditors&rsquo; rights generally, (y) as enforceability of any indemnification or contribution
provision may be limited under the federal and state securities laws, and (z) that the remedy of specific performance and injunctive
and other forms of equitable relief may be subject to the equitable defenses and to the discretion of the court before which any proceeding
therefore may be brought. None of such agreements or instruments has been assigned by the Company, and neither the Company nor, to the
best of the Company&rsquo;s knowledge, any other party is in default thereunder and, to the best of the Company&rsquo;s knowledge, no
event has occurred that, with the lapse of time or the giving of notice, or both, would constitute a default thereunder. To the best
of the Company&rsquo;s knowledge, performance by the Company of the material provisions of such agreements or instruments will not result
in a violation of any existing applicable law, rule, regulation, judgment, order or decree of any governmental agency or court, domestic
or foreign, having jurisdiction over the Company or any of its assets or businesses, including, without limitation, those relating to
environmental laws and regulations, except for a violation which would not reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<U>Material Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest audited financial statements included
within the Registration Statement and Prospectus, (i) there has been no event, occurrence or development that has had or that could reasonably
be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other
than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities
not required to be reflected in the Company&rsquo;s financial statements pursuant to GAAP or disclosed in filings made with the Commission,
(iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of
cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital
stock, (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company
stock option plans and (vi) no officer or director of the Company has resigned from any position with the Company. Unless otherwise disclosed
in the Registration Statement and Prospectus, the Company has not: (i) issued any securities or incurred any liability or obligation,
direct or contingent, for borrowed money; or (ii) declared or paid any dividend or made any other distribution on or in respect to its
capital stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<U>Litigation</U>. There is no material action, suit, proceeding, arbitration, litigation or governmental proceeding pending or, to the
knowledge of the Company, threatened against or involving the Company or, to the knowledge of the Company, any of its directors or officers
(collectively, an &ldquo;<U>Action</U>&rdquo;) which is required to be disclosed but has not been disclosed in the Registration Statement
or the Prospectus. Without limitation of the foregoing, and to the knowledge of the Company, there is not pending or threatened, any
investigation by the Commission, of the Company, or director or officer of the Company or any of its Subsidiaries. The Commission has
not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary
under the Exchange Act or the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
<U>Labor Relations</U>. No material labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the
employees of the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its
Subsidiaries&rsquo; employees is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary,
and neither the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries
believe that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company
or any Subsidiary, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure
or proprietary information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in
favor of any third party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries
to any liability with respect to any of the foregoing matters. The Company and its Subsidiaries are in material compliance with all U.S.
federal, state, local and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment
and wages and hours, except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected
to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
<U>Compliance</U>. Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that
has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor
has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture,
loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound
(whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator
or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental
authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational
health and safety, product quality and safety and employment and labor matters, except in each case as could not have or reasonably be
expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
<U>Regulatory Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate
federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the Prospectus,
except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (each, a &ldquo;<U>Material
Permit</U>&rdquo;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification
of any Material Permit. The disclosures in the Registration Statement concerning the effects of federal, state, local and all foreign
regulation on the Company&rsquo;s business as currently contemplated are correct in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
<U>Title to Assets</U>. The Company and the Subsidiaries have good and marketable title in fee simple to, or have valid and marketable
rights to lease or otherwise use, all real property and all personal property that is material to the business of the Company and the
Subsidiaries, in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and
do not materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens
for the payment of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP, and
the payment of which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company
and the Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are
in compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)
<U>Intellectual Property</U>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks,
trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights
and similar rights necessary or required for use in connection with their respective businesses as described in the Registration Statement
and Prospectus and which the failure to do so could have a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual Property
Rights</U>&rdquo;). Except as disclosed in the Registration Statement and Prospectus, none of, and neither the Company nor any Subsidiary
has received a notice (written or otherwise) that any of, the Intellectual Property Rights has expired, terminated or been abandoned,
or is expected to expire or terminate or be abandoned, within two (2) years from the date of this Agreement. Except as disclosed in the
Registration Statement and Prospectus, neither the Company nor any Subsidiary has received, since the date of the latest audited financial
statements included within the Registration Statement and Prospectus, a written notice of a claim or otherwise has any knowledge that
the Intellectual Property Rights violate or infringe upon the rights of any Person. Except as disclosed in the Registration Statement
and Prospectus, to the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement
by another Person of any of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security measures
to protect the secrecy, confidentiality and value of all of their intellectual properties, except where failure to do so could not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)
<U>Insurance</U>. The Company and the Subsidiaries carry or are entitled to the benefits of insurance, with reputable insurers, in such
amounts and covering such risks which the Company believes are adequate, and all such insurance is in full force and effect. Neither
the Company nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when
such coverage expires or to obtain comparable coverage from similar insurers as may be necessary to continue its business as it is now
conducted and at a cost that would not result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)
<U>Transactions With Affiliates and Employees</U>. Except as set forth in the Registration Statement and Prospectus, none of the officers
or directors of the Company or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary
is presently a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors),
including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real
or personal property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to
or from, any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any
such employee has a substantial interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess
of $120,000 other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on
behalf of the Company and (iii) other employee benefits, including stock option agreements under any stock option plan of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)
<U>Sarbanes-Oxley; Internal Accounting Controls</U>. The Company and the Subsidiaries are in compliance with any and all applicable requirements
of the Sarbanes-Oxley Act of 2002 that are applicable to it as of the date hereof, and any and all applicable rules and regulations promulgated
by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. Except as disclosed in the Registration
Statement and Prospectus, the Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable
assurance that: (i) transactions are executed in accordance with management&rsquo;s general or specific authorizations, (ii) transactions
are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability,
(iii) access to assets is permitted only in accordance with management&rsquo;s general or specific authorization, and (iv) the recorded
accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to
any differences. The Company and the Subsidiaries have established disclosure controls and procedures (as defined in Exchange Act Rules
13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and procedures to ensure that information
required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized
and reported, within the time periods specified in the Commission&rsquo;s rules and forms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)
<U>Certain Fees</U>. Except as set forth in the Registration Statement and Prospectus, no brokerage or finder&rsquo;s fees or commissions
are or will be payable by the Company, any Subsidiary or Affiliate of the Company to any broker, financial advisor or consultant, finder,
placement agent, investment banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents.
To the Company&rsquo;s knowledge, there are no other arrangements, agreements or understandings of the Company or, to the Company&rsquo;s
knowledge, any of its stockholders that may affect the Underwriters&rsquo; compensation, as determined by FINRA. The Company has not
made any direct or indirect payments (in cash, securities or otherwise) to: (i) any person, as a finder&rsquo;s fee, consulting fee or
otherwise, in consideration of such person raising capital for the Company or introducing to the Company persons who raised or provided
capital to the Company; (ii) any FINRA member; or (iii) any person or entity that has any direct or indirect affiliation or association
with any FINRA member, within the twelve months prior to the Execution Date. None of the net proceeds of the Offering will be paid by
the Company to any participating FINRA member or its affiliates, except as specifically authorized herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)
<U>Investment Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities
will not be or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
<U>Registration Rights</U>. No Person has any right to cause the Company or any Subsidiary to effect the registration under the Securities
Act of any securities of the Company or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)
<U>Listing and Maintenance Requirements</U>. The Common Stock will be registered pursuant to Section 12(b) of the Exchange Act, and the
Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the
Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such
registration. The Common Stock is currently eligible for electronic transfer through the Depository Trust Company or another established
clearing corporation and the Company is current in payment of the fees of the Depository Trust Company (or such other established clearing
corporation) in connection with such electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)
<U>Application of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in order
to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement)
or other similar anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents) or the
laws of its state of incorporation that is or could become applicable as a result of the Underwriters and the Company fulfilling their
obligations or exercising their rights under the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y)
<U>Disclosure; 10b-5</U>. The Registration Statement (and any further documents to be filed with the Commission) contains all exhibits
and schedules as required by the Securities Act. Each of the Registration Statement and any post-effective amendment thereto, if any,
at the time each became effective, complied in all material respects with the Securities Act and the Exchange Act and the applicable
rules and regulations under the Securities Act and did not and, as amended or supplemented, if applicable, will not, contain any untrue
statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein
not misleading. The Preliminary Prospectus and Prospectus, each as of its respective date, comply in all material respects with the Securities
Act and the applicable rules and regulations. The Preliminary Prospectus and the Prospectus, as amended or supplemented, each as of its
respective date, did not and will not contain as of the date thereof any untrue statement of a material fact or omit to state a material
fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. No
post-effective amendment to the Registration Statement reflecting any facts or events arising after the date thereof which represent,
individually or in the aggregate, a fundamental change in the information set forth therein is required to be filed with the Commission.
There are no documents required to be filed with the Commission in connection with the transaction contemplated hereby that (x) have
not been filed as required pursuant to the Securities Act or (y) will not be filed within the requisite time period. There are no contracts
or other documents required to be described in the Preliminary Prospectus or Prospectus, or to be filed as exhibits or schedules to the
Registration Statement, which have not been described or filed as required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)
<U>Intentionally omitted</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa)
<U>Intentionally omitted</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb)
<U>Tax Status</U>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a
Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income
and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii)
has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such
returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material
taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material
amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no
basis for any such claim. The provisions for taxes payable, if any, shown on the financial statements filed with or as part of the Registration
Statement are sufficient for all accrued and unpaid taxes, whether or not disputed, and for all periods to and including the dates of
such consolidated financial statements. The term &ldquo;taxes&rdquo; mean all federal, state, local, foreign, and other net income, gross
income, gross receipts, sales, use, ad valorem, transfer, franchise, profits, license, lease, service, service use, withholding, payroll,
employment, excise, severance, stamp, occupation, premium, property, windfall profits, customs, duties or other taxes, fees, assessments,
or charges of any kind whatsoever, together with any interest and any penalties, additions to tax, or additional amounts with respect
thereto. The term &ldquo;returns&rdquo; means all returns, declarations, reports, statements, and other documents required to be filed
in respect to taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc)
<U>Foreign Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any
agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful
contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful
payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate
funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf
of which the Company is aware) which is in violation of law, or (iv) taken any action that would reasonably be expected to subject the
Company to any damage or penalty in any civil, criminal or governmental litigation or proceeding under any provision of FCPA. The Company
has taken reasonable steps to ensure that its accounting controls and procedures are sufficient to cause the Company to comply in all
material respects with the FCPA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd)
<U>Accountants</U>. To the knowledge and belief of the Company, the Company Auditor is an independent registered public accounting firm
as required by the Exchange Act. Except as disclosed in the Registration Statement and the Prospectus, the Company Auditor has not, during
the periods covered by the financial statements included in the Prospectus, provided to the Company any non-audit services, as such term
is used in Section 10A(g) of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee)
<U>FDA</U>. As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&ldquo;<U>FDA</U>&rdquo;) under
the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&ldquo;<U>FDCA</U>&rdquo;) that is manufactured,
packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a &ldquo;<U>Pharmaceutical
Product</U>&rdquo;), such Pharmaceutical Product is, to the knowledge of the Company, being manufactured, packaged, labeled, tested,
distributed, sold and/or marketed by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and
regulations relating to registration, investigational use, premarket clearance, licensure, or application approval, good manufacturing
practices, good laboratory practices, good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing
of reports, except where the failure to be in compliance would not have a Material Adverse Effect. There is no pending, completed or,
to the Company&rsquo;s knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding,
charge, complaint, or investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries
has received any notice, warning letter or other communication from the FDA or any other governmental entity, which (i) contests the
premarket clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the
testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall,
suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical
Product, (iii) imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production
at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction
with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company
or any of its Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties,
business and operations of the Company have been and are being conducted in all material respects in accordance with all applicable laws,
rules and regulations of the FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license
or use in the United States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any
concern as to approving or clearing for marketing any product being developed or proposed to be developed by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ff)
<U>Stock Option Plans</U>. Each stock option granted by the Company under the Company&rsquo;s stock option plan was granted (i) in accordance
with the terms of the Company&rsquo;s stock option plan and (ii) with an exercise price at least equal to the fair market value of the
Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted under the
Company&rsquo;s stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no Company
policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with, the
release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results or
prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(gg)
<U>Office of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company&rsquo;s knowledge, any director,
officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the
Office of Foreign Assets Control of the U.S. Treasury Department.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(hh)
<U>Money Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance in
all material respects with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting
Act of 1970, as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the &ldquo;<U>Money
Laundering Laws</U>&rdquo;), and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator
involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any
Subsidiary, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
<U>D&amp;O Questionnaires</U>. To the Company&rsquo;s knowledge, all information contained in the questionnaires completed by each of
the Company&rsquo;s directors and officers prior to the Offering and in the Lock-Up Agreement provided to the Underwriters is true and
correct in all respects and the Company has not become aware of any information which would cause the information disclosed in such questionnaires
become inaccurate and incorrect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(jj)
<U>FINRA Affiliation</U>. To the Company&rsquo;s knowledge, no officer, director or any beneficial owner of 5% or more of the Company&rsquo;s
unregistered securities has any direct or indirect affiliation or association with any FINRA member (as determined in accordance with
the rules and regulations of FINRA) that is participating in the Offering. The Company will advise the Representative and AFS if it learns
that any other officer, director or owner of 5% or more of the Company&rsquo;s outstanding shares of Common Stock or Common Stock Equivalents
is or becomes an affiliate or associated person of a FINRA member firm.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(kk)
<U>Officers&rsquo; Certificate</U>. Any certificate signed by any duly authorized officer of the Company and delivered to the Representative
or AFS shall be deemed a representation and warranty by the Company to the Underwriters as to the matters covered thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ll)
<U>Board of Directors</U>. The Board of Directors is, and upon completion of this offering will be, comprised of the persons set forth
under the heading of the Prospectus captioned &ldquo;Management.&rdquo; The qualifications of the persons serving as board members and
the overall composition of the Board of Directors comply with any applicable provision of the Sarbanes-Oxley Act of 2002 and the rules
promulgated thereunder applicable to the Company and the rules of the Trading Market. At least one member of the Board of Directors qualifies
as a &ldquo;financial expert&rdquo; as such term is defined under the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder
and the rules of the Trading Market. In addition, by the end of the phase-in period permitted by the rules of the Trading Market, at
least a majority of the persons serving on the Board of Directors will qualify as &ldquo;independent&rdquo; as defined under the rules
of the Trading Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ll)
<U>Environmental Laws</U>. The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating
to pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface
strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or
toxic or hazardous substances or wastes (collectively, &ldquo;Hazardous Materials&rdquo;) into the environment, or otherwise relating
to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well
as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders,
permits, plans or regulations, issued, entered, promulgated or approved thereunder (&ldquo;Environmental Laws&rdquo;); (ii) have received
all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses;
and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i), (ii) and
(iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"> (mm) <U>Emerging
Growth Company</U>. From the time of the initial confidential submission of the Registration Statement to the Commission through the
date hereof, the Company has been and is an &ldquo;emerging growth company,&rdquo; as defined in Section 2(a) of the Securities Act. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"> (nn) <U>Testing-the-Waters
Communications</U>. The Company has not (i) alone engaged in any Testing-the-Waters Communications and (ii) authorized anyone to engage
in Testing-the-Waters Communications. The Company confirms that the Representative has been authorized to act on its behalf in undertaking
Testing-the-Waters Communications. The Company has not distributed any Written Testing-the-Waters Communications. &ldquo;Written Testing-the-Waters
Communication&rdquo; means any Testing-the-Waters Communication that is a written communication within the meaning of Rule 405 under
the Securities Act; &ldquo;Testing-the-Waters Communication&rdquo; means any oral or written communication with potential investors undertaken
in reliance on Section 5(d) of the Securities Act. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"> (oo) <U>Smaller
Reporting Company</U>. The Company is a &ldquo;smaller reporting company,&rdquo; as defined in Rule 12b-2 of the Exchange Act. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"> (pp) <U>Cybersecurity;
Data Protection</U>. The Company&rsquo;s information technology assets and equipment, computers, systems, networks, hardware, software,
websites, applications, and databases (including all data of their respective employees, suppliers, vendors and any third-party data
under the control of and maintained by the Company) (collectively, &ldquo;IT Systems&rdquo;) are adequate for, and operate and perform
in all material respects as required in connection with, the operation of the business of the Company as currently conducted, and to
the knowledge of the Company, such IT Systems are free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware
and other corruptants. The Company has implemented and maintained commercially reasonable controls, policies, procedures, and safeguards
designed to maintain and protect its material confidential information and the integrity, continuous operation, redundancy and security
of all IT Systems and data (including all personal, personally identifiable, sensitive, confidential or regulated data (&ldquo;Personal
Data&rdquo;)) used in connection with its businesses. To the knowledge of the Company, there have been no breaches, violations, outages
or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability or the duty
to notify any other person, nor any material incidents under internal review or investigations relating to the same, except as otherwise
disclosed in each of the Registration Statement, Preliminary Prospectus and Prospectus. Except as would not reasonably be expected, individually
or in the aggregate, to have a Material Adverse Effect, the Company is presently in compliance with all applicable laws or statutes and
all applicable judgments, orders, rules and regulations of any applicable court or arbitrator or governmental or regulatory authority,
internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to the protection
of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification (collectively, the &ldquo;Data Security
Obligations&rdquo;). The Company has not received any written, or, to the knowledge of the Company, other notification of or complaint
regarding, or is aware of any other facts that, individually or in the aggregate, would reasonably indicate, non-compliance with any
Data Security Obligation and there is no action, suit or proceeding. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
IV.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OTHER
AGREEMENTS OF THE PARTIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
<U>Amendments to Registration Statement</U>. The Company has delivered, or will as promptly as practicable deliver, to the Underwriters
complete conformed copies of the Registration Statement and of each consent and certificate of experts, as applicable, filed as a part
thereof, and conformed copies of the Registration Statement (without exhibits) and the Prospectus, as amended or supplemented, in such
quantities and at such places as an Underwriter reasonably requests. Neither the Company nor any of its directors and officers has distributed
and none of them will distribute, prior to the Closing Date, any offering material in connection with the offering and sale of the Securities
other than the Prospectus, the Registration Statement, and copies of the documents incorporated by reference therein. The Company shall
not file any such amendment or supplement to which the Representative shall reasonably object in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
<U>Federal Securities Laws</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Compliance</U>. During the time when a Prospectus is required to be delivered under the Securities Act, the Company will use its reasonable
best efforts to comply with all requirements imposed upon it by the Securities Act and the rules and regulations thereunder and the Exchange
Act and the rules and regulations thereunder, as from time to time in force, so far as necessary to permit the continuance of sales of
or dealings in the Securities in accordance with the provisions hereof and the Prospectus. If at any time when a Prospectus relating
to the Securities is required to be delivered under the Securities Act, any event shall have occurred as a result of which, in the opinion
of counsel for the Company or counsel for the Underwriters, the Prospectus, as then amended or supplemented, includes an untrue statement
of a material fact or omits to state any material fact required to be stated therein or necessary to make the statements therein, in
light of the circumstances under which they were made, not misleading, or if it is necessary at any time to amend the Prospectus to comply
with the Securities Act, the Company will notify the Underwriters promptly and prepare and file with the Commission, subject to Section
4.1 hereof, an appropriate amendment or supplement in accordance with Section 10 of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Filing of Final Prospectus</U>. The Company will file the Prospectus (in form and substance satisfactory to the Representative) with
the Commission pursuant to the requirements of Rule 424.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Exchange Act Registration</U>. For a period of three years from the Execution Date, the Company will use its reasonable best efforts
to maintain the registration of the Common Stock under the Exchange Act. The Company will not deregister the Common Stock under the Exchange
Act without the prior written consent of the Representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Free Writing Prospectuses</U>. The Company represents and agrees that it has not made and will not make any offer relating to the
Securities that would constitute an issuer free writing prospectus, as defined in Rule 433 of the rules and regulations under the Securities
Act, without the prior written consent of the Representative. Any such free writing prospectus consented to by the Representative is
herein referred to as a <B>&ldquo;</B><U>Permitted Free Writing Prospectus</U>.&rdquo; The Company represents that it will treat each
Permitted Free Writing Prospectus as an &ldquo;issuer free writing prospectus&rdquo; as defined in rule and regulations under the Securities
Act, and has complied and will comply with the applicable requirements of Rule 433 of the Securities Act, including timely Commission
filing where required, legending and record keeping.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3
<U>Delivery to the Underwriters of Prospectuses</U>. The Company will deliver to the Underwriters, without charge, from time to time
during the period when the Prospectus is required to be delivered under the Securities Act or the Exchange Act such number of copies
of each Prospectus as the Underwriters may reasonably request and, as soon as the Registration Statement or any amendment or supplement
thereto becomes effective, deliver to you two original executed Registration Statements, including exhibits, and all post-effective amendments
thereto and copies of all exhibits filed therewith or incorporated therein by reference and all original executed consents of certified
experts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4
<U>Effectiveness and Events Requiring Notice to the Underwriters</U>. The Company will use its reasonable best efforts to cause the Registration
Statement to remain effective with a current prospectus until nine (9) months from the Execution Date, and confirm the notice in writing:
(i) of the effectiveness of the Registration Statement and any amendment thereto; (ii) of the issuance by the Commission of any stop
order or of the initiation, or the threatening, of any proceeding for that purpose; (iii) of the issuance by any state securities commission
of any proceedings for the suspension of the qualification of the Securities for offering or sale in any jurisdiction or of the initiation,
or the threatening, of any proceeding for that purpose; (iv) of the mailing and delivery to the Commission for filing of any amendment
or supplement to the Registration Statement or Prospectus; (v) of the receipt of any comments or request for any additional information
from the Commission; and (vi) of the happening of any event during the period described in this Section 4.4 that, in the judgment of
the Company, makes any statement of a material fact made in the Registration Statement or the Prospectus untrue or that requires the
making of any changes in the Registration Statement or the Prospectus in order to make the statements therein, in light of the circumstances
under which they were made, not misleading. If the Commission or any state securities commission shall enter a stop order or suspend
such qualification at any time, the Company will make every reasonable effort to obtain promptly the lifting of such order.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5
<U>Intentionally omitted</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6
<U>Reports to the Underwriters Expenses of the Offering</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Trading Reports</U>. During such time as the Closing Shares are listed on the Trading Market, the Company shall provide to the Underwriters,
at the Company&rsquo;s expense, such reports published by the Trading Market relating to price and trading of such shares, as the Underwriters
shall reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>General Expenses Related to the Offering</U>. The Company hereby agrees to pay on the Closing Date all expenses incident to the performance
of the obligations of the Company under this Agreement, including, but not limited to: (a) all filing fees and communication expenses
relating to the registration of the Securities to be sold in the Offering with the Commission; (b) all FINRA Public Offering Filing System
fees associated with the review of the Offering by FINRA; (c) all fees and expenses relating to the listing of such Closing Shares on
the Trading Market and such other stock exchanges as the Company and the Representative together determine; (d) all fees, expenses and
disbursements relating to the registration or qualification of such Securities under the &ldquo;blue sky&rdquo; securities laws of such
states and other foreign jurisdictions as the Representative may reasonably designate (including, without limitation, all filing and
registration fees, and the fees and expenses of Blue Sky counsel); (e) the costs of all mailing and printing of the underwriting documents
(including, without limitation, the Underwriting Agreement, any Blue Sky Surveys and, if appropriate, any Agreement Among Underwriters,
Selected Dealers&rsquo; Agreement, Underwriters&rsquo; Questionnaire and Power of Attorney), Registration Statements, Prospectuses and
all amendments, supplements and exhibits thereto and as many preliminary and final Prospectuses as the Representative may reasonably
deem necessary; (f) the costs and expenses of the Company&rsquo;s public relations firm; (g) the costs of preparing, printing and delivering
the Securities; (h) fees and expenses of the Transfer Agent for the Securities (including, without limitation, any fees required for
same-day processing of any instruction letter delivered by the Company); (i) stock transfer and/or stamp taxes, if any, payable upon
the transfer of securities from the Company to the Underwriters; (j) the fees and expenses of the Company&rsquo;s accountants; (k) the
fees and expenses of the Company&rsquo;s legal counsel and other agents and representatives; (l) the Underwriters&rsquo; costs of mailing
prospectuses to prospective investors; (m) the costs associated with advertising the Offering in the national editions of the Wall Street
Journal and New York Times after the Closing Date; (n) the fees and expenses of AFS; (o) all fees, expenses and disbursements relating
to background checks of the Company&rsquo;s officers and directors; (p) the cost for the Underwriters&rsquo; use of IPreo&rsquo;s book-building,
prospectus tracking and compliance software (or other similar software) for the Offering; and (q) the Underwriters&rsquo; actual &ldquo;road
show&rdquo; expenses for the Offering; provided that the maximum reimbursable amount payable to the Underwriters pursuant to (m)-(q)
above shall not exceed $175,000. The Underwriters may also deduct from the net proceeds of the Offering payable to the Company
on the Closing Date the expenses set forth herein to be paid by the Company to the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"> (c) <U>Non-accountable
Expenses</U>. The Company further agrees that, in addition to the expenses payable pursuant to Section 4.6(b), on the Closing Date it
shall pay to the Representative, by deduction from the net proceeds of the Offering contemplated herein, a non-accountable expense allowance
equal to 1.0% of the gross proceeds received by the Company from the sale of the Shares. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7
<U>Application of Net Proceeds</U>. The Company will apply the net proceeds from the Offering received by it in a manner consistent with
the application described under the caption &ldquo;Use of Proceeds&rdquo; in the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8
<U>Delivery of Earnings Statements to Security Holders</U>. The Company will make generally available to its security holders as soon
as practicable, but not later than the first day of the fifteenth full calendar month following the Execution Date, an earnings statement
(which need not be certified by independent public or independent certified public accountants unless required by the Securities Act
or the Rules and Regulations under the Securities Act, but which shall satisfy the provisions of Rule 158(a) under Section 11(a) of the
Securities Act) covering a period of at least twelve consecutive months beginning after the Execution Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9
<U>Stabilization</U>. Neither the Company, nor, to its knowledge, any of its employees, directors or shareholders (without the consent
of the Representative) has taken or will take, directly or indirectly, any action designed to or that has constituted or that might reasonably
be expected to cause or result in, under the Exchange Act, or otherwise, stabilization or manipulation of the price of any security of
the Company to facilitate the sale or resale of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10
<U>Internal Controls</U>. The Company will maintain a system of internal accounting controls sufficient to provide reasonable assurances
that: (i) transactions are executed in accordance with management&rsquo;s general or specific authorization; (ii) transactions are recorded
as necessary in order to permit preparation of financial statements in accordance with GAAP and to maintain accountability for assets;
(iii) access to assets is permitted only in accordance with management&rsquo;s general or specific authorization; and (iv) the recorded
accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any
differences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11
<U>Accountants</U>. The Company shall continue to retain a nationally recognized independent certified public accounting firm for a period
of at least three years after the Execution Date. The Underwriters acknowledge that the Company Auditor is acceptable to the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12
<U>FINRA</U>. Except as disclosed in the Registration Statement and the Prospectus, the Company shall advise the Underwriters (who shall
make an appropriate filing with FINRA) if it is aware that any 5% or greater shareholder of the Company becomes an affiliate or associated
person of an Underwriter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13
<U>No Fiduciary Duties</U>. The Company acknowledges and agrees that the Underwriters&rsquo; responsibility to the Company is solely
contractual and commercial in nature, based on arms-length negotiations and that neither the Underwriters nor their affiliates or any
selected dealer shall be deemed to be acting in a fiduciary capacity, or otherwise owes any fiduciary duty to the Company or any of its
affiliates in connection with the Offering and the other transactions contemplated by this Agreement. Notwithstanding anything in this
Agreement to the contrary, the Company acknowledges that the Underwriters may have financial interests in the success of the Offering
that are not limited to the difference between the price to the public and the purchase price paid to the Company by the Underwriters
for the Securities and the Underwriters have no obligation to disclose, or account to the Company for, any of such additional financial
interests. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against
the Underwriters with respect to any breach or alleged breach of fiduciary duty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14
<U>Right of Participation</U>. Provided that the Closing Shares are sold in accordance with the terms of this Agreement, the Representative
shall have the right for a period of nine (9) months after the date the Offering is completed (a) to act as the Company&rsquo;s
exclusive financial advisor if the Company or any of its Subsidiaries decides to dispose of or acquire business units or acquire any
of its outstanding securities or make any exchange or tender offer or enter into a merger, consolidation or other business combination
or any recapitalization, reorganization, restructuring or other similar transaction, including, without limitation, an extraordinary
dividend or distributions or a spin-off or split-off, and the Company decides to retain a financial advisor for such transaction; or
(b) to act as sole book-runner, sole manager, sole placement agent or sole agent if the Company or any of its Subsidiaries decides to
finance or refinance any indebtedness using a manager or agent; or (c) to act as sole book-running manager, sole underwriter or sole
placement agent if the Company or any of its Subsidiaries decides to raise funds by means of a public offering (including at-the-market
facility) or a private placement or any other capital-raising financing of equity, equity-linked or debt securities using an underwriter
or placement agent. The Company shall provide notice in writing to the Representative of any of the foregoing activities who shall notify
the Company within fifteen (15) business days of its receipt of the written offer contemplated above as to whether or not it agrees
to accept such retention. If Representative or one of its affiliates decides to accept any such engagement, the agreement governing such
engagement will contain, among other things, provisions for customary fees for transactions of similar size and nature and the provisions
of this Agreement, including indemnification, which are appropriate to such a transaction. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15
<U>Reserved.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16
<U>Securities Laws Disclosure; Publicity</U>. At the request of the Representative, by 8:00 a.m. (New York City time) on the Business
Day following the date hereof, the Company shall issue a press release disclosing the material terms of the Offering. The Company and
the Representative shall consult with each other in issuing any other press releases with respect to the Offering, and neither the Company
nor any Underwriter shall issue any such press release nor otherwise make any such public statement without the prior consent of the
Company, with respect to any press release of such Underwriter, or without the prior consent of such Underwriter, with respect to any
press release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law,
in which case the disclosing party shall promptly provide the other party with prior notice of such public statement or communication.
The Company will not issue press releases or engage in any other publicity, without the Representative&rsquo;s prior written consent,
for a period ending at 5:00 p.m. (New York City time) on the first business day following the 45th day following the Closing Date, other
than normal and customary releases issued in the ordinary course of the Company&rsquo;s business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.17
<U>Shareholder Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person,
that any Underwriter of the Securities is an &ldquo;Acquiring Person&rdquo; under any control share acquisition, business combination,
poison pill (including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter
adopted by the Company, or that any Underwriter of Securities could be deemed to trigger the provisions of any such plan or arrangement,
by virtue of receiving Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.18
<U>Reserved</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.19
<U>Listing of Securities</U>. The Company hereby agrees to use reasonable best efforts to maintain the listing or quotation of the Common
Stock on the Trading Market on which it is currently listed, and concurrently with the Closing, the Company shall apply to list or quote
all of the Closing Shares on the Nasdaq Capital Market and promptly secure the listing of all of the Closing Shares on such Trading Market.
The Company further agrees, if the Company applies to have the Common Stock traded on any other Trading Market, it will then include
in such application all of the Closing Shares, and will take such other action as is necessary to cause all of the Closing Shares to
be listed or quoted on such other Trading Market as promptly as possible. The Company will then take all action reasonably necessary
to continue the listing and trading of its Common Stock on a Trading Market and will comply in all respects with the Company&rsquo;s
reporting, filing and other obligations under the bylaws or rules of the Trading Market. The Company agrees to maintain the eligibility
of the Common Stock for electronic transfer through the Depository Trust Company or another established clearing corporation, including,
without limitation, by timely payment of fees to the Depository Trust Company or such other established clearing corporation in connection
with such electronic transfer.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.20
<U>Subsequent Equity Sales</U>. (a) From the date hereof until 180 days from Closing neither the Company nor any Subsidiary shall
issue, enter into any agreement to issue any shares of Common Stock or Common Stock Equivalents; and (b) notwithstanding the foregoing,
this Section 4.20 shall not apply in respect of an Exempt Issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.21
<U>Research Independence</U>. The Company acknowledges that each Underwriter&rsquo;s research analysts and research departments, if any,
are required to be independent from their respective investment banking divisions and are subject to certain regulations and internal
policies, and that such Underwriter&rsquo;s research analysts may hold and make statements or investment recommendations and/or publish
research reports with respect to the Company and/or the offering that differ from the views of its investment bankers. The Company hereby
waives and releases, to the fullest extent permitted by law, any claims that the Company may have against such Underwriter with respect
to any conflict of interest that may arise from the fact that the views expressed by their independent research analysts and research
departments may be different from or inconsistent with the views or advice communicated to the Company by such Underwriter&rsquo;s investment
banking divisions. The Company acknowledges that the Representative is a full service securities firm and as such from time to time,
subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short
position in debt or equity securities of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
V.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEFAULT
BY UNDERWRITERS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">If
on the Closing Date any Underwriter shall fail to purchase and pay for the portion of the Closing Shares, which such Underwriter has
agreed to purchase and pay for on such date (otherwise than by reason of any default on the part of the Company), the Representative,
or if a Representative is the defaulting Underwriter, the non-defaulting Underwriters, shall use their reasonable efforts to procure
within 36 hours thereafter one or more of the other Underwriters, or any others, to purchase from the Company such amounts as may be
agreed upon and upon the terms set forth herein, the Closing Shares, which the defaulting Underwriter or Underwriters failed to purchase.
If during such 36 hours the Representative shall not have procured such other Underwriters, or any others, to purchase the Closing Shares
agreed to be purchased by the defaulting Underwriter or Underwriters, then (a) if the aggregate number of Closing Shares with respect
to which such default shall occur does not exceed 10% of the Closing Shares covered hereby, the other Underwriters shall be obligated,
severally, in proportion to the respective numbers of Closing Shares, which they are obligated to purchase hereunder, to purchase the
Closing Shares, which such defaulting Underwriter or Underwriters failed to purchase, or (b) if the aggregate number of Closing Shares
with respect to which such default shall occur exceeds 10% of the Closing Shares covered hereby, the Company or the Representative will
have the right to terminate this Agreement without liability on the part of the non-defaulting Underwriters or of the Company except
to the extent provided in Article VI hereof. In the event of a default by any Underwriter or Underwriters, as set forth in this Article
V, the applicable Closing Date may be postponed for such period, not exceeding seven days, as the Representative, or if a Representative
is the defaulting Underwriter, the non-defaulting Underwriters, may determine in order that the required changes in the Prospectus or
in any other documents or arrangements may be effected. The term &ldquo;Underwriter&rdquo; includes any Person substituted for a defaulting
Underwriter. Any action taken under this Section shall not relieve any defaulting Underwriter from liability in respect of any default
of such Underwriter under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
VI.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INDEMNIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1
<U>Indemnification of the Underwriters</U>. Subject to the conditions set forth below, the Company agrees to indemnify and hold harmless
the Underwriters, and each dealer selected by each Underwriter that participates in the offer and sale of the Securities (each a &ldquo;<U>Selected
Dealer</U>&rdquo;) and each of their respective directors, officers and employees and each Person, if any, who controls such Underwriter
or any Selected Dealer (&ldquo;<U>Controlling Person</U>&rdquo;) within the meaning of Section 15 of the Securities Act or Section 20
of the Exchange Act, against any and all loss, liability, claim, damage and expense whatsoever (including but not limited to any and
all documented legal or other expenses reasonably incurred in investigating, preparing or defending against any litigation, commenced
or threatened, or any claim whatsoever, whether arising out of any action between such Underwriter and the Company or between such Underwriter
and any third party or otherwise) to which they or any of them may become subject under the Securities Act, the Exchange Act or any other
statute or at common law or otherwise or under the laws of foreign countries, arising out of or based upon any untrue statement or alleged
untrue statement of a material fact contained in (i) any Preliminary Prospectus, if any, the Registration Statement or the Prospectus
(as from time to time each may be amended and supplemented); (ii) any materials or information provided to investors by, or with the
approval of, the Company in connection with the marketing of the offering of the Securities, including any &ldquo;road show&rdquo; or
investor presentations made to investors by the Company (whether in person or electronically); or (iii) any application or other document
or written communication (in this Article VI, collectively called &ldquo;<U>application</U>&rdquo;) executed by the Company or based
upon written information furnished by the Company in any jurisdiction in order to qualify the Securities under the securities laws thereof
or filed with the Commission, any state securities commission or agency, Trading Market or any securities exchange; or the omission or
alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein, in light of
the circumstances under which they were made, not misleading, unless such statement or omission was made in reliance upon and in conformity
with written information furnished to the Company with respect to the applicable Underwriter by or on behalf of such Underwriter expressly
for use in any Preliminary Prospectus, if any, the Registration Statement or Prospectus, or any amendment or supplement thereto, or in
any application, as the case may be. With respect to any untrue statement or omission or alleged untrue statement or omission made in
the Preliminary Prospectus, if any, the indemnity agreement contained in this Section 6.1 shall not inure to the benefit of an Underwriter
to the extent that any loss, liability, claim, damage or expense of such Underwriter results from the fact that a copy of the Prospectus
was not given or sent to the Person asserting any such loss, liability, claim or damage at or prior to the written confirmation of sale
of the Securities to such Person as required by the Securities Act and the rules and regulations thereunder, and if the untrue statement
or omission has been corrected in the Prospectus, unless such failure to deliver the Prospectus was a result of non-compliance by the
Company with its obligations under this Agreement. The Company agrees promptly to notify each Underwriter of the commencement of any
litigation or proceedings against the Company or any of its officers, directors or Controlling Persons in connection with the issue and
sale of the Public Securities or in connection with the Registration Statement or Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2
<U>Procedure</U>. If any action is brought against an Underwriter, a Selected Dealer or a Controlling Person in respect of which indemnity
may be sought against the Company pursuant to Section 6.1, such Underwriter, such Selected Dealer or Controlling Person, as the case
may be, shall promptly notify the Company in writing of the institution of such action and the Company shall assume the defense of such
action, including the employment and reasonable and documented fees of counsel (subject to the reasonable approval of such Underwriter
or such Selected Dealer, as the case may be) and payment of actual, reasonable and documented expenses as such expenses are incurred.
Such Underwriter, such Selected Dealer or Controlling Person shall have the right to employ its or their own counsel in any such
case, but the fees and expenses of such counsel shall be at the expense of such Underwriter, such Selected Dealer or Controlling Person
unless (i) the employment of such counsel at the expense of the Company shall have been authorized in writing by the Company in connection
with the defense of such action, or (ii) the Company shall not have employed counsel to have charge of the defense of such action, or
(iii) such indemnified party or parties shall have reasonably concluded that there may be defenses available to it or them which are
different from or additional to those available to the Company (in which case the Company shall not have the right to direct the defense
of such action on behalf of the indemnified party or parties), in any of which events the reasonable fees and expenses of not more than
one additional firm of attorneys selected by such Underwriter (in addition to local counsel), Selected Dealer and/or Controlling Person
shall be borne by the Company. Notwithstanding anything to the contrary contained herein, if any Underwriter, Selected Dealer or Controlling
Person shall assume the defense of such action as provided above, the Company shall have the right to approve the terms of any settlement
of such action which approval shall not be unreasonably withheld.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3
<U>Indemnification of the Company</U>. Each Underwriter severally and not jointly agrees to indemnify and hold harmless the Company,
its directors, officers and employees and agents who control the Company within the meaning of Section 15 of the Securities Act or Section
20 of the Exchange Act against any and all loss, liability, claim, damage and expense described in the foregoing indemnity from the Company
to such Underwriter, as incurred, but only with respect to untrue statements or omissions, or alleged untrue statements or omissions
made in any Preliminary Prospectus, if any, the Registration Statement or Prospectus or any amendment or supplement thereto or in any
application, in reliance upon, and in strict conformity with, written information furnished to the Company with respect to such Underwriter
by or on behalf of such Underwriter expressly for use in such Preliminary Prospectus, if any, the Registration Statement or Prospectus
or any amendment or supplement thereto or in any such application. In case any action shall be brought against the Company or any other
Person so indemnified based on any Preliminary Prospectus, if any, the Registration Statement or Prospectus or any amendment or supplement
thereto or any application, and in respect of which indemnity may be sought against such Underwriter, such Underwriter shall have the
rights and duties given to the Company, and the Company and each other Person so indemnified shall have the rights and duties given to
such Underwriter by the provisions of this Article VI. Notwithstanding the provisions of this Section 6.3, no Underwriter shall be required
to indemnify the Company for any amount in excess of the underwriting discounts and commissions applicable to the Securities purchased
by such Underwriter. The Underwriters&rsquo; obligations in this Section 6.3 to indemnify the Company are several in proportion to their
respective underwriting obligations and not joint.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4
<U>Contribution</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Contribution Rights</U>. In order to provide for just and equitable contribution under the Securities Act in any case in which (i)
any Person entitled to indemnification under this Article VI makes a claim for indemnification pursuant hereto but it is judicially determined
(by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of
the last right of appeal) that such indemnification may not be enforced in such case notwithstanding the fact that this Article VI provides
for indemnification in such case, or (ii) contribution under the Securities Act, the Exchange Act or otherwise may be required on the
part of any such Person in circumstances for which indemnification is provided under this Article VI, then, and in each such case, the
Company and each Underwriter, severally and not jointly, shall contribute to the aggregate losses, liabilities, claims, damages and expenses
of the nature contemplated by said indemnity agreement incurred by the Company and such Underwriter, as incurred, in such proportions
that such Underwriter is responsible for that portion represented by the percentage that the underwriting discount appearing on the cover
page of the Prospectus bears to the initial offering price appearing thereon and the Company is responsible for the balance; provided,
that, no Person guilty of a fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled
to contribution from any Person who was not guilty of such fraudulent misrepresentation. For purposes of this Section, each director,
officer and employee of such Underwriter or the Company, as applicable, and each Person, if any, who controls such Underwriter or the
Company, as applicable, within the meaning of Section 15 of the Securities Act shall have the same rights to contribution as such Underwriter
or the Company, as applicable. Notwithstanding the provisions of this Section 6.4, no Underwriter shall be required to contribute any
amount in excess of the underwriting discounts and commissions applicable to the Securities purchased by such Underwriter. The Underwriters&rsquo;
obligations in this Section 6.4 to contribute are several in proportion to their respective underwriting obligations and not joint.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Contribution Procedure</U>. Within fifteen days after receipt by any party to this Agreement (or its representative) of notice of
the commencement of any action, suit or proceeding, such party will, if a claim for contribution in respect thereof is to be made against
another party (&ldquo;<U>contributing party</U>&rdquo;), notify the contributing party of the commencement thereof, but the failure to
so notify the contributing party will not relieve it from any liability which it may have to any other party other than for contribution
hereunder. In case any such action, suit or proceeding is brought against any party, and such party notifies a contributing party or
its representative of the commencement thereof within the aforesaid fifteen days, the contributing party will be entitled to participate
therein with the notifying party and any other contributing party similarly notified. Any such contributing party shall not be liable
to any party seeking contribution on account of any settlement of any claim, action or proceeding affected by such party seeking contribution
without the written consent of such contributing party. The contribution provisions contained in this Section 6.4 are intended to supersede,
to the extent permitted by law, any right to contribution under the Securities Act, the Exchange Act or otherwise available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
VII.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MISCELLANEOUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1
<U>Termination</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Termination Right</U>. The Representative shall have the right to terminate this Agreement at any time prior to any Closing Date,
(i) if any domestic or international event or act or occurrence has materially disrupted, or in its opinion will in the immediate future
materially disrupt, general securities markets in the United States; or (ii) if trading on any Trading Market shall have been suspended
or materially limited, or minimum or maximum prices for trading shall have been fixed, or maximum ranges for prices for securities shall
have been required by FINRA or by order of the Commission or any other government authority having jurisdiction, or (iii) if the United
States shall have become involved in a new war or an increase in major hostilities, or (iv) if a banking moratorium has been declared
by a New York State or federal authority, or (v) if a moratorium on foreign exchange trading has been declared which materially adversely
impacts the United States securities markets, or (vi) if the Company shall have sustained a material loss by fire, flood, accident, hurricane,
earthquake, theft, sabotage or other calamity or malicious act which, whether or not such loss shall have been insured, will, in the
Representative&rsquo;s opinion, make it inadvisable to proceed with the delivery of the Securities, or (vii) if the Company is in material
breach of any of its representations, warranties or covenants hereunder, or (viii) if the Representative shall have become aware after
the date hereof of such a material adverse change in the conditions or prospects of the Company, or such adverse material change in general
market conditions as in the Representative&rsquo;s judgment would make it impracticable to proceed with the offering, sale and/or delivery
of the Securities or to enforce contracts made by the Underwriters for the sale of the Securities; or (ix) in the event the Trading
Market refuses to initiate trading or ceases trading of the Common Stock in advance of settlement, the Representative shall have the
right to terminate the Offering and return all funds invested in the Offering to the investors. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Expenses</U>. In the event this Agreement shall be terminated pursuant to Section 7.1(a), within the time specified herein or any
extensions thereof pursuant to the terms herein, the Company shall be obligated to pay to the Representative their actual and accountable
out of pocket expenses related to the transactions contemplated herein then due and payable, including the fees and disbursements of
AFS; <U>provided</U> that such expenses may not exceed the amounts set forth in Section 4.6(b) (and <U>further provided</U>, that such
expense cap in no way limits or impairs the indemnification and contribution provisions of this Agreement).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Indemnification</U>. Notwithstanding any contrary provision contained in this Agreement, any election hereunder or any termination
of this Agreement, and whether or not this Agreement is otherwise carried out, the provisions of Article VI shall not be in any way effected
by such election or termination or failure to carry out the terms of this Agreement or any part hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2
<U>Entire Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto and the Prospectus, contain the
entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings,
oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3
<U>Notices</U>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in
writing and shall be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is
delivered via facsimile at the facsimile number or e-mail attachment at the email address set forth on the signature pages attached hereto
at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the time of transmission, if such notice
or communication is delivered via facsimile at the facsimile number or e-mail attachment at the e-mail address as set forth on the signature
pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (c) the second
(2<SUP>nd</SUP>) Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service or (d) upon
actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as
set forth on the signature pages attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.4
<U>Amendments; Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument
signed, in the case of an amendment, by the Company and the Representative. No waiver of any default with respect to any provision, condition
or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver
of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder
in any manner impair the exercise of any such right.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.5
<U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to
limit or affect any of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6
<U>Successors and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and
permitted assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.7
<U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents
shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the
principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and
defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto
or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively
in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or
in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of
any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that
it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient
venue for such Proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such Action or Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and
sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process
in any other manner permitted by law. If either party shall commence an Action or Proceeding to enforce any provisions of the Transaction
Documents, then, in addition to the obligations of the Company under Article VI, the prevailing party in such Action or Proceeding shall
be reimbursed by the other party for its reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation,
preparation and prosecution of such Action or Proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.8
<U>Survival</U>. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.9
<U>Execution</U>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one
and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party,
it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission
or by e-mail delivery of a &ldquo;.pdf&rdquo; format data file, such signature shall create a valid and binding obligation of the party
executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or &ldquo;.pdf&rdquo; signature
page were an original thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.10
<U>Severability</U>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to
be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall
remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would
have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared
invalid, illegal, void or unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.11
<U>Remedies</U>. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages,
the Underwriters and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary
damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents
and hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense that a remedy at
law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.12
<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.13
<U>Construction</U>. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise
the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against
the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each
and every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse
and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the
date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.14
<B><U>WAIVER OF JURY TRIAL</U>. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY ARISING
OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST
EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVE FOREVER ANY RIGHT TO TRIAL BY
JURY.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Pages Follow)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the foregoing correctly sets forth the understanding between the Underwriters and the Company, please so indicate in the space provided
below for that purpose, whereupon this letter shall constitute a binding agreement among the Company and the several Underwriters in
accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JUPITER NEUROSCIENCES, INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christer Ros&eacute;n</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
for Notice:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christer
Ros&eacute;n</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
Executive Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter
Neurosciences, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1001
North US HWY 1, Suite 504</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter,
Florida 33477</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Copy
to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Laura
Anthony, Esq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Craig
D. Linder, Esq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anthony
L.G., PLLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">625
N. Flagler Drive, Suite 600</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">West
Palm Beach, Florida 33401</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accepted
on the date first above written.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REVERE
</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECURITIES LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> 560 Lexington Ave., 16<SUP>th</SUP> Floor </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10022 </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the representative of the several underwriters,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
any, named in <U>Schedule I</U> hereto</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U></U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
for Notice:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REVERE
</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECURITIES LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> 560 Lexington Ave., 16<SUP>th</SUP> Floor </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10022 </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Copy
to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Cavas Pavri</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ArentFox
Schiff LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1717
K Street NW</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Washington,
DC 20006</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SCHEDULE
I</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Schedule
of Underwriters</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">UNDERWRITERS</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">CLOSING SHARES</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">CLOSING PURCHASE PRICE</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 30%; text-align: left"> REVERE SECURITIES LLC</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 25%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 37%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">TOTAL</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>LOCK-UP
AGREEMENT</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[______
__], 2024 </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REVERE
</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECURITIES LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> 560 Lexington Ave., 16<SUP>th</SUP> Floor </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10022 </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:
<B>Jupiter Neurosciences, Inc.</B> (the &ldquo;<B>Company</B>&rdquo;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned is an owner of record or beneficially of certain shares of the Company&rsquo;s common stock of the Company, $0.0001 par value
per share (&ldquo;<B>Common Stock</B>&rdquo;), or securities convertible into, exchangeable, or exercisable for Common Stock (&ldquo;<B>Securities</B>&rdquo;).
The Company proposes to enter into an underwriting agreement (the &ldquo;<B>Underwriting Agreement</B>&rdquo;) with you as Representative
of the underwriters (the &ldquo;<B>Representative</B>&rdquo;), with respect to a public offering of the Company&rsquo;s Common Stock
(the &ldquo;<B>Offering</B>&rdquo;). The undersigned acknowledges that the Offering will be of benefit to the undersigned. The undersigned
also acknowledges that you and each underwriter to be named in the Underwriting Agreement will rely on the representations and agreements
of the undersigned contained in this letter in connection with entering into the Underwriting Agreement and performing your and their
obligations thereunder. Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Underwriting
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration of the foregoing and as an inducement to the underwriters, the undersigned hereby agrees that the undersigned will not,
without your prior written consent (which consent may be withheld in your sole discretion), directly or indirectly, sell, offer to sell,
contract to sell, or grant any option for the sale (including without limitation any short sale), grant any security interest in, pledge,
hypothecate, hedge, establish an open &ldquo;put equivalent position&rdquo; within the meaning of Rule 16a-1(h) under the Securities
Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (collectively, the &ldquo;<B>Exchange Act</B>&rdquo;)
or otherwise dispose of or enter into any transaction which is designed to, or could be expected to, result in the disposition (whether
by actual disposition or effective economic disposition due to cash settlement or otherwise by the Company or any affiliate of the Company
or any person in privity with the Company or any affiliate of the Company) (collectively, a &ldquo;<B>Disposition</B>&rdquo;) of any
shares of Common Stock or any Securities currently or hereafter owned either of record or beneficially (as defined in Rule 13d-3 under
the Exchange Act) by the undersigned, or publicly announce the undersigned&rsquo;s intention to do any of the foregoing (<I>provided,
however, </I>that the undersigned may (i) complete one or more gift transfers of Securities to immediate family member(s) (as defined
in Item 404(a) of Regulation S-K under the Exchange Act) who agree in writing to be similarly bound for the remainder of the Lock-up
Period (as defined below), (ii) transfer Securities to one or more trusts for bona fide estate planning purposes, in each case without
prior written consent and upon three (3) business days&rsquo; written notice to you, ), for a period commencing on the date hereof and
continuing through the close of trading on the date 180 days following the Closing Date, as defined in the Underwriting Agreement,
subject to adjustment as discussed below (the &ldquo;<B>Lock-up Period</B>&rdquo;) or (iii) transfer Securities by means of a private
resale transaction to one or more institutional investors who agree in writing to be similarly bound for the remainder of the Lock-up
Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing restrictions have been expressly agreed to preclude the holder of shares of Common Stock and/or the Securities from engaging
in any hedging or other transaction which is designed to or reasonably expected to lead to or result in a Disposition of shares of Common
Stock or Securities during the Lock-up Period, even if such shares of Common Stock or Securities would be disposed of by someone other
than such holder. Such prohibited hedging or other transactions would include, without limitation, any short sale (whether or not against
the box) or any purchase, sale, or grant of any right (including, without limitation, any put or call option) with respect to any shares
of Common Stock or Securities or with respect to any security (other than a broad-based market basket or index) that includes, relates
to, or derives any significant part of its value from shares of Common Stock or Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned also agrees and consents to the entry of stop transfer instructions with the Company&rsquo;s transfer agent and registrar
against the transfer of shares of Common Stock or Securities held by the undersigned except in compliance with the foregoing restrictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned understands that the underwriters are entering into the Underwriting Agreement and proceeding with the Offering in reliance
upon this Lock-Up Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
agreement is irrevocable and will be binding on the undersigned and the respective successors, heirs, personal representatives, and assigns
of the undersigned.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Lock-up Agreement will be deemed to have been made and delivered in the State of New York, and both the binding provisions of this Agreement
and the transactions contemplated hereby will be governed as to validity, interpretation, construction, effect and in all other respects
by the internal laws of the State of New York, without regard to the conflict of laws principles thereof. The undersigned: (i) agrees
that any legal suit, action or proceeding arising out of or relating to this Lock-up Agreement will be instituted exclusively in the
courts located in the City of New York, State of New York, (ii) waives any objection which it may have or hereafter to the venue of any
such suit, action or proceeding, and (iii) irrevocably consents to the exclusive jurisdiction of the state and federal courts located
in the City of New York, State of New York, in any such suit, action or proceeding, waiving any, and agreeing not to assert any, basis
for seeking transfer or removal of such action to any other court, whether federal or state, unless the New York court in which such
action or proceeding was commenced first declines jurisdiction. The undersigned further agrees to accept and acknowledge service of any
and all process which may be served in any such suit, action or proceeding in such courts and agrees that service of process upon the
undersigned mailed by certified mail to the undersigned&rsquo;s address will be deemed in every respect effective service of process
upon the undersigned. Nothing in this Lock-up Agreement shall constitute an obligation to purchase shares of Common Stock, or Securities
of the Company. Whether or not the Offering actually occurs depends on a number of factors, including market conditions. Any Offering
will only be made pursuant to the Underwriting Agreement, the terms of which are subject to negotiation among the Company and the Representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signature
Page Follows]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Lock-Up Agreement and
that, upon request, the undersigned will execute any additional documents necessary in connection with the enforcement hereof. All authority
herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs
or personal representatives of the undersigned.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Printed
    Name of Holder</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Printed Name of Person Signing</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(and
    indicate capacity of person signing if signing as</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>custodian,
trustee, or on behalf of an entity)</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>FORM
OF OFFICER&rsquo;S CERTIFICATE</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OFFICERS&rsquo;
CERTIFICATE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JUPITER
NEUROSCIENCES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned, Christer Ros&eacute;n, and Dana Eschenburg Perez, the duly elected and duly qualified Chief Executive Officer, and
Chief Financial Officer and Secretary, respectively, of Jupiter Neurosciences, Inc., a Delaware corporation (the
&ldquo;<U>Company</U>&rdquo;), hereby certify the following on behalf of the Company, in connection with the transactions
contemplated by the Underwriting Agreement (the &ldquo;<U>Underwriting Agreement</U>&rdquo;), dated [______] [__], 2024, by
and among the Company and Revere Securities LLC, as representative of the several Underwriters named on <U>Schedule I</U>
thereto:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    undersigned officers have carefully examined the Registration Statement, the General Disclosure Package, and the Prospectus and,
    in their opinion, the Registration Statement and each amendment thereto, as of time it became effective and as of the Closing Date
    did not include any untrue statement of a material fact and did not omit to state a material fact required to be stated therein or
    necessary to make the statements therein not misleading, and the General Disclosure Package, as of its date and as of the Closing
    Date, and the Prospectus and each amendment or supplement thereto, as of the respective date thereof and as of the Closing Date,
    did not include any untrue statement of a material fact and did not omit to state a material fact necessary in order to make the
    statements therein, in the light of the circumstances in which they were made, not misleading.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    Since the effective date of the Registration Statement, no event has occurred which should have been set forth in a supplement or
    amendment to the Registration Statement, the General Disclosure Package or the Prospectus.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;To
    the best of their knowledge after reasonable investigation, as of the Closing Date, the representations and warranties of the Company
    in the Underwriting Agreement are true and correct and the Company has complied in all material respects with all agreements and
    satisfied all conditions on its part to be performed or satisfied hereunder at or prior to the Closing Date.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT>.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There has not been, subsequent to [_______], 202[_], any material adverse change in the financial position or results of operations
    of the Company, or any change or development that, singularly or in the aggregate, would involve a Material Adverse Effect.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    correspondence between the Company or its counsel and the Commission are accurate and complete in all material respects.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attached
    as Exhibit 1 is a true and correct copy of a good standing certificate for the Company issued by the State of Delaware.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Attached
    as Exhibit 2 is a true and correct copy of the written consent executed by the Board of Directors of the Company, authorizing the
    execution of the Underwriting Agreement and the transactions contemplated thereby.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalized
terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Underwriting Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
certificate is to assist the Underwriters in conducting and documenting their investigation of the affairs of the Company in connection
with the Offering of the Securities pursuant to the terms of the Underwriting Agreement and the other transactions described in the Transaction
Documents, and each of the Underwriters, and ArentFox Schiff LLP is entitled to rely on this Certificate for such purpose and (if applicable)
in connection with the delivery by such counsel of their respective legal opinions and negative assurance statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF, </B>the undersigned have executed this Officers&rsquo; Certificate on behalf of the Company as of this __th day of [______],
2024. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christer
Ros&eacute;n</FONT></P></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dana
Eschenburg Perez</FONT></P></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer &amp; Secretary</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
C</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>FORM
OF SECRETARY&rsquo;S CERTIFICATE</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECRETARY&rsquo;S
CERTIFICATE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter
Neurosciences, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1001
North US HWY 1, Suite 504</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter,
Florida 33477</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[
&nbsp;&nbsp;&nbsp;&nbsp;] 2024 </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned, acting solely in her capacity as the duly elected, qualified and acting Secretary of Jupiter Neurosciences, Inc., a Delaware
corporation (the &ldquo;Company&rdquo;), and not in his individual capacity, hereby gives this certificate pursuant to that certain underwriting
agreement, dated [______] [__], 2021, by and among the Company and Revere Securities LLC, as representative of the several Underwriters
named on Schedule I thereto: (the &ldquo;Underwriting Agreement&rdquo;). Unless otherwise defined herein, the capitalized terms used
herein shall have the meanings ascribed to them in the Underwriting Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned, Dana Eschenburg Perez, Secretary of the Company, hereby certifies as of the date hereof as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
Attached hereto as Exhibit 1 is a true, correct and complete copy of the Company&rsquo;s amended and restated certificate of incorporation,
as further amended, in effect on the date hereof (the &ldquo;Certificate of Incorporation&rdquo;). The Certificate of Incorporation is
in full force and effect on the date hereof, and no amendments or modifications to the Certificate of Incorporation have been authorized
or filed with the Secretary of State of the State of Delaware since [___], 202[_].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Attached hereto as Exhibit 2 is a true, correct and complete copy of the Company&rsquo;s amended and restated bylaws, in effect on the
date hereof (the &ldquo;Bylaws&rdquo;), and no amendments or modifications to the Bylaws have been authorized since [___], 202[_].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Attached hereto as Exhibit 3 is a true, correct and complete copies of resolutions duly adopted by the Company&rsquo;s board of directors
or a committee thereof at meetings held on ______, 202[_] and ______, 202[_], in which the transactions contemplated by the Registration
Statement, the Prospectus and the Transaction Documents were authorized and approved. Such resolutions are in full force and effect,
have not been amended, modified or rescinded and are the only resolutions related to the subject matter thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
Each person who, as a director or officer of the Company, signed, and delivered by facsimile, portable document file (.pdf) or otherwise
(a) the Underwriting Agreement, (b) the Transaction Documents and (c) any and all other documents or instruments executed and delivered
to the Representative in connection with the transactions contemplated by the Underwriting Agreement, was duly elected or appointed,
qualified and acting as such director or officer, and was duly authorized to execute and deliver such documents or other instruments
at the respective times of such execution and delivery.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
All persons who, as officers or directors of the Company or attorneys-in-fact of such officers or directors, signed, and delivered by
facsimile, portable document file (.pdf) or otherwise: (a) the Registration Statement on Form S-1, as amended (File No. 333- 260183),
that the Company filed with the Commission on [_______] which was subsequently declared effective by the Commission on [______] , 202[_],
and (b) any and all other documents or instruments executed and delivered to the Commission in connection with such Registration Statement
were, at the respective times of such signing, delivery or filing, duly elected or appointed, qualified and acting as such director,
officer or duly appointed and acting as such attorney-in-fact, and the signatures of such persons appearing on such documents are their
genuine signatures or true facsimiles or portable document thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
Attached hereto as Exhibit 4 is a true, correct and complete copy of a good standing (or equivalent) certificate as of a recent date
for the Company by the States of Delaware and Florida, and such certificates attached thereto have not been amended (except as attached
thereto) since the date reflected thereon.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
Christer Ros&eacute;n, the Company&rsquo;s Chief Executive Officer, has executed and delivered on behalf of the Company the Underwriting
Agreement and the other Transaction Documents in accordance with their respective terms thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
certificate is to assist the Underwriters in conducting and documenting their investigation of the affairs of the Company in connection
with the Offering of the Securities pursuant to the terms of the Underwriting Agreement and the other transactions described in the Transaction
Documents, and each of the Underwriters and ArentFox Schiff LLP is entitled to rely on this Certificate for such purpose and (if applicable)
in connection with the delivery by such counsel of their respective legal opinions and negative assurance statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
certificate may be executed in multiple counterparts, each of which shall be deemed an original, and all of which taken together shall
constitute one and the same instrument. Delivery of an executed signature page of this certificate by electronic or facsimile transmission
shall be as effective as delivery of a manually executed counterpart hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signature
page follows]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, I have hereunder signed my name on this [____] day of [______], 2024. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dana
    Eschenburg Perez</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Secretary
    &nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned as Chief Executive Officer of the Company hereby certifies that Dana Eschenburg Perez is the duly elected, appointed, qualified
and acting Secretary of the Company, and that the signature appearing above is her genuine signature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christer
    Ros&eacute;n</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 42; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT>&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.6
<SEQUENCE>3
<FILENAME>ex3-6.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
3.6</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATE
OF AMENDMENT TO THE </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATE
OF INCORPORATION </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OF
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter
Neurosciences, Inc. (the &ldquo;Corporation&rdquo;), a corporation organized and existing under the Delaware General Corporation Law
(the &ldquo;DGCL&rdquo;), hereby certifies as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FIRST:
The date of filing of the original Certificate of Incorporation of the Corporation with the Secretary of State of the State of Delaware
is January 1, 2016 (as amended to date, the &ldquo;Certificate&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECOND:
The Certificate is hereby amended as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            new Section 4(d) is hereby added to the Certificate immediately following Section 4(c) of
                                            the Certificate, and providing as follows:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Forward</U> Split. Upon the effectiveness of this Certificate of Amendment (the &ldquo;Effective Time&rdquo;), each share of the Common
Stock issued and outstanding at the Effective Time (collectively, the &ldquo;Pre-Split Common Stock&rdquo;) shall automatically and without
any action on the part of the holder thereof be subdivided and reclassified such that each one (1) share of the Common Stock issued and
outstanding as of the Effective Time shall become three and three quarters (3 &frac34;) shares of Common Stock (i.e., a 3.75-for-one
forward split), provided that any resulting fractional shares of Common Stock shall be rounded up to the nearest whole share of Common
Stock (the &ldquo;Forward Split&rdquo;). Each certificate that immediately prior to the Effective Time represented shares of Pre-Split
Common Stock (&ldquo;Old Certificates&rdquo;), shall thereafter represent that number of shares of Common Stock into which the shares
of Common Stock represented by the Old Certificate shall have been combined and reclassified as a result of the Forward Split. The number
of authorized shares of Common Stock, and the par value per share of Common Stock, shall not be affected by the Reverse Split, other
than as set forth in this Certificate of Amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
                                            the time of the effectiveness of this Certificate of Amendment and the Forward Split, Section
                                            IV(a) of the Certificate is hereby amended and restated in its entirety to provide as follows:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Classes
and Number of Shares</U>. The total number of shares of all classes of stock, which the Corporation shall have authority to issue shall
be One Hundred and Twenty Five Million (125,000,000) shares of common stock, par value of $0.0001 per share (the &ldquo;Common Stock&rdquo;)
and Five Million (5,000,000) shares of preferred stock, par value of $0.0001 per share (the &ldquo;Preferred Stock&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIRD:
This Certificate of Amendment to the Certificate of Incorporation was duly adopted and approved by the Board of Directors of the Corporation
in accordance with Section 242 of the DGCL. Pursuant to Section 242(d)(1) of the DGCL, the approval of the stockholders of the Corporation
is not required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOURTH:
The remaining provisions of the Certificate not affected by the aforementioned amendments shall remain in full force and not be affected
by this Certificate of Amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
effective date of this Certificate of Amendment to the Certificate of Incorporation shall be upon filing with the Secretary of State
of the State of Delaware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be signed by its duly authorized officer as of this 27<SUP>th
</SUP>day of March, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter Neurosciences.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Christer Rosen</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christer
    Rosen </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>ex5-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
5.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="ex5-1_001.jpg" ALT="" STYLE="height: 114px; width: 570px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>LAURA
    ANTHONY, ESQ.</I></B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>CRAIG
    D. LINDER, ESQ.*</I></B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>JOHN
    CACOMANOLIS, ESQ.**</I></B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><U>WWW.ALCLAW.COM</U></B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>WWW.SECURITIESLAWBLOG.COM</U></B></FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>ASSOCIATES
    AND OF COUNSEL:</I></B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>CHAD
    FRIEND, ESQ., LLM</I></B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>MICHAEL
    R. GEROE, ESQ., CIPP/US***</I></B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>JESSICA
    HAGGARD, ESQ. ****</I></B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>PETER
    P. LINDLEY, ESQ., CPA, MBA</I></B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>JOHN
    LOWY, ESQ.*****</I></B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>STUART
    REED, ESQ.</I></B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>LAZARUS
    ROTHSTEIN, ESQ.</I></B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>SVETLANA
    ROVENSKAYA, ESQ.******</I></B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>HARRIS
    TULCHIN, ESQ. *******</I></B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>DIRECT
    E-MAIL: LANTHONY@ALCLAW.COM</I></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*licensed
in CA, FL and NY</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**licensed
in FL and NY</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">***licensed
in CA, DC, MO and NY</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">****licensed
in Missouri</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*****licensed
in NY and NJ</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">******licensed
in NY and NJ</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*******licensed
in CA and HI (inactive in HI)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">July 12, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter
Neurosciences, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1001
North US HWY 1, Suite 504</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter,
Florida 33477</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Jupiter
    Neurosciences, Inc. - Registration Statement on Form S-1</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have acted as counsel for Jupiter Neurosciences, Inc., a Delaware corporation
(the &ldquo;Company&rdquo;) in connection with the preparation and filing of that certain Registration Statement on Form S-1 (File No.:
333-260183) (as amended, the &ldquo;Registration Statement&rdquo;) under the Securities Act of 1933, as amended (the &ldquo;Securities
Act&rdquo;). The Registration Statement relates to: (a) the proposed offering and sale by the Company of 2,750,000 shares (the &ldquo;Primary
Shares&rdquo;) of the Company&rsquo;s common stock, par value $0.0001 per share (the &ldquo;Common Stock&rdquo;) and (b) the resale by
the selling stockholders (the &ldquo;Selling Stockholders&rdquo;) set forth in the Registration Statement (including the prospectus constituting
part thereof (the &ldquo;Resale Prospectus&rdquo;) of 3,600,000 shares of Common Stock (the &ldquo;Resale Shares&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We understand that the Primary Shares are proposed to be offered for sale
to the public as described in the Registration Statement and pursuant to an underwriting agreement, substantially in the form to be filed
as an exhibit to the Registration Statement, to be entered into by the Company and the representative (the &ldquo;Underwriting Agreement&rdquo;).
The Resale Shares are proposed to be sold by the Selling Stockholders from time to time in accordance with the Plan of Distribution contained
in the Resale Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As counsel to the Company, we have examined the originals or copies of
such documents, corporate records and other instruments and undertaken such further inquiry as we have deemed necessary or appropriate
for purposes of this opinion, including, but not limited to, the Registration Statement, corporate resolutions authorizing the issuance
of the Primary Shares and the Resale Shares and the Certificate of Incorporation and Bylaws of the Company, including amendments thereto.
In such examination, we have assumed the following: (a)&nbsp;the authenticity of original documents and the genuineness of all signatures;
(b)&nbsp;the legal capacity of all natural persons, the accuracy and completeness of all documents submitted to us; (c) the conformity
to the originals of all documents submitted to us as copies; (d) the genuineness of all signatures contained in the records, documents,
instruments and certificates we have reviewed; and (e)&nbsp;the truth, accuracy and completeness of the information, representations and
warranties contained in the records, documents, instruments and certificates we have reviewed. This opinion letter is given, and all statements
herein are made, in the context of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on and subject to the foregoing, we are of the opinion that upon
the effectiveness of the Registration Statement: (a) the Primary Shares have been duly authorized by all necessary corporate action of
the Company and, when issued, delivered and paid for as contemplated in the Registration Statement and in accordance with the terms of
the Underwriting Agreement, the Primary Shares will be validly issued, fully paid and non-assessable; and (b) the Resale Shares are duly
authorized by all necessary corporate action of the Company and are validly issued, fully paid and nonassessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding anything in this letter which might be construed to the
contrary, our opinion expressed herein is limited to the General Corporation Law of the State of Delaware and the Federal laws of the
United States of America. We express no opinion with respect to the applicability to, or the effect on, the subject transactions of the
laws of any other jurisdiction or as to any matters of municipal law or the laws of any local agencies. The opinion expressed herein is
based upon the General Corporation Law of the State of Delaware and Federal laws of the United States of America in effect on the date
hereof and as of the effective date of the Registration Statement, and we assume no obligation to revise or supplement this opinion after
the effective date of the Registration Statement should such law be changed by legislative action, judicial decision, or otherwise. Except
as expressly set forth in our opinion above: (i) we express no opinion as to whether the laws of any other jurisdiction are applicable
to the subject matter hereof and (ii) we express no opinion as to compliance with any other federal or state law, rule or regulation relating
to securities, or to the sale or issuance thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We hereby consent to the filing of this opinion as an exhibit to the Registration
Statement and to the reference to our firm appearing under the caption &ldquo;Legal Matters&rdquo; in the prospectus that forms a part
of the Registration Statement. In giving this consent, we do not hereby admit that we are in the category of persons whose consent is
required under Section 7 of the Securities Act, or the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely
yours,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Laura E. Anthony</I></FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Laura
    E. Anthony,</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the Firm</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>1700
PALM BEACH LAKES BLVD., SUITE 820&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&nbsp;<FONT STYLE="font-variant: small-caps">WEST
PALM BEACH, FLORIDA&nbsp;</FONT>&#9679;&nbsp;<FONT STYLE="font-variant: small-caps">33401 &#9679; PHONE: 561-514-0936</FONT></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.35
<SEQUENCE>5
<FILENAME>ex10-35.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Exhibit 10.35<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JUPITER
NEUROSCIENCES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>And</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OPTIMIZE
WELLNESS LIMITED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CRO
SERVICES AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
AGREEMENT is made on the &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;day of 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BETWEEN:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
    Neurosciences, Inc. of </B>1001 North US Highway 1, Suite 504 Jupiter, FL 33477 (&ldquo;<B>JN</B>&rdquo;); and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OPTIMIZE
    WELLNESS LIMITED (&ldquo;CRO&rdquo;)</B> a company incorporated in Hong Kong whose office located at ROOM 401, On Hong Commercial
    Building, 145 Hennessy Road, Wan Chai, Hong Kong</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(JN
and CRO are in some place referred to as a &ldquo;Party&rdquo; or when together &ldquo;Parties&rdquo;. )</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS
JN wishes CRO to provide certain services, as outlined in Schedule 1, in connection with advancing the business objectives of JN in Southeast
Asia; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS
CRO wishes to assist JN in accelerating JN&rsquo;s desire to get its products developed and distributed in the Asian market; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS
CRO has the skills and knowhow regarding clinical trial strategy and execution of pharmaceutical clinical trials in the South-East Asian
markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IT
IS HEREBY AGREED as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><B>1.</B></TD>
  <TD STYLE="text-align: justify"><B><U>INTERPRETATION</U></B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    this Agreement, unless the context requires otherwise:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Services&rdquo;
means the services set out in Schedule 1 or any other services which the Parties may agree from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Territory&rdquo;
means the countries of: China (including Hong Kong), Singapore and Malaysia.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Products&rdquo;
means the uniquely patented product, JOTROL, developed by JN as well as any other product JN might develop during the timeframe of this
Agreement (&ldquo;Products&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Equity&rdquo;
means common shares of JN that includes registration rights in a public offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 44pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">References
    herein to Clauses and Schedules are to Clauses and Schedules in this Agreement unless the context requires otherwise.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    headings are inserted for convenience only and shall not affect the construction of this Agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
    the context requires otherwise, words importing the singular include the plural and vice versa and words importing a gender include
    every gender.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><B>2.</B></TD>
  <TD STYLE="text-align: justify"><B><U>APPOINTMENT</U></B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JN
    hereby confirms the engagement of CRO and CRO hereby confirms its agreement to provide to JN the Services upon and subject to the
    terms set out in this Agreement.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    engagement of CRO to provide the Services shall commence upon closing of this Agreement, and services will be provided as outlined
    in Schedule 1, for a thirty-six (36) month period, with payment terms as outlined in &lsquo;Fees and Expenses.&rsquo;.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><B>3.</B></TD>
  <TD STYLE="text-align: justify"><B><U>CRO&rsquo;S UNDERTAKINGS</U></B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CRO
warrants and undertakes to JN that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CRO
    will have the necessary skill and expertise to provide the Services on the terms set out herein;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CRO
    will provide independent and unbiased advice to JN in relation to the Services;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Services will be provided in a timely and professional manner;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    announcement or publicity concerning this Agreement or the Services or any matter ancillary thereto shall be made by any of the Parties
    without the prior written consent of the other Party.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 80pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>JN&rsquo;S
    OBLIGATIONS</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JN
shall provide full documentation and support to CRO regarding the details of JN&rsquo;s Products necessary for clinical trials, regulatory
filings and approvals of the Products in the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>ASSIGNMENT
    AND OWNERSHIP</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
Party shall be entitled to assign or sub-contract any of its/his rights or obligations under this Agreement without written approval
by the other party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
inventions and data that might be the result of CRO&rsquo;s actions and efforts with a product shall be completely owned by JN.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>FEES
    AND EXPENSES</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JN
has disclosed to CRO that JN has limited amount of cash to set up and support an accelerated operation in the Asian market. It has therefore
been agreed by CRO that JN will issue, credited as fully paid and free from encumbrances and restrictions to CRO equity in the form of
310,000 common shares (&ldquo;Consideration Shares&rdquo;) upon closing of this Agreement to be regarded as pre-payment in full for 36
months of services specified in Schedule 1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Consideration Shares will have registration rights in a JN Initial Public Offering (&ldquo;IPO&rdquo;) according to Schedule 2, as long
as an IPO is closed no later than March 31, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
additional expenses to meet the requested Services outlined, will be of the sole responsibility of CRO unless the Parties agree otherwise
in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>INVESTMENT
    BY CRO</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-decoration: none">CRO
commits, in addition to providing services to JN, to purchase 10,000 shares, prior to the IPO from JN as an investment in JN. The purchase
price of these shares is $5 per share and shall be paid according to the terms in a separate Stock Subscription Agreement that is attached
as Schedule 3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>TERMINATION</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either
Party may terminate this Agreement without liability if:-</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JN
    fails to complete an Initial Public Offering of at least US$10 million gross proceed on or before May 31, 2025; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    petition is presented for the winding up or liquidation of the other Party, or anything analogous thereto occurs in respect of the
    other Party; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    any of the Parties are deemed to be involved in any illegal activities.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Agreement can be terminated at any time as long as this is agreed to by both parties.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>CONFIDENTIALITY</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CRO
shall not disclose to a third party any confidential information made available to it by, or on behalf, JN and will use such confidential
information only in connection with this Agreement; provided that such confidential information will not include any information : (i)
already in CRO possession prior to the date JN disclosed it to CRO; (ii) that becomes generally available to the public without violation
of this paragraph by CRO or its representatives; or (iii) that becomes available to CRO on a non-confidential basis from a third party
not bound by a confidentiality obligation to JN with respect to such information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>MUTUAL
    REPRESENTATION AND WARRANTIES</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
information made available to JN and CRO will, at all times during the period of this Agreement, to the best of CRO and JN&rsquo;s actual
knowledge, be complete and correct in all material respects and will not contain any untrue statements of material fact or omit to state
a material fact necessary in order to make the statements therein not misleading in light of the circumstances under which such statements
are made. All projections or guidance provided to the JN by CRO will have been prepared in good faith and will be based upon reasonable
assumptions derived from the best estimates and facts then available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>FORCE
    MAJEURE</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
Party shall be liable for any delay in performing any of its obligations under this Agreement if such delay is caused by circumstances
beyond the reasonable control of the Party so delaying and such Party shall be entitled (subject to giving the other Party full particulars
of the circumstances in question and to using its best endeavors to resume full performance without avoidable delay) to a reasonable
extension of time for the performance of such obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>LEGAL
    DISPUTES</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
disputes or controversies that may arise between the Parties in the interpretation or implementation of this Agreement shall be finally
settled by sole arbitration in Geneva, Switzerland in accordance with the Rules of the ICC International Court of Arbitration (ICC Rules).
The arbitration shall be conducted in the English language. The award rendered by arbitrator shall be final and binding upon the Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>GENERAL
    PROVISIONS</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    notice, demand or other communication between the Parties:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">may
    be sent by personal delivery, post, facsimile or other written form of electronic communication to the last known address;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    sent by post to an address to either Party, shall be treated as served on the second day following dispatch;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    sent by facsimile or other form of electronic communication, shall be treated as served at the time of sending.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    accommodation or indulgence or failure to enforce a right shall not be construed as a waiver of the right of any Party exercisable
    under this Agreement unless a waiver shall be specifically stated in writing signed by such Party.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    Agreement constitutes the entire understanding between the Parties concerning the subject matter hereof. No amendments or changes
    shall be made to this Agreement unless agreed to in writing by both Parties. Each provision of this Agreement shall be construed
    separately and notwithstanding that the whole or any part of any such provision may prove to be illegal or unenforceable the other
    provisions of this Agreement and the remainder of the provision in question shall continue in full force and effect.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    Party shall bear its own costs and expenses in connection with the preparation, negotiation and execution of this Agreement.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    formation, validity, performance and interpretation of this Agreement and of each Clause and part hereof shall be governed by the
    laws of State of Florida in the United States and the Parties agree to the non-exclusive jurisdiction of the courts of Palm Beach
    Country.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>COUNTERPART</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement may be executed in any number of counterparts, which when taken together shall constitute one and the same instrument and is
binding on each and every Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF the parties hereto have signed this Agreement the day and year first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNED
    Christer Ros&eacute;n</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    &amp; CEO</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Christer Ros&eacute;n</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    and on behalf of</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter
    Neurosciences, Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNED
    by Luk Kee Yan Kelvin</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    and on behalf of</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Luk Kee Yan Kelvin</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Optimize
    Wellness Limited</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>SCHEDULE
1</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>The
Services</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
CRO Service Company shall provide services including, not limited to or inclusive of, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide
    JN with strategic guidance regarding pharmaceutical products clinical trial environment in the Territory;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide
    and guide JN with a clinical strategy to possibly obtain a regulatory approval in several countries in the Territory.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Propose
    priority of indications for an accelerated approval path;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
    up and execute of all aspects of clinical trials to be performed;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assist
    and coordinate with any professional advisors, such as Key Opinion Leaders, in the clinical field.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 44pt; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SCHEDULE
2</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Registration
rights of shares issued for payment of services.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares to be issued according to Paragraph 6 above shall have the same registration rights and provisions as described in the Stock Subscription
Agreement attached in Schedule 3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SCHEDULE
3</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
Subscription Agreement</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
and Among</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter
Neurosciences, Inc.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">And</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Optimize
Wellness Limited</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>



<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Table
of Contents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Article
    I.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Definitions
    and Interpretation</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    1.01</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitions.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    1.02</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interpretive
    Provisions.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Article
    II.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Subscription</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    2.01</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    2.02</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deliverables
    at Closing.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    2.03</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Closing.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Article
    III.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Piggyback
    Registration Rights.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    3.01</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration
    Rights.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    3.02</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Limitations.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    3.03</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Withdrawal.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    3.04</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notification.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    3.05</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    3.06</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees
    and Expenses.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Article
    IV.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Representations
    and Warranties of the Company</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    4.01</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorization
    of Transactions.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    4.02</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governmental
    Approvals; Non-contravention.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    4.03</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brokers.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Article
    V.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Representations
    and Warranties of Subscriber</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    5.01</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorization
    of Transactions.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    5.02</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governmental
    Approvals; Non-contravention.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    5.03</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment
    Representations.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    5.04</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brokers.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Article
    VI.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Indemnification</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    6.01</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnification
    With Respect to Registration Rights.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    6.02</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    Indemnification.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    6.03</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Procedures
    for Indemnification.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    6.04</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    6.05</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect
    of Knowledge on Indemnification.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Article
    VII.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Miscellaneous</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.01</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notices.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.02</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attorneys&rsquo;
    Fees</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.03</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments;
    No Waivers; No Third-Party Beneficiaries.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.04</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    Consequential Damages.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.05</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.06</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further
    Assurances.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">13<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.07</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successors
    and Assigns.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>13</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.08</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governing
    Law; Etc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.09</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Resolution
    of Disputes.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.10</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Survival.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.12</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severability.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">15</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.13</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entire
    Agreement.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">15</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.14</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specific
    Performance.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">15</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.15</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Construction.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">15</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.16</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Counterparts.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">15<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B></B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Stock
Subscription Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Stock Subscription Agreement (this &ldquo;Agreement&rdquo;) is entered into as of June 3, 2024 (the &ldquo;Closing Date&rdquo;), by and
among Jupiter Neurosciences, Inc., a Delaware corporation (the &ldquo;Company&rdquo;) and OPTIMIZE WELLNESS LIMITED, a company incorporated
in Hong Kong whose office located at ROOM 401, On Hong Commercial Building, 145 Hennessy Road, Wan Chai, Hong Kong (&ldquo;Subscriber&rdquo;).
The Company and Subscriber may be collectively referred to herein as the &ldquo;Parties&rdquo; and individually as a &ldquo;Party.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Company desires to issue and sell to the Subscriber certain shares of the Company&rsquo;s common stock, par value $0.0001 per share
(the &ldquo;Common Stock&rdquo;), and Subscriber desires to subscribe for and acquire certain shares of the Common Stock, as set forth
herein; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1in; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
    I.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Definitions
    and Interpretation</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
II. Definitions. In addition to the terms defined elsewhere in this Agreement, the following terms, as used herein, have the following
meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
III. &ldquo;Affiliate&rdquo; means, with respect to a specified Person, any other Person that directly or indirectly Controls, is Controlled
by or is under common Control with, the specified Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
IV. &ldquo;Business Day&rdquo; means any day except Saturday, Sunday and any legal holiday or a day on which banking institutions in
Delaware generally are authorized or required by Law or other governmental actions to close.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
V. &ldquo;Contract&rdquo; means any contract, commitment, understanding or agreement (whether oral or written).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
VI. &ldquo;Control&rdquo; means (a) the possession, directly or indirectly, of the power to vote 10% or more of the securities or other
equity interests of a Person having ordinary voting power, (b) the possession, directly or indirectly, of the power to direct or cause
the direction of the management and policies of a Person, by contractor otherwise, or (c) being a director, officer, executor, trustee
or fiduciary (or their equivalents) of a Person or a Person that controls such Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
VII. &ldquo;Governmental Entity&rdquo; means any federal, state, municipal, local or foreign government and any court, tribunal, arbitral
body, administrative agency, department, subdivision, entity, commission or other governmental, government appointed, quasi-governmental
or regulatory authority, reporting entity or agency, domestic, foreign or supranational.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
VIII. &ldquo;Law&rdquo; means any applicable foreign, federal, state or local law (including common law), statute, treaty, rule, directive,
regulation, ordinances and similar provisions having the force or effect of law or an Order of any Governmental Entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
IX. &ldquo;Liabilities&rdquo; means liabilities, obligations or responsibilities of any nature whatsoever, whether direct or indirect,
matured or un-matured, fixed or unfixed, known or unknown, asserted or un asserted, choate or inchoate, liquidated or unliquidated, secured
or unsecured, absolute, contingent or otherwise, including any direct or indirect indebtedness, guaranty, endorsement, claim, loss, damage,
deficiency, cost or expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
X. &ldquo;Lien&rdquo; means, with respect to any property or asset, any lien, security interest, mortgage, pledge, charge, claim, lease,
agreement, right of first refusal, option, limitation on transfer or use or assignment or licensing, restrictive easement, charge or
any other restriction of any kind, and any conditional sale or voting agreement or proxy, and including any restriction on the ownership,
use, voting, transfer, possession, receipt of income or other exercise of any attributes of ownership, in respect of such property or
asset, and any agreement to give any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XI. &ldquo;Order&rdquo; means any judgment, writ, decree, determination, award, compliance agreement, settlement agreement, injunction,
ruling, charge, judicial or administrative order, determination or other restriction of any Governmental Entity or arbitrator.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XII. &ldquo;Person&rdquo; means a natural person, a corporation, a limited liability company, a partnership, an association, a trust
or any other entity or organization, including a government or political subdivision or any agency or instrumentality thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XIII. &ldquo;Securities Act&rdquo; means the United States Securities Act of 1933, as amended, and the rules and regulation promulgated
thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XIV. &ldquo;Transactions&rdquo; means the subscription and issuance of the Shares and the other transactions contemplated under the Transaction
Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XV. &ldquo;Transaction Documents&rdquo; means this Agreement and any other agreement, document, certificate or writing delivered or to
be delivered in connection with this Agreement and any other document related to the Transactions related to the forgoing, including,
without limitations, those delivered at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XVI. Interpretive Provisions. Unless the express context otherwise requires, the words &ldquo;hereof,&rdquo; &ldquo;herein,&rdquo; and
&ldquo;hereunder&rdquo; and words of similar import, when used in this Agreement, shall refer to this Agreement as a whole and not to
any particular provision of this Agreement; terms defined in the singular shall have a comparable meaning when used in the plural, and
vice versa; the terms &ldquo;Dollars&rdquo; and &ldquo;$&rdquo; mean United States Dollars, unless otherwise specified herein; references
herein to a specific Section, Subsection or Recital shall refer, respectively, to Sections, Subsections or Recitals of this Agreement;
wherever the word &ldquo;include,&rdquo; &ldquo;includes,&rdquo; or &ldquo;including&rdquo; is used in this Agreement, it shall be deemed
to be followed by the words &ldquo;without limitation&rdquo;; references herein to any gender shall include each other gender; references
herein to any Person shall include such Person&rsquo;s heirs, executors, personal representatives, administrators, successors and assigns;
provided, however, that nothing contained in this Article XVI is intended to authorize any assignment or transfer not otherwise permitted
by this Agreement; references herein to a Person in a particular capacity or capacities shall exclude such Person in any other capacity;
references herein to any contract or agreement (including this Agreement) mean such contract or agreement as amended, supplemented or
modified from time to time in accordance with the terms thereof; with respect to the determination of any period of time, the word &ldquo;from&rdquo;
means &ldquo;from and including&rdquo; and the words &ldquo;to&rdquo; and &ldquo;until&rdquo; each means &ldquo;to but excluding&rdquo;;
references herein to any Law or any license mean such Law or license as amended, modified, codified, reenacted, supplemented or superseded
in whole or in part, and in effect from time to time; and references herein to any Law shall be deemed also to refer to all rules and
regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article
  XVII.</B></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Subscription</U></B></FONT></TD></TR>
</TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 44pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XVIII. Subscription. Subject to the terms and conditions of this Agreement and as set forth below, at the Closing (as defined below)
the Company shall issue and sell to Subscriber 10,000 shares of Common Stock (the &ldquo;Shares&rdquo;) at a subscription price of US$5
per Share, for a resulting total subscription price of US$50,000 (the &ldquo;Subscription Price&rdquo;). Such Shares shall be free from
any encumbrance liens and third-party rights whatever and shall rank pari passu with all shares in issue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XIX. Deliverables at Closing. At the Closing (as defined below):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XX. Subscriber shall deliver to the Company the Subscription Price, via wire transfer to an account as designated by the Company; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXI. The Company shall issue to Subscriber the Shares via book entry in the books and records of the Company, and the Parties acknowledge
that the Shares shall not be certificated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXII. Closing. On the terms set forth herein, the closing of the Transactions (the &ldquo;Closing&rdquo;) shall take place by conference
call and electronic communication (i.e., emails/pdf) or facsimile, with exchange of original signatures to follow by mail, on the Closing
Date, immediately after the execution of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article
  XXIII.</B></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Piggyback
  Registration Rights.</U></B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXIV. Registration Rights. For purposes herein, &ldquo;Registrable Securities&rdquo; means the Shares acquired by the Subscriber hereunder.
If at any time while the Subscriber remains the holder of any Registrable Securities the Company proposes to file any registration statement
under the Securities Act with respect to the Common Stock (a &ldquo;Registration Statement&rdquo;) for its own account or for shareholders
of the Company for their account (or by the Company and by shareholders of the Company), other than a Registration Statement (i) filed
in connection with any employee stock option or other benefit plan, (ii) for a dividend reinvestment plan or (iii) in connection with
a merger or acquisition, then the Company shall (x) give written notice of such proposed filing to Subscriber as soon as practicable
but in no event less than ten (10) days before the anticipated filing date of the Registration Statement, which notice shall describe
the amount and type of securities to be included in such Registration Statement, the intended method(s) of distribution, and the name
of the proposed managing underwriter or underwriters, if any, of the offering, and (y) offer to Subscriber in such notice the opportunity
to register the sale of such number of Registrable Securities as Subscriber may request in writing within five (5) days following receipt
of such notice (a &ldquo;Piggyback Registration&rdquo;). The Company shall cause such Registrable Securities to be included in such registration
and shall cause the managing underwriter or underwriters of a proposed underwritten offering to permit the Registrable Securities requested
to be included in a Piggyback Registration on the same terms and conditions as any similar securities of the Company and to permit the
sale or other disposition of such Registrable Securities in accordance with the intended method(s) of distribution thereof. If Subscriber
proposes to distribute its Registrable Securities through a Piggyback Registration that involves an underwriter or underwriters, then
it shall enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such Piggyback Registration,
and the Subscriber also agrees to execute and deliver a customary lock-up agreement if so requested by the Company and/or the underwriter(s),
pursuant to which the Subscriber agrees to customary restrictions on resale of the securities of the Company for a period of 180 days.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXV. Limitations. If a Piggyback Registration is initiated as a primary underwritten offering on behalf of the Company and the managing
underwriter advises the Company and the Subscriber and other persons who are holders of any other shares of Common Stock which are also
&ldquo;Registrable Securities&rdquo; under an agreement similar to this Article III (if any holders of Registrable Securities have elected
to include Registrable Securities in such Piggyback Registration) in writing that in its reasonable and good faith opinion the number
of shares of Common Stock proposed to be included in such registration, including all Registrable Securities and all other shares of
Common Stock proposed to be included in such underwritten offering, exceeds the number of shares of Common Stock which can be sold in
such offering and/or that the number of shares of Common Stock proposed to be included in any such registration or takedown would adversely
affect the price per share of the Common Stock to be sold in such offering, the Company shall include in such registration (i) first,
the shares of Common Stock that the Company proposes to sell; and (ii) the shares of Common Stock requested to be included therein by
the Subscriber and the other holders of Registrable Securities, allocated among the Subscriber and such other holders pro rata based
on the number of Registrable Securities held by each of Subscriber and such other holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Options: NewSection; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXVI. Withdrawal. Subscriber may elect to withdraw such Subscriber&rsquo;s request for inclusion of Registrable Securities in any Piggyback
Registration by giving written notice to the Company of such request to withdraw prior to the effectiveness of the Registration Statement.
The Company (whether on its own determination or as the result of a withdrawal by persons making a demand pursuant to written contractual
obligations) may withdraw a Registration Statement at any time prior to the effectiveness of such Registration Statement. Notwithstanding
any such withdrawal, the Company shall pay all expenses incurred by Subscriber of Registrable Securities in connection with such Piggyback
Registration as provided in Section 3.06.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXVII. Notification. The Company shall notify Subscriber at any time when a prospectus relating to such Subscriber&rsquo;s Registrable
Securities is required to be delivered under the Securities Act, upon discovery that, or upon the happening of any event as a result
of which, the prospectus included in such Registration Statement, as then in effect, includes an untrue statement of a material fact
or omits to state any material fact required to be stated therein or necessary to make the statements therein not misleading in light
of the circumstances then existing. At the request of Subscriber, the Company shall also prepare, file and furnish to Subscriber a reasonable
number of copies of a supplement to or an amendment of such prospectus as may be necessary so that, as thereafter delivered to Subscriber,
such prospectus shall not include an untrue statement of a material fact or omit to state a material fact required to be stated therein
or necessary to make the statements therein not misleading in light of the circumstances then existing. Subscriber shall not offer or
sell any Registrable Securities covered by the Registration Statement after receipt of such notification until the receipt of such supplement
or amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXVIII. Information. The Company may request that Subscriber furnish the Company such information with respect to Subscriber and Subscriber&rsquo;s
proposed distribution of the Registrable Securities pursuant to the Registration Statement as the Company may from time to time reasonably
request in writing or as shall be required by law or by the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) in connection
therewith, and Subscriber shall furnish the Company with such information as a condition of the exercise of Subscriber of the rights
as set forth in this Article III.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXIX. Fees and Expenses. <FONT STYLE="text-transform: uppercase">A</FONT>ll fees and expenses incident to the performance of or compliance
with this Article III by the Company shall be borne by the Company whether or not any Registrable Securities are sold pursuant to a Registration
Statement. The fees and expenses referred to in the foregoing sentence shall include, without limitation, (i) all registration and filing
fees (including, without limitation, fees and expenses of the Company&rsquo;s counsel and independent registered public accountants)
(A) with respect to filings made with the SEC, (B) with respect to filings required to be made with any trading market on which the Common
Stock is then listed for trading, (C) in compliance with applicable state securities or Blue Sky laws reasonably agreed to by the Company
in writing (including, without limitation, fees and disbursements of counsel for the Company in connection with Blue Sky qualifications
or exemptions of the Registrable Securities) and (D) with respect to any filing that may be required to be made by any broker through
which Subscriber of Registrable Securities intends to make sales of Registrable Securities with the FINRA, (ii) printing expenses, (iii)
messenger, telephone and delivery expenses, (iv) fees and disbursements of counsel for the Company, (v) Securities Act liability insurance,
if the Company so desires such insurance, and (vi) fees and expenses of all other persons or entities retained by the Company in connection
with the consummation of the transactions contemplated by this Article III. In addition, the Company shall be responsible for all of
its internal expenses incurred in connection with the consummation of the transactions contemplated by this Article III (including, without
limitation, all salaries and expenses of its officers and employees performing legal or accounting duties), the expense of any annual
audit and the fees and expenses incurred in connection with the listing of the Registrable Securities on any securities exchange as required
hereunder. In no event shall the Company be responsible for any broker or similar commissions of Subscriber.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article XXX.</B></FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Representations and Warranties of the Company</U></B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company represents and warrants to Subscriber that the following representations and warranties contained in this Ariticle XXXI to XL
are true and correct as of the Closing Date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXXI. Authorization of Transactions. The Company is a corporation duly authorized and in good standing in the State of Delaware and has
the requisite power and capacity to execute and deliver the Transaction Documents to which it is a party and to perform its obligations
hereunder and thereunder. The execution, delivery and performance by the Company of the applicable Transaction Documents and the consummation
of the Transactions have been duly and validly authorized by all requisite action on the part of the Company. The Transaction Documents
to which the Company is a party have been duly and validly executed and delivered by The Company. Each Transaction Document to which
the Company is a party constitutes the valid and legally binding obligation of the Company, enforceable against the Company in accordance
with its terms and conditions, except to the extent enforcement thereof may be limited by applicable bankruptcy, insolvency or other
Laws affecting the enforcement of creditors&rsquo; rights or by the principles governing the availability of equitable remedies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXXII. Governmental Approvals; Non-contravention.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXXIII. No consent, Order, action or non-action of, or filing, notification, declaration or registration with, any Governmental Entity
or Person is necessary for the execution, delivery or performance by the Company of this Agreement or any other Transaction Document
to which the Company is a party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXXIV. The execution, delivery and performance by the Company of the Transaction Documents to which the Company is a party, and the consummation
by the Company of the Transactions, do not (i) violate any Laws or Orders to which the Company is subject or (ii) violate, breach or
conflict with any provision of the Company&rsquo;s organizational documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXXV. Brokers. The Company has not engaged, or caused to be incurred any Liability or obligation to, any investment banker, finder, broker
or sales agent or any other Person in connection with the origin, negotiation, execution, delivery or performance of the Transaction
Documents to which it is a party, or the Transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article XXXVI.</B></FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Representations and Warranties of Subscriber</U></B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscriber
represents and warrants to the Company that the following statements contained in this Article V are true and correct as of the Closing
Date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXXVII. Authorization of Transactions. Subscriber is OPTIMIZE WELLNESS LIMITED, duly authorized and in good standing in the jurisdiction
of its organization and has the requisite power and capacity to execute and deliver the Transaction Documents to which it is a party
and to perform its obligations hereunder and thereunder. The execution, delivery and performance by Subscriber of the applicable Transaction
Documents and the consummation of the Transactions have been duly and validly authorized by all requisite action on the part of Subscriber.
The Transaction Documents to which Subscriber is a party have been duly and validly executed and delivered by Subscriber. Each Transaction
Document to which Subscriber is a party constitutes the valid and legally binding obligation of Subscriber, enforceable against Subscriber
in accordance with its terms and conditions, except to the extent enforcement thereof may be limited by applicable bankruptcy, insolvency
or other Laws affecting the enforcement of creditors&rsquo; rights or by the principles governing the availability of equitable remedies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXXVIII. Governmental Approvals; Non-contravention.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXXIX. No consent, Order, action or non-action of, or filing, notification, declaration or registration with, any Governmental Entity
is necessary for the execution, delivery or performance by Subscriber of this Agreement or any other Transaction Document to which Subscriber
is a party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XL. The execution, delivery and performance by Subscriber of the Transaction Documents to which Subscriber is a party, and the consummation
by Subscriber of the Transactions, do not (i) violate any Laws or Orders to which Subscriber is subject [or (ii) violate, breach or conflict
with any provision of Subscriber&rsquo;s organizational documents].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XLI. Investment Representations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XLII. Subscriber understands and agrees that the consummation of this Agreement including the delivery of the Shares to Subscriber as
contemplated hereby constitutes the offer and sale of securities under the Securities Act and applicable state statutes and that the
Shares are being acquired for Subscriber&rsquo;s own account and not with a present view towards the public sale or distribution thereof,
except pursuant to sales registered or exempted from registration under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XLIII. Subscriber is an &ldquo;accredited investor&rdquo; as that term is defined in Rule 501(a) of Regulation D under the Securities
Act (an &ldquo;Accredited Investor&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XLIV. Subscriber understands that the Shares are being offered and sold to Subscriber in reliance upon specific exemptions from the registration
requirements of United States federal and state securities Laws and that the Company is relying upon the truth and accuracy of, and Subscriber&rsquo;s
compliance with, the representations, warranties, agreements, acknowledgments and understandings of Subscriber set forth herein in order
to determine the availability of such exemptions and the eligibility of Subscriber to acquire the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XLV. Subscriber and its advisors, if any, have been furnished with all materials relating to the business, finances and operations of
the Company and materials relating to the offer and sale of the Shares which have been requested by Subscriber or its advisors. Subscriber
and its advisors, if any, have been afforded the opportunity to ask questions of the Company. Subscriber understands that its investment
in the Shares involves a significant degree of risk.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XLVI. At no time was Subscriber presented with or solicited by any leaflet, newspaper or magazine article, radio or television advertisement,
or any other form of general advertising or solicited or invited to attend a promotional meeting otherwise than in connection and concurrently
with such communicated offer. Subscriber is not purchasing the Shares acquired by Subscriber hereunder as a result of any &ldquo;general
solicitation&rdquo; or &ldquo;general advertising,&rdquo; as such terms are defined in Regulation D under the Securities Act, which includes,
but is not limited to, any advertisement, article, notice or other communication regarding the Shares acquired by Subscriber hereunder
published in any newspaper, magazine or similar media or on the internet or broadcast over television, radio or the internet or presented
at any seminar or any other general solicitation or general advertisement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XLVII. Subscriber is acquiring the Shares for its own account as principal, not as a nominee or agent, for investment purposes only,
and not with a view to, or for, resale, distribution or fractionalization thereof in whole or in part and no other person has a direct
or indirect beneficial interest in the Shares. Further, Subscriber does not have any contract, undertaking, agreement or arrangement
with any person to sell, transfer or grant participations to such person or to any third person, with respect to the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XLVIII. Subscriber understands that (i) the sale or re-sale of the Shares has not been and is not being registered under the Securities
Act or any applicable state securities laws, and the Shares may not be transferred unless (1) the Shares are sold pursuant to an effective
registration statement under the Securities Act, (2) Subscriber shall have delivered to the Company, at the cost of Subscriber, an opinion
of counsel that shall be in form, substance and scope customary for opinions of counsel in comparable transactions to the effect that
the Shares to be sold or transferred may be sold or transferred pursuant to an exemption from such registration, which opinion shall
be accepted by the Company, (3) the Shares are sold or transferred to an &ldquo;affiliate&rdquo; (as defined in Rule 144 promulgated
under the Securities Act (or a successor rule) (&ldquo;Rule 144&rdquo;)) of Subscriber who agrees to sell or otherwise transfer the Shares
only in accordance with this Section and who is an Accredited Investor, (4) the Shares are sold pursuant to Rule 144, (5) the Shares
are sold pursuant to Regulation S under the Securities Act (or a successor rule) (&ldquo;Regulation S&rdquo;), or (6) the Shares are
sold pursuant to the exemption from registration afforded under Section 4(a)(1) or Section 4(a)(7) of the Securities Act, and Subscriber
shall have delivered to the Company, at the cost of Subscriber, an opinion of counsel that shall be in form, substance and scope customary
for opinions of counsel in corporate transactions, which opinion shall be accepted by the Company; (ii) any sale of such Shares made
in reliance on Rule 144 may be made only in accordance with the terms of said Rule and further, if said Rule is not applicable, any re-sale
of such Shares under circumstances in which the seller (or the person through whom the sale is made) may be deemed to be an underwriter
(as that term is defined in the Securities Act) may require compliance with some other exemption under the Securities Act or the rules
and regulations of the SEC thereunder; and (iii) neither the Company nor any other person is under any obligation to register such Shares
under the Securities Act or any state securities laws or to comply with the terms and conditions of any exemption thereunder (in each
case).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XLIX. Subscriber understands that no public market now exists for the Shares, and that the Company has made no assurances that a public
market will ever exist for the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
L. Subscriber, either alone or together with its representatives, has such knowledge, sophistication and experience in business and financial
matters so as to be capable of evaluating the merits and risks of the prospective investment in the Shares, and has so evaluated the
merits and risks of such investment. Subscriber is able to bear the economic risk of an investment in the Shares and, at the present
time, is able to afford a complete loss of such investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LI. Subscriber understands that no United States federal or state agency or any other governmental or state agency has passed on or made
recommendations or endorsement of the Shares or the suitability of the investment in the Shares nor have such authorities passed upon
or endorsed the merits of the transactions set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LII. Any legend required by the securities laws of any state to the extent such laws are applicable to the Shares represented by the
certificate so legended shall be included on any certificates representing the Shares. Subscriber also understands that the Shares may
bear the following or a substantially similar legend:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, NOR REGISTERED OR QUALIFIED
UNDER ANY STATE SECURITIES LAWS. SUCH SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, DELIVERED AFTER SALE, TRANSFERRED, PLEDGED, OR HYPOTHECATED
UNLESS QUALIFIED AND REGISTERED UNDER APPLICABLE STATE AND FEDERAL SECURITIES LAWS OR UNLESS, IN THE OPINION OF COUNSEL REASONABLY SATISFACTORY
TO THE COMPANY, SUCH QUALIFICATION AND REGISTRATION ARE NOT REQUIRED. ANY TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE
IS FURTHER SUBJECT TO OTHER RESTRICTIONS, TERMS AND CONDITIONS WHICH ARE NOT SET FORTH HEREIN.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LIII. Brokers. Subscriber has not engaged any investment banker, finder, broker or sales agent or any other Person in connection with
the origin, negotiation, execution, delivery or performance of any Transaction Document to which it is a party, or the Transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article LIV. </B></FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Indemnification</U></B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LV. Indemnification With Respect to Registration Rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LVI. <I>By the Company. </I>The Company shall indemnify and hold harmless Subscriber, the officers, directors, members, partners, agents
and employees (and any other individuals or entities with a functionally equivalent role of a person holding such titles, notwithstanding
a lack of such title or any other title) of Subscriber, each individual or entity who controls Subscriber (within the meaning of Section
15 of the Securities Act or Section 20 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;) and the officers,
directors, members, partners, agents and employees (and any other individuals or entities with a functionally equivalent role of a person
holding such titles, notwithstanding a lack of such title or any other title) of each such controlling individual or entity (each, a
&ldquo;Subscriber Indemnified Party&rdquo;), to the fullest extent permitted by applicable law, from and against any and all Losses,
as incurred, arising out of or relating to (1) any untrue or alleged untrue statement of a material fact contained in a Registration
Statement, any related prospectus or any form of prospectus or in any amendment or supplement thereto or in any preliminary prospectus,
or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make
the statements therein (in the case of any such prospectus or supplement thereto, in light of the circumstances under which they were
made) not misleading or (2) any violation or alleged violation by the Company of the Securities Act, the Exchange Act or any state securities
law, or any rule or regulation thereunder, in connection with the performance of its obligations under Article III, except to the extent,
but only to the extent, that (i) such untrue statements or omissions are based upon information regarding Subscriber furnished to the
Company by such party for use therein. The Company shall notify Subscriber promptly of the institution, threat or assertion of any proceeding
arising from or in connection with the transactions contemplated by Article III of which the Company is aware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Article
LVII. By Subscriber. </I>Subscriber and its successors and assigns shall indemnify and hold harmless the Company, the officers, directors,
members, partners, agents and employees (and any other individuals or entities with a functionally equivalent role of a person holding
such titles, notwithstanding a lack of such title or any other title) of the Company, each individual or entity who controls the company
(within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) and the officers, directors, members, partners,
agents and employees (and any other individuals or entities with a functionally equivalent role of a person holding such titles, notwithstanding
a lack of such title or any other title) of each such controlling individual or entity (each, a &ldquo;Company Indemnified Party&rdquo;),
to the fullest extent permitted by applicable law, from and against any and all Losses, as incurred, arising out of or relating to (1)
any untrue or alleged untrue statement of a material fact contained in a Registration Statement, any related prospectus or any form of
prospectus or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission
or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any
such prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading or (2) any violation
or alleged violation by the Company of the Securities Act, the Exchange Act or any state securities law, or any rule or regulation thereunder,
in connection with the performance of its obligations under Article III, but only to the extent that such untrue statements or omissions
are based upon information regarding Subscriber furnished to the Company by such Party for use therein. Subscriber shall notify the Company
promptly of the institution, threat or assertion of any proceeding arising from or in connection with the transactions contemplated by
Article III of which Subscriber is aware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LVIII. <I>Contribution. </I>If the indemnification under Section 6.01(a) or Section 6.01(b), as applicable, is unavailable to a Company
Indemnified Party or a Subscriber Indemnified Party or is insufficient to hold a Company Indemnified Party or a Subscriber Indemnified
Party, as applicable, harmless for any Losses, then the Indemnifying Party shall contribute to the amount paid or payable by such Company
Indemnified Party or a Subscriber Indemnified Party, as applicable, in such proportion as is appropriate to reflect the relative fault
of the Indemnifying Party and Company Indemnified Party or a Subscriber Indemnified Party, as applicable, in connection with the actions,
statements or omissions that resulted in such Losses pursuant to this Section 6.01, as well as any other relevant equitable considerations.
The relative fault of the Indemnifying Party and Company Indemnified Party or a Subscriber Indemnified Party, as applicable, shall be
determined by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of a
material fact or omission or alleged omission of a material fact, has been taken or made by, or relates to information supplied by, the
Indemnifying Party or the Company Indemnified Party or a Subscriber Indemnified Party, as applicable, and the Parties&rsquo; relative
intent, knowledge, access to information and opportunity to correct or prevent such action, statement or omission. The amount paid or
payable by a Party as a result of any Losses shall be deemed to include any reasonable attorneys&rsquo; or other fees or expenses incurred
by such Party in connection with any proceeding to the extent such Party would have been indemnified for such fees or expenses if the
indemnification provided for in Section 6.01(a) or Section 6.01(b), as applicable, was available to such Party in accordance with its
terms. It is agreed that it would not be just and equitable if contribution pursuant to this Section 6.01(c) were determined by pro rata
allocation or by any other method of allocation that does not take into account the equitable considerations referred to in the immediately
preceding sentence. The provisions of this Section 6.01(c) shall apply solely to the indemnification obligations as set forth in this
Section 6.01.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LIX. General Indemnification. Each Party (as required herein, the &ldquo;Indemnifying Party&rdquo;) agrees to indemnify, defend and hold
harmless the other Party and such other Party&rsquo;s Affiliates and each of their respective directors, officers, managers, partners,
employees, agents, equity holders, successors and assigns (as required herein, and including any Company Indemnified Party or a Subscriber
Indemnified Party, as applicable, pursuant to Section 6.01, each, an &ldquo;Indemnified Party&rdquo;), from and against any and all losses,
claims, damages, liabilities, costs (including, without limitation, reasonable attorneys&rsquo; fees) and expenses (collectively, &ldquo;Losses&rdquo;),
incurred or suffered by any Indemnified Party arising out of, based upon or resulting from any breach of any representation or warranty
of the Indemnifying Party herein or breach by the Indemnifying Party of, or any failure the Indemnifying Party to perform, any of the
covenants, agreements or obligations contained in or made pursuant to this Agreement of the other Transaction Documents by the Indemnifying
Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LX. Procedures for Indemnification. In the event that an Indemnified Party shall incur or suffer any Losses in respect of which indemnification
may be sought under this Article VI against the Indemnifying Party, the Indemnified Party shall assert a claim for indemnification by
providing a written notice (the &ldquo;Notice of Loss&rdquo;) to the Indemnifying Party stating the nature and basis of such indemnification.
The Notice of Loss shall be provided to the Indemnifying Party as soon as practicable after the Indemnified Party becomes aware that
it has incurred or suffered a Loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXI. Payment. Upon a determination of liability under this Article VI the Indemnifying Party shall pay or cause to be paid to the Indemnified
Party the amount so determined within five (5) Business Days after the date of such determination. If there should be a dispute as to
the amount or manner of determination of any indemnity obligation owed under this Agreement or the other Transaction Documents, the Indemnifying
Party shall nevertheless pay when due such portion, if any, of the obligation that is not subject to dispute. Upon the payment in full
of any amounts due under this Article VI with respect to any claim, the Indemnifying Party shall be subrogated to the rights of the Indemnified
Party against any Person with respect to the subject matter of such claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXII. Effect of Knowledge on Indemnification. The right to indemnification, reimbursement or other remedy based upon any representations,
warranties, covenants and obligations set forth in this Agreement or the other Transaction Documents shall not be affected by any investigation
conducted with respect to, or any knowledge acquired (or capable of being acquired) at any time, whether before or after the execution
and delivery of this Agreement or the other Transaction Documents, with respect to the accuracy or inaccuracy of or compliance with any
such representation, warranty, covenant or obligation. The waiver of any condition based upon the accuracy of any representation or warranty,
or on the performance of or compliance with any covenant or obligation, shall not affect the right to indemnification, reimbursement
or other remedy based upon such representations, warranties, covenants or obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article LXIII. </B></FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Miscellaneous</U></B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXIV. Notices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXV. Any notice or other communications required or permitted hereunder shall be in writing and shall be sufficiently given if personally
delivered to it or sent by email, overnight courier or registered mail or certified mail, postage prepaid, addressed as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
to the Company, to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter
Neurosciences, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Christer Ros&eacute;n</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1001
North US Hwy 1, Ste 504</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter,
FL 33477</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
c.rosen@jupiterneurosciences.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
a copy, which shall not constitute notice, to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anthony,
Linder &amp; Cacomanolis, PLLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
John Cacomanolis</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1700
Palm Beach Lakes Blvd., Suite 820</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">West
Palm Beach, FL 33401</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
jcacomanolis@alclaw.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to Subscriber, to the address as set forth on the signature pages hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXVI. Any Party may change its address for notices hereunder upon notice to each other Party in the manner for giving notices hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXVII. Any notice hereunder shall be deemed to have been given (i) upon receipt, if personally delivered, (ii) on the day after dispatch,
if sent by overnight courier, (iii) upon dispatch, if transmitted by email with return receipt requested and received and (iv) three
(3) days after mailing, if sent by registered or certified mail.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXVIII. Attorneys&rsquo; Fees. In the event that any Party institutes any action or suit to enforce this Agreement or the other Transaction
Documents or to secure relief from any default hereunder or breach hereof, the prevailing Party shall be reimbursed by the losing Party
for all costs, including reasonable attorney&rsquo;s fees, incurred in connection therewith and in enforcing or collecting any judgment
rendered therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXIX. Amendments; No Waivers; No Third-Party Beneficiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXX. This Agreement may be amended, modified, superseded, terminated or cancelled, and any of the terms, covenants, representations,
warranties or conditions hereof may be waived, only by a written instrument executed by all of the Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXI. Every right and remedy provided herein shall be cumulative with every other right and remedy, whether conferred herein, at law,
or in equity, and may be enforced concurrently herewith, and no waiver by any Party of the performance of any obligation by another Party
shall be construed as a waiver of the same or any other default then, theretofore, or thereafter occurring or existing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXII. Neither any failure or delay in exercising any right or remedy hereunder or in requiring satisfaction of any condition herein
nor any course of dealing shall constitute a waiver of or prevent any Party from enforcing any right or remedy or from requiring satisfaction
of any condition. No notice to or demand on a Party waives or otherwise affects any obligation of that Party or impairs any right of
the Party giving such notice or making such demand, including any right to take any action without notice or demand not otherwise required
by this Agreement or the other Transaction Documents. No exercise of any right or remedy with respect to a breach of this Agreement or
the other Transaction Documents shall preclude exercise of any other right or remedy, as appropriate to make the aggrieved Party whole
with respect to such breach, or subsequent exercise of any right or remedy with respect to any other breach.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXIII. This Agreement is intended for the benefit of the Parties and their respective successors and permitted assigns and is not for
the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Article VI.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXIV. No Consequential Damages. <FONT STYLE="font-variant: small-caps">Notwithstanding anything else contained herein, no Party shall
seek, nor shall any Party be liable for, consequential, punitive or exemplary damages, under any tort, contract, equity, or other legal
theory, with respect to any breach (or alleged breach) of this Agreement or the other Transaction Documents or any provision hereof or
any matter otherwise relating hereto or arising in connection herewith.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXV. Expenses. Unless otherwise contemplated or stipulated by this Agreement, all costs and expenses incurred in connection with this
Agreement or the other Transaction Documents shall be paid by the Party incurring such cost or expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXVI. Further Assurances. Following the Closing, each Party shall execute and deliver such documents and other papers and take such
further action as may be reasonably required to carry out the provisions of the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXVII. Successors and Assigns. This Agreement shall be binding upon and shall inure to the benefit of the Parties and their respective
successors and permitted assigns. No Party shall have any power or any right to assign or transfer, in whole or in part, this Agreement,
or any of its rights or any of its obligations hereunder, including, without limitation, any right to pursue any claim for damages pursuant
to this Agreement or the transactions contemplated herein, or to pursue any claim for any breach or default of this Agreement, or any
right arising from the purported assignor&rsquo;s due performance of its obligations hereunder, without the prior written consent of
the other Party and any such purported assignment in contravention of the provisions herein shall be null and void and of no force or
effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXVIII. Governing Law; Etc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXIX. This Agreement, and any and all claims, proceedings or causes of action relating to this Agreement or arising from this Agreement
or the transactions contemplated herein, including, without limitation, tort claims, statutory claims and contract claims, shall be interpreted,
construed, governed and enforced under and solely in accordance with the substantive and procedural laws of the State of Delaware, in
each case as in effect from time to time and as the same may be amended from time to time, and as applied to agreements performed wholly
within the State of Delaware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXX. SUBJECT TO Section 7.09, ANY LEGAL SUIT, ACTION OR PROCEEDING ARISING OUT OF OR BASED UPON THIS AGREEMENT, THE OTHER TRANSACTION
DOCUMENTS OR THE CONTEMPLATED TRANSACTIONS SHALL BE INSTITUTED SOLELY IN THE STATE OF FLORIDA OR THE FEDERAL COURTS OF THE UNITED STATES,
IN EACH CASE LOCATED IN PALM BEACH COUNTY, FLORIDA, AND EACH PARTY IRREVOCABLY SUBMITS TO THE PERSONAL JURISDICTION OF SUCH COURTS IN
ANY SUCH SUIT, ACTION OR PROCEEDING. THE PARTIES IRREVOCABLY AND UNCONDITIONALLY WAIVE ANY OBJECTION TO THE LAYING OF VENUE OF ANY SUIT,
ACTION OR ANY PROCEEDING IN SUCH COURTS AND IRREVOCABLY WAIVE AND AGREE NOT TO PLEAD OR CLAIM IN ANY SUCH COURT THAT ANY SUCH SUIT, ACTION
OR PROCEEDING BROUGHT IN ANY SUCH COURT HAS BEEN BROUGHT IN AN INCONVENIENT FORUM.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXXI. EACH PARTY HERETO HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN
ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS, THE PERFORMANCE THEREOF
OR THE FINANCINGS CONTEMPLATED THEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). EACH PARTY HERETO (A) CERTIFIES THAT NO
REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE
EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED
TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS Section 7.08(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXXII. Each of the Parties acknowledge that each has been represented in connection with the signing of this waiver by independent legal
counsel selected by the respective Party and that such Party has discussed the legal consequences and import of this waiver with legal
counsel. Each of the Parties further acknowledge that each has read and understands the meaning of this waiver and grants this waiver
knowingly, voluntarily, without duress and only after consideration of the consequences of this waiver with legal counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXXIII. Resolution of Disputes. Except as otherwise provided herein, all controversies, disputes or actions between the Parties arising
out of the Transactions or this Agreement or the other Transaction Documents, including their respective Affiliates, owners, officers,
directors, agents and employees, arising from or relating to this Agreement or the other Transaction Documents shall on demand of either
party be submitted for arbitration to in accordance with the rules and regulations of the American Arbitration Association. The arbitration
shall be conducted by one arbitrator jointly selected by each Party, provided, however, that if the Parties are unable to agree on the
identity of the arbitrator within 10 Business Days of commencement of efforts to do so, each Party shall select one arbitrator and the
arbitrators so selected shall select a final arbitrator, and the final arbitrator shall conduct the arbitration alone. The Parties agree
that, in connection with any such arbitration proceeding, each shall submit or file any claim which would constitute a compulsory counterclaim
(as defined by Rule 13 of the Federal Rules of Civil Procedures) within the same proceeding as the claim to which it relates. Any such
claim which is not submitted or filed in such proceeding shall be barred. The arbitrator shall be instructed to use every reasonable
effort to perform its services within seven days of request, and, in any case, as soon as practicable. The Parties agree to be bound
by the provisions of any limitation on the period of time by which claims must be brought under Delaware law or any applicable federal
law. The arbitrator(s) shall have the right to award the relief which he or she deems proper, consistent with the terms of this Agreement
or the other Transaction Documents, including compensatory damages (with interest on unpaid amounts from due date), injunctive relief,
specific performance, legal damages and costs. The award and decision of the arbitrator(s) shall be conclusive and binding on all Parties,
and judgment upon the award may be entered in any court of competent jurisdiction. Any right to contest the validity or enforceability
of this award shall be governed exclusively by the United States Arbitration Act. The arbitration shall be conducted in Jupiter, Florida.
The provisions of this Section 7.09 shall continue in full force and effect subsequent to and notwithstanding the expiration or termination
of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXXIV. Survival. The representations and warranties in this Agreement shall survive the Closing for a period of 12 months from the Closing
Date, and no claim for indemnification may be made after such time. All covenants and agreements in this Agreement will survive until
fully performed; provided, however, that, nothing herein shall prevent a Party from making any claim hereunder, or relieve any other
Party from any liability hereunder, after such time for any breach thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 26; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXXVI. Severability. If any provision of this Agreement is invalid, illegal or incapable of being enforced by any rule of law, or public
policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic
or legal substance of the Transactions is not affected in any manner adverse to any Party. Upon such determination that any provision
is invalid, illegal or incapable of being enforced, the Parties shall negotiate in good faith to modify this Agreement so as to effect
the original intent of the Parties as closely as possible in an acceptable manner to the end that the Transactions are fulfilled to the
extent possible.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXXVII. Entire Agreement. This Agreement and the other Transaction Documents constitute the entire agreement between the Parties with
respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, both oral and written, between
the Parties with respect to the subject matter hereof and thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXXVIII. Specific Performance. Each Party agrees that irreparable damage would occur if any provision of this Agreement and the other
Transaction Documents were not performed in accordance with the terms hereof and that each Party shall be entitled to seek specific performance
of the terms hereof and thereof in addition to any other remedy at law or in equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXXIX. Construction. The table of contents and headings contained in this Agreement are for reference purposes only and will not affect
in any way the meaning or interpretation of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XC. Counterparts. This Agreement may be executed in multiple counterparts, each of which shall be deemed an original and all of which
taken together shall be but a single instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic
signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart
so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signature
page follows]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 27; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed as of the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter
    Neurosciences, Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U STYLE="text-decoration: none">/s/
    Christer Ros&eacute;n</U></I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christer
    Ros&eacute;n</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OPTIMIZE
    WELLNESS LIMITED</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U STYLE="text-decoration: none">/s/
    Luk Kee Yan Kelvin</U></I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Luk
    Kee Yan Kelvin</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.36
<SEQUENCE>6
<FILENAME>ex10-36.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.36</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JUPITER
NEUROSCIENCES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2.1pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2.1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>And</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2.1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>REGIS
HEALTHCARE GROUP LIMITED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 50%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGULATORY
SERVICES AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 50%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
AGREEMENT is made on the 3<SUP>rd</SUP> day June of 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BETWEEN:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
    Neurosciences, Inc. with address </B>1001 North US Highway 1, Suite 504 Jupiter, FL 33477 (&ldquo;<B>JN</B>&rdquo;); and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regis
    Healthcare Group Limited (&ldquo;RSC&rdquo;)</B>, with address (CCS Trustees Limited, Mandar House, 3rd Floor, Johnson&rsquo;s Ghut,
    Tortola, British Virgin Islands)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(JN
and RSC are in some place referred to as a &ldquo;Party&rdquo; or when together the &ldquo;Parties&rdquo;.)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS
JN wishes RSC to provide certain services, as outlined in Schedule 1, in connection with advancing the business objectives of JN in Southeast
Asia; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS
RSC wishes to assist JN in accelerating JN&rsquo;s desire to get its products manufactured in the Asian market to support possible sales
and distribution; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS
RSC has the skills and knowhow regarding manufacturing of pharmaceutical products in the South-East Asian markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IT
IS HEREBY AGREED as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>INTERPRETATION</U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    this Agreement, unless the context requires otherwise:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Services&rdquo;
means the services set out in Schedule 1 or any other services which the Parties may agree from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Territory&rdquo;
means the countries of: China (including Hong Kong), Singapore and Malaysia.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Products&rdquo;
means the uniquely patented product, JOTROL, developed by JN as well as any other product JN might develop during the timeframe of this
Agreement (&ldquo;Products&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Equity&rdquo;
means common shares of JN that includes registration rights in a public offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">References
    herein to Clauses and Schedules are to Clauses and Schedules in this Agreement unless the context requires otherwise.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    headings are inserted for convenience only and shall not affect the construction of this Agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
    the context requires otherwise, words importing the singular include the plural and vice versa and words importing a gender include
    every gender.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>APPOINTMENT</U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JN
    hereby confirms the engagement of RSC and RSC hereby confirms its agreement to provide to JN the Services upon and subject to the
    terms set out in this Agreement.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    engagement of RSC to provide the Services shall commence upon closing of this Agreement, and services will be provided as outlined
    in Schedule 1, for a thirty-six (36) month period, with payment terms as outlined in &lsquo;Fees and Expenses.&rsquo;.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>RSC&rsquo;S
    UNDERTAKINGS</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CRO
warrants and undertakes to JN that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RSC
    will have the necessary skill and expertise to provide the Services on the terms set out herein;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RSC
    will provide independent and unbiased advice to JN in relation to the Services;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Services will be provided in a timely and professional manner;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    announcement or publicity concerning this Agreement or the Services or any matter ancillary thereto shall be made by any of the Parties
    without the prior written consent of the other Party.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>JN&rsquo;S
    OBLIGATIONS</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JN
shall provide full documentation and support to CRO regarding the details of JN&rsquo;s Products necessary for clinical trials, regulatory
filings and approvals of the Products in the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>ASSIGNMENT
    AND OWNERSHIP</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
Party shall be entitled to assign or sub-contract any of its/his rights or obligations under this Agreement without written approval
by the other party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
inventions and data that might be the result of RSC&rsquo;s actions and efforts with a product shall be completely owned by JN.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>FEES
    AND EXPENSES</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JN
has disclosed to RSC that JN has limited amount of cash to set up and support an accelerated operation in the Asian market. It has therefore
been agreed by RSC that JN will issue, credited as fully paid and free from encumbrances and restrictions to RSC equity in the form of
310,000 common shares (&ldquo;Consideration Shares&rdquo;) upon closing of this Agreement to be regarded as pre-payment in full for 36
months of services specified in Schedule 1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Consideration Shares will have registration rights in a JN Initial Public Offering (&ldquo;IPO&rdquo;) according to Schedule 2, as long
as an IPO is effective no later than March 31, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
additional expenses to meet the requested Services outlined, will be of the sole responsibility of RSC unless the Parties agree otherwise
in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>INVESTMENT
    BY RSC</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-decoration: none">RSC
commits, in addition to providing services to JN, to purchase 10,000 shares, prior to the IPO from JN as an investment in JN. The purchase
price of these shares is $5 per share and shall be paid accordint to terms stated in a separate Stock Subscription Agreement that is
attached as Schedule 3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>TERMINATION</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either
Party may terminate this Agreement without liability if:-</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JN
    fails to complete an Initial Public Offering of at least US$10 million gross proceeds on or before March 31 2025; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    petition is presented for the winding up or liquidation of the other Party, or anything analogous thereto occurs in respect of the
    other Party; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    any of the Parties are deemed to be involved in any illegal activities.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Agreement can be terminated at any time as long as this is agreed to by both parties.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>CONFIDENTIALITY</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RSC
shall not disclose to a third party any confidential information made available to it by, or on behalf, JN and will use such confidential
information only in connection with this Agreement; provided that such confidential information will not include any information : (i)
already in RSC possession prior to the date JN disclosed it to RSC; (ii) that becomes generally available to the public without violation
of this paragraph by RSC or its representatives; or (iii) that becomes available to RSC on a non-confidential basis from a third party
not bound by a confidentiality obligation to JN with respect to such information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>MUTUAL
    REPRESENTATION AND WARRANTIES</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
information made available to JN and RSC will, at all times during the period of this Agreement, to the best of RSC and JN&rsquo;s actual
knowledge, be complete and correct in all material respects and will not contain any untrue statements of material fact or omit to state
a material fact necessary in order to make the statements therein not misleading in light of the circumstances under which such statements
are made. All projections or guidance provided to the JN by RSC will have been prepared in good faith and will be based upon reasonable
assumptions derived from the best estimates and facts then available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>FORCE
    MAJEURE</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
Party shall be liable for any delay in performing any of its obligations under this Agreement if such delay is caused by circumstances
beyond the reasonable control of the Party so delaying and such Party shall be entitled (subject to giving the other Party full particulars
of the circumstances in question and to using its best endeavors to resume full performance without avoidable delay) to a reasonable
extension of time for the performance of such obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>LEGAL
    DISPUTES</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
disputes or controversies that may arise between the Parties in the interpretation or implementation of this Agreement shall be finally
settled by sole arbitration in Geneva, Switzerland in accordance with the Rules of the ICC International Court of Arbitration (ICC Rules).
The arbitration shall be conducted in the English language. The award rendered by arbitrator shall be final and binding upon the Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>GENERAL
    PROVISIONS</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    notice, demand or other communication between the Parties:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">may
    be sent by personal delivery, post, facsimile or other written form of electronic communication to the last known address;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    sent by post to an address to either Party, shall be treated as served on the second day following dispatch;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    sent by facsimile or other form of electronic communication, shall be treated as served at the time of sending.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    accommodation or indulgence or failure to enforce a right shall not be construed as a waiver of the right of any Party exercisable
    under this Agreement unless a waiver shall be specifically stated in writing signed by such Party.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    Agreement constitutes the entire understanding between the Parties concerning the subject matter hereof. No amendments or changes
    shall be made to this Agreement unless agreed to in writing by both Parties. Each provision of this Agreement shall be construed
    separately and notwithstanding that the whole or any part of any such provision may prove to be illegal or unenforceable the other
    provisions of this Agreement and the remainder of the provision in question shall continue in full force and effect.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    Party shall bear its own costs and expenses in connection with the preparation, negotiation and execution of this Agreement.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    formation, validity, performance and interpretation of this Agreement and of each Clause and part hereof shall be governed by the
    laws of State of Florida in the United States and the Parties agree to the non-exclusive jurisdiction of the courts of Palm Beach
    Country.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>COUNTERPART</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement may be executed in any number of counterparts, which when taken together shall constitute one and the same instrument and is
binding on each and every Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF the parties hereto have signed this Agreement the day and year first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNED
    Christer Ros&eacute;n</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    &amp; CEO</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Christer Ros&eacute;n</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    and on behalf of</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter
    Neurosciences, Inc.</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNED
    by Deng Hai</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Deng Hai</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    and on behalf of</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regis
    Healthcare Group Limited</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>SCHEDULE
1</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>The
Services</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
RSC Service Company shall provide services including, not limited to or inclusive of, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide
    JN with strategic guidance regarding pharmaceutical products regulatory environment in the Territory;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide
    and guide JN with a regulatory strategy to possibly obtain a regulatory approval in the Territory.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Propose
    priority of indications for an accelerated approval path;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Monitor
    regulatory changes within the Territory so JN and its partners can adapt its business strategy;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Participate
    in any required regulatory inspections that might be triggered by local and other authorities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assist
    and coordinate with any professional advisors in the regulatory field.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SCHEDULE
2</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Registration
rights of shares issued for payment of services.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares to be issued according to Paragraph 6 above shall have the same registration rights and provisions as described in the Stock Subscription
Agreement attached in Schedule 3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SCHEDULE
3</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
Subscription Agreement</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
and Among</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter
Neurosciences, Inc.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">And</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regis
Healthcare Group Limited</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="border-bottom: Black 1.5pt solid; font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Table
of Contents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: justify; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
    I.</FONT></TD>
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitions
    and Interpretation</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: small-caps bold 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    1.01</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitions.</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    1.02</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interpretive
    Provisions.</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
    II.</FONT></TD>
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    2.01</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    2.02</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deliverables
    at Closing.</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    2.03</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Closing.</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
    III.</FONT></TD>
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Piggyback
    Registration Rights.</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    3.01</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration
    Rights.</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right">3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    3.02</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Limitations.</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right">4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    3.03</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Withdrawal.</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right">4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    3.04</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notification.</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right">4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    3.05</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information.</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right">4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    3.06</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees
    and Expenses.</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right">4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
    IV.</FONT></TD>
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Representations
    and Warranties of the Company</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>5</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    4.01</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorization
    of Transactions.</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>5</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    4.02</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governmental
    Approvals; Non-contravention.</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>5</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    4.03</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brokers.</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
    V.</FONT></TD>
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Representations
    and Warranties of Subscriber</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>6</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    5.01</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorization
    of Transactions.</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>6</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    5.02</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governmental
    Approvals; Non-contravention.</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>6</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    5.03</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment
    Representations.</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>6</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    5.04</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brokers.</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
    VI.</FONT></TD>
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnification</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>8</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    6.01</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnification
    With Respect to Registration Rights.</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>8</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    6.02</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    Indemnification.</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>10</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    6.03</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Procedures
    for Indemnification.</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>10</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    6.04</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment.</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    6.05</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect
    of Knowledge on Indemnification.</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
    VII.</FONT></TD>
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Miscellaneous</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.01</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notices.</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.02</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attorneys&rsquo;
    Fees</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.03</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments;
    No Waivers; No Third-Party Beneficiaries.</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.04</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    Consequential Damages.</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.05</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses.</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.06</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further
    Assurances.</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.07</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successors
    and Assigns.</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.08</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governing
    Law; Etc.</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.09</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Resolution
    of Disputes.</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.10</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Survival.</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.12</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severability.</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>15</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.13</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entire
    Agreement.</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>16</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.14</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specific
    Performance.</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>16</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.15</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Construction.</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>16</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.16</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Counterparts.</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Stock
Subscription Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Stock Subscription Agreement (this &ldquo;Agreement&rdquo;) is entered into as of June 3, 2024 (the &ldquo;Closing Date&rdquo;), by and
among Jupiter Neurosciences, Inc., a Delaware corporation (the &ldquo;Company&rdquo;) and Regis Healthcare Group Limited, a corporation
with address (CCS Trustees Limited, Mandar House, 3rd Floor, Johnson&rsquo;s Ghut, Tortola, British Virgin Islands)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(&ldquo;Subscriber&rdquo;).
The Company and Subscriber may be collectively referred to herein as the &ldquo;Parties&rdquo; and individually as a &ldquo;Party.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Company desires to issue and sell to the Subscriber certain shares of the Company&rsquo;s common stock, par value $0.0001 per share
(the &ldquo;Common Stock&rdquo;), and Subscriber desires to subscribe for and acquire certain shares of the Common Stock, as set forth
herein; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article
I. <U>Definitions and Interpretation</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
II. Definitions. </FONT>In addition to the terms defined elsewhere in this Agreement, the following terms, as used herein, have the
following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
III. &ldquo;Affiliate&rdquo; means, with respect to a specified Person, any other Person that directly or indirectly Controls, is Controlled
by or is under common Control with, the specified Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
IV. &ldquo;Business Day&rdquo; means any day except Saturday, Sunday and any legal holiday or a day on which banking institutions in
Delaware generally are authorized or required by Law or other governmental actions to close.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
V. &ldquo;Contract&rdquo; means any contract, commitment, understanding or agreement (whether oral or written).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
VI. &ldquo;Control&rdquo; means (a) the possession, directly or indirectly, of the power to vote 10% or more of the securities or other
equity interests of a Person having ordinary voting power, (b) the possession, directly or indirectly, of the power to direct or cause
the direction of the management and policies of a Person, by contractor otherwise, or (c) being a director, officer, executor, trustee
or fiduciary (or their equivalents) of a Person or a Person that controls such Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
VII. &ldquo;Governmental Entity&rdquo; means any federal, state, municipal, local or foreign government and any court, tribunal, arbitral
body, administrative agency, department, subdivision, entity, commission or other governmental, government appointed, quasi-governmental
or regulatory authority, reporting entity or agency, domestic, foreign or supranational.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
VIII. &ldquo;Law&rdquo; means any applicable foreign, federal, state or local law (including common law), statute, treaty, rule, directive,
regulation, ordinances and similar provisions having the force or effect of law or an Order of any Governmental Entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
IX. &ldquo;Liabilities&rdquo; means liabilities, obligations or responsibilities of any nature whatsoever, whether direct or indirect,
matured or un-matured, fixed or unfixed, known or unknown, asserted or un asserted, choate or inchoate, liquidated or unliquidated, secured
or unsecured, absolute, contingent or otherwise, including any direct or indirect indebtedness, guaranty, endorsement, claim, loss, damage,
deficiency, cost or expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
X. &ldquo;Lien&rdquo; means, with respect to any property or asset, any lien, security interest, mortgage, pledge, charge, claim, lease,
agreement, right of first refusal, option, limitation on transfer or use or assignment or licensing, restrictive easement, charge or
any other restriction of any kind, and any conditional sale or voting agreement or proxy, and including any restriction on the ownership,
use, voting, transfer, possession, receipt of income or other exercise of any attributes of ownership, in respect of such property or
asset, and any agreement to give any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XI. &ldquo;Order&rdquo; means any judgment, writ, decree, determination, award, compliance agreement, settlement agreement, injunction,
ruling, charge, judicial or administrative order, determination or other restriction of any Governmental Entity or arbitrator.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XII. &ldquo;Person&rdquo; means a natural person, a corporation, a limited liability company, a partnership, an association, a trust
or any other entity or organization, including a government or political subdivision or any agency or instrumentality thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XIII. &ldquo;Securities Act&rdquo; means the United States Securities Act of 1933, as amended, and the rules and regulation promulgated
thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XIV. &ldquo;Transactions&rdquo; means the subscription and issuance of the Shares and the other transactions contemplated under the Transaction
Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XV. &ldquo;Transaction Documents&rdquo; means this Agreement and any other agreement, document, certificate or writing delivered or to
be delivered in connection with this Agreement and any other document related to the Transactions related to the forgoing, including,
without limitations, those delivered at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XVI. Interpretive Provisions. </FONT>Unless the express context otherwise requires, the words &ldquo;hereof,&rdquo;
&ldquo;herein,&rdquo; and &ldquo;hereunder&rdquo; and words of similar import, when used in this Agreement, shall refer to this
Agreement as a whole and not to any particular provision of this Agreement; terms defined in the singular shall have a comparable
meaning when used in the plural, and vice versa; the terms &ldquo;Dollars&rdquo; and &ldquo;$&rdquo; mean United States Dollars,
unless otherwise specified herein; references herein to a specific Section, Subsection or Recital shall refer, respectively, to
Sections, Subsections or Recitals of this Agreement; wherever the word &ldquo;include,&rdquo; &ldquo;includes,&rdquo; or
&ldquo;including&rdquo; is used in this Agreement, it shall be deemed to be followed by the words &ldquo;without limitation&rdquo;;
references herein to any gender shall include each other gender; references herein to any Person shall include such Person&rsquo;s
heirs, executors, personal representatives, administrators, successors and assigns; provided, however, that nothing contained in
this Article XVI is intended to authorize any assignment or transfer not otherwise permitted by this Agreement; references herein to
a Person in a particular capacity or capacities shall exclude such Person in any other capacity; references herein to any contract
or agreement (including this Agreement) mean such contract or agreement as amended, supplemented or modified from time to time in
accordance with the terms thereof; with respect to the determination of any period of time, the word &ldquo;from&rdquo; means
&ldquo;from and including&rdquo; and the words &ldquo;to&rdquo; and &ldquo;until&rdquo; each means &ldquo;to but excluding&rdquo;;
references herein to any Law or any license mean such Law or license as amended, modified, codified, reenacted, supplemented or
superseded in whole or in part, and in effect from time to time; and references herein to any Law shall be deemed also to refer to
all rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article
XVII. <U>Subscription</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XVIII. Subscription. Subject to the terms and conditions of this Agreement and as set forth below, at the Closing (as defined below)
the Company shall issue and sell to Subscriber 10,000 shares of Common Stock (the &ldquo;Shares&rdquo;) at a subscription price of US$5
per Share, for a resulting total subscription price of US$50,000 (the &ldquo;Subscription Price&rdquo;). Such Shares shall be free from
any encumbrance liens and third-party rights whatever and shall rank pari passu with all shares in issue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XIX. Deliverables at Closing. </FONT>At the Closing (as defined below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XX. Subscriber shall deliver to the Company the Subscription Price, via wire transfer to an account as designated by the Company; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXI. The Company shall issue to Subscriber the Shares via book entry in the books and records of the Company, and the Parties acknowledge
that the Shares shall not be certificated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXII. Closing. On the terms set forth herein, the closing of the Transactions (the &ldquo;Closing&rdquo;) shall take place by conference
call and electronic communication (i.e., emails/pdf) or facsimile, with exchange of original signatures to follow by mail, on the Closing
Date, immediately after the execution of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article
XXIII. <U>Piggyback Registration Rights.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXIV. Registration Rights. For purposes herein, &ldquo;Registrable Securities&rdquo; means the Shares acquired by the Subscriber hereunder.
If at any time while the Subscriber remains the holder of any Registrable Securities the Company proposes to file any registration statement
under the Securities Act with respect to the Common Stock (a &ldquo;Registration Statement&rdquo;) for its own account or for shareholders
of the Company for their account (or by the Company and by shareholders of the Company), other than a Registration Statement (i) filed
in connection with any employee stock option or other benefit plan, (ii) for a dividend reinvestment plan or (iii) in connection with
a merger or acquisition, then the Company shall (x) give written notice of such proposed filing to Subscriber as soon as practicable
but in no event less than ten (10) days before the anticipated filing date of the Registration Statement, which notice shall describe
the amount and type of securities to be included in such Registration Statement, the intended method(s) of distribution, and the name
of the proposed managing underwriter or underwriters, if any, of the offering, and (y) offer to Subscriber in such notice the opportunity
to register the sale of such number of Registrable Securities as Subscriber may request in writing within five (5) days following receipt
of such notice (a &ldquo;Piggyback Registration&rdquo;). The Company shall cause such Registrable Securities to be included in such registration
and shall cause the managing underwriter or underwriters of a proposed underwritten offering to permit the Registrable Securities requested
to be included in a Piggyback Registration on the same terms and conditions as any similar securities of the Company and to permit the
sale or other disposition of such Registrable Securities in accordance with the intended method(s) of distribution thereof. If Subscriber
proposes to distribute its Registrable Securities through a Piggyback Registration that involves an underwriter or underwriters, then
it shall enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such Piggyback Registration,
and the Subscriber also agrees to execute and deliver a customary lock-up agreement if so requested by the Company and/or the underwriter(s),
pursuant to which the Subscriber agrees to customary restrictions on resale of the securities of the Company for a period of 180 days.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXV. Limitations. If a Piggyback Registration is initiated as a primary underwritten offering on behalf of the Company and the managing
underwriter advises the Company and the Subscriber and other persons who are holders of any other shares of Common Stock which are also
&ldquo;Registrable Securities&rdquo; under an agreement similar to this Article III (if any holders of Registrable Securities have elected
to include Registrable Securities in such Piggyback Registration) in writing that in its reasonable and good faith opinion the number
of shares of Common Stock proposed to be included in such registration, including all Registrable Securities and all other shares of
Common Stock proposed to be included in such underwritten offering, exceeds the number of shares of Common Stock which can be sold in
such offering and/or that the number of shares of Common Stock proposed to be included in any such registration or takedown would adversely
affect the price per share of the Common Stock to be sold in such offering, the Company shall include in such registration (i) first,
the shares of Common Stock that the Company proposes to sell; and (ii) the shares of Common Stock requested to be included therein by
the Subscriber and the other holders of Registrable Securities, allocated among the Subscriber and such other holders pro rata based
on the number of Registrable Securities held by each of Subscriber and such other holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXVI. Withdrawal. Subscriber may elect to withdraw such Subscriber&rsquo;s request for inclusion of Registrable Securities in any Piggyback
Registration by giving written notice to the Company of such request to withdraw prior to the effectiveness of the Registration Statement.
The Company (whether on its own determination or as the result of a withdrawal by persons making a demand pursuant to written contractual
obligations) may withdraw a Registration Statement at any time prior to the effectiveness of such Registration Statement. Notwithstanding
any such withdrawal, the Company shall pay all expenses incurred by Subscriber of Registrable Securities in connection with such Piggyback
Registration as provided in Section 3.06.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXVII. Notification. The Company shall notify Subscriber at any time when a prospectus relating to such Subscriber&rsquo;s Registrable
Securities is required to be delivered under the Securities Act, upon discovery that, or upon the happening of any event as a result
of which, the prospectus included in such Registration Statement, as then in effect, includes an untrue statement of a material fact
or omits to state any material fact required to be stated therein or necessary to make the statements therein not misleading in light
of the circumstances then existing. At the request of Subscriber, the Company shall also prepare, file and furnish to Subscriber a reasonable
number of copies of a supplement to or an amendment of such prospectus as may be necessary so that, as thereafter delivered to Subscriber,
such prospectus shall not include an untrue statement of a material fact or omit to state a material fact required to be stated therein
or necessary to make the statements therein not misleading in light of the circumstances then existing. Subscriber shall not offer or
sell any Registrable Securities covered by the Registration Statement after receipt of such notification until the receipt of such supplement
or amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXVIII. Information. The Company may request that Subscriber furnish the Company such information with respect to Subscriber and Subscriber&rsquo;s
proposed distribution of the Registrable Securities pursuant to the Registration Statement as the Company may from time to time reasonably
request in writing or as shall be required by law or by the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) in connection
therewith, and Subscriber shall furnish the Company with such information as a condition of the exercise of Subscriber of the rights
as set forth in this Article III.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXIX. Fees and Expenses. <FONT STYLE="text-transform: uppercase">A</FONT>ll fees and expenses incident to the performance of or compliance
with this Article III by the Company shall be borne by the Company whether or not any Registrable Securities are sold pursuant to a Registration
Statement. The fees and expenses referred to in the foregoing sentence shall include, without limitation, (i) all registration and filing
fees (including, without limitation, fees and expenses of the Company&rsquo;s counsel and independent registered public accountants)
(A) with respect to filings made with the SEC, (B) with respect to filings required to be made with any trading market on which the Common
Stock is then listed for trading, (C) in compliance with applicable state securities or Blue Sky laws reasonably agreed to by the Company
in writing (including, without limitation, fees and disbursements of counsel for the Company in connection with Blue Sky qualifications
or exemptions of the Registrable Securities) and (D) with respect to any filing that may be required to be made by any broker through
which Subscriber of Registrable Securities intends to make sales of Registrable Securities with the FINRA, (ii) printing expenses, (iii)
messenger, telephone and delivery expenses, (iv) fees and disbursements of counsel for the Company, (v) Securities Act liability insurance,
if the Company so desires such insurance, and (vi) fees and expenses of all other persons or entities retained by the Company in connection
with the consummation of the transactions contemplated by this Article III. In addition, the Company shall be responsible for all of
its internal expenses incurred in connection with the consummation of the transactions contemplated by this Article III (including, without
limitation, all salaries and expenses of its officers and employees performing legal or accounting duties), the expense of any annual
audit and the fees and expenses incurred in connection with the listing of the Registrable Securities on any securities exchange as required
hereunder. In no event shall the Company be responsible for any broker or similar commissions of Subscriber.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article
XXX. <U>Representations and Warranties of the Company</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company represents and warrants to Subscriber that the following representations and warranties contained in this Article XXXI to XL
are true and correct as of the Closing Date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXXI. Authorization of Transactions. The Company is a corporation duly authorized and in good standing in the State of Delaware and has
the requisite power and capacity to execute and deliver the Transaction Documents to which it is a party and to perform its obligations
hereunder and thereunder. The execution, delivery and performance by the Company of the applicable Transaction Documents and the consummation
of the Transactions have been duly and validly authorized by all requisite action on the part of the Company. The Transaction Documents
to which the Company is a party have been duly and validly executed and delivered by The Company. Each Transaction Document to which
the Company is a party constitutes the valid and legally binding obligation of the Company, enforceable against the Company in accordance
with its terms and conditions, except to the extent enforcement thereof may be limited by applicable bankruptcy, insolvency or other
Laws affecting the enforcement of creditors&rsquo; rights or by the principles governing the availability of equitable remedies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXXII. Governmental Approvals; Non-contravention.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXXIII. No consent, Order, action or non-action of, or filing, notification, declaration or registration with, any Governmental Entity
or Person is necessary for the execution, delivery or performance by the Company of this Agreement or any other Transaction Document
to which the Company is a party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXXIV. The execution, delivery and performance by the Company of the Transaction Documents to which the Company is a party, and the consummation
by the Company of the Transactions, do not (i) violate any Laws or Orders to which the Company is subject or (ii) violate, breach or
conflict with any provision of the Company&rsquo;s organizational documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXXV. Brokers. The Company has not engaged, or caused to be incurred any Liability or obligation to, any investment banker, finder, broker
or sales agent or any other Person in connection with the origin, negotiation, execution, delivery or performance of the Transaction
Documents to which it is a party, or the Transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article
XXXVI. <U>Representations and Warranties of Subscriber</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscriber
represents and warrants to the Company that the following statements contained in this Article V are true and correct as of the Closing
Date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXXVII. Authorization of Transactions. Subscriber is a corporation, duly authorized and in good standing in the jurisdiction of its organization
and has the requisite power and capacity to execute and deliver the Transaction Documents to which it is a party and to perform its obligations
hereunder and thereunder. The execution, delivery and performance by Subscriber of the applicable Transaction Documents and the consummation
of the Transactions have been duly and validly authorized by all requisite action on the part of Subscriber. The Transaction Documents
to which Subscriber is a party have been duly and validly executed and delivered by Subscriber. Each Transaction Document to which Subscriber
is a party constitutes the valid and legally binding obligation of Subscriber, enforceable against Subscriber in accordance with its
terms and conditions, except to the extent enforcement thereof may be limited by applicable bankruptcy, insolvency or other Laws affecting
the enforcement of creditors&rsquo; rights or by the principles governing the availability of equitable remedies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXXVIII. Governmental Approvals; Non-contravention.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXXIX. No consent, Order, action or non-action of, or filing, notification, declaration or registration with, any Governmental Entity
is necessary for the execution, delivery or performance by Subscriber of this Agreement or any other Transaction Document to which Subscriber
is a party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XL. The execution, delivery and performance by Subscriber of the Transaction Documents to which Subscriber is a party, and the consummation
by Subscriber of the Transactions, do not (i) violate any Laws or Orders to which Subscriber is subject or (ii) violate, breach or conflict
with any provision of Subscriber&rsquo;s organizational documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XLI. Investment Representations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XLII. Subscriber understands and agrees that the consummation of this Agreement including the delivery of the Shares to Subscriber as
contemplated hereby constitutes the offer and sale of securities under the Securities Act and applicable state statutes and that the
Shares are being acquired for Subscriber&rsquo;s own account and not with a present view towards the public sale or distribution thereof,
except pursuant to sales registered or exempted from registration under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XLIII. Subscriber is an &ldquo;accredited investor&rdquo; as that term is defined in Rule 501(a) of Regulation D under the Securities
Act (an &ldquo;Accredited Investor&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XLIV. Subscriber understands that the Shares are being offered and sold to Subscriber in reliance upon specific exemptions from the registration
requirements of United States federal and state securities Laws and that the Company is relying upon the truth and accuracy of, and Subscriber&rsquo;s
compliance with, the representations, warranties, agreements, acknowledgments and understandings of Subscriber set forth herein in order
to determine the availability of such exemptions and the eligibility of Subscriber to acquire the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XLV. Subscriber and its advisors, if any, have been furnished with all materials relating to the business, finances and operations of
the Company and materials relating to the offer and sale of the Shares which have been requested by Subscriber or its advisors. Subscriber
and its advisors, if any, have been afforded the opportunity to ask questions of the Company. Subscriber understands that its investment
in the Shares involves a significant degree of risk.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XLVI. At no time was Subscriber presented with or solicited by any leaflet, newspaper or magazine article, radio or television advertisement,
or any other form of general advertising or solicited or invited to attend a promotional meeting otherwise than in connection and concurrently
with such communicated offer. Subscriber is not purchasing the Shares acquired by Subscriber hereunder as a result of any &ldquo;general
solicitation&rdquo; or &ldquo;general advertising,&rdquo; as such terms are defined in Regulation D under the Securities Act, which includes,
but is not limited to, any advertisement, article, notice or other communication regarding the Shares acquired by Subscriber hereunder
published in any newspaper, magazine or similar media or on the internet or broadcast over television, radio or the internet or presented
at any seminar or any other general solicitation or general advertisement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XLVII. Subscriber is acquiring the Shares for its own account as principal, not as a nominee or agent, for investment purposes only,
and not with a view to, or for, resale, distribution or fractionalization thereof in whole or in part and no other person has a direct
or indirect beneficial interest in the Shares. Further, Subscriber does not have any contract, undertaking, agreement or arrangement
with any person to sell, transfer or grant participations to such person or to any third person, with respect to the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XLVIII. Subscriber understands that (i) the sale or re-sale of the Shares has not been and is not being registered under the Securities
Act or any applicable state securities laws, and the Shares may not be transferred unless (1) the Shares are sold pursuant to an effective
registration statement under the Securities Act, (2) Subscriber shall have delivered to the Company, at the cost of Subscriber, an opinion
of counsel that shall be in form, substance and scope customary for opinions of counsel in comparable transactions to the effect that
the Shares to be sold or transferred may be sold or transferred pursuant to an exemption from such registration, which opinion shall
be accepted by the Company, (3) the Shares are sold or transferred to an &ldquo;affiliate&rdquo; (as defined in Rule 144 promulgated
under the Securities Act (or a successor rule) (&ldquo;Rule 144&rdquo;)) of Subscriber who agrees to sell or otherwise transfer the Shares
only in accordance with this Section and who is an Accredited Investor, (4) the Shares are sold pursuant to Rule 144, (5) the Shares
are sold pursuant to Regulation S under the Securities Act (or a successor rule) (&ldquo;Regulation S&rdquo;), or (6) the Shares are
sold pursuant to the exemption from registration afforded under Section 4(a)(1) or Section 4(a)(7) of the Securities Act, and Subscriber
shall have delivered to the Company, at the cost of Subscriber, an opinion of counsel that shall be in form, substance and scope customary
for opinions of counsel in corporate transactions, which opinion shall be accepted by the Company; (ii) any sale of such Shares made
in reliance on Rule 144 may be made only in accordance with the terms of said Rule and further, if said Rule is not applicable, any re-sale
of such Shares under circumstances in which the seller (or the person through whom the sale is made) may be deemed to be an underwriter
(as that term is defined in the Securities Act) may require compliance with some other exemption under the Securities Act or the rules
and regulations of the SEC thereunder; and (iii) neither the Company nor any other person is under any obligation to register such Shares
under the Securities Act or any state securities laws or to comply with the terms and conditions of any exemption thereunder (in each
case).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XLIX. Subscriber understands that no public market now exists for the Shares, and that the Company has made no assurances that a public
market will ever exist for the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
L. Subscriber, either alone or together with its representatives, has such knowledge, sophistication and experience in business and financial
matters so as to be capable of evaluating the merits and risks of the prospective investment in the Shares, and has so evaluated the
merits and risks of such investment. Subscriber is able to bear the economic risk of an investment in the Shares and, at the present
time, is able to afford a complete loss of such investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LI. Subscriber understands that no United States federal or state agency or any other governmental or state agency has passed on or made
recommendations or endorsement of the Shares or the suitability of the investment in the Shares nor have such authorities passed upon
or endorsed the merits of the transactions set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LII. Any legend required by the securities laws of any state to the extent such laws are applicable to the Shares represented by the
certificate so legended shall be included on any certificates representing the Shares. Subscriber also understands that the Shares may
bear the following or a substantially similar legend:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, NOR REGISTERED OR QUALIFIED
UNDER ANY STATE SECURITIES LAWS. SUCH SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, DELIVERED AFTER SALE, TRANSFERRED, PLEDGED, OR HYPOTHECATED
UNLESS QUALIFIED AND REGISTERED UNDER APPLICABLE STATE AND FEDERAL SECURITIES LAWS OR UNLESS, IN THE OPINION OF COUNSEL REASONABLY SATISFACTORY
TO THE COMPANY, SUCH QUALIFICATION AND REGISTRATION ARE NOT REQUIRED. ANY TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE
IS FURTHER SUBJECT TO OTHER RESTRICTIONS, TERMS AND CONDITIONS WHICH ARE NOT SET FORTH HEREIN.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LIII. Brokers. Subscriber has not engaged any investment banker, finder, broker or sales agent or any other Person in connection with
the origin, negotiation, execution, delivery or performance of any Transaction Document to which it is a party, or the Transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article
LIV. <U>Indemnification</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LV. Indemnification With Respect to Registration Rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LVI. <I>By the Company. </I>The Company shall indemnify and hold harmless Subscriber, the officers, directors, members, partners, agents
and employees (and any other individuals or entities with a functionally equivalent role of a person holding such titles, notwithstanding
a lack of such title or any other title) of Subscriber, each individual or entity who controls Subscriber (within the meaning of Section
15 of the Securities Act or Section 20 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;) and the officers,
directors, members, partners, agents and employees (and any other individuals or entities with a functionally equivalent role of a person
holding such titles, notwithstanding a lack of such title or any other title) of each such controlling individual or entity (each, a
&ldquo;Subscriber Indemnified Party&rdquo;), to the fullest extent permitted by applicable law, from and against any and all Losses,
as incurred, arising out of or relating to (1) any untrue or alleged untrue statement of a material fact contained in a Registration
Statement, any related prospectus or any form of prospectus or in any amendment or supplement thereto or in any preliminary prospectus,
or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make
the statements therein (in the case of any such prospectus or supplement thereto, in light of the circumstances under which they were
made) not misleading or (2) any violation or alleged violation by the Company of the Securities Act, the Exchange Act or any state securities
law, or any rule or regulation thereunder, in connection with the performance of its obligations under Article III, except to the extent,
but only to the extent, that (i) such untrue statements or omissions are based upon information regarding Subscriber furnished to the
Company by such party for use therein. The Company shall notify Subscriber promptly of the institution, threat or assertion of any proceeding
arising from or in connection with the transactions contemplated by Article III of which the Company is aware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Article
LVII. By Subscriber. </I>Subscriber and its successors and assigns shall indemnify and hold harmless the Company, the officers, directors,
members, partners, agents and employees (and any other individuals or entities with a functionally equivalent role of a person holding
such titles, notwithstanding a lack of such title or any other title) of the Company, each individual or entity who controls the company
(within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) and the officers, directors, members, partners,
agents and employees (and any other individuals or entities with a functionally equivalent role of a person holding such titles, notwithstanding
a lack of such title or any other title) of each such controlling individual or entity (each, a &ldquo;Company Indemnified Party&rdquo;),
to the fullest extent permitted by applicable law, from and against any and all Losses, as incurred, arising out of or relating to (1)
any untrue or alleged untrue statement of a material fact contained in a Registration Statement, any related prospectus or any form of
prospectus or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission
or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any
such prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading or (2) any violation
or alleged violation by the Company of the Securities Act, the Exchange Act or any state securities law, or any rule or regulation thereunder,
in connection with the performance of its obligations under Article III, but only to the extent that such untrue statements or omissions
are based upon information regarding Subscriber furnished to the Company by such Party for use therein. Subscriber shall notify the Company
promptly of the institution, threat or assertion of any proceeding arising from or in connection with the transactions contemplated by
Article III of which Subscriber is aware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LVIII. <I>Contribution. </I>If the indemnification under Section 6.01(a) or Section 6.01(b), as applicable, is unavailable to a Company
Indemnified Party or a Subscriber Indemnified Party or is insufficient to hold a Company Indemnified Party or a Subscriber Indemnified
Party, as applicable, harmless for any Losses, then the Indemnifying Party shall contribute to the amount paid or payable by such Company
Indemnified Party or a Subscriber Indemnified Party, as applicable, in such proportion as is appropriate to reflect the relative fault
of the Indemnifying Party and Company Indemnified Party or a Subscriber Indemnified Party, as applicable, in connection with the actions,
statements or omissions that resulted in such Losses pursuant to this Section 6.01, as well as any other relevant equitable considerations.
The relative fault of the Indemnifying Party and Company Indemnified Party or a Subscriber Indemnified Party, as applicable, shall be
determined by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of a
material fact or omission or alleged omission of a material fact, has been taken or made by, or relates to information supplied by, the
Indemnifying Party or the Company Indemnified Party or a Subscriber Indemnified Party, as applicable, and the Parties&rsquo; relative
intent, knowledge, access to information and opportunity to correct or prevent such action, statement or omission. The amount paid or
payable by a Party as a result of any Losses shall be deemed to include any reasonable attorneys&rsquo; or other fees or expenses incurred
by such Party in connection with any proceeding to the extent such Party would have been indemnified for such fees or expenses if the
indemnification provided for in Section 6.01(a) or Section 6.01(b), as applicable, was available to such Party in accordance with its
terms. It is agreed that it would not be just and equitable if contribution pursuant to this Section 6.01(c) were determined by pro rata
allocation or by any other method of allocation that does not take into account the equitable considerations referred to in the immediately
preceding sentence. The provisions of this Section 6.01(c) shall apply solely to the indemnification obligations as set forth in this
Section 6.01.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LIX. General Indemnification. Each Party (as required herein, the &ldquo;Indemnifying Party&rdquo;) agrees to indemnify, defend and hold
harmless the other Party and such other Party&rsquo;s Affiliates and each of their respective directors, officers, managers, partners,
employees, agents, equity holders, successors and assigns (as required herein, and including any Company Indemnified Party or a Subscriber
Indemnified Party, as applicable, pursuant to Section 6.01, each, an &ldquo;Indemnified Party&rdquo;), from and against any and all losses,
claims, damages, liabilities, costs (including, without limitation, reasonable attorneys&rsquo; fees) and expenses (collectively, &ldquo;Losses&rdquo;),
incurred or suffered by any Indemnified Party arising out of, based upon or resulting from any breach of any representation or warranty
of the Indemnifying Party herein or breach by the Indemnifying Party of, or any failure the Indemnifying Party to perform, any of the
covenants, agreements or obligations contained in or made pursuant to this Agreement of the other Transaction Documents by the Indemnifying
Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LX. Procedures for Indemnification. In the event that an Indemnified Party shall incur or suffer any Losses in respect of which indemnification
may be sought under this Article VI against the Indemnifying Party, the Indemnified Party shall assert a claim for indemnification by
providing a written notice (the &ldquo;Notice of Loss&rdquo;) to the Indemnifying Party stating the nature and basis of such indemnification.
The Notice of Loss shall be provided to the Indemnifying Party as soon as practicable after the Indemnified Party becomes aware that
it has incurred or suffered a Loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXI. Payment. Upon a determination of liability under this Article VI the Indemnifying Party shall pay or cause to be paid to the Indemnified
Party the amount so determined within five (5) Business Days after the date of such determination. If there should be a dispute as to
the amount or manner of determination of any indemnity obligation owed under this Agreement or the other Transaction Documents, the Indemnifying
Party shall nevertheless pay when due such portion, if any, of the obligation that is not subject to dispute. Upon the payment in full
of any amounts due under this Article VI with respect to any claim, the Indemnifying Party shall be subrogated to the rights of the Indemnified
Party against any Person with respect to the subject matter of such claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXII. Effect of Knowledge on Indemnification. The right to indemnification, reimbursement or other remedy based upon any representations,
warranties, covenants and obligations set forth in this Agreement or the other Transaction Documents shall not be affected by any investigation
conducted with respect to, or any knowledge acquired (or capable of being acquired) at any time, whether before or after the execution
and delivery of this Agreement or the other Transaction Documents, with respect to the accuracy or inaccuracy of or compliance with any
such representation, warranty, covenant or obligation. The waiver of any condition based upon the accuracy of any representation or warranty,
or on the performance of or compliance with any covenant or obligation, shall not affect the right to indemnification, reimbursement
or other remedy based upon such representations, warranties, covenants or obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article
LXIII. <U>Miscellaneous</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXIV. Notices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXV. Any notice or other communications required or permitted hereunder shall be in writing and shall be sufficiently given if personally
delivered to it or sent by email, overnight courier or registered mail or certified mail, postage prepaid, addressed as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
to the Company, to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter
Neurosciences, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Christer Ros&eacute;n</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1001
North US Hwy 1, Ste 504</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter,
FL 33477</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
c.rosen@jupiterneurosciences.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
a copy, which shall not constitute notice, to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anthony,
Linder &amp; Cacomanolis, PLLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
John Cacomanolis</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1700
Palm Beach Lakes Blvd., Suite 820</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">West
Palm Beach, FL 33401</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
jcacomanolis@alclaw.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to Subscriber, to the address as set forth on the signature pages hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXVI. Any Party may change its address for notices hereunder upon notice to each other Party in the manner for giving notices hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXVII. Any notice hereunder shall be deemed to have been given (i) upon receipt, if personally delivered, (ii) on the day after dispatch,
if sent by overnight courier, (iii) upon dispatch, if transmitted by email with return receipt requested and received and (iv) three
(3) days after mailing, if sent by registered or certified mail.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXVIII. Attorneys&rsquo; Fees. In the event that any Party institutes any action or suit to enforce this Agreement or the other Transaction
Documents or to secure relief from any default hereunder or breach hereof, the prevailing Party shall be reimbursed by the losing Party
for all costs, including reasonable attorney&rsquo;s fees, incurred in connection therewith and in enforcing or collecting any judgment
rendered therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXIX. Amendments; No Waivers; No Third-Party Beneficiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXX. This Agreement may be amended, modified, superseded, terminated or cancelled, and any of the terms, covenants, representations,
warranties or conditions hereof may be waived, only by a written instrument executed by all of the Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXI. Every right and remedy provided herein shall be cumulative with every other right and remedy, whether conferred herein, at law,
or in equity, and may be enforced concurrently herewith, and no waiver by any Party of the performance of any obligation by another Party
shall be construed as a waiver of the same or any other default then, theretofore, or thereafter occurring or existing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXII. Neither any failure or delay in exercising any right or remedy hereunder or in requiring satisfaction of any condition herein
nor any course of dealing shall constitute a waiver of or prevent any Party from enforcing any right or remedy or from requiring satisfaction
of any condition. No notice to or demand on a Party waives or otherwise affects any obligation of that Party or impairs any right of
the Party giving such notice or making such demand, including any right to take any action without notice or demand not otherwise required
by this Agreement or the other Transaction Documents. No exercise of any right or remedy with respect to a breach of this Agreement or
the other Transaction Documents shall preclude exercise of any other right or remedy, as appropriate to make the aggrieved Party whole
with respect to such breach, or subsequent exercise of any right or remedy with respect to any other breach.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXIII. This Agreement is intended for the benefit of the Parties and their respective successors and permitted assigns and is not for
the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Article VI.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXIV. No Consequential Damages. <FONT STYLE="font-variant: small-caps">Notwithstanding anything else contained herein, no Party shall
seek, nor shall any Party be liable for, consequential, punitive or exemplary damages, under any tort, contract, equity, or other legal
theory, with respect to any breach (or alleged breach) of this Agreement or the other Transaction Documents or any provision hereof or
any matter otherwise relating hereto or arising in connection herewith.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXV. Expenses. Unless otherwise contemplated or stipulated by this Agreement, all costs and expenses incurred in connection with this
Agreement or the other Transaction Documents shall be paid by the Party incurring such cost or expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXVI. Further Assurances. Following the Closing, each Party shall execute and deliver such documents and other papers and take such
further action as may be reasonably required to carry out the provisions of the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXVII. Successors and Assigns. This Agreement shall be binding upon and shall inure to the benefit of the Parties and their respective
successors and permitted assigns. No Party shall have any power or any right to assign or transfer, in whole or in part, this Agreement,
or any of its rights or any of its obligations hereunder, including, without limitation, any right to pursue any claim for damages pursuant
to this Agreement or the transactions contemplated herein, or to pursue any claim for any breach or default of this Agreement, or any
right arising from the purported assignor&rsquo;s due performance of its obligations hereunder, without the prior written consent of
the other Party and any such purported assignment in contravention of the provisions herein shall be null and void and of no force or
effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXVIII. Governing Law; Etc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXIX. This Agreement, and any and all claims, proceedings or causes of action relating to this Agreement or arising from this Agreement
or the transactions contemplated herein, including, without limitation, tort claims, statutory claims and contract claims, shall be interpreted,
construed, governed and enforced under and solely in accordance with the substantive and procedural laws of the State of Delaware, in
each case as in effect from time to time and as the same may be amended from time to time, and as applied to agreements performed wholly
within the State of Delaware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXX. SUBJECT TO Section 7.09, ANY LEGAL SUIT, ACTION OR PROCEEDING ARISING OUT OF OR BASED UPON THIS AGREEMENT, THE OTHER TRANSACTION
DOCUMENTS OR THE CONTEMPLATED TRANSACTIONS SHALL BE INSTITUTED SOLELY IN THE STATE OF FLORIDA OR THE FEDERAL COURTS OF THE UNITED STATES,
IN EACH CASE LOCATED IN PALM BEACH COUNTY, FLORIDA, AND EACH PARTY IRREVOCABLY SUBMITS TO THE PERSONAL JURISDICTION OF SUCH COURTS IN
ANY SUCH SUIT, ACTION OR PROCEEDING. THE PARTIES IRREVOCABLY AND UNCONDITIONALLY WAIVE ANY OBJECTION TO THE LAYING OF VENUE OF ANY SUIT,
ACTION OR ANY PROCEEDING IN SUCH COURTS AND IRREVOCABLY WAIVE AND AGREE NOT TO PLEAD OR CLAIM IN ANY SUCH COURT THAT ANY SUCH SUIT, ACTION
OR PROCEEDING BROUGHT IN ANY SUCH COURT HAS BEEN BROUGHT IN AN INCONVENIENT FORUM.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXXI. EACH PARTY HERETO HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN
ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS, THE PERFORMANCE THEREOF
OR THE FINANCINGS CONTEMPLATED THEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). EACH PARTY HERETO (A) CERTIFIES THAT NO
REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE
EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED
TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS Section 7.08(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXXII. Each of the Parties acknowledge that each has been represented in connection with the signing of this waiver by independent legal
counsel selected by the respective Party and that such Party has discussed the legal consequences and import of this waiver with legal
counsel. Each of the Parties further acknowledge that each has read and understands the meaning of this waiver and grants this waiver
knowingly, voluntarily, without duress and only after consideration of the consequences of this waiver with legal counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXXIII. Resolution of Disputes. Except as otherwise provided herein, all controversies, disputes or actions between the Parties arising
out of the Transactions or this Agreement or the other Transaction Documents, including their respective Affiliates, owners, officers,
directors, agents and employees, arising from or relating to this Agreement or the other Transaction Documents shall on demand of either
party be submitted for arbitration to in accordance with the rules and regulations of the American Arbitration Association. The arbitration
shall be conducted by one arbitrator jointly selected by each Party, provided, however, that if the Parties are unable to agree on the
identity of the arbitrator within 10 Business Days of commencement of efforts to do so, each Party shall select one arbitrator and the
arbitrators so selected shall select a final arbitrator, and the final arbitrator shall conduct the arbitration alone. The Parties agree
that, in connection with any such arbitration proceeding, each shall submit or file any claim which would constitute a compulsory counterclaim
(as defined by Rule 13 of the Federal Rules of Civil Procedures) within the same proceeding as the claim to which it relates. Any such
claim which is not submitted or filed in such proceeding shall be barred. The arbitrator shall be instructed to use every reasonable
effort to perform its services within seven days of request, and, in any case, as soon as practicable. The Parties agree to be bound
by the provisions of any limitation on the period of time by which claims must be brought under Delaware law or any applicable federal
law. The arbitrator(s) shall have the right to award the relief which he or she deems proper, consistent with the terms of this Agreement
or the other Transaction Documents, including compensatory damages (with interest on unpaid amounts from due date), injunctive relief,
specific performance, legal damages and costs. The award and decision of the arbitrator(s) shall be conclusive and binding on all Parties,
and judgment upon the award may be entered in any court of competent jurisdiction. Any right to contest the validity or enforceability
of this award shall be governed exclusively by the United States Arbitration Act. The arbitration shall be conducted in Jupiter, Florida.
The provisions of this Section 7.09 shall continue in full force and effect subsequent to and notwithstanding the expiration or termination
of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXXIV. Survival. The representations and warranties in this Agreement shall survive the Closing for a period of 12 months from the Closing
Date, and no claim for indemnification may be made after such time. All covenants and agreements in this Agreement will survive until
fully performed; provided, however, that, nothing herein shall prevent a Party from making any claim hereunder, or relieve any other
Party from any liability hereunder, after such time for any breach thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXXVI. Severability. If any provision of this Agreement is invalid, illegal or incapable of being enforced by any rule of law, or public
policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic
or legal substance of the Transactions is not affected in any manner adverse to any Party. Upon such determination that any provision
is invalid, illegal or incapable of being enforced, the Parties shall negotiate in good faith to modify this Agreement so as to effect
the original intent of the Parties as closely as possible in an acceptable manner to the end that the Transactions are fulfilled to the
extent possible.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXXVII. Entire Agreement. This Agreement and the other Transaction Documents constitute the entire agreement between the Parties with
respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, both oral and written, between
the Parties with respect to the subject matter hereof and thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXXVIII. Specific Performance. Each Party agrees that irreparable damage would occur if any provision of this Agreement and the other
Transaction Documents were not performed in accordance with the terms hereof and that each Party shall be entitled to seek specific performance
of the terms hereof and thereof in addition to any other remedy at law or in equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXXIX. Construction. The table of contents and headings contained in this Agreement are for reference purposes only and will not affect
in any way the meaning or interpretation of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XC. Counterparts. This Agreement may be executed in multiple counterparts, each of which shall be deemed an original and all of which
taken together shall be but a single instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic
signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart
so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signature
page follows]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed as of the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter
    Neurosciences, Inc. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Christer Ros&eacute;n</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christer
    Ros&eacute;n</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regis
    Healthcare Group Limited</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(CCS
    Trustees Limited, Mandar House, 3rd Floor, Johnson&rsquo;s Ghut, Tortola, British Virgin Islands)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Deng Hai</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deng
    Hai</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.37
<SEQUENCE>7
<FILENAME>ex10-37.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.37</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JUPITER
NEUROSCIENCES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>And</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LONGEVITY
TECHNOLOGY GROUP LIMITED </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 50%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PRODUCT
SERVICES AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 50%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
AGREEMENT is made on the 3<SUP>rd</SUP> day June of 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BETWEEN:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
    Neurosciences, Inc. of </B>1001 North US Highway 1, Suite 504 Jupiter, FL 33477 (&ldquo;<B>JN</B>&rdquo;); and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Longevity
    Technology Group Limited (&ldquo;CMC&rdquo;)</B> a company incorporated in British Virgin Islands whose office registered at CCS
    Trustees Limited, Mandar House, 3rd Floor, Johnson&rsquo;s Ghut, Tortola, British Virgin Islands.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(JN
and CMC are in some place referred to as a &ldquo;Party&rdquo; or when together &ldquo;Parties&rdquo;.)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS
JN wishes CMC to provide certain services, as outlined in Schedule 1, in connection with advancing the business objectives of JN in Southeast
Asia; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS
CMC wishes to assist JN in accelerating JN&rsquo;s desire to get its products manufactured in the Asian market to support possible sales
and distribution; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS
CMC has the skills and knowhow regarding manufacturing of pharmaceutical products in the South-East Asian markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IT
IS HEREBY AGREED as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>INTERPRETATION</U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    this Agreement, unless the context requires otherwise:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Services&rdquo;
means the services set out in Schedule 1 or any other services which the Parties may agree from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Territory&rdquo;
mean the countries of: China (including Hong Kong), Singapore and Malaysia.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Products&rdquo;
means the uniquely and patented product, JOTROL, developed by JN as well as any other product JN might develop during the timeframe of
this agreement. (&ldquo;Products&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Equity&rdquo;
means common shares of JN that includes registration rights in a public offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">References
    herein to Clauses and Schedules are to Clauses and Schedules in this Agreement unless the context requires otherwise.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    headings are inserted for convenience only and shall not affect the construction of this Agreement.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
    the context requires otherwise, words importing the singular include the plural and vice versa and words importing a gender include
    every gender.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif;width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>APPOINTMENT</U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JN
    hereby confirms the engagement of CMC and CMC hereby confirms its agreement to provide to JN the Services upon and subject to the
    terms set out in this Agreement.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    engagement of CMC to provide the Services shall commence upon closing of this Agreement, and services will be provided as outlined
    in Schedule 1, for a thirty-six (36) month period, with payment terms as outlined in &lsquo;Fees and Expenses.&rsquo;.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>CMC&rsquo;S
    UNDERTAKINGS</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CRO
warrants and undertakes to JN that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CMC
    will have the necessary skill and expertise to provide the Services on the terms set out herein;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CMC
    will provide independent and unbiased advice to JN in relation to the Services;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Services will be provided in a timely and professional manner;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    announcement or publicity concerning this Agreement or the Services or any matter ancillary thereto shall be made by any of the Parties
    without the prior written consent of the other Party.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>JN&rsquo;S
    OBLIGATIONS </U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JN
shall provide full documentation and support to CRO regarding the details of JN&rsquo;s Products necessary for clinical trials, regulatory
filings and approvals of the Products in the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>ASSIGNMENT
    AND OWNERSHIP</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
Party shall be entitled to assign or sub-contract any of its/his rights or obligations under this Agreement without written approval
by the other party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
inventions and data that might be the result of CMC&rsquo;s actions and efforts with a product shall be completely owned by JN.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>FEES
    AND EXPENSES</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JN
has disclosed to CMC that JN has limited amount of cash to set up and support an accelerated operation in the Asian market. It has therefore
been agreed by CMC that JN will issue, credited as fully paid and free from encumbrances and restrictions to CMC equity in the form of
310,000 common shares (&ldquo;Consideration Shares&rdquo;) upon closing of this Agreement to be regarded as pre-payment in full for 36
months of services specified in Schedule 1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Consideration Shares will have registration rights in a JN Initial Public Offering (&ldquo;IPO&rdquo;) according to Schedule 2, as long
as an IPO is closed no later than March 31, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
additional expenses to meet the requested Services outlined, will be of the sole responsibility of CMC unless the Parties agree otherwise
in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>INVESTMENT
    BY CMC</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-decoration: none">CMC
commits, in addition to providing services to JN, to purchase 10,000 shares, prior to the IPO from JN as an investment in JN. The purchase
price of these shares is $5 per share and shall be paid according to set in a separate Stock Subscription Agreement that is attached
as Schedule 3. </FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>TERMINATION</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either
Party may terminate this Agreement without liability if:-</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JN
    fails to complete an Initial Public Offering of at least US$10 million gross proceeds on or before March 31, 2025; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    petition is presented for the winding up or liquidation of the other Party, or anything analogous thereto occurs in respect of the
    other Party; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    any of the Parties are deemed to be involved in any illegal activities.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Agreement can be terminated at any time as long as this is agreed to by both parties.</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>CONFIDENTIALITY</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CMC
shall not disclose to a third party any confidential information made available to it by, or on behalf, JN and will use such confidential
information only in connection with this Agreement; provided that such confidential information will not include any information : (i)
already in CMC possession prior to the date JN disclosed it to CMC; (ii) that becomes generally available to the public without violation
of this paragraph by CMC or its representatives; or (iii) that becomes available to CMC on a non-confidential basis from a third party
not bound by a confidentiality obligation to JN with respect to such information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>MUTUAL
    REPRESENTATION AND WARRANTIES</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
information made available to JN and CMC will, at all times during the period of this Agreement, to the best of CMC and JN&rsquo;s actual
knowledge, be complete and correct in all material respects and will not contain any untrue statements of material fact or omit to state
a material fact necessary in order to make the statements therein not misleading in light of the circumstances under which such statements
are made. All projections or guidance provided to the JN by CMC will have been prepared in good faith and will be based upon reasonable
assumptions derived from the best estimates and facts then available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>FORCE
    MAJEURE</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
Party shall be liable for any delay in performing any of its obligations under this Agreement if such delay is caused by circumstances
beyond the reasonable control of the Party so delaying and such Party shall be entitled (subject to giving the other Party full particulars
of the circumstances in question and to using its best endeavors to resume full performance without avoidable delay) to a reasonable
extension of time for the performance of such obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>LEGAL
    DISPUTES</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
disputes or controversies that may arise between the Parties in the interpretation or implementation of this Agreement shall be finally
settled by sole arbitration in Geneva, Switzerland in accordance with the Rules of the ICC International Court of Arbitration (ICC Rules).
The arbitration shall be conducted in the English language. The award rendered by arbitrator shall be final and binding upon the Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>GENERAL
    PROVISIONS</U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    notice, demand or other communication between the Parties:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">may
    be sent by personal delivery, post, facsimile or other written form of electronic communication to the last known address;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    sent by post to an address to either Party, shall be treated as served on the second day following dispatch;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    sent by facsimile or other form of electronic communication, shall be treated as served at the time of sending.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    accommodation or indulgence or failure to enforce a right shall not be construed as a waiver of the right of any Party exercisable
    under this Agreement unless a waiver shall be specifically stated in writing signed by such Party.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    Agreement constitutes the entire understanding between the Parties concerning the subject matter hereof. No amendments or changes
    shall be made to this Agreement unless agreed to in writing by both Parties. Each provision of this Agreement shall be construed
    separately and notwithstanding that the whole or any part of any such provision may prove to be illegal or unenforceable the other
    provisions of this Agreement and the remainder of the provision in question shall continue in full force and effect.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    Party shall bear its own costs and expenses in connection with the preparation, negotiation and execution of this Agreement.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    formation, validity, performance and interpretation of this Agreement and of each Clause and part hereof shall be governed by the
    laws of State of Florida in the United States and the Parties agree to the non-exclusive jurisdiction of the courts of Palm Beach
    Country.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>COUNTERPART</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement may be executed in any number of counterparts, which when taken together shall constitute one and the same instrument and is
binding on each and every Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF the parties hereto have signed this Agreement the day and year first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNED
    Christer Ros&eacute;n</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    &amp; CEO</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Christer Ros&eacute;n</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    and on behalf of</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter
    Neurosciences, Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNED
    by Ng Hao Feng</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    and on behalf of</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Ng Hao Feng</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LONGEVITY
    TECHNOLOGY GROUP LIMITED</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>SCHEDULE
1</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>The
Services</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
CMC Service Company shall provide services including, not limited to or inclusive of, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide
    JN with strategic guidance regarding pharmaceutical product manufacturing in the Territory;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide
    and guide JN with all aspects of technology transfer needs. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluation
    of best manufacturing sites and companies to use for product manufacturing;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oversee
    all work and execution of tech transfers between Aquanova, JN and designated manufacturers in the Territory;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluate
    and propose best packaging and distribution channels for finished goods;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oversee
    any required regulatory inspections that might be triggered by local and other authorities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assist
    and coordinate with any professional advisors in the CMC field</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt .5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SCHEDULE
2</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Registration
rights of shares issued for payment of services.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares to be issued according to Paragraph 6 above shall have the same registration rights and provisions as described in the Stock Subscription
Agreement attached in Schedule 3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SCHEDULE
3</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
Subscription Agreement</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
and Among</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter
Neurosciences, Inc.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">And</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>LONGEVITY
TECHNOLOGY GROUP LIMITED</I></FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="border-bottom: Black 1.5pt solid; font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Table
of Contents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
    I.</FONT></TD>
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitions
    and Interpretation</FONT></TD>
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: right">1</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    1.01</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitions.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    1.02</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interpretive
    Provisions.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
    II.</FONT></TD>
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription</FONT></TD>
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: right">2</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    2.01</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    2.02</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deliverables
    at Closing.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    2.03</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Closing.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
    III.</FONT></TD>
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Piggyback
    Registration Rights.</FONT></TD>
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: right">3</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    3.01</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration
    Rights.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    3.02</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Limitations.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    3.03</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Withdrawal.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    3.04</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notification.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    3.05</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    3.06</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees
    and Expenses.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
    IV.</FONT></TD>
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Representations
    and Warranties of the Company</FONT></TD>
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: right">5</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    4.01</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorization
    of Transactions.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    4.02</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governmental
    Approvals; Non-contravention.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    4.03</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brokers.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
    V.</FONT></TD>
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Representations
    and Warranties of Subscriber</FONT></TD>
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: right">6</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    5.01</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorization
    of Transactions.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    5.02</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governmental
    Approvals; Non-contravention.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    5.03</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment
    Representations.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    5.04</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brokers.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
    VI.</FONT></TD>
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnification</FONT></TD>
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: right">8</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    6.01</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnification
    With Respect to Registration Rights.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    6.02</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    Indemnification.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    6.03</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Procedures
    for Indemnification.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    6.04</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    6.05</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect
    of Knowledge on Indemnification.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
    VII.</FONT></TD>
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Miscellaneous</FONT></TD>
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: right">10</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.01</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notices.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.02</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attorneys&rsquo;
    Fees</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.03</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments;
    No Waivers; No Third-Party Beneficiaries.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.04</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    Consequential Damages.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.05</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.06</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further
    Assurances.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.07</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successors
    and Assigns.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.08</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governing
    Law; Etc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.09</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Resolution
    of Disputes.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">13</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.10</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Survival.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">13</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.12</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severability.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">13</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.13</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entire
    Agreement.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">13</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.14</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specific
    Performance.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">13</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.15</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Construction.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">13</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.16</FONT></TD>
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Counterparts.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">13</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Stock
Subscription Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Stock Subscription Agreement (this &ldquo;Agreement&rdquo;) is entered into as of June 3, 2024 (the &ldquo;Closing Date&rdquo;), by and
among Jupiter Neurosciences, Inc., a Delaware corporation (the &ldquo;Company&rdquo;) and LONGEVITY TECHNOLOGY GROUP LIMITED (&ldquo;Subscriber&rdquo;).
The Company and Subscriber may be collectively referred to herein as the &ldquo;Parties&rdquo; and individually as a &ldquo;Party.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Company desires to issue and sell to the Subscriber certain shares of the Company&rsquo;s common stock, par value $0.0001 per share
(the &ldquo;Common Stock&rdquo;), and Subscriber desires to subscribe for and acquire certain shares of the Common Stock, as set forth
herein; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article
I. <U>Definitions and Interpretation</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article
II. <FONT STYLE="font-size: 10pt">Definitions. In addition to the terms defined elsewhere in this Agreement, the following terms, as used
herein, have the following meanings:</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
III. &ldquo;Affiliate&rdquo; means, with respect to a specified Person, any other Person that directly or indirectly Controls, is Controlled
by or is under common Control with, the specified Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
IV. &ldquo;Business Day&rdquo; means any day except Saturday, Sunday and any legal holiday or a day on which banking institutions in
Delaware generally are authorized or required by Law or other governmental actions to close.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
V. &ldquo;Contract&rdquo; means any contract, commitment, understanding or agreement (whether oral or written).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
VI. &ldquo;Control&rdquo; means (a) the possession, directly or indirectly, of the power to vote 10% or more of the securities or other
equity interests of a Person having ordinary voting power, (b) the possession, directly or indirectly, of the power to direct or cause
the direction of the management and policies of a Person, by contractor otherwise, or (c) being a director, officer, executor, trustee
or fiduciary (or their equivalents) of a Person or a Person that controls such Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
VII. &ldquo;Governmental Entity&rdquo; means any federal, state, municipal, local or foreign government and any court, tribunal, arbitral
body, administrative agency, department, subdivision, entity, commission or other governmental, government appointed, quasi-governmental
or regulatory authority, reporting entity or agency, domestic, foreign or supranational.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
VIII. &ldquo;Law&rdquo; means any applicable foreign, federal, state or local law (including common law), statute, treaty, rule, directive,
regulation, ordinances and similar provisions having the force or effect of law or an Order of any Governmental Entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
IX. &ldquo;Liabilities&rdquo; means liabilities, obligations or responsibilities of any nature whatsoever, whether direct or indirect,
matured or un-matured, fixed or unfixed, known or unknown, asserted or un asserted, choate or inchoate, liquidated or unliquidated, secured
or unsecured, absolute, contingent or otherwise, including any direct or indirect indebtedness, guaranty, endorsement, claim, loss, damage,
deficiency, cost or expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
X. &ldquo;Lien&rdquo; means, with respect to any property or asset, any lien, security interest, mortgage, pledge, charge, claim, lease,
agreement, right of first refusal, option, limitation on transfer or use or assignment or licensing, restrictive easement, charge or
any other restriction of any kind, and any conditional sale or voting agreement or proxy, and including any restriction on the ownership,
use, voting, transfer, possession, receipt of income or other exercise of any attributes of ownership, in respect of such property or
asset, and any agreement to give any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XI. &ldquo;Order&rdquo; means any judgment, writ, decree, determination, award, compliance agreement, settlement agreement, injunction,
ruling, charge, judicial or administrative order, determination or other restriction of any Governmental Entity or arbitrator.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XII. &ldquo;Person&rdquo; means a natural person, a corporation, a limited liability company, a partnership, an association, a trust
or any other entity or organization, including a government or political subdivision or any agency or instrumentality thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XIII. &ldquo;Securities Act&rdquo; means the United States Securities Act of 1933, as amended, and the rules and regulation promulgated
thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XIV. &ldquo;Transactions&rdquo; means the subscription and issuance of the Shares and the other transactions contemplated under the Transaction
Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XV. &ldquo;Transaction Documents&rdquo; means this Agreement and any other agreement, document, certificate or writing delivered or to
be delivered in connection with this Agreement and any other document related to the Transactions related to the forgoing, including,
without limitations, those delivered at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XVI. Interpretive Provisions. Unless the express context otherwise requires, the words &ldquo;hereof,&rdquo; &ldquo;herein,&rdquo; and
&ldquo;hereunder&rdquo; and words of similar import, when used in this Agreement, shall refer to this Agreement as a whole and not to
any particular provision of this Agreement; terms defined in the singular shall have a comparable meaning when used in the plural, and
vice versa; the terms &ldquo;Dollars&rdquo; and &ldquo;$&rdquo; mean United States Dollars, unless otherwise specified herein; references
herein to a specific Section, Subsection or Recital shall refer, respectively, to Sections, Subsections or Recitals of this Agreement;
wherever the word &ldquo;include,&rdquo; &ldquo;includes,&rdquo; or &ldquo;including&rdquo; is used in this Agreement, it shall be deemed
to be followed by the words &ldquo;without limitation&rdquo;; references herein to any gender shall include each other gender; references
herein to any Person shall include such Person&rsquo;s heirs, executors, personal representatives, administrators, successors and assigns;
provided, however, that nothing contained in this Article XVI is intended to authorize any assignment or transfer not otherwise permitted
by this Agreement; references herein to a Person in a particular capacity or capacities shall exclude such Person in any other capacity;
references herein to any contract or agreement (including this Agreement) mean such contract or agreement as amended, supplemented or
modified from time to time in accordance with the terms thereof; with respect to the determination of any period of time, the word &ldquo;from&rdquo;
means &ldquo;from and including&rdquo; and the words &ldquo;to&rdquo; and &ldquo;until&rdquo; each means &ldquo;to but excluding&rdquo;;
references herein to any Law or any license mean such Law or license as amended, modified, codified, reenacted, supplemented or superseded
in whole or in part, and in effect from time to time; and references herein to any Law shall be deemed also to refer to all rules and
regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article
XVII. <U>Subscription</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Article XVIII. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription.
Subject to the terms and conditions of this Agreement and as set forth below, at the Closing (as defined below) the Company shall
issue and sell to Subscriber 10,000 shares of Common Stock (the &ldquo;Shares&rdquo;) at a subscription price of US$5 per Share, for
a resulting total subscription price of US$50,000 (the &ldquo;Subscription Price&rdquo;). Such Shares shall be free from any
encumbrance liens and third-party rights whatever and shall rank pari passu with all shares in issue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XIX. Deliverables at Closing. At the Closing (as defined below):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XX. Subscriber shall deliver to the Company the Subscription Price, via wire transfer to an account as designated by the Company; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXI. The Company shall issue to Subscriber the Shares via book entry in the books and records of the Company, and the Parties acknowledge
that the Shares shall not be certificated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXII. Closing. On the terms set forth herein, the closing of the Transactions (the &ldquo;Closing&rdquo;) shall take place by conference
call and electronic communication (i.e., emails/pdf) or facsimile, with exchange of original signatures to follow by mail, on the Closing
Date, immediately after the execution of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article
XXIII. <U>Piggyback Registration Rights.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXIV. Registration Rights. For purposes herein, &ldquo;Registrable Securities&rdquo; means the Shares acquired by the Subscriber hereunder.
If at any time while the Subscriber remains the holder of any Registrable Securities the Company proposes to file any registration statement
under the Securities Act with respect to the Common Stock (a &ldquo;Registration Statement&rdquo;) for its own account or for shareholders
of the Company for their account (or by the Company and by shareholders of the Company), other than a Registration Statement (i) filed
in connection with any employee stock option or other benefit plan, (ii) for a dividend reinvestment plan or (iii) in connection with
a merger or acquisition, then the Company shall (x) give written notice of such proposed filing to Subscriber as soon as practicable
but in no event less than ten (10) days before the anticipated filing date of the Registration Statement, which notice shall describe
the amount and type of securities to be included in such Registration Statement, the intended method(s) of distribution, and the name
of the proposed managing underwriter or underwriters, if any, of the offering, and (y) offer to Subscriber in such notice the opportunity
to register the sale of such number of Registrable Securities as Subscriber may request in writing within five (5) days following receipt
of such notice (a &ldquo;Piggyback Registration&rdquo;). The Company shall cause such Registrable Securities to be included in such registration
and shall cause the managing underwriter or underwriters of a proposed underwritten offering to permit the Registrable Securities requested
to be included in a Piggyback Registration on the same terms and conditions as any similar securities of the Company and to permit the
sale or other disposition of such Registrable Securities in accordance with the intended method(s) of distribution thereof. If Subscriber
proposes to distribute its Registrable Securities through a Piggyback Registration that involves an underwriter or underwriters, then
it shall enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such Piggyback Registration,
and the Subscriber also agrees to execute and deliver a customary lock-up agreement if so requested by the Company and/or the underwriter(s),
pursuant to which the Subscriber agrees to customary restrictions on resale of the securities of the Company for a period of 180 days.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXV. Limitations. If a Piggyback Registration is initiated as a primary underwritten offering on behalf of the Company and the managing
underwriter advises the Company and the Subscriber and other persons who are holders of any other shares of Common Stock which are also
&ldquo;Registrable Securities&rdquo; under an agreement similar to this Article III (if any holders of Registrable Securities have elected
to include Registrable Securities in such Piggyback Registration) in writing that in its reasonable and good faith opinion the number
of shares of Common Stock proposed to be included in such registration, including all Registrable Securities and all other shares of
Common Stock proposed to be included in such underwritten offering, exceeds the number of shares of Common Stock which can be sold in
such offering and/or that the number of shares of Common Stock proposed to be included in any such registration or takedown would adversely
affect the price per share of the Common Stock to be sold in such offering, the Company shall include in such registration (i) first,
the shares of Common Stock that the Company proposes to sell; and (ii) the shares of Common Stock requested to be included therein by
the Subscriber and the other holders of Registrable Securities, allocated among the Subscriber and such other holders pro rata based
on the number of Registrable Securities held by each of Subscriber and such other holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXVI. Withdrawal. Subscriber may elect to withdraw such Subscriber&rsquo;s request for inclusion of Registrable Securities in any Piggyback
Registration by giving written notice to the Company of such request to withdraw prior to the effectiveness of the Registration Statement.
The Company (whether on its own determination or as the result of a withdrawal by persons making a demand pursuant to written contractual
obligations) may withdraw a Registration Statement at any time prior to the effectiveness of such Registration Statement. Notwithstanding
any such withdrawal, the Company shall pay all expenses incurred by Subscriber of Registrable Securities in connection with such Piggyback
Registration as provided in Section 3.06.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXVII. Notification. The Company shall notify Subscriber at any time when a prospectus relating to such Subscriber&rsquo;s Registrable
Securities is required to be delivered under the Securities Act, upon discovery that, or upon the happening of any event as a result
of which, the prospectus included in such Registration Statement, as then in effect, includes an untrue statement of a material fact
or omits to state any material fact required to be stated therein or necessary to make the statements therein not misleading in light
of the circumstances then existing. At the request of Subscriber, the Company shall also prepare, file and furnish to Subscriber a reasonable
number of copies of a supplement to or an amendment of such prospectus as may be necessary so that, as thereafter delivered to Subscriber,
such prospectus shall not include an untrue statement of a material fact or omit to state a material fact required to be stated therein
or necessary to make the statements therein not misleading in light of the circumstances then existing. Subscriber shall not offer or
sell any Registrable Securities covered by the Registration Statement after receipt of such notification until the receipt of such supplement
or amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXVIII. Information. The Company may request that Subscriber furnish the Company such information with respect to Subscriber and Subscriber&rsquo;s
proposed distribution of the Registrable Securities pursuant to the Registration Statement as the Company may from time to time reasonably
request in writing or as shall be required by law or by the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) in connection
therewith, and Subscriber shall furnish the Company with such information as a condition of the exercise of Subscriber of the rights
as set forth in this Article III.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXIX. Fees and Expenses. <FONT STYLE="text-transform: uppercase">A</FONT>ll fees and expenses incident to the performance of or compliance
with this Article III by the Company shall be borne by the Company whether or not any Registrable Securities are sold pursuant to a Registration
Statement. The fees and expenses referred to in the foregoing sentence shall include, without limitation, (i) all registration and filing
fees (including, without limitation, fees and expenses of the Company&rsquo;s counsel and independent registered public accountants)
(A) with respect to filings made with the SEC, (B) with respect to filings required to be made with any trading market on which the Common
Stock is then listed for trading, (C) in compliance with applicable state securities or Blue Sky laws reasonably agreed to by the Company
in writing (including, without limitation, fees and disbursements of counsel for the Company in connection with Blue Sky qualifications
or exemptions of the Registrable Securities) and (D) with respect to any filing that may be required to be made by any broker through
which Subscriber of Registrable Securities intends to make sales of Registrable Securities with the FINRA, (ii) printing expenses, (iii)
messenger, telephone and delivery expenses, (iv) fees and disbursements of counsel for the Company, (v) Securities Act liability insurance,
if the Company so desires such insurance, and (vi) fees and expenses of all other persons or entities retained by the Company in connection
with the consummation of the transactions contemplated by this Article III. In addition, the Company shall be responsible for all of
its internal expenses incurred in connection with the consummation of the transactions contemplated by this Article III (including, without
limitation, all salaries and expenses of its officers and employees performing legal or accounting duties), the expense of any annual
audit and the fees and expenses incurred in connection with the listing of the Registrable Securities on any securities exchange as required
hereunder. In no event shall the Company be responsible for any broker or similar commissions of Subscriber.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article
XXX. <U>Representations and Warranties of the Company</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company represents and warrants to Subscriber that the following representations and warranties contained in this Article XXXI to XL
are true and correct as of the Closing Date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXXI. Authorization of Transactions. The Company is a corporation duly authorized and in good standing in the State of Delaware and has
the requisite power and capacity to execute and deliver the Transaction Documents to which it is a party and to perform its obligations
hereunder and thereunder. The execution, delivery and performance by the Company of the applicable Transaction Documents and the consummation
of the Transactions have been duly and validly authorized by all requisite action on the part of the Company. The Transaction Documents
to which the Company is a party have been duly and validly executed and delivered by The Company. Each Transaction Document to which
the Company is a party constitutes the valid and legally binding obligation of the Company, enforceable against the Company in accordance
with its terms and conditions, except to the extent enforcement thereof may be limited by applicable bankruptcy, insolvency or other
Laws affecting the enforcement of creditors&rsquo; rights or by the principles governing the availability of equitable remedies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXXII. Governmental Approvals; Non-contravention.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXXIII. No consent, Order, action or non-action of, or filing, notification, declaration or registration with, any Governmental Entity
or Person is necessary for the execution, delivery or performance by the Company of this Agreement or any other Transaction Document
to which the Company is a party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXXIV. The execution, delivery and performance by the Company of the Transaction Documents to which the Company is a party, and the consummation
by the Company of the Transactions, do not (i) violate any Laws or Orders to which the Company is subject or (ii) violate, breach or
conflict with any provision of the Company&rsquo;s organizational documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXXV. Brokers. The Company has not engaged, or caused to be incurred any Liability or obligation to, any investment banker, finder, broker
or sales agent or any other Person in connection with the origin, negotiation, execution, delivery or performance of the Transaction
Documents to which it is a party, or the Transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article
XXXVI. <U>Representations and Warranties of Subscriber</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscriber
represents and warrants to the Company that the following statements contained in this Article V are true and correct as of the Closing
Date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXXVII. Authorization of Transactions. Subscriber is Longevity Technology Group Limited, duly authorized and in good standing in the
jurisdiction of its organization and has the requisite power and capacity to execute and deliver the Transaction Documents to which it
is a party and to perform its obligations hereunder and thereunder. The execution, delivery and performance by Subscriber of the applicable
Transaction Documents and the consummation of the Transactions have been duly and validly authorized by all requisite action on the part
of Subscriber. The Transaction Documents to which Subscriber is a party have been duly and validly executed and delivered by Subscriber.
Each Transaction Document to which Subscriber is a party constitutes the valid and legally binding obligation of Subscriber, enforceable
against Subscriber in accordance with its terms and conditions, except to the extent enforcement thereof may be limited by applicable
bankruptcy, insolvency or other Laws affecting the enforcement of creditors&rsquo; rights or by the principles governing the availability
of equitable remedies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXXVIII. Governmental Approvals; Non-contravention.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XXXIX. No consent, Order, action or non-action of, or filing, notification, declaration or registration with, any Governmental Entity
is necessary for the execution, delivery or performance by Subscriber of this Agreement or any other Transaction Document to which Subscriber
is a party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XL. The execution, delivery and performance by Subscriber of the Transaction Documents to which Subscriber is a party, and the consummation
by Subscriber of the Transactions, do not (i) violate any Laws or Orders to which Subscriber is subject or (ii) violate, breach or conflict
with any provision of Subscriber&rsquo;s organizational documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article
XLI. <FONT STYLE="font-size: 10pt">Investment Representations.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XLII. Subscriber understands and agrees that the consummation of this Agreement including the delivery of the Shares to Subscriber as
contemplated hereby constitutes the offer and sale of securities under the Securities Act and applicable state statutes and that the
Shares are being acquired for Subscriber&rsquo;s own account and not with a present view towards the public sale or distribution thereof,
except pursuant to sales registered or exempted from registration under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XLIII. Subscriber is an &ldquo;accredited investor&rdquo; as that term is defined in Rule 501(a) of Regulation D under the Securities
Act (an &ldquo;Accredited Investor&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XLIV. Subscriber understands that the Shares are being offered and sold to Subscriber in reliance upon specific exemptions from the registration
requirements of United States federal and state securities Laws and that the Company is relying upon the truth and accuracy of, and Subscriber&rsquo;s
compliance with, the representations, warranties, agreements, acknowledgments and understandings of Subscriber set forth herein in order
to determine the availability of such exemptions and the eligibility of Subscriber to acquire the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XLV. Subscriber and its advisors, if any, have been furnished with all materials relating to the business, finances and operations of
the Company and materials relating to the offer and sale of the Shares which have been requested by Subscriber or its advisors. Subscriber
and its advisors, if any, have been afforded the opportunity to ask questions of the Company. Subscriber understands that its investment
in the Shares involves a significant degree of risk.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XLVI. At no time was Subscriber presented with or solicited by any leaflet, newspaper or magazine article, radio or television advertisement,
or any other form of general advertising or solicited or invited to attend a promotional meeting otherwise than in connection and concurrently
with such communicated offer. Subscriber is not purchasing the Shares acquired by Subscriber hereunder as a result of any &ldquo;general
solicitation&rdquo; or &ldquo;general advertising,&rdquo; as such terms are defined in Regulation D under the Securities Act, which includes,
but is not limited to, any advertisement, article, notice or other communication regarding the Shares acquired by Subscriber hereunder
published in any newspaper, magazine or similar media or on the internet or broadcast over television, radio or the internet or presented
at any seminar or any other general solicitation or general advertisement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XLVII. Subscriber is acquiring the Shares for its own account as principal, not as a nominee or agent, for investment purposes only,
and not with a view to, or for, resale, distribution or fractionalization thereof in whole or in part and no other person has a direct
or indirect beneficial interest in the Shares. Further, Subscriber does not have any contract, undertaking, agreement or arrangement
with any person to sell, transfer or grant participations to such person or to any third person, with respect to the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XLVIII. Subscriber understands that (i) the sale or re-sale of the Shares has not been and is not being registered under the Securities
Act or any applicable state securities laws, and the Shares may not be transferred unless (1) the Shares are sold pursuant to an effective
registration statement under the Securities Act, (2) Subscriber shall have delivered to the Company, at the cost of Subscriber, an opinion
of counsel that shall be in form, substance and scope customary for opinions of counsel in comparable transactions to the effect that
the Shares to be sold or transferred may be sold or transferred pursuant to an exemption from such registration, which opinion shall
be accepted by the Company, (3) the Shares are sold or transferred to an &ldquo;affiliate&rdquo; (as defined in Rule 144 promulgated
under the Securities Act (or a successor rule) (&ldquo;Rule 144&rdquo;)) of Subscriber who agrees to sell or otherwise transfer the Shares
only in accordance with this Section and who is an Accredited Investor, (4) the Shares are sold pursuant to Rule 144, (5) the Shares
are sold pursuant to Regulation S under the Securities Act (or a successor rule) (&ldquo;Regulation S&rdquo;), or (6) the Shares are
sold pursuant to the exemption from registration afforded under Section 4(a)(1) or Section 4(a)(7) of the Securities Act, and Subscriber
shall have delivered to the Company, at the cost of Subscriber, an opinion of counsel that shall be in form, substance and scope customary
for opinions of counsel in corporate transactions, which opinion shall be accepted by the Company; (ii) any sale of such Shares made
in reliance on Rule 144 may be made only in accordance with the terms of said Rule and further, if said Rule is not applicable, any re-sale
of such Shares under circumstances in which the seller (or the person through whom the sale is made) may be deemed to be an underwriter
(as that term is defined in the Securities Act) may require compliance with some other exemption under the Securities Act or the rules
and regulations of the SEC thereunder; and (iii) neither the Company nor any other person is under any obligation to register such Shares
under the Securities Act or any state securities laws or to comply with the terms and conditions of any exemption thereunder (in each
case).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XLIX. Subscriber understands that no public market now exists for the Shares, and that the Company has made no assurances that a public
market will ever exist for the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
L. Subscriber, either alone or together with its representatives, has such knowledge, sophistication and experience in business and financial
matters so as to be capable of evaluating the merits and risks of the prospective investment in the Shares, and has so evaluated the
merits and risks of such investment. Subscriber is able to bear the economic risk of an investment in the Shares and, at the present
time, is able to afford a complete loss of such investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LI. Subscriber understands that no United States federal or state agency or any other governmental or state agency has passed on or made
recommendations or endorsement of the Shares or the suitability of the investment in the Shares nor have such authorities passed upon
or endorsed the merits of the transactions set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LII. Any legend required by the securities laws of any state to the extent such laws are applicable to the Shares represented by the
certificate so legended shall be included on any certificates representing the Shares. Subscriber also understands that the Shares may
bear the following or a substantially similar legend:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, NOR REGISTERED OR QUALIFIED
UNDER ANY STATE SECURITIES LAWS. SUCH SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, DELIVERED AFTER SALE, TRANSFERRED, PLEDGED, OR HYPOTHECATED
UNLESS QUALIFIED AND REGISTERED UNDER APPLICABLE STATE AND FEDERAL SECURITIES LAWS OR UNLESS, IN THE OPINION OF COUNSEL REASONABLY SATISFACTORY
TO THE COMPANY, SUCH QUALIFICATION AND REGISTRATION ARE NOT REQUIRED. ANY TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE
IS FURTHER SUBJECT TO OTHER RESTRICTIONS, TERMS AND CONDITIONS WHICH ARE NOT SET FORTH HEREIN.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LIII. Brokers. Subscriber has not engaged any investment banker, finder, broker or sales agent or any other Person in connection with
the origin, negotiation, execution, delivery or performance of any Transaction Document to which it is a party, or the Transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article
LIV. <U>Indemnification</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LV. Indemnification With Respect to Registration Rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LVI. <I>By the Company. </I>The Company shall indemnify and hold harmless Subscriber, the officers, directors, members, partners, agents
and employees (and any other individuals or entities with a functionally equivalent role of a person holding such titles, notwithstanding
a lack of such title or any other title) of Subscriber, each individual or entity who controls Subscriber (within the meaning of Section
15 of the Securities Act or Section 20 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;) and the officers,
directors, members, partners, agents and employees (and any other individuals or entities with a functionally equivalent role of a person
holding such titles, notwithstanding a lack of such title or any other title) of each such controlling individual or entity (each, a
&ldquo;Subscriber Indemnified Party&rdquo;), to the fullest extent permitted by applicable law, from and against any and all Losses,
as incurred, arising out of or relating to (1) any untrue or alleged untrue statement of a material fact contained in a Registration
Statement, any related prospectus or any form of prospectus or in any amendment or supplement thereto or in any preliminary prospectus,
or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make
the statements therein (in the case of any such prospectus or supplement thereto, in light of the circumstances under which they were
made) not misleading or (2) any violation or alleged violation by the Company of the Securities Act, the Exchange Act or any state securities
law, or any rule or regulation thereunder, in connection with the performance of its obligations under Article III, except to the extent,
but only to the extent, that (i) such untrue statements or omissions are based upon information regarding Subscriber furnished to the
Company by such party for use therein. The Company shall notify Subscriber promptly of the institution, threat or assertion of any proceeding
arising from or in connection with the transactions contemplated by Article III of which the Company is aware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Article
LVII. By Subscriber. </I>Subscriber and its successors and assigns shall indemnify and hold harmless the Company, the officers, directors,
members, partners, agents and employees (and any other individuals or entities with a functionally equivalent role of a person holding
such titles, notwithstanding a lack of such title or any other title) of the Company, each individual or entity who controls the company
(within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) and the officers, directors, members, partners,
agents and employees (and any other individuals or entities with a functionally equivalent role of a person holding such titles, notwithstanding
a lack of such title or any other title) of each such controlling individual or entity (each, a &ldquo;Company Indemnified Party&rdquo;),
to the fullest extent permitted by applicable law, from and against any and all Losses, as incurred, arising out of or relating to (1)
any untrue or alleged untrue statement of a material fact contained in a Registration Statement, any related prospectus or any form of
prospectus or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission
or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any
such prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading or (2) any violation
or alleged violation by the Company of the Securities Act, the Exchange Act or any state securities law, or any rule or regulation thereunder,
in connection with the performance of its obligations under Article III, but only to the extent that such untrue statements or omissions
are based upon information regarding Subscriber furnished to the Company by such Party for use therein. Subscriber shall notify the Company
promptly of the institution, threat or assertion of any proceeding arising from or in connection with the transactions contemplated by
Article III of which Subscriber is aware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LVIII. <I>Contribution. </I>If the indemnification under Section 6.01(a) or Section 6.01(b), as applicable, is unavailable to a Company
Indemnified Party or a Subscriber Indemnified Party or is insufficient to hold a Company Indemnified Party or a Subscriber Indemnified
Party, as applicable, harmless for any Losses, then the Indemnifying Party shall contribute to the amount paid or payable by such Company
Indemnified Party or a Subscriber Indemnified Party, as applicable, in such proportion as is appropriate to reflect the relative fault
of the Indemnifying Party and Company Indemnified Party or a Subscriber Indemnified Party, as applicable, in connection with the actions,
statements or omissions that resulted in such Losses pursuant to this Section 6.01, as well as any other relevant equitable considerations.
The relative fault of the Indemnifying Party and Company Indemnified Party or a Subscriber Indemnified Party, as applicable, shall be
determined by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of a
material fact or omission or alleged omission of a material fact, has been taken or made by, or relates to information supplied by, the
Indemnifying Party or the Company Indemnified Party or a Subscriber Indemnified Party, as applicable, and the Parties&rsquo; relative
intent, knowledge, access to information and opportunity to correct or prevent such action, statement or omission. The amount paid or
payable by a Party as a result of any Losses shall be deemed to include any reasonable attorneys&rsquo; or other fees or expenses incurred
by such Party in connection with any proceeding to the extent such Party would have been indemnified for such fees or expenses if the
indemnification provided for in Section 6.01(a) or Section 6.01(b), as applicable, was available to such Party in accordance with its
terms. It is agreed that it would not be just and equitable if contribution pursuant to this Section 6.01(c) were determined by pro rata
allocation or by any other method of allocation that does not take into account the equitable considerations referred to in the immediately
preceding sentence. The provisions of this Section 6.01(c) shall apply solely to the indemnification obligations as set forth in this
Section 6.01.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LIX. General Indemnification. Each Party (as required herein, the &ldquo;Indemnifying Party&rdquo;) agrees to indemnify, defend and hold
harmless the other Party and such other Party&rsquo;s Affiliates and each of their respective directors, officers, managers, partners,
employees, agents, equity holders, successors and assigns (as required herein, and including any Company Indemnified Party or a Subscriber
Indemnified Party, as applicable, pursuant to Section 6.01, each, an &ldquo;Indemnified Party&rdquo;), from and against any and all losses,
claims, damages, liabilities, costs (including, without limitation, reasonable attorneys&rsquo; fees) and expenses (collectively, &ldquo;Losses&rdquo;),
incurred or suffered by any Indemnified Party arising out of, based upon or resulting from any breach of any representation or warranty
of the Indemnifying Party herein or breach by the Indemnifying Party of, or any failure the Indemnifying Party to perform, any of the
covenants, agreements or obligations contained in or made pursuant to this Agreement of the other Transaction Documents by the Indemnifying
Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LX. Procedures for Indemnification. In the event that an Indemnified Party shall incur or suffer any Losses in respect of which indemnification
may be sought under this Article VI against the Indemnifying Party, the Indemnified Party shall assert a claim for indemnification by
providing a written notice (the &ldquo;Notice of Loss&rdquo;) to the Indemnifying Party stating the nature and basis of such indemnification.
The Notice of Loss shall be provided to the Indemnifying Party as soon as practicable after the Indemnified Party becomes aware that
it has incurred or suffered a Loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXI. Payment. Upon a determination of liability under this Article VI the Indemnifying Party shall pay or cause to be paid to the Indemnified
Party the amount so determined within five (5) Business Days after the date of such determination. If there should be a dispute as to
the amount or manner of determination of any indemnity obligation owed under this Agreement or the other Transaction Documents, the Indemnifying
Party shall nevertheless pay when due such portion, if any, of the obligation that is not subject to dispute. Upon the payment in full
of any amounts due under this Article VI with respect to any claim, the Indemnifying Party shall be subrogated to the rights of the Indemnified
Party against any Person with respect to the subject matter of such claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXII. Effect of Knowledge on Indemnification. The right to indemnification, reimbursement or other remedy based upon any representations,
warranties, covenants and obligations set forth in this Agreement or the other Transaction Documents shall not be affected by any investigation
conducted with respect to, or any knowledge acquired (or capable of being acquired) at any time, whether before or after the execution
and delivery of this Agreement or the other Transaction Documents, with respect to the accuracy or inaccuracy of or compliance with any
such representation, warranty, covenant or obligation. The waiver of any condition based upon the accuracy of any representation or warranty,
or on the performance of or compliance with any covenant or obligation, shall not affect the right to indemnification, reimbursement
or other remedy based upon such representations, warranties, covenants or obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article
LXIII. <U>Miscellaneous</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXIV. Notices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXV. Any notice or other communications required or permitted hereunder shall be in writing and shall be sufficiently given if personally
delivered to it or sent by email, overnight courier or registered mail or certified mail, postage prepaid, addressed as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
to the Company, to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter
Neurosciences, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Christer Ros&eacute;n</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1001
North US Hwy 1, Ste 504</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter,
FL 33477</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
c.rosen@jupiterneurosciences.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
a copy, which shall not constitute notice, to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anthony,
Linder &amp; Cacomanolis, PLLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
John Cacomanolis</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1700
Palm Beach Lakes Blvd., Suite 820</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">West
Palm Beach, FL 33401</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
jcacomanolis@alclaw.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to Subscriber, to the address as set forth on the signature pages hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXVI. Any Party may change its address for notices hereunder upon notice to each other Party in the manner for giving notices hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXVII. Any notice hereunder shall be deemed to have been given (i) upon receipt, if personally delivered, (ii) on the day after dispatch,
if sent by overnight courier, (iii) upon dispatch, if transmitted by email with return receipt requested and received and (iv) three
(3) days after mailing, if sent by registered or certified mail.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXVIII. Attorneys&rsquo; Fees. In the event that any Party institutes any action or suit to enforce this Agreement or the other Transaction
Documents or to secure relief from any default hereunder or breach hereof, the prevailing Party shall be reimbursed by the losing Party
for all costs, including reasonable attorney&rsquo;s fees, incurred in connection therewith and in enforcing or collecting any judgment
rendered therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXIX. Amendments; No Waivers; No Third-Party Beneficiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXX. This Agreement may be amended, modified, superseded, terminated or cancelled, and any of the terms, covenants, representations,
warranties or conditions hereof may be waived, only by a written instrument executed by all of the Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXI. Every right and remedy provided herein shall be cumulative with every other right and remedy, whether conferred herein, at law,
or in equity, and may be enforced concurrently herewith, and no waiver by any Party of the performance of any obligation by another Party
shall be construed as a waiver of the same or any other default then, theretofore, or thereafter occurring or existing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXII. Neither any failure or delay in exercising any right or remedy hereunder or in requiring satisfaction of any condition herein
nor any course of dealing shall constitute a waiver of or prevent any Party from enforcing any right or remedy or from requiring satisfaction
of any condition. No notice to or demand on a Party waives or otherwise affects any obligation of that Party or impairs any right of
the Party giving such notice or making such demand, including any right to take any action without notice or demand not otherwise required
by this Agreement or the other Transaction Documents. No exercise of any right or remedy with respect to a breach of this Agreement or
the other Transaction Documents shall preclude exercise of any other right or remedy, as appropriate to make the aggrieved Party whole
with respect to such breach, or subsequent exercise of any right or remedy with respect to any other breach.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXIII. This Agreement is intended for the benefit of the Parties and their respective successors and permitted assigns and is not for
the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Article VI.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXIV. No Consequential Damages. <FONT STYLE="font-variant: small-caps">Notwithstanding anything else contained herein, no Party shall
seek, nor shall any Party be liable for, consequential, punitive or exemplary damages, under any tort, contract, equity, or other legal
theory, with respect to any breach (or alleged breach) of this Agreement or the other Transaction Documents or any provision hereof or
any matter otherwise relating hereto or arising in connection herewith.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article
LXXV. <FONT STYLE="font-size: 10pt">Expenses. Unless otherwise contemplated or stipulated by this Agreement, all costs and expenses incurred
in connection with this Agreement or the other Transaction Documents shall be paid by the Party incurring such cost or expense.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXVI. Further Assurances. Following the Closing, each Party shall execute and deliver such documents and other papers and take such
further action as may be reasonably required to carry out the provisions of the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXVII. Successors and Assigns. This Agreement shall be binding upon and shall inure to the benefit of the Parties and their respective
successors and permitted assigns. No Party shall have any power or any right to assign or transfer, in whole or in part, this Agreement,
or any of its rights or any of its obligations hereunder, including, without limitation, any right to pursue any claim for damages pursuant
to this Agreement or the transactions contemplated herein, or to pursue any claim for any breach or default of this Agreement, or any
right arising from the purported assignor&rsquo;s due performance of its obligations hereunder, without the prior written consent of
the other Party and any such purported assignment in contravention of the provisions herein shall be null and void and of no force or
effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXVIII. Governing Law; Etc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXIX. This Agreement, and any and all claims, proceedings or causes of action relating to this Agreement or arising from this Agreement
or the transactions contemplated herein, including, without limitation, tort claims, statutory claims and contract claims, shall be interpreted,
construed, governed and enforced under and solely in accordance with the substantive and procedural laws of the State of Delaware, in
each case as in effect from time to time and as the same may be amended from time to time, and as applied to agreements performed wholly
within the State of Delaware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXX. SUBJECT TO Section 7.09, ANY LEGAL SUIT, ACTION OR PROCEEDING ARISING OUT OF OR BASED UPON THIS AGREEMENT, THE OTHER TRANSACTION
DOCUMENTS OR THE CONTEMPLATED TRANSACTIONS SHALL BE INSTITUTED SOLELY IN THE STATE OF FLORIDA OR THE FEDERAL COURTS OF THE UNITED STATES,
IN EACH CASE LOCATED IN PALM BEACH COUNTY, FLORIDA, AND EACH PARTY IRREVOCABLY SUBMITS TO THE PERSONAL JURISDICTION OF SUCH COURTS IN
ANY SUCH SUIT, ACTION OR PROCEEDING. THE PARTIES IRREVOCABLY AND UNCONDITIONALLY WAIVE ANY OBJECTION TO THE LAYING OF VENUE OF ANY SUIT,
ACTION OR ANY PROCEEDING IN SUCH COURTS AND IRREVOCABLY WAIVE AND AGREE NOT TO PLEAD OR CLAIM IN ANY SUCH COURT THAT ANY SUCH SUIT, ACTION
OR PROCEEDING BROUGHT IN ANY SUCH COURT HAS BEEN BROUGHT IN AN INCONVENIENT FORUM.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXXI. EACH PARTY HERETO HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN
ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS, THE PERFORMANCE THEREOF
OR THE FINANCINGS CONTEMPLATED THEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). EACH PARTY HERETO (A) CERTIFIES THAT NO
REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE
EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED
TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS Section 7.08(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXXII. Each of the Parties acknowledge that each has been represented in connection with the signing of this waiver by independent legal
counsel selected by the respective Party and that such Party has discussed the legal consequences and import of this waiver with legal
counsel. Each of the Parties further acknowledge that each has read and understands the meaning of this waiver and grants this waiver
knowingly, voluntarily, without duress and only after consideration of the consequences of this waiver with legal counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXXIII. Resolution of Disputes. Except as otherwise provided herein, all controversies, disputes or actions between the Parties arising
out of the Transactions or this Agreement or the other Transaction Documents, including their respective Affiliates, owners, officers,
directors, agents and employees, arising from or relating to this Agreement or the other Transaction Documents shall on demand of either
party be submitted for arbitration to in accordance with the rules and regulations of the American Arbitration Association. The arbitration
shall be conducted by one arbitrator jointly selected by each Party, provided, however, that if the Parties are unable to agree on the
identity of the arbitrator within 10 Business Days of commencement of efforts to do so, each Party shall select one arbitrator and the
arbitrators so selected shall select a final arbitrator, and the final arbitrator shall conduct the arbitration alone. The Parties agree
that, in connection with any such arbitration proceeding, each shall submit or file any claim which would constitute a compulsory counterclaim
(as defined by Rule 13 of the Federal Rules of Civil Procedures) within the same proceeding as the claim to which it relates. Any such
claim which is not submitted or filed in such proceeding shall be barred. The arbitrator shall be instructed to use every reasonable
effort to perform its services within seven days of request, and, in any case, as soon as practicable. The Parties agree to be bound
by the provisions of any limitation on the period of time by which claims must be brought under Delaware law or any applicable federal
law. The arbitrator(s) shall have the right to award the relief which he or she deems proper, consistent with the terms of this Agreement
or the other Transaction Documents, including compensatory damages (with interest on unpaid amounts from due date), injunctive relief,
specific performance, legal damages and costs. The award and decision of the arbitrator(s) shall be conclusive and binding on all Parties,
and judgment upon the award may be entered in any court of competent jurisdiction. Any right to contest the validity or enforceability
of this award shall be governed exclusively by the United States Arbitration Act. The arbitration shall be conducted in Jupiter, Florida.
The provisions of this Section 7.09 shall continue in full force and effect subsequent to and notwithstanding the expiration or termination
of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXXIV. Survival. The representations and warranties in this Agreement shall survive the Closing for a period of 12 months from the Closing
Date, and no claim for indemnification may be made after such time. All covenants and agreements in this Agreement will survive until
fully performed; provided, however, that, nothing herein shall prevent a Party from making any claim hereunder, or relieve any other
Party from any liability hereunder, after such time for any breach thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXXVI. Severability. If any provision of this Agreement is invalid, illegal or incapable of being enforced by any rule of law, or public
policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic
or legal substance of the Transactions is not affected in any manner adverse to any Party. Upon such determination that any provision
is invalid, illegal or incapable of being enforced, the Parties shall negotiate in good faith to modify this Agreement so as to effect
the original intent of the Parties as closely as possible in an acceptable manner to the end that the Transactions are fulfilled to the
extent possible.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXXVII. Entire Agreement. This Agreement and the other Transaction Documents constitute the entire agreement between the Parties with
respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, both oral and written, between
the Parties with respect to the subject matter hereof and thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXXVIII. Specific Performance. Each Party agrees that irreparable damage would occur if any provision of this Agreement and the other
Transaction Documents were not performed in accordance with the terms hereof and that each Party shall be entitled to seek specific performance
of the terms hereof and thereof in addition to any other remedy at law or in equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
LXXXIX. Construction. The table of contents and headings contained in this Agreement are for reference purposes only and will not affect
in any way the meaning or interpretation of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
XC. Counterparts. This Agreement may be executed in multiple counterparts, each of which shall be deemed an original and all of which
taken together shall be but a single instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic
signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart
so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signature
page follows]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed as of the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter
    Neurosciences, Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Christer Ros&eacute;n</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christer
    Ros&eacute;n</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Longevity
    Technology Group Limited</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Ng Hao Feng</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ng
    Hao Feng</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.38
<SEQUENCE>8
<FILENAME>ex10-38.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><B>Exhibit
10.38</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 33%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 33%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUMMARY
    STATEMENT</B></FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 24%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROGRAM
    CONTACT:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(
    Privileged Communication )</B></FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Release
    Date:&nbsp;&nbsp;</I></B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>07/06/2023</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Laurie
    Ryan</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Revised
    Date:&nbsp;&nbsp;</I></B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>301.496.9350</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ryanl@nia.nih.gov</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 50%">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Application
Number:</I> 1R01AG084962-01</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 253pt; text-align: justify; background-color: transparent"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Principal
Investigators (Listed Alphabetically):</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HAYWARD,
MARSHALL (Contact)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TURNER,
RAYMOND SCOTT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Applicant
Organization: JUPITER NEUROSCIENCES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Review
    Group:</I></B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 78%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CNN</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Clinical
    Neuroscience and Neurodegeneration Study Section</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 27pt; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Meeting
    Date:</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 28%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>06/13/2023</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Opportunity
    Number:</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 28%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PAR-23-081</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Council:</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OCT
    2023</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>PCC:</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3CCCTLR</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Requested
    Start:</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12/01/2023</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 1.25in; background-color: Transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 1.25in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Project
    Title:</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 78%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ph
    II Follow-up Alzheimer&rsquo;s Study of Resveratreol as Highly Bioavailable JOTROL</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>SRG
    Action:</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">++</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Next
    Steps:</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Visit
    https://grants.nih.gov/grants/next_steps.htm</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Human
    Subjects: </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>30-Human
    subjects involved - Certified, no SRG concerns</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Animal
    Subjects: </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10-No
    live vertebrate animals involved for competing appl.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 13pt; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%; margin-left: 0.25in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Project</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Direct Costs</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Requested</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-weight: bold; text-align: center">1</TD><TD STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 20%; font-weight: bold; text-align: right">7,780,920</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center">2</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">6,160,647</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">3</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: right">6,035,167</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; font-weight: bold">TOTAL</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">19,976,734</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>++NOTE
TO APPLICANT: Members of the Scientific Review Group (SRG) were asked to identify those applications with the highest scientific merit,
generally the top half. Written comments, criterion scores, and preliminary impact scores were submitted by the assigned reviewers prior
to the SRG meeting. At the meeting, the more meritorious applications were discussed and given final impact scores; by concurrence of
the full SRG, the remaining applications, including this application, were not discussed or scored. The reviewers&rsquo; comments (largely
unedited by NIH staff) and criterion scores for this application are provided below. Because applications deemed by the SRG to have the
highest scientific merit generally are considered for funding first, it is highly unlikely that an application with an ND recommendation
will be funded. Each applicant should read the written critiques carefully and, if there are questions about the review or future options
for the project, discuss them with the Program Contact listed above.</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEW
INVESTIGATOR</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1R01AG084962-01
Hayward, Marshall</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEW
INVESTIGATOR</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DESCRIPTION
(provided by applicant): </B>Resveratrol (RSV) has shown potential therapeutic utility in several disorders characterized by neuronal
degradation, mitochondrial dysfunction, inflammation, and the presence of reactive oxygen species. RSV showed beneficial outcomes in
Mild Cognitive Impairment (MCI) and Alzheimer&rsquo;s Disease (AD) patients, including in a National Institute on Aging supported Phase
II dose-escalation trial that we previously conducted. RSV evaluations in AD clinical trials and positive responses have been reported
with respect to AD biomarkers and CNS inflammation. In our previous 52-week AD trial, high dose (unformulated) RSV demonstrated stabilization
of key biomarkers, including amyloid levels in plasma and CSF. RSV treatment attenuated declines in mini-mental state examination (MMSE)
scores, change in activities of daily living (ADL) scores and plasma and CSF A&szlig;42 levels. Further, compared to the placebo-treated group,
at 52 weeks, RSV markedly improved other disease biomarkers such as matrix metalloproteinase 9, macrophage-derived chemokine, interleukin
6 and fibroblast growth factor 2, among other positive outcomes. These preliminary data suggest that the major effect of RSV, SIRT1 activation,
is a viable target for treatment of neurodegenerative disorders such as AD. However, at doses that correlate with positive clinical and
biomarker outcomes, gastrointestinal intolerability becomes dose limiting. Exacerbating the need for these poorly tolerated doses is
the less than 1% oral bioavailability arising from rapid and extensive RSV first pass metabolism. This, therefore, presented a conundrum:
in all cases where biomarkers and clinical efficacy is observed in response to RSV, these same high doses are associated with dose limiting
GI adverse effects. To address this issue, we developed a novel high-bioavailability orally administered RSV formulation (JOTROL). As
preliminary data, a National Institute on Aging supported Phase I pharmacokinetic clinical trial of JOTROL has been conducted in healthy
volunteers. Trial outcomes show superior exposure at a fraction of the dose. Indeed, the levels of circulating RSV attainable with JOTROL
are expected to elicit the full beneficial effects of RSV, without GI side effects. Notably, none of the Phase I trial volunteers reported
GI-related adverse events, while simultaneously achieving plasma RSV levels at or above the therapeutically relevant thresholds seen
in previous AD trials. With this excellent bioavailability, here we propose a follow-up Phase II trial of JOTROL for safety and tolerability
in the early AD/MCI intent-to-treat population as a necessary next-step to inform a future Phase III efficacy trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PUBLIC
HEALTH RELEVANCE: </B>Resveratrol (RSV) is a promising potential treatment for Mild Cognitive Impairment (MCI) and Alzheimer&rsquo;s
Disease (AD), however, due to its low bioavailability a proper clinical trial to evaluate therapeutic potential has not been possible.
With the JOTROL formulation of RSV we developed, much higher resveratrol levels are achieved in humans after oral administration. A Phase
II trial of JOTROL is proposed here to extend our findings from a previous resveratrol trial and in support of a future Phase III efficacy
trial for MCI and AD.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CRITIQUE
1</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significance:
2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investigator(s):
3</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Innovation:
2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approach:
6</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Environment:
2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overall
Impact: </B>This proposal aims to address the current gap in alternative treatment options for AD, as most drug discovery efforts focus
on reducing A&szlig; or tau. Recent evidence from AD trials suggests the need for multimodal approaches. The potential impact of this proposal
is high because, if successful, the treatment would address multiple aspects of A/T/N burden by acting synergistically on neuroinflammation,
neuroprotection, and oxidative metabolism to improve prognosis, rather than directly targeting A&szlig; or tau pathologies. The proposed treatment
is innovative in terms of formulating resveratrol as JOTROL to achieve greater bioavailability even at lower doses. The approach has
several strong aspects, including promising safety and tolerability data from previous unformulated resveratrol studies and a Phase I
study conducted on cognitively healthy individuals. Evidence from previous unformulated resveratrol studies on the effects of the compound
on AD biomarker trajectories and immune response, even at nonoptimal bioavailability levels, further supports its potential. Additionally,
the inclusion of a wide spectrum of plasma biomarkers is a strength of the study&rsquo;s design, as it helps understand the mechanism
of JOTROL in impacting disease progression. However, the study&rsquo;s reliance on the effects of plasma abeta 40 in previous unformulated
resveratrol studies is not supported, as the decreased ratio of amyloid 42/40 is a well-established marker of Alzheimer&rsquo;s disease,
while amyloid 40 is the most common variant. There is also some inconsistency in the presentation regarding whether plasma abeta40 or
plasma abeta 40/42 ratio is the primary efficacy indicator for this Phase 2 trial. The proposed Phase 2 trial is designed to assess the
safety and tolerability of JOTROL within MCI/early AD patients, considering that the Phase 1 trial involved healthy controls with PK/PD
analysis as the secondary aim. A 12-month trial duration might be sufficient for the first two aims but might be short for the exploratory
aim, which focuses on molecular biomarker and clinical outcome measure changes. While the inclusion of patients treated with newly approved
aducanumab or lecanemab is an important aspect of the study design to understand treatment synergy in combination trials, the analysis
plan lacks detailed modeling of the effect of disease-modifying AD treatments on biomarkers and clinical outcome measures, as well as
their potential interaction with JOTROL. As an oral medication with strict dosing requirements, given that resveratrol absorption and
bioavailability might be influenced by dietary factors, it is unclear whether there are adequate plans to ensure participant compliance.
The investigator team&rsquo;s experience in AD clinical trials and resveratrol treatment is a strength, demonstrated by the successful
completion of the Phase 2 unformulated resveratrol trial and the Phase 1 JOTROL trial. However, despite the enthusiasm for developing
treatment alternatives to popular monoclonal disease-modifying treatments, there are concerns regarding the weaknesses in the approach
as well as inconsistency in certain details of the study design.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B></FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Significance:</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Strengths</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 37pt; text-align: justify; text-indent: -0.25in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: Transparent"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alternative
                                            treatment options for AD are needed since the majority of drug discovery efforts concentrate
                                            on reducing A&szlig; or tau. Recent evidence from AD trials indicates the necessity for multimodal
                                            approaches.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 37pt; text-align: justify; text-indent: -0.25in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: Transparent"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            proposed treatment aims to address various aspects of A/T/N burden by synergistically acting
                                            on neuroinflammation, neuroprotection, and oxidative metabolism. Its goal is to improve prognosis
                                            without directly targeting A&szlig; or tau pathologies.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weaknesses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 19pt; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None noted.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investigator(s):</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Strengths</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Experience in AD clinical trials.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weaknesses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 37pt; text-align: justify; text-indent: -0.25in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: Transparent"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
                                            plasma and MRI biomarkers are exploratory, the team might benefit from use of these biomarkers
                                            in clinical trials.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Innovation:</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Strengths</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 37pt; text-align: justify; text-indent: -0.25in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: Transparent"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            formulation of resveratrol as JOTROL is an innovative approach that enhances the bioavailability
                                            of resveratrol even at lower doses. This formulation demonstrates improved safety and tolerability,
                                            providing a highly favorable outcome.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weaknesses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 37pt; text-align: justify; text-indent: -0.25in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: Transparent"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            utilization of plasma biomarkers to monitor the disease-modifying effects of the treatment
                                            is somewhat innovative. However, it is important to note that some of these plasma biomarkers,
                                            particularly those related to AD, have not yet been established as the gold standard for
                                            studying pathophysiological changes.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.</B></FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Approach:</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Strengths</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 37pt; text-align: justify; text-indent: -0.25in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: Transparent"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            target exposure level for the trial is established based on the exposures and outcomes observed
                                            in previous trials. However, it is important to note that PK/PD assessments and bioavailability
                                            will be further evaluated in MCI/early AD patients, as these factors may differ from those
                                            observed in healthy volunteers during the Phase 1 trial.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
                                            a Phase I trial of JOTROL in healthy individuals demonstrated acceptable safety and tolerability,
                                            it is essential to closely monitor these aspects in the Phase 2 trial involving MCI/early
                                            AD patients.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            study outlines specific efforts to recruit a minimum of 20% of historically underrepresented
                                            groups. However, it is worth noting that the enrollment table is currently empty.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                            part of the study, CSF biomarkers will be assessed in a subset of patients to monitor the
                                            disease-modifying effects of the treatment.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weaknesses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 37pt; text-align: justify; text-indent: -0.25in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: Transparent"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            proposal suggests using plasma Abeta40 as the primary biomarker outcome measure, but it should
                                            be noted that while amyloid 40 is the most common variant of beta-amyloid, the decreased
                                            ratio of amyloid 42/40 is an established strong marker of AD. There is inconsistency in the
                                            proposal regarding whether the outcome measure of interest is plasma Abeta40 or plasma Abeta40/42
                                            ratio. The study design requires baseline amyloid PET for AD biomarker positivity screening,
                                            and the schedule of events includes follow-up amyloid PET scans, at least at 6 months and
                                            possibly at 12 months (which was not consistent across different sections of the proposal).
                                            Compared to plasma biomarkers, amyloid PET remains the gold standard. The justification for
                                            using changes in plasma Abeta40 instead of changes in amyloid PET is not clear. Additionally,
                                            there was mention of participants being screened using plasma Abeta40 before the positive
                                            PET screening, but this detail was not consistent across different sections of the proposal.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
                                            is proposed that the APOE genotype will be disclosed to the participants, but it is unclear
                                            why APOE disclosure is required. It is also not clear if proper genetic counseling will be
                                            provided.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
                                            a 12-month trial duration might be sufficient for the first two aims, it might be too short
                                            for the exploratory aim, which focuses on changes in molecular biomarkers and clinical outcome
                                            measures.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 37pt; text-align: justify; text-indent: -0.25in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: Transparent"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
                                            to the proposed timeline, there will be an additional 1-year follow-up period after the completion
                                            of the 12-month treatment. However, no information was provided about this follow-up period
                                            or the reason for it.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
                                            the inclusion of patients treated with newly approved aducanumab or lecanemab is important
                                            to understand treatment synergy in combination trials, the analysis plan lacks detailed modeling
                                            of the effect of disease-modifying AD treatments on biomarkers and clinical outcome measures,
                                            as well as their potential interaction with JOTROL.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                            an oral medication with strict dosing requirements, considering that resveratrol absorption
                                            and bioavailability might be influenced by dietary factors, it remains unclear whether there
                                            are adequate plans to ensure participant compliance. While the study protocol mentions reminders
                                            for participants to bring unused study drug and completed drug compliance diaries to each
                                            visit, it is not clear to what extent the drug compliance diary will capture the timing of
                                            dosing around meals, which plays a significant role in bioavailability. The study mentions
                                            measuring resveratrol levels in both the experimental and placebo groups, with non-compliant
                                            participants being removed from the study. However, it is not clear if a specific resveratrol
                                            saturation level has been established to ensure targeted bioavailability and subsequent response.
                                            Furthermore, the study protocol lists certain dietary restrictions to avoid large quantities
                                            of resveratrol-containing foods or supplements, but it is not clear if a detailed dietary
                                            diary will be used to monitor the influence of other dietary factors on the treatment&rsquo;s
                                            efficacy.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            study hypothesizes that JOTROL will decrease CNS BBB permeability, neuroinflammation, and
                                            MMP9, while increasing macrophage-derived chemokine (MDC), interleukin (IL)-6, and fibroblast
                                            growth factor (FGF)-2 in the CSF. CSF biomarkers could provide information about the mechanism
                                            of the treatment, but lumbar puncture for CSF sample collection is optional according to
                                            the study design.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MRI
                                            will be conducted to assess changes in ventricular volume over time. However, the justification
                                            for limiting the MRI outcome measure to ventricular volume is unclear. While ventricular
                                            volume changes can capture gross atrophy, if dysregulated inflammation is the primary mechanism
                                            targeted by this treatment, other MRI modalities or outcome measures that are more sensitive
                                            to neuroinflammation-related changes may provide more informative results. Figure 10, which
                                            suggests that resveratrol increased brain volume loss, was interpreted as an indication of
                                            the anti-inflammatory actions of resveratrol. However, additional supporting data are needed
                                            to establish why ventricular or total brain volume measures are indicative of inflammation.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.</B></FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Environment:</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Strengths</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 19pt; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: Transparent">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ongoing Phase 1 and Phase 2 at established clinical trial sites.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weaknesses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 19pt; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: Transparent">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">None noted.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Study
Timeline:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Strengths</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 19pt; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: Transparent">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None noted.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weaknesses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: Transparent"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&lsquo;Longtidunal
                                            tracking&rsquo; beyond 52 weeks treatment period is included in the timeline but not discussed
                                            in the proposal.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Protections
for Human Subjects:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acceptable
Risks and/or Adequate Protections</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Data
and Safety Monitoring Plan (Applicable for Clinical Trials Only): </B>Acceptable</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Inclusion
Plans:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 19pt; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: Transparent">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sex/Gender: Distribution justified scientifically.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Race/Ethnicity: Distribution justified scientifically.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For NIH-Defined Phase III trials, Plans for valid design and
analysis: Not applicable</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inclusion/Exclusion Based on Age: Distribution justified scientifically.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Vertebrate
Animals:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable (No Vertebrate Animals)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Biohazards:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acceptable</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Applications
from Foreign Organizations:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable (No Foreign Organizations)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Select
Agents:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable (No Select Agents)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Resource
Sharing Plans:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acceptable</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Authentication
of Key Biological and/or Chemical Resources:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acceptable</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Budget
and Period of Support:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recommend
as Requested</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CRITIQUE
2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significance:
4</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investigator(s):
3</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Innovation:
4</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approach:
4</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Environment:
3</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overall
Impact: </B>This is a new submission from New Investigators (PI Hayward, mPI Turner) to conduct a Phase II clinical trial of a new formulation
of resveratrol (RSV), JOTROL, in MCI/early AD. This will be a first-in-patient, safety, and tolerability study. The investigators plan
to enroll 201 subjects (67 in each of 3 groups) to receive placebo, 200 mg JOTROL, or 500 mg JOTROL. They will undergo physical exams,
blood draws, and cognitive assessments on a nearly monthly basis, as well as florbetaben PET/LP at baseline and at 12 months, and MRI
at baseline, 3 months, 6 months, and 12 months. The trial is well-designed, and the investigators and environment are excellent. The
new formulation of RSV is innovative, although the concept of RSV in the setting of AD is not particularly novel. The trial is also ambitious
with 13 visits in 1 year and numerous study procedures, which call into question feasibility and generalizability to clinical practice.
Although the investigators suggest that RSV could be a therapy used in combination with anti-amyloid therapies, inclusion of subjects
on lecanemab/aducanumab could confound the trial, particularly given only 67 subjects in each arm. The scientific premise is also not
strong since most of the benefits of RSV have been shown in rodents. Overall, this is an ambitious proposal, which could have impact
in the field if JOTROL is shown to be efficacious but is high-risk.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B></FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Significance:</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Strengths</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 37pt; text-align: justify; text-indent: -0.25in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: Transparent"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RSV
                                            is a natural compound in grapes, red wine, blueberries, that is anti-inflammatory, improves
                                            neuronal survival, is a free radical scavenger.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            investigators have shown preliminary evidence that RSV can stabilize amyloid levels in CSF
                                            and plasma, as well as reduce inflammatory cytokines, but GI adverse effects are dose-limiting.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
                                            formulation, JOTROL, may allow for higher target exposure levels to demonstrate efficacy
                                            in a Phase III trial.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weaknesses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 19pt; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: Transparent">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The benefits of RSV have largely been shown in rodent models.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investigator(s):</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Strengths</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 37pt; text-align: justify; text-indent: -0.25in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: Transparent"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
                                            Investigator, PI Hayward from Jupiter Neurosciences, PI of R44 for JOTROL pharmacokinetics.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">mPI
                                            Turner from Georgetown, Professor of Neurology, Director of the Memory Disorders Program.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moussa
                                            (Georgetown), Thomas (UCSD biostatistics), Kemper (Pharma Navigators), Brothers (U Miami).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weaknesses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 19pt; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: Transparent">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None noted.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 20pt; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Innovation:</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Strengths</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 37pt; text-align: justify; text-indent: -0.25in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: Transparent"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previous
                                            formulation of RSV was limited by bioavailability and gastrointestinal intolerability. This
                                            new formulation (JOTROL) has higher bioavailability and fewer GI side effects.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weaknesses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 37pt; text-align: justify; text-indent: -0.25in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: Transparent"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Imaging
                                            (ventricular volumes on MRI) and fluid biomarkers used in this study are not particularly
                                            novel.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.</B></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Approach:</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Strengths</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: transparent"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
                                            proposal builds on a NIA-supported Phase II dose-escalation trial (52 weeks), which showed
                                            stabilization of plasma and CSF amyloid levels, slower decline in MMSE, and slower decline
                                            in ADL scores. Other improved measures included MMP-9, macrophage-derived chemokine, IL-6,
                                            fibroblast growth factor 2. Also builds on an NIA-supported Phase I of new RSV formulation.
                                            (JOTROL)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use
                                            of multiple biomarker assays in plasma and CSF to assess therapeutic effects.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amyloid PET at the start
  and end of the trial will be informative.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weaknesses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: transparent">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subjects will be screened
  with plasma Abeta40: unclear why Abeta40 versus Abeta 42.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ethics surrounding genetic
  testing of APOE4, then relaying directly to patient, are not discussed.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Feasibility should be discussed:
  Aim 1 includes 13 visits in 1 year.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Test-retest reliability of
  plasma and CSF biomarkers should be discussed.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
                                            on anti-amyloid therapies will not be excluded, but could confound the results, since amyloid
                                            will be decreasing at different rates from visit-to-visit. May be difficult to tease out
                                            the heterogeneity in only 67 subjects per arm.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harmonization
                                            of the MRI protocol across sites is not discussed. Even if the same scanner is used at baseline,
                                            3 months, and 12 months for individual subjects, would be important to harmonize the protocol
                                            to pool the imaging data.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 37pt; text-align: justify; text-indent: -0.25in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.
Environment:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Strengths</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: transparent"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            investigators have the necessary facilities/resources to oversee study procedures: Jupiter
                                            Neurosciences, Georgetown, UCSD, Pharma Navigators, U Miami.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 37pt; text-align: justify; text-indent: -0.25in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weaknesses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: transparent">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It is unclear how many sites
  will be recruiting subjects.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Study
Timeline:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Strengths</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: transparent">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included in this proposal.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weaknesses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: transparent">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Feasibility of recruitment
  and retention is unclear.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Protections
for Human Subjects:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acceptable
Risks and/or Adequate Protections</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Data
and Safety Monitoring Plan (Applicable for Clinical Trials Only):</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acceptable</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Inclusion
Plans:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: transparent">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sex/Gender: Distribution
  not justified scientifically.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Race/Ethnicity: Distribution
  justified scientifically.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For NIH-Defined Phase III
  trials, Plans for valid design and analysis: Not applicable</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: transparent">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inclusion/Exclusion Based
  on Age: Distribution justified scientifically.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ages
                                            55-85, may include more women than men (but will be difficult to assess SABV if too imbalanced)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 37pt; text-align: justify; text-indent: -0.25in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Vertebrate
Animals:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable (No Vertebrate Animals)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Biohazards:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acceptable</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Applications
from Foreign Organizations:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable (No Foreign Organizations)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Select
Agents:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable (No Select Agents)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Resource
Sharing Plans:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acceptable</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Authentication
of Key Biological and/or Chemical Resources:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acceptable</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Budget
and Period of Support:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Budget
Modifications Recommended (in amount/time)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recommended
budget modifications or possible overlap identified:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: transparent">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs are high for Trial
  Coordination. (Peachtree)</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CRITIQUE
3</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significance:
1</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investigator(s):
3</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Innovation:
3</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approach:
4</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Environment:
3</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overall
Impact: </B>This exciting proposal to study a new formulation of resveratrol (RSV) that minimizes side effects while maximizing effective
dose. The proposal has many strengths, including the potentially massive impact of a therapeutic that slows progression of Alzheimer&rsquo;s
disease (AD). However, there are also some weaknesses including the lack of detail for some analytical aspects as well as the lack of
clarity in terms of whether the investigators have collaborated together previously given the scope of this project.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Significance:</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strengths</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: transparent">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AD is an urgent public health
  problem.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            development of a micellar formulation that improves tolerability of RSV would be highly significant,
                                            as gastrointestinal side effects limit dosage.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior data showing RSV effects
  on cognition and serum biomarkers are convincing. </FONT></TD></TR>

</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weaknesses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: transparent">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None noted.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investigator(s):</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Strengths</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: transparent"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PI
                                            Hayward is Chief Scientific Officer of Jupiter and an expert in drug discovery and development
                                            (PhD in Biochemistry and Molecular Biology).</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PI Turner is a Professor
  of Neurology at Georgetown who runs the Memory Disorders Program.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">They
                                            are joined by an excellent team of neurologists, biostatisticians, chemists, and pharmacologists.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 37pt; text-align: justify; text-indent: -0.25in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weaknesses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: transparent"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 19.05pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PI
                                            Hayward proposes to work on this project almost entirely &ndash; at 10 calendar months in the budget,
                                            but at 12 months on the budget justification. It seems unlikely that he will have no other
                                            administrative nor research roles during the study period.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 37pt; text-align: justify; text-indent: -0.25in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.
Innovation:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Strengths</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: transparent">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The formulation of JOTROL
  is innovative and reduces first-pass metabolism.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weaknesses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: transparent">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The study design is relatively
  standard, which is appropriate.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.
Approach:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Strengths</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: transparent">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Including participants on
  other FDA-approved therapies is a strength for generalizability.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An extensive baseline assessment
  will be performed, including a lumbar puncture.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Follow-up will be close and
  include EKG as well as blood work.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weaknesses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: transparent"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Imaging
                                            will be employed with a harmonized protocol, but on multiple scanners. It is unclear how
                                            harmonization will be conducted, or whether scanner will be included in statistical modeling.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The statistical analysis
  section is limited and lacking detail.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The power analysis is detailed
  but rather challenging to parse.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.
Environment:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Strengths</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: transparent">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The proposed environment
  at Jupiter, George Washington, and Miami is good.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weaknesses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: transparent">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It is unclear whether the
  investigators have worked together in the past.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Study
Timeline:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Strengths</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: transparent">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acceptable</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weaknesses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: transparent">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None noted.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Protections
for Human Subjects:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acceptable
Risks and/or Adequate Protections</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Data
and Safety Monitoring Plan (Applicable for Clinical Trials Only):</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acceptable</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Inclusion
Plans:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: transparent">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sex/Gender: Distribution
  justified scientifically.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Race/Ethnicity: Distribution
  justified scientifically.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For NIH-Defined Phase III
  trials, Plans for valid design and analysis: Scientifically acceptable.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inclusion/Exclusion Based
  on Age: Distribution justified scientifically.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Vertebrate
Animals:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable (No Vertebrate Animals)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Biohazards:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable (No Biohazards)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Applications
from Foreign Organizations:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable (No Foreign Organizations)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Select
Agents:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable (No Select Agents)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Resource
Sharing Plans:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acceptable</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Authentication
of Key Biological and/or Chemical Resources:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acceptable</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Budget
and Period of Support:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Budget
Modifications Recommended (in amount/time)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recommended
budget modifications or possible overlap identified:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: transparent">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PI Hayward should decrease
  requested effort.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
                                            of the Peachtree budget items seem excessive; for example, there are almost 300K in fees
                                            for teleconferences. Additional details are also necessary for some items such as monitoring
                                            visit, which are to cost 1.2M.</FONT></TD></TR></TABLE>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Footnotes
                                            for 1R01AG084962-01; PI Name: Hayward, Marshall</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NIH
has modified its policy regarding the receipt of resubmissions (amended applications).See Guide Notice NOT-OD-18-197 at https://grants.nih.gov/grants/guide/notice-files/NOT-OD-18-
197.html. The impact/priority score is calculated after discussion of an application by averaging the overall scores (1-9) given by all
voting reviewers on the committee and multiplying by 10. The criterion scores are submitted prior to the meeting by the individual reviewers
assigned to an application, and are not discussed specifically at the review meeting or calculated into the overall impact score. Some
applications also receive a percentile ranking. For details on the review process, see http://grants.nih.gov/grants/peer_review_process.htm#scoring.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MEETING
ROSTER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Clinical
Neuroscience and Neurodegeneration Study Section</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Brain
Disorders and Clinical Neuroscience Integrated Review Group</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CENTER
FOR SCIENTIFIC REVIEW</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CNN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>06/13/2023
- 06/14/2023</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notice
of NIH Policy to All Applicants: </B>Meeting rosters are provided for information purposes only. Applicant investigators and institutional
officials must not communicate directly with study section members about an application before or after the review. Failure to observe
this policy will create a serious breach of integrity in the peer review process, and may lead to actions outlined in NOT-OD-22-044 at
https://grants.nih.gov/grants/guide/notice-files/NOT-OD-22-044.html, including removal of the application from immediate review.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 53%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U></U></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHEN,
    SHU G., PHD *</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>CHAIRPERSON(S)</U></B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROFESSOR</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">DEPARTMENT
    OF PATHOLOGY AND</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BENZINGER,
    TAMMIE LEE SMITH, MD, PHD</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> NEUROBIOLOGY </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROFESSOR</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNIVERSITY
    OF ALABAMA, BIRMINGHAM</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEPARTMENT
    OF RADIOLOGY</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BIRMINGHAM,
    AL 35233</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHOOL
    OF MEDICINE</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WASHINGTON
    UNIVERSITY</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHIANG,
    GLORIA CHIA-YI, MD</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ST.
    LOUIS, MO 63110</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASSOCIATE
    PROFESSOR</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEPARTMENT
    OF RADIOLOGY</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>MEMBERS</U></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WEILL
    CORNELL MEDICAL COLLEGE</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEW
    YORK CITY, NY 10065</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AMARA,
    AMY WILLIS, MD, PHD *</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROFESSOR</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHIU,
    SHANNON, MD *</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEPARTMENT
    OF NEUROLOGY</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASSISTANT
    PROFESSOR</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHOOL
    OF MEDICINE</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEPARTMENT
    OF NEUROLOGY</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNIVERSITY
    OF COLORADO DENVER</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNIVERSITY
    OF FLORIDA</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DENVER,
    CO 80204</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COLLEGE
    OF MEDICINE</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GAINESVILLE,
    FL 32610</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AMARIGLIO,
    REBECCA E, PHD *</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASSOCIATE
    PROFESSOR</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CLAASSEN,
    DANIEL OLIVER, MD</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEPARTMENT
    OF NEUROLOGY</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROFESSOR</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HARVARD
    MEDICAL SCHOOL</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEPARTMENT
    OF NEUROLOGY</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BRIGHAM
    AND WOMEN&rsquo;S HOSPITAL</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VANDERBILT
    UNIVERSITY</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BOSTON,
    MA 02114</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NASHVILLE,
    TN 37232</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BAKKER,
    ARNOLD, PHD</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COHEN,
    ANN D, PHD</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASSOCIATE
    PROFESSOR</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASSOCIATE
    PROFESSOR</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEPARTMENTS
    OF PSYCHIATRY AND </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEPARTMENT
    OF PSYCHIATRY</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BEHAVIORAL
    SCIENCES AND NEUROLOGY</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHOOL
    OF MEDICINE</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JOHNS
    HOPKINS UNIVERSITY</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNIVERSITY
    OF PITTSBURGH</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BALTIMORE,
    MD 21287</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PITTSBURGH,
    PA 15213</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHEN,
    NAN-KUEI, PHD</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CURIEL
    CID, ROSIE E, PSYD</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASSOCIATE
    PROFESSOR</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASSOCIATE
    PROFESSOR</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEPARTMENT
    OF BIOMEDICAL ENGINEERING </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEPARTMENT
    OF PSYCHIATRY AND BEHAVIORAL</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNIVERSITY
    OF ARIZONA</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCIENCES</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TUCSON,
    AZ 85721</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MILLER
    SCHOOL OF MEDICINE</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNIVERSITY
    OF MIAMI</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MIAMI,
    FL 33136</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EIDELBERG,
    DAVID, MD</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NATION,
    DANIEL A, PHD</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROFESSOR</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASSOCIATE
    PROFESSOR</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEPARTMENT
    OF NEUROLOGY AND NEUROSCIENCE </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEPARTMENT
    OF PSYCHOLOGICAL SCIENCE </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FEINSTEIN
    INSTITUTE FOR MEDICAL RESEARCH </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INSTITUTE
    FOR MEMORY IMPAIRMENTS AND </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MANHASSET,
    NY 11030</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEUROLOGICAL
    DISORDERS</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNIVERSITY
    OF CALIFORNIA AT IRVINE </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GLASS,
    JONATHAN DAVID, MD</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IRVINE,
    CA 92603</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROFESSOR</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEPARTMENTS
    OF NEUROLOGY AND PATHOLOGY </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OSORIO,
    RICARDO S, MD</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHOOL
    OF MEDICINE</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASSOCIATE
    PROFESSOR </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EMORY
    UNIVERSITY</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEPARTMENT
    OF PSYCHIATRY </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ATLANTA,
    GA 30322</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LANGONE
    MEDICAL CENTER </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEW
    YORK UNIVERSITY </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GOLD,
    BRIAN TIMOTHY, PHD *</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEW
    YORK, NY 10016</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROFESSOR</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEPARTMENT
    OF NEUROSCIENCE AND RADIOLOGY </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RAFII,
    MICHAEL S, MD, PHD</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNIVERSITY
    OF KENTUCKY</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROFESSOR</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEXINGTON,
    KY 40536</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEPARTMENT
    OF NEUROLOGY </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KECK
    SCHOOL OF MEDICINE </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HAEUSLER,
    AARON RAYMOND, PHD</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNIVERSITY
    OF SOUTHERN CALIFORNIA</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASSISTANT
    PROFESSOR </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LOS
    ANGELES, CA 90033</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEPARTMENT
    OF NEUROSCIENCE T</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HOMAS
    JEFFERSON UNIVERSITY </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RANE,
    SWATI, PHD *</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PHILADELPHIA,
    PA 19107</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASSOCIATE
    PROFESSOR </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEPARTMENT
    OF RADIOLOGY</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JUNG,
    MIYEON, PHD *</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNIVERSITY
    OF WASHINGTON MEDICAL CENTER </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASSISTANT
    PROFESSOR</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEATTLE,
    WA 98195</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHOOL
    OF NURSING</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INDIANA
    UNIVERSITY PURDUE UNIVERSITY </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROSA-NETO,
    PEDRO, MD, PHD *</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INDIANAPOLIS
    INDIANAPOLIS, IN 46202</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROFESSOR</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEPARTMENT
    OF NEUROLOGY AND</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LENG,
    XIAOYAN, MD, PHD</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEUROSURGERY
    AND PSYCHIATRY </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASSOCIATE
    PROFESSOR</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MCGILL
    UNIVERSITY </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEPARTMENT
    OF BIOSTATISTICAL </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MONTREAL,
    QC H3A 0G4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCIENCES
    DIVISION OF</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CANADA</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PUBLIC
    HEALTH SCIENCES SCHOOL OF MEDICINE </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WAKE
    FOREST UNIVERSITY</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SHA,
    SHARON J, MD *</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WINSTON-SALEM,
    NC 27157</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CLINICAL
    ASSOCIATE PROFESSOR </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEPARTMENT
    OF NEUROLOGY </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LI,
    DANNI, PHD</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">STANFORD
    UNIVERSITY </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASSOCIATE
    PROFESSOR</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">STANFORD,
    CA 94305</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEPARTMENT
    OF LABORATORY MEDICINE AND </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PATHOLOGY</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SHINOHARA,
    RUSSELL TAKESHI, PHD</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNIVERSITY
    OF MINNESOTA </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROFESSOR</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MINNEAPOLIS,
    MN 55455</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEPARTMENT
    OF BIOSTATISTICS, </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EPIDEMIOLOGY
    AND INFORMATICS </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MAO,
    QINWEN, MD, PHD *</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PERELMAN
    SCHOOL OF MEDICINE </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROFESSOR</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNIVERSITY
    OF PENNSYLVANIA </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEPARTMENT
    OF PATHOLOGY</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PHILADELPHIA,
    PA 19104</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNIVERSITY
    OF UTAH</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SALT
    LAKE CITY, UT 84112</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TOSUN-TURGUT,
    DUYGU, PHD *</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROFESSOR</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MURRAY,
    MELISSA ERIN, PHD</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEPARTMENT
    OF RADIOLOGY AND </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASSOCIATE
    PROFESSOR </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BIOMEDICAL
    IMAGING UNIVERSITY OF</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEPARTMENT
    OF NEUROSCIENCES </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CALIFORNIA,
    SAN FRANCISCO</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MAYO
    CLINIC, JACKSONVILLE</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SAN
    FRANCISCO, CA 94121</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JACKSONVILLE,
    FL 32266</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WINDHAM,
BEVERLY GWEN, MD</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROFESSOR</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEPARTMENT
OF MEDICINE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DIVISION
OF GERIATRICS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNIVERSITY
OF MISSISSIPPI MEDICAL CENTER</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JACKSON,
MS 39216</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WINSTON,
CHARISSE N, PHD *</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASSISTANT
PROJECT SCIENTIST</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEPARTMENT
OF NEUROSCIENCE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNIVERSITY
OF CALIFORNIA, SAN DIEGO</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LA
JOLLA, CA 92093</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZHU,
DAVID C, PHD *</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROFESSOR</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COLLEGE
OF ENGINEERING</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MICHIGAN
STATE UNIVERSITY</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EAST
LANSING, MI 48824</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SCIENTIFIC
REVIEW OFFICER</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MOORE,
JORDAN M, PHD</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCIENTIFIC
REVIEW OFFICER</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CENTER
FOR SCIENTIFIC REVIEW</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NATIONAL
INSTITUTES OF HEALTH</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BETHESDA,
MD 20892</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>EXTRAMURAL
SUPPORT ASSISTANT</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">STROTHERS,
JUWAN ANDRE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXTRAMURAL
SUPPORT ASSISTANT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CENTER
FOR SCIENTIFIC REVIEW</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NATIONAL
INSTITUTES OF HEALTH</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BETHESDA,
MD 20892</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Temporary Member. For grant applications, temporary members may participate in the entire meeting or may review only selected applications
as needed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consultants
are required to absent themselves from the room during the review of any application if their presence would constitute or appear to
constitute a conflict of interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.39
<SEQUENCE>9
<FILENAME>ex10-39.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.39</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JUPITER
NEUROSCIENCES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>And</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DOMINANT
TREASURE HEALTH COMPANY LIMITED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 50%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STRATEGIC
SERVICES AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 50%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
AGREEMENT is made on the &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;day of 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BETWEEN:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
                                            Neurosciences, Inc. of </B>1001 North US Highway 1, Suite 504 Jupiter, FL 33477 (&ldquo;<B>JN</B>&rdquo;);
                                            and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DOMINANT
                                            TREASURE HEALTH COMPANY LIMITED (&ldquo;MSC&rdquo;)</B>, a company incorporated in the British
                                            Virgin Islands whose registered office is at OMC Chambers, Wickhams Cay 1, Road Town, Tortola,
                                            British Virgin Islands</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(JN
and MSC are in some places referred to as a &ldquo;Party&rdquo; or when together, the &ldquo;Parties&rdquo;.)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS
JN wishes MSC to provide certain services, as outlined in Schedule 1, in connection with advancing the business objectives of JN in South-East
Asia; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS
MSC wishes to assist JN in accelerating JN&rsquo;s desire to get its products developed and distributed in the South-East Asian market;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS
MSC has the skills and knowhow to manage various service providers in the South-East Asian markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IT
IS HEREBY AGREED as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>INTERPRETATION</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            this Agreement, unless the context requires otherwise:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Services&rdquo;
means the services set out in Schedule 1 or any other services which the Parties may agree from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Territory&rdquo;
means the countries of China (including Hong Kong), Singapore and Malaysia.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 44pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Products&rdquo;
means the uniquely and patented product, JOTROL, developed by JN as well as any other products which JN might develop during the timeframe
of this Agreement (&ldquo;Products&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">References
                                            herein to Clauses and Schedules are to Clauses and Schedules in this Agreement unless the
                                            context requires otherwise.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            headings are inserted for convenience only and shall not affect the construction of this
                                            Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 44pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
                                            the context requires otherwise, words importing the singular include the plural and vice
                                            versa and words importing a gender include every gender.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>APPOINTMENT</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JN
                                            hereby confirms the engagement of MSC and MSC hereby confirms its agreement to provide to
                                            JN the Services upon and subject to the terms set out in this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            engagement of the MSC to provide the Services shall commence upon closing of this Agreement,
                                            and services will be provided as outlined in Schedule 1, for a thirty-six (36) month period,
                                            with payment terms as outlined in &lsquo;Fees and Expenses.&rsquo;.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>MSC&rsquo;S
                                            UNDERTAKINGS</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MSC
warrants and undertakes to JN that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MSC
                                            will have the necessary skill and expertise to provide the Services on the terms set out
                                            herein;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 80pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MSC
                                            will provide independent and unbiased advice to JN in relation to the Services;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 44pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MSC
                                            and JN will establish a Joint Steering Committee (&ldquo;JSC&rdquo;) that will meet on a
                                            regular basis and establish specific tasks, follow-ups and time schedules;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Services will be provided in a timely and professional manner and in accordance with the
                                            time schedules reasonably stipulated by the JSC;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
                                            announcement or publicity concerning this Agreement or the Services or any matter ancillary
                                            thereto shall be made by any of the Parties without the prior written consent of the other
                                            Party.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>JN&rsquo;S
                                            OBLIGATIONS </U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JN
shall provide full documentation and support to MSC regarding the details of JN&rsquo;s Products details necessary for manufacturing,
development, regulatory approval and marketing of the Products in the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>ASSIGNMENT
                                            AND OWNERSHIP</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
Party shall be entitled to assign or sub-contract any of its/his rights or obligations under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
inventions and data that might be the result of MSC&rsquo;s actions and efforts with a JN&rsquo;s product shall be completely owned by
JN.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>FEES
                                            AND EXPENSES</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration of the provision of the Services, JN shall pay MSC a fee of US$ 2,300,000 to be delivered after closing of a minimum of
$10 million gross proceeds from a JN public offering to take place no later than 31 March 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
additional expenses to meet the requested Services outlined, will be of the sole responsibility of MSC unless the Parties are negotiating
another arrangement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SUCCESS
                                            FEES</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 44pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
MSC is involved in generating negotiations and conclusion of a distribution agreement for JN in the Territory, then JN will pay MSC a
success fee of 5% of any upfront and/or milestone payments to be received by JN. If such agreement will include a royalty payment to
JN then MSC will receive 5% of such royalty payments.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 44pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>JOINT
                                            STEERING COMMITTEE</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Th
JSC shall consist of a minimum of 1 person from each JN and MSC. The JSC will hold quarterly virtual meetings for a period of 36 months
to discuss and update on Services as outlined in Schedule 1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>TERMINATION</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either
Party may terminate this Agreement without liability if:-</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JN
                                            fails to complete a public listing raising at least US$10 million of gross proceeds on or
                                            before March 31, 2025; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 80pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            petition is presented for the winding up or liquidation of the other Party, or anything analogous
                                            thereto occurs in respect of the other Party.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 44pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            any of the Parties are deemed to be involved in any illegal activities.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 44pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
                                            Agreement can also be terminated at any time if the Parties mutually agree to do so.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevertheless,
JN shall continue to pay MSC as outlined in Paragraph 7 if JN terminates this Agreement for any other reasons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>CONFIDENTIALITY</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MSC
shall not disclose to a third party any confidential information made available to it by, or on behalf, JN and will use such confidential
information only in connection with this Agreement; provided that such confidential information will not include any information : (i)
already in MSC possession prior to the date JN disclosed it to MSC; (ii) that becomes generally available to the public without violation
of this paragraph by MSC or its representatives; or (iii) that becomes available to MSC on a non-confidential basis from a third party
not bound by a confidentiality obligation to JN with respect to such information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>MUTUAL
                                            REPRESENTATION AND WARRANTIES</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
information made available to JN and MSC will, at all times during the period of this Agreement, to the best of MSC and JN&rsquo;s actual
knowledge, be complete and correct in all material respects and will not contain any untrue statements of material fact or omit to state
a material fact necessary in order to make the statements therein not misleading in light of the circumstances under which such statements
are made. All projections or guidance provided to the JN by MSC will have been prepared in good faith and will be based upon reasonable
assumptions derived from the best estimates and facts then available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>FORCE
                                            MAJEURE</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
Party shall be liable for any delay in performing any of its obligations under this Agreement if such delay is caused by circumstances
beyond the reasonable control of the Party so delaying and such Party shall be entitled (subject to giving the other Party full particulars
of the circumstances in question and to using its best endeavours to resume full performance without avoidable delay) to a reasonable
extension of time for the performance of such obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>LEGAL
                                            DISPUTES</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 44pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
disputes or controversies that may arise between the Parties in the interpretation or implementation of this Agreement shall be finally
settled by sole arbitration in Geneva, Switzerland in accordance with the Rules of the ICC International Court of Arbitration (ICC Rules).
The arbitration shall be conducted in the English language. The award rendered by arbitrator shall be final and binding upon the Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>14.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>GENERAL
                                            PROVISIONS</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            notice, demand or other communication between the Parties:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">may
                                            be sent by personal delivery, post, facsimile or other written form of electronic communication
                                            to the last known address;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            sent by post to an address to either Party, shall be treated as served on the second day
                                            following dispatch;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            sent by facsimile or other form of electronic communication, shall be treated as served at
                                            the time of sending.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            accommodation or indulgence or failure to enforce a right shall not be construed as a waiver
                                            of the right of any Party exercisable under this Agreement unless a waiver shall be specifically
                                            stated in writing signed by such Party.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
                                            Agreement constitutes the entire understanding between the Parties concerning the subject
                                            matter hereof. No amendments or changes shall be made to this Agreement unless agreed to
                                            in writing by both Parties. Each provision of this Agreement shall be construed separately
                                            and notwithstanding that the whole or any part of any such provision may prove to be illegal
                                            or unenforceable the other provisions of this Agreement and the remainder of the provision
                                            in question shall continue in full force and effect.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
                                            Party shall bear its own costs and expenses in connection with the preparation, negotiation
                                            and execution of this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            formation, validity, performance and interpretation of this Agreement and of each Clause
                                            and part hereof shall be governed by the laws of State of Florida in the United States and
                                            the Parties agree to the non-exclusive jurisdiction of the courts of Palm Beach Country.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>15.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>COUNTERPART</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement may be executed in any number of counterparts, which when taken together shall constitute one and the same instrument and is
binding on each and every Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF the parties hereto have signed this Agreement the day and year first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNED
    by Christer Ros&eacute;n</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    &amp; CEO</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    and on behalf of</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter
    Neurosciences, Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNED
    by LAW, Kam Yan Debby</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    and on behalf of</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DOMINANT
    TREASURE HEALTH </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPANY
    LIMITED</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>SCHEDULE
1</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>The
Services</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Strategic Service Provider shall provide services including, not limited to or inclusive of, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide
                                            JN with strategic guidance regarding the pharmaceutical market in the Territory;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide
                                            JN with business development leads to potentially expand pipeline development opportunities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide
                                            commercial guidance regarding potential distribution and commercialization of pipeline products;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oversee
                                            and report on the operations of JN&rsquo;s partner, CMC Management Company, in the CMC area;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oversee
                                            and report on the operations of JN&rsquo;s partner, Regulatory Management Company, regarding
                                            regulatory strategy and execution;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oversee
                                            and report on the operations of JN&rsquo;s partner, CRO Management Company, clinical trial
                                            strategy, cost and execution; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assist
                                            and coordinate with professional advisors.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.40
<SEQUENCE>10
<FILENAME>ex10-40.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.40</B></FONT></P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; background-color: white"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; background-color: white"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B><U>Jupiter
Neurosciences, Inc.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B><U>2023
Equity Incentive Plan</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B><U>Adopted
October 4, 2023</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B><U>Table
of Contents</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article I.</B></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Purposes and Definitions</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    1.01</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purposes
    of this Plan; Structure.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    1.02</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitions.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    1.03</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    Interpretations.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article II.</B></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock Subject to this Plan; Administration.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    2.01</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    Subject to this Plan.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    2.02</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Administration
    of this Plan.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    2.03</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eligibility.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    2.04</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnification.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article III.</B></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Awards.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    3.01</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    Options.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    3.02</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    Appreciation Rights.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    3.03</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    Stock.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    3.04</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    Stock Units.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    3.05</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Performance
    Units and Performance Shares.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    3.06</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash-Based
    Awards and Other Stock-Based Awards.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    3.07</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Award Agreements.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article IV.</B></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Additional Provisions Applicable to this Plan and Awards</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    4.01</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outside
    Director Limitations.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    4.02</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance
    With Code Section 409A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    4.03</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leaves
    of Absence/Transfer Between Locations.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    4.04</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Limited
    Transferability of Awards.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    4.05</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments;
    Dissolution, Merger, Etc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    4.06</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
    Withholding.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    4.07</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance
    with Securities Laws.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    4.08</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    Effect on Employment or Service.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    4.09</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repurchase
    Rights.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    4.10</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fractional
    Shares.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    4.11</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeiture
    Events.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    4.12</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
    of Grant.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    4.13</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term
    of Plan.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    4.14</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment
    and Termination of this Plan.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    4.15</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conditions
    Upon Issuance of Shares.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    4.16</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inability
    to Obtain Authority.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    4.17</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholder
    Approval.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    4.18</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retirement
    and Welfare Plans.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    4.19</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficiary
    Designation.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    4.20</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severability.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    4.21</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    Constraint on Corporate Action.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    4.22</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unfunded
    Obligation.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    4.23</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Choice
    of Law.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Exhibits</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    A</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Award Agreement for Options</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    B</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Award Agreement for Stock Appreciation Rights</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    C</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Award Agreement for Restricted Stock </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    D</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Award Agreement for Restricted Stock Units</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence -->)</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>2021
Equity Incentive Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article
I. <FONT STYLE="font-variant: small-caps"><U>Purposes and Definitions</U></FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
1.01 <U>Purposes of this Plan; Structure.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    purposes of this Plan are (i) to attract and retain the best available personnel for positions of substantial responsibility, (ii)
    to provide additional incentive to Employees, Directors and Consultants, and (ii) to promote the success of the Company&rsquo;s business.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    Plan permits the grant of Incentive Stock Options, Nonstatutory Stock Options, Stock Appreciation Rights, Restricted Stock, Restricted
    Stock Units, Performance Awards, Cash-Based Awards and Other Stock-Based Awards.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
1.02 <U>Definitions.</U></B> As used herein, the following definitions will apply:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Administrator&rdquo;
    means the Board or any of its Committees as will be administering this Plan, in accordance with Section 2.02.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Affiliate&rdquo;
    means, with respect to any Person, any other Person directly or indirectly Controlling, Controlled by, or under common Control with
    such Person.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Applicable
    Laws&rdquo; means the legal and regulatory requirements relating to the administration of equity-based awards, including but not
    limited to the related issuance of shares of Common Stock, including but not limited to under U.S. federal and state corporate laws,
    U.S. federal and state securities laws, the Code, any stock exchange or quotation system on which the Common Stock is listed or quoted
    and the applicable laws of any non-U.S. country or jurisdiction where Awards are, or will be, granted under this Plan.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Award&rdquo;
    means, individually or collectively, a grant under this Plan of Options, Stock Appreciation Rights, Restricted Stock, Restricted
    Stock Units, Performance Units, Performance Shares, Cash-Based Award or Other Stock-Based Award.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Award
    Agreement&rdquo; means the written or electronic agreement setting forth the terms and provisions applicable to each Award granted
    under this Plan, which Award Agreement shall be is subject to the terms and conditions of this Plan.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Board&rdquo;
    means the Board of Directors of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Cash-Based
    Award&rdquo; means an Award denominated in cash and granted pursuant to Section 3.06.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Change
    in Control&rdquo; means the occurrence of any of the following events, subject to the provisions of Section 1.03:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Change
    in Ownership of the Company</U>. A change in the ownership of the Company which occurs on the date that any one person, or more than
    one person acting as a group (&ldquo;Person&rdquo;), acquires ownership of the stock of the Company that, together with the stock
    held by such Person, constitutes more than fifty percent (50%) of the total voting power of the stock of the Company; provided, however,
    that for purposes of this Section 1.02(h)(i), the acquisition of additional stock by any one Person, who is considered to own more
    than fifty percent (50%) of the total voting power of the stock of the Company will not be considered a Change in Control. Further,
    if the stockholders of the Company immediately before such change in ownership continue to retain immediately after the change in
    ownership, in substantially the same proportions as their ownership of shares of the Company&rsquo;s voting stock immediately prior
    to the change in ownership, direct or indirect beneficial ownership of fifty percent (50%) or more of the total voting power of the
    stock of the Company or of the ultimate parent entity of the Company, such event shall not be considered a Change in Control under
    this Section 1.02(h)(i). For this purpose, indirect beneficial ownership shall include, without limitation, an interest resulting
    from ownership of the voting securities of one or more corporations or other business entities which own the Company, as the case
    may be, either directly or through one or more subsidiary corporations or other business entities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Change
    in Effective Control of the Company</U>. A change in the effective control of the Company which occurs on the date that a majority
    of members of the Board is replaced during any twelve (12) month period by Directors whose appointment or election is not endorsed
    by a majority of the members of the Board prior to the date of the appointment or election. For purposes of this Section 1.02(h)(ii),
    if any Person is considered to be in effective control of the Company, the acquisition of additional control of the Company by the
    same Person will not be considered a Change in Control.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Change
    in Ownership of a Substantial Portion of the Company&rsquo;s Assets</U>. A change in the ownership of a substantial portion of the
    Company&rsquo;s assets which occurs on the date that any Person acquires (or has acquired during the twelve (12) month period ending
    on the date of the most recent acquisition by such person or persons) assets from the Company that have a total gross fair market
    value equal to or more than fifty percent (50%) of the total gross fair market value of all of the assets of the Company immediately
    prior to such acquisition or acquisitions; provided, however, that for purposes of this Section 1.02(h)(iii), the following will
    not constitute a change in the ownership of a substantial portion of the Company&rsquo;s assets: (A) a transfer to an entity that
    is controlled by the Company&rsquo;s stockholders immediately after the transfer, or (B) a transfer of assets by the Company to:
    (1) a stockholder of the Company (immediately before the asset transfer) in exchange for or with respect to the Company&rsquo;s stock,
    (2) an entity, fifty percent (50%) or more of the total value or voting power of which is owned, directly or indirectly, by the Company,
    (3) a Person, that owns, directly or indirectly, fifty percent (50%) or more of the total value or voting power of all the outstanding
    stock of the Company, or (4) an entity, at least fifty percent (50%) of the total value or voting power of which is owned, directly
    or indirectly, by a Person described in clause (B)(3) of this Section 1.02(h)(iii). For purposes of this Section 1.02(h)(iii), gross
    fair market value means the value of the assets of the Company, or the value of the assets being disposed of, determined without
    regard to any liabilities associated with such assets.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Code&rdquo;
    means the Internal Revenue Code of 1986, as amended, and reference to a specific section of the Code or regulation thereunder shall
    include such section or regulation, any valid regulation promulgated under such section, and any comparable provision of any future
    legislation or regulation amending, supplementing or superseding such section or regulation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Committee&rdquo;
    means a committee of Directors or of other individuals satisfying Applicable Laws appointed by the Board, or by a duly authorized
    committee of the Board, in accordance with Section 2.02.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Common
    Stock&rdquo; means the common stock, par value $0.0001 per share, of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Company&rdquo;
    means Jupiter Neurosciences, Inc., a Delaware corporation, or any successor thereto.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Consultant&rdquo;
    means any natural person, including an advisor, engaged by the Company or a Parent or Subsidiary to render bona fide services to
    such entity, provided the services (i) are not in connection with the offer or sale of securities in a capital-raising transaction,
    and (ii) do not directly promote or maintain a market for the Company&rsquo;s securities, in each case, within the meaning of Form
    S-8 promulgated under the Securities Act, and provided further, that a Consultant will include only those persons to whom the issuance
    of Shares may be registered under Form S-8 promulgated under the Securities Act.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Control&rdquo;
    of a Person means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies
    of such Person, whether through the ownership of voting securities, by contract, or otherwise.&rdquo; Controlled&rdquo;, &ldquo;Controlling&rdquo;
    and &ldquo;under common Control with&rdquo; have correlative meanings. Without limiting the foregoing a Person (the &ldquo;Controlled
    Person&rdquo;) shall be deemed Controlled by (a) any other Person (the &ldquo;10% Owner&rdquo;) (i) owning beneficially, as meant
    in Rule 13d-3 under the Exchange Act, securities entitling such Person to cast 10% or more of the votes for election of directors
    or equivalent governing authority of the Controlled Person or (ii) entitled to be allocated or receive 10% or more of the profits,
    losses, or distributions of the Controlled Person; (b) an officer, director, general partner, partner (other than a limited partner),
    manager, or member (other than a member having no management authority that is not a 10% Owner ) of the Controlled Person; or (c)
    a spouse, parent, lineal descendant, sibling, aunt, uncle, niece, nephew, mother-in-law, father-in-law, sister-in-law, or brother-in-law
    of an Affiliate of the Controlled Person or a trust for the benefit of an Affiliate of the Controlled Person or of which an Affiliate
    of the Controlled Person is a trustee.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Director&rdquo;
    means a member of the Board.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Disability&rdquo;
    means total and permanent disability as defined in Code Section 22(e)(3), provided that in the case of Awards other than Incentive
    Stock Options, the Administrator in its discretion may determine whether a permanent and total disability exists in accordance with
    uniform and non-discriminatory standards adopted by the Administrator from time to time.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Dividend
    Equivalent Right&rdquo; means the right of a Participant, granted at the discretion of the Administrator or as otherwise provided
    by this Plan, to receive a credit for the account of such Participant in an amount equal to the cash dividends paid on one Share
    for each Share represented by an Award held by such Participant.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Employee&rdquo;
    means any person, including Officers and Directors, employed by the Company or any Parent or Subsidiary of the Company, provided
    that neither service as a Director nor payment of a director&rsquo;s fee by the Company will be sufficient to constitute &ldquo;employment&rdquo;
    by the Company or any Parent or Subsidiary of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Exchange
    Act&rdquo; means the Securities Exchange Act of 1934, as amended.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Exchange
    Program&rdquo; means a program under which (i) outstanding Awards are surrendered or cancelled in exchange for awards of the same
    type (which may have higher or lower exercise prices and different terms), awards of a different type, and/or cash, (ii) Participants
    would have the opportunity to transfer any outstanding Awards to a financial institution or other person or entity selected by the
    Administrator, and/or (iii) the exercise price of an outstanding Award is reduced or increased. The Administrator will determine
    the terms and conditions of any Exchange Program in its sole discretion.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Fair
    Market Value&rdquo; means, as of any date, the value of Common Stock determined as follows:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    the Common Stock is listed on any established stock exchange or a national market system (other than an over-the counter market,
    which will not be considered an established stock exchange of national market system for the purposes of this definition), including
    without limitation the New York Stock Exchange, the Nasdaq Global Select Market, the Nasdaq Global Market or the Nasdaq Capital Market
    of The Nasdaq Stock Market, its Fair Market Value will be the closing sales price for such stock (or, if no closing sales price was
    reported on that date, as applicable, on the last trading date such closing sales price was reported) as quoted on such exchange
    or system on the day of determination, as reported in The Wall Street Journal or such other source as the Administrator deems reliable;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    the Common Stock is regularly quoted by a recognized securities dealer but selling prices are not reported, the Fair Market Value
    of a Share will be the mean between the high bid and low asked prices for the Common Stock on the day of determination (or, if no
    bids and asks were reported on that date, as applicable, on the last trading date such bids and asks were reported), as reported
    in The Wall Street Journal or such other source as the Administrator deems reliable;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    the absence of an established market for the Common Stock, the Fair Market Value will be determined in good faith by the Administrator.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Fiscal
    Year&rdquo; means the fiscal year of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Incentive
    Stock Option&rdquo; means an Option that by its terms qualifies and is otherwise intended to qualify as an incentive stock option
    within the meaning of Code Section 422 and the regulations promulgated thereunder.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Nonstatutory
    Stock Option&rdquo; means an Option that by its terms does not qualify or is not intended to qualify as an Incentive Stock Option.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Officer&rdquo;
    means a person who is an officer of the Company within the meaning of Section 16 of the Exchange Act and the rules and regulations
    promulgated thereunder.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Option&rdquo;
    means a stock option granted pursuant to this Plan.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Outside
    Director&rdquo; means a Director who is not an Employee.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Other
    Stock-Based Award&rdquo; means an Award denominated in Shares and granted pursuant to Section 3.06.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Parent&rdquo;
    means a &ldquo;parent corporation,&rdquo; whether now or hereafter existing, as defined in Code Section 424(e).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Participant&rdquo;
    means the holder of an outstanding Award.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Performance
    Award&rdquo; means an Award of Performance Shares or Performance Units.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ff)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Performance
    Award Formula&rdquo; means, for any Performance Award, a formula or table established by the Administrator pursuant to Section 3.05
    which provides the basis for computing the value of a Performance Award at one or more levels of attainment of the applicable Performance
    Goal(s) measured as of the end of the applicable Performance Period.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(gg)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Performance
    Share&rdquo; means an Award denominated in Shares which may be earned in whole or in part upon attainment of performance goals or
    other vesting criteria as the Administrator may determine pursuant to Section 3.05.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(hh)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Performance
    Unit&rdquo; means an Award which may be earned in whole or in part upon attainment of performance goals or other vesting criteria
    as the Administrator may determine and which may be settled for cash, Shares or other securities or a combination of the foregoing
    pursuant to Section 3.05.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Period
    of Restriction&rdquo; means the period during which the transfer of Shares of Restricted Stock are subject to restrictions and therefore,
    the Shares are subject to a substantial risk of forfeiture. Such restrictions may be based on the passage of time, the achievement
    of target levels of performance, or the occurrence of other events as determined by the Administrator.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(jj)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Person&rdquo;
    means an individual, corporation, partnership (including a general partnership, limited partnership or limited liability partnership),
    limited liability company, association, trust or other entity or organization, including a government, domestic or foreign, or political
    subdivision thereof, or an agency or instrumentality thereof.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(kk)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Plan&rdquo;
    means this 2023 Equity Incentive Plan.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ll)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Restricted
    Stock&rdquo; means Shares issued pursuant to an Award of Restricted Stock under Section 3.03, or issued pursuant to the early exercise
    of an Option.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(mm)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Restricted
    Stock Unit&rdquo; means a bookkeeping entry representing an amount equal to the Fair Market Value of one Share, granted pursuant
    to Section 3.04. Each Restricted Stock Unit represents an unfunded and unsecured obligation of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(nn)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Rule
    16b-3&rdquo; means Rule 16b-3 of the Exchange Act or any successor to Rule 16b-3, as in effect when discretion is being exercised
    with respect to this Plan.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(oo)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Section
    16(b)&rdquo; means Section 16(b) of the Exchange Act.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(pp)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Securities
    Act&rdquo; means the Securities Act of 1933, as amended.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(qq)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Service
    Provider&rdquo; means an Employee, Director or Consultant.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(rr)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Share&rdquo;
    means a share of the Common Stock, as adjusted in accordance with Section 4.05.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ss)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Stock
    Appreciation Right&rdquo; means an Award, granted alone or in connection with an Option, that pursuant to Section 3.02 is designated
    as a Stock Appreciation Right.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(tt)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Subsidiary&rdquo;
    means a &ldquo;subsidiary corporation,&rdquo; whether now or hereafter existing, as defined in Code Section 424(f).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
1.03 <U>Additional Interpretations.</U></B> For purposes of Section 1.02(h), persons will be considered to be acting as a group if they
are owners of a corporation that enters into a merger, consolidation, purchase or acquisition of stock, or similar business transaction
with the Company. Notwithstanding the foregoing, a transaction will not be deemed a Change in Control unless the transaction qualifies
as a change in control event within the meaning of Code Section 409A, as it has been and may be amended from time to time, and any proposed
or final Treasury Regulations and Internal Revenue Service guidance that has been promulgated or may be promulgated thereunder from time
to time. Further and for the avoidance of doubt, a transaction will not constitute a Change in Control if: (i) its sole purpose is to
change the jurisdiction of the Company&rsquo;s incorporation, or (ii) its sole purpose is to create a holding company that will be owned
in substantially the same proportions by the persons who held the Company&rsquo;s securities immediately before such transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article
II. <FONT STYLE="font-variant: small-caps"><U>Stock Subject to this Plan; Administration.</U></FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
2.01 <U>Stock Subject to this Plan.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to the provisions of Section 2.01(a) and Section 4.05, the maximum aggregate number of Shares that may be subject to Awards and sold
    under this Plan is 1,070,076 Shares. The Shares may be authorized but unissued, or reacquired Common Stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    an Award expires or becomes un-exercisable without having been exercised in full, is surrendered pursuant to an Exchange Program,
    or, with respect to Restricted Stock, Restricted Stock Units, Performance Units or Performance Shares, is forfeited to or repurchased
    by the Company due to the failure to vest, the unpurchased Shares (or for Awards other than Options or Stock Appreciation Rights
    the forfeited or repurchased Shares) which were subject thereto will become available for future grant or sale under this Plan (unless
    this Plan has terminated). With respect to Stock Appreciation Rights, only Shares actually issued pursuant to a Stock Appreciation
    Right will cease to be available under this Plan; all remaining Shares under Stock Appreciation Rights will remain available for
    future grant or sale under this Plan (unless this Plan has terminated). Shares that have actually been issued under this Plan under
    any Award will not be returned to this Plan and will not become available for future distribution under this Plan; provided, however,
    that if Shares issued pursuant to Awards of Restricted Stock, Restricted Stock Units, Performance Shares or Performance Units are
    repurchased by the Company or are forfeited to the Company due to the failure to vest, such Shares will become available for future
    grant under this Plan. Shares used to pay the exercise price of an Award or to satisfy the tax withholdings related to an Award will
    become available for future grant or sale under this Plan. To the extent an Award under this Plan is paid out in cash rather than
    Shares, such cash payment will not result in reducing the number of Shares available for issuance under this Plan. Notwithstanding
    the foregoing and, subject to adjustment as provided in Section 4.05, the maximum number of Shares that may be issued upon the exercise
    of Incentive Stock Options will equal the aggregate Share number stated in Section 2.01(a), plus, to the extent allowable under Code
    Section 422 and the Treasury Regulations promulgated thereunder, any Shares that become available for issuance under this Plan pursuant
    to Section 2.01(b) and Section 2.01(c).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company, during the term of this Plan, will at all times reserve and keep available such number of Shares as will be sufficient to
    satisfy the requirements of this Plan.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
2.02 <U>Administration of this Plan.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Procedure</I>.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Compensation
    Committee</I>. To the extent required by Applicable Laws, the Compensation Committee of the Board shall administer this Plan.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Rule
    16b-3</I>. To the extent desirable to qualify transactions hereunder as exempt under Rule 16b-3, the transactions contemplated hereunder
    will be structured to satisfy the requirements for exemption under Rule 16b-3.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Other
    Administration</I>. Other than as provided above, this Plan will be administered by (A) the Board or (B) a Committee other than the
    Compensation Committee, which Committee will be constituted to satisfy Applicable Laws.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Powers
    of the Administrator</I>. Subject to the provisions of this Plan, and in the case of a Committee, subject to the specific duties
    delegated by the Board to such Committee, the Administrator will have the authority, in its discretion:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    determine the Fair Market Value;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    select the Service Providers to whom Awards may be granted hereunder;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    determine the number of Shares to be covered by each Award granted hereunder;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    approve forms of Award Agreements for use under this Plan;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    determine the terms and conditions, not inconsistent with the terms of this Plan, of any Award granted hereunder, with such terms
    and conditions including, but not being limited to, the exercise price, the time or times when Awards may be exercised (which may
    be based on performance criteria), any vesting acceleration or waiver of forfeiture restrictions, and any restriction or limitation
    regarding any Award or the Shares relating thereto, based in each case on such factors as the Administrator will determine;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    determine whether an Award will be settled in Shares, cash, other property or in any combination thereof;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    institute and determine the terms and conditions of an Exchange Program;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    construe and interpret the terms of this Plan and Awards granted pursuant to this Plan;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    prescribe, amend and rescind rules and regulations relating to this Plan, including rules and regulations relating to sub-plans established
    for the purpose of satisfying applicable non-U.S. laws or for qualifying for favorable tax treatment under applicable non-U.S. laws;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    modify or amend each Award (subject to Section 4.14(c)), including but not limited to the discretionary authority to extend the post-termination
    exercisability period of Awards; provided, however, that in no case will an Option or Stock Appreciation Right be extended beyond
    its original maximum term;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xi)&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    allow Participants to satisfy tax withholding obligations in a manner prescribed in Section 4.05(d);</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xii)&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    authorize any person to execute on behalf of the Company any instrument required to effect the grant of an Award previously granted
    by the Administrator;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiii)&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    allow a Participant to defer the receipt of the payment of cash or the delivery of Shares that otherwise would be due to such Participant
    under an Award;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiv)&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    prescribe, amend or rescind rules, guidelines and policies relating to this Plan, or to adopt sub-plans or supplements to, or alternative
    versions of, this Plan, including, without limitation, as the Administrator deems necessary or desirable to comply with the laws
    of, or to accommodate the tax policy, accounting principles or custom of, foreign jurisdictions whose residents may be granted Awards;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xv)&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    correct any defect, supply any omission or reconcile any inconsistency in this Plan or any Award Agreement and to make all other
    determinations and take such other actions with respect to this Plan or any Award as the Administrator may deem advisable to the
    extent not inconsistent with the provisions of this Plan or applicable law; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xvi)&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    make all other determinations deemed necessary or advisable for administering this Plan.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Option
    or Stock Appreciation Right Repricing</I>. The Administrator shall have the authority, without additional approval by the stockholders
    of the Company, to approve a program providing for either (a) the cancellation of outstanding Options or Stock Appreciation Rights
    having exercise prices per share greater than the then Fair Market Value of a Share (&ldquo;Underwater Awards&rdquo;) and the grant
    in substitution therefor of new Options or Stock Appreciation Rights covering the same or a different number of shares but with an
    exercise price per share equal to the Fair Market Value per share on the new grant date or payments in cash, or (b) the amendment
    of outstanding Underwater Awards to reduce the exercise price thereof to the Fair Market Value per share on the date of amendment.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Effect
    of Administrator&rsquo;s Decision</I>. The Administrator&rsquo;s decisions, determinations and interpretations will be final and
    binding on all Participants and any other holders of Awards and will be given the maximum deference permitted by Applicable Laws</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
2.03 <U>Eligibility.</U></B> Nonstatutory Stock Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units, Performance
Shares and Performance Units may be granted to Service Providers. Incentive Stock Options may be granted only to Employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
2.04 <U>Indemnification.</U></B> In addition to such other rights of indemnification as they may have as members of the Board or the
Administrator or as officers or employees of the Company or any of its Affiliates, to the extent permitted by applicable law, members
of the Board or the Administrator and any officers or employees of the Company or any of its Affiliates to whom authority to act for
the Board, the Administrator or the Company is delegated shall be indemnified by the Company against all reasonable expenses, including
attorneys&rsquo; fees, actually and necessarily incurred in connection with the defense of any action, suit or proceeding, or in connection
with any appeal therein, to which they or any of them may be a party by reason of any action taken or failure to act under or in connection
with this Plan, or any right granted hereunder, and against all amounts paid by them in settlement thereof (provided such settlement
is approved by independent legal counsel selected by the Company) or paid by them in satisfaction of a judgment in any such action, suit
or proceeding, except in relation to matters as to which it shall be adjudged in such action, suit or proceeding that such person is
liable for gross negligence, bad faith or intentional misconduct in duties; provided, however, that within sixty (60) days after the
institution of such action, suit or proceeding, such person shall offer to the Company, in writing, the opportunity at its own expense
to handle and defend the same.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article
III. <FONT STYLE="font-variant: small-caps"><U>Awards</U></FONT>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
3.01 <U>Stock Options.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Grant
    of Options</I>. Subject to the terms and provisions of this Plan, the Administrator, at any time and from time to time, may grant
    Options in such amounts as the Administrator, in its sole discretion, will determine.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Option
    Agreement</I>. Each Award of an Option will be evidenced by an Award Agreement that will specify the exercise price, the term of
    the Option, the number of Shares subject to the Option, the exercise restrictions, if any, applicable to the Option, and such other
    terms and conditions as the Administrator, in its sole discretion, will determine.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Limitations</I>.
    Each Option will be designated in the Award Agreement as either an Incentive Stock Option or a Nonstatutory Stock Option. Notwithstanding
    such designation, however, to the extent that the aggregate Fair Market Value of the Shares with respect to which Incentive Stock
    Options are exercisable for the first time by the Participant during any calendar year (under all plans of the Company and any Parent
    or Subsidiary) exceeds one hundred thousand dollars ($100,000), such Options will be treated as Nonstatutory Stock Options. For purposes
    of this Section 3.01(c), Incentive Stock Options will be taken into account in the order in which they were granted, the Fair Market
    Value of the Shares will be determined as of the time the Option with respect to such Shares is granted, and the calculation will
    be performed in accordance with Code Section 422 and Treasury Regulations promulgated thereunder.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Term
    of Option</I>. The term of each Option will be stated in the Award Agreement. In the case of an Incentive Stock Option, the term
    will be no more than ten (10) years from the date of grant thereof. In the case of an Incentive Stock Option granted to a Participant
    who, at the time the Incentive Stock Option is granted, owns stock representing more than ten percent (10%) of the total combined
    voting power of all classes of stock of the Company or any Parent or Subsidiary, the term of the Incentive Stock Option will be five
    (5) years from the date of grant or such shorter term as may be provided in the Award Agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Option
    Exercise Price and Consideration</I>.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Exercise
    Price</U>. The per Share exercise price for the Shares to be issued pursuant to the exercise of an Option will be determined by the
    Administrator, subject to the following:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    the case of an Incentive Stock Option:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">granted
    to an Employee who, at the time the Incentive Stock Option is granted, owns stock representing more than ten percent (10%) of the
    voting power of all classes of stock of the Company or any Parent or Subsidiary, the per Share exercise price will be no less than
    one hundred ten percent (110%) of the Fair Market Value per Share (or the fair market value per Share as determined in accordance
    with Treas. Reg. 1.409A-1(b)(5)(iv)(A)) on the date of grant;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">granted
    to any Employee other than an Employee described in Section 3.01(e)(i)(1)(A), the per Share exercise price will be no less than one
    hundred percent (100%) of the Fair Market Value per Share on the date of grant;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    the case of a Nonstatutory Stock Option, the per Share exercise price will be no less than one hundred percent (100%) of the Fair
    Market Value per Share on the date of grant (or the fair market value per Share as determined in accordance with Treas. Reg. 1.409A-1(b)(5)(iv)(A)).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
    the foregoing provisions of this Section 3.01(e), Options may be granted with a per Share exercise price of less than one hundred
    percent (100%) of the Fair Market Value per Share on the date of grant pursuant to a transaction described in, and in a manner consistent
    with, Code Section 424(a).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Waiting
    Period and Exercise Dates</U>. At the time an Option is granted, the Administrator will fix the period within which the Option may
    be exercised and will determine any conditions that must be satisfied before the Option may be exercised.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Form
    of Consideration</U>. The Administrator will determine the acceptable form of consideration for exercising an Option, including the
    method of payment. In the case of an Incentive Stock Option, the Administrator will determine the acceptable form of consideration
    at the time of grant. Such consideration may consist entirely of: (1) cash; (2) check; (3) promissory note, to the extent permitted
    by Applicable Laws; (4) other Shares, provided that such Shares have a Fair Market Value on the date of surrender equal to the aggregate
    exercise price of the Shares as to which such Option will be exercised and provided further that accepting such Shares will not result
    in any adverse accounting consequences to the Company, as the Administrator determines in its sole discretion; (5) consideration
    received by the Company under a broker assisted (or other) cashless exercise program (whether through a broker or otherwise) implemented
    by the Company in connection with this Plan; (6) by net exercise; (7) such other consideration and method of payment for the issuance
    of Shares to the extent permitted by Applicable Laws; or (8) any combination of the foregoing methods of payment. In making its determination
    as to the type of consideration to accept, the Administrator will consider if acceptance of such consideration may be reasonably
    expected to benefit the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Exercise
    of Option</I>.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Procedure
    for Exercise; Rights as a Stockholder</U>. Any Option granted hereunder will be exercisable according to the terms of this Plan and
    at such times and under such conditions as determined by the Administrator and set forth in the Award Agreement. An Option may not
    be exercised for a fraction of a Share. An Option will be deemed exercised when the Company receives: (i) notice of exercise (in
    such form as the Administrator may specify from time to time) from the person entitled to exercise the Option, and (ii) full payment
    for the Shares with respect to which the Option is exercised (together with applicable tax withholding). Full payment may consist
    of any consideration and method of payment authorized by the Administrator and permitted by the Award Agreement and this Plan. Shares
    issued upon exercise of an Option will be issued in the name of the Participant or, if requested by the Participant, in the name
    of the Participant and his or her spouse. Until the Shares are issued (as evidenced by the appropriate entry on the books of the
    Company or of a duly authorized transfer agent of the Company), no right to vote or receive dividends or any other rights as a stockholder
    will exist with respect to the Shares subject to an Option, notwithstanding the exercise of the Option. The Company will issue (or
    cause to be issued) such Shares promptly after the Option is exercised. No adjustment will be made for a dividend or other right
    for which the record date is prior to the date the Shares are issued, except as provided in Section 4.05. Exercising an Option in
    any manner will decrease the number of Shares thereafter available, both for purposes of this Plan and for sale under the Option,
    by the number of Shares as to which the Option is exercised.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Termination
    of Relationship as a Service Provider</U>. If a Participant ceases to be a Service Provider, other than upon the Participant&rsquo;s
    termination as the result of the Participant&rsquo;s death or Disability, the Participant may exercise his or her Option within such
    period of time as is specified in the Award Agreement to the extent that the Option is vested on the date of termination (but in
    no event later than the expiration of the term of such Option as set forth in the Award Agreement). In the absence of a specified
    time in the Award Agreement, the Option will remain exercisable for three (3) months following the Participant&rsquo;s termination.
    Unless otherwise provided by the Administrator, if on the date of termination the Participant is not vested as to his or her entire
    Option, the Shares covered by the unvested portion of the Option will revert to this Plan. If after termination the Participant does
    not exercise his or her Option within the time specified by the Administrator, the Option will terminate, and the Shares covered
    by such Option will revert to this Plan.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Disability
    of Participant</U>. If a Participant ceases to be a Service Provider as a result of the Participant&rsquo;s Disability, the Participant
    may exercise his or her Option within such period of time as is specified in the Award Agreement to the extent the Option is vested
    on the date of termination (but in no event later than the expiration of the term of such Option as set forth in the Award Agreement).
    In the absence of a specified time in the Award Agreement, the Option will remain exercisable for twelve (12) months following the
    Participant&rsquo;s termination. Unless otherwise provided by the Administrator, if on the date of termination the Participant is
    not vested as to his or her entire Option, the Shares covered by the unvested portion of the Option will revert to this Plan. If
    after termination the Participant does not exercise his or her Option within the time specified herein, the Option will terminate,
    and the Shares covered by such Option will revert to this Plan.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Death
    of Participant</U>. If a Participant dies while a Service Provider, the Option may be exercised following the Participant&rsquo;s
    death within such period of time as is specified in the Award Agreement to the extent that the Option is vested on the date of death
    (but in no event may the option be exercised later than the expiration of the term of such Option as set forth in the Award Agreement),
    by the Participant&rsquo;s designated beneficiary, provided such beneficiary has been designated prior to Participant&rsquo;s death
    in a form acceptable to the Administrator. If no such beneficiary has been designated by the Participant, then such Option may be
    exercised by the personal representative of the Participant&rsquo;s estate or by the person(s) to whom the Option is transferred
    pursuant to the Participant&rsquo;s will or in accordance with the laws of descent and distribution. In the absence of a specified
    time in the Award Agreement, the Option will remain exercisable for twelve (12) months following Participant&rsquo;s death. Unless
    otherwise provided by the Administrator, if at the time of death Participant is not vested as to his or her entire Option, the Shares
    covered by the unvested portion of the Option will immediately revert to this Plan. If the Option is not so exercised within the
    time specified herein, the Option will terminate, and the Shares covered by such Option will revert to this Plan. .</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
3.02 <U>Stock Appreciation Rights.</U></B></FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Grant
    of Stock Appreciation Rights</I>. Subject to the terms and conditions of this Plan, a Stock Appreciation Right may be granted to
    Service Providers at any time and from time to time as will be determined by the Administrator, in its sole discretion.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Number
    of Shares</I>. The Administrator will have complete discretion to determine the number of Shares subject to any Award of Stock Appreciation
    Rights.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Exercise
    Price and Other Terms</I>. The per Share exercise price for the Shares that will determine the amount of the payment to be received
    upon exercise of a Stock Appreciation Right as set forth in Section 3.02(f) will be determined by the Administrator and will be no
    less than one hundred percent (100%) of the Fair Market Value per Share on the date of grant. Otherwise, the Administrator, subject
    to the provisions of this Plan, will have complete discretion to determine the terms and conditions of Stock Appreciation Rights
    granted under this Plan. Stock Appreciation Rights which have become exercisable may be exercised by delivery of written or electronic
    notice of exercise to the Company in accordance with the terms of the Award Agreement, specifying the number of Stock Appreciation
    Rights to be exercised and the date on which such Stock Appreciation Rights were awarded and vested.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Stock
    Appreciation Right Agreement</I>. Each Stock Appreciation Right grant will be evidenced by an Award Agreement that will specify the
    exercise price, the term of the Stock Appreciation Right, the conditions of exercise, and such other terms and conditions as the
    Administrator, in its sole discretion, will determine.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Expiration
    of Stock Appreciation Rights</I>. A Stock Appreciation Right granted under this Plan will expire upon the date determined by the
    Administrator, in its sole discretion, and set forth in the Award Agreement. Notwithstanding the foregoing, the rules of Section
    3.01(d) relating to the maximum term and Section 3.01(f) relating to exercise also will apply to Stock Appreciation Rights.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Payment
    of Stock Appreciation Right Amount</I>. Upon exercise of a Stock Appreciation Right, a Participant will be entitled to receive payment
    from the Company in an amount determined by multiplying (i) the difference between the Fair Market Value of a Share on the date of
    exercise over the exercise price; and (ii) the number of Shares with respect to which the Stock Appreciation Right is exercised.
    At the discretion of the Administrator, the payment upon Stock Appreciation Right exercise may be in cash, in Shares of equivalent
    value, or in some combination thereof.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Deemed
    Exercise of Stock Appreciation Rights</I>. If, on the date on which a Stock Appreciation Rights would otherwise terminate or expire,
    the Stock Appreciation Right by its terms remains exercisable immediately prior to such termination or expiration and, if so exercised,
    would result in a payment to the holder of such Stock Appreciation Right, then any portion of such Stock Appreciation Right which
    has not previously been exercised shall automatically be deemed to be exercised as of such date with respect to such portion.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
3.03 <U>Restricted Stock.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Grant
    of Restricted Stock</I>. Subject to the terms and provisions of this Plan, the Administrator, at any time and from time to time,
    may grant Shares of Restricted Stock to Service Providers in such amounts as the Administrator, in its sole discretion, will determine.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Restricted
    Stock Agreement</I>. Each Award of Restricted Stock will be evidenced by an Award Agreement that will specify the Period of Restriction,
    the number of Shares granted, and such other terms and conditions as the Administrator, in its sole discretion, will determine. Unless
    the Administrator determines otherwise, the Company as escrow agent will hold Shares of Restricted Stock until the restrictions on
    such Shares have lapsed.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Transferability</I>.
    Except as provided in this Section 3.03 or as the Administrator determines, Shares of Restricted Stock may not be sold, transferred,
    pledged, assigned, or otherwise alienated or hypothecated until the end of the applicable Period of Restriction.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Other
    Restrictions</I>. The Administrator, in its sole discretion, may impose such other restrictions on Shares of Restricted Stock as
    it may deem advisable or appropriate.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Removal
    of Restrictions</I>. Except as otherwise provided in this Section 3.03, Shares of Restricted Stock covered by each Restricted Stock
    grant made under this Plan will be released from escrow as soon as practicable after the last day of the Period of Restriction or
    at such other time as the Administrator may determine. The Administrator, in its discretion, may accelerate the time at which any
    restrictions will lapse or be removed.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting
    Rights</I>. During the Period of Restriction, Service Providers holding Shares of Restricted Stock granted hereunder may exercise
    full voting rights with respect to those Shares, unless the Administrator determines otherwise.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dividends
    and Other Distributions</I>. During the Period of Restriction, Service Providers holding Shares of Restricted Stock will be entitled
    to receive all dividends and other distributions paid with respect to such Shares, unless the Administrator provides otherwise. If
    any such dividends or distributions are paid in Shares, the Shares will be subject to the same restrictions on transferability and
    forfeitability as the Shares of Restricted Stock with respect to which they were paid.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Return
    of Restricted Stock to Company</I>. On the date set forth in the Award Agreement, the Restricted Stock for which restrictions have
    not lapsed will revert to the Company and again will become available for grant under this Plan.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
3.04 <U>Restricted Stock Units.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Grant</I>.
    Restricted Stock Units may be granted at any time and from time to time as determined by the Administrator. After the Administrator
    determines that it will grant Restricted Stock Units under this Plan, it will advise the Participant in an Award Agreement of the
    terms, conditions, and restrictions related to the grant, including the number of Restricted Stock Units.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Vesting
    Criteria and Other Terms</I>. The Administrator will set vesting criteria in its discretion, which, depending on the extent to which
    the criteria are met, will determine the number of Restricted Stock Units that will be paid out to the Participant. The Administrator
    may set vesting criteria based upon the achievement of Company-wide, divisional, business unit, or individual goals (including, but
    not limited to, continued employment or service), applicable federal or state securities laws, or any other basis determined by the
    Administrator in its discretion.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Earning
    Restricted Stock Units</I>. Upon meeting the applicable vesting criteria, the Participant will be entitled to receive a payout as
    determined by the Administrator or as set forth in the applicable Award Agreement. Notwithstanding the foregoing, at any time after
    the grant of Restricted Stock Units, the Administrator, in its sole discretion, may reduce or waive any vesting criteria that must
    be met to receive a payout.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Form
    and Timing of Payment</I>. Payment of earned Restricted Stock Units will be made as soon as practicable after the date(s) determined
    by the Administrator and set forth in the Award Agreement. The Administrator, in its sole discretion, may settle earned Restricted
    Stock Units in cash, Shares, or a combination of both.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting
    Rights, Dividend Equivalent Rights and Distributions</I>. Participants shall have no voting rights with respect to Shares represented
    by Restricted Stock Units until the date of the issuance of such shares (as evidenced by the appropriate entry on the books of the
    Company or of a duly authorized transfer agent of the Company). However, the Administrator, in its discretion, may provide in the
    Award Agreement evidencing any Restricted Stock Unit Award that the Participant shall be entitled to Dividend Equivalent Rights with
    respect to the payment of cash dividends on Stock during the period beginning on the date such Award is granted and ending, with
    respect to each share subject to the Award, on the earlier of the date the Award is settled or the date on which it is terminated.
    Dividend Equivalent Rights, if any, shall be paid by crediting the Participant with a cash amount or with additional whole Restricted
    Stock Units as of the date of payment of such cash dividends on Stock, as determined by the Administrator. The number of additional
    Restricted Stock Units (rounded to the nearest whole number), if any, to be credited shall be determined by dividing (a) the amount
    of cash dividends paid on the dividend payment date with respect to the number of Shares represented by the Restricted Stock Units
    previously credited to the Participant by (b) the Fair Market Value per Share on such date. Such cash amount or additional Restricted
    Stock Units shall be subject to the same terms and conditions and shall be settled in the same manner and at the same time as the
    Restricted Stock Units originally subject to the Restricted Stock Unit Award. In the event of a dividend or distribution paid in
    Shares or other property or any other adjustment made upon a change in the capital structure of the Company as described in Section
    4.05, appropriate adjustments shall be made in the Participant&rsquo;s Restricted Stock Unit Award so that it represents the right
    to receive upon settlement any and all new, substituted or additional securities or other property (other than regular, periodic
    cash dividends) to which the Participant would be entitled by reason of the Shares issuable upon settlement of the Award, and all
    such new, substituted or additional securities or other property shall be immediately subject to the same vesting conditions as are
    applicable to the Award.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cancellation</I>.
    On the date set forth in the Award Agreement, all unearned Restricted Stock Units will be forfeited to the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
3.05 <U>Performance Units and Performance Shares.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Issuance</I>.
    Performance Awards may be granted to Service Providers at any time and from time to time, as will be determined by the Administrator,
    in its sole discretion. The Administrator will have complete discretion in determining the number of Performance Units and Performance
    Shares granted to each Participant.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Value
    of Performance Units/Shares</I>. Each Performance Unit will have an initial value that is established by the Administrator on or
    before the date of grant. Each Performance Share will have an initial value equal to the Fair Market Value of a Share on the date
    of grant.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Performance
    Objectives and Other Terms</I>. The Administrator will set performance objectives or other vesting provisions (including, without
    limitation, continued status as a Service Provider) in its discretion which, depending on the extent to which they are met, will
    determine the number or value of Performance Units/Shares that will be paid out to the Service Providers. The time period during
    which the performance objectives or other vesting provisions must be met will be called the &ldquo;Performance Period.&rdquo; Each
    Performance Awards will be evidenced by an Award Agreement that will specify the Performance Period, and such other terms and conditions
    as the Administrator, in its sole discretion, will determine.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Performance
    Targets and Goals</I>. The Administrator may set performance objectives based upon the achievement of Company-wide, divisional, business
    unit or individual goals (including, but not limited to, continued employment or service), applicable federal or state securities
    laws, or any other basis determined by the Administrator in its discretion (&ldquo;Performance Goals&rdquo;). Performance Goals shall
    be established by the Administrator on the basis of targets to be attained (&ldquo;Performance Targets&rdquo;) with respect to one
    or more measures of business or financial performance (each, a &ldquo;Performance Measure&rdquo;), subject to the following:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Performance
    Measures</U><B><I>.</I></B> Performance Measures shall be calculated in accordance with the Company&rsquo;s financial statements,
    or, if such measures are not reported in the Company&rsquo;s financial statements, they shall be calculated in accordance with generally
    accepted accounting principles, a method used generally in the Company&rsquo;s industry, or in accordance with a methodology established
    by the Administrator prior to the grant of the Performance Award. As specified by the Administrator, Performance Measures may be
    calculated with respect to the Company and its Subsidiaries consolidated therewith for financial reporting purposes, one or more
    Subsidiaries or such division or other business unit of any of them selected by the Administrator. Unless otherwise determined by
    the Administrator prior to the grant of the Performance Award, the Performance Measures applicable to the Performance Award shall
    be calculated prior to the accrual of expense for any Performance Award for the same Performance Period and excluding the effect
    (whether positive or negative) on the Performance Measures of any change in accounting standards or any unusual or infrequently occurring
    event or transaction, as determined by the Administrator, occurring after the establishment of the Performance Goals applicable to
    the Performance Award. Each such adjustment, if any, shall be made solely for the purpose of providing a consistent basis from period
    to period for the calculation of Performance Measures in order to prevent the dilution or enlargement of the Participant&rsquo;s
    rights with respect to a Performance Award. Performance Measures may be based upon one or more of the following, as determined by
    the Administrator: (1) revenue; (2) sales; (3) expenses; (4) operating income; (5) gross margin; (6) operating margin; (7) earnings
    before any one or more of: stock-based compensation expense, interest, taxes, depreciation and amortization; (8) pre-tax profit;
    (9) net operating income; (10) net income; (11) economic value added; (12) free cash flow; (13) operating cash flow; (14) balance
    of cash, cash equivalents and marketable securities; (15) stock price; (16) earnings per share; (17) return on stockholder equity;
    (18) return on capital; (19) return on assets; (20) return on investment; (21) total stockholder return; (22) employee satisfaction;
    (23) employee retention; (24) market share; (25) customer satisfaction; (26) product development; (27) research and development expenses;
    (28) completion of an identified special project; and (29) completion of a joint venture or other corporate transaction.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Performance
    Targets.</U> Performance Targets may include a minimum, maximum, target level and intermediate levels of performance, with the final
    value of a Performance Award determined under the applicable Performance Award Formula by the Performance Target level attained during
    the applicable Performance Period. A Performance Target may be stated as an absolute value, an increase or decrease in a value, or
    as a value determined relative to an index, budget or other standard selected by the Administrator.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Earning
    of Performance Units/Shares</I>. After the applicable Performance Period has ended, the holder of Performance Units/Shares will be
    entitled to receive a payout of the number of Performance Units/Shares earned by the Participant over the Performance Period, to
    be determined as a function of the extent to which the corresponding performance objectives or other vesting provisions have been
    achieved. After the grant of a Performance Unit/Share, the Administrator, in its sole discretion, may reduce or waive any performance
    objectives or other vesting provisions for such Performance Unit/Share.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Form
    and Timing of Payment of Performance Units/Shares</I>. Payment of earned Performance Units or Performance Shares will be made as
    soon as practicable after the expiration of the applicable Performance Period. The Administrator, in its sole discretion, may pay
    earned Performance Units/Shares in the form of cash, in Shares (which have an aggregate Fair Market Value equal to the value of the
    earned Performance Units/Shares at the close of the applicable Performance Period) or in a combination thereof.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cancellation
    of Performance Units/Shares</I>. On the date set forth in the Award Agreement, all unearned or unvested Performance Units or Performance
    Shares will be forfeited to the Company, and again will be available for grant under this Plan.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Qualified
    Performance-Based Awards. </I>Restricted Stock and Restricted Stock Units granted to officers and Employees of the Company or any
    Parent or Subsidiary of the Company (within the meaning of Code Section 424) may be granted with the intent that the award satisfy
    the &ldquo;Performance-Based Exception&rdquo; (any such award intended to satisfy the Performance-Based Exception, a &ldquo;Qualified
    Performance-Based Award&rdquo;). The grant, vesting, or payment of a Qualified Performance-Based Awards may depend on the degree
    of achievement of one or more performance goals relative to a pre-established targeted level or levels using one or more performance
    targets as determined by the Administrator (on an absolute or relative (including, without limitation, relative to the performance
    of one or more other companies or upon comparisons of any of the indicators of performance relative to one or more other companies)
    basis, any of which may also be expressed as a growth or decline measure relative to an amount or performance for a prior date or
    period) for the Company on a consolidated basis or for one or more of the Company&rsquo;s Subsidiaries, segments, divisions, or business
    or operational units, or any combination of the foregoing. The performance period applicable to any Performance Units or Performance
    Shares may not be less than three (3) months nor more than ten (10) years. To satisfy the Performance-Based Exception, the performance
    measure(s) applicable to the Qualified Performance-Based Award and specific performance formula, goal or goals (&ldquo;targets&rdquo;),
    including must be established and approved by the Administrator during the first ninety (90) days of the applicable Performance Period
    (and, in the case of Performance Periods of less than one year, in no event after 25% or more of the Performance Period has elapsed)
    and while performance relating to such target(s) remains substantially uncertain within the meaning of Section 162(m) of the Code.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting
    Rights; Dividend Equivalent Rights and Distributions</I>. Participants shall have no voting rights with respect to Shares represented
    by Performance Share Awards until the date of the issuance of such Shares, if any (as evidenced by the appropriate entry on the books
    of the Company or of a duly authorized transfer agent of the Company). However, the Administrator, in its discretion, may provide
    in the Award Agreement evidencing any Performance Share Award that the Participant shall be entitled to Dividend Equivalent Rights
    with respect to the payment of cash dividends on Stock during the period beginning on the date the Award is granted and ending, with
    respect to each share subject to the Award, on the earlier of the date on which the Performance Shares are settled or the date on
    which they are forfeited. Such Dividend Equivalent Rights, if any, shall be credited to the Participant either in cash or in the
    form of additional whole Performance Shares as of the date of payment of such cash dividends on Stock, as determined by the Administrator.
    The number of additional Performance Shares (rounded to the nearest whole number), if any, to be so credited shall be determined
    by dividing (a) the amount of cash dividends paid on the dividend payment date with respect to the number of Shares represented by
    the Performance Shares previously credited to the Participant by (b) the Fair Market Value per Share on such date. Dividend Equivalent
    Rights, if any, shall be accumulated and paid to the extent that the related Performance Shares become nonforfeitable. Settlement
    of Dividend Equivalent Rights may be made in cash, Shares, or a combination thereof as determined by the Administrator, and may be
    paid on the same basis as settlement of the related Performance Share as provided in Section 3.05(e). Dividend Equivalent Rights
    shall not be paid with respect to Performance Units. In the event of a dividend or distribution paid in Shares or other property
    or any other adjustment made upon a change in the capital structure of the Company as described in Section 4.05, appropriate adjustments
    shall be made in the Participant&rsquo;s Performance Share Award so that it represents the right to receive upon settlement any and
    all new, substituted or additional securities or other property (other than regular, periodic cash dividends) to which the Participant
    would be entitled by reason of the Shares issuable upon settlement of the Performance Share Award, and all such new, substituted
    or additional securities or other property shall be immediately subject to the same Performance Goals as are applicable to the Award.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
3.06 <U>Cash-Based Awards and Other Stock-Based Awards.</U></B> Cash-Based Awards and Other Stock-Based Awards shall be evidenced by
Award Agreements in such form as the Administrator shall establish. Such Award Agreements may incorporate all or any of the terms of
this Plan by reference and shall comply with and be subject to the following terms and conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Grant
    of Cash-Based Awards.</I> Subject to the provisions of this Plan, the Administrator, at any time and from time to time, may grant
    Cash-Based Awards to Participants in such amounts and upon such terms and conditions, including the achievement of performance criteria,
    as the Administrator may determine.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Grant
    of Other Stock-Based Awards.</I> The Administrator may grant other types of equity-based or equity-related Awards not otherwise described
    by the terms of this Plan (including the grant or offer for sale of unrestricted securities, stock-equivalent units, stock appreciation
    units, securities or debentures convertible into common stock or other forms determined by the Administrator) in such amounts and
    subject to such terms and conditions as the Administrator shall determine. Other Stock-Based Awards may be made available as a form
    of payment in the settlement of other Awards or as payment in lieu of compensation to which a Participant is otherwise entitled.
    Other Stock-Based Awards may involve the transfer of actual Shares to Participants, or payment in cash or otherwise of amounts based
    on the value of a Share and may include, without limitation, Awards designed to comply with or take advantage of the applicable local
    laws of jurisdictions other than the United States.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Value
    of Cash-Based and Other Stock-Based Awards.</I> Each Cash-Based Award shall specify a monetary payment amount or payment range as
    determined by the Administrator. Each Other Stock-Based Award shall be expressed in terms of Shares or units based on such Shares,
    as determined by the Administrator. The Administrator may require the satisfaction of such Service requirements, conditions, restrictions
    or performance criteria, including, without limitation, Performance Goals as described in Section 3.05, as shall be established by
    the Administrator and set forth in the Award Agreement evidencing such Award. If the Administrator exercises its discretion to establish
    performance criteria, the final value of Cash-Based Awards or Other Stock-Based Awards that will be paid to the Participant will
    depend on the extent to which the performance criteria are met. The establishment of performance criteria with respect to the grant
    or vesting of any Cash-Based Award or Other Stock-Based Award intended to result in Performance-Based Compensation shall follow procedures
    substantially equivalent to those applicable to Performance Awards set forth in Section 3.05.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Payment
    or Settlement of Cash-Based Awards and Other Stock-Based Awards.</I> Payment or settlement, if any, with respect to a Cash-Based
    Award or an Other Stock-Based Award shall be made in accordance with the terms of the Award, in cash, Shares or other securities
    or any combination thereof as the Administrator determines. The determination and certification of the final value with respect to
    any Cash-Based Award or Other Stock-Based Award intended to result in Performance-Based Compensation shall comply with the requirements
    applicable to Performance Awards set forth in Section 3.05. To the extent applicable, payment or settlement with respect to each
    Cash-Based Award and Other Stock-Based Award shall be made in compliance with the requirements of Section 409A.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting
    Rights; Dividend Equivalent Rights and Distributions.</I> Participants shall have no voting rights with respect to Shares represented
    by Other Stock-Based Awards until the date of the issuance of such Shares (as evidenced by the appropriate entry on the books of
    the Company or of a duly authorized transfer agent of the Company), if any, in settlement of such Award. However, the Administrator,
    in its discretion, may provide in the Award Agreement evidencing any Other Stock-Based Award that the Participant shall be entitled
    to Dividend Equivalent Rights with respect to the payment of cash dividends on Stock during the period beginning on the date such
    Award is granted and ending, with respect to each share subject to the Award, on the earlier of the date the Award is settled or
    the date on which it is terminated. Such Dividend Equivalent Rights, if any, shall be paid in accordance with the provisions set
    forth in Section 3.04(e). Dividend Equivalent Rights shall not be granted with respect to Cash-Based Awards. In the event of a dividend
    or distribution paid in Shares or other property or any other adjustment made upon a change in the capital structure of the Company
    as described in Section 4.05, appropriate adjustments shall be made in the Participant&rsquo;s Other Stock-Based Award so that it
    represents the right to receive upon settlement any and all new, substituted or additional securities or other property (other than
    regular, periodic cash dividends) to which the Participant would be entitled by reason of the Shares issuable upon settlement of
    such Award, and all such new, substituted or additional securities or other property shall be immediately subject to the same vesting
    conditions and performance criteria, if any, as are applicable to the Award.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Nontransferability
    of Cash-Based Awards and Other Stock-Based Awards. </I>Prior to the payment or settlement of a Cash-Based Award or Other Stock-Based
    Award, the Award shall not be subject in any manner to anticipation, alienation, sale, exchange, transfer, assignment, pledge, encumbrance,
    or garnishment by creditors of the Participant or the Participant&rsquo;s beneficiary, except transfer by will or by the laws of
    descent and distribution. The Administrator may impose such additional restrictions on any Shares issued in settlement of Cash-Based
    Awards and Other Stock-Based Awards as it may deem advisable, including, without limitation, minimum holding period requirements,
    restrictions under applicable federal securities laws, under the requirements of any stock exchange or market upon which such Shares
    are then listed and/or traded, or under any state securities laws or foreign law applicable to such Shares.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
3.07 <U>Form of Award Agreements.</U></B> A form of Award Agreement for a grant of Options is attached hereto as Exhibit A, a form of
Award Agreement for a grant of Stock Appreciation Rights is attached hereto as Exhibit B, a form of Award Agreement for a grant of Restricted
Stock is attached hereto as Exhibit C; and a form of Award Agreement for a grant of Restricted Stock Units is attached hereto as Exhibit
D, provided that the Administrator shall have the discretion to modify such forms and to replace such forms with any other agreement
as determined by the Administrator. In the event of a conflict between the terms of any Award Agreement and the provisions in the body
of this Plan, the terms of the Award Agreement shall control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article
IV. <FONT STYLE="font-variant: small-caps"><U>Additional Provisions Applicable to this Plan and Awards</U></FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.01 <U>Outside Director Limitations.</U></B> No Outside Director may be granted, in any Fiscal Year, Awards with a grant date fair value
(computed as of the date of grant in accordance with U.S. generally accepted accounting principles) of more than $300,000. Any Awards
granted to an individual while he or she was an Employee, or while he or she was a Consultant but not an Outside Director, will not count
for purposes of the limitations under this Section 4.01.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.02 <U>Compliance With Code Section 409A.</U></B> Awards will be designed and operated in such a manner that they are either exempt
from the application of, or comply with, the requirements of Code Section 409A such that the grant, payment, settlement or deferral will
not be subject to the additional tax or interest applicable under Code Section 409A, except as otherwise determined in the sole discretion
of the Administrator. This Plan and each Award Agreement under this Plan is intended to meet the requirements of Code Section 409A and
will be construed and interpreted in accordance with such intent, except as otherwise determined in the sole discretion of the Administrator.
To the extent that an Award or payment, or the settlement or deferral thereof, is subject to Code Section 409A the Award will be granted,
paid, settled or deferred in a manner that will meet the requirements of Code Section 409A, such that the grant, payment, settlement
or deferral will not be subject to the additional tax or interest applicable under Code Section 409A. In no event will the Company have
any obligation under the terms of this Plan to reimburse a Participant for any taxes or other costs that may be imposed on Participant
as a result of Section 409A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.03 <U>Leaves of Absence/Transfer Between Locations.</U></B> Unless the Administrator provides otherwise, vesting of Awards granted
hereunder will be suspended during any unpaid leave of absence. A Participant will not cease to be an Employee in the case of (i) any
leave of absence approved by the Company or (ii) transfers between locations of the Company or between the Company, its Parent, or any
Subsidiary. For purposes of Incentive Stock Options, no such leave may exceed three (3) months, unless reemployment upon expiration of
such leave is guaranteed by statute or contract. If reemployment upon expiration of a leave of absence approved by the Company is not
so guaranteed, then six (6) months following the first (1<SUP>st</SUP>) day of such leave, any Incentive Stock Option held by the Participant
will cease to be treated as an Incentive Stock Option and will be treated for tax purposes as a Nonstatutory Stock Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.04 <U>Limited Transferability of Awards.</U></B> Unless determined otherwise by the Administrator, Awards may not be sold, pledged,
assigned, hypothecated, or otherwise transferred in any manner other than by will or by the laws of descent and distribution, and may
be exercised, during the lifetime of the Participant, only by the Participant. If the Administrator makes an Award transferable, such
Award will contain such additional terms and conditions as the Administrator deems appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.05 <U>Adjustments; Dissolution, Merger, Etc.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Adjustments</I>.
    In the event that any dividend or other distribution (whether in the form of cash, Shares, other securities, or other property),
    recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase,
    or exchange of Shares or other securities of the Company, or other change in the corporate structure of the Company affecting the
    Shares occurs, the Administrator, in order to prevent diminution or enlargement of the benefits or potential benefits intended to
    be made available under this Plan, will adjust the number and class of shares of stock that may be delivered under this Plan and/or
    the number, class, and price of shares of stock covered by each outstanding Award, and the numerical Share limits of Section 2.01.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dissolution
    or Liquidation</I>. In the event of the proposed dissolution or liquidation of the Company, the Administrator will notify each Participant
    as soon as practicable prior to the effective date of such proposed transaction. To the extent it has not been previously exercised,
    an Award will terminate immediately prior to the consummation of such proposed action.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Change
    in Control</I>.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
    otherwise specifically set forth in an Award Agreement, in the event of a merger of the Company with or into another corporation
    or other entity or a Change in Control, each outstanding Award will be treated as the Administrator determines (subject to the provisions
    of Section 4.05(c)(ii)) without a Participant&rsquo;s consent, including, without limitation, that (i) Awards will be assumed, or
    substantially equivalent awards will be substituted, by the acquiring or succeeding corporation (or an Affiliate thereof) with appropriate
    adjustments as to the number and kind of shares and prices; (ii) upon written notice to a Participant, that the Participant&rsquo;s
    Awards will terminate upon or immediately prior to the consummation of such merger or Change in Control; (iii) outstanding Awards
    will vest and become exercisable, realizable, or payable, or restrictions applicable to an Award will lapse, in whole or in part
    prior to or upon consummation of such merger or Change in Control, and, to the extent the Administrator determines, terminate upon
    or immediately prior to the effectiveness of such merger or Change in Control; (iv) (A) the termination of an Award in exchange for
    an amount of cash and/or property, if any, equal to the amount that would have been attained upon the exercise of such Award or realization
    of the Participant&rsquo;s rights as of the date of the occurrence of the transaction (and, for the avoidance of doubt, if as of
    the date of the occurrence of the transaction the Administrator determines in good faith that no amount would have been attained
    upon the exercise of such Award or realization of the Participant&rsquo;s rights, then such Award may be terminated by the Company
    without payment), or (B) the replacement of such Award with other rights or property selected by the Administrator in its sole discretion;
    or (v) any combination of the foregoing. In taking any of the actions permitted under this Section 4.05(c), the Administrator will
    not be obligated to treat all Awards, all Awards held by a Participant, or all Awards of the same type, similarly.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    the event that the successor corporation does not assume or substitute for the Award (or portion thereof), the Participant will fully
    vest in and have the right to exercise all of his or her outstanding Options and Stock Appreciation Rights, including Shares as to
    which such Awards would not otherwise be vested or exercisable, all restrictions on Restricted Stock and Restricted Stock Units will
    lapse, and, with respect to Awards with performance-based vesting, all performance goals or other vesting criteria will be deemed
    achieved at one hundred percent (100%) of target levels and all other terms and conditions met, in all cases, unless specifically
    provided otherwise under the applicable Award Agreement or other written agreement between the Participant and the Company or any
    of its Subsidiaries or Parents, as applicable. In addition, if an Option or Stock Appreciation Right is not assumed or substituted
    in the event of a merger or Change in Control, the Administrator will notify the Participant in writing or electronically that the
    Option or Stock Appreciation Right will be exercisable for a period of time determined by the Administrator in its sole discretion,
    and the Option or Stock Appreciation Right will terminate upon the expiration of such period.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the purposes of this Section 4.05(c) and Section 4.05(d), an Award will be considered assumed if, following the merger or Change
    in Control, the Award confers the right to purchase or receive, for each Share subject to the Award immediately prior to the merger
    or Change in Control, the consideration (whether stock, cash, or other securities or property) received in the merger or Change in
    Control by holders of Common Stock for each Share held on the effective date of the transaction (and if holders were offered a choice
    of consideration, the type of consideration chosen by the holders of a majority of the outstanding Shares); provided, however, that
    if such consideration received in the merger or Change in Control is not solely common stock of the successor corporation or its
    Parent, the Administrator may, with the consent of the successor corporation, provide for the consideration to be received upon the
    exercise of an Option or Stock Appreciation Right or upon the payout of a Restricted Stock Unit, Performance Unit, or Performance
    Share, for each Share subject to such Award, to be solely common stock of the successor corporation or its Parent equal in fair market
    value to the per share consideration received by holders of Common Stock in the merger or Change in Control.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
    anything in this Section 4.05(c) to the contrary, an Award that vests, is earned or paid-out upon the satisfaction of one or more
    performance goals will not be considered assumed if the Company or its successor modifies any of such performance goals without the
    Participant&rsquo;s consent, in all cases, unless specifically provided otherwise under the applicable Award Agreement or other written
    agreement between the Participant and the Company or any of its Subsidiaries or Parents, as applicable; provided, however, a modification
    to such performance goals only to reflect the successor corporation&rsquo;s post-Change in Control corporate structure will not be
    deemed to invalidate an otherwise valid Award assumption.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
    anything in this Section 4.05(c) to the contrary, and unless otherwise provided in an Award Agreement, if an Award that vests, is
    earned or paid-out under an Award Agreement is subject to Code Section 409A and if the change in control definition contained in
    the Award Agreement does not comply with the definition of &ldquo;change of control&rdquo; for purposes of a distribution under Code
    Section 409A, then any payment of an amount that is otherwise accelerated under this Section 4.05(c) will be delayed until the earliest
    time that such payment would be permissible under Code Section 409A without triggering any penalties applicable under Code Section
    409A.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Administrator may, without affecting the number of Shares reserved or available hereunder, authorize the issuance or assumption of
    benefits under this Plan in connection with any merger, consolidation, acquisition of property or stock, or reorganization upon such
    terms and conditions as it may deem appropriate, subject to compliance with Section 409A and any other applicable provisions of the
    Code.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Outside
    Director Awards</I>. In the event of a Change in Control, with respect to Awards granted to an Outside Director, the Outside Directors
    will fully vest in and have the right to exercise Options and/or Stock Appreciation Rights as to all of the Shares underlying such
    Award, including those Shares which would not otherwise be vested or exercisable, all restrictions on Restricted Stock and Restricted
    Stock Units will lapse, and, with respect to Awards with performance-based vesting, all performance goals or other vesting criteria
    will be deemed achieved at one hundred percent (100%) of target levels and all other terms and conditions met, unless specifically
    provided otherwise under the applicable Award Agreement or other written agreement between the Participant and the Company or any
    of its Subsidiaries or Parents, as applicable.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.06 <U>Tax Withholding</U></B><U>.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Withholding
    Requirements</I>. Prior to the delivery of any Shares or cash pursuant to an Award (or exercise thereof) or such earlier time as
    any tax withholding obligation is due, the Company will have the power and the right to deduct or withhold, or require a Participant
    to remit to the Company, an amount sufficient to satisfy federal, state, local, non-U.S. or other taxes (including the Participant&rsquo;s
    FICA obligation) required to be withheld with respect to such Award (or exercise thereof).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Withholding
    Arrangements</I>. The Administrator, in its sole discretion and pursuant to such procedures as it may specify from time to time,
    may permit a Participant to satisfy such tax withholding obligation, in whole or in part by such methods as the Administrator shall
    determine, including, without limitation, (i) paying cash, (ii) electing to have the Company withhold otherwise deliverable cash
    or Shares having a fair market value equal to the minimum statutory amount required to be withheld or such greater amount as the
    Administrator may determine if such amount would not have adverse accounting consequences, as the Administrator determines in its
    sole discretion, (iii) delivering to the Company already-owned Shares having a fair market value equal to the minimum statutory amount
    required to be withheld or such greater amount as the Administrator may determine, in each case, provided the delivery of such Shares
    will not result in any adverse accounting consequences, as the Administrator determines in its sole discretion, (iv) selling a sufficient
    number of Shares otherwise deliverable to the Participant through such means as the Administrator may determine in its sole discretion
    (whether through a broker or otherwise) equal to the amount required to be withheld, or (v) any combination of the foregoing methods
    of payment. The amount of the withholding requirement will be deemed to include any amount which the Administrator agrees may be
    withheld at the time the election is made, not to exceed the amount determined by using the maximum federal, state or local marginal
    income tax rates applicable to the Participant with respect to the Award on the date that the amount of tax to be withheld is to
    be determined or such greater amount as the Administrator may determine if such amount would not have adverse accounting consequences,
    as the Administrator determines in its sole discretion. The fair market value of the Shares to be withheld or delivered will be determined
    as of the date that the taxes are required to be withheld.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Tax
    Withholding in General.</I> The Company shall have the right to deduct from any and all payments made under this Plan, or to require
    the Participant, through payroll withholding, cash payment or otherwise, to make adequate provision for, the federal, state, local
    and foreign taxes (including social insurance), if any, required by law to be withheld by the Company or any of its Affiliates with
    respect to an Award or the Shares acquired pursuant thereto. The Company shall have no obligation to deliver Shares, to release Shares
    from an escrow established pursuant to an Award Agreement, or to make any payment in cash under this Plan until the Company or its
    Affiliate&rsquo;s, as applicable, withholding obligations have been satisfied by the Participant.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Withholding
    in or Directed Sale of Shares.</I> The Company shall have the right, but not the obligation, to deduct from the Shares issuable to
    a Participant upon the exercise or settlement of an Award, or to accept from the Participant the tender of, a number of whole Shares
    having a Fair Market Value, as determined by the Administrator, equal to all or any part of the tax withholding obligations of any
    the Company or its Affiliates, as applicable. The Fair Market Value of any Shares withheld or tendered to satisfy any such tax withholding
    obligations shall not exceed the amount determined by the applicable minimum statutory withholding rates. The Administrator may require
    a Participant to direct a broker, upon the vesting, exercise or settlement of an Award, to sell a portion of the shares subject to
    the Award determined by the Administrator in its discretion to be sufficient to cover the tax withholding obligations of the Company
    or its Affiliates, as applicable, and to remit an amount equal to such tax withholding obligations to the Company or its Affiliates,
    as applicable, in cash.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.07 <U>Compliance with Securities Laws.</U></B> The grant of Awards and the issuance of Shares pursuant to any Award shall be subject
to compliance with all applicable requirements of federal, state and foreign law with respect to such securities and the requirements
of any stock exchange or market system upon which the Stock may then be listed. In addition, no Award may be exercised or shares issued
pursuant to an Award unless (a) a registration statement under the Securities Act shall at the time of such exercise or issuance be in
effect with respect to the shares issuable pursuant to the Award, or (b) in the opinion of legal counsel to the Company, the shares issuable
pursuant to the Award may be issued in accordance with the terms of an applicable exemption from the registration requirements of the
Securities Act. The inability of the Company to obtain from any regulatory body having jurisdiction the authority, if any, deemed by
the Company&rsquo;s legal counsel to be necessary to the lawful issuance and sale of any shares under this Plan shall relieve the Company
of any liability in respect of the failure to issue or sell such shares as to which such requisite authority shall not have been obtained.
As a condition to issuance of any Stock, the Company may require the Participant to satisfy any qualifications that may be necessary
or appropriate, to evidence compliance with any applicable law or regulation and to make any representation or warranty with respect
thereto as may be requested by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.08 <U>No Effect on Employment or Service.</U></B> Neither this Plan nor any Award will confer upon a Participant any right with respect
to continuing the Participant&rsquo;s relationship as a Service Provider with the Company or its Subsidiaries or Parents, as applicable,
nor will they interfere in any way with the Participant&rsquo;s right or the right of the Company and its Subsidiaries or Parents, as
applicable to terminate such relationship at any time, with or without cause, to the extent permitted by Applicable Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.09 <U>Repurchase Rights.</U></B> Shares issued under this Plan may be subject to one or more repurchase options, or other conditions
and restrictions as determined by the Administrator in its discretion at the time the Award is granted. The Company shall have the right
to assign at any time any repurchase right it may have, whether or not such right is then exercisable, to one or more persons as may
be selected by the Company. Upon request by the Company, each Participant shall execute any agreement evidencing such transfer restrictions
prior to the receipt of Shares hereunder and shall promptly present to the Company any and all certificates representing Shares acquired
hereunder for the placement on such certificates of appropriate legends evidencing any such transfer restrictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.10 <U>Fractional Shares.</U></B> The Company shall not be required to issue fractional shares upon the exercise or settlement of any
Award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.11 <U>Forfeiture Events.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    Awards under this Plan will be subject to recoupment under any clawback policy that the Company is required to adopt pursuant to
    the listing standards of any national securities exchange or association on which the Company&rsquo;s securities are listed or as
    is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other Applicable Laws. In addition, the
    Administrator may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the Administrator determines
    necessary or appropriate, including but not limited to a reacquisition right regarding previously acquired Shares or other cash or
    property. Unless this Section 4.11 is specifically mentioned and waived in an Award Agreement or other document, no recovery of compensation
    under a clawback policy or otherwise will be an event that triggers or contributes to any right of a Participant to resign for &ldquo;good
    reason&rdquo; or &ldquo;constructive termination&rdquo; (or similar term) under any agreement with the Company or a Subsidiary or
    Parent of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
    any other provision of this Plan, if the Participant&rsquo;s service to the Company or any of its Affiliates as a Service Provider
    is terminated or ceases for any reason, then any Award which has not vested as of such time in accordance with its terms shall automatically
    be forfeited and cancelled and shall cease to vest, be exercisable or otherwise provide any benefit to Participant, provided that
    such provision may be modified in any Award Agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Administrator may specify in an Award Agreement that the Participant&rsquo;s rights, payments, and benefits with respect to an Award
    will be subject to reduction, cancellation, forfeiture, or recoupment upon the occurrence of additional of specified events as determined
    by the Administrator, in addition to any otherwise applicable vesting or performance conditions of an Award.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.12 <U>Date of Grant.</U></B> The date of grant of an Award will be, for all purposes, the date on which the Administrator makes the
determination granting such Award, or such other later date as is determined by the Administrator. Notice of the determination will be
provided to each Participant within a reasonable time after the date of such grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.13 <U>Term of Plan.</U></B> This Plan will become effective upon its adoption by the Board. It will continue in effect for a term of
ten (10) years from the date adopted by the Board, unless terminated earlier under Section 4.14.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.14 <U>Amendment and Termination of this Plan.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Amendment
    and Termination</I>. The Administrator may at any time amend, alter, suspend or terminate this Plan.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Stockholder
    Approval</I>. The Company will obtain stockholder approval of any Plan amendment to the extent necessary and desirable to comply
    with Applicable Laws.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Effect
    of Amendment or Termination</I>. No amendment, alteration, suspension or termination of this Plan will impair the rights of any Participant,
    unless mutually agreed otherwise between the Participant and the Administrator, which agreement must be in writing and signed by
    the Participant and the Company. Termination of this Plan will not affect the Administrator&rsquo;s ability to exercise the powers
    granted to it hereunder with respect to Awards granted under this Plan prior to the date of such termination.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.15 <U>Conditions Upon Issuance of Shares.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Legal
    Compliance</I>. Shares will not be issued pursuant to the exercise of an Award unless the exercise of such Award and the issuance
    and delivery of such Shares will comply with Applicable Laws and will be further subject to the approval of counsel for the Company
    with respect to such compliance.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Investment
    Representations</I>. As a condition to the exercise of an Award, the Company may require the person exercising such Award to represent
    and warrant at the time of any such exercise that the Shares are being purchased only for investment and without any present intention
    to sell or distribute such Shares if, in the opinion of counsel for the Company, such a representation is required.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.16 <U>Inability to Obtain Authority.</U></B> The inability of the Company to obtain authority from any regulatory body having jurisdiction
or to complete or comply with the requirements of any registration or other qualification of the Shares under any state, federal or non-U.S.
law or under the rules and regulations of the Securities and Exchange Commission, the stock exchange on which Shares of the same class
are then listed, or any other governmental or regulatory body, which authority, registration, qualification or rule compliance is deemed
by the Company&rsquo;s counsel to be necessary or advisable for the issuance and sale of any Shares hereunder, will relieve the Company
of any liability in respect of the failure to issue or sell such Shares as to which such requisite authority, registration, qualification
or rule compliance will not have been obtained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.17 <U>Stockholder Approval.</U></B> This Plan will be presented for approval by the stockholders of the Company within twelve (12)
months after the date this Plan is adopted by the Board. Such stockholder approval will be obtained in the manner and to the degree required
under Applicable Laws. No Option granted under this Plan may be treated as an Incentive Stock Option if this Plan is not approved by
stockholders of the Company within twelve (12) months after the date this Plan is adopted by the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.18 <U>Retirement and Welfare Plans.</U></B> Neither Awards made under this Plan nor Shares or cash paid pursuant to such Awards may
be included as &ldquo;compensation&rdquo; for purposes of computing the benefits payable to any Participant under the Company&rsquo;s
or any of its Affiliates&rsquo; retirement plans (both qualified and non-qualified) or welfare benefit plans unless such other plan expressly
provides that such compensation shall be taken into account in computing a Participant&rsquo;s benefit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.19 <U>Beneficiary Designation.</U></B> Subject to local laws and procedures, each Participant may file with the Company a written designation
of a beneficiary who is to receive any benefit under this Plan to which the Participant is entitled in the event of such Participant&rsquo;s
death before he or she receives any or all of such benefit. Each designation will revoke all prior designations by the same Participant,
shall be in a form prescribed by the Company, and will be effective only when filed by the Participant in writing with the Company during
the Participant&rsquo;s lifetime. If a married Participant designates a beneficiary other than the Participant&rsquo;s spouse, the effectiveness
of such designation may be subject to the consent of the Participant&rsquo;s spouse. If a Participant dies without an effective designation
of a beneficiary who is living at the time of the Participant&rsquo;s death, the Company will pay any remaining unpaid benefits to the
Participant&rsquo;s legal representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.20 <U>Severability.</U></B> If any one or more of the provisions (or any part thereof) of this Plan shall be held invalid, illegal
or unenforceable in any respect, such provision shall be modified so as to make it valid, legal and enforceable, and the validity, legality
and enforceability of the remaining provisions (or any part thereof) of this Plan shall not in any way be affected or impaired thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.21 <U>No Constraint on Corporate Action.</U></B> Nothing in this Plan shall be construed to: (a) limit, impair, or otherwise affect
the Company&rsquo;s or any of its Affiliate&rsquo;s right or power to make adjustments, reclassifications, reorganizations, or changes
of its capital or business structure, or to merge or consolidate, or dissolve, liquidate, sell, or transfer all or any part of its business
or assets; or (b) limit the right or power of the Company any of its Affiliates to take any action which such entity deems to be necessary
or appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.22 <U>Unfunded Obligation.</U></B> Participants shall have the status of general unsecured creditors of the Company. Any amounts payable
to Participants pursuant to this Plan shall be considered unfunded and unsecured obligations for all purposes, including, without limitation,
Title I of the Employee Retirement Income Security Act of 1974. Neither the Company nor any of its Affiliates shall be required to segregate
any monies from its general funds, or to create any trusts, or establish any special accounts with respect to such obligations. The Company
shall retain at all times beneficial ownership of any investments, including trust investments, which the Company may make to fulfill
its payment obligations hereunder. Any investments or the creation or maintenance of any trust or any Participant account shall not create
or constitute a trust or fiduciary relationship between the Administrator, the Company or any of its Affiliates and a Participant, or
otherwise create any vested or beneficial interest in any Participant or the Participant&rsquo;s creditors in any assets of the Company
or any of its Affiliates. The Participants shall have no claim against the Company or any of its Affiliates for any changes in the value
of any assets which may be invested or reinvested by the Company with respect to this Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.23 <U>Choice of Law.</U></B> Except to the extent governed by applicable federal law, the validity, interpretation, construction and
performance of this Plan and each Award Agreement, and any and all claims, proceedings or causes of action relating to this Plan or any
Award Agreement or arising from this this Plan or any Award Agreement or the transactions contemplated herein or therein, including,
without limitation, tort claims, statutory claims and contract claims, shall be interpreted, construed, governed and enforced under and
solely in accordance with the substantive and procedural laws of the State of Delaware, in each case as in effect from time to time and
as the same may be amended from time to time, and as applied to agreements performed wholly within the State of Delaware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">***</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form
of Option Award Agreement</B></FONT></P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Option
Award Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
grant of an Award to purchase Shares is made pursuant to this Option Award Agreement (this &ldquo;Agreement&rdquo;) as of [_______________]
(the &ldquo;Effective Date&rdquo;) by Jupiter Neurosciences, Inc., a Delaware corporation (the &ldquo;Company&rdquo;) under the Jupiter
Neurosciences, Inc. 2023 Equity Incentive Plan (the &ldquo;Plan&rdquo;), to [__________________] (the &ldquo;Participant&rdquo;). Under
applicable provisions of the Internal Revenue Code of 1986, as amended, the Option is treated as <I>[an incentive option][a non-qualified
option]</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>By
signing this cover sheet, you hereby accept the Option (as defined below) and agree to all of the terms and conditions described in this
Agreement and in the Plan.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 10%">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Participant Name: _____________________________</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature: _____________________________</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter Neurosciences, Inc.</FONT></TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 5%">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 45%">&nbsp;</TD>
    <TD STYLE="width: 40%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">___________________________________</FONT></TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">___________________________________</FONT></TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">___________________________________</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>This
is not a stock certificate or a negotiable instrument. This grant of Option is a</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>voluntary,
revocable grant from the Company and Participant hereby acknowledges that the Company has no obligation to make additional grants in
the future.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UPON
RECEIPT OF YOUR SIGNED AGREEMENT, A BOOKKEEPING ENTRY WILL BE ENTERED INTO THE COMPANY&rsquo;S BOOKS AND RECORDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TO
EVIDENCE THE OPTIONS GRANTED TO YOU.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>***</B></FONT></P>


<!-- Field: Page; Sequence: 30; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Grant</U>.
    As of the Effective Date, the Company grants to the Participant an option (the &ldquo;Option&rdquo;) to purchase on the terms and
    conditions hereinafter set forth all or any part of an aggregate of [________________] shares of Common Stock, (the &ldquo;Option
    Shares&rdquo;), at the purchase price of $[____________] per share (the &ldquo;Option Price&rdquo;) pursuant to the terms and conditions
    of the Plan. Any capitalized, but undefined, term used in this Agreement shall have the meaning ascribed to it in this Plan. The
    Participant shall have the cumulative right to exercise the Option, and the Option is only exercisable, with respect to the following
    number of Option Shares on or after the following dates, subject to earlier vesting and forfeiture as set forth in the Plan:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 96%; border-collapse: collapse; margin-left: 0.25in">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 83%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of Options Vested and Shares Which May be Acquired</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator may, in its sole discretion, accelerate the date on which the Participant may purchase Option Shares. Any capitalized,
but undefined, term used in this Agreement shall have the meaning ascribed to it in this Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Term</U>.
    The Option granted hereunder shall expire in all events at 5:00 p.m., Eastern time on [______________], unless sooner terminated
    as provided herein or in the Plan.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Change
    in Accounting Treatment</U>. If the Administrator finds that a change in the financial accounting treatment for options granted under
    this Agreement or the Plan adversely affects the Company or, in the determination of the Administrator, may adversely affect the
    Company in the foreseeable future, the Administrator may, in its discretion, set an accelerated termination date for the Option.
    In such event, the Administrator may take whatever other action, including acceleration of any exercise provisions, it deems necessary.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Blackout
    Periods</U>. The Administrator reserves the right to suspend or limit the Participant&rsquo;s rights to exercise and sell Shares
    acquired through the exercise of Options to comply with Applicable Requirements and any Company&rsquo;s insider trading policy, any
    Applicable Law, or at any other times that it deems appropriate.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Transfers</U>.
    Except as otherwise provided herein or in any separate provisions applicable to this Option, the Option is transferable by the Participant
    only by will or pursuant to the laws of descent and distribution in the event of the Participant&rsquo;s death, in which event the
    Option may be exercised by the heirs or legal representatives of the Participant as set forth in this Plan. Any attempt at assignment,
    transfer, pledge or disposition of the Option contrary to the provisions hereof or the levy of any execution, attachment or similar
    process upon the Option shall be null and void and without effect. Any exercise of the Option by a Person other than the Participant
    shall be accompanied by appropriate proofs of the right of such person to exercise the Option.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Adjustments
    on Changes in Common Stock</U>. In the event that, prior to the delivery by the Company of all of the Option Shares in respect of
    which the Option is granted, there shall be an increase or decrease in the number of issued shares of Common Stock of the Company
    as a result of a subdivision or consolidation of Shares or other capital adjustment, or the payment of a stock dividend or other
    increase or decrease in such Shares, effected without receipt of consideration by the Company, the remaining number of Option Shares
    still subject to the Option and the Option Price therefor shall be adjusted in a manner determined by the Administrator so that the
    adjusted number of Option Shares and the adjusted Option Price shall be the substantial equivalent of the remaining number of Option
    Shares still subject to the Option and the Option Price thereof prior to such change. For purposes of this Section 7 no adjustment
    shall be made as a result of the issuance of Common Stock upon the conversion of other securities of the Company which are convertible
    into Shares.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Legal
    Requirements</U>. If the listing, registration or qualification of the Option Shares upon any securities exchange or under any federal
    or state law, or the consent or approval of any governmental regulatory body is necessary as a condition of or in connection with
    the purchase of such Option Shares, the Company shall not be obligated to issue or deliver the certificates representing the Option
    Shares as to which the Option has been exercised unless and until such listing, registration, qualification, consent or approval
    shall have been effected or obtained. If registration is considered unnecessary by the Company or its counsel, the Company may cause
    a legend to be placed on the Option Shares being issued calling attention to the fact that they have been acquired for investment
    and have not been registered.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Administration</U>.
    The Option has been granted pursuant to, and is subject to the terms and provisions of, this Plan. All questions of interpretation
    and application of this Plan and the Option shall be determined by the Administrator, and such determination shall be final, binding
    and conclusive. The Option shall not be treated as an incentive stock option (as such term is defined in section 422(b) of the Code)
    for federal income tax purposes unless expressly indicated as same hereupon.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Severability</U>.
    Should a court of competent jurisdiction deem any of the provisions in this Agreement to be unenforceable in any respect, it is the
    intention of the parties to this Agreement that this Agreement be deemed, without further action on the part of the parties hereto,
    modified, amended and limited to the extent necessary to render the same valid and enforceable. It is further the parties&rsquo;
    intent that all provisions not deemed to be overbroad shall be given their full force and effect. You acknowledge that you are freely,
    knowingly and voluntarily entering into this Agreement after having an opportunity for consultation with your own independent counsel.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Notices</U>.
    Any notice to be given to the Company shall be addressed to the Administrator at its principal executive office, and any notice to
    be given to the Participant shall be addressed to the Participant at the address then appearing on the personnel or other records
    of the Company, or at such other address as either party hereafter may designate in writing to the other. Any such notice shall be
    deemed to have been duly given when deposited in the United States mail, addressed as aforesaid, registered or certified mail, and
    with proper postage and registration or certification fees prepaid.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Reservation
    of Right to Terminate</U>. Nothing herein contained shall affect the right of the Company or any Affiliate to terminate the Participant
    in its applicable capacity as a Service Provider at any time for any reason whatsoever.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Choice
    of Law; Jurisdiction</U>. This Agreement, and any and all claims, proceedings or causes of action relating to this Agreement or arising
    from this Agreement or the transactions contemplated herein, including, without limitation, tort claims, statutory claims and contract
    claims, shall be interpreted, construed, governed and enforced under and solely in accordance with the substantive and procedural
    laws of the State of Delaware, in each case as in effect from time to time and as the same may be amended from time to time, and
    as applied to agreements performed wholly within the State of Delaware. ANY LEGAL SUIT, ACTION OR PROCEEDING ARISING OUT OF OR BASED
    UPON THIS AGREEMENT SHALL BE INSTITUTED SOLELY IN THE COURTS OF THE STATE OF FLORIDA OR THE FEDERAL COURTS OF THE UNITED STATES,
    IN EACH CASE LOCATED IN PALM BEACH COUNTY, FLORIDA, AND EACH PARTY IRREVOCABLY SUBMITS TO THE PERSONAL JURISDICTION OF SUCH COURTS
    IN ANY SUCH SUIT, ACTION OR PROCEEDING.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Taxes</U>.
    You agree to comply with the appropriate procedures established by the Company, from time to time, to provide for payment or withholding
    of such income or other taxes as may be required by law to be paid or withheld in connection with the Options and exercise thereof.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">***</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form
of Stock Appreciation Right Award Agreement</B></FONT></P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Jupiter
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Stock
Appreciation Rights Award Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of SARs</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Grant
    Date</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Vesting
    Schedule</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise
Price: $_______________ per share of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter
Neurosciences, Inc., a Delaware corporation (the &ldquo;Company&rdquo;), hereby grants to [_________] (the &ldquo;Participant&rdquo;,
also referred to as &ldquo;you&rdquo;) Stock Appreciation Rights (the &ldquo;SARs&rdquo;), pursuant to the terms of this Stock Appreciation
Rights Award Agreement (this &ldquo;Agreement&rdquo;) and the Jupiter Neurosciences, Inc. 2023 Equity Incentive Plan (the &ldquo;Plan&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>By
signing this cover sheet, you agree to all of the terms and conditions described in this Agreement and in the Plan.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 10%">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Participant: _____________________________</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature: _____________________________</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter Neurosciences, Inc.</FONT></TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 5%">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 45%">&nbsp;</TD>
    <TD STYLE="width: 40%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">___________________________________</FONT></TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">___________________________________</FONT></TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">___________________________________</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>This
is not a stock certificate or a negotiable instrument. This grant of SAR is a</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>voluntary,
revocable grant from the Company and Participant hereby acknowledges that the</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Company
has no obligation to make additional grants in the future.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UPON
RECEIPT OF YOUR SIGNED AGREEMENT, A BOOKKEEPING ENTRY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WILL
BE ENTERED INTO THE COMPANY&rsquo;S BOOKS AND RECORDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TO
EVIDENCE THE SAR GRANTED TO YOU.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>***</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 33; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STOCK
APPRECIATION RIGHTS AWARD AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>SAR/Nontransferability</U>.
    This Agreement evidences the grant to you on the Grant Date set forth on the cover page of this Agreement the Stock Appreciation
    Rights as set forth therein (the &ldquo;SARs&rdquo;) pursuant to the Plan. These SARs represent the right to receive, upon exercise
    thereof, an amount in cash as set forth in this Plan. These SARs will NOT be credited with dividends to the extent dividends are
    paid on the Common Stock of the Company. Your SARs may not be transferred, assigned, pledged or hypothecated, whether by operation
    of law or otherwise, nor may the SARs be made subject to execution, attachment or similar process. Any capitalized, but undefined,
    term used in this Agreement shall have the meaning ascribed to it in this Plan.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>The
    Plan</U>. The SARs are issued in accordance with and is subject to and conditioned upon all of the terms and conditions of this Agreement
    and this Plan as amended from time to time; provided, however, that no future amendment or termination of this Plan shall, without
    your consent, alter or impair any of your rights or obligations under this Plan, all of which are incorporated by reference in this
    Agreement as if fully set forth herein.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Cash
    Value Determination upon Vesting and Exercise</U>. Subject to the terms and conditions set forth in this Agreement, the SARs covered
    by this grant shall vest on the vesting date set forth on the cover page of this Agreement, subject to earlier vesting and forfeiture
    as set forth in the Plan. The payment of the value of the SARs shall be made no later than ten (10) days following exercise. The
    payment of amounts with respect to the SARs is subject to the provisions of this Plan and to interpretations, regulations and determinations
    concerning this Plan as established from time to time by the Administrator in accordance with the provisions of this Plan, including,
    but not limited to, provisions relating to (i) rights and obligations with respect to withholding taxes, (ii) capital or other changes
    of the Company and (iii) other requirements of applicable law.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No
    Stockholder Rights</U>. SARs are not Shares. Neither the Participant, nor any Person entitled to exercise the Participant&rsquo;s
    rights in the event of the Participant&rsquo;s death, shall have any of the rights and privileges of a holder of Shares.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Severability</U>.
    Should a court of competent jurisdiction deem any of the provisions in this Agreement to be unenforceable in any respect, it is the
    intention of the parties to this Agreement that this Agreement be deemed, without further action on the part of the parties hereto,
    modified, amended and limited to the extent necessary to render the same valid and enforceable. It is further the parties&rsquo;
    intent that all provisions not deemed to be overbroad shall be given their full force and effect. You acknowledge that you are freely,
    knowingly and voluntarily entering into this Agreement after having an opportunity for consultation with your own independent counsel.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Notices</U>.
    Any notice to be given to the Company shall be addressed to the Administrator at its principal executive office, and any notice to
    be given to the Participant shall be addressed to the Participant at the address then appearing on the personnel or other records
    of the Company, or at such other address as either party hereafter may designate in writing to the other. Any such notice shall be
    deemed to have been duly given when deposited in the United States mail, addressed as aforesaid, registered or certified mail, and
    with proper postage and registration or certification fees prepaid.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Reservation
    of Right to Terminate</U>. Nothing herein contained shall affect the right of the Company or any Affiliate to terminate the Participant
    in its applicable capacity as a Service Provider at any time for any reason whatsoever.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Choice
    of Law; Jurisdiction</U>. This Agreement, and any and all claims, proceedings or causes of action relating to this Agreement or arising
    from this Agreement or the transactions contemplated herein, including, without limitation, tort claims, statutory claims and contract
    claims, shall be interpreted, construed, governed and enforced under and solely in accordance with the substantive and procedural
    laws of the State of Delaware, in each case as in effect from time to time and as the same may be amended from time to time, and
    as applied to agreements performed wholly within the State of Delaware. ANY LEGAL SUIT, ACTION OR PROCEEDING ARISING OUT OF OR BASED
    UPON THIS AGREEMENT SHALL BE INSTITUTED SOLELY IN THE COURTS OF THE STATE OF FLORIDA OR THE FEDERAL COURTS OF THE UNITED STATES,
    IN EACH CASE LOCATED IN PALM BEACH COUNTY, FLORIDA, AND EACH PARTY IRREVOCABLY SUBMITS TO THE PERSONAL JURISDICTION OF SUCH COURTS
    IN ANY SUCH SUIT, ACTION OR PROCEEDING.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Taxes</U>.
    You agree to comply with the appropriate procedures established by the Company, from time to time, to provide for payment or withholding
    of such income or other taxes as may be required by law to be paid or withheld in connection with the SARs.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">***</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
C</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form
of Restricted Stock Award Agreement</B></FONT></P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Jupiter
Neurosciences, Inc. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Restricted
Stock Award Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of Shares</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Grant
    Date</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Vesting
    Schedule</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter
Neurosciences, Inc., a Delaware corporation (the &ldquo;Company&rdquo;), hereby grants to [_________] (the &ldquo;Participant&rdquo;,
also referred to as &ldquo;you&rdquo;) shares of Restricted Stock (the &ldquo;Shares&rdquo;), pursuant to the terms of this Restricted
Stock Award Agreement (this &ldquo;Agreement&rdquo;) and the Jupiter Neurosciences, Inc. 2023 Equity Incentive Plan (the &ldquo;Plan&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>By
signing this cover sheet, you agree to all of the terms and conditions described in this Agreement and the Plan.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 10%">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Participant: _____________________________</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature: _____________________________</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter Neurosciences, Inc.</FONT></TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 5%">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 45%">&nbsp;</TD>
    <TD STYLE="width: 40%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">___________________________________</FONT></TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">___________________________________</FONT></TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">___________________________________</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>This
is not a stock certificate or a negotiable instrument. This grant of Shares is a</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>voluntary,
revocable grant from the Company and Participant hereby acknowledges that the</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Company
has no obligation to make additional grants in the future.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UPON
RECEIPT OF YOUR SIGNED AGREEMENT, A BOOKKEEPING ENTRY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WILL
BE ENTERED INTO THE COMPANY&rsquo;S BOOKS AND RECORDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TO
EVIDENCE THE SHARES GRANTED TO YOU.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RESTRICTED
STOCK AWARD AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Award</U>.
    This Agreement evidences the grant to Participant on the Grant Date set forth on the cover page of this Agreement the shares of Restricted
    Stock as set forth therein (the &ldquo;Shares&rdquo;) pursuant to the Plan. Any capitalized, but undefined, term used in this Agreement
    shall have the meaning ascribed to it in this Plan.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Non-Transferability
    of the Shares</U>. Your Shares may not be transferred, assigned, pledged or hypothecated, whether by operation of law or otherwise,
    nor may the Shares be made subject to execution, attachment or similar process. Except as may be required by federal income tax withholding
    provisions or by the tax laws of any state, your interests (and the interests of your beneficiaries, if any) under this Agreement
    are not subject to the claims of your creditors and may not be voluntarily or involuntarily sold, transferred, alienated, assigned,
    pledged, anticipated, or encumbered. Any attempt to sell, transfer, alienate, assign, pledge, anticipate, encumber, charge or otherwise
    dispose of any right to benefits payable hereunder shall be void. Your rights to your Shares are no greater than that of other general,
    unsecured creditors of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Vesting</U>.
    Subject to the terms and conditions set forth in this Agreement, the Shares covered by this grant shall vest on the vesting date
    set forth on the cover page of this Agreement, subject to earlier vesting and forfeiture as set forth in the Plan.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Delivery
    of Shares</U>.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Vesting</U>.
    Shares that vest (together with any payment due pursuant to the terms herein in respect of such Shares) shall be delivered to Participant
    (or the person to whom ownership rights may have passed by will or the laws of descent and distribution), on or as soon as administratively
    practicable after, the date of such vesting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Certain
    Limitations</U>. Notwithstanding the foregoing provisions of this Section 3, delivery of Shares, if any, by reason of Participant&rsquo;s
    termination of employment shall be delayed until the six (6) month anniversary of the date of Participant&rsquo;s termination of
    employment to the extent necessary to comply with Code Section 409A(a)(B)(i), and the determination of whether or not there has been
    a termination of Participant&rsquo;s employment with the Company shall be made by the Administrator consistent with the definition
    of &ldquo;separation from service&rdquo; (as that phrase is used for purposes of Code Section 409A, and as set forth in Treasury
    Regulation Section 1.409A-1(h)).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Withholding
                                            Taxes</U>. Participant shall be responsible to pay to the Company the amount of withholding
                                            taxes as determined by the Company with respect to the date the Shares are delivered. If
                                            Participant does not arrange for payment of the applicable withholding taxes by providing
                                            such amount to the Company in cash prior to the date established by the Company as the deadline
                                            for such payment, Participant shall be treated as having elected to relinquish to the Company
                                            a portion of the Shares that would otherwise have been transferred to Participant having
                                            a fair market value, based on the Fair Market Value of the Common Stock on the business day
                                            immediately preceding the date of delivery of the Shares, equal to the amount of such applicable
                                            withholding taxes, in lieu of paying such amount to the Company in cash. Participant authorizes
                                            the Company to withhold in accordance with applicable law from any compensation payable to
                                            him or her any taxes required to be withheld for federal, state or local law in connection
                                            with this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Legal
                                            Requirements</U>. If the listing, registration or qualification of Shares deliverable in
                                            respect of an Shares upon any securities exchange or under any federal or state law, or the
                                            consent or approval of any governmental regulatory body is necessary as a condition of or
                                            in connection with the issuance of such Shares, the Company shall not be obligated to issue
                                            or deliver such Shares unless and until such listing, registration, qualification, consent
                                            or approval shall have been effected or obtained. If registration is considered unnecessary
                                            by the Company or its counsel, the Company may cause a legend to be placed on any Shares
                                            being issued calling attention to the fact that they have been acquired for investment and
                                            have not been registered. The Administrator may from time to time impose any other conditions
                                            on the Shares it deems necessary or advisable to ensure that Shares are issued and resold
                                            in compliance with the Securities Act of 1933, as amended.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Severability</U>.
                                            Should a court of competent jurisdiction deem any of the provisions in this Agreement to
                                            be unenforceable in any respect, it is the intention of the parties to this Agreement that
                                            this Agreement be deemed, without further action on the part of the parties hereto, modified,
                                            amended and limited to the extent necessary to render the same valid and enforceable. It
                                            is further the parties&rsquo; intent that all provisions not deemed to be overbroad shall
                                            be given their full force and effect. You acknowledge that you are freely, knowingly and
                                            voluntarily entering into this Agreement after having an opportunity for consultation with
                                            your own independent counsel.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Notices</U>.
                                            Any notice to be given to the Company shall be addressed to the Administrator at its principal
                                            executive office, and any notice to be given to the Participant shall be addressed to the
                                            Participant at the address then appearing on the personnel or other records of the Company,
                                            or at such other address as either party hereafter may designate in writing to the other.
                                            Any such notice shall be deemed to have been duly given when deposited in the United States
                                            mail, addressed as aforesaid, registered or certified mail, and with proper postage and registration
                                            or certification fees prepaid.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Reservation
                                            of Right to Terminate</U>. Nothing herein contained shall affect the right of the Company
                                            or any Affiliate to terminate the Participant in its applicable capacity as a Service Provider
                                            at any time for any reason whatsoever.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Choice
    of Law; Jurisdiction</U>. This Agreement, and any and all claims, proceedings or causes of action relating to this Agreement or arising
    from this Agreement or the transactions contemplated herein, including, without limitation, tort claims, statutory claims and contract
    claims, shall be interpreted, construed, governed and enforced under and solely in accordance with the substantive and procedural
    laws of the State of Delaware, in each case as in effect from time to time and as the same may be amended from time to time, and
    as applied to agreements performed wholly within the State of Delaware. ANY LEGAL SUIT, ACTION OR PROCEEDING ARISING OUT OF OR BASED
    UPON THIS AGREEMENT SHALL BE INSTITUTED SOLELY IN THE COURTS OF THE STATE OF FLORIDA OR THE FEDERAL COURTS OF THE UNITED STATES,
    IN EACH CASE LOCATED IN PALM BEACH COUNTY, FLORIDA, AND EACH PARTY IRREVOCABLY SUBMITS TO THE PERSONAL JURISDICTION OF SUCH COURTS
    IN ANY SUCH SUIT, ACTION OR PROCEEDING.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Taxes</U>.
    You agree to comply with the appropriate procedures established by the Company, from time to time, to provide for payment or withholding
    of such income or other taxes as may be required by law to be paid or withheld in connection with the Restricted Stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">***</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
D</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form
of Restricted Unit Award Agreement</B></FONT></P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Jupiter
Neurosciences, Inc. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Restricted
Unit Award Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of Restricted Stock Units</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Grant
    Date</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Vesting
    Schedule/Performance Period/Performance Vesting Requirements</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter
Neurosciences, Inc., a Delaware corporation (the &ldquo;Company&rdquo;), hereby grants to [_________] (the &ldquo;Participant&rdquo;,
also referred to as &ldquo;you&rdquo;) the Restricted Stock Units (the &ldquo;Restricted Stock Units&rdquo; or &ldquo;RSUs&rdquo;), pursuant
to the terms of this Restricted Unit Award Agreement (this &ldquo;Agreement&rdquo;) and the Jupiter Neurosciences, Inc. 2023 Equity Incentive
Plan (the &ldquo;Plan&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>By
signing this cover sheet, you agree to all of the terms and conditions described in this Agreement and the Plan.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 10%">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Participant: _____________________________</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature: _____________________________</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter Neurosciences, Inc.</FONT></TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 5%">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 45%">&nbsp;</TD>
    <TD STYLE="width: 40%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">___________________________________</FONT></TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">___________________________________</FONT></TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">___________________________________</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>This
is not a stock certificate or a negotiable instrument. This grant of RSUs is a</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>voluntary,
revocable grant from the Company and Participant hereby acknowledges that the</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Company
has no obligation to make additional grants in the future.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UPON
RECEIPT OF YOUR SIGNED AGREEMENT, A BOOKKEEPING ENTRY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WILL
BE ENTERED INTO THE COMPANY&rsquo;S BOOKS AND RECORDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TO
EVIDENCE THE RSUs GRANTED TO YOU.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jupiter
Neurosciences, Inc. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RESTRICTED
UNIT AWARD AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Award</U>.
    This Agreement evidences the grant to Participant on the Grant Date set forth on the cover page of this Agreement the Restricted
    Stock Units as set forth therein (the &ldquo;Restricted Stock Units&rdquo; or &ldquo;RSUs&rdquo;) pursuant to the Plan. As used herein,
    the term &ldquo;Restricted Stock Unit&rdquo; or &ldquo;RSU&rdquo; shall mean a non-voting unit of measurement which is deemed for
    bookkeeping purposes to be equivalent to one outstanding Share solely for purposes of this Plan and this Agreement. The Restricted
    Stock Units shall be used solely as a device for the determination of the payment to eventually be made to the Participant if such
    Restricted Stock Units vest pursuant to this Award Agreement. The Restricted Stock Units shall not be treated as property or as a
    trust fund of any kind. Any capitalized, but undefined, term used in this Agreement shall have the meaning ascribed to it in this
    Plan.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Non-Transferability
    of the RSUs</U>. Your RSUs may not be transferred, assigned, pledged or hypothecated, whether by operation of law or otherwise, nor
    may the RSUs be made subject to execution, attachment or similar process. Except as may be required by federal income tax withholding
    provisions or by the tax laws of any state, your interests (and the interests of your beneficiaries, if any) under this Agreement
    are not subject to the claims of your creditors and may not be voluntarily or involuntarily sold, transferred, alienated, assigned,
    pledged, anticipated, or encumbered. Any attempt to sell, transfer, alienate, assign, pledge, anticipate, encumber, charge or otherwise
    dispose of any right to benefits payable hereunder shall be void. Your rights to your RSUs are no greater than that of other general,
    unsecured creditors of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Vesting</U>.
    Subject to the terms and conditions set forth in this Agreement, the RSUs covered by this grant shall vest on the vesting date set
    forth on the cover page of this Agreement and subject to the satisfaction or attainment of the performance criteria set forth therein,
    if any, provided the Participant is employed by the Company on the date of vesting, subject to earlier vesting and forfeiture as
    set forth in the Plan. The Administrator may not accelerate vesting of Restricted Stock Units for any reason.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Dividends</U>.
    Participant shall not be entitled to any cash, securities or property that would have been paid or distributed as dividends with
    respect to the RSUs subject to this Agreement prior to the date the RSUs are delivered to Participant; provided, however, that the
    Company shall keep a hypothetical account in which any such items shall be recorded, and shall pay to Participant the amount of such
    dividends (in cash or in kind as determined by the Company) on the same date that the RSUs to which such payments or distributions
    relate are required to be delivered under this Agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Timing
    and Manner of Payment on RSUs</U>.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    or as soon as administratively practical following the vesting event pursuant to this Agreement (and in all events not later than
    two and one-half (2&frac12;) months after such vesting event), the Company shall deliver to the Participant a number of Shares (either
    by delivering one or more certificates for such Shares or by entering such Shares in book entry form, as determined by the Company
    in its discretion) equal to the number of Shares subject to the RSU that vest on the Vesting Date, less any withholding or expenses
    as set forth herein, or may settle the RSU in cash or other payment as provided in this Plan, as determined by the Administrator.
    The Company&rsquo;s obligation to deliver Shares or otherwise make payment with respect to vested RSUs is subject to the condition
    precedent that the Participant or other person entitled under this Plan to receive any Shares or payment with respect to the vested
    RSUs deliver to the Company any representations or other documents or assurances required pursuant to this Plan. The Participant
    shall have no further rights with respect to any RSUs that are paid or that terminate pursuant to this Agreement or this Plan.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Certain
    Limitations</U>. Notwithstanding the foregoing provisions of this Section 3, delivery of Shares or other payment, if any, with respect
    to RSUs by reason of Participant&rsquo;s termination of employment shall be delayed until the six (6) month anniversary of the date
    of Participant&rsquo;s termination of employment to the extent necessary to comply with Code Section 409A(a)(B)(i), and the determination
    of whether or not there has been a termination of Participant&rsquo;s employment with the Company shall be made by the Administrator
    consistent with the definition of &ldquo;separation from service&rdquo; (as that phrase is used for purposes of Code Section 409A,
    and as set forth in Treasury Regulation Section 1.409A-1(h)).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Rights
                                            of Participant</U>. Participant shall have none of the rights of a stockholder at any time
                                            prior to the delivery of any Shares pursuant to the RSUs subject to this Agreement, except
                                            as expressly set forth in this Plan or herein.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Withholding
                                            Taxes</U>. Participant shall be responsible to pay to the Company the amount of withholding
                                            taxes as determined by the Company with respect to the date the RSUs are settled. If Participant
                                            does not arrange for payment of the applicable withholding taxes by providing such amount
                                            to the Company in cash prior to the date established by the Company as the deadline for such
                                            payment, Participant shall be treated as having elected to relinquish to the Company a portion
                                            of the Shares that would otherwise have been transferred to Participant having a fair market
                                            value, based on the Fair Market Value of the Common Stock on the business day immediately
                                            preceding the date of delivery of the Shares, equal to the amount of such applicable withholding
                                            taxes, in lieu of paying such amount to the Company in cash, or an amount in cash if the
                                            RSU is settled in cash. Participant authorizes the Company to withhold in accordance with
                                            applicable law from any compensation payable to him or her any taxes required to be withheld
                                            for federal, state or local law in connection with this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Legal
                                            Requirements</U>. If the listing, registration or qualification of Shares deliverable in
                                            respect of an RSU upon any Securities Exchange or any Applicable Requirement, or the consent
                                            or approval of any governmental regulatory body is necessary as a condition of or in connection
                                            with the issuance of such Shares, the Company shall not be obligated to issue or deliver
                                            such Shares unless and until such Applicable Requirements shall have been effected or obtained.
                                            If registration is considered unnecessary by the Company or its counsel, the Company may
                                            cause a legend to be placed on any Shares being issued calling attention to the fact that
                                            they have been acquired for investment and have not been registered. The Administrator may
                                            from time to time impose any other conditions on the Shares it deems necessary or advisable
                                            to ensure that Shares are issued and resold in compliance with the Securities Act of 1933,
                                            as amended.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Severability</U>.
                                            Should a court of competent jurisdiction deem any of the provisions in this Agreement to
                                            be unenforceable in any respect, it is the intention of the parties to this Agreement that
                                            this Agreement be deemed, without further action on the part of the parties hereto, modified,
                                            amended and limited to the extent necessary to render the same valid and enforceable. It
                                            is further the parties&rsquo; intent that all provisions not deemed to be overbroad shall
                                            be given their full force and effect. You acknowledge that you are freely, knowingly and
                                            voluntarily entering into this Agreement after having an opportunity for consultation with
                                            your own independent counsel.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Notices</U>.
                                            Any notice to be given to the Company shall be addressed to the Administrator at its principal
                                            executive office, and any notice to be given to the Participant shall be addressed to the
                                            Participant at the address then appearing on the personnel or other records of the Company,
                                            or at such other address as either party hereafter may designate in writing to the other.
                                            Any such notice shall be deemed to have been duly given when deposited in the United States
                                            mail, addressed as aforesaid, registered or certified mail, and with proper postage and registration
                                            or certification fees prepaid.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Reservation
                                            of Right to Terminate</U>. Nothing herein contained shall affect the right of the Company
                                            or any Affiliate to terminate the Participant in its applicable capacity as a Service Provider
                                            at any time for any reason whatsoever.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Choice
                                            of Law; Jurisdiction</U>. This Agreement, and any and all claims, proceedings or causes of
                                            action relating to this Agreement or arising from this Agreement or the transactions contemplated
                                            herein, including, without limitation, tort claims, statutory claims and contract claims,
                                            shall be interpreted, construed, governed and enforced under and solely in accordance with
                                            the substantive and procedural laws of the State of Delaware, in each case as in effect from
                                            time to time and as the same may be amended from time to time, and as applied to agreements
                                            performed wholly within the State of Delaware. ANY LEGAL SUIT, ACTION OR PROCEEDING ARISING
                                            OUT OF OR BASED UPON THIS AGREEMENT SHALL BE INSTITUTED SOLELY IN THE COURTS OF THE STATE
                                            OF FLORIDA OR THE FEDERAL COURTS OF THE UNITED STATES, IN EACH CASE LOCATED IN PALM BEACH
                                            COUNTY, FLORIDA, AND EACH PARTY IRREVOCABLY SUBMITS TO THE PERSONAL JURISDICTION OF SUCH
                                            COURTS IN ANY SUCH SUIT, ACTION OR PROCEEDING.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Taxes</U>.
    You agree to comply with the appropriate procedures established by the Company, from time to time, to provide for payment or withholding
    of such income or other taxes as may be required by law to be paid or withheld in connection with the RSUs.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">***</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>11
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>CONSENT OF INDEPENDENT ACCOUNTANTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We hereby consent to the incorporation by reference in this Registration
Statement on Form S-1 of Jupiter Neurosciences, Inc. of our report dated July 11, 2024, relating to our audit of the financial statements
as of December 31, 2023 and 2022 and for the years ended December 31, 2023 and 2022, which appears in the Registration Statement on Form
S-1 of Jupiter Neurosciences, Inc. for the years then ended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We also consent to the reference to our firm under the caption &ldquo;Experts&rdquo;
in the Prospectus, which is part of this Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
  Assurance Dimensions</I></FONT></TD>
  <TD STYLE="padding-bottom: 1.5pt; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assurance
Dimensions</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Margate,
Florida</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">July 12, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>12
<FILENAME>ex107.htm
<DESCRIPTION>CALCULATION OF FILING FEE TABLES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 107</B></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Calculation of Filing Fee Tables</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Form S-1</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Form Type)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Jupiter Neurosciences, Inc.</B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact Name of Registrant as Specified in its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>Table 1: Newly Registered and Carry Forward
Securities</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Security Type</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Security Class Title</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fee Calculation or Carry Forward Rule</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount Registered</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Proposed Maximum Offering Price Per Share</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Maximum Aggregate Offering Price<SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fee Rate</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amount of Registration Fee <SUP>(4)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 10%; text-align: left; padding-bottom: 1.5pt">Fees previously paid</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 10%; padding-bottom: 1.5pt">Equity</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 12%; padding-bottom: 1.5pt">Common stock, par value $0.0001 per share</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center; padding-bottom: 1.5pt">Rule 457(o)</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 8%; border-bottom: Black 1.5pt solid; text-align: right">13,750,000</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; border-bottom: Black 1.5pt solid; text-align: right">0.0001476</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 8%; border-bottom: Black 1.5pt solid; text-align: right">2,029.50</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Fees previously paid</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">Equity</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock, par value $0.0001 per share, registered on behalf of certain selling stockholders <SUP>(2) (3)</SUP></FONT></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">Rule 457(a)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,600,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5.00</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><SUP>(7)</SUP></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">18,000,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.0001476</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,656.80</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="font-weight: bold; text-align: center">Total Offering Amounts</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">31,750,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,686.30</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="font-weight: bold; text-align: center">Total Fees Previously Paid</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,370.81</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="font-weight: bold; text-align: center">Total Fee Offsets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">Net Fee Due</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">315.49</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated solely for the purpose of calculating the amount of the registration
fee pursuant to Rule 457(o) of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;). </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to Rule 416, the securities being registered hereunder include
such indeterminate number of additional shares of common stock as may be issued after the date hereof as a result of stock splits, stock
dividends or similar transactions.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents 3,600,000 shares of common stock held by selling stockholders.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">(4)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Estimated solely for purposes of calculating the registration fee pursuant
to Rule 457(a).</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>forms-1a_001.jpg
<TEXT>
begin 644 forms-1a_001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "/ > # 2(  A$! Q$!_\0
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M-Q,,3A4(D8["&/J'P5_X*J?L-?M%>-O#_P /?@G\8]9^(GB;Q/JTFAZ2NB?
M[]H1/#_]JQ6<]])::GXTU#X5V7@S03%;V\CR3Z_K^EVZ$+$\J330QOW5<FSB
MA3E6KY3F=&C"_/6K8#%4J4;*[YJE2A""LM?B:\[:GGT<]R3$U8T,/G&5XBO-
MVA1H9A@Z]67O..E.CB:M3XE;6"UTWT/T0HKQ;XY?'WX:_LY^!O\ A8_Q:U77
M=%\)+JVFZ$][X=^'WQ$^).H)JFK^>+")O#GPQ\+^,/$RVTK6TJR:@='&G6KB
M..[O+=[BW$OP.W_!<#_@E[!?W6EW_P"U-IVC:I83"WO],\0_"3X^>&]1L+@"
M-F@O[+7OA;I]U93;)8Y1%=11.(768J8CYE98;+<QQL7/!X#&XN";4IX;"U\1
M&+5KQDZ-.HTU=73CU6IMBLURO S5/'9E@,'-I24,7C,/AI-.]FE7JT[IV:33
MU_+]8:*_*2[_ ."WO_!+6R0/-^UWX/E!!/\ H/@CXN:D0 P4973OA_=L&)9?
ME8!B,L 5!(RH/^"ZO_!*VXN$M8_VL=)CDDD,8DNOA+\?;*U# D9>\O/A9!9Q
M1DX_>R7"Q;2&#E2N[J7#^?M-K(\Y:5[M95F%E;>[^JV5NMWIU.1\2<.QDHRS
M_)$VKV>;9<G]WUR_W)^I^N%%?-OP,_;"_9<_:9AE?X!?M ?"/XM7=M;F[O=%
M\%>-]$U7Q-I=L"%:XUGPHMVGB;1HU8@$ZII-IU'K7T;')O.!@C!((]B!US@]
M3GI@@BO,JTJM"HZ5>E5H58_%2K4ZE&K'_%3JPIU%ZN%O,]2AB*&)IQK8:O1Q
M%&:O"M0JTZU*>WPU:4ZE-O5:*=_+:\M%>/\ QP^.?PZ_9W\"7/Q*^*FIZYH_
M@ZRU'3=+O+_P_P" OB#\2-1AO-7G^RZ>O_"-?#/PQXN\3O;RW'[N6^31FL+0
ME#>75N)(R_Y_1_\ !<'_ ()=-=3V%Q^U9HVF:A:W#6EW8ZY\+?CKX?O+&Z0C
M?;7]KKGPQT^XL9X@098KN.%T#HTBQJZ%NC#9?F&-4I8/ XW%QC?F>%PM?$)-
M6NG[&G4:>JW2TZ]#GQ6:99@9JGC<QP.#G)*48XO%X?#-Q;Y5)>WJTDTWI=-^
MA^L-%?D]=_\ !</_ ():VLT-M_PUGX>N[BXFBM[:#2/AM\;-=GNKBX*);VUM
M#HWPUOWN+F>21(8;> 232S$0QH9<QC[R^ _[0OPO_:4\$/\ $;X0:QKVN^#T
MUO4/#O\ :/B/X>_$;X:7DFJZ7!9SWT<&@?$_PIX-\0W%G&E_:^3JT&E2Z3>2
M>?!9WTUQ:7<4!B<OS#!14L9E^.PD9-*,L3A,1AXR;=DH^VITW)O6UHM:/56#
M"YIEF.E*."S' 8R44Y2CA,9AL3**C;F<E0JU;<MTWK=)IVU/;Z*_-O\ :K_X
M*N?L<?L5?&[PM\"?VB_&7BKP9XD\5?#NW^)L&NZ9\/\ Q/XU\+Z/X?O_ !!K
MOAK1X-=;P7:Z_P"*+74M;U+PQX@_L^.S\*W]C';:3--J&H637-A'=<)IW_!<
M+_@EEJ<7GP?M<^%88R%(74O /QCT6XRW.#;:Q\.K&XR.01Y6Y>-X7.*Z*>1Y
MU6H4<31R?-*V&Q$/:4*]' 8JM1K4W*45.G4I4:D7%RA-:N+]UOEM:3YJO$&0
MT<17PM?.LIH8G#3]GB*%?,<'1K49\L9<M2G6KTI)\LXO9KWDKIWBOU?HK\K_
M /A]?_P2[_Z/!\!CT_XIKXE'))P/^9(&.?K1_P /L/\ @EUT_P"&P/ F?;PU
M\2__ )AOZ_F:K^P,^M?^Q,XMW_LO'_\ S*1_K)PZVU_;^277_4VR[_YL/U0H
MK\KS_P %K_\ @EYG_D[_ ,!\YQGPW\2\D=>G_""]<=0*I:A_P6__ ."6VG6[
MW4W[77A&:),@IIO@7XP:U=;AS\MEI'P]O;Q\J#C9;MEL 9) (LASQ[9+F[\E
MEF/;OV_W7>^GJ/\ UCX=2N\_R1)?]3?+OTQC/U=HKYT_9F_:F^#/[8'PIL/C
M7^S_ .*KGQE\.=2U[Q+X:LM:O_"_BCP?=S:MX5U:;1]6A?0_&&EZ'K=M&MW#
MNM9;K3X4N[>:&XC(1L5\E>,_^"R'_!.[X=:I<Z/\0?CKX@\"W]KJ=_HK+XO_
M &>OVF_#EM/JNESW%O?6=AJ&L_!NST_4WADM+DJ=.NKI)X89;FW>6WC,E<D<
MOQ\\14PE/!8NIBJ,W2JX:&'JSKTJD79PG1C!U8S4ER\C@Y*6CBF=D\SRZGAJ
M6,J8_!T\)7@JE#%5,31IX>M3DKQG3K3G&E.$DTXRC-IIIWLS]0**_*J'_@MK
M_P $N9XQ(O[7W@>,$L-LWA+XIVT@VL028KKP+#* <95C$%8<H67#5)_P^P_X
M)=#K^V!X#^O_  C?Q*_^8;ZXY.<''0@=CX?SY;Y'G*_[I>8?E]4NNVO70X5Q
M+PXW9<09)?\ [&^6_P#S98_5&BOREO/^"WG_  2VLH3-)^UUX/F55D8K8^"O
MBWJDQ\M22!;:9\/KJX+'&%58BTC?+$KL0I^M/V3_ -LCX#_ML>!O$?Q,_9U\
M3ZKXR\!>&O'FJ?#JZ\1ZIX,\7>"(K_Q'H^A>'_$-^-)TWQKI&A:U=Z=%8>)M
M+5=0DTRWC>Z^U6_EJT&YL,1E.:X2B\1B\LS#"T%*$'6Q6"Q.'I*=1M0@ZE>C
M2CS3<6HQ3E)M.T=&UTX;.<GQM>.&P>:Y;B\1.$ZD:&%QV%Q-9TZ2BZD_9X>M
M6DH04HN<I*,5S+6[2/J:BO-/B_\ %OP/\"_A[K_Q2^(]_JVF>"_"_P#9S:W?
M:%X/\9^/=5MX]4U6RT6S:U\*?#[0/%'BW5-VH:C:1S?V5H=Z+.W>6_O?L]A;
M75U#^=MU_P %O/\ @F'INI7.C:W^T]#X=UBT53=Z3XH^#/[0GA;5+0."T;7>
MG^(?A1IMW;)* ?*:>&,2E'6,NR,%SPV7X_&IO!X'&8M)N+>%PU;$)223Y7[&
MG4:=G>W*].QIBLSRW 24<=F&"P<G'G2Q>*H8:\6VN:]>I35KIJ_,?J[17Y27
M?_!;W_@EM9)NE_:Z\(2C;N)LO _Q>U$@9 ^YI_P_NFW9/W#AL L!@';DP?\
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MD6.-GBM['3=+L+:.?4-<U_6M1GMM(\/^'M)M;S5]>UF\L]*TJSN[^ZM[>3^
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MU)X!.=K GH.#GVZU_%__ ,'1_P -?!WASXQ?L@_%'1="T_3_ !G\4? _QO\
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M'XO^+;56(\Z:>XU'PAX#$BJ?]7&EKXXN#$^Y3(UG, 7A1J_(K]D3X.1_'_\
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M]K]9H*,N:*I8IY%CI2A"*C)XVNI-RJJ1_47;A54*B+'&J(L<:*%5$50JJH
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M6MXJK^W3_@WX('_!+#X"D\ >+OCS_P"KU^(-?Q%_\%"?^3^?VW?^SL?VAO\
MU:WBJO[<_P#@WZ_Y17? 7_L;OCQ_ZO;X@U_0/B,[>'O#GKDJ^_)F?S3X7?\
M)S.*?\&>+_S,4S]IV_U9_P!P_P#H-?R"?\'5O_(2_8&_Z\_VK?\ T=^S37]?
MA&4(]5QSTY'>OY!/^#JL%M0_8%8*<?9/VK%)(. 6E_9I*@L 5#,,D*2&PK$
M@$C\V\.?^2UR'_K]BW\O[-QI^L>*/_)!<0_]@^$_]6&!/@W_ (-O?^4D=Q_V
M;5\7_P#U)/A97]]J]O\ =7^M?P&_\&X$T<?_  4E9'<(UQ^S;\7XX0>LDO\
MPD'PSG\M?]H0VT\ISQMC/.>*_OQC8,,CL IZ=1]">.>*]/Q93_UPJ::/*LKM
MYVI8M.WH]/70\+P63_U*I^6;YK?RN\#;[Q]%%%?FQ^N'^<%_P7M_Y2@_M?\
M_7E\)?\ UG?X95_H;_"3_DF'PT_[)WX,_P#4=TRO\\;_ (+V.A_X*@?M@$,#
MML_A,K 9)##]G7X8,5( )W . 5&6!X(SC/\ H@_"ZUFLOAQ\/+6X4)/:^!/"
M-I.F2=D\'A_3TE7) SM9&&>O3CGC]7X^_P"23\/?/*W;_P (L!_6Q^,>&S7^
MN'B7_P!C6FOG]=QVGJ=]7\K'_!TS_P D<_9 _P"RN_$/_P!0.WK^J>OY6/\
M@Z9_Y(Y^R!_V5WXA_P#J!V]?->'O_):</?\ 8=_[KXH^N\2O^2%XD_[ 8?\
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MWI'_  = ?M)>%O\ A#_V=_V3=(U6SOO%4GC.]_: \>:?:R"6[\,Z!H?AO7?
M?P_AU6(#_1W\9W_B[QAJ&F0(SW(A\%S230PPWVGR7/VG_P $#O\ @G+XE_9#
M^"VO_'CXT>'9] ^/7[1-AHDJ>%]6M1!KWPO^$.F^=J7AGPIK%M,GVG1O%OB[
M4;L>+_&^CR-#=:;'!X-\-ZW96GB#PKJ<,?\ -#_P2R_:2^!,/_!1CPO\9_\
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M;R6US8^,/"/B[Q%X=\6PR+)'&95/B+3M3FAO4W0W\$L>H6\L]O=12R?RQ?\
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M[']*9AAWC,!CL)&48RQ>#Q>%C*2;C&6(PV(H1<DK-Q4JT7*VO*G;6R?X!_\
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M*^-?V_?V3-'_ &U_V2OC'^SM?WEGI&L>-- AO/ OB/40[67AGXE>&;ZV\0^
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M M;L=?T*^"N)+/4+>#4;'2]:TB^A%UH_B'1YK#4[&6^T;5()[C_1X_X)W_\
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MMSXB\1R^.+C5KBWUNST?X7:G!IUKJ>H?3_\ P2;_ ."9?CO]@>#XZ?$+XO\
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M7M,ZE2AKL[RIR?>\6E=Q;7ZZCH/H*& ((8!@< @\@C/.0>"/7/'K33(BD L
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M*RZ52:G4IX7,\QIX:KRN\8U<*\54H5$MO>I\S7N^TY?=/C']N_\ 9OF_:?\
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M=&<,FRBD\-@7)2B\3/EI4ZF+E!N\(RIT*5*A"2YE2@Y/E]HHQ^-\.>#:O"^
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ML@$MQ<^$_$GAHV>N"(.+2/6=&E+>5=1,W[HO.B1LS8"JA+%V55554DEB3A5
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MV?PUK%[,0SW/BKX>":PT;4)9)'EN+V_T"Z\+Z[J%Q-+<:CK-VTC(?Q&^+/\
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2BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_004.jpg
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  W 2P# 2(  A$! Q$!_\0
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MTB*;4;2.1;<!D>=00<GJ":Z6+5M-N)5B@U"TED;[J),K$_0 U$ZU52:7Y?\
M &H1L+I=G_9VD6=DTQF-M D)E88+[5 W'ZXS7@&F:7=^*?B#J&D_VM<6BF>=
MPZDMC:QXQD5]&5X-X"ECB^+]^TCJB[[KEC@?>-/#MI3DM[!-:I'0-\'K]%+0
M^+KH2#E<PL.?J)*S](\6^(? _BN/0/%$YN[20J!.[%BJL<!U8\E?4'I@^E>O
M2:E81(7DO+=$')9I5 'ZUX9X^OX?'7CNQT[1"+@(HMQ,HR&8L2Q'^R!W]CVI
MTI2J-QJ;?D*24=4>_5X#XY2ZO_BZ^F1WTUNES-;0[D8X3<B#.,CUS7OBC:H7
M).!U->$>*W2+XZV\DCJB+>6;,S'   CY)J<-\3]&54V1T7_"F[K_ *&V[_[\
M'_XY6AH7PNN-%URUU%O$EQ<I;OO,+1$!^.F=Y_E7;_V[I'_05L?_  (3_&I[
M:]M;Q6-M<PSA3AC%(&Q]<5#KU;6?Y?\  &H1(]6L1J6DW5D2 9HRJD]%;L?P
M.#7AL4*W;QH;6-[F0LB12K&69UX>-"ZE=ZGJI + @AAD*/?Z\4\665IIGCV\
MTK4#Y6DZX%N(YA_R[7'($@_X%G/LWM5X>>\1374R[?2[#49'BMM%TW4KA"0]
MIYDFGWBD=04+%#C_ &<U2DT_P2DYMM4MO$.AW7=)0LB+^:AC^5:4AM=0U%O#
MGC7-GK-N0EKK*=6'\/F'^)3QAC^8.34NI:KXF\',NG>*;&#7=(8XBDN%WAA_
MLR$9!]FR?3UKJN[V3_'\NC,M"G!\/O#NJX_LGQO9NS?=BN(O+8_@6!_2G7/P
M7\1Q#=;W.GW*]MLK*3^:X_6K-OX;\">,R/[$U&71[]O^72X^92?1<GG\&_"J
M=WX/\?>$"9-.GNY;<<[]/F9A^*=?T(IJ<D[*5GV:"R[?<9-U\,_%]IDMH\D@
M]8I$?/X YK$NO#NMV.?M6D7\('>2W<#\\5UMA\7?%>G/Y=V]O>;3AEN(=K#\
M5QS]:ZS3OCC9OA=3TB>$]WMW$@_(XQ^9JW.O'>*?H*T'U/&(+>6XN8[:)"TT
MCA$3N6)P!^=?5^@Z3'HF@V6FQ8VVT00D?Q-_$?Q.3^-5=&U/2O%-A%J=I 9(
MP_R//;[2&'<$CL>X[BMSM7!B*[J6BU:QM"'+J+1117,:!1110 =Z\T^-W_(F
M6?\ V$$_]%R5Z7WKS3XW?\B99_\ 803_ -%R5K0_B1(G\+.?\)?"G2/$'A>R
MU2XOKZ.:X5F98RFT88CC*^U<MJGAVT\%^.H+76[=[S2&<.K9*F2(\9XQRIZC
MOCWKV?X:_P#)/-(_ZYM_Z&U/\<^%(_%F@26P"K>0YDM9".C_ -TGT/0_@>U=
M"Q$E4<9/0CD7+=&_8I:)I\"V*Q+:>6/)$0 39CC&.V*P?B-_R3_6/^N(_P#0
MA7"?#'QLNFK+X:UZ<6IMV(MY+AMH0@_-&Q/3!Z9]QZ5VWC^:.?X=:M+$ZO&]
MN&5T.006&"#WK'D<*J3[E\R<3S'X<_#_ $GQ=HMU>7\]Y')%<&)1 ZJ,;5/.
M5//-=FOP5\-*P87>J9!S_K8__B*Y_P"%'BS0] \/7EOJ>HQVTSW9=596.5V*
M,\#U!KO?^%D^$/\ H-P?]\/_ (5M6E551J-[$14+:G5UD>)=%C\0^';[2Y,#
MSXR$8_PN.5/X$"G:-XATKQ DKZ7>I=+$0)"H(VD].H'I6K7'K%^9KHT>-?!G
M5Y;2_P!2\.7>4<$S1HW574[77Z]/R-95TI^(7Q?\G[^GV\FP^GDQGG_OIL_]
M]"G_ !)M+OPCX\CU_3#Y7VU&=7 X63;M<?B"#]6KI_@SH'V+0IM9F3$U\VV(
MGJ(E/]6S^0KT)-13K+JOQZF*NWR]CU  #@# %>6_'#_D6]-_Z^__ &0UZG7E
MGQP_Y%O3?^OO_P!D-<F'_BQ-)_"RAX7^$^@ZWX8T_4;BYU!9[B(.XCE0*#GM
ME#73Z%\+-$\/ZU;ZK:75^\]N6*++(A4Y4KR @/0^M4?!OCKPSIO@_3+.\U>&
M*XA@"R1E6RIR?05N_P#"R?"'_0<@_P"^'_PK2I*LVUK8F*C8ZNOG#1?#MMXH
M^)&HZ9=S311--</NB(W9#'U!KZ#TS4K/5M/COK&=9[:7.R100#@D'K[@UXK\
M/O\ DL-__OW7_H1IX=N,9OJD$]6BQXO^$<.CZ!+J.CW-U<R6_P \L4VTYC[E
M< <CK],UM_!R30Y=(F^S6D<6L1?+<.22TB$\,,]!V('<>XKU(@$$$9![5X3X
MGTR[^&?CB#6]*0_V;<.2L8X7!^_$?;N/P]*J%25:+IR>O3_('%1?,CW>OGWQ
MQ8QZI\9?L$S.L5S/:PN4.&"LJ XSWYKVS1?$>E>(+:.;3KV&8L@<Q!QYB?[R
M]17C'C&[AL_C=%=7$@C@ANK221ST50L9)_*IPR:FUULPJ6:1VG_"D_#7_/WJ
MO_?Z/_XBNG\*^#].\(6]Q!ITMS(MPX=S.ZL00,<8 JM_PLGPA_T'(/\ OA_\
M*?#\0O"EQ-'#%K,+22,$10C\DG '2LI.M)6E>Q245L=17FOQET;[=X7BU.-<
MRV$N6/\ TS? /Z[?UKTJJ6J:?#JNE7=A-_JKB)HF]LC&?PJ*<^2:D5)75CQ?
M3K=/B5X-^R,R_P#"2:1'B%V/-Q#V!/?TSV.#_$:K^#_'HL(F\->+(?M&F$^3
MF=-S08.-K \E0?Q'\N3T?5+[P;XJ6Y4$3V<S13Q9X< X=3^OZ&O0_B-X5M_$
M&D1^,M!7S%DB$ERB#[Z8^_C^\.C#V]CGTY1BGR2^%[>3.=-M76Y2\6_"AX8?
M[4\+.;NT<>9]F#;G"GG*'^,>W7ZUA^'OB9XA\.N+>>0WUJAVF"Z)W+CL&ZCZ
M'('I4G@'XA7GABX2QNA)=:7(W,0Y>(GNG]5_E7J/B;P%HWC6R74+8BWO9$#Q
MW2)C?QQO7C/Z$?I42ER/DK*Z[E)7UB9]IXA\"?$%5AU*U@AOFX"7("29]%D&
M,_3.?:J\GP3TC^U8IXM0N18A]TMLX!9AZ!QC _ G'>K/A?X0Z5I02YU=EU&[
M'/ED8A4_3^+\>/:O1U544*H 4#  ' %<LZO([4I.Q:C?XD,M[>&TMH[>WB2*
M&-0B(@P% Z "IJ**YC0**** "BBB@ K+UG0M-\06B6NJ6HN8$D$BH69<, 1G
M@CL3^=:E%";3N@*6G:=::580V-E"(;:($1Q@D[03GJ>>IJ[110W<#FM1\">&
MM6OY+V^TJ.:YDP7?>Z[L#'0$"M.31-.FT0:/);AM/$2PB'<<;!C SG/8=ZT:
M*?-)]161R7_"LO!W_0%C_P"_TG_Q5'_"LO!W_0$C_P"_TG_Q5=;7#P:]KNNZ
MQK%IIEUIUD=-G,"P7,+223$?Q'##:I[$ U<9SE?WOQ):BNAT.B^'-(\.I,FE
M6:VRS$&0!V;<1TZD^M:]9^D3WUQI<$NI6BVEZ5_?0JX<*V>Q!/!Z_C7+:)J_
MBC7UOI[>YTBWBM[V6V5);61F(0\$D2#UJ>5N[;'=(Z76= TSQ!;1V^JV:7,4
M;[T5F(PV,9R"#WJ[:6D%C9PVEM&L4$*".-%Z*H& *K7M^NE:-/?WC!A;0&64
MH, [1DX!]>U<K#J7C*Y\/)KUO'IS"2,3QZ6(79VB/('F;OOE>?N]:$I-;Z V
MD=U65K/A_2_$-O'!JEH+F*-]Z*69<'&,\$4V_P!3E@\+76J) 8ITLGN!#,.5
M8(6VL/8\&J,6OW<GP[/B K#]K&FM=[0IV;Q&6QC.<9'K2BI;KO8;:*__  K+
MP=_T!(_^_P!)_P#%4?\ "LO!W_0%C_[_ $G_ ,56UH-_-J?AW3=0G"+-<VL<
MSA!@!F4$XSVYKBK'Q;XHN/!A\3N-'>V0.[V_ER1N51BIP^\C)QQQ6J=1W][\
M27R]CN],TRST?3X[#3X1#:Q9V1@DXR23R23U)K/L/".A:9JSZI9:>L5ZY8M*
M'<D[N3P3CFK]O?B[T:+4(T*":W$ZH_497< :S/"&LW?B#PC9ZI<B%+FX5R1&
MI" AV4<$D]AWK/WK-W]2M#H:S]5TBPURQ:SU&V6XMV(8HV1R.A!'(KE+O5O%
MUKXGT[16NM&9KV*242BTEPNP=,>9SFNIDFO;/0II[EX)+R&!W9HT*QE@"1@$
MDXZ=Z?*XV=Q7N5-'\(:#X>NGN=+T];>:1/+9@[ME<@XY)[@5#J?@?PYK6H27
MVH:8D]U)@/(9'&<  < @= *L>%-4N-<\,V&IW2QK/<1;V$8(4')'&2:P=%UG
MQ/K[:G);7.D6\-I?S6BK+:R,Q"$8)(D'8^E-<UV[ZKS#2VQ<_P"%8^#O^@+'
M_P!_9/\ XJGP_#GPE!-'/%H\:R1L'1A+)P0<@_>K7U"^FTG0+F_FC%Q/:VS2
MNL8*AV5<G'7 )'OBN9TO5O%6H:7I^LVTFEZA#<E#-90(8VB1NN)"Y!9>X(]:
M:E-J]_Q%:*Z'=4445D6<Q?> /"^IWLM[>:1'+<3-ND?S'&X^N V*U=)T33]#
ML/L6G6_DV^XMY>]F )Z_>)K2I*;E)JS8K(J6NF6-@NVRLK:V'I#$J?R%7***
M5[C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR_Q%K?A]=3O+/Q=HR)
M>I(?L<]LN7EB_@(<$%6]C@445O0BI2LR)['6>"(]4A\(6":Q*9+S8269][;2
M25RW<[<5YUI-SX4L9M5AU_1UNKQM1G</Y*O\A;@9)^M%%:4ES2D2]D>G:G:)
MXB\'W%K;GRUOK,B+=QMW+\N<?A7&6/CPZ9H<'AT64W_"36T:V:6QVF-I0,*2
M^[&W@$\^U%%132E=,J6ECM[FSO-0\+365VT0O;BS:*5H\A!(R$''?&37G<?B
MN"'P8W@U[6?^WOLC:=]G&W:7*E-V_.W'.:****4M&*70])T.QDTSP_IUA*P:
M2UM8X7*]"54 X_*O*M+\(QW7POM]3@A#:I:2O<[)9"T4H21B49"=N"H';K^-
M%%*$FDWYH;2/4[2]CU3P['>Q*42XMO,"GJN5Z?ATK%^&D;Q?#W2D<88+)GG_
M *:-114_9?J-;HBU>)F^*'AV0#Y5M+D$Y]172ZPI;1+]1U-O(!_WR:**3^S_
M %U!=3'^'Z-'X#T=&X*P8/YFO/-+N/"UA?:W%X@TA;J\;4[B17\E7_=DC R3
MZ@\>]%%;05Y2(>R/5/M<LWAL7FE0(SO;"6VBE.U3E<JIQT]*\MO=2TG5I+6+
MPUI[Z;XN,J;Q!B)$(/S[R#M=>?<G/UHHHI16K[#ET/9Z***Y30**** "BBB@
/ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>forms-1a_026.jpg
<TEXT>
begin 644 forms-1a_026.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "Q G\# 2(  A$! Q$!_\0
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M@$]SNN/]2"0 &XZY(H XVBN@TWP;JNJV$E[:>0T"/,A8R8R8TWMCCIMZ5S]
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MAGF_\ Q_\71_PS1:_P#0SS?^ 8_^+KWFB@#P;_AFBU_Z&>;_ , Q_P#%T?\
M#-%K_P!#/-_X!C_XNO>:* /!O^&:+7_H9YO_  #'_P 71_PS1:_]#/-_X!C_
M .+KWFB@#P;_ (9HM?\ H9YO_ ,?_%T?\,T6O_0SS?\ @&/_ (NO>:* /!O^
M&:+7_H9YO_ ,?_%T?\,T6O\ T,\W_@&/_BZ]YHH \&_X9HM?^AGF_P# ,?\
MQ='_  S1:_\ 0SS?^ 8_^+KWFB@#P;_AFBU_Z&>;_P  Q_\ %T?\,T6O_0SS
M?^ 8_P#BZ]YHH \&_P"&:+7_ *&>;_P#'_Q='_#-%K_T,\W_ (!C_P"+KWFB
M@#P;_AFBU_Z&>;_P#'_Q='_#-%K_ -#/-_X!C_XNO>:* /!O^&:+7_H9YO\
MP#'_ ,71_P ,T6O_ $,\W_@&/_BZ]YHH \&_X9HM?^AGF_\  ,?_ !='_#-%
MK_T,\W_@&/\ XNO>:* /!O\ AFBU_P"AGF_\ Q_\71_PS1:_]#/-_P" 8_\
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MF>F3[U1VK_='Y4>P7</K$ET.E_X4+X>_Z'VW_P"^(_\ XY1_PH7P]_T/MO\
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M*3</?\J-P]_RH 6BDW#W_*C</?\ *@!:*3</?\J-P]_RH 6BDW#W_*C</?\
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M%;;_ "AGY)3)GKWSB@#9DU_28FN5DU"W0VHS-N?&P9QS^)Q4">([$W#*[^7
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MV-R@X.1D=#2T >?0P:S8WNFZ;')+$FH2SF95;F%8YFDW+_OJRK^-07$?B?\
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MF\V$YV_/C/7.*WY9=SSW6I/_ )=G4C0-/P\TFG7$<'V0RR?O"3 ^2%4#'))
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M$JLC$,2V ,#.?IBHAI=VT2R(BLK2^2I5P<M_A[UM]6I?S'GO.,:MZ:^YG?\
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M0 9'J*,CU%&T>@HVCT% !D>HHR/44;1Z"C:/04 'RYSQFC(]11M'H*-H]!0
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MBB@ HHHH **** "BBB@!!U/UI:** "BBB@ HHHH **** "BBB@!J?<%.HHH
L**** "BBB@ HHHH *1ONT44 +1110 4444 %%%% !1110 4A^^/QHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img_001.jpg
<TEXT>
begin 644 img_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #_ /<# 2(  A$! Q$!_\0
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MIWV_B,G: <;.O?UKJK?PCH5I(TT-@@<J5&6)"@]0H[5=&AZ<$V"U3'V?[/\
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MH?UK=^%=G;V'Q UN"UC$4(M8SL!XS457?AK_ ,E(US_KTBH ]@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \]\7W-L=2A>58[R%(
MWC-K*[)M?^^,#FNF\,*R^';(-<"X^3_6!L@_0^U<?XUMHK?7EN8X6:62']X\
MUTT<87<!P%KK?"S1/X=L6AB2)-G"(20/7!/6@#?HH[5S4GBVP2:^A42R/9NB
M. F-SMT"^M '2T5RI\9V"XS#<<9\]0HS!@X^:I[;Q9I\]X(?GB1MWE3R8$<N
MTX.#0!@^!?\ D>O&O_7W'_Z#7#77_)2_%G_76/\ ]!KMO 3I+XU\9R1NKHUU
M'AE.0?EKB;K_ )*7XL_ZZQ_^@T 7:*** "KOPU_Y*1KG_7I%5*KOPU_Y*1KG
M_7I%0![!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!YOXNDU'_A(E,<$T4"VYC\QO+:.7/;:QKK_#QG;0[,W*QK-Y?S"/&T?3'%<O
MXR$<6O64Y:WDE:,QB&> R@ G[W'2NJT.:.XT6UEB,3*4QF)-B_@O:@#7[5R>
MH^&I[N\OKN":-))7A>(,. T9)Y^N:ZP=** .#;P9?%IW%U#OU ,+[Y3C!.?D
MI/\ A H+WR++51'<:7:%_L\0R&.XY^8^U=[1B@#S/X9Z9:Z3XG\76-G'Y5O%
M=(J)DG''O7(W7_)2_%G_ %UC_P#0:[GP+_R/7C7_ *^X_P#T&N'NO^2E^*_^
MNL?_ *#0!<HHHH *N_#7_DI&N?\ 7I%5*KOPU_Y*1KG_ %Z14 >P4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <#XUM[2ZU:VBO)F
ML5$#.EXLA7<PZ)70^%B#X;L=MN8!L'R$G\\^_6N=\:220ZE:-<RS?V>48;89
MEC/F=OO'FNKTG']E6VT2@>6,>8X9OQ(ZT :E% Z44 %%%% 'GW@7_D>O&O\
MU]Q_^@UP]U_R4OQ7_P!=8O\ T&NX\"_\CUXU_P"ON/\ ]!KA[K_DI?BO_KK'
M_P"@T 7**** "KOPU_Y*1KG_ %Z152J[\-?^2D:Y_P!>D5 'L%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '!^*$N)/$$'V&.VENA
M9R%X[M<QA?4?[5;7A 1_\(S9>6[,I3JW4'/(^E9OB^_T:&:W@U'39[^?&Y1
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MF)64$D]Z /?^U>5?$O7]>L?$FDZ5H^IFP6ZB=W<1AN16G_PG?B7_ *$+4?\
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M!3TH ^BE(VCZ45PMEXQU^XNDAF\&WT"8/[QI%]** .W,,;')C0GU*BG  #
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M,?EQAQM<1?W']2/6@"MX/TZWNK*+5IH%^TN#&VY>?E/&[U(Z9KLU0*,!0._
MQ5>VMH;2!(((UCB085%Z"K5 "4M%0W%Q':PO+*V$49H D)&*X;Q#XF26=;&P
MO)K8%RLMS%%N(P/X.QYQFKCZNGB&TDTS%SITMY$6MIFQ^\7U4C^5&@>&?L:*
M;FW2,!MWV=>460?\M$],]Q0!F>#K==1FFGO+=?/MY3L('KU_!NNWM7H 4#H
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LP .U24 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>form1-a_026.jpg
<TEXT>
begin 644 form1-a_026.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $A -8# 2(  A$! Q$!_\0
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M $"DI?#_ /R57PO_ +MQ_P"@4 >_4444 %%%% !1110 4444 %%%% !1110
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M_7N:8'D]A_R#K7_KDO\ *K%5[#_D'6W_ %R7^56* "BBB@ I?#__ "57PO\
M[MQ_Z!24OA__ )*KX7_W;C_T"@#WZBBB@ HHHH **** "BBB@ HHHH ****
M$J&41B)S*%\L*2V[ICWJ;M6=KD5M-H5]'>2F*V:!Q+(.JKCDT@,K3M:\)K>+
M%I][IJW,AV!82 S'TKI:\JTVQM+K5;"2)[ORV>)V8:84WN@P&5_X01C->J#K
M^-,0V10Z%3T(QQ7G2V\&F6]P0OE64&K,TFX$@ KU/XUZ533&C*59%(/4$=:0
MSRV)62#R'#"YNTMC9J5Y8"0D[?3 P35S2Q?22M!IDB)J4$$RN9%X1R_R[J]%
M\M,J2BY7[IQT^E 1%)944%NI ZTPZ'D/@^'Q/!\6W7Q5<6T]X=))C:W& $W_
M ..:[+XF?\DXUO\ Z]S5 _\ )<1_V!/_ &I6A\3?^2<ZW_U[F@#R:P_Y!UK_
M -<E_E5BJ]A_R#K7_KDO\JL4 %%%% !2^'_^2J^%_P#=N/\ T"DI?#__ "57
MPO\ [MQ_Z!0![]1110 4444 %%%% !1110 4444 %%%% !VK-UR*6;0K^*!
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MS6UQJ*6]]+=:<L@,!9<*<C)Q0@.XHHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "F;03G%/HH ;L7TI0,4M%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
F%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>forms1-a_005.jpg
<TEXT>
begin 644 forms1-a_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $. < # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ K#
M\1ZQ-H>EO?16T$R1MF4SW/DJJ_7:Q+$X55 Y)'(K<K,U33&U&!8TU"\LV!.7
MMRF6!&"I#JRD'Z9'8BEZ#1B3>+Y8]8U&T%@GE6JA8Y)))$,TQ52(P3%Y?5\'
M$A88)VXJ1_$5^+0)'I4#:E'+*DUL;PB-1& S,LFS+9#)C*CEN<8S5A_"]LQ=
M6O+TVXBV00%U*VQVA=T;%=V<#^)B!Z42>%XWT];==3U!;CS'DDO4:,32EQA@
MWR;0",#Y5&-HQC%#O;02\R5/%GA][F&U;6M/BO)A'LM)+J-9B7 *#83G)##
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M.1+0%E.[9-Y3,?O8R"HQQ^!H;L8UJB@DWU9ZC10.E%!N%%%% !1110 4444
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MG:%?WL0#2V]O)*H;H2JDC..W%<?\,_$=YK<6IP7,<*B&3SE,8(),KR.V<D\
M]/;UI7Z%RJ*-11ZL]#HHHIFX4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?_2>&MFA(QI0C&/*EH<_H>J2R/-I.IR'^UK3.\F,)]HBW$),@!(((QG'1LC
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M\J7(]:\SUOX9Z;I.AW]UX6EUC2[R*WDD6+3KR7_275245@2Q.#D #!^8UA^
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MK0VL-%1-&1+AM25KR;,AVJ(57+EL[BQXP,*<GH"#/7:*\_\ ^%)?#W_H7_\
MR<N/_CE'_"DOA[_T+_\ Y.7'_P <H ] HKR+2O@EX<_X277Y-1T9#I!>!=+B
M%W-N4",>:QP^<%S@;B3\IX QG<_X4E\/?^A>_P#)VX_^.4 >@T5Y]_PI+X>_
M]"]_Y.W'_P <K#\)?!+P[%X;MH_$^BQS:NCRK/+'>3!7 D;8PVN!@IM/0'U
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MEAADO[:\4GR[@<A[9P,-$P/W?X>.AR*[G%9,LUCX8T#?(TJV5E$%!)>9]HX
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ME'>$&Z6!!,<YRX4;OUS5ZBCI8.MPHHHH **** "BBB@ HHHH **** "BBB@
6HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>forms1-a_006.jpg
<TEXT>
begin 644 forms1-a_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %F D # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M ?13/-C_ .>B_G1YL?\ ST7\Z 'T4SS8_P#GHOYT>;'_ ,]%_.@!]%,\V/\
MYZ+^= E0G 8'Z'- #Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI6EZUC<:2MO');P&0,X<DCCZBKLGQ<\(RW,5Q)I^KO-#GRI#IS$ID8.T]LT
M6O$G@>3Q/XST6[U:UM[O3+>QEAN03M_>MT*KU]<5@I\/O$-MX<&E0_9%ET74
M1>:+<%@!,G]R0#H<'&XUM?\ "Z/# X^R:U_X -2_\+H\,?\ /IK7_@O:@"O;
M:!XO\1^)(M>UR&TT::PM)H-/BMY!,?-D&#(QZ8]JR-'\$>)I_%VCZEJ.BZ7I
M<FGRE[K4;*4![[C'*+C&>^:W_P#A=/AC_GSUK_P :C_A=/AC_GSUK_P :@#T
M6EKSC_A=7AC_ )]=:_\  !J7_A=/AC_GTUK_ , &H ]&H-><_P#"ZO#'_/IK
M7_@ U'_"ZO#'_/IK7_@ U &_XZU#4=*\+W=]86@O%BC;[1;YPQC((+*?49S]
M :YSX5W>I:I\-K=);-;:TCM/LUIN/S38!!D/H"> /:G/\9_"TB%&L]9*L,$'
M3VP14=O\8/"-G EO;Z?J\4,8VHB:<P51Z 4 9NG_  \UJ+2/!=G/'#$VF"Z6
M]=)!E1(& (_O=15/PW\-M<M]MKJ5I%$EC8W%K;7C7S2^89 5!6/HBX/(-='_
M ,+I\,?\^>M?^ #4O_"Z?#'_ #YZU_X -0!S6G^"?&$\6G17^GV=O%IVC76F
MQ[+H,9'=2%8\< \?2M>X\&Z[I^@^#KK3K6UN=3T",B6QDD"I+N7!PW3</6KO
M_"Z?#'_/IK7_ (+VH_X73X8_Y\]:_P#!>U &'%X%\2Z<+/Q#!:6EQK":K-J$
MNF"8+"JRJ%*JQXR  <_6J;_#SQ2+.WO_ +- VHV^K3WOV.UO/)#QRJ!\DG\)
M'O74?\+I\,?\^FM?^"]J7_A=/AC_ )\]:_\ !>U '&W>GS^ KSPW?R-IEKJ'
ME72RVUY.Y@ D()(E(/S#C([YXJEX?\(:YJ'A30-;TVU:YDC%Y"]LERUJ6225
MBKHW7;SR.XKN9_B_X0NDV7&FZK,@.=LFFEA^M2+\9O"R*%6RUD < #3V % %
M+2? &J:=JNFR"WMEMK?0)K%E64L$F=BV!NY(YZUA7?PU\2VZVKP6<=X;C28]
M/NHAJ!@6%E/4D??0CM76?\+I\,?\^>M?^ #4?\+I\,?\^>M?^ #4 )I7@W5-
M,UG7KJV%O$)]*M[2QE)W[72/:>#SC..M<MIGP_\ %DT][/J-G'%)/H<^GM)+
M?^<7F;HV.B*?0<"NJ_X73X8_Y\]:_P# !J3_ (71X7_Y\]:_\%[4 8B^ ?$6
ML6<$.H6\&GD>'FTEBDP?#AAL;CL<9/UI)O!GBS78+J74=.L=/FMM$DTNTBMY
MPPN&88W,?X5] :W/^%T^&/\ GTUK_P %[4?\+I\,?\^FM?\ @O:@"31/">I:
M=XP\/Z@\,*VMCH7V"8JXR)=P. ._3K3/'7_)2/ '_7Y-_P"BZ3_A=/AC_GTU
MK_P7M6'=>*;7QQ\1O"#:-9ZCLL)Y9;AI[4QA%*8SDT >Q]J*!THH **** "B
MBB@ HHHH 0@9%>4^(KB32_B1?W=EY<-S*NFPM*(U+;7F96_,<5ZL>E>1^,^/
MB!<CU.E'_P F&H ];4<=*=@>E%% "$>E<\GA#2;?7FUFTB:VN)%9;B.%ML5R
M"/\ EHG0D>M=%2'H: .,^%L,,7@&S$,21@S3[MB@9/G..?PKM,"N.^& QX%M
MAZ7%S_Z/>NQH *0@$4M% %"_T73-5>!]0T^VNF@;?$9H@Y0^HSTJ\%4= /2E
MHH *,444 (0/2H8;.VMFD:"WBB:5MTAC0*7/J<=:GHH 3 I:** "BBB@ HHH
MH **** "BBB@ HHHH 2EI*6@ IK,HZL!]32]JX;XH)YOA_3X"SJD^I01OL8J
M2I.",BKIQYY*(GHCM_,3^^OYT>8G]Y?SKBA\*_#.3\E]]?MDG^-'_"JO#/\
M<OO_  ,D_P :TY:7\S^X5V=MYB?WE_.D\Q/[R_G7%?\ "JO#7]R^_P# R3_&
MC_A57AK^Y??^!DG^-'+2_F?W!=G:ET_O+^8HWIZK^8KBO^%5>&O[E]_X&2?X
MT?\ "JO#7]R^_P# R3_&CEI?S/[@NSM=R>J_F*-Z?WE_,5Q7_"JO#7]R^_\
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M_P :.6E_,_N"[.UWIZK^8HWIZK^8KB?^%5^&?[MZ?^WR3_&C_A5?AG^[??\
M@9)_C2Y:7\S^X+L[;>G]Y?S%&]/[R_G7%?\ "J_#/]R^_P# R3_&D_X57X9_
MNWO_ (&2?XT^6E_,_N#4[;>G]Y?S%&Y/5?S%<5_PJKPS_<OO_ R3_&C_ (55
MX:_N7W_@9)_C1RTOYG]W_!"[.UW)ZK^8HWI_>7\Q7%?\*J\-?W+[_P #)/\
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M(OZZ,F6QVR]_K3J:O?ZTZL!K8****!A1110 4F*6B@!,48I:*5@$Q1BEHHL
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M-(O9MO4 ^]>"?"3X2-J4Z:_XBMF6SA?_ $>TD&#,P/WF_P!D'\Z^C4 5<
M< "@!]%%% !1BBD/2@!:*HG5[%;IK5KRW6X09:)I0& ^E7%<,N5^8'H1S0!Y
MY8_\E]U7_L"P_P#H9KT6O.K''_"_=4]]%B_]#KT6@ HHHH *Y3XA^&[KQ7X4
METFS>)97FB<F7[NU7#$'\!75TA&: .-\1^ =/U3PO/I.EP6VES.\<\<L,( $
MJ'*E@.HK)C\->+];US2]1\2S:8D6CEI;>WM"Q^T3[<!W)^Z/:O2"H(YHVB@#
MQ7PQX:U/4;J+QII6L1W7B#^T98]1WEE@DBSM,(!_N@#!K:_X1'QCH?\ :VF>
M'+K3#I&IS23(]UN\RT,GWP /O=\5:^#0SX2U#_L+7/\ Z%7HQ4&@#RS4O ?B
M&U\-VGAO1I]-NM*^Q?9G6^CPT,I)+3H0.2<GCM7HFCV3:9H]E8-,T[6\*Q&5
MNKX&,U?VBC:* %HHHH *#10: /.]2_Y+SHO_ &!Y_P#T(5Z)7G>I?\EYT7_L
M#S_^A"O1* "BBB@ HHHH 3TKB/B;_P @?2?^PM;_ /H5=OV%<1\3?^0/I/\
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M?U/N: ,C1X!:_'.^@#NXCT*! [G+-AL9)]:]+KSJQ_Y+[JO_ &!8?_0S7HM
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MF#.Q(8,P*D$<'OBM.W\):YX:DTF\L_#R:LBZ5)8O92W"L;=V<MG+<,IS@XH
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MM9<FJN"V)**9YJXR,8]<TGG+C_&L1DE%4&U6W358=.82"XFC:5?D.W X.6Z
M^U7 X)X(/TH ?1110 4444 %%%5[V[CLK.>ZFR(H8S(Y'7 &30!8HJII]]#J
M>G6]];DF&XC$D9(P2I&14']N6'VW[)YX\TR&(<<%P,E<],X[4[,+FE0>E,\P
M=_3/6D\P$'M]32 Q?$VH6L6CWUG+*L<\]G*8E?C?A3D#W]JI>!=2M)/#.D6$
M<H:ZCL8WDC7DH,8&?3-3^+O#EOXIT">PD(68#?!+WCD'0Y]#T/UK+\(:/;>
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MD;IDL>3Q6GY:^@].E5/%*_NQ_JP*)XG?0W]EIDUB/M TBWUV5)5E\PJL.W*
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M0;(VEC&X1G+NTC%V=CU+$\DU3Q5[MK7^O^&#E/*-57;N75O[1!72K<:,+?S
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M /W^'^%=S@48%'UBIW_K[@Y4<-_PKVY_Z&_7_P#O\/\ "C_A7MS_ -#?K_\
MW^'^%=S@48%'UBKW_+_(.5'#?\*^N/\ H<-?_P"_P_PH_P"%?7'_ $.&O_\
M?X?X5W.!1@4?6*G?^ON#E1PW_"O;G_H<-?\ ^_P_PH_X5[<?]#AK_P#W^'^%
M=S@4F!1]8J=_R_R#E1P__"O;G_H<-?\ ^_P_PH_X5[<_]#?K_P#W^'^%=Q@4
M&CZQ4[_E_D'*CA_^%?7/_0WZ_P#]_A_A1_PKVY_Z'#7_ /O\/\*[CBD/2CZQ
M4[_E_D'*CB/^%>W/_0X:_P#]_A_A2'X?7 Z^,-?_ ._P_P *Z+6O$.E^'[4W
M&IWT5NG96;YF]@.IKS*^^)'B/Q;</I_@O3)(XB=K7LR\@>O/"_J:AXJ:TO\
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M&.ZC 5,]-W\J[:%-RIU'?9?J1)ZH]JZTM-7I2UQ)EBT4F:*8"T4E+0 4444
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MOG'[K@+UY&>:U]G0:W)N[G2GQ_HK:=>7EO++*+: S[3"R>8O8KD<@GO4=O\
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M/R$_WE]?2ES*]A_5Y<KE'5(]1HI <TM48!11FB@ HHHH **** "BC-)N'K0
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M?0U<I>H!1110 4444 %)2TE '$:#_P E1\5?]<+;_P!!-=N*XC0?^2H^*O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
F444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>forms-1a_007.jpg
<TEXT>
begin 644 forms-1a_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $6 D # 2(  A$! Q$!_\0
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MPU!&TDDUXD:C+,UE* !_WS1[2'<3IS6Z.QHID<BRQK(O*L 0?4&GU9 4444
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M7N2]#UVR_P"/*#_KFO\ *IZ@LO\ CQM_^N2_RJ>ON#XX**** "BBB@ HHHH
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M0^)'/#H/H/Y44@Z#Z#^5+7P<MV?9QV0=J1NA^AI>U(WW?P-5'=!+9G8>"_\
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MC\*/BY;L****H0AZ5PWQ(NGMM,LPPB^SR7 #EVV_-U49!!Q[BNY;@5POQ&G
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M?^!B_P"%']I:Y_T D_\  Q?\* N;>:,UA_VEKG_0"3_P,7_"C^TM<_Z 2?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!%<*7M954$DH0,?2N=TB^CM]$L;6ZL+OS8HE5E^S%@&%=/VI,>
M] F8ES?6%W!-#/I]XZ31F-_]&8$J1@C/6H)7TJ86OF:9>,+5MT(^S-@'&,X[
M\>M=%10,R#JMJP(:QO"#P0;4X(I1J]L  +*\P.WV4UK44 8YU2T.,V-X2IR"
M;4\'V]*=_:UL5VFRO"#P0;5L&M:B@#)35[=!A;.]'TM6%/&MP@8^R7W_ (#-
M6I10!F?VY#_SZ7W_ (#-1_;D/_/I??\ @,U:=% &9_;D/_/I??\ @,U']N0_
M\^E]_P" S5IT4 9G]N0_\^E]_P" S4?VY#_SZ7W_ (#-6G10!F?VY#_SZ7W_
M (#-1_;D/_/I??\ @,U:=% &9_;D/_/I??\ @,U']N0_\^E]_P" S5IT4 9G
M]N0_\^E]_P" S4?VY#_SZ7W_ (#-6G10!F?VY#_SZ7W_ (#-1_;D/_/I??\
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M1L8))CB-9 JEC[5E7/B/0;+2I[^Y@@C6*22(1,JAY&1MIVCOS0&IO?VII_\
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M-PS@NHE\P2_*V ['DJ<@&KEMX9UK1YEGLKFRN'@BDM[;=!M;;)*K%Y6!^8@
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MJ$UO;+&Q V1H&);@\G.!CKF@#I;:*_N=,N[:^6*(OOBA"G/[O&U2WOWK MO
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M5TMG@&\&'R\*,DXWAN>F<]Z;;P>(6;3@;:\&(I(GC9CL YQ,26SO/'R'(YH
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M=H)'4A1SZD"M#39,7:JQQNKSH7<O).IRA<X!YY]>U/AU&8M^[U:7>O/!/^%
MCN]12_GU!F:VU!M.1G1HX#M=G\L;6'/W<YY]<5GS:9K9MYN9C<R"T7=YIVD\
M^;T/3IG%8<>M3B/>VMS;5/().15YM5F$<9?4R"W)W$B@">&SU? 66/4/MB^2
ML,Q?]VJ@$2;O7)SUYZ5MZ(]S+H]L+N"YAN$0)*+A,,6'4^X]ZYS^TRK#.HL4
MXRPR"#]*:-1$D_E#4W+$D @GF@:.T*''UJ$H=V>>*Y$7J%W']J2?*#D'.:C>
M]_<B3^T) #]T\X(H&SK6 ()S6CXUGDMO T[PDABB D)O(!QG /M7&:-=)<76
MTW32#:<ALBO2[[3!JWAZ2P\TQB> )OQNQT[=ZN)$CG8[F:*/PO:6E_#;@Q(S
MQ-<@M(O' SRW?]?:M/4?"%OJ-[?737EPGVZ...5!@C"'(QD<'/-8_B"!++5?
M"EIN622"94;;&,D< ''89R?PKN@W;%608^@VZVSZI&C.R_;F.7<L<E$/4UYM
MXM&?'>KC/\,'_H KT_2?^/G5?^OT_P#HM*\P\6-CQWK ]H/_ $6*B>QTX;^(
MC,+<C%>@_#'_ )%V\_["$O\ ):\\R .!U%>A_#'/_".7A(Q_I\O\EJ*9TXSX
M4=H3BHXKJ":66*.5'DB($B*P)3/(R.U/)SCZU!#:6\%Q-/%!&DTY!D=5 9\<
M#)[UL>:6:*0'-+0 5P?Q G4:AHMHS.$EGW/T 8 C +$_+SZ<UWE8^O:&VLK:
M;+KR#;SB7_5AP^.Q!H H6US--XWN8DU&)K:* !K03*65L#G:.1^//X4__A$+
M0*O^DW 59Y+@;6PP9P0<,.>]9UN\,OQ3NQ&4W)9A7VH.#QU/XUV1/R$<]* ,
MWP[&(_#M@BD[5B4#)R>*\7T]?W,A;@">7_T,U[7H'_( LO\ KD*\1LR6MW'8
M3R_^AFHGL=F$^,FN6$D$H&=NT_CQUKV+PM_R*6C?]>4/_H KQ^7Y+>48PVQO
MPXKV#PM_R*.C>OV*'_T 5-,K&;HTYX(;J!H9XDEB;[R.N0?J*;;6UO:(R6\$
M<*LQ9@BA06/4\=ZY6]\9Z!=!HA=Z@ICD*EK>"0<C((SMP15'1?&&E6EE'+>W
M>JR7 0^8);>1@.3_ +/I3=6"=FT<OLY[V._HJO8WD%_8P7EL^^"=%DC;&,J1
MD&K%:&84444 8-H@E\2:Y&V"&BA!!Z8*FN6MO 5PNDPV<MI8HUK:7$$)1CCS
M6;*2#CCM]"*ZJS;;XEUQO[L</_H)K+L_&\4K6L<EE<,LGE"6Y50$0RDA.,YZ
MC'XT"1%HOA6^L/%L^I7<SRJSR2),L_#!P $9-N3C''..,U-XP\.7FMW%M);6
MEI<*MM-!_I$K)Y3/LVNN <XVGTH\0>*;_3;W4;2WT\LMK;PSK<;@VXO(%V;?
M7KBB[^(-A91QBXL[E+CS)4D@X+((R QXZ_>& .M RG-X/OH;*Z$4-G=W-U=A
MKAY_O31! J\D$*P(ST]:9;^"KV22P34A;W%O"L/G(TC,&*0LA^OS$&NDO/$4
M-IJ.G6?V>1_MJEUE)"(J\=SU;G[O6L27QR;NT5[&RFA:0Q20O< ;98C*(V/!
MX()[^QH U_#<6H6EFFG7L 46<,<:SB3=YS;?FP/0<#\ZQ]7\-:M?^)WO(EM5
MMPK!)@^UR#$R;6^7)^8@]<<=*<OQ)TEH+B40S@(R+"",>=N8J.>B\C//;FK$
M7CRSF,)CL;MHF6)I9=H AWN8QG/)^;T['- &3'X(O[181'!:3P(+5IK9Y659
MG1&5V)P><D$<<XKHO"^AW.B^#K;2)Y(Q<1Q.A>(DJI))&/IFN@ZYHQQ0!YBO
M@35_LLP$-I;/Y%O$P@G.;DQNQ9F)7C=N!P<].:TK?PC>VDD>VUAG3[ ;>)I[
M@L]F_P Y)4[<$'</3&T"N\Q1B@#S^?P+.MSI @0"UMK>..1(;@QE)%?<9 =I
M))X]#Q4,O@_6IKC49[B*UD\^,*L<,WEAY%E+*Y&W& ".#G->C8I,&@#SQ/!6
MKR:U+>W=PKRRPC9-!+L6%_)V;0NW)3=DXR.O3BM;PAX<N]&O]0NI[6UM$N8;
M>-8;>0O\T:D,Q) ZYKKL&C% '&:CX1N=1UZ2YG\F6R>Y\TQ2,3E?(\O&/][F
MJUIX,OX+=&86OVSR[%7FR26,.=^3C)[8^E=Y1B@#SNS\%ZK+<S'4H[(P2SVT
MDD,;?))Y;,7;:  ,@KQ[<FBQ\ W=M916\OV9@R(ESAV_>;;GS!GU^3Y?TZ5Z
M)BC% 'GZ^";ZSEN)K".RC>1;I<,2597D#1J01T S[ U'!X*U&*WA9K>S:?;>
M(I,G, F(9"IV]L$$ #KQ7HF*,&@#@AX2U,:DDI6VW+*LWVWS6\S:(=GD@8^[
MGG.?PS6MX8\.2Z#<286-(9+2W1TC8D&9 0[8/KD<]ZZ?%)CF@"GI'_(*M_\
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M3NS18"<AO6KUM9QVMK!!(1,85 $CCYB1W^M=F/ .EB3S-S>9G._8N<^M2_\
M"&6G_/U-^0HY6%T<!]C6"]NKPR$K(H'ED?*H ZUD:A<:/?VT:QZG';A/GWQ#
MJ.G\Z]6/@NT((^U3<^PJ$> =+"A<G: 1CRUZ'\*.5A='#KK&BQ[K>6Z@25TV
M^^,=:L6&IZ!;6K6_]H13IN!W2>N ,#\1G\:[ > -)W;B-Q]XU/\ 2IO^$(TK
M&!&@^D2_X4<K#F1PC7VD-K:WBZDFX*6,.?E/!&:EN+S1M65-.M[^**=I RB,
M?,3Z5V1\!:5NSC_R&O\ A3XO!&F02B6,!9!R&$:Y'XXHY6',C&AM8X((D(#M
M'&$WLOS,.A/XUE6FD1V33[IGGCEQ^[D PN,]*[O_ (1V'&//D_(4QO#%NW_+
MQ+^0HY6#DC@[C35EO(;I)6B:/^%1PU>IVG_'G!_US7^58I\*6Q_Y>)OR%;L4
M8BB2,'(50H)]JI*Q+=SE/$Z_\5+X>VMY;M<$EO[P&/E/'O5G4KGQ.EUJ L+.
MVD@"1_8V=ADMGYPV3TQ4/BB&637O#SQQRD1W19G5"548'4CI^/'Y5U6T=:HD
MQ[6WU2UENW"6;"XG\T R,-ORJ,?=_P!FN7U;P3J^IZ]>:FMQ91BY"#RR7.W:
MN.N*[\J,5AZOHEYJ%TMQ::O<6+"+9B, C=GAL'V+#\1Z46'&3B[HXZ/X?ZT6
M8/<V*@' R6.1Z]*Z7PSH>K>'M.GM2UC.9;AY]V]UQNQQ]WVJ,>%-26U2W3Q+
M>852&8J"22<@]>WITK?TNUN;'3H;>[O'O)D!#3N "_/H*7*EL7.K*>YS>L:'
MXLU2ZN/*UR*SL9%4+;Q#)7 Y.XIGDUCVO@?Q1;7+31^(YD9'RI9]P/'H5Q^%
M7O$"P6WB1[A]=O(&8*YMX4+",8V[NO![?CT[UDM?R27D]G/XBU-%\L&.-H?W
MR/DD'K@@ 'KUI<I*D=GHMMXDLK-XM1O+/4)C(S+,28R$[*0%QQZUMVYN&C)N
M%C5\](V)&/Q K#\)K>/8W%S<ZH=0BGE+0,0050<8P?>NAJB0HHHH XVUBB_X
M6C?O&=C)9+YBA5P^<<Y SQ]>]7XY_$9DC62VM@GGR!^<#R\?)T/Z_I4,<$P^
M(5W.OFK&UFJL##A'.>/GZ$C\ZZ<* * ,?3X-7L;""V,=B_E+MW"1QG_QVN(@
M^'6LV\;!;RQ8EV<$;\\DGT]Z]0Q7,W/AJ^FOYYX==NX()G),"@$ $<@'J/F)
M-)JY<)N#NCD8O &N75EF2:QMWD4AHR6)7MR0.:[C2[75M,TBRL2EB_V:!(B_
MFN-VU0,XV^U47\,ZPR$+XFN5;=N#B(9!Z=.G2NF162-%9B[  %CU/O0E;8)U
M)3^(X6T\(:S:6[1>?9/^\=_O./O,3CI[TY/#.M3VQ+O9Q.Z$%6=R5)XYXK,<
MQ6=U>HGBK4E>(LCO%"6"D$MMYZX&<?C38;^X-[,L_BF[:>UD(4?9R%52I7$G
MU/ITQ7(\%1<N9K4W6,K)63T.ST:SU?2M%LM/VV$AM8$B+^8XW;1C.-O'2MR(
MN8QY@4/W"G(JGH\5U#I<$5]<"XNE7]Y,O1CZBK]=BT.4**** .<M[JVA\4ZR
MEQ/#'NC@P'D"DC:?6B+3/#4$7EQS6P7=$Q'VD=8SE._8UL7&F6-U+YEQ9P2O
MTW/&&/YFH_[#TK_H&VG_ 'Y7_"@1G7MEX>O[QKJXNH3*\8C?;=;0RAMRY .#
M@BHI]*\-SS^>+N.*?S7E\V&\V,2Q!89!Z$@<=.*UO[$TK_H&V?\ WX7_  I?
M[$TK_H&V?_?A?\* *%_!H>I2V[W-[$WV=@Z)]J 0L#D%ES@X/(S65I'ASP[I
MVGK!-J$=U+QF22Y]'W@*-V%&[G ]*Z/^Q-*_Z!MG_P!^5_PH&B:4/^8;:?\
M?E?\* ,8Z+X9^RRVWVM/)=UD1?MA_<L#D&/YODQ[5.-/\.X;?=PR,T<<;.]W
MN9A&V]<G/.#6E_8FE?\ 0-L_^_*_X4?V)I/_ $#;/_ORO^% QMM=Z9:QLD>H
M0D%F?Y[@,<DDGJ?4U-_:FG_\_P!;?]_E_P :C_L32O\ H&V?_?E?\*/[$TK_
M *!MG_WY7_"@1)_:FG_\_P!;?]_E_P :/[4T_P#Y_K;_ +_+_C4?]B:5_P!
MVS_[\K_A2_V)I7_0-L_^_"_X4 /_ +4T_P#Y_K;_ +_+_C1_:FG_ //]:_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %&!110 4F!11
:0 M%%% !@"BBB@ Q1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>forms-1a_008.jpg
<TEXT>
begin 644 forms-1a_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #T F\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ J"
MIZ@H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#'N_%?AZPNWM+O6;*&Y0X
M:*24!@?0BM=&61%=3E6&0?45YMHNEZG?^+_%<ME<:7';)JZB1+NP\]V_<QYP
MV\8&/8U4BUV[;48;I=<F.MMKWV$Z() 4%OYFUE,6,@"/]YYG;'7% 'JM0FZA
M6[6U,BB=T,BQYY*@@$X],D?G7C]MXJU1=/TW4].UN;4]=NXKE[W2F<.MN51C
M_JNL>Q@H[9].:U?"-S9W/C_39+?Q-)K4C^'YI9M\H?RG::'.,?<S@_+VV^]
M'J-9LVO:3!)-%-J%NDD$J0RJSC*R/]U#[GTKS3Q)XDUJ+Q?JT,6J16365Q;Q
MV4$M\(ED5MI),.QFFW$E>.F.*IC28SJ\<K7EVTA\;R*5\_*[A;LPX[D8 SUP
M3ZT >T9I'=(UW2.J+TRQP*\5TKQ9XF?%_'?Q3:@\%Y)/IS7OG,&16(46ZH#$
M58*.3SGN:-;N;*]\+S);^-+W5%^SV5W=1F3<L3F=?WAE'$>?FS'QC;NQQ0![
M913(MODILD\Q=HP^<[AZY[_6GT %%%% "K]X?6IJA7[P^M34 %%%% !1110
M5!4]04 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\>X454T_4;75+&*\LY5E@D&585;KB:MHST$TU=!1110,**** "BBB@ HHHH
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M]A)[^XKDJX5QUCJCLHXQ2TGHSU&BD!!Z?6EKC.\**** "BBB@ HHHH ****
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MKT2O!OA[=/:^-;';]V7="?Q'^.*]Y'2O*Q,%&IH>UA)N5/4****YCJ"BBB@
MHHHH **** "@U&9X5G6$RH)6&50GDCV%4/$&H?V9X?OKT$ Q0L5SZXXII7=A
M-V5SR?XC>)I-6U=M-MY3]AM'PP'220=3[@5Q/UHRS?,^2[<DGO1P"2>@%>Y3
M@H1LCYVK-U)W9H1Z)?2V"WH6!('1G4R7"(6 R#A203T/3TI1H6I?V9_:!MP+
M?9YG,BB39G&_9G.WWK<L+62]TBWAU73;3^RXK.5DU)7/F0X!=1N#8SOP-N,G
M-65BD_M5-=8*=-.E*&D!&TGRMIC_ -[=GBLO:R3L:^RBU<YJ;0]1M[#[;+ J
MPA%D8"12Z(WW69 <@'CD^HK.Q@]?RKM+J":#5-<UF0@Z?<V#K%+D;93(JA%7
MW&.?3;GM7%@<"M*<W+<RJ04?A.O^'_B:30]:2SF?_B7W;!'!. DAZ,/Z^M>Y
M5\O$9[X(Z>WI7T1X5U(ZKX8T^[<Y=X@'.<_,.#_*N'%TTGS(]/!U7)<K-FBB
MBN$] **** "BBB@ HHHH **:[K&C.Q 51DD]A2131S1B2)U=&Z,IR#0!F^(]
M:CT#0[G4),$QC$:G^)SP!7SU=W5Q?WL]W=2,\\S;G<]2?_K=![5Z-\7-1<S:
M=IJOA1F9QUYZ#^M>9UZF$II1YV>-C*CE/E6R$K5TS0GU41B#4+!)Y,A8)92)
M,CKP 1CCKFLJMC3)4T_1=0U 2J+N8"SMD!P5##+O@= %X'UKJJ-I:;G)!7D)
M:^'+R[M4ECEMEDE#M;P/)B2X5>I08Y'!QGK26WA^[N[&*YCEM@T\;2P0/)B6
M9%)!91CIP<9ZUN:<D,UUX?UG[5!'::;$HNMT@#(8R3@*>6W9XQGD]J2S*7%U
MHNN^?!';6=HL=TAD :.1-V5V]\[@1UZUASSV->2%KG'#D9&>G?BCZ]*5FWLS
M8QDYQZ?Y%%=/34P>^A['\,_$LFJ:<^EWC[KJS4%&)R7C[9]QP*[VOGWP3J#:
M9XRTV4'"2R^1)[J_ _(X/X5] @YKQ\334)Z'MX2HYT]>@M%%%<YUA1110 44
M44 %%%% !7/^,]=/A_PU<749 N'_ ',&?[[9P?P&3^%;DEQ#"\:22HC2'"!F
MQN/M7EWQ>NS]ITNS_A"O,P]R0!_*M*4>::1A7FX4VT>:$LS,S,2Q))8]3]:M
MZ7:+?ZO96;L56XG2)F'4 D#-4ZFM3;K>0FZ$WV?=B3R&VR!>Y4]C7M25HV1X
M47>6IT$WA^W&L)9-::C9(@DEEDN@#NC3.2F!SG'ZBFV^B:?J"6E]:3W,6G,)
MS<B7#21>4H<X(X.X,/I3K?7=/TZ&ULX#>7=H'E,\DJB-@LB[=J*,X(X/7DCM
M26VM:9IL=II]LMU<:>!<"[E=!&\GG*$^102!M"@^]<WOG1[AFZC8VL>GV>H6
M!F%M<,\9CF(+1NO49'!!!S6;T.>]:>I7EF=/L]-L&ED@MV:5YID"&1V]%&<
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M-GG?F_$__GC9_G%1YOQ/_P">-G^<5>B45Q'H'G?F_$__ )XV?7UBH\WXG?\
M/"S_ #BKT2B@#SOS?B?Q^YL_SBH\WXG_ //"SZ>L5>B44 >=^;\3_P#GA9_G
M%1YOQ/\ ^>%G^<5>B44 >)^,9/%8M;,^(E@CB\T^08V3=OQSC!STK#UM=:-M
M83ZRLX4QE;9YQ@L@(_'OQGK7T'+;03O&\L2.T9W(67.T^HKCOB=H[:CX9^V1
M M/8OYO'>,\/^F#^%:T7::N88B-Z;L>*TG." "3Z 9HSD9!^GTI5P64$9&X9
M&,]Z]MO0\!&F/#6NLRK_ &->Y<E1^Y/^1]3BJ\&D:E>7<MG!I]S)<Q?ZV)8S
MNC[<Y_KBM+5=:AOAX@"/,?[0EB>/?G[J^OI6C-<P>(8=7B$-X+66>WE\^&#S
M3O6(KL=,Y()R0>QQ6#J22NT;J$&SE;FVN+2<PW4$D$V-QCD&U@#TR#R*CK=\
M7E1KBQJTC>7:PH?-;+Y"_P 7O6%Z\UM%MJ[,9))V+&G0FXU2RA7[TES&H^I8
M#^M?3%>%_#G2&U/Q5%.ZGR;(><Q[;NBCZ]_PKW,=*\S&23FD>M@HM0=Q:***
MXSO%7[P^M35"OWA]:FH **** "BBB@ J"IZ@H **** "JU_8P:E8S6=RFZ&5
M2K"K-%&P-7/G;Q+X=N_#.IFTN5)@8DP3@?+*OIG^\.XK'//45]*:GI-CK%D]
MI?6Z30MV/4'U![&O+-;^%=_;.TFD3+=0]1'*0KCVST->G1Q2:M,\>OA))W@>
M?]:DBN;B!2L-Q+&K=51R :O77AS6[-RD^DW:GU$98?I3;?P_K-TX2#2;QV/_
M $R(_GBNISAW.14ZBTL9PZ8 X P,5HZ)H=[XAU);&Q3+-_K)#]V)>[-_0=S7
M5Z-\+=5O'5]3=;*#^)5(>0^WH/UKU/1M"T_0K,6UA;B->K,>6<^I/>N:KB4E
M:)UT,)*3O+8?HVDVVB:3!I]JN(XAU[L3R2?J:OT45YC=W=GKI)*R"BBBD,**
M** "BBB@ HHHH **** /$OB-X:DT?66U&&/_ $&\;((Z)(>H/IGJ/<UQ>.:^
MF-0L+;4[*6SO(EE@E7#*?\\&O&?$OP\U'19'GL$>\L<Y&P9=!Z$=_J*]+#XA
M6Y9'D8G"M/F@<=DX R< Y [ ^M36UP;:XCE,23*K;C',I*-]:@_B((Y!Y&.1
M1C/I7=9-' G8TK_5C=V2V<-I%:VXE\UT1GD+M@@9+$G !/'O6=]:0D @<9/1
M<#G_ !KKO#/@#4M;=)KI&L['J7=<.X_V1_4UG*4::NV:*$JKLD)X \,OK^MI
M<S1_Z!9,K2,>CN/NI_C7NF*J:;IMII-A%9640CAC& !W]R>YJW7DUJKJ2N>W
M0HJE&P4445B;A1110 4444 %%%% !1110!1U;3(-8TNXL+D?NYEVD_W3V(^E
M?/6KZ3=:'JDVGWD966+D,?NNN>&'^R?T-?2>*PO$WA>Q\360BN1LGCSY,Z_>
M0^GN/:NBA6]G+R.3$X=5%=;GSX?Q_&COTK;U[PEJWAZ1OM5L9+<<+<1+E#]?
M3\:P^",@Y'M7K1E&>J/%E"4-QREE=67(92""!G!%:-YK=Q=V\T*VUG;K.09V
MMH C2X.?FQVSS@5F4<4W%/5B4FMA:%!9PJ@L['"JHY8GH![U9T[3;W5[D6^G
MVLMQ(3@[!P/J>@KUWP?\/H-#=;W4FCN-0_A51\D7T]3[FL:M>,%YF]+#RJ/R
M+G@#PNWAW1S)=+B_NL-*/[@[+^%==117D2DY.[/=A%0BHH****DH**** "BB
MB@ HHHH *:Z+)&R.H9&!#*>A![4ZCK0!X/XU\(R^&]0::%&;3)FW1/\ \\R?
MX&/\C7+<]^WYU]-75I;WEJ]M<Q)+"XPR.,@BO,M=^%+AVFT.<;,_\>\QZ?[K
M?XUZ5'%*W+,\G$8-\W- \S]/;I3X9YK=BT$TD3$8RC%>/3BM.[\+:]8OMGTF
MZ!]43<#^55XM$U:9PL>EWA).!^Y8?S%=;J4VMSB]G43V*+,22S%F)Y)ZY/J:
MFLK*YU.^BLK.%I;F4[5C7^I[#W/'YUU>D_#/7=0=6NU2PA[F0[G_ .^17J7A
MSPKIGAJU,=G&6F88DGDY=_\  >U<]7$QBK1.FEA9S=Y;!X3\-Q>&M&6U#!YW
M.^:3'WF/]!6[117EMN3NSV(Q459!1112*%7[P^M35"OWA]:FH **** "BBB@
M J"IZ@H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HQ110!DZCX9T75CF^TVWF?^^4PP_$<UD?\*U\*E]W]G-]/M$F/_0J
MZVBJ4Y+9F;IP>Z,C3_"VAZ4=UEIEO$X_CV9;\SS6OCC%%%)MO<M12V"BBBD,
M**** "BBB@ HHHH **** "BBB@ HHHH 1E5U*LH93U!&0:YS4/ ?AO4G:273
MDCE;J\!,9/Y5TE%-2<=F3*$9;HX4_"?P\3D37X]A,/\ "KEI\-?#-HP8V<EP
M?^F\I8?ETKKJ*OVL^Y'L:?8@M;.VL81%:P1PQCHL:A1^E3T45GN:));!1110
M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** %7[P^M
M35"OWA]:FH **** "BBB@ J"IZIS2,AC"@99MO- $M%1_O\ UC_(T?O_ %B_
M(_XT 245$/./1HOR/^-'[_UB_(_XT 2T5%^__O1?D?\ &C]_ZQ?D?\: ):*B
M_?\ ]Z+\C_C0///\4/Y'_&@"6BHL3^L7Y'_&C,_]Z+\C_C0!+147[_\ O1?D
M?\:/W_\ >B_(_P"- $M%1?O_ .]%^1_QHQ/ZQ?D?\: ):*BQ<>L7Y'_&FF25
M9XD;80^>@/89H GHHJ.=F6+*G!R!G'O0!)147ER8_P!<?^^11Y<G_/<_]\B@
M"6BHO+D_Y[G_ +Y%'ER?\]S_ -\B@"6BHO+DSCSSGZ"CRW_Y[G\A0!+14/E2
M'I<-_P!\BCR9?^?AO^^10!-147ER?\]S_P!\BCRWSCSSGZ"@"6BH?+D_Y^#_
M -\BE\J3_GNW_?(H EHJ+RI/^>[?]\BD\J7_ )[M_P!\B@":BH?)E_Y^&_[Y
M%-82QLA\XL"X!!4=* +%%%,F<QPLX ) XS0 ^BH_WW_3/\C1^_\ 6+\C_C0!
M)14?[_UB_(_XT?O_ %B_(_XT 245%^__ +T7Y'_&C]_ZQ?D?\: ):*B_?_WH
MOR/^-'^D?WHOR/\ C0!+147[_P#O1?D?\:/W_P#>B_(_XT 2T5%B?UB_(_XT
M8G]8OR/^- $M%18G]8OR/^-&)_6+\C_C0!+146+CUB_(_P"-,DDGCVEO+*E@
M. >] %BBBB@ HJ+<[3.J[,*!U!H_?^L7Y'_&@"6BHLS9^]%^1_QI?W_K%^1_
MQH DHJ+]_P"L7Y'_ !H_?^L7Y'_&@"6BHL3^L7Y'_&C%QZQ?D?\ &@"6BHOW
M_K%^1_QH_?GHT7Y'_&@"6BHL3^L7Y'_&C]_ZQ?D?\: ):*B_?^L7Y'_&C$_K
M%^1_QH EHJ+$_K%^1_QHQ<?WHO\ OD_XT 3+]X?6IJJ0.[.P?;E6Q\M6Z "B
MBB@ HHHH *IS?>B_WQ5RJ<WWHO\ ?% $M%%(1D8H X:#QG+<>,IK%;F(Z?-Y
MMI:J(_F6>-0V\MT(<EE ]4'K4:^+=031-&OA-'<32Z;/=7$:H/G=%R,@= #U
MQZ5V/]DV M8;9;2$002B:*,+Q&X.0P]\\U':Z'IEE<2W%K8V\,TN0[(F"P)R
M1]#0!2T$7K;)KOQ!'J*SPK((8X8U"$D9*E?FVCISD\\FN8O?$6LR17$L6JPV
M0C@N;U T2MO$;E%BY_W23CGYJ[&VTG1]%>6\M[.ULR4/F2@!0!G)R>P_^M4*
M^'=%GA+-;0W,32M<H7PRJ6 )*^QQGTH S=0\57"?V8+"U$SSW<=O<B4F/R]R
MDX7/4G!Y]O>M;P_>7%Y8S+=R)+/!=2P&15VAPK<'';@@?A5NZM;/4HDAN8HK
MA PD0$YP0>&'N*J:?IEAIFR2&;A T>YI<@LSY)/^T2<4 4F\4>4LLL]A+'"#
M,(F$B$RF.3RR/]G/!R??I1-J.N7F$TZT@@N+>Y1+I9G#KY9 .5((R<'I_*M2
MXTZVEMS B1Q.5<*=@)7><L<'KD\FF:/I":7%-M8.\S[W95"KG&. * ,NV\0R
MP13K>0.P#W30S%P?-"3,H&!TZ@#V%/76[V!TLWL'N9Q(MNTF]4!E:/S,8[*
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MIMQI>O37UR59XXV4H72<@,/EPRC/RGAN@&*OW'BZTM5436ERLV9/,ARFY A
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MDBD=H$.1\H)'YU6@UG5C.!/!;>6OV<L(RQ8^;P ,^AK=MKRTO+,7-M<PSVS
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MH;G[B?\ 71:FJ&Y^XG_71: )J*** (T_U\OT7^M25&G^OE^B_P!:DH ****
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M2SB\2.(6(WOACYAW8YY&..?X<9K4T*:"TU6Z!EBG1P\DER"X:,F7B-@>!][
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M2VBBF186<3.L@;+JH)VD9!/.,]ZDTS1[F[LKMG2&WCE\\6T:HP"M(-N[!&0
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MD,_=1N.![+_=%;=% !1110!%;_Z^?_KH/Y"KE4[?_7S_ /70?R%7* "BBB@
MHHHH *IR_>B_WZN55D&63V:@!]%%% !1BBB@#-U^]O-.T*[O+"Q:^NHDS';J
M<%^1G].?PJ"/5[Q/"J:K=V!AN_)$CVA;D,?X<]JUI72.,O(P1%Y+,< ?CVIK
M>5-!\RQR1,.<X*D&@##_ .$@NHI91=V2+'#*T+M%(6)<0^:,#'3:0/K5?_A+
M)!8M-]D438#HFXG>NS><=\@=>@KH EM*P)6(MN\SC')QMS]<<9J Z=I9MC$;
M.R\C?N*^6NP-ZXZ9H HVWB&2YO(A]F1;626.%9/,RQ9XED''I\V/PJS=ZQ+;
M:@+5=.GE4D9E0':,_A_6I;*ZL;J'S(H@B*Q.6CV@%6,?!Z9^3 ]L5=652VW>
MNX]!GK0!FZNUQ%<:?)%=-%&;I(Y8U _>!CC&>WX5GI*T^MW2QZG,UI$DGVJ0
MNH5&X(5/0J-V3[BNC:-7QN4':=PR,X/K6)J3:'H[F6XL8@\RR,YBM@S&, %V
M; Y49&<^HH 33+N6T\/O?3O<7#R[[B"&0[I/+/W%P.<[<$^F32^&+Z:\M+O[
M1</-+%=R(2T93 SD* 1VSBK0U"P.I16_E-YP&(9#$0I)4$JC$8^[Z4^'4;5M
M2GLH89O,1\2NL!V!R >6QC."* -"H)?^/FV^K?\ H)J>H)?^/FV_WF_]!- $
M]1S?ZO\ $?SJ2F2_<_$?SH ?01GK110 F,4,,TM% '/S^*((/&-MX;-G<F:>
M%I1.H_=@ 9P?RJSJ6NQZ9<F%[6XG*QB61H@"%4MM'4^IK6(&<XY]:K3Z?:7+
M.TL(<N@1CSR <C]: ,BX\46<#(9K2;[2!(6BV@O&J'#'W]@.33Y_%-I;SS1&
M&5_+3>ICPV_ID =C\PX-79M$T^X8M);G?N9RR2NI);&X9!!P<#*]#CI5:XTG
M189C<3PA6E<\M*VTLV"2!G )V@G YQ0!/!JT4]A=7,L,L MV99HWQN4J,GOC
MH1^=+INN6>JB0VY<",9;> ./P)JW;P0Q&66%/]>_F.1_&Q &?R J7 &.,?3B
M@#DXO$5[J1U(:<\$Q06\EM'#M>01,[*S,"<$X7.#C&1FK!U>\#6<WG3"P*A9
MIQ;+D2;]NUAG*_AFMB;2+&Y\TO;[6FV;VC=HV)0DJ05((()/(JA!8:#<W*00
M"-Y;7@QK,W9L_,,_-SSDYYH C\0^(/[+EM[>*:".9V623S6 Q%N"G [DDX'X
MFNA^AR/6L::YT&:QA$UQ!);3N7C+R%MY#DG!)S@,?H.G2K]WJ%I8%!=7$<._
MA=Q_SQ0!:J"YZ1?]=5J8'_&H;GI%_P!=5H GJ.<9A;/M_.I*9-S$PH >:B:V
M@>597AC:11A79 67Z'K4M% $?D1 8$: 8Q@*.F<_SJ*2&T@#SO%;H!\[R,JC
M'^T3^7/M5FH+VR@U"QGL[I"\$Z&.1=Q&5(P1D=* (+7^S[K;J5H;>4,A47$3
M J5SD\CCKUIK2V%XAMX[R'?)N1?)E7?G^+&._//ZU!8^';'1_#;Z+ID9BM_*
M=%#N7)+ C))Y/6JZ>&88WWQ^2AQ;*"L?*B(DD#TSG_&@"U91Z9I\<\L=W$S!
M_P!_+)*O!Z8)Z+TZ5;%Q9;HHS-;;Y%4QKO7++VVCN/3%<_!X7N[:(K'<PEQL
M4,S2$R(K%MK'/RYSU49J:T\*FVMHTDGBDF1($$WEG/[MW;N2<88#KVH WQ#;
MPR-(L4,;D99PH!(]S535-7BTL1;X996DW;4C SA1ECDD#@?C4>I^'[#5IQ-=
M*Y<+M&TCI^(JMK^B2:PD 0V[K'O'EW*%T)(P'Z_>'8T 2#Q':F=5$4WD,2GV
M@@!-^TOMZYSM!_'BK.DZI_:UFETMM+#'(JNF\J=P(!!&">Q%9D?A^]B,, OH
MVM8I?M 9HR9&EV%1GG!7)W8Z\8SSFI=-T2XLDN 6LH1<[5EBLXFB1 %(RG/#
M'(YZ# ^I -"PU6WU*>[CMPY%K)Y;.1PQP#\OJ.?TJ]61HVB'1Y[HK>330R^6
M$20CY JA>P&3QU]JUZ "H;K[B?\ 71:FJ&Y^XG_71: )J*** (U \Z0^R_UI
MQC5C\PS@Y /.#ZTB_P"M?Z#^M/H 3:.??FD**000.>#QUIU% &=8WNE:P!>6
M-Q;W0A9@)8V#;6/!Y^G%*^K:9N:,W]INSM($RY!/'K[X_&F:'X>TKPW:O:Z1
M:+;0O(9&16)RQ^IJDWA>-K26 3*"]I-;;]F2#(V=W)YP<4 6;5-+TVYG O ]
MPJ#S/.G#.B#^0[_C5DZMIBQ1R-?6@CESL8RKAL$ XYYY(S]162WAB47EU-#?
M>4)9))8FVL7C=^O\>WUY !]^*6V\+F*"=9+D.\L5Q'N"-\OFE"<98G^#N2:
M-V6:U@*F:2",G[I=E7/TS4=W=M!:>=;P-=LQ 1(F'S9.,YZ >IJ*ZTBTOK>&
M&[5Y%B7 VR,G.,9^4BHM0TN:?2%L+"Z%HH(5F96<F/NN0P()]00?3'6@"LOB
M>*0(R6<S1C'GMD?N27V8_P!KD'IVJSI>LKJKW BA54AD>,MYRL2RLR\J.5^[
MGFJ1\.SG$:W-O#;RI''<116Y *H<J$RQV\<'.?I4]OI%Y%J#WSWEJUSY30HR
M6FT%2^XE\-\QX4 C '/!S0!;AU:&XU>?3HT<O#&'>3^').-OUJ_6/9>'X=/U
M9KV"XN=C1,GDR2%P"6W$Y-;% !1110!%;_Z^?_KH/Y"KE4[?_7S_ /70?R%7
M* "BBB@ HHHH *JOU3ZU:JLW5?K0 ZBBD8;E*\\C'!P: %HKSZ2:XT&Z\2WM
MO=:A=OITEO';0W=]+)%^\5 <KDYP6/TQ5K_A+]6LI9SJ5M9K!%)<0%X=['?&
MH8-C'W3N QUH Z;7='M]?T6YTN[,@@N%"N8VPW!!X/X57.@1P>%/[#LW=8T@
M\F-I&).,]S7*R>/]1BTI;@V=K+.MU+;2QKN'RA%838YPB[L,.?8UW\#EX(V+
M(V5!W)]T\=1[4 <^?#(BDE>U*02/.[*Z9RB&'9M'_ ANQT[]:KVOAJ[MX8MR
MPR^7(I,#R,8Y,+MW=.&[]ZZL@'J,TH&* ./B\,7\&E):*]J<(JN@+;<"25R
M3G'^L7WXJY:>&Y8&MYY9(WNHI(29 3]U4VL!]:Z2B@#*U#0X]1NUN'N;B,JN
MT+&V!53Q%HDVJK"L8BE1(9(_+E<K\S  -D=> 1@\<UT%% '/_P!F:BVKP7;F
MW8VL919MS!I1MQAEZ+SSD4\:5<OXABO_ "K:%5??))$S;Y1Y>W:PZ8R<Y_V1
M6[BDP/2@!:AE_P"/FV_WF_\ 034U02_\?-M_O-_Z": )Z9)]S\13Z:XR/Q%
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M:5SQGDY SS^HKM-HYXZ\$]Z-J@8  'M0!R,'B74KF!Q$EJ9(?-9W(+;U10P
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M6IZAN?N)_P!=%H FHHHH 3')/>J,NF1RZY;:HTCB2"%X50?=(8@DG_OFK]%
M'+)X'LDLH+?[3.1%90V8;"Y*QOO!Z=2:B/@.!I[R5M3NV-W$\$A(4DQL^YE)
MQWZ9]*ZZB@#-T;2TT;38]/@FDD@A)6$.!E$SD)D=0!QD\\5I=:Y[PF/$@TZ8
M>)I+5[OSF,;6X  0]/\ /YU)HJKI\=]$YGVF_D6/S"SEL\CD\XZ^U &[SZ<T
MA(&-Q R<#GJ:X)+1)8-1:TB1]/C,4X@\MPDP&<HX/)<DC)Y'3-:S6-[%X8TN
MV+!;H74#-C,@BS("1R02 #CGTYH ZCO15'2IKB:RS=',JR.A;;MW!6(!Q[@5
M>H **** "BBB@ HHHH AM_\ 7S_]=!_(5=JG;_Z^?_KH/Y"KE !1110 4444
M %05/4% !12$@=2*-R^H_.@!:*3>O]X?G1O7^\/SH 6BDW+_ 'A^=&Y?[P_.
M@!:*3>O]X?G2;U_O+^= #J*;O7^\OYT;U_O+^= #J*;O3^\OYTN]?[P_.@!:
M*3>O]X?G2;U_O+^= #J@E_X^;;_>;_T$U-O7^\OYU#(RM<VX# G+'@_[)H G
MHHHH **:70'!=0?<TAEC'61/^^A0 ^BF>=%_SUC_ .^A2>?#_P ]H_\ OL4
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0P$4*,] *L444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>forms-1a_009.jpg
<TEXT>
begin 644 forms-1a_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '5 D # 2(  A$! Q$!_\0
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M!@DDX % $E%0^8__ #R;\Q1YK_\ /)OS% $U%0^:_P#SR;\Q1YK_ //)OS%
M$U%0^:__ #R;\Q1YK_\ /)OS% $U%0^:_P#SR;\Q1YK_ //)OS% $U%0^:__
M #R;\Q1YK_\ /)OS% $U%0^:_P#SR;\Q1YK_ //)OS% $U%0^:__ #R;\Q1Y
MK_\ /)OS% $U%0^:_P#SR;\Q1YK_ //)OS% $U%0^:__ #R;\Q1YK_\ /)OS
M% $U%0^:_P#SR;\Q1YK_ //)OS% $U%0^:__ #R;\Q1YK_\ /)OS% $U%0^:
M_P#SR;\Q1YK_ //)OS% $U%0^:__ #R;\Q1YK_\ /)OS% $U%0^:_P#SR;\Q
M1YK_ //)OS% $U%0^:__ #R;\Q1YK_\ /)OS% $U%0^:_P#SR;\Q1YK_ //)
MOS% $U%0^:__ #R;\Q1YK_\ /)OS% $U%0^:_P#SR;\Q1YK_ //)OS% $U%0
M^:__ #R;\Q1YK_\ /)OS% $U%0^:_P#SR;\Q1YK_ //)OTH FHJ'S7_YY-^8
MH\U_^>3?F* )J*A\U_\ GDWYBCS7_P">3?F* )J*A\U_^>3?F*/-?_GDWYB@
M":BH?-?_ )Y-^8H\U_\ GDWYB@":BH?-?_GDWYBCS7_YY-^8H FHJ'S7_P">
M3?F*/-?_ )Y-^8H FHJ'S7_YY-^8H\U_^>3?F* )J*A\U_\ GDWYBCS7_P">
M3?F* )J*A\U_^>3?F*/-?_GDWYB@":BH?-?_ )Y-^8H\U_\ GDWYB@":BH?-
M?_GDWYBCS7_YY-^8H FHJ'S7_P">3?F*/-?_ )Y-^8H FHJ'S7_YY-^8H\U_
M^>3?F* )J*A\U_\ GDWYBCS'_P">3?F* )J*8C;US@CV-/H *A?_ %L?U/\
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MC% +=O\ 5WD31D.H_P!I>HIEG=>,;&]TJRMEU",11VR6]J+8&WDAVCS6E?\
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M2C(H 6BDW#UHW#UH 9%_JQ]:DJ.'_5CZU)0 5"_^MC^I_E4U0O\ ZV/ZG^5
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M +?2@'-4?[6T]HI7^W6QCB;;(WFKA#Z,<\5!!K5DXD:2XCCC2;REDE=561L
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MM?MRW,\MVID8+<*Y.PEO5 1BN@\3:IJ6F^.-):349+;16VHQA57'FDX E!Y
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M)D61_N(6 9OH.] $U<-XQT#6=5U[2;K2H[:-[>3_ (_O,*2PCG(('#J1VKN
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M@5<3Q+?:;%]GBEAM(RZJ;N[5G0!85(7'8L>/_KT :J_#F"%6BM=2>W@FTO\
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MXJDT;5'OKZ?3;FRP+020R2I)^[6-F^[MZ%CT%<Q;>-]9M;)+:.6%S&-L<KQ
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M8H 1? .@)?)=+:R!EB$31B5A'( NT;USACMXR:@B^&_AV'2IM-CAN%MII [
M3MD8&  ?3!Z5UU% %+2]+M='TZWT^RC\JUMT$<29S@"KM%% !44\0EA>-NC
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M=7&,GB2)AQD?Q ^E4]5FB_MO5)-'CF(:PN5N$A#K.LF1\TI;@CKMQVSBO6#
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M% !1110 4444 %%%% !1110 4444 %%%% $<7^K'UJ2HXO\ 5CZU)0 5"_\
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M>9C[[<FM+ ''%/V\YHVU[$*<8*T4>5.<YN\G=B ?2G"@#%%62%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 1Q?ZL?6
MI*CB_P!6/K4E !4+_P"MC^I_E4U0O_K8_J?Y4 34444 %%%% !1110 4444
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M7.>2!W[5I7>B:U<>%7M+F]DO)I4@4VY4)Y>&4M\PY/&: .O%Q&QPLB,2. K
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MJFJ&7B6/ZT 344FX>H_.C</4?G0 M%)N'J/SHW#U'YT +12;AZC\Z-P]1^=
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M]T4^B@!GE1_W11Y4?]T4^B@!GE1_W11Y4?\ =%/HH 9Y4?\ =%'E1_W13Z*
M&>5'_=%'E1_W13Z* &>5'_=%'E1_W13Z* &>5'_=%'E1_P!T4^B@!GE1_P!T
M4>5'_=%/HH 9Y4?]T4>5'_=%/HH 9Y4?]T4>5'_=%/HH 9Y4?]T4>5'_ '13
MZ* &>5'_ '11Y4?]T4^B@!GE1_W11Y4?]T4^B@!GE1_W11Y4?]T4^B@!GE1_
MW11Y4?\ =%/HH 9Y4?\ =%'E1_W13Z* &>5'_=%'E1_W13Z* &>5'_=%'E1_
MW13Z* &>5'_=%'E1_P!T4^B@!GE1_P!T4>5'_=%/HH 9Y4?]T4>5'_=%/HH
M9Y4?]T4>5'_=%/HH 9Y4?]T4>5'_ '13Z* &>5'_ '11Y4?]T4^B@!GE1_W1
M1Y4?]T4^B@!GE1_W11Y4?]T4^B@!GE1_W11Y4?\ =%/HH 9Y4?\ =%'E1_W1
M3Z* &>5'_=%'E1_W13Z* &>5'_=%'E1_W13Z* &>5'_=%'E1_P!T4^B@!GE1
M_P!T4>5'_=%/HH 9Y4?]T4>5'_=%/HH 9Y4?]T4>3'_<%/HH 1551@# I:**
M "F-(J#+,%'J>*?5.^A,L0"HS,IW+@C@_C0!:W ]#QZ]J,UE_9[PRY8X/=@V
M%QCICZT]+>XD9/-R@!!(W^B_XT :(;WH+  DG']*R&MKMH@!O4Y)<A\[_0CG
MBKCQ.UK*FT[V3 )/4XH M[N,]J0OM&2>!UK-:&ZEN(GQ)'&JA2H(R,=>_2FI
M;7?F8<DISW]!@?SH U X89!XIV:SH+:5)4D8MD'##=QC;_C4;V]VUQ,W*JX(
M&&]Q_P#7H U<TU9 RAE;*GN*RY+:[$B>66VH_!W]LCBD6"XCD2 %MI4NV#T.
M3C!]\T :V:7-8Z6MX6AW,P"#&%?ISU.>O%3)%<K;3HI*NQRA+<D4 7VD5"%9
M@"QP,GK2"="Q7>N1U&>E4+>S?SXI)$.$+;06R5!Q_P#7IC6,PGFD !#^9@>F
M1UH TUD5QE7##V.:=FL^WBDC$TAB$0,8 5>3D#K45O;SLL1<.J;@Q4ODYQU_
M/'% &KNI&<*I)( '4FLM+>\19"9&:0-D#=PW/^%)):W1D.#E-A7)?[QQ_C0!
MK!LX.>#THS64EK=9DW._/ (;C'%/^SSJX WL@+!/G^Z<\$^M &EGWI<\_P#U
MJS;:"YC@G#.YE8$*2<C=CJ*9]GN<P>6C(J')S)D]><T ::R*Z[E8%3W%!<!@
MI(R>@K+2UG4.-I/R$1E6P!U[5(T-R[F3R\'#  MZ@4 :.[D#//I06 !). /6
MLA+2YVJ23Y@5U5RV=N<8[\T&UNC:B,AWZ_*6Q@]N<\B@#6,J@J"PRW3GK2AJ
MHW%FTCHZ9WK$4!SC!J,VMPLZA"^T;0&WG@8Y% &D6QS33(!U8#M^=9T=I.CK
M)ER?E/+GK_%3I[-WN92$.UV3Y@W8=: -$-FFF9 VS>N[TSS6:+6[\^(F1]BC
M PWN>OX8J2ZBEGN1B("-5.) 1G=C'/M0!=\^,@D2+C.,YI?-3?MWC=Z9YK+:
MTF,$@\@!VV;5W#JO5JD2";^T?/*80G)Y''% &@9%4?,P'&>:42+_ 'AU]:RI
M+.XD>7<F2RE=Q?ALD8^E.6SGR4+859%*.IYV@4 :8D5C@,"?3-#. 0"P!/0'
MO5&UM989RSG/W_F)]6R*B6WN @/EGS 6+$O][(Z^U &GY@#!2PW'M2Y_SBLI
M+6Z$2JQ/&[)W<X)'?\Z4VDZI* \A# X^?/1N/TH U"V 23@>],\^,J")%P>A
MSUJ!))#"R-#F1!@*3PQQVS5'[%,8AF !F!##(^5B>H]J -;S4YRXXZ\]/K1Y
MR;-^]=OKGBL_[*^^Y!@.UPN"I'S$=^:464C6!A?JSY89' S[4 :'F#=MR-V,
MX[XH+A026X'6LHVET=\A.)F0Q@@]@1C\^:&M+EHD1M[C!Q\^-ISG\: -57#+
MPP.#@FEW5FK#<"8LREASMP^ IR>H[TVWM;D!1*[ !BP&\]QQ^M &IN[DX%-$
MT97<)%VYQG-4+6VG6"9+@NY88(+=?H>U1-:7,MNL7RHBDLNX ]N,X[T :GFK
MYFS>-W]WO2>?&-V9%RO7GI56UMY1.\THVL=OR\<D#UJ![1VDG'E?NVR=I8?,
MW;'I0!IB0'.&'%+NK/M8;B(R*Y&PCY2,9S4/V:]"Q* 1M;.2_/;KS]: -?--
M9PJ[F; ]36;]CN-V_>^[D_?/7=_A48@N9?,.UAEC]Y_O8;CZ8% &QGBFEP&"
MD_,1G%4+2"Y0S&21B6X&<8SSS47V:X\M3Y9#*A!R^22>] &F) 7V9^;&<4[-
M9<5I<D()F;L&PW)&32&TN5@*@R,6 )&_JV3^F,4 :N:7/!YZ52=II;61%C(<
M< $_>^E5X[2Z\N,N[[XP,?-_M'\^* -3>,A21NZXIGGQX)\Q<+U.>E4[6"6.
MZ=Y5/*D%BV=QSV':H6MYGE>5K< F0$ID891_6@#3\U20 P)/09[>M*LB.2%8
M''7':LR.TE1[<^4 55PS9'RYS@5-I\,\"E9>@ ';)/KQVH T**** "BBB@ J
MO<W*6T8>0$J6"\#UJQ4$\"S !B< Y/O0 PWD(FEC8X\M=S$],4CWL"!#O!WX
MP%[YJ'^S$\@Q%V8D8+-W.<TOV#:5VR;>F551SCF@"9;R$G#.H;&<'TH-W"<%
M7!0@G=VJ%+ H'"RNH<8;'?\ PIJZ8@C #MQD@XZ<Y_I0!96[A: S;@J9(R>]
M-^V0'=EP%#;03W/^32&SS;B(R'(?>& [YS44NF^<#OE8DG)XX)X_PH F-Y A
M/F.J$';R>M.6[A=E"R ELX'K436"D.-Q^;/7W.:4V8\U)!(1M;<./7M0!*UU
M#&[(T@#*,G/:F&]M@%9IE ;.,TR2Q$C2?O& <AB/0C_/2C[ I5MSEB^<Y'J<
M_P!* %-_ K*#*,,#AL\<4X7D.0'95+-@9/4U&]CO8E967.<@#J#2_8%4/AC@
MY]\<YH E^U6_S_O%^4<^U"7<4D0D!PK-M!/J*KKIJ(&VMC)R#C)%2&RS:^29
M"3G<&QCG.<T +)>PHH?<&4C)*^F.OZ41WMN[JBL 6 9<_P 6::FG1H-JDXW$
MCV&,8_4TY;/ 7+DL-O/^[0 /?01R,A.&0C=QP,T\74)*#S5_>?<YZTCVNZ5G
MWG!8-C'<5"-/7SDDW<C@Y7WS0!,UT@F,6UF(^\1T7ZT&]M@A82IMS@G/M37M
M"9I'61E$@^=0.O&*CBTY(@H!X4YZ>V.: +"W4)8KYBD@#]:#<P[PF\;CQ@=Z
MKG3^>)6'RA1QZ'.:<MD1)&YE8E6+$XP3G^E $INX%D,;2*''4$].]-^V6Q3?
MYB[3QGWJ%[ S2R&1SL9MRJ!T.W&:1M/;<I60Y))9L=L8Z4 66N(E4MO4CZ]>
M,TQ[^!(RY<9"ABHY(!J,6 7Y1(P0#[OJ<8I!IJAV8R,<KM'Z?X4 3&\A .]@
MHS@'/6GK=0M(8UD4OZ5!)8;V+B5@[9!./48IZ6BQNC*Q^5LC\L4 /-W '9?,
M4,H)8>GK2?;(6*J'!9AE1[5"+!G>1I'X)8J .F:=-9!I#("<9#;.@) P/PH
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M4-R#$$F]L!4XSR"<_I47]J)'DE"5;&P <],G-6I;&&3:",*I!P.^.U*;*WP
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M<;C[4AOLJ65"Y/W0..V:L&PMFSF('/)I396Y7:8E(]_IB@"(W1$<&$+22KG
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M$8!48&*$LK= 0(@,G/Z8_E0! U\(S$)(F4R=L]!VI4O&\B-MF^1V*A0>N/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
5HH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>form1-a_027.jpg
<TEXT>
begin 644 form1-a_027.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %+ F\# 2(  A$! Q$!_\0
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M HHHH **** "BBB@ J9?NCZ5#4R_='TH 6BBB@ HHHH **** "BBB@ HHHH
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M-=(T4BI+OMG7RMV-A;C@'(P3ZU9?Q3I2:C]B-PV_SA;F38?+$IZ(7Z9]OPH
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M(H M44T2QLA<2(4'5@PP/QJG8:K;ZA=7UO!N)LY1$[=F)0,"#Z8:@"]1110
M4444 %3+]T?2H:F7[H^E "T444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!!1110 4444 <CJ7@E;_5M3O!=[$NH<PQ[/]1<X \X>^$3\
MCZT6OA?4-':PNM-NH);R&S-K<FY#!9BS;S(,9(.XDXQSGVKKJ* .7T+PJVBW
MMM<F[$IBLY() $QND>3S&8>@SGBJMCX3U#1WL;JPN[9[J"*>"03JP1DDD\S(
MQR&!Q]?:NRHH X>V\ %4T1;B\5OL0=+Q53BZ0OO53GH V#^=6+'P2]EH\EF;
MX2S/?PW(F9>D43*4C_!5QGWS784=L]J .-_X134U:&SCO+8:;#J?]H*2K>:<
MR%RA[=2><_A3M#\'-I%Y$K164]K!/)-#,^_SEW$D#'W<C<1N'4=JZPSPK]Z:
M,?5Q0)X6Z31'Z.* )**!R,CIZT4 %%%% !1110 4C#*,/4&EH) !). .IH \
M^TK0[FRO/"UU?:2\TUO926TKA!(T,A92I8^F W-7O$.FSQ^(;.^T[3VN9T6.
M-8I+?= $WY)#_P#+)@"3GOP*ZFRU&SU&Q2]M;B.2V?.) >.#BK((8 @@@]"*
M ./\7K WB+PX+JRDO8-\Y:!$W[L)_=[XJCI7A>X>^T9K_3S]BMVO9(X)6W"W
M5W4Q(1W( /':NX9+2:XCE;RGFASL;()3(P?I4AFB"EC*@4'!)88SZ4 >>6NA
MWZ&TA;39EUF'4C<3:J>%>'S"3\^>04^7;V].*SK33+O4+/3[IX[B[TQ6O8FC
MCB$Y21KAL,4/7@$!AT_&O4Y4CFB>.3#(RD,,]C3;6VM[*WCM;6)(H8QA(TX
M% '$V^CO8:C =1TN[U:S^PP16C2()7@=2=P8?PDY4Y]NO%0ZEH%X7\50:=I[
MP7-[+%-%<1H )8@L?F1AO4[7&#ZUW%IJ-G?>?]FN(Y/(D:*7!^XPZ@U95U==
MR,K*>ZG(H \X_L"9;"26VL;][9KR![JP: 0"2- =VQ!UR2I/][;70^$[%K2Y
MUJ5-,?3[6YNED@B= GR^6JD[1TY!XKIZ* "BBB@ HHHH *F7[H^E0U,OW1]*
M %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@""BBB@
MHHHH ***0D*I9B !R23@"@!:YKQ/XZT#PG'G4[Y5F(^6WC^:1OP[5YK\0_C.
M8I9M)\+2*6&5EO\ &0#Z1^OUKP^>::ZG>XN)9)IG.YY)&W,Q]R:[*.&<]9:(
MRE42V/6]?^/FK73-%H>GQ6<6<"6<[W/OCH/UK@-2\<>*=6<F\UV]8-U6.0QK
M^2XKGZ,UW1H4X[(Q<Y,FDN[N4YDN[AS_ +<K'^M(EU=1G*75PA_V96']:CS1
MS6G)'L3S,W-/\9^)M*939Z[?(%Z*TI=?R;-=WH7QYUVS98]8M(+^+N\?[N3'
M\C^E>3YHK.5&G+=#4VCZW\+?$7P[XM4)8WGE7>.;6?Y)!]/7\*ZROAY'>)UD
MB9D=#E74D%3Z@CI7L?P^^,\]F\>E^*93-;'"QWQ'S1^S^H]ZX:N%<=8[&\:B
M>Y[]13(9HYX4FB=7C<;E93D$4^N,U"FR1K+$\;J&5U*D'N#3J* /,=-T::ST
M/1;6?1KLVEE<R_VA:I$?WI.[8X /SJ..GK[5TOANSN+71-3\\36-I+/*]K'(
M3OMX2H]>G.YL=LUU&1ZTC!'4HP# C!![T"NCR'18&N;:)I+62TU"71[BWLT1
M'!O6*Y\PL>"V!D?[QYKH!H TU]'^TZ3<7>F+8%9K>(-(RW)VY=EZL2 1GM^-
M==9:%I>G3":TLXXI "JL,G:/09/ ^E:6:!GF:>&]?:TTRVVSI#?1R6=\&F.Z
MV@\PNG.?O;"4SUY'I71>#M/U2$W=SK"NDZ;;*$,V0T460)/JQ)/Y5U61ZT9H
M \U.AW=O;ZS:V^E3J7U874PB! N;4L"55NY(SE?J*Z'PS9R0ZKJMS!9SV6E3
M^5Y%O,I4[P#O95/W0?EX[XS74YHR/6@ HI,CUHR/6@5T+11D44#"BBB@ J9?
MNCZ5#4R_='TH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9>E=CHW@\+<7*^=YLDG(<C/R\=/K_2O0M+T"#3K7F)?[Q/K6<JW*4HW/#)?
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MD?45X];#5*+]Y'T>%S"CB%[KU+]%%%<QWA1110 4444 %3+]T?2H:F7[H^E
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MP5,OW1]*AJ9?NCZ4ABT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 04444 %
M%%% !17%ZUJ\MGK5VT%X9F6U<Q1QN3]GD16)\Q!C*GCGUXID'BB_26PL?-MK
MB;]W'-*(V)ES'O:10#@* ,=\G- ';T5P%KXCU.+28;J>XM[B9;/SVDR4CW._
M";<X+ !N.#QCBK3Z[?27&HA[A98A/!!#!#&T<BY4.[=<]R/PH [6BN23Q+<M
M!I\HN-/;[7.J,D:EFB!'3&X;B"0"1T]*B\0W%^NN220,LT-C#$T=MEEW3RR;
M5)(/( 'H>IH [*BN,N?%6I6LETKQ6TKV_F!X(T;S,*FX/UX4M@ =\_A4MIKV
MO/J$=O<V=H%%U';R&/=U:+>V/]WIGO[4 ==17#Z[?ZI%JNKVEO<7$44,,5\9
M%Z)&N=RCW8KR!VHMO$NHI>.653Y\L<BP2!O,,3X V#. %09)(/.1Q0!W%%<-
M-K^J>5IVI7,:1Q^4]R((]P&UBJ)YA/L^X\<8I\>JZC-X7US4$F+W$UTUO:&-
M611RL:D YP,Y.: .VHKB-2U_5],U5OM$$(6""--L<I:/=(V-[D[>@0_G1+XO
MU"">W@DCM/.RHG1 S;@4+EE.>%P,9.>: .WHKSA;W6?L<M@+T/,R6D*1'(D#
MN0SN6STPQ'T%=#-J]])X5:\W+%+]H\EIH4)"1^;M,@4Y_AY_6@#IJ*X>75;B
MRU/;H=Q)J-O*L<),TC21B=G !#>R[BP'' IT_C&\M[]X2EM((1*)456#+L(7
M>QZ*"S#CGY>: .VHKA#XOUAH[@P06<JPK-)YWEN%8(550!G/S,6&?05/+XCN
MX]3>""6W2>6Y(\J<LP$2 !F7D<[L@ #D_C0!VE%<!+XLU&]B9;6XM+9'EM@)
MO+8^5YC$LI)."0J\D=SBK3>)[R)Y/(2(EY'>)9MY,X#^6%C';[I/MD<4 =K1
M7,Z/KNI:CJJ1S6T,=I*)V3:&WA$<*C$YQ\V3Q[5TU !1110 4444 %%%% !4
MR_='TJ&IE^Z/I0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 04444 %%%% #=BDG*C)&#QUH\M 00H!'H*=10 SRDQC8N/3%*$7=N
MVC<>IQ3J* &B- >$4<YX'>JMKIEM923R1!S)</OE>1RY8]N3V'8=*N44 -V*
M6+%1D\'CK2[1UQ2T4 (5!SP#D8/'44FQ<YVC.,9Q3J* &E%*[2HQC&,=J-HQ
MC QZ8IU% #2BDDE0<\'(ZT>6N<[1GUQ3J* &B- 20HR>^.:7:-I&!CTI:* &
MA$50%10!T '2J4&D6EO>RW:J[SR J6ED+D*3G:,G@>PJ_10 T1KC[H_*D,49
M<,8U+#H2.13Z* &>6G]T?3%+L7CY1D=#BG44 (% P0!GUQ2T44 %%%% !111
M0 4444 %3+]T?2H:F7[H^E "T444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
..4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>forms-1a_012.jpg
<TEXT>
begin 644 forms-1a_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &? D # 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W*_U*STR
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MU+#_ )^X?^^J/[4L/^?N'_OJCE?8/:0[EVBJ7]J6'_/W#_WU1_:EA_S]P_\
M?5'*^P>TAW+O%%4O[4L/^?N'_OJC^U+#_G[A_P"^J.5]@]I'N7>*.*I?VI8?
M\_</_?5']J6'_/W#_P!]4<K[![2/<N\4<52_M2P_Y^X?^^A1_:EA_P _</\
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MAE8D$4U)-Z,3ARJ[3'?9;O\ YXR_D:/LMU_SQE_(U%YLG_/1_P#OHTOFR?\
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MCZ?'JO\ :<=I%'=^28/,1=OR9SC XSGOUJ*RTM['Q!J6HQ3CR;](B\0!!65
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MUH1VUU#+/M-G&Q385 7)Y/WCSUK1.T48R3E-ZG2^=<?\_,O_ 'T/\*/.N/\
MGYE_[Z'^%<U#XK^T-"T>E7 M;MY8K*Y:1<3R("<%>J [3@FJL'B^ZB\*66L7
MVF1H\Z%V'VN-%( SE<GDGLO7BGS1%[.1U_G7'_/S+_WT/\*/.G_Y^9O^^A_A
M6#HFIOJ>OZBHD=K/R+2:"-AC8)$+'\>E9&EZWK&MG3[**]CM9G@GN;BZ^SJQ
MVK,8T55/ Z<FCF0<C[G:^;<?\_,O_?0_PH\ZX_Y^9O\ OH?X5QGB/Q'J&@S6
M%O\ :K:66WA^U:DQ54,L6\)A%)X)R6X_NU7U_P 3ZC8^);FQLKU?D^R"TM_L
M@D2X,I^8-+_!QR.:7,NPU3D^IW?G7'_/S+_WT/\ "CSI_P#GYE_[Z'^%<Q::
MI?CQ=/8:C>-: S.+2S:U'EW,0'#)+U+=21[=*M3^)(;?79M,>W(6W@^T33/*
MJD)M+91#RX&,''0FG="<))V-WSKC_GYE_P"^A_A1YUQ_S\R_]]#_  KG!XFN
M#:6LSZ'<I)?.BV,1F3,^Y2V2?X,*,G/J*:OBMYIK2UM](N9;Z>::W>W\U%\E
MXL;]S'@C!SD=:.:(N21TOG7'_/S-_P!]?_6H\ZX_Y^9?^^A_A7,:=XUL=2UJ
M/3H8F"S22Q0S>8I+-'UR@Y4'!P3UQ734TTR9*4=Q?.N/^?F7_OH?X4>=<?\
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M^9?^^A_A1YMQ_P _,O\ WT/\*XO0?$%UKLN+B^N+4WZ3BS@%F$3"Y *2GEG
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M/\*3<I.5^Z1D?0T59GJ+YUQ_S\R_]]#_  H\ZX_Y^9?^^A_A244!=B^=<?\
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M0M&_WD/!!!_,4IT.-(/(M;Z]LXDACAB2WF $00\%<CJ>A]:Z'^RH_P#GO/\
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M\]YOS'^%']E1_P#/>;\Q_A1S(.211Y]1^='/J/SJ]_94?_/>;\Q_A1_9,?\
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MZA+8I:+#AX0N\*^_.6)*'(Z<^U=)I]IJ5OJ=S/=:BUQ;^5%';HV,[ER7D;
M#,3C [ 5G6W@ZTM+Z.=+V\^SV\TMQ:V99?+MY9,[G7C)/S,0"<#-#N"MU':W
MJ.JV&N:'';FT73KR[%O,&4M*Q*L>.R@;1[U)I5_</XCU_2KB4RBUDAGMV(^[
M%*F=GO@@_G3+_P ,2ZA_9OF:]J*-I[+)&RB,EY "-[94Y."1Z5/I6ESVVMZW
MJET4\R]EB2$(V<0QIA2?]HDL: NK&O2T8HQ5$!11CWHQ[T#"BC%&/>@ I*7'
MO1CWH *KW?\ R[_]=E_K5BJ]W_R[_P#7=::(>QF>(=0O;>?2=.TV2*&[U.Y,
M(N)4WB%50LS!>YXP,^M4+3Q-=Q^#=7U.]CBFO-*EN()/+&Q)FB. P'8'(R/K
M6QK&C1ZNEJ3<S6MQ:3B>WN(,;XWP1T(((()!!%58O"MG%I@TYKF[DM)%G%TC
MN/\ 2VE^\\AQ]X'D8QBH:=S5<MCG-2\2>(="M[V"]N;.ZN!80W\<Z6^P0JT@
M20;,_/M!RHZGIS6[X,UFZUW2+BZN)X[E([N2&"<1>2\D:XY>/^!LYXX]:A_X
M0>VDA;[5JNHW-T%A6&[E9-\ A.Y HV[3SR20<UJZ/HR:0+M_M,UU<WDWGW%Q
M,%#.^ HX4    =!22=QR<;:&E12XHQ5F84AZ&EI".#]*!,I:I)+'K$XCE9,J
MF<8YX]ZJ^==#_EY?/T'^%6-7_P"0Q/\ [J?RKS_6/$FI6GBB\LK6[B9H'M%@
MT[[-O:Y$@!<[QRN,YSTXJT[11E).4VD=OY]U_P _+_I_A1]HNO\ GY?]/\*Y
M'3/$\R7<T&HV\_V=]2N;:&^++L&S+!-H^; 4'FIU\81"W-Q<:9=6\$EG)>VC
MNZ'[3&@W' 'W6(P0#V-5S(7).YT_VBY_Y^7_ $H^T7/_ #\O^G^%<JWC.WM[
M6XEOM/NK.2..&6.&5T)E64X0Y!PO/7/2B'QG'=I EGID]U=RSR6_D0S1D!D4
M,3OSM*X/44<T0Y)G5_:+G_GY?]/\*3S[K_GY?\A_A7*6WC>TEMQ=W-A=V=J]
MI)=PRR;3YJ1G#@ '(.2 ,]:O>'_$=OK\UU!'#Y,]L$9U\U905<'!#)QG@Y'4
M47B)QFE=F[Y]S_S\O^0_PI?/NO\ GY?]*Y:W\80W.FRWL=A,5^T+:V\0E1I)
MI2Q4*5!_=GC)W=J?<^*);4RH^AW9FM8/M%[&)8_]'C)(!SG#D@$X':CFB/DF
M=+Y]S_S\O^G^%+Y]U_S\O^0_PKF9?%UO%+J#_8YVL;")99KT,H7#H'0!3R2<
MCZ9JSH/B.VUYKJ..+RI[8IYB"591AAE2&7@^XZBB\6)PFE<W//N?^?E_R'^%
M'GW/_/R_Z?X4VBJLB+L=Y]S_ ,_+_I_A1]HN?^?E_P A_A3:.U%D%V.,]SWN
M7Z>@_P *9!-<"&,+.X&.!@<?I2G^E1P?ZI/I196%=W)_/NO^?E_T_P *3S[G
M_GY?\A6#H%[J5U>ZQ;:G);O):7*(GV=-JJK(&QSR>O4U2U76;S3_ !1I]HE^
MK1W5PD9M7M"D:QE3D^<>"^1P!],5-U8TY7>USJ_/N?\ GY?\A_A1Y]S_ ,_+
M_D/\*P[^^EC\3Z99).8;<6\]W<GC#HN%4'T&22?I5'Q%K$\>A2:QHNM6@@B7
M:B+")OM,Q8!8P<\9Z8'/>FV@49.RN=5Y]S_S\O\ D/\ "E\^Z_Y^7_2LS4Y;
MB'2&F6X-C(JHTDBVYN#'TW!4'WCSCO5+PEJEQK&@K=W4B22>?+&'5-A95;"E
MD_@;'4=J5UL*SM<W_/N?^?E_R'^%'GW/_/R_Z5R?B7Q%=6.IVMGIK0#RYX/M
MSR8.U9'VJ@']X\L3V ]ZM^)]3N-.GL(8KQ;"VN))%FOF@\X18&57;_M'O[4<
MR*4)::[G0^?<_P#/R_Y#_"CS[G_GY?\ (?X5Q^@Z_=ZE<:#//(##J5I.CQJ,
M*)HG^^HZC<N>*Z[M333)DG%VN.\^Y_Y^7_3_  H\^Y_Y^7_3_"FT4[(F['>?
M<_\ /R_Z?X4>?<_\_+_I_A3:*+(+L=Y]S_S\O^G^%'GW/_/R_P"0_P *;1BC
M0+L>9[GC_29/R'^%16\UP+= L[J/0 4OI4*2B"S,S E8XV<@=P 31T%JVBSY
M]U_S\O\ D/\ "CS[G_GY?\A_A7):+JVK27FCG4+B">'5[62=8XX=GV=E 8*#
M_$-K=^XIVJ^(;F+Q1INGV+P+:+>Q6U^[X)+2 D(OI@#)/N!4<RL:^SE>QUGG
MW/\ S\O^0H^T7/\ S\O^0_PKD](U>\DUZ6UU2]DBD>69;>S>P\M9$5CM*R_Q
M';@XKJ<52::)DG%V8[S[G_GY?]/\*//N?^?E_P!/\*;13T)NQXGNC_R\O^G^
M%1)-<>?*1<.&.,GCGBE/3\:C3_72?A_*@5V3F>Z_Y^7_ "%'GW/_ #\O^E<I
MK/B&ZA\26%A8O"MNEU%#?R/@DF0';&OH0!N)^E2^)M:GT^^T_3[622%[KS9'
MFBM3<.B(!]U!U)SU/ J>9&O)+3S.F\^Y_P"?E_R'^%'GW/\ S\O^0_PKF=4U
MAU\%K?Z==^?/<K%%!=*FWYI&";]O8C)X]14]Q>:E:^,M.TYIH&T^>";"[,RL
MT:CYF;W)Z"BX<K[F_P"?<_\ /R_Z4>?<_P#/R_Y#_"N>U6[U*76X=*TVZBLV
M^QR73S/")"2"%50#T!)Y-7]"OVU?0M/U"1 CW,*NZKT!/7'XBA--V):DE>YI
M>?=?\_+_ )#_  H\^Y_Y^7_(?X5Q&D>)=1O/%_\ 9LUQ&W[ZX2:W\D!(T3[A
MCES^\8Y&X=N>F*T?$UYJNF&VN;*^A_>3Q01:>UN&:X9F^;YLY&%YXZ8YI*2:
MN4X2O:YTWGW/_/R_Z?X4>?<_\_+_ *?X5C:9=3G7-;TZXE,@MIDE@8]1'(N0
MOX$''UK7JE9DRNG8=Y]S_P _+_D/\*//N?\ GY?]/\*;13LB;ON.\^Y_Y^7_
M $_PH\^Y_P"?E_T_PIM%%D%V.\^Y_P"?E_T_PH\^Y_Y^7_3_  IM%%D%V.\^
MY_Y^7_3_  H\^Z_Y^7_3_"FT46078[[1<_\ /R_Y#_"HY9IR8]T[MAP1P.#^
M5.J.3K'_ +XHT$VR83W./^/E_P A1Y]S_P _+_D*YWQ/J=]9RZ1I^FR107>J
M7@MUN)8]XB7!).WN>*IZ1XFNY?!6IZM?QQRW>F/<12^6NU93%T..V>*GF29J
MH2:3N==]HN?^?E_R'^%'VBY_Y^7_ $_PK@-*UGQ)=7HTRXU*P6>[TN/4H;MK
M;"6REAO4C/S8!X)(K6\#:OJ6MZ)/=:DT<P2[>*WNHX_+6XC7HX7MSFDI)NPY
M4Y15VSJ?/N?^?E_R'^%'GW/_ #\O^G^%-HJ[(RN^X[S[G_GY?\A_A1YUR?\
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MA@W\.=HR!GVQ6=F;:7*VG>*M2N[O2[N6"T72=5O);.W10WG1%-VUV.<'=L/
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M6EK^35LXHQ1SL/91"BBBI-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#Q'<Z8]M%:K"@81S2$7# A2'"8P4Y(R"<$<U$? V@AYW6%HX9?-S"K!8E\Q
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M9Q<LP4*B@-DYYQS^%)R;6P'$II.L6NG:[);6$9N]1OI;:%A$RS!'DY=Y,GY
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M#D+$HVHOY9)]S6W14N38'$#P!Y<%J+?43%/:PQI%(8 0724R!F&>>I&*6V\
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M0$'WK2T;PU)I&KWMX+W=#<1JGV=(MB[A_P M&Y.7.,9&,]ZZ2BDY2M8#AO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *0TM(: (;BXCMH7FFD6.-!EF8X %<9>?$W3892EK:SW*
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BXU>2 _VM"%E;+Y1-JISPF"<G'KWK;!HQ2XJ6[F4G=W/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>forms-1a_013.jpg
<TEXT>
begin 644 forms-1a_013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %B D # 2(  A$! Q$!_\0
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M=!9BT4F]/[Z_G1N7^^OYT[H+,6D?[AHW+_>7\Z:SIL/S+^=2VK#BG<WO%O\
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M+8?\*/\ A+M3_P">6F?^"V+_  K"HH]E#L'MI]S=_P"$NU/_ )Y:9_X+8?\
M"C_A+M3_ .>6F?\ @MA_PK"HH]E#L'M9]S=_X2[4_P#GEIG_ (+8O\*1O%VI
MA2?*TOC_ *AL7^%8=(WW#2=*%MAQJSON=GXE\3:A:^(+F%(]/*JL>"]A$QY0
M'J165_PEVI_\\M,_\%L7^%-\6_\ (S7?^Y%_Z+6L2HITX."T*J59\SU-W_A+
MM3_YY:9_X+8?\*/^$NU/_GEIG_@MA_PK"HJ_90[$>VGW-W_A+M3_ .>6F?\
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MP3Y6F?\ @MB_PK6UKQ/J$-OH[+'IV9;!9&W6$38.YAQD<#CI7&'[IK:\0?\
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MUTR/3REI-%$K+ TT6YX0W4*<_P Z]I)QUA@Q_P!<%_PI'D6-"[Q6ZJ.26@0
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M(ZN&&5((R.XK4N_$=Y>C5!*8?^)G(DEQM0CE.FWTKVO>/^>-O_WX3_"C>/\
MGC!_WX3_  J)8CF=W$I4DM%(\/MM4CBT6_TR=&D2X=)H64X\N53C)]05)%2V
M_B.[MA:I$(/)MX'@\ADRDJN?GWCN3QD^PKVO</\ GC;_ /?A/\*-X_YXV_\
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M\3.?6UEFU,QN)TMWU"5I A*AU\I<9([9'Z4V.SE>XL'99VEMY+I8F=FP /\
M5[O7ZGK71<T$FBP^<Y6Q%^8W-O._VT6S^<C))DR8XR6^4$'.,5-=V]E=Z!?Q
M6HO9'\E6D60R9W@@GKU;KD"NA-Q']H6V,G[TH9 G^R#@G\S1'.L[2!)-QB?8
M_P#LMC.*+!S,P[AG+R&%KHZ<1;EBF[=Y?S;L=^N,XYQ491YB([.2[73C=PA&
MRP;&#YF">0G3K[UT>23G)]:"22<YSTYHL+G\CF;Z*2".:+S9TMXKIO)1Q(RN
MI0$*67YA@YP>1FN@M69[2!WC:-VC4M&YRR\=">YJ8%@>"<^U%"5A.5PHHYQF
MBF2%%,DD2%=TAVKD#..Y.!3^?2@ HH[X[G@4<^E !111TY- !10.>F#[T4 %
M%!XZ\?6F22)$H:1MH+!1]3T% #Z*,$\8YJO9W<=[$985E\K<55G3&_'!*^HH
MT"Q8HHIDDJ11L[L%51ECZ4!8?11[]J* "DI:!28UN6+_ /X_7^B_R%5ZL:A_
MQ_/]%_D*KBE'8<]V%%%%42%%%% !1110 45!%>6\]S/;Q2JTUN5$JC^ GD9I
ML]_;6SLDCG>NW*JA8_-G' [G'2@=F6:*IG5; 0P2FZ0)/)Y4>>"SYQMQUSFK
M,<T<WF>6VXQN8W'HPZB@+,?1110(**** "BBB@ JQ=_<MO\ KB/YU7JS=?<M
MO^N(_G4O=%KX65J***H@**** "BBB@ HHZG%5;74;:\?; 9&ZX8Q,%.#@X8C
M!H M457GOK>V9EEDVLJ"0C:3@$X'3U-)'J%K+:2W2R[8H<^:7!4QXZ[@>11H
M.S+-%11W,4DOE*W[SRQ+M(P=IZ&I:!!1110 4444 %%%% &WH70_[X_E70US
MVA=#_O\ ]*Z&N*K\1Z^&^!"T445F=)QNI_\ '\_T'\JJ"MNYCMVN&,D =^,M
MN(J+R;3M:_\ CYKL4[+8\B=*\F[F316FJV3LRI C%#A@LI)4^A]*5([*10R0
M*RGH5D)%/G\B/8ON<M>3166NVMU<N(H&MY(?-;[JON5@">V1G'TK+^U 74<S
M74UK87MY._F)E=Z!0%).,JI(/-=\8;3!!M01_OFH9+&RDNH+AH&WPA@H#G!W
M#!S2<C14[=3BY+UQ]E5M0N4L'O)$%R/O21!,\MC[H;(W4L]Y<K:O]GN7DL?M
M0074CD'R]N3\X&=N[C=BNSEL;*:XMYF@8- 6* 2'!R,'/X5-Y-I_S[#_ +[-
M'./D.)M6N[I[*/[>[6[SR_/ Y)9 H(4N0,\YY[UHWXEEU/38$GEBAD,AE\LX
MW *" 3V%=-Y-I_S[?^/FD\FTQ_Q[?^/FES"]GKN<'9WE]->)YEXL=SOD$\!=
MF**,XQ'MP,<$'/-0C49DLE4W\Y_TB$2W4+F12K9#;<C*GCD<XKT/R;7.?L__
M (^:AN+&RN##NMV'E2K*NV0C)'3/M1S#Y#C_ +5(@N!8W<MS:K+;A)B=Y#-(
M ZANXVXSZ4AGE@TMI[BYN6:>[>+<TOEI$H=L9./E7  SWXKM_)M/^?8?]]FC
MR;3/_'L/^^S3Y@Y#@(9#.-)N+N[F58;R:(2"0J"-IVY)&3GID]:LVMV[2VA%
MY,^I/.%N;1ONHF3N^7'RA1C!KMO)M2?^/8'_ (&:BB.GSJ'ABCD5AD%92<C.
M/Y@_E1S X'&Q3W%EHMOJT]S<3;'+W*OSF+)' [8X/YUH+#<3:!*ER\GVB6%V
M;8<,I8$A1].!6]>:;97T:1R1R)$'#/&DF!* <X;CIGTJSY5J3S;?^/FCF$Z?
MF<1I>93IJ0WMP]M'8!V57SND# 8)]N1BJL.IW;O*]I+(YDM7D\MI#*T3!AU&
M  P!/RCTKO9!81!3)"J;W"+F0C+'H/K3_*M/^?;W^^:.8?(</J LY]%N3;:G
M=7$4<D3N_FD[/F&><>G)':M>^E:.U@:VE9@UQ$N\'.Y"W//N*Z+RK3_GV'_?
M9H$-IGBU'_?9HYA>S?<XJR-WLTR:6[N7>ZGEBF4G"A/GQ@=B-HYK/@>:RTO3
M(&N'AM&MW<R33LA\S>0%W8.,#D#O7HODVG_/M_X^:/*M/^?;\W-',-19Q(NG
M_<KJNHR6Z_9D:.2$E!*Y)R>G) V\>_2F71^RWNM21W4XN6@B>)&8G(Z$JOM7
M<^5:=[8=<_?-((;7_GV_\?-',+D.*N+N027!-W,FI+/M@LP?E9,C;A<?,",D
MFG%KM?-N_M4Y9=3\A8OX/*+A<8[\<YKM/)M/^?8?]]F@0VG_ #[?^/FCF$Z9
MDGK16MY-I_SZC_OLTAAM,?\ 'J/^^S0Y^1*HZ[E*_P#^/U_HO\A5>MNYBMC<
M-NM]QP.=Y]*A\FT_Y]1_WV:(STV'*DVWJ95%:WDVG_/J/^^S2>3:?\^H_P"^
MS3Y_(7L7W,JBM7R;3_GV'_?9H\FT_P"?8?\ ?9HY_(7L?,RJBN#,MK*;95:X
M"'RPQP"W;-;7DVG_ #[?^/FCR;3_ )]O_'S1S^0_96ZG&Z-%/;ZM=PR6AC7[
M/"6E,H8N^7))QU).:ECN8[2?53<7#0,]TJB;;GRP8QL8^@X/)XS76F&T_P"?
M8?\ ?9I@M+$3M,+-1(RA"V\Y*@Y /KUI<Y?L_,X>--VA [?.*WZ[+K;\TZF5
M29/;/?''%:]K_P AK5=H.S=%D]M^WG]-M=)Y5H/^78?]]FF16=A"&$=F%WL7
M;]X>6/4T<_D)T_,S:*U?)M/^?;_Q\T>3:?\ /L/^^S3Y_(CV+[F516KY-I_S
M[#_OLT>3:?\ /J/^^S1S^0_8^9E45J^3:?\ /L/^^S1Y-I_S[?\ CYHY_(7L
M?,RJLW?W+;_KB/YU=\FT_P"?;_Q\U+/%;;8=UOG]WQ\YX&:3GJM"U2T>IB45
MJ^3:?\^H_P"^S1Y-I_SZC_OLT^?R(]B^YE45J^3:?\^W_CYH\FT_Y]O_ !\T
M<_D/V+[F516MY-I_SZC_ +[-'DVG_/L/^^S1S^0>Q?<R0<'(Y]JP-.FCBOK:
MVTZ]GN;9ED,\,H_U&.0>@*G=Q@]17:^3:?\ /M_X^:#%:'_EV_\ 'S2Y_(I4
MO,Y,7,=GJ.JRW+E/FAPX4G:A7 /T#;N:Q^)E,$U\S6#WV^?4MH'GD*"JGC &
M>,XQ\M>@?9+#S_/^QCSMFS?O.=N<XI_DVH'_ ![#_OLT<Q2AYG&6%Q/=:E9O
M(3*P6Y59MNWS(0R[6(]S^>,UO5I"TL1,T_V,>:RA"V\YP#P/UI_DVG_/M_X^
M:%/R)E2OU,JBM7R;3_GV_P#'S1Y-I_SZC_OLT^?R(]CYF516MY-I_P ^P_[[
M-)Y-I_S[#_OLT<_D'L?,RJ*U?)M/^?7_ ,?-'DVG_/M_X^:.?R'[%]R;0NA_
MW_Z5T-8VG+$L@$4>P;N1G.:V:YJCNSTL.K0L+11169N<[<_Z]OPJ+M4MP<S'
MUXJ*NI;'FO<Y6V1]/U75=9@5F5;]H[V)>3)$$3#@?WDZ_3-0:=J=PNG6%I8$
ME)8IKCSHT63>/-8  $@8[D]:Z](XXRY1%4NVYL#[Q]35=],T^2VCMGL;8P1\
MQQ&(;4]<#M2L.Z,VQO=4U"]\DO;VVVSCF9-N_,CEAUS]W@&JW_"0W+VC2QI$
MCP(D5QYGW8IV?;SZ!0"WXBNA2&&-MT<4:-M"?*H!VCH/H,TGV> +*H@BVS$F
M4!1B0D8.[UXHLQ71BW&IWFG7ILY;F"YP\!,P0+M5W*E6 .!V(-.NM3O7N+^"
MQ,3_ &>ZCARNUG"E-S!02 S9[9Z5J1Z;816LEK'9VZP2??B$8VO]1WI/[+T\
MVYM_L%L86()C\L8)'0_6BP716_M":?PY]NLI(I9VC!1I!Y:ELX.03P>O&<9J
M@-?DM($N;F0R0+))!/OA$;I*%W(" 2.>G'!)%;@AM9;3R!'"]L1M\L*"F/3'
M2JEQI$4T=M:1)!#81RK,\"Q_?93E1Z 9P3WXH"Z*,&HZE%J-K%?R1Q1RF.,>
M5&'4R.N2K'.48'@<8.*I6^H:E:VD,)N7N9;F^GB$@B4F,(2< $@$G' /2ND^
MRV4UT+X00/<8P)PH+<<=::VFV$@F5[.W83,'E!C'SMZGWH'=&1;ZAJ]W<VEI
MO@MFD2=GE*!V8(0%8*#@$YY&>*?IFI:A-)I<EW) T>H12,8XTQY3)CH<\@Y[
MULQ6MM (Q#;Q1B-2J;$ V@]0*5;>!/+VPQKY0(CPOW,]<>F:!710GN;J76)+
M."[AM%@@68M*@8R;B?4C"C')'K6!H]_>+HT"V26K3_889 XQ\VZ5PVTG&>!\
MH/>NKN;&TO"AN;6&8I]PR(&*TC6%F\1B:T@,14(4\L8V@Y QZ DFBP[HR+?4
M[F_EM;2&\2*1UE,L\D #;D8+L"9QD9R>?I3;75;^]GM8TDA5=EPTSQQ[O-\I
MP 4YX#?I6P^FV,MJEL]E;M ARD9C&U3["I4@AC,92)$,:[$VJ!M7T'H*+!='
M-S75U=0Z'=S7EJ\=U>Q.+9%P4ZD!3G)(Z'-+9:WJ=SY-PT(\B=96*,BJ(]H)
M&T[LL00 01WK>33;".X-PEE;K,6W&01C=GUSZTJ:?91W#W"6=NLT@(>01C<V
M>N3[T6871@OJ>K0Z98WDUQ"4E@^T3O#"&,? X"%@2G7+#FNE5@Z*ZG*LH(/J
M#4$VGV5PL2SV<$@B_P!6'C!V>P]*L4Q,****!!1113 **** "@444 2W7_'R
MWT'\JBJ6Z_X^6^@_E452MARW"BBBJ$%%%%( HHHI@%%&!_DTA95R695 Y))Q
M@4 +11U&001ZYXHR#T(- !1112 **** "BBB@ '6I9_NP_\ 7/\ K47>II_N
MP_\ 7/\ K0^A2V9#1113)"BBBD 4444 %%%("I)4,I8=0&!(^HH 6BC@'!('
MU-(K*XRK!E]001^= "T4<'/.<>]%, HHHI %%%% !1110!=T[[X_WA6S6-IW
MWQ_O5LUA/<[:/PBT445!L<Y<?Z\_05'4D_\ KC]*CKJ1YC"BBB@##U)[M/$^
MG_8X(IG-G/N664QC&Y.<X.:HQ:G>65SJ/F6Z"[N=12%4C+2JG[E3G  )X'3B
MNG-O&TZW'EJ9D4HKXY53@D?0X'Y5#-IMG.DR26Z,)W#R=B6  #9Z@@ <B@I,
MR?[8OS:JODK%=F5U56MI&,J* =X0'*CG!R>/>IK#5;W5)+4626T3&V2YE,P+
M#+$C: #TX.3VXJVVBZ<T,<36BE(R63YF!!/WN<Y.>_/-$FC:=+%!$UG&$@79
M$%RNU?[O!Z>W2E9A='.V6LW%CX>@,"Q/)''+/+"L;28'F-_$" H.#@G/2MZW
MO;Z]OI19BVC@MW1)/.W%W)4,<$'@8/!YR12OH.DO$D36$/E(AC"+D+MR3M('
M!&2>#ZU++I5A-<1W$EJAFC"A6Y'"_=!P><=LYHLPNC$TB]O++3[(RQPFSFGG
MC"H#YBX+L&ST.=IXQWJUI6LWU_/;&6S(MKF,R*RPLOE<9&6/#Y]N]:R6=LB0
MHL"!87,D8Q]UCG)'YG\ZBMM+L+.=I[>V6.0@C()X!Z@ G S[4:@VBY1113)"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ H]:*/6@"6Z_X^F^@_E452W7
M_'RWT'\JBI(<MPHHHIB"BBB@ J&[N!9VDURT;R")"^Q!EFP.@%34<YXSGVH
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M_D,TOFV?_/U_Y#-,CYBT4WSK3_GY_P#(9I?.L_\ GY_\AFD,6BD\ZT_Y^O\
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M\W[+M&"V=V-W7;NYQ4EKIT=G<13+([-&LB@''.]]Y_6C4+Q*R:V)+R(+;O\
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MMDETL[I";:'$?E[5; 9FY.3M'08%;*(L:+&G"J H^@XIHF5N@M%%%,@****
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M6FEDF"D8P&.0"/IBK]!+W"BBBF(**** "BBB@#;T+H?]_P#I70USVA=#_O\
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M]\?RKH:YW03P?]_^E=%7%5^(]?#? A:***S.@PKMV6Y8 )T'5 :@\UO[L?\
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M]^Q1YK?W8_\ OV*9119!=C_-;^['_P!^Q1YK?W8_^_8IE%%D%V/\UO[L?_?
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MK#E5E=FC_:,/_/I_Y$/^%']I0_\ /I_Y$-9^*,4^1$^UD7_[1A_Y]3_W\/\
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M1110 4444 %%%% !1110 4444 %%%% !1110 8HQ110 4444 %%%% !1110
M4444 %%%% !BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *2EHH
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MW$OWI".YK1HJ7)O<84444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2OF'XXQQI\1W*(JE[*)
MG(&-QY&3ZG@445V8/^*1/8\WKWO]GF-/[(UR78OF?:8TWXYV[>F?2BBN[&?P
MF8P^(]K[TE%%>&SI"BBB@0M%%%,8@I:**D IK=***8'+>.[B:VT2-H)I(F,H
F!*,5)'X5I>9)_;.FIO;:UJ[,N>"?EY-%%6MC3[*-D4M%%(S/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>forms-1a_014.jpg
<TEXT>
begin 644 forms-1a_014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #" F\# 2(  A$! Q$!_\0
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M:6KQI<74,+2MMC620*7/H,GD_2K&: ,#_A,=+_Y]=<_\$5[_ /&:/^$QTO\
MY]=<_P#!%>__ !FM_-&: ,#_ (3'2_\ GUUS_P $5[_\9H_X3'2_^?77/_!%
M>_\ QFMB&]MKF66*"XBEDA;;*J.&*'T;'0\5/GWH P/^$QTO_GUUS_P17O\
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MY7#J&4@J1D$=#2YH P/^$QTO_GUUS_P17O\ \9H_X3'2_P#GUUS_ ,$5[_\
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M?"6CP7>L7"V:YUA(X[R,_<=44JH"CIP30!Q$OC3QCH]JAU2STUVU%[>+3IE
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M]!^/_P %Z?\ Q5 'K%%>3_\ "1>*O^@_'_X+T_\ BJ/^$B\5?]!^/_P7I_\
M%4 >L45Y/_PD7BK_ *#\?_@O3_XJC_A(O%7_ $'X_P#P7I_\50!ZQ17D_P#P
MD7BK_H/Q_P#@O3_XJC_A(O%7_0?C_P#!>G_Q5 'K%%>3_P#"1>*O^@_'_P""
M]/\ XJC_ (2+Q5_T'X__  7I_P#%4 >L45Y/_P )%XJ_Z#\?_@O3_P"*H_X2
M+Q5_T'X__!>G_P 50!ZQ17D__"1>*O\ H/Q_^"]/_BJ#XB\4X_Y#\73C.GI_
M\50!ZQFBN/\ "'BRZU:ZGTO58H(]0A02I)!D1W$><%@I)*D' *Y.,CGFNPH
M**** "BBB@ HHHH **** #-&<UA^*/$"^'=+%P(3<7,TH@MK<-M\V0@G!.#@
M !F)[!37!_\ "2^+)&+OK5I$S'_5P:>"B^P+.2?J?R% 'K%%>3_\)%XJ_P"@
M_'_X+T_^*H_X2+Q5_P!!^/\ \%Z?_%4 >L45Y/\ \)%XJ_Z#\?\ X+T_^*H_
MX2+Q5_T'X_\ P7I_\50!ZQ17D_\ PD7BK_H/Q_\ @O3_ .*H_P"$B\5?]!^/
M_P %Z?\ Q5 'K%%>3_\ "1>*O^@_'_X+T_\ BJ/^$B\5?]!^/_P7I_\ %4 >
ML45Y/_PD7BK_ *#\?_@O3_XJC_A(O%7_ $'X_P#P7I_\50!ZQ17D_P#PD7BK
M_H/Q_P#@O3_XJC_A(O%7_0?C_P#!>G_Q5 'K%%>3_P#"1>*O^@_'_P""]/\
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M/#7_ %_2?^DL] 'L0Z5SFE_\C_XB_P"O6R_]K5T=<YI?_(_^(O\ KULO_:U
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MF1I%5VA:1UW-RQ7$8S[GVKK-U;GC+0+#P[%ID=BCC[9J=S<RL_):5XG8\X]
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MT)L^-O#7_7[)_P"DL]9^^KOAT-)XW\.;5)VW4LA]E%M,,_FP_.@#VJN;TO\
MY'_Q%_UZV7_M:NC'2N<TO_D?_$7_ %ZV7_M:@#I**** "BBB@ HHHH ****
M,?Q/_P BSJ/_ %P:M2#_ %*?[H_E67XG_P"19U'_ *X-6I!_J4_W1_*@"2N;
M\7>%(O$]C"HG^RWUK(9+6Y";MA(P5([JPX(R.W<5TE% 'C4_@SQ=;N$_LJSN
MN,^9;7X"_B)$4@_G]:C_ .$3\7?]"^O_ ('Q5[3BDXH \7_X1/Q=_P!"^O\
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MRUO-@X]5D4;<CL"W0\]*]EI,"@#Q;_A$_%W_ $+Z_P#@?%2_\(GXN_Z%]?\
MP/BKVCBCB@#Q?_A$_%W_ $+Z_P#@?%1_PB?B[_H7U_\  ^*O:>** /%O^$3\
M7?\ 0OK_ .!\5'_")^+O^A?7_P #XJ]II.* /%_^$3\7?]"^O_@?%1_PB?B[
M_H7U_P# ^*O::* /%O\ A$_%W_0OK_X'Q4?\(GXN_P"A?7_P/BKVFB@#Q;_A
M$_%W_0OK_P"!\5'_  B?B[_H7U_\#XJ]IHH \6_X1/Q=_P!"^O\ X'Q4?\(G
MXN_Z%]?_  /BKVFB@#Q;_A$_%W_0OK_X'Q4?\(GXN_Z%]?\ P/BKVFDXH \7
M_P"$3\7?]"^O_@?%1_PB?B[_ *%]?_ ^*O:.*6@#Q;_A$_%W_0OK_P"!\5'_
M  B?B[_H7U_\#XJ]IHH \6_X1/Q=_P!"^O\ X'Q4?\(GXN_Z%]?_  /BKVFB
M@#Q;_A$_%W_0OK_X'Q4?\(GXN_Z%]?\ P/BKVFB@#Q=?"/BYW5/[#ACW$#=)
MJ";5]S@$X^@/TKL?!W@F;1[XZMJT\,VHE#'%';Y,5NI/."V"S' RV!TP!7;D
M9HQ0 F*YS2_^1_\ $7_7K9?^UJZ2N;TO_D?_ !%_UZV7_M:@#I**** "BBB@
M HHHH **** ,?Q/_ ,BQJ/\ UP:M2#_4I_NC^59?B?\ Y%C4O^N#5J0?ZE/]
MT?RH DHHHH *YWQEXHC\'^&[G6I[*XNHH"H9(648W,%!))X&2!P">>G6NBK@
M?C(CW'PMU:V@C>6>5H!''&I9G(F1B !UX!/T% &MJWBPV5QIUC9:=)?ZE>V[
M72VRRA D2@%F9B#CDA0,<D]NM9FK?$[3-(T;0=9:VDDTO5Y!$)RX5H&/7>I[
M+AL\\8K.U&XCT?Q?H?B6Z5CID^A26!F2(OY<N5D4$#D;@"!QUX[UA1^&Q'X,
M\$>'M:B:/[1-=FX1D),(F64J6]"&D3KWQ0!Z!XT\;67@NSLYKF%KB:\N!;PP
M(X5F)_BY[#C/U%9.J?$B;2=2U6SE\.7<XTF*.>]EMKA&$<;C(8 X+8 .<#M7
MF>KZ;KUQX1MIM=@+WNF7]OI-JD4;L6B@<^9-TR0V%^;_ &?>NQ_L.R\5?$_Q
M;:W=S?1V%U9VJXMW,:7(5?G4MCD#(R >] &[=?$F*7^TY-$TQ]4MM+M(KN[=
M9Q$P21/,78I!W?+R>GH,GBMA/$URWC"/P_\ V42'MOM8NOM"[?*Z?=QG.XXQ
MZ<YKSKQI9:+:ZGJ,^E7-[H'B/2((X+"2U1RM_&(D*)@*0^"=F.<87/'3HM)U
M&>;XEZ6^IPM;WTGA]([A5C;RTN&8.T8;D9'/&>U #S\54MY+E[_0;J"QM+\:
M==7B3HZ0S'&.."5Y'S8[UWOVJ'Y\S1#8N]OG'RC&<GT%>4^$O#.G^)M4\3?V
ME)>-;IKQO(K7>4AF  V.01\PR#WP<5SFFI;7GC&P+Z3,GFW>H6]S:G39"P#Y
M($\Q7$I8X; ^5%Q0![+::^NJ?V7<:5 +S3;T.S78E5!$H7(.P_,V3Z=,Y-:Z
MSQDN!(A*?? 8?+]?2O!_#MO!#;>##H]BUIK$-G>6\LCVKQ@7+0X0L2N#E\#=
MT)XR:S[73-(N_!^IM'I^KKK$6BR6VH0RVWEQ^<""FXA<RRM+AEY)P&)/&" >
M^ZEK.GZ3IUQJ%]=PPVMN/WDC., ^GU/&!UYJT+J%B@$L9+C*C>,D>U>":WHV
MEBPUZVTC308I= LYC''"S!KE)6WMSU<(1GO@_6KACT]_B-876C6$<]F]]91K
M93V;P36JK&K+-;G:,1 ,2R-CG/\ >& #W'SX]X3S$W$XV[AG.,XQ0)HVE,0D
M0R*,E-PR!]*\#O=$TF35/$MOI4!7Q5%X@A.F&,N71?W;.<CHNWS"Q/X]JEL;
M'3[B^GCU:UU3_A);6:]^V;8/+C>)PV9'EQEXRNP!=V<D <<T >RZ[XBTWP_H
MEUJU_<*+6V0,VPAF8G[JJ.Y;(Q]:Q3XLU6V?3)-3\-RV=KJ%S';K(+H2/ TA
MPGFH%^7)P."0">:\^?P6TGP5TR?P]IQ?54-K=WENV[?<O%G<A4]QDX'H,#M6
MOXG\2KXFU'PJGA^_U-/M5ZBZC:Q"2)HK;.7\T8^0CIG/T/>@#U43QY*^8F0,
MD;AD#UI/M,.(SYT>)#A#O'S?3UKP2RT"RM_!(U.STJ5Y(=9>/5@L4AE>P\YG
MV!3]Y"/+8@=0#[U/>VEI;WM_K6G63#PU:^)--NK5XK5BL0 !N7C7&X+G&=HP
M2.* /=%N873>LT;(3@,'&,^E2(ZR*&1@RD9!!R#7SWY/AVZ^RRW>GF&R_P"$
MOD7;/:R0H+:2-SC:0!@E 2.H &<5Z=\+K,67A_4$MXYH],?4YY--24%2+8D;
M<!N0I(8C/U[T =Q1110 4444 %%%% !0111D"@#GO%?A/3_%FE_9+LO%/&WF
M6MW$=LMM(.CH>H[9'?\ *N+@^(NJ>'!)X;\1:=->^*8]JV M4.S4U/"N&Z+T
M^;/3!^E=7XR\8P^&+>&"W@-]K5ZWEV&GQ_?F?U/H@[FN?L_A7#J5A<7_ (JN
MY;KQ+>,LK7UO(4-FPY18/[H7]: -SPIX5N+&[FU[7ITO?$=XN)9@/DM4ZB&$
M'[J#UZL>3775Q'ASQ)?66KCPIXH9%UA5+6EX!MBU&(?Q+Z2#^)/Q&17:@@T
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MG\Z\?^V:S_T,NL_]_(O_ (W1]LUG_H9=9_[^1?\ QN@#V C/>C;SGOZUX_\
M;-9_Z&76?^_D7_QNC[9K/_0RZS_W\B_^-T >A:_X737[[3+J35-0M&TV;SX4
MMFC"F3!&Y@Z-G@D?0FMX=<^M>/\ VS6?^AEUG_OY%_\ &Z/MFL_]#+K/_?R+
M_P"-T >Q45X[]LUG_H9=9_[^1?\ QNC[9K/_ $,NL_\ ?R+_ .-T >Q9I-PK
MQ[[9K/\ T,NL_P#?R+_XW1]NUQ>8_$VKJXZ%C"X_(QX- 'L(.:6N*\'^*;R_
MOY='U9HI+M(O/M[B)-@GC! ;<O0,I9>G!# BNTS@4 *3BN7\8^,8/#%O!#!
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M'VS6?^AEUG_OY%_\;H ]@QCI^-8-MX6AMO&%UXE&H7KW5S +=X&,?E",'(
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MW]_0_P#O_-_\17KN*,4 >1?\*^\7?W]#_P"_\W_Q%'_"OO%W]_0_^_\ -_\
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M^_H?_?\ F_\ B*]=Q1B@#R+_ (5]XN_OZ'_W_F_^(H_X5]XN_OZ'_P!_YO\
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M$M\.?]![3/\ P*3_ !K0_LZR_P"?.W_[]+_A1_9UE_SYV_\ WZ7_  H S_\
MA+?#G_0>TS_P*3_&C_A+?#G_ $'M,_\  I/\:T/[.LO^?.W_ ._2_P"%']G6
M7_/G;_\ ?I?\* ,__A+?#G_0>TS_ ,"D_P :/^$M\.?]![3/_ I/\:T/[.LO
M^?.W_P"_2_X4?V=9?\^=O_WZ7_"@#/\ ^$M\.?\ 0>TS_P "D_QH_P"$M\.?
M]![3/_ I/\:T/[.LO^?.W_[]+_A1_9UE_P ^=O\ ]^E_PH S_P#A+?#G_0>T
MS_P*3_&C_A+?#G_0>TS_ ,"D_P :T/[.LO\ GSM_^_2_X4?V=9?\^=O_ -^E
M_P * ,__ (2WPY_T'M,_\"D_QH_X2WPY_P!![3/_  *3_&M#^SK+_GSM_P#O
MTO\ A1_9UE_SYV__ 'Z7_"@#/_X2WPY_T'M,_P# I/\ &C_A+?#G_0>TS_P*
M3_&M#^SK+_GSM_\ OTO^%']G67_/G;_]^E_PH S_ /A+?#G_ $'M,_\  I/\
M:/\ A+?#G_0>TS_P*3_&M#^SK+_GSM_^_2_X4?V=9?\ /G;_ /?I?\* ,_\
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M]+_A1_9UE_SYV_\ WZ7_  H S_\ A+?#G_0>TS_P*3_&C_A+?#G_ $'M,_\
M I/\:T/[.LO^?.W_ ._2_P"%']G67_/G;_\ ?I?\* ,__A+?#G_0>TS_ ,"D
M_P :/^$M\.?]![3/_ I/\:T/[.LO^?.W_P"_2_X4?V=9?\^=O_WZ7_"@#/\
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M_2_X4?V=9?\ /G;_ /?I?\* ,_\ X2WPY_T'M,_\"D_QH_X2WPY_T'M,_P#
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>forms-1a_016.jpg
<TEXT>
begin 644 forms-1a_016.jpg
M_]C_X  02D9)1@ ! 0  W #<  #_X0" 17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (  (=I  0    !    3@
M      #<     0   -P    !  .@ 0 #     0 !  "@ @ $     0   H2@
M P $     0   DL     _^T .%!H;W1O<VAO<" S+C  .$))300$
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M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" C_W0 $ "G_V@ , P$
M A$#$0 _ /[^**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*\*_:,_:6^!7[)7PGU/XX_M%^)M,\)^%M)4->:KJDFU2[<)%$B@R2RN>$CC5
MG;L*]TSSBO\ */\ ^#HW_@H]X_\ VT/^"@^J_LN^$[RX;P'\)=2?POI&D6KD
MQ7^OC:FH7LB*<22>;_H\61\B)@8+,2 ?NW^TC_P>R? SPMXBN-'_ &6?A!KG
MBVR@D,<>L^+-3CT2.Y4?QQV\,5W*JGMO(;U KSSX._\ ![YX5O\ 78K7X^?
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M^ ($GB:)I;"VEM;A0PQF.6&1'1AV93D'F@#Y)_X)E_\ !S3^PC_P4>^*=C\
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M;_T??5_H64 %%%% !1110 4444 %%%% !1110 4444 %%%% '__0_OXHHHH
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MD18EAFPT]N-TKR QR%1N#?Z"/Q41(_A?XB5  !H.H  < ?Z-)7^51_P;>_\
M!7WQ-_P3;_:XMO@3\9=1GA^$OQ#U2'1?$=I?R,D/A_5I'$-OJRJW$01SY=V,
M#,1W-S& ?]5+XG3PW/PK\07,#K)')X?OWCD0Y5E:VD(((X((Z&@#_'E_X(+?
M\IJO@/\ ]E$'_HF>O]%C_@Z$_P"4*GQ;^F@_^GJRK_.G_P"""QQ_P6J^ _\
MV40?^B9Z_P!%C_@Z$_Y0J?%OZ:#_ .GJRH _S-_^":O_  4Z_:P_X)@?$#Q'
M\1_V2TT5]4\2Z/%HNJG6M,.I(+6*83KY:ADV-O R>XXK]"?VC?\ @XT_X+0?
MM@_##5O@5K6KPZ;H_B2RETC5;7P7X;6TO+NTN5,<MN)PLLRK(I*MY;*Q!(SS
M7Z*?\&5_AKPYXH_:^^,-GXFTZPU&)/AS9.D=_;Q7"JW]I(,J)%8 XXR*_P!(
M?2/ G@CP].+G0=&TJRD'22SM(86'_ D130!_GQ?\&O/_  0A_:$T3]HG1_\
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M "BBB@ HHHH **** "BBB@#_T?[^**** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*,BORR_X+%_\%'_#/_!+W]AOQ-^T;=K;W?B.4#0/ VD7#8%]KUXK"W##J8H%
M5YY<?P1E>"0:_'7_ (-[/BE_P4U_;H_8#^*_[3?[1_Q2\2ZAJGBM=3\,?"AI
MH+*!-/N+&W8/J< 2V56)O7$2[@R 0L,'F@#^M>BO\QK_ ()(?\%YO^"E>O\
M_!5+X9_ +]KKXIZSK_A36?&,O@GQ!I&HPV,,)N[M9;.W+-';1NICO#&?O#I@
MU_H[?M*_&?1_V=/V=_'/Q\\0M&EGX,\):KXFG\YMJ,-.M9+@(6[;V0+^- 'M
M^0>E%?XZ=]_P<?\ _!9:[OIKFW^-WB.%99GECB6VTW9&&)(4#['T ./H*_U<
MOV"?VB+?]J[]BOX6_M&1W$=U-XN\#:1K-_+%C'V^6V07BX'0K<"12,#!&.*
M/KJBO\TS_@N+_P %Z/\ @HE\-?\ @J7\0?V?OV//B5K'AKPMX5O['PC9:3I=
MO9R))J<$*+>/F:WE<NUR[)C=C"C@5_5G_P %9?CK^U=^QE_P0SN_BUX<\7ZM
MI_Q6\/>&O",.J^*S';F]?5)Y[.+47=&B,.9'>12!& ,\"@#^@"BO\C[X%_\
M!9?_ (.)_P!I[5+_ $3]G/QS\4/'%YI5NEUJ5MX6T2TU*6VAD;8DDJV]BQ16
M;@$\$\5])?\ #9__  =K_P#/C^T)_P"$;_\ >V@#_4OR*,@=:_A _P""'O[2
MO_!P=\1_^"C'A'PI^WO;?&&+X93:9K;ZRWBSPT-.TSSX["9K3S;C[%#M/GA=
M@WC+8'.<']R/^#DS]K#]H+]C#_@F5J/QO_9E\2WGA3Q1!XUT'38]6L$A>46U
MT\BS1XGCD3#@#/RY]#0!^^]%?Y)GP)_X+!_\''/[4/\ :7_#./C/XJ^.?['\
MG^U?^$6T*UU+[)]HW>5YWV>P;9OV-MSC.#CI7T)_PV?_ ,';'_/C^T+_ .$;
M_P#>V@#_ %+Z,BOXB_\ @@!^T3_P7C^*'[>3^&_^"C-O\6H?AZ/!>JW"GQEX
M=&F:<=31X/L^9_L<!\S!?8H?GG@XK[Z_X.G?VW?VI/V$OV,_ 7Q,_91\7ZAX
M.UK5/B1%HVH7VG1V\CSV;:;>3&%A<12KM\R-6X .1UQQ0!_3UD45_++_ ,&J
MG[=G[5?[>?[*?Q+^('[6/C#4/&6JZ+\0HM'TR[U&.WC:WM#IL$QC46\40P9'
M+<@GFOJ3_@NM_P %O?A=_P $H/@G+X=\*36.N?&3Q-82#P=X69PXL4D#H-6U
M%!RMK$ZGRT.#/(-@^4.R@'[[9%%?YK/_  1P_:P_X."?^"N?[0:^$]"^./C'
MP]\/=%G2Y\=>.UTS3FMK*+<K?8K0FS$;WTZDB&/)"+\[_*,'_2*\,Z+)X<\.
MV'A^:]O=2:QLX;1]1U)UDN[HPH$,T[HJ*TLF-SE54%B< #B@#<HR**_ #_@O
M#_P7"\'?\$B/A1I.C^$=+M/%'Q3\90W#>%]"NY2EG8VT&$?4M0"$2-"KMMCB
M4J97!&Y0K&@#]_\ (HR!UK_)[F_X+F_\''7QB\*:M^U)X+U[QP/!6EW#R7FL
M>%_!]J?#.GA#EHWE^PRQE(^C&65R!]]J_JM_X-T_^#A3QA_P4PU[4OV4/VL;
M32K/XH:1I#ZYH^O:3&+6T\16%NR)<*UJ"5BO(-X=A&?+D3<RJFTB@#^M?('6
MBOX?O^"Z_P#P4[_X*(?\$BO^"IW@#XF>&_%.L:[\#/%>GVFLS> [R.U-C,UH
MS6FKV$4X@$L;[#'<0DR95W!.5R*_LN^"7QE^'O[0OPA\-_''X4:A#JOAOQ7H
M]KKFC7\!#++:W2!TSCHRYVNIY5@5/(H ]3HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]/^_BBBB@ HHHH
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MP2AU+X::_= W7PC\6ZM83AV^9-)U!?[5MG8^@>2Y0>BQX[5T7P]_X)A/>_\
M!K:G['.HZ>8?$FH_":;XAFW"$S#Q!,Q\0P(4ZB7<$@*GH>#TK^+C_@BW_P %
M%KW]B3X#?M8_#E]2CT^3QE\&;B;PXEPXC+>(+.;[%"D8/65H+^9L=<1\=* /
M/_\ @G'X(U'_ (*(_P#!>3P=<>(/,O(O%'QDO?'6LLPW;K'3KJ;6)5<'JC)
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MNLV-O:);+:7#3B1&A9BQ8G&#P/Y?/_\ P=W_ /*'/5O^RA>&?_1LM '\R_\
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M 4444 %%%% !1110 4444 %%%% !1110!__4_OXHHHH **** "BBB@ HHHH
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MXC=OV1O^B*?$?_P8Z9_\77[-?\0UO_!%G_HB>D_^#+5/_DJC_B&M_P""+/\
MT1/2?_!EJG_R50!\D_\ !.7_ (.C?V>/^"C_ .UMX;_9(\!?"_QKX=U/Q''?
M2P:OJ][82VL(L;9[EMZ0L7.X)M&!U/I7S'_P>K<_\$]_AH!_T5N'_P!-%_7[
ME?LU?\$1?^"8W[(/QCTOX^_L[_"_3_#GBS1EN$TW5X+Z_F>$7430RX2:X>,[
MHV*\J<9XKZ@_;&_8/_95_;\\":9\,_VL_"=MXNT31]6&N:=8W,]Q;K#>K%)
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M% !11FF[UQD$'Z<T .HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH __];^_BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M* /[8QTI:_EU_P"(O7_@CU_T%_'W_A,3_P#QZC_B+U_X(]?]!?Q]_P"$Q/\
M_'J /ZBJ*_EU_P"(O7_@CU_T%_'W_A,3_P#QZC_B+U_X(]?]!?Q]_P"$Q/\
M_'J /ZBJ*_EU_P"(O7_@CU_T%_'W_A,3_P#QZC_B+U_X(]?]!?Q]_P"$Q/\
M_'J /ZBJ*_EU_P"(O7_@CU_T%_'W_A,3_P#QZC_B+U_X(]?]!?Q]_P"$Q/\
M_'J /ZBJY_6?%?AGPY=6=EK^H6-C-J-P+33XKNXCA>YF;I'"KLID<Y'RKD^U
M?S*_\1>O_!'K_H+^/O\ PF)__CU?S;_\%ZO^"S7[)W_!37XN?LXR_L<:OXI%
MUX(\9W%UJLNI6$VD-$]]<Z?]F>%O,)9@87Y&"OXT ?Z:5%%% !1110 4444
M%%%% !1110!__]?^_BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MDU_T0#X:?^"E/\:/^')?_!)K_H@'PT_\%*?XU^I-% 'Y;?\ #DO_ ()-?]$
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MT_\ !2G^-?J310!^6W_#DO\ X)-?]$ ^&G_@I3_&OYE_^#@O_@C%I&D_%/\
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M^%_#4FJ6VBPWQM+J]:6]NP[1Q)#:12R,=D;N3MP%4DGU /K.BN<\'>+O#/Q
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M%=]\"OV<OA_\$=3NHK^Y\&^"=#\*W%] I2.XETFPAM'E16Y"N8BP!Y ->V4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__2_OXHHHH
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M'_IO@KWBO!_V6/\ DV+X<?\ 8AZ!_P"F^"O>* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH 0G KX-^*?\ P5'_ ."<OP1\
M9WGPY^+7QN^&>@:]I\K07^DZCKUG'=6TJ'#1RQ^861U/!5L$=Q7WF>E?Y[/[
M2'_!F5^TQ\5_V@_&_P 4O!?QG\$II/B7Q7JGB"PCUJPU#[>D6HW4ER$N/*$B
M&1/,VEE8AL9XS@ ']=__  ^A_P""3G_1PWPG_P#"AM/_ (NC_A]#_P $G/\
MHX;X3_\ A0VG_P 77\%/[5?_  :&_M0?LH_LV>.?VEO%'Q;\ :IIW@7PQ?\
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M$9_P9(_\GL_&'_LED'_IVMJ+ ?Z45%)E:,K0 M%)D4M !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!__U?[^**** "BBB@ HHHH *^(_^"D/[6.K
M?L,_L-?$O]K+0-&3Q!?^"/#<NJV.D2LZ0SW#2)#%YS("PA1Y \A&#L4X(ZU]
MN5^3/_!<[XY?$S]G+_@E-\9/BU\)+&UOM:L?#2V<:WUG'?V\-OJ%S#9W,\EM
M,KQ2K%#*[XD5DXRP(% 'X*^!/^"M_P#P5U_9\U3]E;X]?M6:Y\(_'WP__:B\
M0V>BQ^#?!FER6NKZ!'J$D"12P7*2OYYB6X#29\U593&QR0U?77[</_!2O_@I
M7\9O^"H&K_\ !+G_ ()3Q> ]&U;P%X+_ .$O\<^+?'4#W:2320Q3QV<"*'6-
M2+B"('RF9I)"2R(N:_G0UCX+?LM?\$\?AS^PW^VM^P-\0O\ A8/Q?\3>+M-T
M_5?!^HWEMKEM>1:NB?VBMKI;*_\ 93V\[BU4QJCAI P.],U^N7PI^-?PL_8C
M_P"#I_\ :&\5_M2:YIG@G1_'?PJM-0\.ZSXBG2QLKD0VNF3NB7$Q6,G%I.H^
M8;FC*C)XH _9_P#X(@_\%1/%?_!1O]DW5/&'[0=CH_AKXD> ?%EWX$\>V%@Q
M@LC?VH#1W$22NYB\Y=P:/>VUT?:=I%?S6_\ ![]K&D:LO[-ATJ[MKG9)XXW_
M &>5)-N?[%QG:3C..,UY/_P3B_X)>_%S_@K5^P!^T!?_  A\7Q> M+\=_M3R
M^-_#7B#4(+EX[RPTV&^6552W:-P2U_&,YVY1@>1Q^*'_  6R_P"",OQG_P""
M2?\ PKA_BW\2K'XA'QV^MBP%G!=P_8/[(^Q&3=]JDDSYOVM<;<?<.>U '^LK
M^RQ_R;%\./\ L0] _P#3?!7O%>"?LJ)Y?[+WPWCZ[? /A\9^FG05[W0 44AK
M\)_C7_P<C?\ !(KX"?%77?@WXV^)%Q/K/AS4)-*U5M%T>_U&T2[@.V:)+F"%
MHI#&^4<HQ 8$9XH _=FBOYU_^(J+_@C'_P!% UW_ ,)G5/\ XQ2?\14G_!&+
M_HH.N?\ A-:I_P#&* /Z*:*_G6/_  =1?\$8N_Q!UW_PFM5_^,5^MW[%W[<_
M[,7_  4$^$!^.7[*GB1/$F@1ZE-H]W(8)K2XM+ZW56>">WN$22-PKHPR,,K
M@D4 ?7=%%% !1110 444F0* %HK^<?\ :*_X.G/^"3G[-GQEU_X'^)M9\::W
MJOAK49](U6Z\,Z']KL$O+5VBGACGEG@\PQNI4LBE"1PQKQ/_ (C$/^"07I\4
M_P#PFXO_ ).H _JDHK^5O_B,0_X)!>GQ3_\ ";B_^3J/^(Q#_@D%_P!53_\
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M_,%'_!(OX&=?^$L^(/3_ *"D7_R/2_\ #HSX&?\ 0V?$'_P:1?\ R/7]1_\
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M+ZDDDU^CE%% !1110 5_"W_P<"8_X?G?L_?]DJU;_P!'7]?W25_"U_P<"_\
M*<W]G_\ [)5JW_HZ_K]'\'_^2IRG_K]#_P!*1]+P:_\ A6P?^./YG"8P,444
M5_O2?WZW8****!7$_&E^M%% [WT/S)_X*J ?\*%\-C_JHVA?SEK_ $^?"_\
MR+.G?]>-O_Z+6O\ ,&_X*J?\D&\-_P#91]!_G+7^GSX7_P"19T[_ *\;?_T6
MM?Y _30?_&:S_P"O</U/X[\;?^1V_P#!']3=HHHK^33\A"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "ORO_X+?_\
M*([]H3_LF6K?^@"OU0K\K_\ @M__ ,HCOVA/^R9:M_Z * /XV/\ @R3_ .3I
M/CC_ -B3I'_IQ:O]'>O\XC_@R3_Y.D^./_8DZ1_Z<6K_ $=Z "BBB@ HHHH
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M *]FHHH **** "BBB@ K^ K_ (/CNG[-7_73QS_[A:_OUK^ K_@^.Z?LU?\
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M_M.:AJ&D_LX_$?X\>/+K28(KG5+?P?;W6KR6D,S%(Y)UM()#&KL"%+8!((%
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M\'?\C;!_XX_F<)1117^])_?KW"BBB@04444#6Y^9/_!53_D@WAO_ +*/H/\
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MBG3X=+UAM6M4U17M[:4S1A%G@8(=YR2.>U?JG_P^A_X.%S_S4/X6?^$[9_\
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M'?#OBS]IK_@ECK_BG5)==LK3PWXPTGQ;>,^H:4T+FYBBGM7C1HV8DE9%+1R
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M9]GEQMSC;SC(H _T9?V6@3^S'\.?^Q#\/_\ IO@K^.3_ (.,O^4R_P"S8/\
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M **LJ_0VO\4_IV_\EW/_ *]4_P F?ZB?13_Y)&E_CG^84445_&=S^E HHHH
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M  5B_P"35A_V-.E?^A25_J0^$/\ D4]+_P"P=;?^BEK[SA[_ '9>K/\  _\
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M_$3XDZ%)=*L=S+HNHBQ:9%)*K(8-A8*22 <XS7[*T5:^DAQLE;^UI_\ DO\
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MD&\-_P#91]!_G+7^GSX7_P"19T[_ *\;?_T6M?Y@W_!53_D@WAO_ +*/H/\
M.6O]/GPO_P BSIW_ %XV_P#Z+6O\@?IH?\EK/_KW3_4_CSQN_P"1V_\ !']3
M=HHHK^33\A"BBB@ HHHH **** "BBB@ HHHH *_B;_X+V_\ *<K]F[_LE&L_
M^EMW7]LE?Q-_\%[?^4Y7[-W_ &2C6?\ TMNZ_//%S_DELV_Z\U/_ $EGX]](
M3_DA.(?^P:M_Z1(U****_P "C_D0"BBB@ HHHH _*;_@LM_R9B?^QRT7_P!#
MDK_1S^&O_).]!_[ UE_Z(2O\XS_@LM_R9B?^QRT7_P!#DK_1S^&O_).]!_[
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M_P#DJ<J_Z_0_]*1]'P=_R-L'_CC^9PE%%%?[TG]^O<****!!1110-;GYD_\
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MN/[/WC;3_CK^P5X6\(?%OP3;Z+]C\4?"G5&;3]=-Y'-))_:&F7P91)NB94:
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M ,D[T'_L#67_ *(2O\XS_@LM_P F8G_L<M%_]#DK_1S^&O\ R3O0?^P-9?\
MHA*_V ^A/_R1*_Z^U/T/^CW]E_\ \FOA_P!?ZO\ [:=M1117]<'^B9_FR?\
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M:/\ J1='_P#3C+7^C)7^<U_P9%?\G'?&W_L1='_].,M?Z,M !@4444 %%%%
M!7\3?_!>W_E.5^S=_P!DHUG_ -+;NO[9*_B;_P""]O\ RG*_9N_[)1K/_I;=
MU^>>+G_)+9M_UYJ?^DL_'OI"?\D)Q#_V#5O_ $B1J4445_@4?\B 4444 %%%
M% 'Y3?\ !9;_ ),Q/_8Y:+_Z')7^CG\-?^2=Z#_V!K+_ -$)7^<9_P %EO\
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M=\BX[9K]RZ0C- &=_8VD=[2V_P"_2_X5-;V%G:L7MHHHB>"8U"Y';. *N44
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MG^3/]1/HI_\ )(TO\<_S"BBBOXS/Z4"BBB@ K\;?^"D'_)[?['/_ &6NS_\
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MQ6K7!_#'_DF7AT_]0*P_])TKNP,"OY#/]0Q:_B;_ ."]O_*<K]F[_LE&L_\
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M&,,@Y\P2OM18R_K7[$,%OJ__  =E_M22^)U62XLOA;8P:4)P#Y=L8-$0A,]
M4.#CJ": /Z0_V%/VYO@'_P %$OV<](_:;_9ROY[O0M4DEM+BUOH_(OM.OK<@
M3V=W$"P2:,L"<,RLK*RD@@U_&;_P?'=/V:O^NGCG_P!PM>%?\$Y_C+_P4B^
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M ";K,?\ %2_].P.W+_XJ/]3H=!2T@Z"EK_G4/JPHHHH **** /_3_OXHHHH
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M3_Y)&E_CG^84445_&9_2@4444 %?C;_P4@_Y/;_8Y_[+79_^E5G7[)5^-O\
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M\G%X=_["*?\ Z4C_ $3/AC_R3'P[_P!@*P_])TKO*X/X8_\ ),?#O_8"L/\
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M *-DK\X\7_\ DF,S_P"O<OR/WSZ+7_)Q>'?^PBG_ .E(_P!$SX8_\DQ\._\
M8"L/_2=*[RN#^&/_ "3'P[_V K#_ -)TKO*_R./^GP*_B;_X+V_\IROV;O\
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M<<R6D$<<UO\ .R31+O9SEY%4* &:@#^FJOX"O^#X[I^S5_UT\<_^X6OZ@?\
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M@_\ 4G>)_P"<M=R,@#CM7^A7T29I9#B;O_EZ_P#TF)_AQ^TZHSEQGESC%O\
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MJ/X?)XL_:L?Q5H/B:XO]1TRWO=,L;>_\](YM-1Y6+&^MSM*[..3D"LKXB?\
M!H1_P5K^+WV3_A;'Q\\"^*/L'F?8?^$BUKQ'J7V;SMOF>3]ILI-F_8N[;C.T
M9Z"O]!7]GO\ 9X^#'[*OPBT;X$?L_>'[#POX3T"W-MI>CZ<I$<89B[NSL2\D
MDCDM))(S.[$EB37M- '^>):?\&LO_!<+3[2+3[#]J31X(+>)((((?%GBQ(XX
MXP%1$5;8!54   # ' KA_$__  :+_P#!7GQOX@L_%?C7]H/P5K&J:?"UO8:E
MJFN^)+NZMHG)+1PS2V;/&K$DE58 Y-?Z.=!XH:-:-:=.:J4Y--:IK1I^3/\
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MB:CG+:\FV_O9_GF?\0N'_!<W_HZC2_\ PKO%O_R-1_Q"X?\ !<W_ *.HTO\
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M^L__ "NH_P"(*/\ X*&?]%1^$/\ W_UG_P"5U?Z8YI-PI\[[CNS_ #$O&_\
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M^$2.C!U9;C6058'(((T[@@]Z^D5_X-;O^"Y:*$3]JC2@J@* /%WBT  = /\
M1J_T,\TM)MO<1_GF?\0N'_!<W_HZC2__  KO%O\ \C4?\0N'_!<W_HZC2_\
MPKO%O_R-7^AG12 _SC?%/_!HS_P5[\<:[8^*?&O[0?@O6-3TR-XM-U'5-=\2
M7=U:)(<NL$TMFSQACU"D ]Z:/^#17_@KN/\ FX+P5_X/?$G_ ,AU_HZ4$XKK
MP^85Z2M2J.*\FT>=C,GPF(DIXBA&;6EW%-_BC_.+_P"(1;_@KQ_T<%X*_P#!
M[XD_^0ZYSQC_ ,&GG_!6SP7X1U7QCJ/Q_P#!TMOI.FW.ISQPZ[XD\QX[6)I6
M5<V8&XA2!D@9[U_I+ YKD_'GAA/''@;6O!3RFW76-)N],-P%WF,7<+1;PN1G
M;NSC(S71_;>,_P"?\O\ P)G)_JQEO_0)#_P"/^1_D9?\$G_^"6W[?'_!7:+Q
MQ+\#?BY!X<_X02?3X-2'BG6M90SMJ(F,9A^RQS\+Y#;MVWJ,5^PW_$(M_P %
M>/\ HX+P5_X/?$G_ ,AU_4U_P18_X(G:)_P1XB^(<>D>/[OQS_PGMQIDTANM
M,33OL9TX7 P-DTV_?YYZXQ@>M?NQN X-']M8S_G_ "_\"8?ZL9;_ - D/_ (
M_P"1_G&_\0BW_!7C_HX+P5_X/?$G_P AUBZ]_P &>7_!5;Q5IYTGQ/\ '/X>
MZE:EUD-M?ZMXAN(MZ?=;9)8LN1V..*_TC=PH# \"HJ9MBIQ<95I-/S9I1X>P
M%.:J4\-!-;-1BFOP/\\J+_@UL_X+DPQ)!#^U/I*)&H1$7Q;XM"JJC   ML
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MQPU&^GTR<R7^CV=O%:6&C1,9R4>"&(@2,60%CA * /ZN**** "BBB@#\@_\
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M?V?]3N=:\+:1X8MH;1K._OO#OAZVO+V[$XA:9E^UW8 VR@97&,<5^HG[<_\
MP2@D_;5_:ZL_V@M;\26%EH47P'\8_!R[T&:Q>>Y>?Q0LJQWZ3"14"VQ<-LV[
MB5X89X^4/V#?^"#WC7]C7Q-^S;XHU3XAZ5K]S\$QX_F\2SKIMQ'-K]QXR91
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M_M'?#J?X:ZGXJ^ .K?!KX3_"N>_M]0UM[>2TG=[C4)("(4FN+D((H\\!R"0
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M?S+6Y79#\S@@+DKUQQ0!_4)X'_X*?_LX^,O"OPV\9ZI8>.O"MC\5?&=S\/\
MPNWC/P[=Z+*FN01R216][%<A7M1=B)EM7<;97 4')&?T8K^0?_@HU\5?A]\7
M/^"#6C>,/@?\8-:^..J:?\8O"EKX0^)-_!]EU6^\2P>(HO*C2.."WQ+ CM&I
M2,94=3R:_KHTPWW]GP?VEM^T^2GVC9C'F;?FQCC&: -"BBB@#__3_OXHHHH
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M0QB/R<+LV[=F/EVXQC'IBL_3M#T;1T>/2+2VM5D.Z1;:)(@Q]6"@9[]:U:*
M.2?P%X(D8N^CZ22Q))-G"22>I)V=Z\+\*?LE_#/PO^U7XH_;%=[Z_P#&'B7P
MOI?@N*2\9&MM)T32Y))Q:6$:HIC6XN)#-.6+%W"<A5 KZAHH **** "BBB@
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M/1M;1(]9M+6[6-MR+=1)*%)X) <'%/T_2=,TBW^R:3;P6L6=WEVT:QIGUVJ
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CM6L,D5E/?1B,M(+1Y&FB564>:%9MVT"OK*EHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>forms-1a_017.jpg
<TEXT>
begin 644 forms-1a_017.jpg
M_]C_X  02D9)1@ ! 0  W #<  #_X0" 17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (  (=I  0    !    3@
M      #<     0   -P    !  .@ 0 #     0 !  "@ @ $     0   IR@
M P $     0   J@     _^T .%!H;W1O<VAO<" S+C  .$))300$
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M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" C_W0 $ "K_V@ , P$
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M@_8U_;T\5^ _@AKD^H)\-_B5=6/AC7X9 9I3I%^1;3!XL OF-<E>"<T ?[E
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M_#?[3O[(Z:G!\.?$NIMH.L:!J%PUZ=%U5D>> P3R?O#;3QHX"REF1TQO(8
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MTM)_X/B?$;WR#7/V=K);;/[QK3Q?(TH'?"OIB@_0D5^.7_!K)^R/^S=^V?\
M\%#O$'PI_:C\(:3XT\/6WPNU76+?2M8$C0QWL%_I\<<Z^6Z'>J2NHYQACQ7]
M[/Q&_P"#;W_@C'\1?#5SX>G^">BZ,\\31QZGX<O+_3[RW8C DB=+@IN7J-Z.
MOJ#0!P'_  2Y_P"#CG]A7_@IKXJM_A#ICZC\/_B+=G;8>#_%)0_VF51G<:?>
M1$PS,H5CY;%)".B&OZ"!7^,W_P %:_\ @G[\1/\ @C)_P4*D^'OP^UG5!IUG
M-:>-?ACXK+"*^^Q^:7MV>2(*OVJTFC,;LH4,5#;0&Q7^J9_P2:_;.O?V_P#_
M ()[_#/]J;6UMDUGQ!H7D^(HK0$1)J^GRO9WI4?PJ\L1D"_PAL=J /T8HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** /_T?[^**** "BBB@ HHHH
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M$-(^._[.'B*QUG3M2M8Y+O3TF3^T-+N64&2TOK<$O#-$V0P8 '&5)!!KP?\
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M .R.:U_Z<]+K_46K_+B_X,S[FWL_^"I7BB>[D2)!\'-9R\C!1_R$]+[DBO\
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M/[=_A5_"GQ0T>Q71/$D)O[+4DU*2R BCU*.:PFFB ND =D+!E?<.1@U^;/\
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M/L=?\&^.&FUW5?#T>HZ=I/\ 8&K.V;F*);ZX@#V]PQ,T8CSY9+(0 %K^IO\
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M$?\ 7.)C7]LG_!$3_@W=^#'_  2FDE^-/Q$U2W\>_%V^M7LQX@6V,&GZ):S
M"6WTR&0L^^3D27+X=U^55120?Z0\#I2T 5YD)@=1R2A4#ZBO\GKXU_\ !LW_
M ,%KO%'QW\7^/O"/PIC-IJ/B[5M7TR[3Q3H$,AAGO99H)5!U!70E6##(##N
M:_UC3S2 8H _R61_P;=?\'!5X?(N/ VI[3P?-\<Z.5YXY']IG^5??7[%/_!F
MS^V)\1O'-GXB_;K\4Z#X'\,QW23ZEI/A^Z_MO7KV-2"\*RH!:VY<<>:9)BO7
M83BO]*TTW;0!Y'\!O@5\,/V:/@_X<^ WP8TN#1?"_A72X-'T;3H!Q%! NT%F
MZO(YRTCMEG<ECR37KU%% "$9K^,3_@N3_P &MMS^VS\7M9_;!_8@UG2- \;Z
M[B[\4^#M<W6^F:O>HJJ;NUNHU;[-<2A095D0QR/E]R$FO[/*0C- '^1Y:?\
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MO] N8M4T;X>>'5>YTQ;Z$[X9=1O)EB\\0L%98(X@A8?,[*,'^Y-0%7:!@#@
M4[ZT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__3_OXHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ***:V>U #J*_G<^-/_!Q3\ _ ?\ P4CL/^"9OP>\!^*/B3XPN=<LO#-[
MJOAZZM8=/L]3N&/VF!C-EF%G&-\[CY5PRYRIKSS_ (*>_P#!RY\&_P#@ES^U
M;J'[*WQ3^%7C/7KNUTFPUFTUS2[ZSAM+RVOXMX,:3#>/+<-&V?XE/;% '],U
M%?,/[&7[4'A/]M3]EGP-^U3X&M+G3M*\<:!!KMKIUXZ23VGG9#02LGREXV!4
MD<<5^;/_  6#_P""Y_P(_P""/M[X*T/XF>&-<\7ZKXSBO;NWTW0;FWMY+6UL
MRB>=*9\@J[N54#G*F@#]Q**_G7_X)-?\'&/[/'_!6/\ :!U;]G;P'X)\2^#=
M8T[PU-XEMI=>N[6XCO8[>:**6*-8.0ZB4/SQ@&OW7^-?Q4T#X%_![Q5\:O%F
M]M+\)>'=1\27Z1D*[P:;;O<.BD\;F5"%SW(H ]1HK^5C_@G_ /\ !T]\#O\
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M1X3N]"\-MXDEO];O+6XAEC6XC@\I5@^8-F0')XXK^A.61(8S+(P55!9F8X
MY))/04 245_(U^UA_P '@O["_P"SI\>_$'P5\!^#O%7Q&L_#UT=/G\5^'KNT
M@TVZNXLB=;7SOFECB<;!*/E<@E<K@G]U?^":G[=GB/\ X**?L]V_[2\GPS\1
M_#CP[J\O_%+IXHNK>:ZU>T7*M>1PPC,<!<;8V?F0991MP2 ?HA112'..* %H
MK\'O^"D'_!Q)_P $\_\ @FSXRNOA%X]U74O%_CRS0&]\(^#HDNI;!F4.JWUU
M(R06[LIR(]S2 8W( 0:^#OV7?^#PG_@G%\<_B#:^ OBYHOB_X7I?W"6UIKNO
MB"^TM'<X!NI;0EX$]7,;*/XB!D@ _K2HKR+XD?%(^%/@EK7QF^'^G2>,A8>&
M[CQ'I.EZ+<1[]8CAMVN(HK2<DQ%KA0!$V2I)'.#FOR,_X)%?\%Y_V9_^"N7B
M'Q5\/_A]H>M>"O%GA:&._E\.>(YH)9[S3W(C:ZMWAP"(I2$E3&Y-RD\,* /W
M0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@#__4_OXHHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *_-[_@K=^VU;_P#!/7_@GY\1
M?VGX3"=6TG2/[/\ #,$YPLVM:DXM;)< @D)(_FL,CY4-?I#7\-G_  >W_&S4
M= ^ 'P6_9_L9FCB\2^*=7\37T:,1YD>AVT,$2N.Z^9?;AGNH- 'Q'_P9N_LI
MZM\:OVL/B;_P4'^)RW&HS>%;1M T?4[T^:TNO^(2TVH7#.Q+>;':C;N[BY.:
M](_X/;/V<6L_&/P:_:STZV;9>V6H^ M6N@!@R6[?;[)3WSL>XZ^GM7[1?\&B
MGPLMO 7_  2&TWQ6J 7'C#QUKNNRR8P62)HK&-<]PHMCCZUZ#_P=8?L\R_'3
M_@CYXP\1Z?%YE[\/-<TGQU"%7<_D02FRN@#V ANVD;V2@#R+_@T/_:2?XT?\
M$LE^%NHR;[WX9^+K_P .')P1:706^M1@]@)F&>G!K^3#_@[$^-[_ +0?_!7^
M]^&/A68WJ>!O#6C>"(+>,]-2G9[N=!V#%[E%/T&:^W/^#,[]JC2_A+\6/CK\
M(_%]T+;2;GP%%\0P\K8BB/AN1DO& SU-O<AC[1YK\A?^">/A/7/^"L?_  7H
M\-^)/'"RSP>+_BO??$/7EQO$>E:9+)JC0%NR^5!';H3GDK0!B_\ !$+XI>,_
MV ?^"U?PVT?XE1R:)=IXSE^&7BZRG/S0'5V;3FBD*D@;+IHBQY'R_B/]$#_@
MY7_:+A_9U_X(^?%.XCDV7WC&SMO 6GC)4L^M2B*?:5Z%;996_#WK^#K_ (.;
MO@!JG[('_!9;Q-\2O!7G64'C;^S/BAH]U$#&([^9O]*,;CJRWENTI(Z%Q7Z[
M?\'5G[=5O^T7_P $[/V4AX?ND:+XG6#_ !*U6& XC$EK86\&P*#T2YNIU'^[
MQ0!\N?\ !E_\!)_&W[?WCGX]W=LSV?@;P ]A%.5!2.^UVX2.,9/\7DV\V,=L
MU]"_\'P8S\=O@!_V*7B7_P!++.OU8_X,T_V<V^&O_!._Q1\>]0CV77Q&\;S"
MW+)AC8Z'']FC(;NK2R2_B#7Y4?\ !\%_R7?X ?\ 8I>)?_2RSH ['_@@/_P;
M[_\ !.__ (*'_P#!.#0?VE_VBM,\3W/BF_\ $FNZ9=3:7K$MG;M#871BA B5
M" 0G4YY/-?M'_P 0BO\ P1]_Z OC?_PHIO\ XW7\$G[%O_!6K_@KC^R/\!K+
MX*?L@Z[KUAX)L[^]O;.WT_P_%J$*W-W)YEP1<-;2%B7.2"QQ[5]7?\1 /_!P
M=_T-/BW_ ,)*'_Y#H _T*O\ @GE_P0__ &&/^"8GQ1UGXO\ [+FG^(K36-<T
M,^'[]]7U62_B:T,\=P0J.JA6WQK\V>G%?C[_ ,'IW_*,WP'_ -EHTS_TSZM7
MOO\ P;"_MQ?MT_MP?!3XI^)OVYM3U74]4T+Q7IEAH3:GI:Z8T=K/9R22A%2*
M+>"X!)P<'ZUX%_P>G?\ *,WP'_V6C3/_ $SZM0!_/7_P;)?\$>OV-/\ @J7X
M4^+NJ_M66.NWD_@[4- M]%;1]3>P"IJ$=XTXD"*V_)A3![<^M?U,_P#$(K_P
M1]_Z OC?_P **;_XW7^=]_P3\_X*&_\ !17]AO3?$^G?L*ZMJ^FV_B*:RG\1
MKI>CIJGF26BRK;%V:&4QX$DF ",Y/7%?HI_Q$ _\'!W_ $-/BW_PDH?_ )#H
M _O!_9"_X-Q/^";/[$'[0_AW]I[X&:7XKM_%/A>6XGTN74-:ENK<-<V\ML^^
M%D ;,<K8YX//:J'_  <\_P#*%/XN_P"[H?\ Z=K6OR!_X-I?^"G/_!3_ /;5
M_;"\7_#W]MS6M<U'P[IW@.35-.M]2T---B%\+VWC#"5((LML=AM).1VXK]?O
M^#GG_E"G\7?]W0__ $[6M '\DO\ P97\?\%!OB*/^J6R_P#IQMJ^\/\ @YL_
MX.$!I<>M?\$Y/V&]?_TEU;3_ (G>/-$N&5H.66;1+">/ W$86[F1C@$PJ<[\
M?QI?L9?M^?'7]@^Q^(=S^SS<II&O_$'P>W@F7Q'&S"\TNQFN(Y[B2R((V7$B
MQ^6LO6,,67YL$?,%G%XC\ ^*M!\;^--#DNX;F6W\16MIK\,HM=8M%G)+,3M:
M:"9XWC9U;YOF .: /ZT?^#;W_@WLU/\ ;&\1Z;^VY^VAH<UO\)=.E6\\(^'+
M]1&?%UW#("LLT;#=_9<9!W$@?:&^528PQ/\ IHZ7IFG:+IMOH^CV\%I9VD"6
MUI:VR+%###$H6..-$ 5$10%55     Q7PU_P32_;,^!G[=_[&'@K]H/X 0VF
MG:+>:5%IUQX;M B_V#?62+%<:8\: !/L[ !   T91A\K"OO->10 M?ES_P %
ME_VU]2_8 _X)R?$?]H[PNT8\0VFF+HWA8R=!J^JN+:V?&1GR2YEQWV5^HU?R
M.?\ !YCXBO\ 3O\ @EUX<T"VR(=2^*^D"XQP"(+*^D4'VW<_A0!_&Y_P0H_X
M):O_ ,%FOVUM>T;XYZ_KD7A;P]IS^,/'FMVLHDU34;B\N/+AMEN)Q)B6ZE9W
M>5E8A$<CYL&OW'_X*Z?\&D6L^#KCP;X@_P""3FB:]XB&H3W5CXN\/^(M9M-E
MB(T1[:[AN;MK<[9#O21"7(.TC )%?S1?\$Y/^"B_[;/['7A3QI\!OV!K2XA\
M;?%K4-(M)=;T:Q;4==2VTM+H1VFG0A'"O(]T7>38Q 08 Y-?9WAO_@M%_P %
MZ/\ @G#\;;)_C_XG^("7;E;ZZ\%_%VQF>UU"V+?-B.Y2.9 <D!X'4J2/:@#_
M $-O^"$_P'_;;_9B_P"">WAO]F[]N[3+"Q\0^#;FYT?0UM-2@U3S-!&U[-)9
M8&= T.YX@NXX1%K^$3_@H!<:W_P0G_X.)Y/C3\'=]AX?E\067CU=.M@4AN/#
MOB-V&K:?L0@-&?\ 2%5> I"D#*@U_HC_ /!+W_@H5\-_^"F_['GAK]J3X?PK
MI]QJ"-I_B301)YKZ3K-KA;JU+$*64,0\;$#=&RGO7\6G_![;\&K33/CG\%OC
MY:(B2:OX8U3PS=G!S(VFW*7$1)]ENF&* /\ 0J\!^,_#GQ'\$Z/\0O"%REYI
M6N:9;:OIMW&05FM;R)9HG!'9D8&NMK\%_P#@VD^/NL?M _\ !';X5ZIK\AFO
M/#$-_P""99F;)>/1KAHK?/IMMVC0#T4>M?O10 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__5_OXH
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *_SW_P#@^(\/ZH/&/[/'BL*6LFTSQ=IVX<A9UETV7!]V4\?0U_H0
M5_*)_P '?G[*&H_'3_@F9;_&WP[ );[X3^*K7Q#=;!F3^R]1']GW?/\ =5Y8
M9&]DH ^IO^#6W5['5/\ @BO\+8K,J39W>OVEQCM*-5N'.??:XK]E?VK/@GI7
M[1_[,_C_ . 6M#-KXQ\'ZOX<FX!XO[22 'GN"P(]Q7\L_P#P9A_'W2?&G_!/
MOQK\ IKH-J?@CXA3WXM7/S+8:W:PR1.!_<,T,X^H-?V,4 ?X6/PL^,/Q:_8G
M^*WC+3?#$@MM8ET'Q/\ #+7$#,%$&IPRZ;>J.F<#)7(Z@&OZYO\ @RE_9;G\
M1?'WXI?M?ZK;!K7PUX?M_!.CW+<XO-5D6YN@ >ZPP1C(Y^8CO7YM_P#!6C_@
MB'_P44U7_@I)\9/$OP"^#'C3Q!X-UKQSJ&O:!JVC6:RVD]MJ;_:OW;!OX7D9
M3D#!!K^VO_@V,_8C^*W[#W_!,ZU\(_'?P[>^%_&/B;QAJWB;5M(U)0EW!$WE
M6MJLJ@G:?*M]X![-[T ?C%_P>T_LW7FK?#?X-_M8:7 'CT75=1\#ZM*@.X)J
M,8O+0MC^$/;RKDGJP]:_AK^./[4_Q!^/OPL^%?PB\4L38?"KPI=>$]$ 8MOA
MNM2N-0+8[-F98P/1!7^N+_P7L_8W\2_MQ_\ !+CXE?!KX?Z5<:UXJM+.W\4>
M$],M,>?<:II,JRK%$"0"\L/FQH,\LP%?YR7[$?\ P0>_X*6>(?VP?AAI'QA^
M"?CC0_"<GCO17\2ZMJED([2VTR*[CENGF<OPGE*V?Y$T ?Z>?_!*;]FYOV1_
M^"<_P;_9^N0!>:#X$TTZJ%&!_:5\AO;[&<''VF>0#/. *_BQ_P"#X+_DN_P
M_P"Q2\2_^EEG7^B=!!#;0);P*$2) D:CH%48 _ 5_#5_P=T_L$_MF?ME?&+X
M+:S^RW\./$_CFTT/PSK]KJ]QH%M]H2UEN;JU>))#D8+*C$?2@#]-?^#1_/\
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M#_5[8D5^ _\ P<\_\H5/B[_NZ'_Z=K6OY2?^"=7@3_@Y5LOV\?A!=_M&1?M
M#P''\0]$?Q<==NIFTX:2+M/M7VH-(08?+W;\CI7]@_\ P<'_  0^+_[1G_!)
MSXG?"+X&>'=3\5>)]5_L<:=H>D1B6ZG\K4[:20HF1G8BEC[ T ?YUO\ P;G?
M\$SOA+_P4V_;Q_X0+X[W,I\(>#-#;QCK.B0;D?61!/'#%9-*I!CB9Y TI'S%
M 5!!;(_L_P#^#GK_ ()$:)^U7^PSI_QG_9U\-V<'C3X)Z=OTW3=)@\IKKPC
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M@G(P>#744 %%%% !@9S1110 4444 %%%% !1110 4444 %&!110 4444 %&
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M **** "BBB@ HHHH __7_OXHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#_T/[^**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]'^
M_BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU63:6\MF"OM) H ^FZ*** "BBB@ HHHH **** "BBB@#_]+^_BBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "@C
M(Q12'I0!_FA_M.?M[?#7_@FI_P '6/Q3_:O^+&DZQK>C:1')ITUAH8B-V\FI
M>&;2WC9?.9$VJS9;GI7[*?\ $:7^P=_T3/XH?EIW_P ?K.\$?\$T/VC/$?\
MP=.^.?VJ/BM\+9]2^#FH:/=W,/B;6K:UNM%N6D\/6]E"%65GWRBY4ILV;E(+
M' &:_JL'['W[)IZ_#'X?_P#A/V'_ ,9H _ED_P"(TS]@_P#Z)G\4?RTW_P"/
MT?\ $:9^P?\ ]$S^*/Y:;_\ 'Z_J<_X8]_9,_P"B8^ /_"?T_P#^,4?\,>_L
MF?\ 1,? '_A/Z?\ _&* /Y8_^(TS]@__ *)G\4?RTW_X_1_Q&F?L'_\ 1,_B
MC^6F_P#Q^OZG/^&/?V3/^B8^ /\ PG]/_P#C%'_#'O[)G_1,? '_ (3^G_\
MQB@#^6/_ (C3/V#_ /HF?Q1_+3?_ (_1_P 1IG[!_P#T3/XH_EIO_P ?K^IS
M_ACW]DS_ *)CX _\)_3_ /XQ1_PQ[^R9_P!$Q\ ?^$_I_P#\8H _EC_XC3/V
M#_\ HF?Q1_+3?_C]'_$:9^P?_P!$S^*/Y:;_ /'Z_J<_X8]_9,_Z)CX _P#"
M?T__ .,4?\,>_LF?]$Q\ ?\ A/Z?_P#&* /Y8_\ B-,_8/\ ^B9_%'\M-_\
MC]8OB3_@\H_X)W>,= O/"OBSX3?$;4M,U&VDL[_3[^'2Y[:Y@E4K)%+%),4=
M&4D,K @BOZMO^&/?V3/^B8^ /_"?T_\ ^,4?\,>_LF?]$Q\ ?^$_I_\ \8H
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P""-W_0<\>?^$Q<_P#Q5 ']/=%?S"?\1=__  1N_P"@YX\_\)BY_P#BJ/\
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MR**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__0_OXHHHH
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M@M_P;-_\H8/@[_UXZG_Z<[JOWIH **** "BBB@ HHHH **** "BBB@ HHHH
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M5?O37X+?\&S?_*&#X._]>.I_^G.ZK]Z: "BBB@ HHHH **** "BBB@ HHHH
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MDA=H)[IXI-C@,%=67(&0>E?M, !2T4 %%%% !1110 445'+(L49D<@!1DDG
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M^?\ 8+9YQ'N^VMMW[,9P<9Z&O]$ROES]M_\ Y,T^*W_9._$/_IOFH _Q_?\
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M5)-&UV'2_#M[=V\-Y#CS(EF50K["=I*Y&<X)KQ+_ (BU_P#@C?\ ]##X[_\
M"4OO\*ER2ZFD:4GLC^F.OES]M_\ Y,T^*W_9._$/_IOFK\0/^(M?_@C?_P!#
M%X[_ /"4OO\ "O#OVFO^#IO_ ()'_%+]G/QY\-?"FO\ C=]4U_P?K&C:='-X
M6O8T:YO+22&)6<C"@NP!8\ <T<Z[C^KS['\N_P#P9_\ _*7ZU_[)WXE_E;U_
MJMU_CQ_\&\_[='[/_P#P3K_X*%0_M%?M-7.JV'AF/P?K6C-/I5A-J$_VJ]$/
MDKY,(W8.QLMV[U_=S_Q%L?\ !&__ *&'QW_X2E]_A1SKN'L)]C^F.BOYG/\
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M@HHHK]"/HPHHHH *_+C_ (*R?\D1\'_]E&TO_P!!>OU'K\N/^"LG_)$?!_\
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MR\!>)N+L/6Q61X.5:--\LFN71M7ZM&%7$PAI)G^JOE:9(ZA2/:O\JG_A>O\
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M^(?$WA%?!OC7P5XS?[-$8XX8H%N(I&=%D0^1!(5$D;*\7\:L17UO_P $-?\
M@EC\3?V"/@;X[\0?M:WFB^(OBE\7_&,OC3QVU@!<V,+DNT-LK.H65EDEED9E
M0+E]JYVY(!_!Y_P5B_X.-/CS_P %5/V9[?\ 9M^)?PQ\,^$K"W\1V?B%-5TB
MZO9IS+:)(@BVSG9M82$D]>.*_O3_ .#:JZ>Z_P""+7P5#J%\K2]2B'N!J=SS
M^M?G5_P>%^$O">A?\$M-+N]$TO3K.4_$S1T,MK;11/CR;G(W(H.#CI7Z1_\
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MRZ+LSZ._X-->?^"-7@\?]33XE_\ 2P5_2T,XYK^:7_@TU_Y0U>#O^QI\3?\
MI8*_I;K_ *1FK'^)C"OSM_X*W_\ *,?X[_\ 9+]?_P#25Z_1*OSM_P""M_\
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M*** /SI_X*Q_\F">._\ KG8?^E4=?W0?\$[/^4?GP+_[(YX+_P#3):5_"_\
M\%8_^3!/'?\ USL/_2J.O[H/^"=G_*/SX%_]D<\%_P#IDM*_UE^@O_R2F)_Z
M_2_])@?]#/[*C_DWN,_["9_^FZ9]C4A&1BEHK^TS_3<_B%_X.\ACXT_LC#_J
M9O$W_H6E5^.;_?/U-?L9_P '>G_):?V1O^QF\2_^A:57XYO]\_4U_M'^S(7_
M !CN;?\ 7V/_ *2?/YQ\41M%%%?Z:GCA1110 4444 ?H7_P;/_\ *9/XU?\
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M@?\ ]@34/_3G=4 ?D9_P=H_\E1_8_P#^RCZS_P"@Z=7Q8_WS]37VG_P=H_\
M)4?V/_\ LH^L_P#H.G5\6/\ ?/U-?&\3?Q(>A_M)^R\_Y$&=?]?H?^D#:***
M^9/]1 HHHH **** /!/@S_RG/_9)_P"P]J/_ *2W%?Z1=?YNGP9_Y3G_ +)/
M_8>U'_TEN*_TBZ_1LH_W:!_S>?32_P"3EYU_BC_Z1$****](_EH_S\_V:?\
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MOGZFOV,_X.]/^2T_LC?]C-XE_P#0M*K\<W^^?J:_VD_9D_\ )/9M_P!?8_\
MI!\_G'Q1&T445_IH>.%%%% !1110!^A7_!M!_P ID_C7_P!DNL__ $HM:_O^
MK^ '_@V@_P"4R?QK_P"R76?_ *46M?W_ %?\POC]_P EMGG_ &$5?_2V?98;
M^'$****_(38**** /__7_OX-?Q\_\'4:>._V@/%7[,7_  3UT+7;GP]H?Q:^
M)PM?$-Y!EE9(VBMHC)&"/,$(N))%0G:7"YZ C^P4]*_E-_X.+_V-?^"A?[07
MQD_9\^.G_!/[P@OB?7OA=K=_X@:6::T2"UNE>W>U,D5U+&)%9HSD#/3GK0!_
M/_\ M8_LF?M&?\&V_P"WIX \*_\ !+_Q1XC\;ZQ\</!&I^&[+P]K-O')))JQ
ME2U1_L\.(9S%))'<6Y=1Y;A@Q*9S^\7_  1R_P"#??XP_ 3]H:T_X*6?\%&_
M'^K>,/C?<M=:A#I$%V;JUT^6_A:)S>WCC=<S*DKJ(H@D,9QM+ 5^,OQV^ O_
M  =2_M%?M2_"[]L'XE_"S0YO&7P@DNY?!TUJFC0VD;7N/-,]NMUMFZ#&3Q7[
M;_\ !.SXS_\ !S;XK_:^\)Z'^WOX)\-Z1\*IY;L>*+ZPL])CFB1;64P;6M[A
MY1F<(/E4^_% ']6@HI!TI: "BBB@ HHHH _DS_X/(/\ E%9I7_93M'_]$W-?
MH)_P;<?\H6?@?_V!-0_].=U7Y]_\'D'_ "BLTK_LIVC_ /HFYK]!/^#;C_E"
MS\#_ /L":A_Z<[J@#\C/^#M'_DJ/['__ &4?6?\ T'3J^+'^^?J:^T_^#M'_
M )*C^Q__ -E'UG_T'3J^+'^^?J:^-XF_B0]#_:3]EY_R(,Z_Z_0_](&T445\
MR?ZB!1110 4444 >"?!G_E.?^R3_ -A[4?\ TEN*_P!(NO\ -T^#/_*<_P#9
M)_[#VH_^DMQ7^D77Z-E'^[0/^;SZ:7_)R\Z_Q1_](B%%%%>D?RT?Y^?[-/\
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MXA^&_ G]N^=_9 U^X,'VK[/M\WR^#G;N&?J*^N#TK\^?VX?^"77[$'_!1PZ
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M_93M'_\ 1-S7Z"?\&W'_ "A9^!__ &!-0_\ 3G=4 ?D9_P ':/\ R5']C_\
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MG0AO)I+U>B/.SC,Z>"PE;&5G:-.+D^ND5=_@C^UO[=9_\]8_^^A_C1]NL_\
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M_P!HU_H]?%C_ ));XD_[ .H_^DTE?YPO_!%[_DTO6/\ LHFN?^T:_DGZ:O\
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M""__ "G%_:>_[$?2/_1T-?RG]+=?\(6&_P"OB_\ 26?Z6?LP/^2RS+_L'?\
MZ<@?VQCO]:6D'4_6EK_/,_W,//?BQ_R2WQ)_V =1_P#2:2O\X7_@B]_R:7K'
M_91-<_\ :-?Z/7Q8_P"26^)/^P#J/_I-)7^<+_P1>_Y-+UC_ +*)KG_M&OY)
M^FK_ ,D3+_K[3_\ ;C_._P#:??\ )KJG_811_P#;C];****_Q]/^;\**** "
MBBB@#\Z?^"L?_)@GCO\ ZYV'_I5'7]T'_!.S_E'Y\"_^R.>"_P#TR6E?PO\
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M7S)_J(%%%% !1110!X)\&?\ E.?^R3_V'M1_]);BO](NO\W3X,_\IS_V2?\
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M% "'H:\L_P"""_\ RG%_:>_[$?2/_1T->IGH:\L_X(+_ /*<7]I[_L1](_\
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M$UM$MS,MU'!,+1I;A8+B"YM2#)&P$L3X8<#'V_\ \$S/^".7_!1F3]O?Q/\
M\%;O^"HNL:!>_%*VT6[M?!'AS2I8[F!;\V!L;>>?R-L4,$$.8XH(V))8L6'0
MQ?\ !-3_ ()I_P#!3O\ :<_X*=VW_!6O_@K9'IGAV]\(V$^C^ _!-FL(D 5)
M8;:00022K;6\(FDE&^5II96RVT"@#^Q8=**!THH *:U.I",T ?QI?MX>$O\
M@AC\4?\ @N3K7@3_ (*2Z1XGT[Q:_@&REM];\=ZNNE> ;U(K:'[*EHT4D<IF
M\II0"\BQ>:CC!?;7Y\?\$P_V#/#O[?VB?MN_\$^/V6?&NK:7^S)>^-M"G^'?
MBJ6V?5[."_LKYKB5;(3O%YHE@B5&</N:,1.V203_ &T_M9?\$\OV*/VZ;?3X
M/VM?AQX;\;MI(9=-NM4A=+RV1CN9([JW>*=8V/)3?M)YQ7L/P _9Q^!7[*_P
MUM/@]^SKX5T7P=X9LG>6WT?0K9;>#S9,;Y7QEI)6P-TCLSM@9)P* /\ ,A_X
M+._\&W.D_P#!*#]D^U_:5LOBM/XS>Y\467AW^R9-!CTX*+M)7\WSEN9B2OE_
M=V\YZU_;I_P;5V8L_P#@BU\%2&W>=I>I3'C&-VIW0Q^E?!'_  >0?\HK=*/_
M %4W1Q_Y!N:_03_@VX_Y0L_ _P#[ FH?^G.ZH _(S_@[1_Y*C^Q__P!E'UG_
M -!TZOBQ_OGZFOM/_@[1_P"2H_L?_P#91]9_]!TZOBQ_OGZFOC>)OXD/0_VD
M_9>?\B#.O^OT/_2!M%%%?,G^H@4444 %%%% '@GP9_Y3G_LD_P#8>U'_ -);
MBO\ 2+K_ #=/@S_RG/\ V2?^P]J/_I+<5_I%U^C91_NT#_F\^FE_R<O.O\4?
M_2(A1117I'\M'^?G^S3_ ,IJOVX/^Q\D_P#2UZ_72OR+_9I_Y35?MP?]CY)_
MZ6O7ZZ5_AI]-3_DX>8>E/_TW$_U9^C'_ ,D=A/6?_I3"BBBOY2/W\**** "O
M+OCC_P D4\8?]BOJO_I+)7J->7?''_DBGC#_ +%?5?\ TEDKV^&O^1CA?\<?
M_2D>;G/^YU_\,OR9]'?\&FO_ "AJ\'?]C3XF_P#2P5_2W7\TG_!IK_RAJ\'?
M]C3XF_\ 2P5_2W7_ $O/<_PZ85^=O_!6_P#Y1C_'?_LE^O\ _I*]?HE7YV_\
M%;_^48_QW_[)?K__ *2O2!'\)W_!-C_DR'P%_P!>-U_Z635]QU\.?\$V/^3(
M? 7_ %XW7_I9-7W'7^]WA+_R3&5?]>:?_I*/[\X/_P"15@_\$?R04445^A'T
M84444 %?EQ_P5D_Y(CX/_P"RC:7_ .@O7ZCU^7'_  5D_P"2(^#_ /LHVE_^
M@O7XO](C_DBLV_Z]_JCXOQ$_Y$F,_P /ZH_U)AU/UI:0=3]:6O\ #<_A,0]/
MQK^+O_@YL_Y2-?L0?]A_Q)_Z/TJO[1#T_&OXN_\ @YL_Y2-?L0?]A_Q)_P"C
M]*KZ'A+_ )&F$_QQ_P#2D?%^)'_).YI_UYJ_^D2.XD^^?K3*?)]\_6F5_LLM
MC_D\>X4444Q!1110 AZ&O+/^""__ "G%_:>_[$?2/_1T->IGH:\L_P"""_\
MRG%_:>_[$?2/_1T-?RI]+;_D18;_ *^+_P!)9_I9^S _Y++,O^P=_P#IR!_;
M&.I^M+2#J?K2U_GD?[F'GOQ8_P"26^)/^P#J/_I-)7^<+_P1>_Y-+UC_ +*)
MKG_M&O\ 1Z^+'_)+?$G_ & =1_\ 2:2O\X7_ ((O?\FEZQ_V437/_:-?R3]-
M7_DB9?\ 7VG_ .W'^=_[3[_DUU3_ +"*/_MQ^ME%%%?X^G_-^%%%% !1110!
M^=/_  5C_P"3!/'?_7.P_P#2J.O[H/\ @G9_RC\^!?\ V1SP7_Z9+2OX7_\
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M$U#_ -.=U7Y]_P#!Y!_RBLTK_LIVC_\ HFYK]!/^#;C_ )0L_ __ + FH?\
MISNJ /R,_P"#M'_DJ/['_P#V4?6?_0=.KXL?[Y^IK[3_ .#M'_DJ/['_ /V4
M?6?_ $'3J^+'^^?J:^-XF_B0]#_:3]EY_P B#.O^OT/_ $@;1117S)_J(%%%
M% !1110!X)\&?^4Y_P"R3_V'M1_]);BO](NO\W3X,_\ *<_]DG_L/:C_ .DM
MQ7^D77Z-E'^[0/\ F\^FE_R<O.O\4?\ TB(4445Z1_+1_GY_LT_\IJOVX/\
ML?)/_2UZ_72OR+_9I_Y35?MP?]CY)_Z6O7ZZ5_AI]-3_ ).'F'I3_P#3<3_5
MGZ,?_)'83UG_ .E,****_E(_?PHHHH *\N^./_)%/&'_ &*^J_\ I+)7J->7
M?''_ )(IXP_[%?5?_262O;X:_P"1CA?\<?\ TI'FYS_N=?\ PR_)GT=_P::_
M\H:O!W_8T^)O_2P5_2W7\TG_  ::_P#*&KP=_P!C3XF_]+!7]+=?]+SW/\.F
M%?G;_P %;_\ E&/\=_\ LE^O_P#I*]?HE7YV_P#!6_\ Y1C_ !W_ .R7Z_\
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M1_N8>>_%C_DEOB3_ + .H_\ I-)7^<+_ ,$7O^32]8_[*)KG_M&O]'KXL?\
M)+?$G_8!U'_TFDK_ #A?^"+W_)I>L?\ 91-<_P#:-?R3]-7_ )(F7_7VG_[<
M?YW_ +3[_DUU3_L(H_\ MQ^ME%%%?X^G_-^%%%% !1110!^=/_!6/_DP3QW_
M -<[#_TJCK^Z#_@G9_RC\^!?_9'/!?\ Z9+2OX7_ /@K'_R8)X[_ .N=A_Z5
M1U_=!_P3L_Y1^? O_LCG@O\ ],EI7^LOT%_^24Q/_7Z7_I,#_H9_94?\F]QG
M_83/_P!-TS[&HHHK^TS_ $W/XA?^#O3_ )+3^R-_V,WB7_T+2J_'-_OGZFOV
M,_X.]/\ DM/[(W_8S>)?_0M*K\<W^^?J:_VD_9D_\D]FW_7V/_I!\_G'Q1&T
M445_IH>.%%%% !1110!^A7_!M!_RF3^-?_9+K/\ ]*+6O[_J_@!_X-H/^4R?
MQK_[)=9_^E%K7]_U?\POC]_R6V>?]A%7_P!+9]EAOX<0HHHK\A-@HHHH __7
M_OXHHHH **** "BBB@ HHHH **** /Y,_P#@\@_Y16:5_P!E.T?_ -$W-?H)
M_P &W'_*%GX'_P#8$U#_ -.=U7Y]_P#!Y!_RBLTK_LIVC_\ HFYK]!/^#;C_
M )0L_ __ + FH?\ ISNJ /R,_P"#M'_DJ/['_P#V4?6?_0=.KXL?[Y^IK[3_
M .#M'_DJ/['_ /V4?6?_ $'3J^+'^^?J:^-XF_B0]#_:3]EY_P B#.O^OT/_
M $@;1117S)_J(%%%% !1110!X)\&?^4Y_P"R3_V'M1_]);BO](NO\W3X,_\
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M]+!7]+=?]+SW/\.F%?G;_P %;_\ E&/\=_\ LE^O_P#I*]?HE7YV_P#!6_\
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M_2P5_2W7\TG_  ::_P#*&KP=_P!C3XF_]+!7]+=?]+SW/\.F%?G;_P %;_\
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M __3_OXHHHH **** "BBB@ HHHH **,CI1D4 ?R9_P#!Y!_RBLTK_LIVC_\
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M"BBBOT(^C"BBB@ K\N/^"LG_ "1'P?\ ]E&TO_T%Z_4>ORX_X*R?\D1\'_\
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MG_K]+_TF!_T,_LJ/^3>XS_L)G_Z;IGV-1117]IG^FY_$+_P=Z?\ ):?V1O\
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M_6-17\>WA'_@X%_;>\9:G/I?A3X9Z!K5Q ADGM=+M-1N)HEW;=SK$[L #QR
M,\5Z'_P^Z_X*/?\ 1#?_ "DZQ_A1_P 2*\>_\^J7_@U?Y!_Q-;PE_P _)_\
M@#/ZQJ\N^./_ "13QA_V*^J_^DLE?S$_\/N_^"CW_1#?_*3K'_Q-<]XN_P""
MS/\ P45\8>$]4\(WGP0>.'5=/N-.FDCTC6-R)<QM&S+E<9 ;(SWKTLF^@]QW
M0Q="M.G2M&2;_>+H[]CCS+Z4W"E7#U:<*D[R32]Q]58_LE_X--2!_P $:O!_
M_8T^)O\ TL%?TMYS7^4Q_P $\/\ @N'_ ,%0_P#@F]^S!I?[*WP@^#46J:)I
M.H7VHPWNM:#J[7;R7\OFN&,11<*>%P.E?;__ !%:?\%E1_S0S1O_  0:Y_\
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M?Q*_Y\4?_!J_R/ZAR01@5Y7_ ,$%S_QO%_:>_P"Q'TC_ -'0U_.7_P /AO\
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M/PROS8V5N]U9_$&W@?1I8[2.%(9_*\NZDSY; C:#G% ']T!M;,<^5%_WR/\
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M0T#QI_PEWAK1--U%K6WO,)JFH1VTB>5<QR1G>&QDJ2.U '[5FTLQ_P LHO\
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M+_[3/QR'[+^H:/X_^&WQ(N-+DUO2?!WQ0T"XT"^U:RB!+RV!FS'.5 )**V[
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M\9:)\&_ U]ILVC16\EGK-T]LP@M-1:9'=(0RG#1892V>0,'X*T/X5VW[0O\
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M ((V?LC?LWW7B>7P7_PC/QN\%W'B;QU;A%GTS4[N.]O-3U8>8K+N@GEDD7S
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M&@#\!_\ @I#O_P"'[_[ Y&<;?B>#^.BQU\S?\%9O@Q\2_C__ ,%Z/V9?A?\
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M.,U]O?\ !OI>7NH?\$;/@)>ZA--/-+X/=Y)IW:21R;VYY+,23^)KDM$_8O\
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MY]J%  P./84M% #%0+DCN<_6GT44 %%%% !1110 4444 %%%% !2$$C I:*
M&(H7H ._%/HHH **** "BBB@ HHHH **** &E03NP,]CZ4ZBB@ HHHH ****
M "BBB@ HHHH **** &JH484 ?2@( VX 9(QGO3J* "BBB@ HHHH **** "BB
8B@ HHHH *;M&2<#)[TZB@ '2BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>forms-1a_18.jpg
<TEXT>
begin 644 forms-1a_18.jpg
M_]C_X  02D9)1@ ! 0  W #<  #_X0" 17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (  (=I  0    !    3@
M      #<     0   -P    !  .@ 0 #     0 !  "@ @ $     0   H&@
M P $     0   D,     _^T .%!H;W1O<VAO<" S+C  .$))300$
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M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" C_W0 $ "G_V@ , P$
M A$#$0 _ /[^**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+_AZ+_P3E_Z+?\,?_"@LO_CE 'WA17P?_P /1?\ @G+_ -%O^&/_ (4%E_\
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MO&%]IULMY?6GAW4X+Z6"!VV+)(L3L54MP">] 'T717RG\5?VZ/V-O@7XOF\
M?&3XG^"/#&N6\,=Q/I.N:O;6=U'%,NZ-VBE=6 8<@XY%?2/A_P 2^'_%?AVR
M\6^&KVVO]+U&TBO[#4+60207%M.@DCEC=<AD="&5@<$'- &W17PQ>_\ !3C_
M ()XZ;>3:??_ !J^&D,]O,T$\,FOV:O'(A*LK R9!!!!'K7U!\*OC!\+/CGX
M-A^(GP:\0Z1XHT*YEE@@U?0[J.\M))(&*2(LL192R,"&&<@T >CT5YO\5OC#
M\*_@7X-G^(?QD\0Z1X7T*VEB@GU?7+J.TM(Y)W"1HTLI5078@*,\FOF;2O\
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MSP+K+O/I?B'Q!;S:GJVO8;#SVUJ9(F,!.0+B:50Q'R!QDC\]_P#@J1XDUO\
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M-7&I?"OXR^!_$FIQQLUOIFI:3>:.L[ $A!<"6[523P"RXYY(%?C?_P $]?\
M@H7^VM_P0?\ VZ+KX>_$2+5[;2M)UH>'/B=\-=6N&:SEMA(HDF@7+QQW$2$2
MV\\8PZX!+(Y%?[#>T5_EW?\ !Y=\-= \'_\ !3WPWXWT>)(KCQ7\+M,OM49
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M/^UAX*TKQKI>C^!+34=+M-5\T+;7,FH1PM*AB="&*,5ZU[I_P<D_\&]?@O\
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M<L,L>Z.1&'!5E(((Z@U_FV?\'8W_  2X^(OA[]N;0_VE_P!FOP/K.L:/\2M
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MOQ3L[F"6U\_QFOCWPY<L,+/9ZFZW]O,C<@X?<AQT=&'4$5_K'_L"?M:?#O\
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M#-%I4"/')&P#*ZL""I&0>* /\K3_ () H7_X.#/AH%ZCXU:H?R>]/]*^I?\
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MZYJ;O#IMI*H//V> >8JG^.<'&54T ?TW_LW?\%W/A5^TS_P3Y^)__!1KP?\
M#?QU:>#?AB\ZW5E>M9_;M4%E%'->O9A)#&5MXY07+,,D$#D5P?\ P2[_ .#C
M7]E'_@J;^T7<_LT?"WPOXN\-:W#X<N_$=O-XC-KY%S%92Q1RQ1^1(Q\P"4.
M?X03V-?8W['7_!.GP-\#O^"36A?\$^Y[:V2+4/AA<^'_ !/,D8 N=5UVR?\
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MX@\1KX;M[;P\8!/',UO+<;W^T.B[-L1'!SDU^"8_X/6?V$/^B8_$[_OK3O\
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M*A\27WAIK'7S";DSV,<,C2#R&==C"9<<YZYK^57_ (/B1GX>_L[C_J->+O\
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MI/[)?QDCUB]L[8M\0].95N9DBR/[-/(W$9H _ X_&[_@[&_Y_?VG/_ "[_\
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MN-6\%>-'C2.?5K2R0/<65_L"J]S$@:6.8 &1%8/EE!;]1?\ @Z+^%]C\2O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=(\:?L/>'[;Q3\4++PII3>&-"O(5GAN7?1[A)PT;2P@[8&D<?O!R._0_>?\
MPW[_ ,'>@X'[._A__P $L'_RTH _N.HK^''_ (;^_P"#O7_HW?P__P""6#_Y
M:4?\-_?\'>O_ $;OX?\ _!+!_P#+2@#^XZBOX<?^&_O^#O7_ *-W\/\ _@E@
M_P#EI1_PW]_P=Z_]&[^'_P#P2P?_ "TH _N.HK^''_AO[_@[U_Z-W\/_ /@E
M@_\ EI1_PW]_P=Z_]&[^'_\ P2P?_+2@#^XZBOX<?^&_O^#O7_HW?P__ ."6
M#_Y:4?\ #?W_  =Z_P#1N_A__P $L'_RTH _N.-?P[?\%[O^"6_[87[3G[9#
M^&/V)Q\7+J3QKIDGQ.\:WVMZSM^'T=YX3M5ATBQTV%$)@U,R+B/>1\TNY0R^
M8RQ?\-_?\'>O_1N_A_\ \$L'_P M*/\ AO[_ (.]?^C=_#__ ()8/_EI0!^_
M/_!#+X#ZW\(/V)K3QGXW7XPVOBOX@:G)XN\8:7\:=2&I:U:ZS)&EO<M$X5&6
MVF\H21AP'((+*&)K]E:_AQ_X;^_X.]?^C=_#_P#X)8/_ ):4?\-_?\'>O_1N
M_A__ ,$L'_RTH _N.HK^''_AO[_@[U_Z-W\/_P#@E@_^6E'_  W]_P '>O\
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MGPRGQ.^+LWQ8L]%M9FTO5(+6W@^RV+W"R(SIYN^>01L@;84;C-?A7_P<I?\
M!&7]CO\ X)4^$?A7K'[+W_"4>?XPU35K35_^$AU$7R^7910M'Y0$:;3F0Y/.
M>* /]0SPSXDT7QCX;T_Q?X:G6ZT[5;&#4M/ND!"S6US&LL4@! .&1@1D9YK<
MKY^_9,C$/[*WPSA4DA/A_P"'5!)R>-.@')KZ!H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ I",TM% 'X9>/O^",&G^./^"T/AG_@K8?',UNN@:"-.D\%_V>K^
M?=1V,VGHZW?F#;$8YB[ QEMRX!P<C]RE7  XX'I3Z* &X^GY48^GY4ZB@!N/
MI^5&/I^5.HH ;CZ?E1CZ?E3J* &X^GY48^GY4ZB@!N/I^5&/I^5.HH ;CZ?E
M1CZ?E3J* &X^GY48^GY4ZB@!N/I^5&/I^5.HH ;CZ?E1CZ?E3J* &X^GY4FT
MYSQ_*GT4 ?B-_P $W?\ @CG9?\$^?VS?V@OVL;7QO+XD3XV:Z^KV^BR6 M3I
M23W]SJ,J/,)'\XB2Y*(0JC8H)&3@?MS110 4444 %%%% !1110 4444 ?__1
M_OXHHHH **** "BBB@!K*KKM89![4BQHHVJ,"GT4 1+!"CF1$4,WWF Y/U-)
M);P3#$RJX!SAAGGUYJ:B@! H'2OX._\ @]\_Y)[\ O\ L.^(?_1-M7]XM?P=
M?\'OG_)/?@%_V'?$/_HFVH _M(_92_Y-<^&O_8@^'O\ TW05[[7@7[*7_)KG
MPU_[$'P]_P"FZ"O?: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BOQU_
MX+B_\%*O''_!+#]AR^_:4^&>@:9XBU^3Q!IGA[3+36GD6PC>_9R\TRPLDCA(
MXFVJK#+$9. 17WQ^QW\<-5_:7_94^'/[0FNV-OIE[XU\%Z1XGN]/M':2"VFU
M&UCGDBC9_F9$9B%SSC&>: /I*BBB@ HHHH \(_:0_:0^$_[*'P3\3_M _&G4
M'L/#7A#2FUK7+BU@DN[B*S1UC,BV\(:5_F8#"J:[;X7?$_P9\8OA_H/Q-\!W
M7VK2O$F@Z=XETMY%,4S6&JP+<VLDD+@/&7C<':P!!R#R#7\S'_!PS_P2X^*/
M[;OC+P)<_LR:+X_E\<>-WMOASXB\8:?XA>T\(>'?"L,SW=R^LZ4IW72S>8^U
M5VJ74;B6V ^G?\&Y_P"P3\2/V3/AKXR\3_M&^%OB)X?^)RWB> -8U3Q9XCDU
MC1O$&E^'I9$T^]T6U<[[:T5#LB5P0%/[H[#M4 _I:HHHH ***:V>U #J*_GZ
M^!/_  5^^+'Q3_X+L?$S_@E1K?A70;?PGX0\)MK&D>(K62?^U)+JVAL9Y#<!
MF,+1R"\*JJ(I78#DY(K^@0=* %HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#__TO[^**** "BBB@ HHHH **** "BBB@ K^#K_ (/?/^2>
M_ +_ +#OB'_T3;5_>+7\'7_![Y_R3WX!?]AWQ#_Z)MJ /[2/V4O^37/AK_V(
M/A[_ --T%>^UX%^RE_R:Y\-?^Q!\/?\ IN@KWV@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA+^UMXR;Q_\ $+1_AKK$7B+Q:UU<7AU"62+2I8F,]TJS/LB9$RX'W<#@"O\
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M_BBBB@ HHHH **** "F221Q(TDA"JH+,6.  .I)["GU\"_\ !4OPCXE\>_\
M!.CXU>#_  ?XHL/!>HW_ ,.-:@M_$^JWG]G6=CFV8N]Q=Y'D1L@:-I/X0V:
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M HHHH **** "BBB@ HHHH **** &-C(!K_-/_;]_X.DO^"N'PF_;&^(7PH\
M:-X;\$Z-X8\3W^@:=H&K:";R^CM[*=XXY;B>23YY)D ?* (01M&.3_I9$ ]:
MX?6/A?\ #3Q%J#ZMX@\.Z%?74F/,N;RPMYI6P,#+NA8X'J: /\L(_P#!VG_P
M6?4%FU7P8 !DD^&$P!_W\J"'_@[>_P""RUPVV#6O!#D<X3PU$Q_22O\ 29_;
M1^$'PEL/V/\ XIWEEX6\.12Q?#WQ"\<D>F6JLK+I\Q!!$>00>017^>/_ ,&<
M?AOP[XI_X*0^+-.\3Z?8ZE;CX8WSB"_MX[B,,+RVPP616 /OUH \F_XBTO\
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M7NHF'3[AX([B>5KJ$%KA%64!4"@,-N1R?CO_ (C$O^"OG_/+X5?^$W<?_)U
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M(O141 %51V &*T: "BBB@ HHHH **** /__7_OXHHHH **** "BBB@ HHHH
M**** "OX.O\ @]\_Y)[\ O\ L.^(?_1-M7]XM?P=?\'OG_)/?@%_V'?$/_HF
MVH _M(_92_Y-<^&O_8@^'O\ TW05[[7@7[*7_)KGPU_[$'P]_P"FZ"O?: $(
MR,5\R?$[]BK]D#XU>*&\;_%[X7^ ?$VLR((I-5US0K&\NW5>@>:6)G;';+'
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M*:&5-(N2DD;K &1U/*L""#@@@BOUBKX-_P""I?\ RC2_: _[(UXQ_P#31<T
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M4 %%%% !1110!\O_ +;G_)FWQ6_[)UXB_P#3=/7^<Y_P9C?\I+O%O_9+[_\
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M*$J;>RE%QOZ72/IFBBBJ/-"BD) ZTFX"@!U?!O\ P5+_ .4:7[0'_9&O&/\
MZ:+FOO#>M?!W_!4I@?\ @FG^T !_T1KQC_Z:+F@#^"G_ (,G?^4A7Q1_[(Y/
M_P"GK3*_TR:_S-O^#)W_ )2%?%'_ +(W/_Z>M-K_ $R"P'% "T4W>M+N&,T
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M?\E-@O\ KRO_ $N9_*'CS_R,Z'^#_P!N9]W4445_$A^'!1110 4444 %%%%
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M\F5_&#_LEWBO_P!--S0!_G#?\&9O_*5'Q#_V236?_2_3Z_U':_RXO^#,[/\
MP]1\0_\ 9(]9_P#2_3Z_U':& 44A.* <]*+@+1110 4444 %%%% '__2_OXK
M\X_V_O\ @E/^Q)_P4M\,6NB_M2^$HK_4].B,6C>+=)D.GZ_IJD[MMO?1C=Y>
MX[O*D$D1/)7/-?HY2'/^- '\;7B?_@V(_;*\#W"Z7^RS^VS\6]"T$.1#I>MW
MFHL;>'/$<;6E]'&<#N(T^@KW?X)_\&L?P7O/$EGXS_X*"?&3XI_M 7%FZ7$.
M@^)-5NK;11*IR1(AN)KB5,X^42Q@]&!'!['XV_\ !TA^R)X1_:\TC]DKX ^%
M?$OQ)EN/&EAX'USQCIS)8Z#I]_?7:V92.:5'>X,;DY(54?:=C-UK]8OV)/\
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M HHHH ^)?^"CG_)DOQ!_[!4'_I9!7]YG_!+[_E'-\#?^R6>&_P#T@AK^#/\
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MR_%I?!'B"XT^;1WU;1H)#/+83.DCQ/YB$ ,T:$C!Y4<U^@__  UQ_P %N_\
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MDZU-J$L=C/'/YIG07MU<*&9?E^4 ^IQ0!_0+1110 4A.*6OS8_X*V?MZP?\
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M@W_D;X'_ *^T_P#TI'C<1_\ (OQ7^"7_ *2S])O^#:;_ )0M_!C_ +!VI?\
MIRN:_=NOPD_X-IO^4+?P8_[!VI?^G*YK]VZ_Z4S_ !!>Y&W\7X5_GO?MK_\
M*PS^T/\ ]B9X5_\ 3?8U_H0M_%^%?Y[W[:__ "L,_M#_ /8F>%?_ $WV-?N?
MT:/^2XRG_&__ $EGW7AE_P C[!_XOT9Z+1117^WI_<H4444 %%%% 'Q+_P %
M'/\ DR7X@_\ 8*@_]+(*_O,_X)??\HYO@;_V2SPW_P"D$-?P9_\ !1S_ ),E
M^(/_ &"H/_2R"O[S/^"7W_*.;X&_]DL\-_\ I!#7^57TZO\ DIL%_P!>5_Z7
M,_E#QY_Y&=#_  ?^W,^[J***_B0_#@HHHH **** "BBB@ HHHH **** "OX1
MO^"C_P#RLA>(/^R(:5_Z"*_NYK^$;_@H_P#\K(7B#_LB&E?^@BOQ_P ?_P#D
MB\X_Z]2_0_G'Z7O_ ";'B3_KQ/\ 0]IHHHK_  G/^3Y[A1110(****:*CU/E
M_P#;:_Y- ^)?_8FZC_Z*K^F3_@WX_P"4,W[/O_8CC_TLN*_F;_;:_P"30/B7
M_P!B;J/_ **K^F3_ (-^/^4,W[/O_8CC_P!++BO]2/H&?\B/,O\ K['_ -)/
M][/V2W_)*9U_U_C_ .FT?L91117]WG^L1_!M_P '1?\ RE._9N_[$'Q!_P"C
MI*_,"OT__P"#HO\ Y2G?LW?]B#X@_P#1TE?F!7^XO[-7_DBL;_V$2_\ 2('S
M^<?Q%Z!1117^B9XX4444 %8?B?\ Y%C4_P#L'7/_ **:MRL/Q/\ \BQJ?_8.
MN?\ T4U>+Q)_R+L5_@G_ .DLNG\2/ZP/^#2W_E#CX7_['/Q1_P"EBU_3)7\S
M?_!I;_RAQ\+_ /8Y^*/_ $L6OZ9*_P"4O'?QZGJ_S/LX;(****Y2@HHHH __
MUO[^*\.\8_LU? #XA?%KP]\=_''@[P[JWC/PG&T/AKQ/?V44VI:9&Y8LMK<,
M-\0)=B0I[FO<:* $%&T&EHH **** "L77O#?A[Q5IYTCQ1866I6C,':UOX$N
M(2R\@E) RY'8XK:HH _)_P#:2_X(_?LP?M)_M=?"3]KW6UET74_A%<R7&F>'
M]%LK"+2M4,DHE(OXF@)< \#!''YU\]_\%#/^"#WPA_;;^.UK^U%\*_B'XV^"
M/Q$;0F\*Z_XC^'TBQ?VWHQC$0M;J$/%RL0$897P450RMM7'[R48% 'QM^P5^
MPS\"_P#@G3^S/HG[+?[/EM=1:'I#37=Q>ZBZRW^I7]TV^XO+N1516ED( X4*
MJ*J* J@5_('_ ,'O?'P\^ 0_ZCOB'_T1;5_>+7\'7_![Y_R3WX!?]AWQ#_Z)
MMJ /[2/V4>/V6_AJ/^I \/?^FZ"OX7/^"KW_ "L<^*?^R/:+_P"DHK^Z/]E+
M_DUSX:_]B#X>_P#3=!7\+G_!5[_E8Y\4_P#9'M%_])17GYK_ +O,_H3Z*/\
MR<7(/^OR_)FA1117YN?],:V"BBB@84444UN!\Z?M>?\ )KOC[_L5[[_T6:_L
MW_X(4_\ *(/]G[_LGEE_Z')7\9'[7G_)KOC[_L5[[_T6:_LW_P""%/\ RB#_
M &?O^R>67_H<E?9\-?PY^J/\4OVG_P#R4>3_ /7F7_I9^LE%%%?2'^8A_%%_
MP59_Y61_A5_V02[_ /1VI5]BU\=?\%6?^5D?X5?]D$N__1VI5]BU_C9]/_\
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M_4CZ!G_(CS+_ *^Q_P#23_>S]DM_R2F=?]?X_P#IM'[&4445_=Y_K$?P;?\
M!T7_ ,I3OV;O^Q!\0?\ HZ2OS K]/_\ @Z+_ .4IW[-W_8@^(/\ T=)7Y@5_
MN+^S5_Y(K&_]A$O_ $B!\_G'\1>@4445_HF>.%%%% !6'XG_ .18U/\ [!US
M_P"BFK<K#\3_ /(L:G_V#KG_ -%-7B\2?\B[%?X)_P#I++I_$C^L#_@TM_Y0
MX^%_^QS\4?\ I8M?TR5_,W_P:6_\H<?"_P#V.?BC_P!+%K^F2O\ E+QW\>IZ
MO\S[.&R"BBBN4H**** /_]#^_BBBB@ HHHH **** "BBB@ HHHH *_@Z_P"#
MWS_DGOP"_P"P[XA_]$VU?WBU_!U_P>^?\D]^ 7_8=\0_^B;:@#^TC]E+_DUS
MX:_]B#X>_P#3=!7\+G_!5[_E8Y\4_P#9'M%_])17]T?[*7_)KGPU_P"Q!\/?
M^FZ"OX7/^"KW_*QSXI_[(]HO_I**\_-?]WF?T)]%'_DXN0?]?E^3-"BBBOS<
M_P"F-;!1110,****:W ^=/VO/^37?'W_ &*]]_Z+-?V;_P#!"G_E$'^S]_V3
MRR_]#DK^,C]KS_DUWQ]_V*]]_P"BS7]F_P#P0I_Y1!_L_?\ 9/++_P!#DK[/
MAK^'/U1_BE^T_P#^2CR?_KS+_P!+/UDHHHKZ0_S$/XHO^"K/_*R/\*O^R"7?
M_H[4J^Q:^.O^"K/_ "LC_"K_ +()=_\ H[4J^Q:_QL^G_P#\EGA_^O$/_2ZA
M_I=]$+_DF:O_ %]E^40HHHK^&C^J@HHHH *\6_:1_P"3>/'?_8GZQ_Z1RU[3
M7BW[2/\ R;QX[_[$_6/_ $CEKZ7@W_D;X'_K[3_]*1XW$?\ R+\5_@E_Z2S]
M)O\ @VF_Y0M_!C_L':E_Z<KFOW;K\)/^#:;_ )0M_!C_ +!VI?\ IRN:_=NO
M^E,_Q!>Y&W\7X5_GO?MK_P#*PS^T/_V)GA7_ --]C7^A"W\7X5_GO?MK_P#*
MPS^T/_V)GA7_ --]C7[G]&C_ )+C*?\ &_\ TEGW7AE_R/L'_B_1GHM%%%?[
M>G]RA1110 4444 ?$O\ P4<_Y,E^(/\ V"H/_2R"O[S/^"7W_*.;X&_]DL\-
M_P#I!#7\&?\ P4<_Y,E^(/\ V"H/_2R"O[S/^"7W_*.;X&_]DL\-_P#I!#7^
M57TZO^2FP7_7E?\ I<S^4/'G_D9T/\'_ +<S[NI,G=CVI:B<X8"OXD/PX=D@
MX_6G;A7\=/[9O_!<G_@J5X2_X*)_%W]CS]B[X:?#+Q!HOPMGTJVGOO$\]S'>
M2_VC8PW7F,PO+>,Y>1E"JORA<DG->._\/G_^#A[_ *(M\#__  .N/_EI7U64
M\#9SCJ*Q&$P<ZD'UC%M?>D?G7$?B]PKE&*E@LUS>C0JI)N,ZD8R2>SLW?4_M
MXW9Z5\>_\%"R3^P'\<<C_FCWC/\ ],MW7\I/_#Y__@X>_P"B+? __P #KC_Y
M:5YK\9_^"IW_  <!_&_X/>+/@OXF^#GP7MM.\7^&M4\+ZA<V=_,+B*VU6UDM
M)7B+ZDRAU24E=RD9'((KTO\ B%_$7_0NJ_\ @$O\CPO^)AN!/^B@PW_@Z'_R
M1^9'_!EOQ_P4X\;8Y_XLUJG_ *=M+K_3XR?2O\I/_@EC\%/^"M__  2G^/.L
M_M!? SX=>#=7U75/#5QX2GM?%>IPR6OV6XN+>Z:6,6MW$^_?;J 2V,$\=Q^^
MW_#Y_P#X.'O^B+? _P#\#KC_ .6='_$+^(O^A=5_\ E_D.7TA.!%H^(,-_X.
MA_\ )']NVX4%C_#7\0__  ^?_P"#A[_HBWP/_P# ZX_^6E>5?&W_ (."/^"[
MW[/7PSU'XO\ Q2^#_P %+30M(\EKZ>&XNYW43RK"FU(]29CEF X''6N?%^'.
M?4*4ZU; 5(QBKMN#226[9UY=XZ\%XO$4\+A,\P\ZDVHQC&K!N3;LDDG=MO9'
M]Y19A4M>/_ 'XE7/QD^!G@[XMW]LEE/XG\,:9KT]I$Q=(9+^VCG:-6(R54N0
M"><5[!7Q9^K!7\(W_!1__E9"\0?]D0TK_P!!%?W<U_"-_P %'_\ E9"\0?\
M9$-*_P#017X_X_\ _)%YQ_UZE^A_./TO?^38\2?]>)_H>TT445_A.?\ )\]P
MHHHH$%%%%-%1ZGR_^VU_R:!\2_\ L3=1_P#15?TR?\&_'_*&;]GW_L1Q_P"E
MEQ7\S?[;7_)H'Q+_ .Q-U'_T57],G_!OQ_RAF_9]_P"Q''_I9<5_J1] S_D1
MYE_U]C_Z2?[V?LEO^24SK_K_ !_]-H_8RBBBO[O/]8C^#;_@Z+_Y2G?LW?\
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M\;7+P6%M;R)%+'9VBI<VN9MDT>2TA)=]@3Y&- ']-8(/2OX._P#@]\_Y)[\
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MG[_LGEE_Z')7V?#7\.?JC_%+]I__ ,E'D_\ UYE_Z6?K)1117TA_F(?Q1?\
M!5G_ )61_A5_V02[_P#1VI5]BU\=?\%6?^5D?X5?]D$N_P#T=J5?8M?XV?3_
M /\ DL\/_P!>(?\ I=0_TN^B%_R3-7_K[+\HA1117\-']5!1110 5XM^TC_R
M;QX[_P"Q/UC_ -(Y:]IKQ;]I'_DWCQW_ -B?K'_I'+7TO!O_ "-\#_U]I_\
MI2/&XC_Y%^*_P2_])9^DW_!M-_RA;^#'_8.U+_TY7-?NW7X2?\&TW_*%OX,?
M]@[4O_3E<U^[=?\ 2F?X@O<C;^+\*_SWOVU_^5AG]H?_ +$SPK_Z;[&O]"%O
MXOPK_/>_;7_Y6&?VA_\ L3/"O_IOL:_<_HT?\EQE/^-_^DL^Z\,O^1]@_P#%
M^C/1:***_P!O3^Y0HHHH **** /B7_@HY_R9+\0?^P5!_P"ED%?WF?\ !+[_
M )1S? W_ +)9X;_]((:_@S_X*.?\F2_$'_L%0?\ I9!7]YG_  2^_P"4<WP-
M_P"R6>&__2"&O\JOIU?\E-@O^O*_]+F?RAX\_P#(SH?X/_;F?=U(>AI:0]#7
M\2'X<?P2:M_RG7_;,_Z_?"/_ *:K>OLROC/5O^4Z_P"V9_U^^$?_ $U6]?9E
M?Z;_ $9/^23H?XI_F?\ /3^T._Y.9B_^O=+_ -)"BBBOZ!/X="BBB@ K\T?^
M"P/_ "CO^('^[I?_ *<(*_2ZOS1_X+ _\H[_ (@?[NE_^G""OAO$W_DG<R_Z
M]3_])9^R?1W_ .2\X>_[":/_ *<B?W*?L,_\F7_";_LG7AW_ --T-?55?*O[
M#/\ R9?\)O\ LG7AW_TW0U]55_D ]V?]2@5_"-_P4?\ ^5D+Q!_V1#2O_017
M]W-?PC?\%'_^5D+Q!_V1#2O_ $$5^/\ C_\ \D7G'_7J7Z'\X_2]_P"38\2?
M]>)_H>TT445_A.?\GSW"BBB@04444T5'J?+_ .VU_P F@?$O_L3=1_\ 15?T
MR?\ !OQ_RAF_9]_[$<?^EEQ7\S?[;7_)H'Q+_P"Q-U'_ -%5_3)_P;\?\H9O
MV??^Q''_ *67%?ZD?0,_Y$>9?]?8_P#I)_O9^R6_Y)3.O^O\?_3:/V,HHHK^
M[S_6(_@V_P"#HO\ Y2G?LW?]B#X@_P#1TE?F!7Z?_P#!T7_RE._9N_[$'Q!_
MZ.DK\P*_W%_9J_\ )%8W_L(E_P"D0/G\X_B+T"BBBO\ 1,\<**** "L/Q/\
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M?^R/:+_Z2BO/S7_=YG]"?11_Y.+D'_7Y?DS0HHHK\W/^F-;!1110,****:W
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MG]&C_DN,I_QO_P!)9]UX9?\ (^P?^+]&>BT445_MZ?W*%%%% !1110!\2_\
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M " >[/\ J4"OX1O^"C__ "LA>(/^R(:5_P"@BO[N:_A&_P""C_\ RLA>(/\
MLB&E?^@BOQ_Q_P#^2+SC_KU+]#^<?I>_\FQXD_Z\3_0]IHHHK_"<_P"3Y[A1
M110(****:*CU/E_]MK_DT#XE_P#8FZC_ .BJ_ID_X-^/^4,W[/O_ &(X_P#2
MRXK^9O\ ;:_Y- ^)?_8FZC_Z*K^F3_@WX_Y0S?L^_P#8CC_TLN*_U(^@9_R(
M\R_Z^Q_])/\ >S]DM_R2F=?]?X_^FT?L91117]WG^L1_!M_P=%_\I3OV;O\
ML0?$'_HZ2OS K]/_ /@Z+_Y2G?LW?]B#X@_]'25^8%?[B_LU?^2*QO\ V$2_
M](@?/YQ_$7H%%%%?Z)GCA1110 5A^)_^18U/_L'7/_HIJW*P_$__ "+&I_\
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MBOX:/ZJ"BBB@ KQ;]I'_ )-X\=_]B?K'_I'+7M->+?M(_P#)O'CO_L3]8_\
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MU_VS/^OWPC_Z:K>OLRO]-_HR?\DG0_Q3_,_YZ?VAW_)S,7_U[I?^DA1117]
MG\.A1110 5^:/_!8'_E'?\0/]W2__3A!7Z75^:/_  6!_P"4=_Q _P!W2_\
MTX05\-XF_P#).YE_UZG_ .DL_9/H[_\ )></?]A-'_TY$_N4_89_Y,O^$W_9
M.O#O_INAKZJKY5_89_Y,O^$W_9.O#O\ Z;H:^JJ_R >[/^I0*_A&_P""C_\
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M ,&R_P#D3X._X7C\$_\ H<?"O_@UM/\ XY4:?';X(2<)XR\+''7_ (FMI_\
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M_3M:LKC3X;HS:B1!)=1RF)9,,I"%MW(XYK[$_P"&E_V;AU^(?@7_ ,'UA_\
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M7X\_%+X1?$KQGX@\*6W@#3;>]LKS0[>VGENFFO9+4B5;@%5 5,_+W-?TT_\
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M3K*\MRVH7#*)8)YTD0E2"-RC((-?M3_P\7_X)^_]%P^$G_A7:1_\DU_*T?\
M@R*_9*//_"[/B+_X+=,_^)I/^((G]DK_ *+9\1O_  6Z9_\ $U_H8?QF?U2_
M\/%O^"?O_1</A)_X5VD?_)-?PH_M>?'CX'>)O^"\OQZ^(WASQGX5O_#^H^$/
M#,.GZY::K:2Z?<R16-DLB0W*RF*1D92&"L2""#TK]"?^((G]DK_HMGQ%_P#!
M;IG_ ,32_P#$$5^R5C'_  NSXC?^"W3/_B:^V\.N,Y\/9UA<YITE4=%WY6[7
MT:WU[GM\.9S++L=1QL8\S@[V[Z'QU_PO7X(_]#EX5_#5K3_X[2_\+U^"/_0X
M^%?_  ;6G_QVOL/_ (@B?V2O^BV?$;_P6Z9_\31_Q!$_LE?]%L^(W_@MTS_X
MFO[,_P")]\?_ -">'_@Q_P#R)^S_ /$?L3_T"+_P)_Y'QY_PO7X(=_&?A3_P
M;6G_ ,=J)/CY\"I<^7XU\)MCJ!JUI_\ ':^O=0_X,DOV2K*PGO!\:_B*QAA>
M7!T[3.=JD_W?:OYK_P#@A3_P18^$_P#P5G^-?Q7^%GQ*\9^(?"=O\/;&SNK&
MZT.VMIY+LW-Y<6S"87 (4!801M[DU+^GMC_^A1#_ ,&/_P"1#_B/V)_Z!(_^
M!/\ R/V7'QV^"/\ T./A7_P:VG_QVE_X7K\$?^AQ\*_^#:T_^.U]A_\ $$3^
MR5_T6SXC?^"W3/\ XFC_ (@B?V2O^BV?$;_P6Z9_\35?\3[X[_H40_\ !C_^
M1#_B/V)_Z!%_X$_\C\=?^"@GQ=^$_B#]C7QWH^@>*/#M[>3Z; L%I9ZE;332
M$7<!(2-)"S$ $\#I7]K7_!.#]O;]AOPE^P%\&/#'BCXQ_"[3=2L/AIX>M+ZP
MOO%&EP7-O/%8Q*\4L4EPKHZL"&5@"",&OPP'_!D5^R4.GQL^(W_@MTS_ .)I
M/^((G]DKI_PNSXB_^"W3/_B:_F'QL\8*W&F8T<QK8947"')92<K^\W?5+N?F
M7&_&<\[Q$,14IJ'+&UD[]6_U/ZIO^'B__!/W_HN'PD_\*[2/_DFFM_P47_X)
M_=OCA\)/P\7:3_\ )-?RM_\ $$3^R5_T6SXC?^"W3/\ XFC_ (@B?V2O^BV?
M$7_P6Z9_\37XV?%'QQ=?M _ :_\ ^"U?[77CVS\;^$9=#UJ[\*MH^LIJ]F;&
M^$.F0)(;:X\WRY=C JVQC@@@U]B_\-%_L\_]#[X+_P#!W9?_ !VG_P#$$3^R
M5_T6SXB_^"W3/_B:/^((G]DK_HMGQ%_\%NF?_$U_1OAS](C$\.Y7#+*6#C44
M6W=R:W=^B/X0\>?H*Y;QWQ%5XAQ.:SHRG&,>6,(M+E5MW+KZ#/\ AHO]GG_H
M??!7_@[LO_CM(?VC/V>1U\>^"_\ P=V7_P =J3_B")_9*_Z+9\1?_!;IG_Q-
M5KO_ (,D/V2;:VDN/^%U_$7Y(V?_ )!NF?P@G^[7W?\ Q.'CO^A;#_P-_P"1
M^-?\4LLE_P"A]5_\%P_^2$C_ &E/V<IB5B^('@IB.H&MV7_QVI_^&B_V>?\
MH??!7_@[LO\ X[7\T'_!"_\ X(N?"?\ X*Q?'?XJ_"3XE>,_$/A2V^'VGVUY
M97>AVUM/+=M->S6I$HG!50%C##;W-?TP_P#$$3^R5_T6SXB_^"W3/_B:%],+
M'?\ 0MA_X&_\AO\ 99Y*_P#F?5?_  7#_P"2&_\ #1?[//\ T/O@O_P=V7_Q
MVOSH_P""LGQI^#/BO]@7QUH'A;Q?X7U._G73?(LM/U6UN+B3;?P,VR..1F;
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M3-ECN"G 8 _IG\%?M_\ [)OQ8_99\7?M<^$_$IN_AYX/&NV_B;6Q9W49M?\
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MQ/%J'PPMM$O_ !!<>(8;>X!BL]+,@NV>V:,3AXC&X:,IOR.!7BEI_P %>_\
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M1<]J_A.^"V@ZSI/P@^%W_!+K0]+N+CPG^T!X1\%?M$ZU,O-O##X>T?5)-8B
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M TG7? _B.3XQ6<T_AF^U,7=YH4S3V):T%S:R&([">3"VPY[U^FGB+P=9?\%
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M=C<QR65_9W"I<6\L;@K)%-&VY&5@2&1A@C@BO&_A#^SC^S%\#]4OKSX$>!_
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M;_$/5_AOX,TJX\+Q>([WQ#>Z(0D]]J<\\\?E02R$;8XE#*I[D98 _6+]L_\
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MEX;;Q=J%S]EBLUBAU222ZLK<0Q*J@0VSQ)GJV,GDU_._\"_VEO\ @LS\4?V
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MY^PK\&;]=.O/&][J_CKQYJ*PQSRQ^$_#5N2UI'YFX1M?7DD,1DQN6-7VD$Y
M!^K1Z5\%?MO_ /!.G]G[]OBV\)WWQ:E\3:+XB\!ZK+K/@KQCX+U:?1=<T:YN
M46.<VUU 00LR(H=64@[1T(S7\^7PE_X.%?AMX$_9^_:<\%_M3_%S2-,^+_A7
MXB?$[0?ACIUQIS+-#9Z8DD/A] L%NT,F+E, R'+?Q<5[)\*O^"D/[7OB.3_@
MFVFL>)8IO^%_VGB*3XI_Z!;K_:K6&EI<P%<)^XV2$G]UMSWS0!^SWPJ_X)E?
ML>_"7]C[6?V&['PY+K7@+Q,=1F\5P>)+N;4;_6KS5I#+>7M[>R-YSW,DAWB4
M,K(P4IMP*^4_A'_P08_8D^%WQ#\'^.]=U+XF^.[;X=WB7_P]\+_$+Q;?ZYH/
MAVXA_P!1)9V$[>7NAP/*\S<%P..!7P1I'[6__!1']N]OB_\ M+?##XY?#[]F
MSX.?#/Q]J_P]\)2>)-#M=3.LWVB2BVEO-9O[VXB2VMY[C"K'$H8*>,D9;<_:
M/_X*D?M-_!O_ ()I_!O]I[XD^-OAE9>('^-_ASP;\4/%/PTOX/$?AJXT0W3C
M4)(I$67R'DM@KRQ)N>(YVGD"@#]Q/VG?V)?@W^UE\0OA5\2OBBVK+J/P>\;P
M^/\ PG_9MR((CJ< "J+I2K>;%\HRN1WYJS\6/V+_ (0?&3]J?X7_ +7_ (M?
M51XK^$<.NP>%4M;D1V17Q#:_8[O[3%M/F$1?<^8;3SS7X]^ _P#@LS\-/VN_
M^"M_P:_9Y_8I^)6F>*OAYJO@7QAJ/CS3K"S8'^TK!(GTYFFN88Y%PI<X0X..
M:]$_X+9_M*_M:_"#XH_LO_ O]D[QRGP_N_C+\6G\!ZWKS:5;:N8;::*$1R+!
M<X4F-G+8#+N[F@#[G\+?\$POV6_!'[5'Q$_:O\*V.HVFH_%K0&\/_$CPL)U?
MPWKZ.NQKFYT]T*_:&7*LZL-P9\@[VS\:6/\ P;L?\$][1K3PI>7'Q.O_ (=6
M&MCQ#8?![4/&.IW'@B"]60RKMTQI"#$K$D1%RO)R#SGP7P1^W1^V9_P3T_;C
MU?\ 8U_;X\9Z3\7_  UJ?P6UWXP^#?&VEZ)'H&KQ2>&A+)?Z9=V\,DD#AX8F
M>.08P2H[D#Q;X7?&C_@M]^U!^Q%>?\%6_A[\5OA]X3T^[T/5O'GA#X'S>%EO
MM.F\/:>9I8K6^U=IUN?M<\$)Q(BA59AT_A /UJ_:Q_X)%_L_?M9?'GPW^TC?
M^)_B/X$\6>%/"C>"]%U#X:ZZ_A]H=*:1Y3 #!&6"G>5P"!M &.*^OOV5/V:-
M._95^&TGPVTWQAX\\;1R:C-J/]K_ !$UF77=34S!085N9@&$2[?E3H,GUK^;
M3]K'_@LQ^U7\0?V/?V:OVHO@K]M^$GPW^+.GZA<_%;XI:7X7G\=3>#[RQ_<Q
MVJV,979!/<1R8N)%8[,  LI![OPK_P %'?VKY/\ @CO^T9^TQX?^,OPR^*VH
M_#[3Y[KX:_%#P-:BUU&6WQ&P7Q!H-PFVQO8RQ 0Y5T(89QD@']55)@'K7\D7
M_!.7]NW5_P!H#]HOX=>%7_;ZTKXBZIJQAO\ 4OA9!\/8--DU$K:F>YL1J QY
M7E\_O!_=X'-?KS_P31_:O^*GQ:^(7QY_92_: OX=5\8_!#XHW7A^+6TA2VDU
M3PUJT*:EHEU/#$ BSK;3>5(5 #; V 2<@'>_%;_@E-^R)\8OV_?!G_!23QOI
MFHW'Q&\#Z<EAI#)=%=.D,"SK;3W%MM/F36_VAS$VX88*<$J*YS]KK_@D]\$?
MVO?VB=(_:FUKQC\3_!7C31O";>#+35OAUXADT*4Z4]R]T\+M"A=@\C9;YL':
MO'%?J4O2EH _)G4?^"0GP2\6?LXZG^S'\5?'GQ=\;Z'J7C#2/&AO_&7B>;5M
M3MKS1G22WBM[F="8[<O&&>,##$D]Z^L/BY^QK\(_C/\ 'GX6_M&>+GU5=?\
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MI?LQ:?\ LH?#F?X<Z;XR\?>-XY]3EU/^UOB-K4NNZE&941/)2YF 80KLRJ=
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M:;KLL<3?V-J<5P\S36KS(N9D*N?FQC@\K_P4T_X*A?M9_#/]LBW\!7/Q-?\
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MXKV7QH^&MSXZ\0:[H?AR;P=X1E\;^(KO68?#>A3R"5[#2X9B$@B9AC[I;;D
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MHVH6<LL2ML:-+J*XV?>,?(R<"OZ6:A:WA:59V52Z9V,0,KNZX/;/>@#^;_\
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M\,%R.*_=$U%#!%;Q"&W541?NJ@  [\ 4 2T444 %%%% !1110 4444 ?A/\
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MSU\/;;P)!K6H6<VH^&/$&FFT6&^TV_MAY-P;>20%XI%(="2=N<$?T.8]Z7%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
6**** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>forms1-a_025.jpg
<TEXT>
begin 644 forms1-a_025.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )C WL# 2(  A$! Q$!_\0
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M_P"@7;?]\"C_ (0W1/\ H%VW_? K9HH QO\ A#=$_P"@7;?]\"C_ (0W1/\
MH%VW_? K9HH QO\ A#=$_P"@7;?]\"C_ (0W1/\ H%VW_? K9HH QO\ A#=$
M_P"@7;?]\"C_ (0W1/\ H%VW_? K9HH QO\ A#=$_P"@7;?]\"C_ (0W1/\
MH%VW_? K9HH QO\ A#=$_P"@7;?]\"C_ (0W1/\ H%VW_? K9HH QO\ A#=$
M_P"@7;?]\"C_ (0W1/\ H%VW_? K9HH QO\ A#=$_P"@7;?]\"C_ (0W1/\
MH%VW_? K9HH QO\ A#=$_P"@7;?]\"C_ (0W1/\ H%VW_? K9HH QO\ A#=$
M_P"@7;?]\"C_ (0W1/\ H%VW_? K9HH QO\ A#=$_P"@7;?]\"C_ (0W1/\
MH%VW_? K9HH QO\ A#=$_P"@7;?]\"C_ (0W1/\ H%VW_? K9HH QO\ A#=$
M_P"@7;?]\"C_ (0W1/\ H%VW_? K9HH QO\ A#=$_P"@7;?]\"C_ (0W1/\
MH%VW_? K9HH QO\ A#=$_P"@7;?]\"C_ (0W1/\ H%VW_? K9HH QO\ A#=$
M_P"@7;?]\"C_ (0W1/\ H%VW_? K9HH QO\ A#=$_P"@7;?]\"C_ (0W1/\
MH%VW_? K9HH QO\ A#=$_P"@7;?]\"C_ (0W1/\ H%VW_? K9HH QO\ A#=$
M_P"@7;?]\"C_ (0W1/\ H%VW_? K9HH QO\ A#=$_P"@7;?]\"C_ (0W1/\
MH%VW_? K9HH QO\ A#=$_P"@7;?]\"C_ (0W1/\ H%VW_? K9HH QO\ A#=$
M_P"@7;?]\"C_ (0W1/\ H%VW_? K9HH QO\ A#=$_P"@7;?]\"C_ (0W1/\
MH%VW_? K9HH QO\ A#=$_P"@7;?]\"C_ (0W1/\ H%VW_? K9HH QO\ A#=$
M_P"@7;?]\"C_ (0W1/\ H%VW_? K9HH QO\ A#=$_P"@7;?]\"C_ (0W1/\
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M_P"@7;?]\"C_ (0W1/\ H%VW_? K9HH QO\ A#=$_P"@7;?]\"C_ (0W1/\
MH%VW_? K9HH QO\ A#=$_P"@7;?]\"C_ (0W1/\ H%VW_? K9HH QO\ A#=$
M_P"@7;?]\"C_ (0W1/\ H%VW_? K9HH QO\ A#=$_P"@7;?]\"C_ (0W1/\
MH%VW_? K9HH QO\ A#=$_P"@7;?]\"C_ (0W1/\ H%VW_? K9HH QO\ A#=$
M_P"@7;?]\"C_ (0W1/\ H%VW_? K9HH QO\ A#=$_P"@7;?]\"C_ (0W1/\
MH%VW_? K9HH QO\ A#=$_P"@7;?]\"C_ (0W1/\ H%VW_? K9HH QO\ A#=$
M_P"@7;?]\"C_ (0W1/\ H%VW_? K9HH QO\ A#=$_P"@7;?]\"C_ (0W1/\
MH%VW_? K9HH QO\ A#=$_P"@7;?]\"C_ (0W1/\ H%VW_? K9HH QO\ A#=$
M_P"@7;?]\"C_ (0W1/\ H%VW_? K9HH QO\ A#=$_P"@7;?]\"C_ (0W1/\
MH%VW_? K9HH QO\ A#=$_P"@7;?]\"C_ (0W1/\ H%VW_? K9HH QO\ A#=$
M_P"@7;?]\"C_ (0W1/\ H%VW_? K9HH QO\ A#=$_P"@7;?]\"C_ (0W1/\
MH%VW_? K9HH QO\ A#=$_P"@7;?]\"C_ (0W1/\ H%VW_? K9HH QO\ A#=$
M_P"@7;?]\"C_ (0W1/\ H%VW_? K9HH QO\ A#=$_P"@7;?]\"C_ (0W1/\
MH%VW_? K9HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MMT:U:U6O;O\ Y')B8PIRM#SZW]'\S1\ZCSJS_,]Z/,]Z]3D.3F-#SJ/.K/\
M,]Z/,]Z.0.8^G_V$9-WQ8UD?]09__1T5?=E?!/[ [[OBYK0S_P P63_T?%7W
MM7Y!Q,K9@_1'W.4.^%7JPHHHKY0]H**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>] %OS?>CS?>JGF>]'F>] %OS?>CS?>JGF>]'F>] %OS?>CS?>JGF>]'F>]
M'U)_P3_?=\7M;'_4$D_]'PU]^U^??_!/EMWQBUS_ + <G_H^&OT$K\<XH_Y&
M+]$?=Y/_ +JO5A1117R9[84444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA]54"I*^-S3'_P!I8EXCEY=$K7OM\D>]@\-]4I>RO<****\D[@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "N5TG_DI'B/_ *\;'_T*>NJKEM)4_P#"QO$9P<?8;'G_
M (%/6L/AEZ?JB);HZFBBBLBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#X5_:
MB\5:SIGQLUNVL]8U"TMUAMBL-O=R1H,PJ3A0P%>4_P#"<^(O^AAU;_P/F_\
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M(]5UCXE:K#?:K?7T2Z4[B.ZNGE4'S8QD!B1GD\U]CU\/_L.R;_BIK'_8'?\
M]'15]P5^7\014,<TNR/KLLDY8=-]V%%%%?-GJA1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?:90[X5>K"BBBOE3V@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?7Y/_NJ]6%%%%?)GMA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8=R.JCGKQ7H]? YSCJ>88MUZ2:5DM?+[SZ; 8>>%H*G/?R"BBBO#/1"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *\VT?\ Y.'\3_\ 8N:=_P"E%W7I->;:/_R</XG_
M .Q<T[_THNZZJ'PU/\/ZHQJ;Q]?T9Z31117*;!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWWA:^\26]A))HEC,L%Q> C;&[8P,9SW'/N*)9?@X_%2BOD@6*KRVD_O9Z/\
M\-2?$S_H9?\ R2@_^(H_X:D^)G_0R_\ DE!_\17COVI<D;AGZUH:=IEUJVGZ
MG?6PB:WTZ-9;AFF52%9MHV@G+'/89QUIO+\)%7=*/W(%BJSVF_O9ZE_PU)\3
M/^AE_P#)*#_XBC_AJ3XF?]#+_P"24'_Q%>3Z=:W6KM<"QMY+LV\+W,PA&[RX
MDQN<^BC(R?>JGVM"0 PS]:?]G82]O91^Y!]:K?SO[V>Q_P##4GQ,_P"AE_\
M)*#_ .(K6\(_M+?$75/%NAV5SXB\RVN;^WAE3[' -R-(JL,A.,@FO!A=H3@,
M"?3-=3X3L[O1_B;X>L+^WDL[R'5K,2P3+M=,RH1D=N"#^-95<OPJA+]U&]GT
M14,56<E[[^]GZ?5YMH__ "</XG_[%S3O_2B[KTFO-M'_ .3A_$__ &+FG?\
MI1=U^2T/AJ?X?U1]I4WCZ_HSTFBBBN4V"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBC_67+?YW]S#^R,7_+^*/A/SJ/.K[L_X=Q^%_P#H<=<_[]0?_$4?\.X_"_\
MT..N?]^H/_B*/]9<M_G?W,/[(Q?\OXH^$_.H\ZONS_AW'X7_ .AQUS_OU!_\
M11_P[C\+_P#0XZY_WZ@_^(H_UERW^=_<P_LC%_R_BCX3\ZCSJ^[/^'<?A?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^#"+_P"*H_X6)X4_Z&?1O_!A%_\ %5%JO\GX?\ KW/YOQ(OL?B__ *"FC_\
M@#)_\=H^Q^+_ /H*:/\ ^ ,G_P =J7_A8GA3_H9]&_\ !A%_\51_PL3PI_T,
M^C?^#"+_ .*HM5_D_#_@![G\WXD7V/Q?_P!!31__  !D_P#CM'V/Q?\ ]!31
M_P#P!D_^.U+_ ,+$\*?]#/HW_@PB_P#BJO:3XFT?7I)$TS5;'47C +K:7*2E
M0>A.TG'2D_:15W#\ 7*]$_Q,S['XO_Z"FC_^ ,G_ ,=H^Q^+_P#H*:/_ . ,
MG_QVNFHK/VC[+[D7R+O^)S/V/Q?_ -!31_\ P!D_^.T?8_%__04T?_P!D_\
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M/_ONX_\ B:,_%;^YX3_[[N/_ (FO1:*/;_W%]P>S_O,\ZS\5O[GA/_ONX_\
MB:,_%;^YX3_[[N/_ (FO1:*/;_W%]P>S_O,\ZS\5O[GA/_ONX_\ B:,_%;^Y
MX3_[[N/_ (FO1:*/;_W%]P>S_O,\ZS\5O[GA/_ONX_\ B:R-,\(_$BW\<ZEX
MFEG\,+<7EA;V!AQ<,H6*25PW;D^:?R%>N44UB7%-**U\A>Q3M=LXC;\1_P#G
MIX6_[]W/_P 51M^(_P#ST\+?]^[G_P"*KMZR-2\7Z%HMT;;4-;TZPN=H;R;F
M[CC?!Z'#$'%*-24G:,$_D-Q2WD_O.?V_$?\ YZ>%O^_=S_\ %4;?B/\ \]/"
MW_?NY_\ BJUO^%B>%/\ H9]&_P#!A%_\51_PL3PI_P!#/HW_ (,(O_BJO][_
M ,^_P)]S^;\3)V_$?_GIX6_[]W/_ ,51M^(__/3PM_W[N?\ XJM;_A8GA3_H
M9]&_\&$7_P 51_PL3PI_T,^C?^#"+_XJC][_ ,^_P#W/YOQ,G;\1_P#GIX6_
M[]W/_P 51M^(_P#ST\+?]^[G_P"*K6_X6)X4_P"AGT;_ ,&$7_Q5'_"Q/"G_
M $,^C?\ @PB_^*H_>_\ /O\  /<_F_$Y]-8\>V_B*UTNY3PY(;BVEN%>+[0N
MW8R @YSG/F?I6SN\:?W-!_[[G_PK$O?'GAEO'VDSCQ'I)A33[I6D%]%M#&2#
M )W=3@_D:Z+_ (6)X4_Z&?1O_!A%_P#%54XSLFJ?3L*+CK[WXD&[QI_<T'_O
MN?\ PHW>-/[F@_\ ?<_^%3_\+$\*?]#/HW_@PB_^*H_X6)X4_P"AGT;_ ,&$
M7_Q59\M3_GW^#*]W^;\2#=XT_N:#_P!]S_X4;O&G]S0?^^Y_\*G_ .%B>%/^
MAGT;_P &$7_Q5'_"Q/"G_0SZ-_X,(O\ XJCEJ?\ /O\ !A[O\WXD&[QI_<T'
M_ON?_"C=XT_N:#_WW/\ X5/_ ,+$\*?]#/HW_@PB_P#BJM:;XOT+6KK[-I^M
M:=?W.TMY-M=QR/@=3A23BD^=*[I_@/W7]K\3.W>-/[F@_P#?<_\ A1N\:?W-
M!_[[G_PKJ**S]I_=17)YLY?=XT_N:#_WW/\ X4;O&G]S0?\ ON?_  KJ**/:
M?W4')YLY?=XT_N:#_P!]S_X4;O&G]S0?^^Y_\*ZBBCVG]U!R>;.7W>-/[F@_
M]]S_ .%&[QI_<T'_ +[G_P *ZBBCVG]U!R>;.7W>-/[F@_\ ?<_^%&[QI_<T
M'_ON?_"NHHH]I_=0<GFSE]WC3^YH/_?<_P#A1N\:?W-!_P"^Y_\ "NHHH]I_
M=0<GFSE]WC3^YH/_ 'W/_A1N\:?W-!_[[G_PKIGD6-2SL%4=V.!4?VRW_P">
M\?\ WV*/:?W4'+YG.[O&G]S0?^^Y_P#"C=XT_N:#_P!]S_X5T7VRW_Y[Q_\
M?8H^V6__ #WC_P"^Q3YW_*ON#E\SG=WC3^YH/_?<_P#A1N\:?W-!_P"^Y_\
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M7[SPK1]+OO$6I16.F6<VH7T@8I!;IN<@ LQ ]@"?PJEYJ-V!SS7U4?!JZ?\
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M#=XZJ[KO_E8^GM8_:.\/WGBK3M8MKK4TLI-:M]5OM)&D6T6SRQS^_5MTS \
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M1+CQ!&C_ &N6S4!=A7=L!*@*6"Y(%4=9^,VIZY+XI>6QLXSX@T^TTZX$9?\
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M>N/6O6;B;2-'^-7B7XM2^,M$OO#%Y9W4UM;Q7RO?7)FMS&EJ;<?.I5F&=PP
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M\&Z+:Z787EG-:V4K363:A8174EE(QRS0NZDH2>>._->+' 8J+DY---WMS/\
MO=;=+Q[[>2.]XFBTK*SMO9>7GY/[_4]-NO#5A\'_ !-\9-?L1BS\/E]$T42'
M<1=72X !/4QQ&3]*Z7XF^&?"&E^&+G2[VR\+Z;-<:=I(T+^S<#5S<R"/SFF4
M'_5D$G+#FO /$WQ*G\1^ ]*\./%*)(K^ZU74KZ:7>]_=3$ 2-QQM08_$FLGQ
M!XWU;Q1X@M];U&>.748(X(HY$B5 %A4+&-HX. H^M;1P-><HSJ3LUOW=N6WW
MV;?E)HB6)IQ3C&.C_6]_NNE\CW>+]G?PE>>+/%NG6/B#6KJQ\)[8-2=XK6"6
M6Y>3:J0M(ZH% #9+GDC ZUF7WP T&ST_QJUIXCNO$U[HLK"WMM"%O(_D>0)%
MN)59\LF3L;RL[2I->::?\9/$VG>)/$&M">SNKCQ Q;5+:\LHY[6Z);=\T+ K
MPW(]*M6GQT\4:?#JB6@TBSDU#S=]Q;Z3!'-"LB".187"YC4JH&%X_.CZOF,7
MI536GZ7Z=[[=&'M<*U\'?];=?0](\2?#'P]]JU+7_$NJ3Z7H.F:9HB;="L(Q
M)+/=0!A\A.W  )9NK?6NT\6?L_Z'XO\ B!XIU;4-5DT31_[4M]*M%L5MH5C/
MV2)VGD$KH-@W E4RQR37@FE_'KQAI-_=745W9S&ZM+6RFM[JPBF@9+90L!\M
M@5WH!PW6IA^T)XQDO]7NKR;3-5_M2X2\N;?4M,AN(//1!&LJ1NI"/M4#(ZXK
M*6$S"Z<*B5E;_P!)OI;NGKK\BU7PMK2CUO\ GY^:.[\*? ;PQJEOHUKJ?BB_
M36-<U>_T;3CIUM'+:-);D 2NY.=C97ID_-[5SOQ.\->#_#_PS\ WNEKJ4?B#
M4K69[EY53R9C',4D9OF)!##"X&"O)YKC].^+7B72IM!EM;J")]#O[C4K#%LF
M(YYB#(2,8(.T87H.U5M2^)&MZQX.LO#%Y):SZ793//;,UJGGQ%V+,JRXW!"S
M$[<XZ>@KMCA\7[6,YU+I.]KVT][R[..G=,YY5:'(XQC9V_R\_4P_.]Z^@?V&
M9-WQZB'_ %"KK^<=?.F^OH3]A-L_'Z$?]0JZ_G'59O\ \B^O_A8L#_O-/U1^
MCE%%%?@Y^DA1110 4444 %%%% !1110 4444 >*?MD-M_9W\3'_:M?\ TICK
M\U6F(4D')K])_P!LXX_9S\4?[UK_ .E,5?F=OK];X3_W&7^-_E$^(SO_ 'E>
MB_-GT+XX\3:C\,/#?@K0O"^CZ?<:5K'AV.^NI9]+CNGU&>4-YN7*EODX "D;
M<9K9^*WA?PMXFTF_E2/4X/%6A>"=+U4W1F0VDD8CC01"/;G.UL[L]>U>(Z'\
M9/&WAOPX^@:7XFOK+1V5E^RQN"$#?>"$@L@.3G:1UK-F^('B&Y-X9=6G<WFG
MQZ3<9V_O+1,;(3Q]T;5]^.M>M' 58SC)-)IO5-WE=IZZ=M+:G$\33<6FKI].
MVG0^F]>^#OA&^U_7=?\ %^L21V7V^PTM'>^AL!"&L897E)$95V&["Q@+D Y.
M:X[XA:IH_A7]GC1]!T.6^E@O==U"&2^BN5$%]Y#Q_O9(]F6#+M*KD;3GKFO+
MM,^.'CO1]2O[^S\3WD5U?B+[4S!'$OEH$C)5E*Y55 ! S@5SNJ>+-7UK3X+&
M_P!0ENK2&XFNXXI",+-*097Z=6(&:BCE^(4X>VG>,6G:[MI&VUN_WCJ8JDU+
MV<;-W_%]_0^E]-^'MI\4_@!X,\-:596\7C%;4ZM:W"HJO<0_;&@G5FZG:KH_
M/]VMCQ=\/?"/Q&USP+I6G"/3O#>F:=JPDN+8I#)>I9,D98R$'&]@3N(. 2:^
M7]+^)?BC0Y=*ET_7+JTDTJWEM+%HB ;>*0DR(O'1B2>:9I?Q&\3:')HKZ?K=
MW9OHIE.GM$P!M_,.9 O'(8]0<@UF\MQ*DY0JVUDUOHY)_P# MV][R*6*HV2E
M#HD_E;_@_@>SZC\+OAQ96VN^)(+^]U[P]I>DVUS<:3I&HI-+%=33&(Q_:?+P
MR*!NSM'4"N[\9^"+?QMXM\6Z+;W5QIMI=2>%;*,311EUCE15R^5R'"]E(!/7
M-?.D?QR\>0^(FUV/Q/=Q:JUM]C:>-8U!ASN"; NW //3K6?J/Q4\6ZM<W]Q>
M>(;V>XOWMI+J9G >5[<Y@8D#.4/0BJ>!Q<I*4JFJ6EVW;6+VLOY7KN[J^UP^
MLT$K*._RZ-=_/8]2TGP-X(\1^*M6@TWP]X@BTK1([@7\FK:S#:0 I*L:RM.T
M?R _-E I.2O/6M+XC^"[+X<^ /BEH&GS23V5KKVBO \[!G"R022!2P SC=C.
M.<9KS23]H7XC2ZI'J3^+KXWD<#6RR8CQY;$%@5V[3DJIR1G(%8&N_$;Q+XG7
M4UU;6;B_&IS0W%[YNW]_)$NR)FP.JKP,5K'"8MU(N<ERJVEV]5)/JO)_?;H9
MNO046HK77HENFO\ (];M_$FH_"WX/?#_ %'PIIEC<7OB&XNVU&\N-/CNWGEC
MFV1VGSJ=HV\X&"<YKTSQ)<>%_AK8_%2*PTJ^L_-UG2K2\CTJ]2 *MQ"7>W7,
M;;4!,@9>^X=,5\Q^#_B]XR^']C-9>'?$5YI5G,_F/!$59-^,;P&!VMCN,&LE
MO&&M26>H6DFIW$MOJ%TE]=K(VXSSIDI(Q/)8;CW[U$\MG4FW)JU[[N[]Y25_
M\*5EO\BHXN,(I+>WEIHUIZO5_J?6WC_28_BIXW\=>&X[V^T^UM=;T?1$2=XI
MHXE>23)B&P&- .B!NO4GH/./#?PU\ >+]?\ $C6MKK>D:3X9MIWNX]6U&.);
MMTF6)")_+_<CDEQM;'RCO7CEQ\2?$]S<:I<2:Y=&?5+F&\O958*TTT1S%(2!
MP5)R,8K9N/CW\0;K6K75Y?%E\^H6T+P13?(!Y;D%U*A=K;B!G<#G J*>7XJC
M#DI325EU:ULD^FM[/TW6NA4L51J2YIQ_!=W;[OQV/1[CX=_#71T\=:RUYJ7B
M/0-&BT][*/2[Y QDN2RM$\NS#!&'W@!D#I7@[3#<VTX7/ /I6QK/Q(\2^(?[
M6&HZQ/=+JQA-\K!0L_D_ZK( &-O;&*YS?7KX6C5I)^UES-VZWV27EUN]M3BK
M5(3:Y%9:_G_E8^\?^">K;O ?BSO_ ,35?_1"5]75\F?\$[VW> ?%O_867_T0
ME?6=?CF??\C*MZK\D?=Y;_NE/^NH4445X!Z84444 %?C[\7KR-?BUXW!E0$:
MY>C[P_Y[O7[!5@S^ ?#%U/)--X<TF::1B[R26,3,S$Y))*\DFOH\ES6.53G.
M4.;F7>QY688)XV,8J5K'XW?;(^OFIC_>%'VZ/_GJG_?0K]:-:\!^&8_'GAF%
M?#FD+%)!>%T%A%AL"+&1M[9/YUTW_"N_"G_0L:-_X+XO_B:^MEQ=3BD_8O7S
M_P" >&LCFVU[1:>7_!/QQ^W1_P#/5/\ OH4?;H_^>J?]]"OV._X5WX4_Z%C1
MO_!?%_\ $T?\*[\*?]"QHW_@OB_^)J/]<*7_ #Y?W_\  '_84_\ GXON_P""
M?CA]LASGS(\_[PH^V1?\]8_^^A7['_\ "N_"G_0L:-_X+XO_ (FC_A7?A3_H
M6-&_\%\7_P 33_UPI?\ /E_?_P  /["G_P _%]W_  3\</MD1SF2/_OH4?:X
M3C,D?_?0K]C_ /A7?A3_ *%C1O\ P7Q?_$T?\*[\*?\ 0L:-_P""^+_XFC_7
M"G_SY?W_ / #^PI_\_%]W_!/QP^V1?\ /6/_ +Z%+]NC_P">J?\ ?0K]CO\
MA7?A3_H6-&_\%\7_ ,31_P *[\*?]"QHW_@OB_\ B:7^N%+_ )\O[_\ @!_8
M4_\ GXON_P""?CC]NC_YZI_WT*/MT?\ SU3_ +Z%?L=_PKOPI_T+&C?^"^+_
M .)H_P"%=^%/^A8T;_P7Q?\ Q-'^N%+_ )\O[_\ @!_84_\ GXON_P""?CC]
MNC_YZI_WT*^P/^"<-PLWB[QQM=6Q8VOW2#_RTDK[._X5WX4_Z%C1O_!?%_\
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MNVN)S)L@RIC:( ?<[^:?R%:G_#N3PI_T-^O?]\0?_$5].^),N5FYO7R9X_\
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M ,^Y?<P]M2_F7WGHE%>=_P##0OPX_P"APTW_ +^'_"C_ (:%^''_ $.&F_\
M?P_X4?4\3_S[E]S#VU+^9?>>B45E>&?%6D^,M*34]$OX=2L'9D6X@.5+*<$?
M@:U:YI1<6XR5FC5--704445(PHHHH **** .7NO^2G:9_P!@>[_]'6]=17+W
M7_)3M,_[ ]W_ .CK>NHK:IM'T_5F<=WZA1116)H%%%% !1110 4444 %%%%
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M,W\:]'^AE_'NYEL_@WXNG@ED@F2P<K)$Y5E/'((Y%?GQ_P )?KG_ $'-4_\
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M]*)*^4XDIQA@XM+[2_)GLY5-RKM-]/U1ZY1117YJ?5A6=XD_Y%W5/^O67_T
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MI7ZJ?!4Y^#_@D_\ 4&M/_1*U\)Q9'EH4O5_D?1Y([U)^AVE%%%?F1]>%%%%
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MQ:7%M;V+:;]DN[..:":W:0RE)488?YV)!/(KSSSZ//K]<^I8?;V:^Y>A\/\
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MC$FX[H^-S$G!Y(]*LZ)X,A\2^#_!5O+I5KJFF:3#XAN7AOKB>.**..\B4,1
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MTL_8[;=^SOX6/_7S_P"E,M?F1YE?II^QJ=W[.?A0_P#7U_Z4RU\5Q9_N,/\
M$ORD?09)_O$O\/ZH]KHHHK\E/M@K*\5?\BOK'_7G-_Z :U:RO%?_ "*^L?\
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M:/\ AN#Q)_T+>D_]_I:^9O.H\ZNW^Q<#_P ^E^/^9S_VAB/YSZ9_X;@\2?\
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M_@=<_P#QRC_6W _R2^Y?_)!_8F(_FC^/^1^7_G&CSC7Z@?\ #&GP=_Z$V/\
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M<<G[%-_Z :U:*J+Y6F)JZL?BE;V]S]GB_P!&G^Z/^63>GTJ3[/<<C[//GO\
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MZLSB]7ZGP#^V')M^/6K#_ISM?_1=>+>=7K7[8UU')\?-6:.19$-G:X9""/\
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M\"_L*R[_ (S7HS_S!IO_ $;#7WU7Y)Q,K8]KR1]ME#OAOFPHHHKY0]H****
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MW,Q_Y_,/[.PG_/M'RI_P[K\!?]##XC_[_0?_ !JC_AW7X"_Z&'Q'_P!_H/\
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MH!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7*>&?^1V\9?]=K7_TG6NKKE/#/_([>,O\ KM:_^DZUM3^&?I^J,Y;Q
M]?T9U=%%8NI>-O#NBWCVFH:]IEC=( 6@N;R.-P",@E68'D5G&,I.T5<MM+<V
MJ*YO_A97A#_H:M$_\&,/_P 51_PLKPA_T-6B?^#&'_XJM/8U?Y7]Q//'N=)1
M7-_\+*\(?]#5HG_@QA_^*H_X65X0_P"AJT3_ ,&,/_Q5'L:O\K^X.>/<Z2BN
M;_X65X0_Z&K1/_!C#_\ %4?\+*\(?]#5HG_@QA_^*H]C5_E?W!SQ[G245S?_
M  LKPA_T-6B?^#&'_P"*H_X65X0_Z&K1/_!C#_\ %4>QJ_RO[@YX]SI**YO_
M (65X0_Z&K1/_!C#_P#%4?\ "RO"'_0U:)_X,8?_ (JCV-7^5_<'/'N=)17-
M_P#"RO"'_0U:)_X,8?\ XJC_ (65X0_Z&K1/_!C#_P#%4>QJ_P K^X.>/<Z2
MBN;_ .%E>$/^AJT3_P &,/\ \55W2?%^A:]<M;Z9K>G:C<*N\Q6EW'*X7(&<
M*2<9(Y]Z3I5(J[B_N#GB]$S7HHHK(L**** .,US2+'6/B1I,5_96]]&FDW;*
MES$L@4^=;C(!!P:U_P#A!O#?_0OZ7_X!1_\ Q-4[K_DIVF?]@>[_ /1UO745
MT3G**BD^GZLRC%-NZZGYM?MB6=KI/QZU:VL[:&TMUL[4B*",(H)CYX Q7BOG
M"O:/VV9-O[1&LC_IRM/_ $77A7F'UK]SRO7 T&_Y8_D?G6,M]9J>K_,N^<*Z
M+X>^.9OAYXRTWQ%;VL5[-8ERMO,Q5'W1LG)'/1L_A7(>8?6CS#ZUZ,Z<:D7"
M2NGHSEC)Q:E'='JNA_'._P!#DT%1IEM<V>FZ+<:%/9R2L([V"5G<E\=""^1C
M^Z*9\)_C5/\ "NQU2SCTB+5;>^E@G.;R:UD1X22@WQ$%D.>4/![UY;YA]:/,
M/K7++!4)1E!QTEOOT=_S9LJ]2+4D]O\ *QZU=?'N^N]4L[YM(M%>V\42>* @
ME?#2OLS#_N?(.>O-:^A_M*R:6UA<W?A'2]4U336NQI]_-<2H]M%<.SO'M4X;
M!=L,1D UX=YA]:/,/K42R_#2CRN&GJ_\_-E+$U4[J7Y'8^#_ !Y<^#-/\26M
MK"LIUO3CISRF1D:%2ZOO7'4_+C\:=H/Q#O?#OA/7=$M8U#:K<V=W]N\QA+ ]
MN[.I7UR6YSZ5QGF'UH\P^M=,J%.5VUNTWZJUOR,54DK6>U_Q.P^(7CAOB%XP
MU#Q#+86^FW-\4>>&V8E&D"A6DY[L1N(]37.>:!TQ5+S#ZT>8?6M(4XTXJ$=E
MH3*3DW)[LN^<*/.%4O,/K1YA]:LD^FOV#I-WQJOA_P!0:?\ ]&PU^@5?GK^P
M,^[XV7P_Z@L__HV&OT*K\>XH_P"1@_\ "C[K)_\ =?FPHHHKY$]P**** .9U
M3_DHGA[_ +!]_P#^AVM=-7,ZI_R43P]_V#[_ /\ 0[6NFK6?PQ]/U9$=Y?UT
M04445D6%9>O>*=&\*PQ3:SJEGI44S;(WO)UB#MC. 6(R<5J5\S_MS-M\'^%\
M_P#01?\ ]$M7?@<.L7B84).R?^1SXBJZ-*51=#VK_A;W@?\ Z&_1/_ ^+_XJ
MC_A;W@?_ *&_1/\ P/B_^*KX7?P+X6\.^&]&N?%.O:A8ZMK-F;^UMK"R6:*W
MA)(C:8E@<L1T4<"IM>^#UU-XL;2_#[VQA2RL9V?4[Z*W+2W$*OL4N5W$L3@#
MFOI_[$PE[.JTM=6K+1VW?F>1_:%:WP+[S[B_X6]X'_Z&_1/_  /B_P#BJ/\
MA;W@?_H;]$_\#XO_ (JOS[A^&?B2:]TNT_L]4NM2OY],MHI)54FXA.)$;)^7
M!/4\&NG^&/P2U/QA=6M[J< M?#\B71,JW4<<\GDHV6C0_,RB0*I('<U53(\'
M3@YRKZ+T\_\ )_<*.85Y/E5/\_ZZGV[_ ,+>\#_]#?HG_@?%_P#%4?\ "WO
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MA^S-;%MOFK+NVE<@@X/&*O\ L+!6O[?3Y"_M"O>WL_S/O'_A;W@?_H;]$_\
M ^+_ .*I\/Q8\%W,T<,7BS1I)9&"(BWT9+,3@ #=R237PA\'OA_I?CKX@'0M
M<U-=-MX@Q9XY$Q,ZN%\M6)YSDX*Y/MCFJ^H:!8^$OC)8Z1IVH+JME;:K:+'>
M*4(D!DC/\)(X)QUSQS@\4GD.&]I*DJCYDK[=/4%F-7E4W%6;L?I%1117PY]
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M]61'>7]=$%%%%9%A7S!^W@^WP;X6]]2?_P!$M7T_7RU^WT^SP7X3_P"PF_\
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M1I__ $1#7)Q$^;*W-]6OZU2_(WRI<N,MZGT]1117Y"?<A1110 4444 %%%%
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M#SJ/.JAYA]:/,/K7?R'-S%_SJ/.JAYA]:/,/K1R!S%_SJ^BOV%I-WQ>U,?\
M4&E_]'0U\S>8?6OH_P#8-8M\8M4Y_P"8++_Z.AKQ<YC;+ZWH=^ E_M5/U/OJ
MBBBOP\_1 HHHH Y>Z_Y*=IG_ &![O_T=;UU%<O=?\E.TS_L#W?\ Z.MZZBMJ
MFT?3]69QW?J%%%%8F@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MF596;Y?XRZ@EC4>L?&[Q1KUQY]W-:&3^UXM<^2V"C[5'&(U/7[NU1\OK7/\
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M21*,GJ0.<9Z9KS#SJT_$'Q U;Q1I5IIU_)"UK:W=U?1".,*WFW#AY23W!*C
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MU]4_R..\RCS/>JOG4>=7KG"6O,K[Z_X)\MN^$^O?]AN3_P!$0U^??G5^@/\
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MRUYWO7TI^P+)N^,NJ#_J"2_^CH:^8=]?3'_!/]L_&C5?^P'-_P"CH:\7.O\
MD75O0]#+_P#>J?J?H11117X4?HP4444 <O=?\E.TS_L#W?\ Z.MZZBN7NO\
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M^H_^ K_(/K=;^=_>SV+_ (:E^)G_ $,G_DE!_P#$4?\ #4OQ,_Z&3_R2@_\
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MZ,2DV;("T;I@K('.6/2O'/!_Q?\ %/@"SN;7P[XFN=)M;A_,DAA=2A?&-X#
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M/][_ ."R/_XNOLVBC_6',_\ G]^$?\@_LO!_R?B_\SXR_P"';MA_T/\ >_\
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MZOF-W[ZZ]OETZ#]KA;+W>W_!,;QMHJ^%?%%_I2"^5;9PH74K;[/<#(!PZ D
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MT..J?]_%_P */^%]?$+_ *''5/\ OXO^%><><3TR?I2I(TC*B!G=C@*O))]
M*/J-#_GW'[D'UFI_,_O/1O\ A?7Q"_Z''5/^_B_X4?\ "^OB%_T..J?]_%_P
MKSEI6C8JP*LIP5;@@^AIOVCWH^HT/^?<?N0?6:G\S^\](_X7U\0O^AQU3_OX
MO^%?2O['WCKQ!XWL?%3Z]K%UJS6TUNL)N6!\L,KD@8'? _*OB+[1[U]=_L&R
M>9IOC3_KXM?_ $"2O"SO"TJ> J3C!)Z=%W1Z&7UISQ,8N3>_7R/JNBBBORX^
MO"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "N4\,_\CMXR_P"NUK_Z3K75URGAG_D=O&7_ %VM?_2=:VI_#/T_5&<M
MX^OZ,ZNLCQ!XNT3PFD#ZUJUEI23DK$UY.L0<@9(&X\XK7KY;_;J;;H_@[_KZ
MN/\ T!:ZL!AEC,3"A)V3O^5S+$570I.HEL>Z?\+A\"_]#?HG_@?%_P#%4?\
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M8:EA9VNM?GV?;IMMK<T8_P!FN"SU"^M]9\:6FF0IJMMI5G.EC),+Q[B%)8&
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M^?WQ'_X'1_\ QJC_ %IR[^]]W_!#^QL5Y?>?GCYU'G5^AW_#OGX9?\_OB/\
M\#H__C5'_#OGX9?\_OB/_P #H_\ XU1_K3EW][[O^"']C8KR^\_/'SJ/.K]#
MO^'?/PR_Y_?$?_@='_\ &J/^'?/PR_Y_?$?_ ('1_P#QJC_6G+O[WW?\$/[&
MQ7E]Y^>/G4>=7Z'?\.^?AE_S^^(__ Z/_P"-4?\ #OGX9?\ /[XC_P# Z/\
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MKK_@[=1GXO>!P)%).N60ZC_GNE<^(_@S]'^1K2_B1]4?L%1117\\'ZF%%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3;^WTBWU62TE33;B5X(;IE_=R2( 64'N1D9^M5RI6N+F;V)/M'O1]H]ZSOM
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M?_@!!_\ $5XU]HH^T4?V;A/^?4?_  %!]<K?SO[SV7_AJOXF?]#!'_X 0?\
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M'/\ S&;/_P!'I7M*BJ&%=.][)Z]]#@]HZE92\S];Z***_G\_30HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %<_XN^'_ (:\?0VT/B30K#7(K9R\
M*7T"RB-B,$KD<$BN@HJXSE3ES0=F3**DK25T><_\,Y_"[_H0/#__ (+X_P#"
MC_AG/X7?]"!X?_\ !?'_ (5Z-173]<Q/_/R7WLR^KT?Y%]R/.?\ AG/X7?\
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MZ$#P_P#^"^/_  KT:BCZYB?^?DOO8?5Z/\B^Y'G/_#.?PN_Z$#P__P""^/\
MPJ>Q^ 'PVTV]M[RT\#:#;W5O(LT,T=C&&C=2"K XX((!_"N_HI?7,2]'4E][
M#V%+^1?<@HHHKD-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *_*7]IZ7;^T)X\'_40_]I1U^K5?,7Q(_85T
M3XD>/-;\47'BS5+*?5)_/>WA@B9(SM5< D9_A[U]5P]C\/E^(G4Q#LG&VS?5
M=CQ<TPU7%4HQI*[3_0_//SJ/.K[H_P"'<'A[_H=M8_\  :'_  H_X=P>'O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
***** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>form1-a_028.jpg
<TEXT>
begin 644 form1-a_028.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  4 %8# 2(  A$! Q$!_\0
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M3+6\J28DC).20?\ $444HRDG>Y<XJVW0N6OA^VMC #/<S-%#Y0>63+$9SDD
+9-%%%)SEW&HH_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>forms-1a_019.jpg
<TEXT>
begin 644 forms-1a_019.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1"  _ #T# 2(  A$! Q$!_\0
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0A:)F,A0,<J-_\7'>@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>forms-1a_020.jpg
<TEXT>
begin 644 forms-1a_020.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  L *T# 2(  A$! Q$!_\0
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MNMV'PUU[2KVXU/09=%1]3EGB>XB1/*PTJMYL2?<:B-"I+H',??N,4$<5Y?\
M #]H7PC^T?X,F\2>#Y;A[2WNFLKF"\@\J>"955BC)_NNOYU\I^-/C+\;OVC_
M -H;QQ\-O@[XDT[P#H'@AQ#J.LW<"S2SS[MFWE'_ (E?:JK_  '+_P -1&E*
M4BKGW]17YZ^*OVK_ (D?L\?'_P"'7A+XFZS-KFG_ /"(O>ZY::#ID5Q+?WOF
MW:++%M17'R11-_"ORFNR\>?M4>%?BVOP,\3>#_B+XA\)Z;K'BO[ VGVNF;_M
M\JO"C6MU\W[I?WJ?-\Z_O:OZO(GF/M?(HR*^&_A/^V_'X0\(_%KQ+\6]>>XL
M=#\<W6@:1;VEFGVAD7[D2*@7=\N[YG_[ZK$^'/[?TOB[]HSXBW<UYJ=M\*?#
M_A)M;_L>[TQ8KV":+[/YO^U_$W\6WYJ?U>H',??W-'-?*=G_ ,%(O@U?^&-0
MU^*]UC[':M:PHATQ_.NIY]^VW@7^-U\I]W\'R_>K2'[?OPOA\">*/$U_%K^E
MOX9GM[?5=%U'3?)U"V\]ML3&)F^ZQ_VJS]A5_E*N?37-'-?-_P -?V[_ (7_
M !/\1:WH]M-JVBW&EZ8^M,^MZ>UJLUFB[VFB&=S+M^?I]VKOPO\ VS/#/QAL
M[R^\*^#_ !S?:= 5VWHT(B&X#%@&C;?\PRC<TO9U%]D9\"?M&W\'@?XJ^*/"
M^D7D,JV-VRM);ON\K?\ .L/^RR*U>*.[3/N9F=W_ (WKQC5/B-K.I>.=;\2W
M$C_VAJEY+>WBR_Q.SNS_ /H5=+:?%RU$7^DV4BR_],6W5^OY?C:4*$(5?C/R
MJOP]/"5)?4H>Y(]+TS5+G2;GS+>1D;_QUZ_07_@G9'8>);7Q3XECN8'U"V>+
M3I+1&^>+CS-[?[+97;_N/7Y0:Q\5YKF)X]/MOL^__EK*VYZ^PO\ @CKXDOE^
M./C72=TCVM]H'VZ;YLKYL5Q$BLW_ ']>O*S[%TZV%E"D>CE.1<F)CC:\??B?
M7?[1?PCT'5?VK?AOX^\8^+_"FB>%K;1+_1;C2->OOL]QJ'FQ7$3")6^5D_TI
M-WS5Y%IW_!,&;1O@9\1_#>@^(-)O-?\ %.IP/IFK7+2^5%I<5PLL2,RJQWOC
MYMGR_=KUW]LSQ9J'@7XE> M;L_"-GXV2U\/>(&N=/U%_W45OYNFK+<,NU]ZH
MOS,JK]W?65!\2/%/P1T#X=_"WP3<VNM/;^%UUF37XO#][K-O*CRLD44$%JZ,
ML7WOG9_E397Y_&511CRGZ"<?XX_8:^+MGXM\:7W@3Q1X5@TWQSX;MO#VM0ZQ
M'.98$2UBMY7MV1>XBSN;^]]RNZ^&/[#^J?#OXT?![Q/'JVG:CHO@;PL^BSI*
MKI<SW3?:&::)=NT+NN/[U;EI^TEXVFU?X8:CK.AVO@_PGKUG;?VG<:C8SSA+
M^6X>+[+YJ-_HWW4>)YDV/YH7<M<YX/\ VQ?&^L:KI/B"Z\,3W7@C4[ZYMS:V
M?AR_2:SMT\WRKC[:_P"XG;]U\Z*J[=_^S1S5W$/=.;^('[$GQ9M/B'\6[KX;
M>,_#=AX8^)JRMK%MK=H[7$3OOW)$ZHV%W2O\W^W]WY:IZ?\ L&_%#X;3_#3Q
M;\//%WAVT^('AG0FT.^358)9K*=-\K;XFV;_ +LNS[E>L^$/C3\5+NZ^$6NZ
MTWA$^%_B)>HJ:?907'VO3HI+*XNHE$K2[9VVQ+N;8FWGY.?EI^%_CI\5/$GA
M_P  !V\*P:UX_NIUTIWL;@6VEV\"2O*TO^D;KB5E1=J)Y7WW^;Y:7M*FP<L3
MQ1?^"<VOZ'H'AZYL?B!HQ^-5GXBG\81+/ 5T^4[XMR+%]_8KK%\^S^/;MKV"
M#]FWXF^(?C]\(_BMXZUWPO->^$K&]M]7BTQ98D<R_:/*^SJR?=198OOO_"]7
M?%[_ !4C^,_@J.#4_"L?BV#PKKWVK4S87$MB\"W=@R;;?S4=6?\ =;OWK[?F
M^]7L7PO^(;_%K]G[0?&4UNMG<:WH2WDMNIRL;O#\RJ?[NZB52I\3#E/-OV(_
M@3J'P4\(>+Y+O6M*UVT\4Z_+K^GW>C3-+$;:5$V#<RK_ '?X>*X+XH?L@?$W
MPU\=M=^)_P !_'.G^&-1\2H5UO2M;@+VTK#'SH=C^N[[ORMO^;YMM5/!'Q7^
M(_ACX.>&K+P@= BTKPM\*=(\4W+:Q:33RW+>5<?Z.FR5-F];7[_S[/[K;J]+
MO?CQXN?XL>&],EBT[P]X-\0Z=!_9E]>Z?/.MY?SV[RI%]H1]L3JVS]U*J>:N
M[8^[Y:GFJ1ES <IX,_9=^($'[1OPT^)7B_Q7I6OZAH/A:32M68,XN+FZ=[IO
M-B39M\K_ $A5_@^Y7FG@O_@GGXW\.>'_ (56,FO^'I'\)>.)?%%R\33[98'>
MU?9%^Z^__H[=?E^Y47@KQ+XJ;X*:>]]/I-YXHE^&?B6_L_$CVT_VVWBBN+=/
M*W^;_MLV[_9B_N?/ZOX6^.WC/P;\ O$]W>RZ9JNL^$_ 6D:Y;7!@EV3RSQ7#
M?O0\NYODBB_B^]OJN:I #S/7_P#@G;XQU+PMXI%MXHT:T\3R>/IO&>A3;'EM
MT5_^65QN3[WNJM]P58C_ &)?C+XN\6_$_P 6>.O%GA*_UWQEX0E\.I_9D<\4
M-O*_E;-R^5]Q5B^_]_FNA\1?&_XA?#+Q[X_CM)+'6#KOC6UTC2X?[)NKU]/_
M .)5;W3OY44NZ5?*7_5)L_>[VW[*]Z_9X^)OB3XF>'M:_P"$ITB33M3TG4WL
M//\ [.N+!+V/:KK*D$_SQ??VLC,WW/\ :IRJ581N'+$\1^*O["^I_$']ESX8
M> (-4TJV\3>!_L\J/<1.^GWDJ)ME5QMW[7^]NQG->?7O_!.GQEK7P9\=Z%)_
MPK[PWXC\03V7V:+P]:W45I!%!-YK;I7W2MO_ -VOT1XHQ64<34AL'*?'/C3]
MD/QEK7QOT_Q[I>I>'1#:> 6\*?8]3BEE5[KRI5WLFW:T7[W^]VKQOP)_P3%^
M)5A?:Q='XGVGPS2Z:/;IO@.2\-L^W<-S^:R-GG(Y;EFYK]*N*,"B.)JPV#E/
MP1_;T_9WU/X ?'G6@+1D\+Z]<RZEH]V%^1U9]SQ?[T3OL_W=K?QU\X5_2-\5
M_A#X1^-7A&X\-^,M$M]:TJ9N$F7YXF_OQO\ >1O]I2#7X<?MJ_ CP[^SS\3[
MW0_#,]_<6"2,5&HRI(PZ=U1?4U]%@,4ZT>21C5B> 5^NO_!)C]G:_P#A_P"!
M=9^)&N6SVMWXG5(-,AD3:WV-?F\T_P#75S\O^RB_WJX#_@G-^Q9\,OB)X1TW
MX@^*=/NO$&I(5DBTZ^E5K"-_[WE! 7^CLP]J_4"*)((Q%&H2-$PH':N/,<4_
MX42Z<?M&1J'@[2=6\0:?K=Y91W.IZ?:SVMM.YR4BGV>:NW[N&\J/_OFN%U#]
MF?X<7NDZ5IG]@-9VNDQRQ6#6-_=6LT$,K[I8%EBE5_*;_GENV?[->LT5X/.S
M8\HD_9I^&S:GHU]%X7M[671XK>*TAM9)8;<+ ^^WWPJWER^4_P R;U;;4VF?
ML[?#W1O%D?B*T\.Q)J,5U+>P*\\SVMM<2Y\V:*W9_*BE;<WSJH;YC7J-%/G8
M'DF@_LR_#?PQXCTW7--\."WO]+F>XT^,7EPT%@[JZN+>%G\N)6#M\J*J\]*V
MM5^"?@S6?!^E^%[G0D.CZ7(LVGQPSRQ2V<J[MKQ3(XDC8;F^=6S\QKT&BCG8
M'!>&/A#X2\(?8WTK23%+96UU:13RW$LLWEW,J2W&]W=F9G=%9G;YO>MKPKX*
MT7P=X0L?#.C:>MAH5E;?98+)&9DCB_N_-\U='12 X.Q^#_@_3=*N-,M=#ABT
M^?18O#DL*LV'TZ)9%CM_O?=42R_[7SFLZ+]G_P !6WBO3_$D6@H-5L!#Y#>=
M,8M\47E12M%O\IY4B^5)67>O9J]-HI\[ \\MO@5X(LM/@T^+088[&#2[K0XH
M1+)A;*Y=6N(?O?==D3\JSM?_ &</AUXAO-.N=0\/+,=/M+>PCA6[G2&6W@??
M!%/$K[)U1ONK*KUZI11SL#S[Q+\%O!OBNVU:VU;18[@:G?1:I/*DLL4OVJ*)
M(XITD1]T3JD2+N3;T_/4\!_#GP]\--*ET_P[IJZ?;W$[W4[M*\TUQ,WWI997
59GD<]V9C76T4K@%%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>forms-1a_021.jpg
<TEXT>
begin 644 forms-1a_021.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  6 %D# 2(  A$! Q$!_\0
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M<>B[-M_\$[CX=^*;_6EU#3]9D)U.TDR0R*C;>A&T <JPY_WA73S_ /(S6/\
MUYW'_H<->.P>+=.M_B6FNZ>L\%C=,%NDF4+@-PY^4G(SA_K7L4_/B6QY_P"7
M.YY_X'#6E-[_ #/%SC#>QJQFH\JG9V[/JOO,L7?B!-'#6;6VH7Z(N^)F0?/D
MAP2I P&! &!RIY/-/^U^*!=7ACLK62%;I4A5V"DQ$@,<ACT SR,G=G QM/.P
M1:2UCMNM(U.)DBBN/+683X 8A4'F$,3F1C@COZ$ Z.EW6DP:U'<VFEZM]I>S
MV#>H.V)6 P06W;AMSCDG'=N*[)02OI?Y?\$\%3;MK^/_  #02;Q2;<%[>$2
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>forms-1a_022.jpg
<TEXT>
begin 644 forms-1a_022.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  Z &(# 2(  A$! Q$!_\0
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D"C<54$XY(YK6$%>_]=3GJU&XV?5?Y?Y$M%%%;'(%%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>forms-1a_023.jpg
<TEXT>
begin 644 forms-1a_023.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !3 )(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HI,C.,C/7%&1G&1GKB@!:**AMY_/C9R-NV1TZ_W6(S^E $U%)N7U'YT;E_
MO#\Z %HI-R_WAQ[T;E_O#\Z %HI-R^H_.@$'H0: %HI,C&<BC(SC/- "T444
M >2>"]=U:\\9V]M=:E=30'S<QO(2IPIQQ7K=>:VO@ZYT;7$U/2;\LR,Q6.YL
M9>AR""5'H>M=-<:EXA^S*+:UL/M&3N,BW&P#C&,1Y/.>*XL%&I3BXU;WN>IF
MM2A5FJE!JUMMM=>AY->>*-?3XPMIZZS>BR&KI%]G$IV;-R_+CTKN-#U1Q=>,
MX+JZU"7R+R2&WP99!$@0$!2,[>2?>L;3?AM</XN7Q%K6K-).+L7;16EA* S@
MY RPX' [5U&BZ7>::WB220J[:M</<1!()L1DKMP3LZ<9R*[#PX*5[LRO"?C@
M0>%+5)Y?M=[#IXO;V:[N]A.XMM52V<L0IXX XYYK7O?B%%#HMQK-MID\FGP"
M',D[>293)CB,$'=M##/0=0,UB^'/"FH^&6AE@^R73-:);7,<]M,%)0G9(AV$
MC@X*X[=:EU?PSJNL0:W!=7T<WVM8Q:2O9S VZKM.P(%PH+#E@2>:"DY<I0US
M5[WP_P")?&=_IB1^=Y>G+ESPGF%E+ 8.3S_7VK7AFO;?XGZK+;Z<LUV^CP,T
M G"KN\QL_.1[#M5/5?"VIZJVN32S0)+J4=IM"V\^U&@;/.5Z-R/;WK<L;._A
M\7W>NW/EM]HL4MO*C@F&UE9F!R4Z<X_#/M0))W_KS-WP[K</B/0;75H(GB2X
M4GRWQE2"5(X]P:FM462QN(W^XTLRM]"[5E^"-*GT/PM;:9<.LDENS_.J.@;<
MQ;HP!_BQ^%:]AG[/+CKY\N/^^VIFL;M*YE&QTPK;3MJ$?W<QNK* X3;GZC"#
M/Y\4Q=(TR6UECCOP56*,R,K+A0#N#\="0 ,^@IITJ"*>&(7NZ202A$2/<!N4
M*Q&#P,G)]S26X@C5DBOB3=%;0J;<[MT:$$=>..<_EUK#VDNIVO#TFKQ;^[S]
M.P2:/IZ_O9=3"I<C<N,*" HY7'L,U/'I>ES2B,W,,S;95*D*=WF8;\P!Q[&J
MP:"XM[%C=N\4.Q8=MNPW%E(7D'OC./P/6G1FTCU!;HWVY@XD9?(.#@"':!GA
MMPP,#/)%'M6'U6%NM_1[].A//I=A)"L+Z@5,< C=MPR=K EOJ6ZGOG%-N+#2
MY=/AM!J"1K;HS%U8;B,;6)/IR0:KSPV23M*\\\;QLURRK"^/E=6RR]#C(Z8)
MSFI+U;6Z9W>Z/[^!K=6CB.TEQO# @\\"CVD@6&IZ;_<2_P!DVKNL:Z@-Q)(0
M!<$,F&!'?*@&EL;&PL)DN!J(DV-UD9<G<JH.?^ #%/\ [%COK7:9W^RSR_:6
M&TJ^XCID]!G\>U.;0G<Q,UR-T,<<28CP-J.K\C/4E0/;FJYI]$1[*BGK(VJ*
MRWL=5:1F75U1220HM@<>W6BJYG_*_P /\R/9Q_G7X_Y&2O@+3%<.+S4MPZ?Z
M1WVA0>G4 <4X>!-,60NMS?#/&!,,8YXZ=.<5U%%68<J.>?P9IC6CVRR74:.5
M+%)<'Y5*\<<=2<CO@TV;P5ITTT<HN+Z-HT1%V3X "C:#TZX[UT=% <J.<MO!
M6FVL_G)<7Q;8R#=/D %=OIZ8_(4R+P180J!'?:B,2&49G!^8XSG(Y' ZUTU%
M ^5'/)X.TZ-759KL!V1B/-X&TYX&,#/.?7-1CP1IBA0LUVH0@K^]!P1MR>1R
M3M&?QKI:* Y49VCZ+;:);R06KSNKL&/G2;R, +P?3 %2VD6ZTFCD4@/+*".F
M07;^E7**!K38S[72+>TN5GC:3>%*<D8(PH]/1!3$T2W2X6<23>:KA]V1R0&'
M3&.C?H/2M.BHY(]C3VT^YE1Z#;PP0PQS3(D+(R ;1\R]">.3ZGVI?[!M-^[=
M+NZYW#[WF>9NZ==W/I[5J44>SCV'[>IW*$VE)-+YK7$_F>6T>X$="03V_P!D
M5&V@V;9P'"F?S]G!7=M*]"#QR3CU.:TZ*?)'L)5IK9C(H_*B6/>[[1C<YR3]
M:?115&;U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>forms1-a_024.jpg
<TEXT>
begin 644 forms1-a_024.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  I $,# 2(  A$! Q$!_\0
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=IH^]53P"ISC/FO84J[DFK;CA$I_BQ13J*[C _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>aud_001.jpg
<TEXT>
begin 644 aud_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !+ HH# 2(  A$! Q$!_\0
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M@ HHHH *H:)_R!;3_KF*OU0T3_D"VG_7,4NH^A?HHHIB"BBB@ HHHH ****
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M&S"I':W:3MO8DD -GGJ3SWK7HCS7=P=NAEZE?R6^H6ML+F&W25'8R2@'E<8
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MP.OUZZI9_P#?#5*/@G?#_F*VG_?MJ]GHJ_JU/^F3[61XW'\%+M9HV?5;8JK
ML/*;D9Z5[&JA%"J, # %+5'4;B^B@86%GY\Q& 6<*H]_>JC"-)-K_,3;F[,\
M6\;1'4O&NHS$?<<1#Z*,?XUC+IG^S7H#>#=:EFDGG@5Y9&+,=XY)I1X.U0?\
MNO\ X\*^<JNO*3?(_N9ZD%322NC@QIG'W:V?#FMW'A2:YEMK.&=YU"DR,1M
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>aud_002.jpg
<TEXT>
begin 644 aud_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1"  E +0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#V6LK7;^YM
MX[>RT\J+^^D\J%F&1$ ,M(1W"CMW) [U<NM1L;)E6[O;>W9AE1+*J$CVR:XQ
M_&6C'Q_<-)?)-!96*QP?9T:8M([9?&P'LJBF(V-(DOM)\12:'?:A+?Q3V_VF
MTGG \P8(61"0 #@E2/8X[5TE>?ZYXF>?7/#]]8Z'JCF*Z>%6F@\A9!)&PV@N
M1W /([5T2ZIXED.1X;AC7_IIJ"Y_130!O457M;I9[*.X9HE#+DE) Z ^S=ZG
MR,XSS0 M%-9U12S,%4=23BHI[NVMMGVBXBA\QMJ>8X7<?09ZF@";-+4$ES;Q
M,5DGBC94WD,X&%Z9^F>](U[:QW<=I)<Q+<2J6CA+@.X'4@=30!/FL#4M;U!Y
M[JVT:VB(LUS<WMQDQQ';N*JJ\NV,'' &>O:MJ"ZMKH.;>>*81N4<QN&VL.H.
M.A'I0EM#&)%2-5$S%I !]XGJ30!S]M;^([NQAO[/Q-!,LT:RQI+IP$; C(SA
MMP_.KVC:S->7,^FZE:BTU*V4,Z*VZ.5#P)(V[KD$<\@\&H/!+'_A$[.%NMN9
M+?\ [X=E'Z 4WQ/_ *%+INMQ\-9W*Q3$?Q0RD(P/T)5O^ T =!G%&:SK:YGB
M:>34;RR\F2YV6AC.WCH%8D\OD'I5L7=L94A%Q%YDFX(@<9;;][ [X[^E $U%
M0+>VAB:474)C1_+9Q(,*V<;2?7/&*1;^S=[A5NH2UK_KP)!^ZXS\WIQZT 6"
M:3-9NIS3.=/^QZC;6RSW*[F<!S.F"VQ.V2!U],TV3Q+HL>K+I+:C"+YG\L0
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M /"!T7 /4U9TZ+Q'9^(8M5U#PO-=M;V*V"O%-&S;T))E3<1A6!^M>B_2DIW
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$0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>forms-1a_029.jpg
<TEXT>
begin 644 forms-1a_029.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  W 2P# 2(  A$! Q$!_\0
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MC;1/B#X7M?$'A_4(]4T>\W^1=PHRH^UV1OO?[2M7YT?L??\ )^/BC_KOK/\
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/ "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>ex5-1_001.jpg
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #_!/H# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%% !1110 4444 %%%% !1110 4444 %%%(30 M%(** %HI** %HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBDH 6BDS10
M M%)FB@!:*** "BBDW4 +124M( HI,TM, HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BDI-U #J*2EH ***3- "T4E% "T4FZC- "T44E
M"T4E+0 4444 %%)10 M%)1SZ4 +1110 4444 %%%% !36IU-?IUQ0 @/OFE^
ME4-6UBQT.U:YU"]ALK=1DR3.%%>%^.OVV/A_X4DDMM/DN?$E^G'D:?&6!/\
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MU1Z6%K3Q$/:25D]C!F^(WAF&9XI->L$DC.UU,Z@J??FFK\2/"[,%'B'3RQ.
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MQL7P6-0N!9MJ7V02>82VS=C/6OTDN/#?A3]D'X1:[K.B03LPA5G\^4OYLV,
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M;:G90:A;.,[9E#*:\3M?V+? %CX@M-5M(;BW-M*)4@5QLR#7OB*(8U1!M50
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MM 1G.,C%>U"G*C&FUZL^>J585I5>9>1XW_P3A\?'0?B-JOAN>3;#J<.]%/\
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MH6.-X_2OUNT/7+/Q'I-KJ6GSK<6ES&)(Y$.05(S7C_[0/[*WAGX\VJW-TO\
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MZ=*I%R7O;'EXKVM2M3DH/W=S]+^_H.F:SM>UVR\,Z3=:CJ,ZVMI;H9))9#@
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M<;<FO48Y%D164@JW(*\YKP#X]? SPW!X/N];TJU72[^R'F!X. WMBNN_9O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
8B@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
